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The EditorsThe Worldwide Environment of Cardiovascular
Disease: Prevalence, Diagnosis, Therapy, and
Policy Issues: A Report From the American College
of Cardiology
The environment in which the ﬁeld of cardiology ﬁnds
itself has been rapidly changing. This supplement, an
expansion of a report created for the Board of Trustees, is
intended to provide a timely snapshot of the socio-
economic, political, and scientiﬁc aspects of this environ-
ment as it applies to practice both in the United States and
internationally. This publication should assist healthcare
professionals looking for the most recent statistics on
cardiovascular disease and the risk factors that contribute
to it, drug and device trends affecting the industry, and
how the practice of cardiology is changing in the United
States. The environment in which the ﬁeld of cardiology
ﬁnds itself has been rapidly changing. This supplement, an
expansion of a report created for the Board of Trustees, is
intended to provide a timely snapshot of the socioeco-
nomic, political, and scientiﬁc aspects of this environment
as it applies to practice both in the United States and
internationally. This publication should assist healthcare
professionals looking for the most recent statistics on
cardiovascular disease and the risk factors that contribute
to it, drug and device trends affecting the industry, and
how the practice of cardiology is changing in the United
States (1).
Cost-Effectiveness of Transcatheter Aortic Valve
Replacement Compared With Surgical Aortic Valve
Replacement in High-Risk Patients With Severe
Aortic Stenosis: Results of the PARTNER
(Placement of Aortic Transcatheter Valves) Trial
(Cohort A)
Objectives The aim of this study was to evaluate the cost-
effectiveness of transcatheter aortic valve replacement
(TAVR) compared with surgical aortic valve replacement
(AVR) for patients with severe aortic stenosis and high
surgical risk.As a service to our readers, we have compiled all the relevant manuscripts in individual
subject areas of cardiology. These collections should provide a single repository of
JACC publications in the speciﬁc areas. In addition, these compilations should put in
perspective the recent advancements and future directions in the important disciplines
of cardiovascular medicine.Background TAVR is an alternative to AVR for patients
with severe aortic stenosis and high surgical risk.
Methods We performed a formal economic analysis based
on cost, quality of life, and survival data collected in the
PARTNER A (Placement of Aortic Transcatheter Valves)
trial in which patients with severe aortic stenosis and high
surgical risk were randomized to TAVR or AVR. Cumu-
lative 12-month costs (assessed from a U.S. societal
perspective) and quality-adjusted life-years (QALYs) were
compared separately for the transfemoral (TF) and trans-
apical (TA) cohorts.
Results Although 12-month costs and QALYs were
similar for TAVR and AVR in the overall population, there
were important differences when results were stratiﬁed by
access site. In the TF cohort, total 12-month costs were
slightly lower with TAVR and QALYs were slightly higher
such that TF-TAVR was economically dominant compared
with AVR in the base case and economically attractive
(incremental cost-effectiveness ratio <$50,000/QALY) in
70.9% of bootstrap replicates. In the TA cohort, 12-month
costs remained substantially higher with TAVR, whereas
QALYs tended to be lower such that TA-TAVR was
economically dominated by AVR in the base case and
economically attractive in only 7.1% of replicates.
Conclusions In the PARTNER trial, TAVR was an
economically attractive strategy compared with AVR for
patients suitable for TF access. Future studies are necessary
to determine whether improved experience and outcomes
with TA-TAVR can improve its cost-effectiveness relative
to AVR. (THE PARTNER TRIAL: Placement of AoRTic
TraNscathetER Valve Trial; NCT00530894) (2).
Zotarolimus-Eluting Peripheral Stents for the
Treatment of Erectile Dysfunction in Subjects With
Suboptimal Response to Phosphodiesterase-5
Inhibitors
Objectives This study sought to evaluate the safety and
feasibility of zotarolimus-eluting stent implantation in focal
atherosclerotic lesions of the internal pudendal arteries
among men with erectile dysfunction (ED) and a subop-
timal response to phosphodiesterase-5 inhibitors.
Background ED, a common condition, is often mediated
by atherosclerosis. Current treatment options are limited.
Methods Male subjects with atherosclerotic ED and
a suboptimal response to phosphodiesterase-5 inhibitors
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safety and feasibility trial. A novel combination of clinical,
duplex ultrasound, and invasive angiographic factors were
used to determine eligibility for stent therapy. The primary
safety endpoint was any major adverse event 30 days after the
procedure. The primary feasibility end point was improve-
ment in the International Index of Erectile Function
(Erectile Dysfunction Domain) score 4 points in 50% of
subjects at 3 months. We report 6-month follow-up results,
including duplex ultrasound and angiography.
Results Forty-ﬁve lesions were treated with stents in 30
subjects. Procedural success was 100% with no major adverse
events through follow-up. The primary feasibility endpoint
at 6 months was achieved by 59.3% of intention-to-treat
subjects (95% conﬁdence interval: 38.8% to 77.6%) and
69.6% of per-protocol subjects (95% conﬁdence interval:
47.1% to 86.8%). Duplex ultrasound peak systolic velocity of
the cavernosal arteries increased from baseline by 14.4 
10.7 cm/s at 30 days and 22.5  23.7 cm/s at 6 months.
Angiographic binary restenosis (50% lumen diameter
stenosis) was reported in 11 (34.4%) of 32 lesions.
Conclusions Among patients with ED and limited
response with pharmacologic therapy, percutaneous stent
revascularization of the internal pudendal artery is feasible
and is associated with clinically meaningful improvement
in both subjective and objective measures of erectile func-
tion. (Safety and Feasibility of the Zotarolimus Stent in
Treating Males With Erectile Dysfunction (ED) (ZEN);
NCT01643200) (3).A Randomized Multicenter Study Comparing
a Paclitaxel Drug-Eluting Balloon With a Paclitaxel-
Eluting Stent in Small Coronary Vessels: The
BELLO (Balloon Elution and Late Loss
Optimization) Study
Objectives The aim of this study was to evaluate the efﬁ-
cacy of drug-eluting balloons (DEB) compared with
paclitaxel-eluting stents (PES) for the reduction of reste-
nosis in small vessels.
Background DEB have been shown to be effective in the
treatment of coronary in-stent restenosis, but data are
limited regarding their efﬁcacy in de novo disease.
Methods BELLO (Balloon Elution and Late Loss Opti-
mization) is a prospective, multicenter trial that randomized
182 patients with lesions located in small vessels (reference
diameter <2.8 mm) to treatment with paclitaxel DEB and
provisional bare-metal stenting (n ¼ 90) or PES implanta-
tion (n ¼ 92). The primary endpoint was noninferiority of
angiographic in-stent (in-balloon) late loss with a delta of
0.25 mm. Secondary endpoints were angiographic reste-
nosis, target lesion revascularization, and major adverse
cardiac events (MACE; death, myocardial infarction, target
vessel revascularization) at 6 months.
Results Baseline characteristics were well matched, except
for a smaller vessel size in the DEB group (2.15  0.27 mmvs. 2.25  0.24 mm; p ¼ 0.003). The majority (89%) of
lesions involved vessels with a diameter <2.5 mm. Bailout
stenting was required in 20% of lesions in the DEB group.
The primary endpoint of in-stent (in-balloon) late loss
was signiﬁcantly less with DEB compared with PES
(0.08  0.38 mm vs. 0.29  0.44 mm; difference 0.21;
95% CI: 0.34 to 0.09; pnoninferiority < 0.001;
psuperiority ¼ 0.001). At 6 months, DEB and PES were
associated with similar rates of angiographic restenosis (8.9%
vs. 14.1%; p¼ 0.25), target lesion revascularization (4.4% vs.
7.6%; p ¼ 0.37), and MACE (7.8% vs. 13.2%; p ¼ 0.77).
Conclusions Treatment of small-vessel disease with
a paclitaxel DEB was associated with less angiographic late
loss and similar rates of restenosis and revascularization as
a PES. (Balloon Elution and Late Loss Optimization
[BELLO]; Study NCT01086579) (4).A New Drug Delivery System for Intravenous
Coronary Thrombolysis With Thrombus Targeting
and Stealth Activity Recoverable by Ultrasound
Objectives The purpose of this study was to develop a new
intelligent drug delivery system for intracoronary throm-
bolysis with a strong thrombolytic effect without increasing
bleeding risk.
Background Rapid recanalization of an occluded coronary
artery is essential for better outcomes in acute myocardial
infarction. Catheter-based recanalization is widely accepted,
but it takes time to transport patients. Although the current
ﬁbrinolytic therapy can be started quickly, it cannot achieve
a high reperfusion rate. Recently, we generated nanoparticles
comprising tissue-type plasminogen activator (tPA), basic
gelatin, and zinc ions, which suppress tPA activity by 50%
with 100% recovery by ultrasound (US) in vitro.
Methods The thrombus-targeting property of nano-
particles was examined by an in vitro binding assay with
von Wilbrand factor and with a mouse arterial thrombosis
model in vivo. The thrombolytic efﬁcacy of nanoparticles
was evaluated with a swine acute myocardial infarction
model.
Results Nanoparticles bound to von Wilbrand factor
in vitro and preferentially accumulated at the site of
thrombus in a mouse model. In a swine acute myocardial
infarction model, plasma tPA activity after intravenous
injection of nanoparticles was approximately 25% of tPA
alone and was recovered completely by transthoracic US (1.0
MHz, 1.0 W/cm2). During US application, plasma tPA
activity near the affected coronary artery was recovered and
was higher than that near the femoral artery. Although
treatment with tPA alone (55,000 IU/kg) recanalized the
occluded coronary artery in only 1 of 10 swine, nanoparticles
containing the same dose of tPA with US achieved recan-
alization in 9 of 10 swine within 30 min.
Conclusions We developed an intelligent drug delivery
system with promising potential for better intravenous
coronary thrombolysis (5).
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e247Effects of Radial Versus Femoral Artery Access in
Patients With Acute Coronary Syndromes With or
Without ST-Segment Elevation
Objectives The purpose of this study was to determine the
consistency of the effects of radial artery access in patients
with ST-segment elevation myocardial infarction (STEMI)
and in those with non–ST-segment elevation acute coronary
syndrome (NSTEACS).
Background The safety associated with radial access may
translate into mortality beneﬁt in higher-risk patients, such
as those with STEMI.
Methods We compared efﬁcacy and bleeding outcomes
in patients randomized to radial versus femoral access in
RIVAL (RadIal Vs femorAL access for coronary inter-
vention trial) (N ¼ 7,021) separately in those with STEMI
(n ¼ 1,958) and NSTEACS (n ¼ 5,063). Interaction tests
between access site and acute coronary syndrome type were
performed.
Results Baseline characteristics were well matched
between radial and femoral groups. There were signiﬁcant
interactions for the primary outcome of death/myocardial
infarction/stroke/non–coronary artery bypass graft–related
major bleeding (p ¼ 0.025), the secondary outcome of
death/myocardial infarction/stroke (p ¼ 0.011) and
mortality (p ¼ 0.001). In STEMI patients, radial access
reduced the primary outcome compared with femoral
access (3.1% vs. 5.2%; hazard ratio [HR]: 0.60; p ¼
0.026). For NSTEACS, the rates were 3.8% and 3.5%,
respectively (p ¼ 0.49). In STEMI patients, death/
myocardial infarction/stroke were also reduced with radial
access (2.7% vs. 4.6%; HR 0.59; p ¼ 0.031), as was all-
cause mortality (1.3% vs. 3.2%; HR: 0.39; p ¼ 0.006),
with no difference in NSTEACS patients. Operator radial
experience was greater in STEMI versus NSTEACS
patients (400 vs. 326 cases/year, p < 0.0001). In primary
PCI, mortality was reduced with radial access (1.4% vs.
3.1%; HR: 0.46; p ¼ 0.041).
Conclusions In patients with STEMI, radial artery access
reduced the primary outcome and mortality. No such
beneﬁt was observed in patients with NSTEACS. The
radial approach may be preferred in STEMI patients when
the operator has considerable radial experience. (A Trial of
Trans-radial Versus Trans-femoral Percutaneous Coronary
Intervention (PCI) Access Site Approach in Patients With
Unstable Angina or Myocardial Infarction Managed With
an Invasive Strategy [RIVAL]; NCT01014273) (6).
Radial Versus Femoral Randomized Investigation
in ST-Segment Elevation Acute Coronary
Syndrome: The RIFLE-STEACS (Radial Versus
Femoral Randomized Investigation in ST-Elevation
Acute Coronary Syndrome) Study
Objectives The purpose of this study was to assess whether
transradial access for ST-segment elevation acute coronary
syndrome undergoing early invasive treatment is associatedwith better outcome compared with conventional trans-
femoral access.
Background In patients with acute coronary syndrome,
bleeding is a signiﬁcant predictor of worse outcome. Access
site complications represent a signiﬁcant source of bleeding
for those patients undergoing revascularization, especially
when femoral access is used.
Methods The RIFLE-STEACS (Radial Versus Femoral
Randomized Investigation in ST-Elevation Acute Coronary
Syndrome) was a multicenter, randomized, parallel-group
study. Between January 2009 and July 2011, 1,001 acute
ST-segment elevation acute coronary syndrome patients
undergoing primary/rescue percutaneous coronary interven-
tion were randomized to the radial (500) or femoral (501)
approach at 4 high-volume centers. The primary endpoint
was the 30-day rate of net adverse clinical events (NACEs),
deﬁned as a composite of cardiac death, stroke, myocardial
infarction, target lesion revascularization, and bleeding).
Individual components of NACEs and length of hospital
stay were secondary endpoints.
Results The primary endpoint of 30-day NACEs occurred
in 68 patients (13.6%) in the radial arm and 105 patients
(21.0%) in the femoral arm (p ¼ 0.003). In particular,
compared with femoral, radial access was associated with
signiﬁcantly lower rates of cardiac mortality (5.2% vs. 9.2%,
p ¼ 0.020), bleeding (7.8% vs. 12.2%, p ¼ 0.026), and
shorter hospital stay (5 days ﬁrst to third quartile range, 4 to
7 days] vs. 6 [range, 5 to 8 days]; p ¼ 0.03).
Conclusions Radial access in patients with ST-segment
elevation acute coronary syndrome is associated with
signiﬁcant clinical beneﬁts, in terms of both lower morbidity
and cardiac mortality. Thus, it should become the recom-
mended approach in these patients, provided adequate
operator and center expertise is present. (Radial Versus
Femoral Investigation in ST Elevation Acute Coronary
Syndrome [RIFLE-STEACS]; NCT01420614) (7).Discontinuation of Long-Term Clopidogrel Therapy
Is Associated With Death and Myocardial
Infarction After Saphenous Vein Graft
Percutaneous Coronary Intervention
Objectives This study sought to examine the pattern of
death and myocardial infarction (MI) after clopidogrel
cessation in patients undergoing percutaneous coronary
intervention (PCI) of the saphenous vein graft (SVG).
Background The timing and incidence of adverse events by
different durations of clopidogrel therapy after SVG PCI
remain unknown.
Methods This is a cohort study of patients undergoing
SVG PCI between 2000 and 2009, followed for all-cause
mortality or MI after stopping clopidogrel. Incidence rates
were calculated across different time periods after clopi-
dogrel cessation. Adjusted incidence rate ratios (IRR) were
calculated with multivariable regression (piecewise expo-
nential and Poisson).
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PCI, of which 411 were event-free at the time of clopidogrel
cessation. The incidence rate (95% conﬁdence interval:
[CI])/1,000 person-days of death or MI after stopping
clopidogrel in the time intervals of 0 to 90 days, 91 to 365
days, and 1 to 2 years were 1.26 (95% CI: 0.93 to 1.70), 0.41
(95% CI: 0.30 to 0.56), and 0.41 (95% CI: 0.30 to 0.55),
respectively. In multivariable analyses, the overall IRR (95%
CI) for death or MI in the 0- to 90-day interval after
stopping clopidogrel compared with the 91- to 365-day
interval was 2.58 (95% CI: 1.64 to 4.07). Similar results
were observed over a broad range of clopidogrel treatment
durations (<6 months, 6 months to 1 year, 1 to 2 years, or
>2 years). The results were also consistent across subgroups,
including sex, stent type, stent diameter, PCI period, and
diabetes status. When death alone was evaluated, there
remained a signiﬁcant increase in the event rate in the 0- to
90-day interval compared with the 91- to 365-day interval
(IRR: 2.33; 95% CI: 1.32 to 4.11).
Conclusions A clustering of events was observed in the
initial 0 to 90 days after clopidogrel cessation in all treatment
durations of clopidogrel investigated after SVG PCI. These
results might have important implications in high-risk
cohorts undergoing PCI. Additional studies are needed to
elucidate the mechanisms underlying the early clustering of
events after clopidogrel cessation (8).A Prospective Randomized Multicenter
Comparison of Balloon Angioplasty and
Infrapopliteal Stenting With the Sirolimus-Eluting
Stent in Patients With Ischemic Peripheral Arterial
Disease: 1-Year Results From the ACHILLES Trial
Objectives The study investigated the efﬁcacy and safety of
a balloon expandable, sirolimus-eluting stent (SES) in
patients with symptomatic infrapopliteal arterial disease.
Background Results of infrapopliteal interventions using
balloon angioplasty and/or bare stents are limited by a rela-
tively high restenosis rate, which could be potentially
improved by stabilizing the lesion with a SES.
Methods Two hundred patients (total lesion length 27 
21 mm) were randomized to infrapopliteal SES stenting or
percutaneous transluminal balloon angioplasty (PTA). The
primary endpoint was 1-year in-segment binary restenosis by
quantitative angiography.
Results Ninety-nine and 101 patients (mean age 73.4
years; 64% diabetics) were randomized to SES and PTA,
respectively (8 crossover bailout cases to SES). At 1 year,
there were lower angiographic restenosis rates (22.4% vs.
41.9%, p ¼ 0.019), greater vessel patency (75.0% vs. 57.1%,
p ¼ 0.025), and similar death, repeat revascularization,
index-limb amputation rates, and proportions of patients
with improved Rutherford class for SES versus PTA.
Conclusions SES implantation may offer a promising
therapeutic alternative to PTA for treatment of infrapopli-
teal peripheral arterial disease (9).Long-Term Outcomes of Older Diabetic Patients
After Percutaneous Coronary Stenting in the
United States: A Report From the National
Cardiovascular Data Registry, 2004 to 2008
Objectives The purpose of this study was to characterize
long-term outcomes of percutaneous coronary intervention
(PCI) in elderly diabetic patients in routine practice.
Background Although drug-eluting stent (DES) implan-
tation in diabetic patients is common practice, pivotal
randomized trials enrolled <2,500 diabetic patients, most of
whom were <65 years of age.
Methods Data from 405,679 patients 65 years old (33%
had diabetes mellitus, of whom 9.8% had insulin-treated
diabetes mellitus [ITDM], and 23.3% had noninsulin-
treated diabetes mellitus [NITDM]) undergoing PCI from
2004 to 2008 at 946 U.S. hospitals were linked with
Medicare inpatient claims data.
Results Over 18.4 months median follow-up (25th to 75th
percentile: 8.0 to 30.8 months), ITDM/NITDM were
associated with signiﬁcantly increased adjusted hazards of
death (hazard ratio [HR]: 1.91 [95% conﬁdence interval
(CI): 1.86 to 1.96], p < 0.001/HR: 1.32 [95% CI: 1.29 to
1.35], p < 0.001) and myocardial infarction (HR: 1.87 [95%
CI: 1.79 to 1.95], p < 0.001/HR: 1.29 [95% CI: 1.25 to
1.34], p < 0.001) compared with nondiabetic patients. The
adjusted hazard of undergoing additional revascularization
procedures (HR: 1.14 [95% CI: 1.10 to 1.18, p< 0.001/HR:
1.08 [95% CI: 1.05 to 1.10], p < 0.001) and subsequent
hospitalization for bleeding (HR: 1.40 [95% CI: 1.31 to
1.50], p < 0.001/HR: 1.18 [95% CI: 1.13 to 1.24], p <
0.001) were also signiﬁcantly increased. Compared with
nondiabetic patients, there were similar excess risks associ-
ated with ITDM/NITDM in patients selected for DES and
BMS use; selection for use of DES was associated with
reductions in death in ITDM/NITDM and myocardial
infarction in ITDM, but not NITDM. There were no
signiﬁcant interactions between diabetes status and stent
type for revascularization or bleeding.
Conclusions One-third of older patients undergoing PCI
have diabetes. After adjustment for other comorbidities,
diabetes, particularly ITDM, remains independently and
strongly associated with increased long-term adverse events
after both DES and BMS implantation (10).
Comparison of the Prognosis of Spontaneous and
Percutaneous Coronary Intervention–Related
Myocardial Infarction
Objectives This study compared prognoses of myocar-
dial infarction related to percutaneous coronary interven-
tion (PCI, procedural MI) using increasing creatine
kinase-myocardial band (CK-MB) thresholds with spon-
taneous MI.
Background Procedural MI usually is deﬁned by a CK-
MB elevation of more than 3 times the upper limit of
normal (ULN), but higher thresholds have been proposed.
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protein IIb/IIIa Inhibition in Non–ST-Segment Elevation
Acute Coronary Syndrome) study and the SYNERGY
(Superior Yield of the New strategy of Enoxaparin, Revas-
cularization and GlYcoprotein IIb/IIIa inhibitors) study
treated with PCI were included. The primary end point was
1-year all-cause mortality from 24 h after PCI. To deter-
mine an enzymatic threshold for procedural MI with
a prognosis similar to that of spontaneous MI, we redeﬁned
procedural MI using increasing CK-MB thresholds and
compared corresponding hazard ratios with those of spon-
taneous MI (CK-MB more than twice the ULN). Hazard
ratios for mortality for procedural and spontaneous MI were
calculated using Cox proportional hazards regression and
Global Registry of Acute Cardiac Events covariates for risk
adjustment.
Results Nine thousand eighty-seven patients who under-
went PCI (46.8%) were included; 773 procedural MI and
239 spontaneous MI occurred within 30 days. Adjusted
hazard ratios for 1-year death were 1.39 (95% conﬁdence
interval [CI]: 1.01 to 1.89) for procedural MI and 5.37 (95%
CI: 3.90 to 7.38) for spontaneous MI. The CK-MB
threshold for procedural MI that achieved the same prog-
nosis as spontaneous MI was 27.7 times the ULN (95% CI:
13.9 to 58.4), but this differed between the SYNERGY
study (57.9 times the ULN, 95% CI: 17.9 to 63.6) and the
EARLY-ACS study (20.4 times the ULN, 95% CI: 5.16 to
24.2). Of all procedural MI, 49 (6%) had CK-MB elevations
of 27.7 or more times the ULN.
Conclusions The current enzymatic deﬁnition of proce-
dural MI (CK-MB more than 3 times the ULN) used in
clinical trials is less strongly associated with death than that
of spontaneous MI. Procedural MI achieves similar prog-
nosis for 1-year mortality when much higher CK-MB
thresholds are applied (11).Retrograde Coronary Chronic Total Occlusion
Revascularization: Procedural and In-Hospital
Outcomes From a Multicenter Registry in the
United States
Objectives This study sought to examine the contemporary
outcomes of retrograde chronic total occlusion (CTO)
interventions among 3 experienced U.S. centers.
Background The retrograde approach, pioneered and
developed in Japan, has revolutionized the treatment of
coronary CTO, yet limited information exists on procedural
efﬁcacy, safety, and reproducibility of outcomes in other
settings.
Methods Between 2006 and 2011, 462 consecutive retro-
grade CTO interventions were performed at 3 U.S. insti-
tutions. Patient characteristics, procedural outcomes, and in-
hospital clinical events were ascertained.
Results Mean patient age was 65  9.7 years, 84% were
men, and 50% had prior coronary artery bypass surgery. The
CTO target vessel was the right coronary artery (66%),circumﬂex (18%), left anterior descending artery (15.5%),
and left main artery or bypass graft (0.5%). The retrograde
approach was used as the primary method in 46% of cases
and after failed antegrade recanalization in 54%. Retrograde
collateral vessels were septal (68%), epicardial (24%), and
bypass grafts (8%). Technical and procedural success was
81.4% (n ¼ 376) and 79.4% (n ¼ 367), respectively. The
mean contrast volume and ﬂuoroscopy time were 345  177
ml and 61  40 min, respectively. A major complication
occurred in 12 patients (2.6%). In multivariable analysis,
years since initiation of retrograde CTO percutaneous
coronary intervention (PCI) at each center, female sex, and
ejection fraction 40% were associated with higher technical
success.
Conclusions Among selected U.S. programs, retrograde
CTO PCI is often performed in patients with prior coronary
bypass graft surgery and is associated with favorably high
success and low complication rates (12).Improved Survival Associated With Pre-Hospital
Triage Strategy in a Large Regional ST-Segment
Elevation Myocardial Infarction Program
Objectives This study sought to compare the 1-year
survival of patients diagnosed with ST-segment elevation
myocardial infarction (STEMI) and transferred via pre-
hospital triage strategy for primary percutaneous coronary
intervention (PCI) with those transferred via inter-hospital
transfer within a large suburban region in Canada.
Background Primary angioplasty is the preferred therapy
for STEMI if it is done within 90 min of door-to-balloon
time by an experienced team in a high-volume center.
Methods Patients identiﬁed to have STEMI on the
ambulances equipped with electrocardiography bypassed the
local hospitals and were sent directly to the PCI center,
whereas other patients that were picked up by ambulances
without electrocardiographic equipment were transported to
the local hospitals where the diagnosis of STEMI was made
and were re-routed to the PCI center. Patient demographic
data, clinical presentation, procedural data, in-hospital
course, and vital statistics were prospectively recorded in
a provincial cardiac registry.
Results A total of 167 patients were brought into the PCI
center via pre-hospital triage strategy, and 427 patients were
brought in via inter-hospital transfer during a 2-year study
period. Baseline demographic data, infarct location, cardio-
vascular history, and hemodynamic status were similar
between the 2 groups. When compared with the inter-
hospital transfer group, a signiﬁcantly higher proportion of
pre-hospital triaged patients achieved the 90-min door-to-
balloon time benchmark (80.4% vs. 8.7%, p < 0.001) and
post-procedural Thrombolysis In Myocardial Infarction ﬂow
grade 3 after the emergency procedure (97.6% vs. 91.4%,
p ¼ 0.02). In addition, the pre-hospital triage strategy was
associated with a signiﬁcantly lower 30-day (5.4% vs. 13.3%,
p ¼ 0.006) and 1-year (6.6% vs. 17.5%, p ¼ 0.019)
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for survival at 1 year (hazard ratio: 0.37, 95% conﬁdence
interval: 0.18 to 0.75, p ¼ 0.006).
Conclusions Pre-hospital triage strategy was associated
with improved survival rate in patients undergoing primary
PCI in a regional STEMI program (13).CYP2C19*2 and *17 Alleles Have a Signiﬁcant
Impact on Platelet Response and Bleeding Risk in
Patients Treated With Prasugrel After Acute
Coronary Syndrome
Objectives The present study was designed to assess the
effect of genetic variants on chronic biological response to
prasugrel and bleeding complications.
Background CYP2C19*2 loss-of-function allele and
CYP2C19*17 gain-of-function allele have been linked with
response to clopidogrel, but preliminary data did not show
any signiﬁcant inﬂuence of these alleles on prasugrel effect.
Methods A total of 213 patients undergoing successful
coronary stenting for acute coronary syndrome and dis-
charged with prasugrel 10 mg daily were included. Prasugrel
response was assessed at 1 month with the platelet reactivity
index (PRI) vasodilator-stimulated phosphoprotein (VASP)
and high on-treatment platelet reactivity (HTPR) deﬁned as
PRI VASP > 50% and hyper-response as PRI VASP <75th
percentile (PRI VASP < 17%). CYP2C19*2 and
CYP2C19*17 genotyping were performed.
Results Carriers of loss-of-function *2 allele had signiﬁ-
cantly higher PRI VASP than noncarriers (33  15% vs.
27  14%, p ¼ 0.03) and higher rate of HTPR (16% vs. 4%,
p ¼ 0.01). Conversely, carriers of *17 gain-of-function allele
had signiﬁcantly lower PRI VASP than noncarriers (25 
13% vs. 31  15%, p ¼ 0.03, p ¼ 0.03), lower rate of HTPR
(1% vs. 10%, p ¼ 0.02), higher rate of hyper-response (34%
vs. 21%, p ¼ 0.02), and higher rate of bleeding complica-
tions than noncarriers: 23% versus 11%, (odds ratio [95%
conﬁdence interval]: 2.5 [1.2 to 5.4]; p ¼ 0.02). No
signiﬁcant inﬂuence of genotypes on platelet reactivity
assessed by adenosine diphosphate–induced platelet aggre-
gation was observed.
Conclusions The present study shows a signiﬁcant inﬂu-
ence of CYP2C19*2 and *17 alleles on response to chronic
treatment by prasugrel 10 mg daily and occurrence of
bleeding complications (14).Safety and Efﬁcacy of High- Versus Low-Dose
Aspirin After Primary Percutaneous Coronary
Intervention in ST-Segment Elevation Myocardial
Infarction: The HORIZONS-AMI (Harmonizing
Outcomes With Revascularization and Stents in
Acute Myocardial Infarction) Trial
Objectives This study sought to examine the relationship
between the aspirin dose prescribed at hospital discharge and
long-term outcomes after ST-segment elevation myocardialinfarction in patients treated with primary percutaneous
coronary intervention (PCI).
Background Patients with ST-segment elevation myocar-
dial infarction who undergo primary PCI are prescribed
maintenance aspirin doses that vary between 75 and 325 mg
daily. Whether the dose of aspirin affects long-term patient
outcomes is unknown.
Methods We compared 3-year outcomes in patients who
were prescribed high-dose (>200 mg daily) versus low-dose
(200 mg daily) aspirin from the large-scale HORIZONS-
AMI (Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction) trial.
Results Among 2,851 patients, 2,289 patients (80.3%)
were discharged on low-dose aspirin and 562 patients
(19.7%) were discharged on high-dose aspirin. Patients
discharged on high-dose rather than low-dose aspirin were
more likely to have a history of hypertension, hyperlipid-
emia, family history of premature coronary disease, prior
treatment with PCI or coronary artery bypass surgery, and to
be enrolled in the United States. Patients discharged on
high-dose aspirin had higher 3-year rates of major adverse
cardiovascular events, reinfarction, ischemic target vessel
revascularization, major bleeding, and stent thrombosis.
After multivariable analysis, discharge on high-dose aspirin
was an independent predictor of major bleeding (hazard
ratio: 2.80; 95% conﬁdence interval: 1.31 to 5.99; p ¼
0.008), but not of adverse ischemic events.
Conclusions In patients with ST-segment elevation
myocardial infarction undergoing primary PCI, discharge on
high-dose rather than low-dose aspirin may increase the rate
of major bleeding without providing additional ischemic
beneﬁt (15).Impact of a New Conduction Defect After
Transcatheter Aortic Valve Implantation on Left
Ventricular Function
Objectives This study sought to evaluate the impact of new
conduction defects after transcatheter aortic valve implan-
tation (TAVI) on the evolution of left ventricular (LV)
function during 1-year follow-up.
Background New left bundle branch block (LBBB) or
need for permanent pacing due to atrioventricular (AV)
block are frequent after TAVI.
Methods A total of 90 consecutive patients treated with
TAVI and who had 12-month echocardiographic follow-up
were included in the study. In 39 patients, a new conduction
defect (new LBBB or need for permanent pacemaker
activity.) persisted 1 month after TAVI. In 51 patients, no
persistent new conduction defect was observed. Two-
dimensional echocardiography using parasternal short-axis,
apical 4-chamber, and apical 2-chamber views was per-
formed before TAVI and at 1-year follow-up to determine
LV volumes and ejection fraction based on Simpson’s rule.
Speckle-tracking echocardiography was applied using stan-
dard LV short-axis images to assess the effect of new
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LV segments as a parameter of LV dyssynchrony.
Results New conduction defects resulted in marked
heterogeneity in time-to-peak strain between the 6
analyzed short-axis segments. During 1-year follow-up after
TAVI, there was a signiﬁcant increase in left ventricular
ejection fraction (LVEF) in patients without new LBBB
(53  11% pre TAVI to 59  10% at follow-up; p <
0.001), whereas there was no change in LVEF in patients
with a new conduction defect (52  11% pre TAVI to
51  12% at follow-up, p ¼ 0.740). Change in LV end-
systolic volume was also signiﬁcantly different between
patient groups (1.0  14.2 vs. 11.2  15.7 ml, p ¼
0.042). New conduction defect and LVEF at baseline were
independent predictors of reduced LVEF at 12-month
follow-up after TAVI.
Conclusions LVEF improves after TAVI for treatment of
severe aortic stenosis in patients without new conduction
defects. In patients with a new conduction defect after
TAVI, there is no improvement in LVEF at follow-up (16).Incidence, Management, and Outcomes of Cardiac
Tamponade During Transcatheter Aortic Valve
Implantation: A Single-Center Study
Objectives The aim of this study was to explore the inci-
dence, causes, and outcomes of cardiac tamponade in
patients undergoing transcatheter aortic valve implantation
(TAVI).
Background Use of TAVI is increasing, but the procedure
is vulnerable to complications, given the cohort of patients.
Cardiac tamponade is a possible complication, and there is
a scarcity of data on the incidence and outcomes of cardiac
tamponade during TAVI.
Methods All patients who sustained cardiac tamponade
during or post-TAVI between 2007 and 2012 were included
in the study.
Results Of 389 patients who underwent TAVI, 17 (4.3%)
had cardiac tamponade. The mean age was 82.3  3.7 years,
and most were women (n ¼ 12, 70.6%). Causes of cardiac
tamponade were right ventricular perforation by temporary
pacemaker (9 patients, 52.9%), annular rupture or aortic
dissection (4 patients, 23.5%), and tear in the left ventricular
free wall caused by Amplatz stiff wire or catheters (4
patients, 23.5%). Mortality occurred in 4 patients (23.5%),
and all had tamponade caused by injury to the high-
pressured left-sided circulation (left ventricle and aorta).
Most patients (n ¼ 14, 82.4%) sustained cardiac tamponade
during the procedured2 patients (11.7%) within 24 h, and
1 patient after 24 h.
Conclusions Cardiac tamponade during TAVI is not
frequent but is associated with high mortality rates especially
when left-sided structures are involved. Meticulous handling
of the equipment and improvements in the safety of
currently used devices could further reduce the occurrence of
this complication (17).A Prospective Randomized Trial of Thrombectomy
Versus No Thrombectomy in Patients With
ST-Segment Elevation Myocardial Infarction and
Thrombus-Rich Lesions: MUSTELA (MUltidevice
Thrombectomy in Acute ST-Segment ELevation
Acute Myocardial Infarction) Trial
Objectives The aim of this study was to evaluate whether
thrombectomy during primary percutaneous coronary
intervention (pPCI) in patients with high thrombus burden
improves myocardial reperfusion and reduces infarct size.
Background Thrombectomy aims at reducing distal
thrombotic embolization during pPCI, improving myocar-
dial reperfusion and clinical outcome.
Methods We randomized 208 patients with high thrombus
burden in a 1:1 ratio to either pPCI with thrombectomy
(Group T) or standard pPCI (Group S). Thrombectomy
was performed with either rheolytic or manual aspiration
catheters. Three-month magnetic resonance imaging was
performed to assess infarct size and transmurality and
microvascular obstruction (MVO). The primary endpoints
were ST-segment elevation resolution (STR) >70% at 60
min and 3-month infarct size.
Results The baseline proﬁle was similar between groups,
except for a higher rate of initial Thrombolysis In Myocardial
Infarction ﬂow grade 3 in Group S (p ¼ 0.002). Group T
showed a signiﬁcantly higher rate of STR (57.4% vs. 37.3%;
p ¼ 0.004) and of ﬁnal myocardial blush 3 (68.3% vs. 52.9%;
p¼ 0.03). Group T and Group S did not differ with regard to
infarct size (20.4  10.5% vs. 19.3  10.6%; p ¼ 0.54) and
transmurality (11.9 12.0% vs. 11.6 12.7%; p¼ 0.92), but
Group T showed signiﬁcantly less MVO (11.4% vs. 26.7%;
p ¼ 0.02) and a higher prevalence of inhomogeneous scar
(p < 0.0001). One-year freedom from major adverse cardiac
events was similar between groups.
Conclusions Thrombectomy as an adjunct to pPCI in
patients with high thrombus load yielded better post-
procedural STR and reduced MVO at 3 months but was
not associated with a reduction in infarct size and trans-
murality. Thromboaspiration in Patients With High
Thrombotic Burden Undergoing Primary Percutaneous
(Coronary Intervention; NCT01472718) (18).
Self-Expanding Versus Balloon-Expandable Stents
in Acute Myocardial Infarction: Results From the
APPOSITION II Study: Self-Expanding Stents in
ST-Segment Elevation Myocardial Infarction
Objectives This study sought to investigate whether self-
expanding stents are more effective than balloon-
expandable stents for reducing stent malapposition at 3
days after implantation in patients with ST-segment eleva-
tion myocardial infarction undergoing primary percutaneous
coronary intervention.
Background Acute myocardial infarction is associated with
vasoconstriction and large thrombus burden. Resolution of
vasoconstriction and thrombus load during the ﬁrst hours to
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lead to stent undersizing and malapposition, which may
subsequently lead to stent thrombosis or restenosis. In
addition, aggressive stent deployment may cause distal
embolization.
Methods Eighty patients with ST-segment elevation
myocardial infarction undergoing primary percutaneous
coronary intervention were randomized to receive a self-
expanding stent (STENTYS, STENTYS SA, Paris,
France) (n ¼ 43) or a balloon-expandable stent (VISION,
Abbott Vascular, Santa Clara, California; or Driver, Med-
tronic, Minneapolis, Minnesota) (n ¼ 37) at 9 European
centers. The primary endpoint was the proportion of stent
strut malapposition at 3 days after implantation measured by
optical coherence tomography. Secondary endpoints
included major adverse cardiac events (cardiac death,
recurrent myocardial infarction, emergent bypass surgery, or
clinically driven target lesion revascularization).
Results At 3 days after implantation, on a per-strut basis,
a lower rate of malapposed stent struts was observed by
optical coherence tomography in the self-expanding stent
group than in the balloon-expandable group (0.58% vs.
5.46%, p < 0.001). On a per-patient basis, none of the
patients in the self-expanding stent group versus 28% in the
balloon-expandable group presented 5% malapposed struts
(p < 0.001). At 6 months, major adverse cardiac events were
2.3% versus 0% in the self-expanding and balloon-
expandable groups, respectively (p ¼ NS).
Conclusions Strut malapposition at 3 days is signiﬁcantly
lower in ST-segment elevation myocardial infarction patients
allocated to self-expanding stents when than in those
allocated to balloon-expandable stents. The impact of this
difference on clinical outcome and the risk of late stent
thrombosis need to be evaluated further. (Randomized Com-
parison Between the STENTYS Self-expanding Coronary
Stent and a Balloon-expandable Stent in Acute Myocardial
Infarction [APPOSITION II]; NCT01008085) (19).Impact of Post-Procedural Aortic Regurgitation on
Mortality After Transcatheter Aortic Valve
Implantation
Objectives The goal of the study was to clarify the impact
of post-procedural aortic regurgitation (post-AR) grade 2/4
on clinical outcomes.
Background Post-AR >2/4 is known to be associated with
poor short- to midterm outcome after transcatheter aortic
valve implantation (TAVI).
Methods We compared clinical outcomes in 400 consec-
utive TAVI recipients according to post-AR grade: grade
0 or 1 (group 1 ¼ 74.8%), grade 2 (group 2 ¼ 22.2%), or
grade 3 or 4 (group 3 ¼ 3.0%).
Results The mean age was similar in the 3 groups (83.4 
6.1 years) as was the logistic EuroSCORE (22.5  11.4%,
24.5  11.6%, and 21.5  9.4%, p ¼ 0.28) and annulus size
(22.0  1.8, 22.2  2.1, and 22.5  2.1 mm, p ¼ 0.53). TheEdwards valve was most frequently used in group 1
compared with groups 2 and 3 (89.3%, 78.7%, and 83.3%,
p ¼ 0.03), and the implanted valve size was similar in all
groups (25.6  2.0, 25.4  2.2, and 25.5  2.2 mm,
respectively, p ¼ 0.69). Post-dilation was required more
frequently in group 3 (4.7%, 24.1%, and 50.0%, respectively,
p < 0.01). Post-procedural increase in mitral regurgitation
was in line with the post-AR grade (0.78  0.73, 1.22 
0.80, and 1.89  0.78, respectively, p < 0.01). Despite the
absence of difference in 30-day mortality, longer-term
outcome was signiﬁcantly poorer in patients with AR
grade 2 than in those with AR grade 0 or 1 (log-rank p <
0.01), albeit better than in patients with AR grade 3 or 4
(p ¼ 0.04), regardless of TAVI type and left ventricular
function. Post-AR 2/4 was also identiﬁed as an inde-
pendent predictor of mid- to long-term mortality (hazard
ratio: 1.68, 95% conﬁdence interval: 1.21 to 1.44, p < 0.01).
Conclusions Post-AR grade 2/4 after TAVI is associated
with worse outcome compared with grade 0 or 1. Careful
valve selection and post-dilation when required to avoid
post-AR grade 2 may contribute to improved clinical
outcome after TAVI (20).
Drug–Drug Interactions in Cardiovascular
Catheterizations and Interventions CME
Patients presenting for invasive cardiovascular procedures are
frequently taking a variety of medications aimed to treat risk
factors related to heart and vascular disease. During the
procedure, antithrombotic, sedative, and analgesic medica-
tions are commonly needed, and after interventional
procedures, new medications are often added for primary
and secondary prevention of ischemic events. In addition to
these prescribed medications, the use of over-the-counter
drugs and supplements continues to rise. Most elderly
patients, for example, are taking 5 or more prescribed
medications and 1 or more supplements, and they often have
some degree of renal insufﬁciency. This polypharmacy might
result in drug–drug interactions that affect the balance of
thrombotic and bleeding events during the procedure and
during long-term treatment. Mixing of anticoagulants, for
instance, might lead to periprocedural bleeding, and this is
associated with an increase in long-term adverse events.
Furthermore, the range of possible interactions with thie-
nopyridine antiplatelets is of concern, because these drugs
are essential to immediate and extended interventional
success. The practical challenges in the ﬁeld are greatdsome
drug–drug interactions are likely present yet not well
understood due to limited assays, whereas other interactions
have well-described biological effects but seem to be more
theoretical, because there is little to no clinical impact.
Interventional providers need to be attentive to the potential
for drug–drug interaction, the associated harm, and the
appropriate action, if any, to minimize the potential for
medication-related adverse events. This review will focus on
drug–drug interactions that have the potential to affect
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complications or compromising longer-term outcome (21).The Effect of Age on Outcomes of Coronary Artery
Bypass Surgery Compared With Balloon
Angioplasty or Bare-Metal Stent Implantation
Among Patients With Multivessel Coronary
Disease: A Collaborative Analysis of Individual
Patient Data From 10 Randomized Trials
Objectives This study sought to assess whether patient age
modiﬁes the comparative effectiveness of coronary artery
bypass graft (CABG) surgery and percutaneous coronary
intervention (PCI).
Background Increasingly, CABG and PCI are performed
in older patients to treat multivessel disease, but their
comparative effectiveness is uncertain.
Methods Individual data from 7,812 patients randomized in
1 of 10 clinical trials of CABG or PCI were pooled. Age was
analyzed as a continuous variable in the primary analysis and
was divided into tertiles for descriptive purposes (56.2 years,
56.3 to 65.1 years,65.2 years). The outcomes assessed were
death, myocardial infarction and repeat revascularization over
complete follow-up, and angina at 1 year.
Results Older patients were more likely to have hyperten-
sion, diabetes, and 3-vessel disease compared with younger
patients (p < 0.001 for trend). Over a median follow-up of
5.9 years, the effect of CABG versus PCI on mortality
varied according to age (interaction p < 0.01), with adjusted
CABG-to-PCI hazard ratios and 95% conﬁdence intervals
(CI) of 1.23 (95% CI: 0.95 to 1.59) in the youngest tertile;
0.89 (95% CI: 0.73 to 1.10) in the middle tertile; and 0.79
(95% CI: 0.67 to 0.94) in the oldest tertile. The CABG-to-
PCI hazard ratio of less than 1 for patients 59 years of age
and older. A similar interaction of age with treatment was
present for the composite outcome of death or myocardial
infarction. In contrast, patient age did not alter the
comparative effectiveness of CABG and PCI on the
outcomes of repeat revascularization or angina.
Conclusions Patient age modiﬁes the comparative effec-
tiveness of CABG and PCI on hard cardiac events, with
CABG favored at older ages and PCI favored at younger
ages (22).The Risk of Adverse Cardiac and Bleeding Events
Following Noncardiac Surgery Relative to
Antiplatelet Therapy in Patients With Prior
Percutaneous Coronary Intervention
Noncardiac surgery (NCS) may be required within the ﬁrst
year after percutaneous coronary intervention (PCI) in
approximately 4% of patients and is the second most
common reason for premature discontinuation of anti-
platelet therapy (APT), which may, in turn, increase the
risk of perioperative ischemic events, particularly stent
thrombosis. Its continuation may increase the risk ofperioperative bleeding. We review current information on
the incidence of these events, particularly related to APT,
describe potentially useful strategies to minimize the risks of
adverse outcomes, and provide recommendations on APT
use. Percutaneous coronary intervention (PCI) is the most
common strategy for myocardial revascularization, with
more than a million procedures performed annually in the
United States alone (1). Enthusiasm has been tempered by
the potentially lethal complication of stent thrombosis (ST)
(2). The most important ST predictor is premature
discontinuation of dual antiplatelet therapy (DAPT) (3,4).
Apart from noncompliance, the second most common
reason for early discontinuation of either DAPT or single
antiplatelet therapy (APT) is the need for noncardiac surgery
(NCS), accounting for one-third of cases (4).
In both retrospective (5) and prospective (6) studies,
approximately 4% of patients undergo NCS within the ﬁrst
year after index PCI (approximately 40,000 patients in the
United States by current PCI usage). This large cohort
presents a challenge for the treating surgeon, anesthesiologist,
and cardiologist in managing APT in the perioperative
period. On the basis of current American College of Cardi-
ology/American Heart Association guidelines, approximately
two-thirds of all NCS procedures in the ﬁrst year after index
PCI are classiﬁed as moderate to high risk for major adverse
cardiac events (MACE) (5,6,7). Surgical stress creates
a prothrombotic state due to increased platelet activation and
decreased ﬁbrinolysis, explaining in part the well-described
MACE increase in the perioperative period (8,9,10).
The small, but persistent, ST risk long after PCI raises the
important issue of perioperative management. On the one
hand, MACE, particularly ST, is a concern after APT
discontinuation; with its continuation, bleeding looms as
a persistent danger. In this paper, we review studies of NCS
outcomes following PCI with either bare-metal stents
(BMS) or drug-eluting stents (DES), particularly in relation
to APT, and potential strategies to decrease these risks (23).A Contemporary View of Diagnostic Cardiac
Catheterization and Percutaneous Coronary
Intervention in the United States: A Report From
the CathPCI Registry of the National
Cardiovascular Data Registry, 2010 Through June
2011
Objectives This study sought to provide a report to the
public of data from the CathPCI Registry of the National
Cardiovascular Data Registry.
Background The CathPCI Registry collects data from
approximately 85% of the cardiac catheterization laboratories
in the United States.
Methods Data were summarized for 6 consecutive calendar
quarters beginning January 1, 2010, and ending June 30,
2011. This report includes 1,110,150 patients undergoing
only diagnostic cardiac catheterization and 941,248 under-
going percutaneous coronary intervention (PCI).
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on-site cardiac surgery was not available in 83% of facilities
performing fewer than 200 PCIs annually, with these facili-
ties representing 32.6% of the facilities reporting, but per-
forming only 12.4% of the PCIs in this data sample. Patients
65 years of age or older represented 38.7% of those under-
going PCI, with 12.3% being 80 years of age or older. Almost
80% of PCI patients were overweight (body mass index 25
kg/m2), 80% had dyslipidemia, and 27.6% were current or
recent smokers. Among patients undergoing elective PCI,
52% underwent a stress study before the procedure, with
stress myocardial perfusion being used most frequently.
Calcium scores and coronary computed tomography angi-
ography were used very infrequently (<3%) before diagnostic
or PCI procedures. Radial artery access was used in 8.3% of
diagnostic and 6.9% of PCI procedures. Primary PCI was
performed with a median door-to-balloon time of 64.5 min
for nontransfer patients and 121 min for transfer patients. In-
hospital risk-adjusted mortality in ST-segment elevation
myocardial infarction patients was 5.2% in this sample.
Conclusions Data from the CathPCI Registry provide
a contemporary view of the current practice of invasive
cardiology in the United States (24).Assessing the Association of Appropriateness of
Coronary Revascularization and Clinical Outcomes
for Patients With Stable Coronary Artery Disease
Objectives The study assessed the appropriateness of
coronary revascularization in Ontario, Canada, and exam-
ined its association with longer-term outcomes.
Background Although appropriate use criteria for coronary
revascularization have been developed to improve the
rational use of cardiac invasive procedures, it is unknown
whether greater adherence to appropriateness guidelines is
associated with improved clinical outcomes in stable coro-
nary artery disease.
Methods A population-based cohort of stable patients
undergoing cardiac catheterization was assembled from
April 1, 2006, to March 31, 2007. The appropriateness for
coronary revascularization at the time of coronary angiog-
raphy was retrospectively adjudicated using the appropriate
use criteria. Clinical outcomes between coronary revascu-
larization and medical treatment without revascularization,
stratiﬁed by appropriateness categories, were compared.
Results In 1,625 patients with stable coronary artery
disease, percutaneous coronary intervention or coronary
artery bypass grafting was only performed in 69% who had
an appropriate indication for coronary revascularization.
Coronary revascularization was associated with a lower
adjusted hazard of death or acute coronary syndrome (hazard
ratio [HR]: 0.61; 95% conﬁdence interval [CI]: 0.42 to
0.88) at 3 years compared with medical therapy in appro-
priate patients. The rate of coronary revascularization was
54% in the uncertain category and 45% in the inappropriate
category. No signiﬁcant difference in death or acute coronarysyndrome between coronary revascularization and no revas-
cularization in the uncertain category (HR: 0.57; 95% CI:
0.28 to 1.16) and the inappropriate category (HR: 0.99; 95%
CI: 0.48 to 2.02) was observed.
Conclusions Using the appropriateness use criteria, we
identiﬁed substantial underutilization and overutilization of
coronary revascularization in contemporary clinical practice.
Underutilization of coronary revascularization is associated
with signiﬁcantly increased risks of adverse outcomes in
patients with appropriate indications (25).
Effects of Renal Sympathetic Denervation on
Arterial Stiffness and Central Hemodynamics in
Patients With Resistant Hypertension
Objectives This study investigated the effect of catheter-
based renal sympathetic denervation (RD) on central
hemodynamics in patients with resistant hypertension.
Background High central blood pressure (BP) increases
cardiovascular events and mortality independently of
peripheral BP. The effect of RD on central BP is unclear.
Methods A total of 110 patients underwent bilateral RD.
Radial artery applanation tonometry and pulse wave analysis
were used to derive central aortic pressure and hemodynamic
indices at baseline and 1, 3, and 6 months after ablation.
Ten patients with resistant hypertension not undergoing RD
served as controls.
Results RD signiﬁcantly reduced mean central aortic BP
from 167/92 mm Hg to 149/88 mm Hg, 147/85 mm Hg,
and 141/85 mm Hg at 1, 3, and 6 months (p < 0.001),
respectively. Aortic pulse pressure decreased from 76.2 
23.3 mm Hg to 61.5  17.5 mm Hg, 62.7  18.1 mm Hg,
and 54.5  15.7 mm Hg 1, 3, and 6 months after RD (p <
0.001), respectively. Six months after RD aortic augmenta-
tion and augmentation index were signiﬁcantly reduced
by 11 mm Hg (p < 0.001) and 5.3% (p < 0.001),
respectively. Carotid to femoral pulse wave velocity showed
a signiﬁcant reduction from 11.6  3.2 m/s to 9.6  3.1 m/s
at 6 months (p < 0.001). Consistently, ejection duration and
aortic systolic pressure load were signiﬁcantly diminished,
indicating improvement of cardiac work load by RD. No
signiﬁcant changes were obtained in control patients.
Conclusions Besides the known effect of RD on brachial
blood pressure, the study showed for the ﬁrst time that this
novel approach signiﬁcantly improves arterial stiffness and
central hemodynamics, which might have important prog-
nostic implications in patients with resistant hypertension at
high cardiovascular risk (26).
Long-Term Outcomes After Transcatheter Aortic
Valve Implantation: Insights on Prognostic Factors
and Valve Durability From the Canadian
Multicenter Experience
Objectives This study sought to evaluate the long-term
outcomes after transcatheter aortic valve implantation
(TAVI) in the Multicenter Canadian Experience study, with
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and valve durability.
Background Very few data exist on the long-term
outcomes associated with TAVI.
Methods This was a multicenter study including 339
patients considered to be nonoperable or at very high
surgical risk (mean age: 81  8 years; Society of Thoracic
Surgeons score: 9.8  6.4%) who underwent TAVI with
a balloon-expandable Edwards valve (transfemoral: 48%,
transapical: 52%). Follow-up was available in 99% of the
patients, and serial echocardiographic exams were evaluated
in a central echocardiography core laboratory.
Results At a mean follow-up of 42  15 months 188
patients (55.5%) had died. The causes of late death (152
patients) were noncardiac (59.2%), cardiac (23.0%), and
unknown (17.8%). The predictors of late mortality were
chronic obstructive pulmonary disease (hazard ratio [HR]:
2.18, 95% conﬁdence interval [CI]: 1.53 to 3.11), chronic
kidney disease (HR: 1.08 for each decrease of 10 ml/min in
estimated glomerular ﬁltration rate, 95% CI: 1.01 to 1.19),
chronic atrial ﬁbrillation (HR: 1.44, 95% CI: 1.02 to 2.03),
and frailty (HR: 1.52, 95% CI: 1.07 to 2.17). A mild
nonclinically signiﬁcant decrease in valve area occurred at 2-
year follow-up (p < 0.01), but no further reduction in valve
area was observed up to 4-year follow-up. No changes in
residual aortic regurgitation and no cases of structural valve
failure were observed during the follow-up period.
Conclusions Approximately one-half of the patients who
underwent TAVI because of a high or prohibitive surgical
risk proﬁle had died at a mean follow-up of 3.5 years. Late
mortality was due to noncardiac comorbidities in more than
one-half of patients. No clinically signiﬁcant deterioration
in valve function was observed throughout the follow-up
period (27).Prospective, Randomized, Multicenter Evaluation
of a Polyethylene Terephthalate Micronet Mesh–
Covered Stent (MGuard) in ST-Segment Elevation
Myocardial Infarction: The MASTER Trial
Objectives This study sought to evaluate the potential
utility of a novel polyethylene terephthalate micronet mesh–
covered stent (MGuard) in patients with acute ST-segment
elevation myocardial infarction (STEMI) undergoing
percutaneous coronary intervention (PCI).
Background Suboptimal myocardial reperfusion after PCI
in STEMI is common and results in increased infarct size
and mortality. The MGuard is a novel thin-strut metal stent
with a polyethylene terephthalate micronet covering
designed to trap and exclude thrombus and friable athero-
matous debris to prevent distal embolization.
Methods A total of 433 patients with STEMI presenting
within 12 h of symptom onset undergoing PCI were
randomized at 50 sites in 9 countries to the MGuard (n ¼
217) or commercially available bare metal or drug-eluting
stents (n ¼ 216). The primary endpoint was the rate ofcomplete (70%) ST-segment resolution measured 60 to 90
min post-procedure.
Results Baseline characteristics were well matched between
the groups. The primary endpoint of post-procedure
complete ST-segment resolution was signiﬁcantly
improved in patients randomized to the MGuard stent
compared with control patients (57.8% vs. 44.7%; differ-
ence: 13.2%; 95% conﬁdence interval: 3.1% to 23.3%; p ¼
0.008). By core laboratory analysis, the MGuard stent
compared with control stents also resulted in superior rates
of Thrombolysis In Myocardial Infarction 3 ﬂow (91.7% vs.
82.9%, p ¼ 0.006) with comparable rates of myocardial
blush grade 2 or 3 (83.9% vs. 84.7%, p ¼ 0.81). Mortality
(0% vs. 1.9%, p ¼ 0.06) and major adverse cardiac events
(1.8% vs. 2.3%, p ¼ 0.75) at 30 days were not signiﬁcantly
different between patients randomized to the MGuard stent
and control stent, respectively.
Conclusions Among patients with acute STEMI under-
going emergent PCI, the MGuard micronet mesh–covered
stent compared with conventional metal stents resulted in
superior rates of epicardial coronary ﬂow and complete ST-
segment resolution. A larger randomized trial is warranted
to determine whether these beneﬁts result in reduced infarct
size and/or improved clinical outcomes. (Safety and Efﬁcacy
Study of MGuard Stent After a Heart Attack [MASTER];
NCT01368471) (28).Catheter Ablation of Long-Standing Persistent
Atrial Fibrillation: 5-Year Outcomes of the Hamburg
Sequential Ablation Strategy
Objectives This study describes the 5-year efﬁcacy of
catheter ablation for long-standing persistent atrial ﬁbrilla-
tion (LS-AF).
Background Long-term outcome data after catheter abla-
tion for LS-AF are limited.
Methods Long-term follow-up of 56 months (range 49 to
67 months) was performed in 202 patients (age 61  9
years) who underwent the sequential ablation strategy for
symptomatic LS-AF. Initial ablation strategy was circum-
ferential pulmonary vein isolation (PVI). Additional ablation
was performed only in acute PVI nonresponder, if direct
current cardioversion failed after PVI.
Results After the ﬁrst ablation procedure, sinus rhythm was
documented in 41 of 202 (20.3%) patients. After multiple
procedures, sinus rhythm was maintained in 91 of 202
(45.0%) patients, including 24 patients receiving antiar-
rhythmic drugs. In 105 patients, PVI was the sole ablative
therapy, 49 (46.7%) of those patients remained in sinus
rhythm during follow-up. Patients with a total AF duration
of <2 years had a signiﬁcantly higher ablation success rate
than patients whose AF duration was >2 years (76.5% vs.
42.2%, respectively; p ¼ 0.033). Persistent AF duration
(hazard ratio: 1.09 [95% conﬁdence interval: 1.04 to 1.13];
p < 0.001) independently predicted arrhythmia recurrences,
and acute PVI responders had a reduced risk of relapse
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p < 0.001) after the ﬁrst ablation.
Conclusions During 5-year follow-up, single- and multiple
ablation procedure success was 20% and 45%, respectively,
for patients with LS-AF. For patients with a total AF
duration of <2 years, the outcomes were favorable (29).Assessment of Clinical, Electrocardiographic, and
Physiological Relevance of Diagonal Branch in Left
Anterior Descending Coronary Artery Bifurcation
Lesions
Objectives This study sought to investigate the clinical,
electrocardiographic, and physiological relevance of main
and side branches in coronary bifurcation lesions.
Background Discrepancy exists between stenosis severity
and clinical outcomes in bifurcation lesions. However, its
mechanism has not been fully evaluated yet.
Methods Sixty-ﬁve patients with left anterior descending
coronary artery (LAD) bifurcation lesions were prospectively
enrolled. Chest pain and 12-lead electrocardiogram were
assessed after 1-min occlusion of coronary ﬂow and coronary
wedge pressure (Pw) was measured using a pressure wire.
Results ST-segment elevation was more frequent during
LAD occlusion (92%) than during diagonal branch occlu-
sion (37%) (p < 0.001). Pain score was also higher with the
occlusion of LAD than with the diagonal branch (p <
0.001). However, both Pw and Pw/aortic pressure (Pa) were
lower in the LAD than in diagonal branches (Pw: 21.0 
6.5 vs. 26.7  9.4, p < 0.0001; Pw/Pa: 0.22  0.07 vs.
0.27  0.08, p ¼ 0.001). The corrected QT interval was
prolonged with LAD occlusion (435.0  39.6 ms to 454.0
 45.4 ms, p < 0.0001) but not with diagonal branch
occlusion. There was no difference in vessel size between the
diagonal branches with and without ST-segment elevation
during occlusion. Positive and negative predictive values
of vessel size (2.5 mm) to determine the presence of
ST-segment elevation were 48% and 72%, respectively.
Conclusions Diagonal branch occlusion caused fewer
anginas, less electrocardiogram change, less arrhythmogenic
potential, and higher Pw than did a LAD occlusion. These
differences seem to be the main mechanism explaining why
aggressive treatment for side branches has not translated into
clinical beneﬁt in coronary bifurcation lesions. (Compari-
son Between Main Branch and Side Branch Vessels;
NCT01046409) (30).Comparison of Nonculprit Coronary Plaque
Characteristics Between Patients With and
Without Diabetes: A 3-Vessel Optical Coherence
Tomography Study
Objectives The aim of the present study was to compare
the characteristics of nonculprit coronary plaques between
diabetes mellitus (DM) and non-DM patients using 3-vessel
optical coherence tomography (OCT) imaging.Background DM patients have a higher recurrent cardio-
vascular event rate.
Methods Patients who had undergone 3-vessel OCT
imaging were identiﬁed from the Massachusetts General
Hospital OCT Registry. Characteristics of noncul-
prit plaques were compared between DM and non-DM
patients.
Results A total of 230 nonculprit plaques were identiﬁed in
98 patients. Compared with non-DM patients, DM
patients had a larger lipid index (LI) (averaged lipid arc 
lipid length; 778.6  596.1 vs. 1358.3  939.2, p < 0.001)
and higher prevalence of calciﬁcation (48.4% vs. 72.2%, p ¼
0.034) and thrombus (0% vs. 8.3%, p ¼ 0.047). DM
patients were divided into 2 groups based on glycated
hemoglobin (A1C) levels of 7.9% and 8.0%. LI was
signiﬁcantly correlated with diabetic status (778.6  596.1
[non-DM] vs. 1,171.5  708.1 [A1C 7.9%] vs. 1,638.5 
1,173.8 [A1C 8%], p value for linear trend ¼ 0.005), and
ﬁbrous cap thickness was inversely correlated with the A1C
level (99.4  46.7 mm [non-DM] vs. 91.7  29.6 mm
[A1C 7.9%] vs. 72.9  22.7 mm [A1C 8%], p value for
linear trend ¼ 0.014). Patients with A1C 8% also had the
highest prevalence of thin-cap ﬁbroatheroma (TCFA) and
macrophage inﬁltration.
Conclusions Compared with non-DM patients, DM
patients have a larger LI and a higher prevalence of calciﬁ-
cation and thrombus. The LI was larger and TCFA and
macrophage inﬁltration were frequent in patients with
A1C 8% (31).Clinical Impact of Second-Generation Everolimus-
Eluting Stent Compared With First-Generation
Drug-Eluting Stents in Diabetes Mellitus Patients:
Insights From a Nationwide Coronary Intervention
Register
Objectives This study sought to study the second-
generation everolimus-eluting stent (EES) as compared
with ﬁrst-generation sirolimus-eluting (SES) and paclitaxel-
eluting stents (PES) in diabetes mellitus (DM) patients.
Background There are limited data available comparing
clinical outcomes in this setting with EES and SES, whereas
studies comparing EES with PES are not powered for low-
frequency endpoints.
Methods All DM patients treated with EES, PES, or SES
from January 18, 2007, to July 29, 2011, from the SCAAR
(Swedish Coronary Angiography and Angioplasty Regis-
tery) were included. The EES was compared with SES or
PES for the primary composite endpoint of clinically driven
detected restenosis, deﬁnite stent thrombosis (ST), and all-
cause mortality.
Results In 4,751 percutaneous coronary intervention-
treated DM patients, 8,134 stents were implanted
(EES ¼ 3,928, PES ¼ 2,836, SES ¼ 1,370). The EES
was associated with signiﬁcantly lower event rates
compared with SES (SES vs. EES hazard ratio [HR]:
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same was observed when compared with PES (PES vs.
EES HR: 1.33; 95% CI: 0.93 to 1.91) but did not reach
statistical signiﬁcance. These results were mainly driven by
lower incidence of ST (SES vs. EES HR: 2.87; 95% CI:
1.08 to 7.61; PES vs. EES HR: 1.74, 95% CI: 0.82 to
3.71) and mortality (SES vs. EES HR: 2.02; 95% CI: 1.03
to 3.98; PES vs. EES HR: 1.69; 95% CI: 1.06 to 2.72).
No signiﬁcant differences in restenosis rates were observed
between EES and SES or PES (SES vs. EES HR: 1.26;
95% CI: 0.77 to 2.08; PES vs. EES HR: 1.05; 95% CI:
0.71 to 1.55).
Conclusions In all-comer DM patients the use of EES was
associated with improved outcomes compared with SES and
PES mainly driven by lower rates of ST and mortality.
These results suggest better safety rather than efﬁcacy with
EES when compared with SES or PES (32).Time-Dependent Detrimental Effects of Distal
Embolization on Myocardium and Microvasculature
During Primary Percutaneous Coronary
Intervention
Objectives The authors sought to investigate the impact of
distal embolization (DE) on myocardial damage and
microvascular reperfusion, according to time-to-treatment,
using contrast-enhanced cardiac magnetic resonance (CE-
CMR).
Background DE, occurring during primary percutaneous
coronary intervention (p-PCI), appears to increase myocar-
dial necrosis and to worsen microvascular perfusion, as
shown by surrogate markers. However, data regarding the
behavior of DE on jeopardized myocardium, and in
particular on necrosis extent and distribution, are still
lacking.
Methods In 288 patients who underwent p-PCI within 6 h
from symptom onset, the authors prospectively assessed the
impact of DE on infarct size and microvascular damage,
using CE-CMR. The impact of DE was assessed according
to time-to-treatment: for group 1, <3 h; for group 2, 3
and 6 h.
Results DE occurred in 41 (14.3%) patients. Baseline
clinical characteristics were not different between the 2
groups. At CE-CMR, patients with DE showed larger
infarct size (p ¼ 0.038) and more often transmural
necrosis compared with patients without DE (p ¼ 0.008)
when time-to-treatment was <3 h, but no impact was
proven after this time (p ¼ NS). Patients with DE
showed more often microvascular obstruction, as evaluated
at ﬁrst-pass enhancement, than patients without DE
(100% vs. 66.5%, p ¼ 0.001) up to 6 h from symptom
onset.
Conclusions These ﬁndings suggest that the detrimental
impact of DE occurring during p-PCI on myocardial
damage is largely inﬂuenced by ischemic time, increasing the
extent of necrosis in patients presenting within the ﬁrsthours after symptom onset, and having limited or no impact
after this time window (33).Walking Beyond the GRACE (Global Registry of
Acute Coronary Events) Model in the Death Risk
Stratiﬁcation During Hospitalization in Patients
With Acute Coronary Syndrome: What Do the AR-G
(ACTION [Acute Coronary Treatment and
Intervention Outcomes Network] Registry and
GWTG [Get With the Guidelines] Database), NCDR
(National Cardiovascular Data Registry), and
EuroHeart Risk Scores Provide?
Objectives This study sought to compare the in-hospital
prognostic values of the original and updated GRACE
(Global Registry of Acute Coronary Events) risk score
(RS) and the AR-G (ACTION [Acute Coronary Treat-
ment and Intervention Outcomes Network] Registry and
the GWTG [Get With the Guidelines] Database) RS in
acute coronary syndromes (ACS). To evaluate the utility
of recalculating risk after percutaneous coronary interven-
tion (PCI) with newer RS models (NCDR [National
Cardiovascular Data Registry] and EHS [EuroHeart
Score] RS).
Background Deﬁned in 2003, GRACE is among the most
popular systems of risk stratiﬁcation in ACS. An updated
version of GRACE has since appeared and new RS have
been developed, aiming to improve risk prediction.
Methods From 2004 to 2010, 4,497 consecutive patients
admitted to a single center in Spain with an ACS were
included (32.1% ST-segment elevation myocardial infarc-
tion, 19.2% unstable angina). Discrimination (C-statistic)
and calibration (Hosmer-Lemeshow [HL]) indexes were
used to assess performance of each RS. A comparative
analysis of RS designed to predict post-PCI mortality
NCDR and EHS RS versus the GRACE and AR-G RS
was performed in a subgroup of 1,113 consecutive patients
included in the study.
Results There were 265 in-hospital deaths (5.9%). Original
and updated GRACE RS and the AR-G RS all demon-
strated good discrimination for in-hospital death (C-statis-
tics: 0.91, 0.90 and 0.90, respectively) with optimal
calibration (HL p: 0.42, 0.50, and 0.47, respectively) in all
spectra of ACS, according to different managements (PCI
vs. conservative) and without signiﬁcant differences between
the 3 different RS. In patients undergoing PCI, EHS and
NCDR RS (C-statistic ¼ 0.80 and 0.84, respectively) were
not superior to GRACE RS (C-statistic ¼ 0.91), albeit in
the subgroup of patients undergoing PCI who were cate-
gorized as high risk using the GRACE RS, both EHS and
NCDR have contributed to decrease the false positive rate
generated by using the GRACE RS.
Conclusions Despite having been developed over 8 years
ago, the GRACE RS still maintains its excellent perfor-
mance for predicting in-hospital risk of death among ACS
patients (34).
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Myocardial Injury and Clinical Outcomes in
Patients Who Underwent Elective Coronary
Interventions With Drug-Eluting Stents
Objectives This study sought to evaluate the associations
between homeostatic indexes of insulin resistance (HOMA-
IR) and post-procedural myocardial injury and clinical
outcome after a percutaneous coronary intervention (PCI)
with a drug-eluting stent.
Background Insulin resistance increases the risk of
cardiovascular events. However, the association between
insulin resistance and clinical outcome after coronary inter-
vention is unclear.
Methods We evaluated 516 consecutive patients who
underwent elective PCI with drug-eluting stents. Blood
samples were collected from venous blood after overnight
fasting, and fasting plasma glucose and insulin levels were
measured. HOMA-IR was calculated according to the
homeostasis model assessment. Post-procedural myocardial
injury was evaluated by analysis of troponin T and creatine
kinase-myocardial band isozyme levels hours after PCI.
Cardiac event was deﬁned as the composite endpoint
of cardiovascular death, myocardial infarction, and any
revascularization.
Results With increasing tertiles of HOMA-IR, post-
procedural troponin T and creatine kinase-myocardial band
levels increased. In the multiple regression analysis,
HOMA-IR was independently associated with troponin T
elevation. During a median follow-up of 623 days, patients
with the highest tertiles of HOMA-IR had the highest risk
of cardiovascular events. The Cox proportional hazard
models identiﬁed HOMA-IR as independently associated
with worse clinical outcome after adjustment for clinical and
procedural factors.
Conclusions These results indicated the impact of insulin
resistance on post-procedural myocardial injury and clinical
outcome after elective PCI with drug-eluting stent deploy-
ment. Evaluation of insulin resistance may provide useful
information for predicting clinical outcomes after elective
PCI (35).Device Closure of Secundum Atrial Septal Defects
in Children <15 kg: Complication Rates and
Indications for Referral
Objectives This study sought to determine institutional
complication rates in a previously underreported patient
population and discuss referral indications.
Background There has been a trend over the years for
referral of younger and smaller patients for “elective” closure
of atrial septal defects (ASD). In general, the risks associated
with ASD device closure are believed and reported to be
relatively low. Complication rates in this group of smaller
patients are not well described in the literature for either
percutaneous or surgical approaches.Methods Retrospective review of all patients who under-
went elective transcatheter closure of secundum ASD
between March 2000 and April 2010. We excluded all
children >15 kg, as well as those with complex congenital
heart defects. Major and minor complications were pre-
deﬁned and indications for referral were evaluated.
Results We identiﬁed 128 patients meeting criteria with
a median procedural age of 1.92 years (3 months to 4.92
years), and median weight of 10.8 kg (4.3 to 14.9 kb). There
were 7 major (5.5%) and 12 minor (9.4%) complications.
Nearly two-thirds of referrals were for right heart enlarge-
ment or poor growth. Rate of resolution of residual shunt
was 99%. When compared with age, there was no difference
in the rate of resolution of right heart enlargement. No
clinically signiﬁcant improvement in growth was observed.
Conclusions Transcatheter ASD closure in small children
is highly successful, but with an increase in previously
perceived complication rates. In small, asymptomatic
patients, deferral of closure until the historically established
timeline of around 4 to 5 years of age should be strongly
considered (36).Randomized Comparison of Conservative Versus
Aggressive Strategy for Provisional Side Branch
Intervention in Coronary Bifurcation Lesions:
Results From the SMART-STRATEGY (SMart
Angioplasty Research Team–Optimal STRATEGY for
Side Branch Intervention in Coronary Bifurcation
Lesions) Randomized Trial
Objectives The authors sought to compare conservative
and aggressive strategies for provisional side branch (SB)
intervention in coronary bifurcation lesions.
Background The optimal provisional approach for coro-
nary bifurcation lesions has not been established.
Methods In this prospective randomized trial, 258 patients
with a coronary bifurcation lesion treated with drug-eluting
stents were randomized to a conservative (n ¼ 128) or
aggressive (n ¼ 130) SB intervention strategy. The criteria
for SB intervention after main vessel stenting differed
between the conservative and aggressive groups; Throm-
bolysis In Myocardial Infarction ﬂow grade <3 versus
diameter stenosis >75% for non–left main bifurcations and
diameter stenosis >75% versus diameter stenosis >50% for
left main bifurcations. The primary endpoint was target
vessel failure (cardiac death, myocardial infarction, or target
vessel revascularization) at 12 months.
Results Left main bifurcation lesions were noted in 114
patients (44%) and true bifurcation lesions in 171 patients
(66%). SB ballooning after main vessel stenting and SB
stenting after SB ballooning were performed less frequently
in the conservative group than in the aggressive group
(25.8% vs. 68.5%, p< 0.001; and 7.0% vs. 30.0%, p< 0.001,
respectively). The conservative strategy was associated
with a lower incidence of procedure-related myocardial
necrosis compared with the aggressive strategy (5.5% vs.
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vessel failure was similar in both groups (9.4% in the conser-
vative group vs. 9.2% in the aggressive group, p ¼ 0.97).
Conclusions Compared with the aggressive strategy, the
conservative strategy for provisional SB intervention was
associated with similar long-term clinical outcomes and
a lower incidence of procedure-related myocardial necro-
sis. (Optimal Strategy for Side Branch Stenting in
Coronary Bifurcation Lesions [SMART-STRATEGY];
NCT00794014) (37).A New Score for Risk Stratiﬁcation of Patients
With Acute Coronary Syndromes Undergoing
Percutaneous Coronary Intervention: The ACUITY-
PCI (Acute Catheterization and Urgent
Intervention Triage Strategy–Percutaneous
Coronary Intervention) Risk Score
Objectives This study sought to develop a new score
speciﬁc for patients with non–ST-segment elevation acute
coronary syndromes (NSTEACS) undergoing percutaneous
coronary intervention (PCI) (the ACUITY-PCI [Acute
Catheterization and Urgent Intervention Triage Strategy–
Percutaneous Coronary Intervention] risk score).
Background The TIMI (Thrombolysis In Myocardial
Infarction) and GRACE (Global Registry for Acute
Coronary Events) risk scores are recommended for risk
stratiﬁcation of patients with NSTEACS. However, these
scores were not optimized for patients undergoing an early
invasive strategy with PCI.
Methods The ACUITY-PCI risk score was created from
data for 1,692 patients enrolled in the formal angiographic
substudy of the ACUITY (Acute Catheterization and
Urgent Intervention Triage Strategy) trial by integrating
clinical, angiographic, laboratory, and electrocardiographic
variables selected by multivariable analysis. The score was
subsequently validated in a different population of 846
patients and compared with the GRACE and TIMI risk
scores, and the SYNTAX (Synergy Between PCI with
Taxus and Cardiac Surgery) and Clinical SYNTAX scores.
Results Six variables (2 clinical, 1 laboratory/electrocar-
diographic, and 3 angiographic) were included in the
ACUITY-PCI score: insulin-treated diabetes; renal insuf-
ﬁciency; baseline cardiac biomarker elevation or ST-segment
deviation; bifurcation lesion; small vessel/diffuse coronary
artery disease; and the extent of coronary artery disease.
Event rates increased signiﬁcantly across tertiles of
ACUITY-PCI score. Compared with the other scores, the
ACUITY-PCI score had the best discrimination (C-
statistic), calibration (Hosmer-Lemeshow statistic), and
index of separation. Moreover, the net reclassiﬁcation
improvement varied from 9% to 38% and the integrated
discrimination index from 1.9% to 2.7%.
Conclusions The ACUITY-PCI risk score is a new tool
integrating clinical, angiographic, and laboratory/electro-
cardiographic variables speciﬁcally developed for patientswith NSTEACS undergoing PCI. This score displayed
better prognostic accuracy in terms of discrimination and
calibration than other currently available scores for risk
stratiﬁcation of patients with NSTEACS. (Comparison of
Angiomax Versus Heparin in Acute Coronary Syndromes
[ACS]; NCT00093158) (38).Development and Validation of a Stent Thrombosis
Risk Score in Patients With Acute Coronary
Syndromes
Objectives This study sought to develop a practical risk
score to predict the risk of stent thrombosis (ST) after
percutaneous coronary intervention (PCI) for acute coronary
syndromes (ACS).
Background ST is a rare, yet feared complication after PCI
with stent implantation. A risk score for ST after PCI in
ACS can be a helpful tool to personalize risk assessment.
Methods This study represents a patient-level pooled
analysis of 6,139 patients undergoing PCI with stent
implantation for ACS in the HORIZONS-AMI (Harmo-
nizing Outcomes With Revascularization and Stents in
Acute Myocardial Infarction) and ACUITY (Acute Cath-
eterization and Urgent Intervention Triage Strategy) trials
who were randomized to treatment with bivalirudin versus
heparin plus a glycoprotein IIb/IIIa inhibitor. The cohort
was randomly divided into a risk score development cohort
(n ¼ 4,093) and a validation cohort (n ¼ 2,046). Cox
regression methods were used to identify clinical, angio-
graphic, and procedural characteristics associated with
Academic Research Consortium–deﬁned deﬁnite/probable
ST at 1 year. Each covariate in this model was assigned an
integer score based on the regression coefﬁcients.
Results Variables included in the risk score were type of
ACS (ST-segment elevation myocardial infarction, non-
ST-segment elevation ACS with ST deviation, or non–
ST-segment elevation ACS without ST changes), current
smoking, insulin-dependent diabetes mellitus, prior PCI,
baseline platelet count, absence of early (pre-PCI) antico-
agulant therapy, aneurysmal/ulcerated lesion, baseline TIMI
(Thrombolysis In Myocardial Infarction) ﬂow grade 0/1,
ﬁnal TIMI ﬂow grade <3, and number of treated vessels.
Risk scores 1 to 6 were considered low risk, 7 to 9 inter-
mediate risk, and 10 or greater high risk for ST. Rates of ST
at 1 year in low-, intermediate-, and high-risk categories
were 1.36%, 3.06%, and 9.18%, respectively, in the devel-
opment cohort (p for trend <0.001), and 1.65%, 2.77%, and
6.45% in the validation cohort (p for trend ¼ 0.006). The
C-statistic for this risk score was over 0.65 in both cohorts.
Conclusions The individual risk of ST can be predicted
using a simple risk score based on clinical, angiographic, and
procedural variables. (Harmonizing Outcomes With
Revascularization and Stents in Acute Myocardial Infarction
[HORIZONS-AMI]; NCT00433966) (Comparison of
Angiomax Versus Heparin in Acute Coronary Syndromes
[ACUITY]; NCT00093158) (39).
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Echocardiography Predicts Mortality
Objectives The goal of this study was to evaluate the ability
of coronary ﬂow reserve (CFR) over regional wall motion to
predict mortality in patients with known or suspected
coronary artery disease (CAD).
Background CFR evaluated using pulsed Doppler echo-
cardiography testing on left anterior descending artery is
the state-of-the-art method during vasodilatory stress
echocardiography.
Methods In a prospective, multicenter, observational
study, we evaluated 4,313 patients (2,532 men; mean age
65  11 years) with known (n ¼ 1,547) or suspected (n ¼
2,766) CAD who underwent high-dose dipyridamole
(0.84 mg/kg over 6 min) stress echocardiography with
CFR evaluation of left coronary descending artery (LAD)
by Doppler. Overall mortality was the only endpoint
analyzed.
Results Stress echocardiography was positive for ischemia
in 765 (18%) patients. Mean CFR was 2.35  0.68. At
individual patient analysis, 1,419 (33%) individuals had
CFR 2. During a median follow-up of 19 months (1st
quartile 8; 3rd quartile 36), 146 patients died. The 4-year
mortality was markedly higher in subjects with CFR 2
than in those with CFR >2, both considering the group
with ischemia (39% vs. 7%; p < 0.0001) and the group
without ischemia at stress echocardiography (12% vs. 3%;
p < 0.0001). At multivariable analysis, CFR on LAD 2
(hazard ratio [HR]: 3.31; 95% conﬁdence interval [CI]: 2.29
to 4.78; p < 0.0001), ischemia at stress echocardiography
(HR: 2.40, 95% CI: 1.65 to 3.48, p < 0.0001), left bundle
branch block (HR: 2.26, 95% CI: 1.50 to 3.41; p < 0.0001),
age (HR: 1.08, 95% CI: 1.06–1.10; p< 0.0001), resting wall
motion score index (HR: 3.52, 95% CI: 2.38 to 5.21; p <
0.0001), male sex (HR: 1.74, 95% CI: 1.12 to 2.52; p ¼
0.003), and diabetes mellitus (HR: 1.47, 95% CI: 1.03 to
2.08; p ¼ 0.03) were independent predictors of mortality.
Conclusions CFR on LAD is a strong and independent
indicator of mortality, conferring additional prognostic value
over wall motion analysis in patients with known or sus-
pected CAD. A negative result on stress echocardiography
with a normal CFR confers an annual risk of death <1% in
both patient groups (40).
Colchicine for Prevention of Early Atrial Fibrillation
Recurrence After Pulmonary Vein Isolation: A
Randomized Controlled Study
Objectives The purpose of the present study was to test the
potential of colchicine, an agent with potent anti-
inﬂammatory action, to reduce atrial ﬁbrillation (AF)
recurrence after pulmonary vein isolation in patients with
paroxysmal AF.
Background Proinﬂammatory processes induced by AF
ablation therapy have been implicated in postablation
arrhythmia recurrence.Methods Patients with paroxysmal AF who received radi-
ofrequency ablation treatment were randomized to a 3-
month course of colchicine 0.5 mg twice daily or placebo.
C-reactive protein (CRP) and interleukin (IL)-6 levels were
measured on day 1 and on day 4 of treatment.
Results In the 3-month follow-up, recurrence of AF was
observed in 27 (33.5%) of 80 patients of the placebo group
versus 13 (16%) of 81 patients who received colchicine (odds
ratio: 0.38, 95% conﬁdence interval: 0.18 to 0.80). Gastro-
intestinal side-effects were the most common symptom
among patients receiving active treatment. Diarrhea was
reported in 7 patients in the colchicine group (8.6%) versus 1
in the placebo group (1.3%, p ¼ 0.03). Colchicine led to
higher reductions in CRP and IL-6 levels: the median
difference of CRP and IL-6 levels between days 4 and 1
was 0.46 mg/l (interquartile range: 0.78 to 0.08 mg/l)
and 0.10 mg/l (0.30 to 0.10 pg/ml), respectively, in the
placebo group versus 1.18 mg/l (2.35 to 0.46 mg/l)
and 0.50 pg/ml (1.15 to 0.10 pg/ml) in the colchicine
group (p < 0.01 for both comparisons).
Conclusions Colchicine is an effective and safe treatment
for prevention of early AF recurrences after pulmonary vein
isolation in the absence of antiarrhythmic drug treatment.
This effect seems to be associated strongly with a signiﬁcant
decrease in inﬂammatory mediators, including IL-6 and
CRP (41).Drug-Eluting Balloon for Treatment of Superﬁcial
Femoral Artery In-Stent Restenosis
Objectives The purpose of this prospective registry was to
evaluate the safety and efﬁcacy, at 1 year, of the use of drug-
eluting balloons (DEB) for the treatment of superﬁcial
femoral artery (SFA) in-stent restenosis (ISR).
Background The use of the self-expanding nitinol stent has
improved the patency rate of SFA after percutaneous
transluminal angioplasty (PTA). As the population with
SFA stenting continues to increase, occurrence of ISR has
become a serious problem. The use of DEB has showed
promising results in reducing restenosis recurrence in coro-
nary stents.
Methods From December 2009 to December 2010, 39
consecutive patients underwent PTA of SFA-ISR in our
institution. All patients underwent conventional SFA PTA
and ﬁnal post-dilation with paclitaxel-eluting balloons
(IN.PACT, Medtronic, Minneapolis, Minnesota). Patients
were evaluated up to 12 months.
Results Technical and procedural success was achieved in
every patient. No in-hospital major adverse cardiac and
cerebrovascular events occurred. At 1 year, 1 patient died
due to heart failure. Primary endpoint, primary patency rate
at 12 months, was obtained in 92.1% (35 patients). At
1 year, patients were asymptomatic for claudication, and
duplex assessment demonstrated lack of recurrent restenosis
(100% rate of Secondary patency). The presence of an
occlusive restenosis at the time of treatment was not
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with non-occlusive restenosis, at 1 year.
Conclusions The data suggest that adjunctive use of DEB
for the treatment of SFA-ISR represents a potentially safe
and effective therapeutic strategy. These data should be
considered hypothesis-generating to design a randomized
trial (42).Predictive Factors and Long-Term Clinical
Consequences of Persistent Left Bundle Branch
Block Following Transcatheter Aortic Valve
Implantation With a Balloon-Expandable Valve
Objectives This study evaluated the predictive factors and
prognostic value of new-onset persistent left bundle branch
block (LBBB) in patients undergoing transcatheter aortic
valve implantation (TAVI) with a balloon-expandable valve.
Background The predictors of persistent (vs. transient or
absent) LBBB after TAVI with a balloon-expandable valve
and its clinical consequences are unknown.
Methods A total of 202 consecutive patients with no
baseline ventricular conduction disturbances or previous
permanent pacemaker implantation (PPI) who underwent
TAVI with a balloon-expandable valve were included.
Patients were on continuous electrocardiographic (ECG)
monitoring during hospitalization and 12-lead ECG was
performed daily until hospital discharge. No patient was lost
at a median follow-up of 12 (range: 6 to 24) months, and
ECG tracing was available in 97% of patients. The criteria
for PPI were limited to the occurrence of high-degree
atrioventricular block (AVB) or severe symptomatic
bradycardia.
Results New-onset LBBB was observed in 61 patients
(30.2%) after TAVI, and had resolved in 37.7% and 57.3%
at hospital discharge and 6- to 12-month follow-up,
respectively. Baseline QRS duration (p ¼ 0.037) and
ventricular depth of the prosthesis (p ¼ 0.017) were inde-
pendent predictors of persistent LBBB. Persistent LBBB at
hospital discharge was associated with a decrease in left
ventricular ejection fraction (p ¼ 0.001) and poorer func-
tional status (p ¼ 0.034) at 1-year follow-up. Patients with
persistent LBBB and no PPI at hospital discharge had
a higher incidence of syncope (16.0% vs. 0.7%; p ¼ 0.001)
and complete AVB requiring PPI (20.0% vs. 0.7%; p <
0.001), but not of global mortality or cardiac mortality
during the follow-up period (all, p > 0.20). New-onset
LBBB was the only factor associated with PPI following
TAVI (p < 0.001).
Conclusions Up to 30% of patients with no prior
conduction disturbances developed new LBBB following
TAVI with a balloon-expandable valve, although it was
transient in more than one third. Longer baseline QRS
duration and a more ventricular positioning of the prosthesis
were associated with a higher rate of persistent LBBB,
which in turn determined higher risks for complete AVB
and PPI, but not mortality, at 1-year follow-up (43).SeQuent Please World Wide Registry: Clinical
Results of SeQuent Please Paclitaxel-Coated
Balloon Angioplasty in a Large-Scale, Prospective
Registry Study
Objectives This study sought to assess the safety and efﬁ-
cacy of paclitaxel-coated balloon (PCB) angioplasty in an
international, multicenter, prospective, large-scale registry
study.
Background In small randomized trials, PCB angioplasty
was superior to uncoated balloon angioplasty for treatment
of bare-metal stent (BMS) and drug-eluting stent (DES)
restenosis.
Methods Patients treated with SeQuent Please PCBs were
included. The primary outcome measure was the clinically
driven target lesion revascularization (TLR) rate at 9
months.
Results At 75 centers, 2,095 patients with 2,234 lesions
were included. The TLR rate was 5.2% after 9.4 months.
Deﬁnite vessel thrombosis occurred in 0.1%. PCB angio-
plasty was performed in 1,523 patients (72.7%) with DES or
BMS restenosis and 572 patients (27.3%) with de novo
lesions. The TLR rate was signiﬁcantly lower in patients
with PCB angioplasty for BMS restenosis compared with
DES restenosis (3.8% vs. 9.6%, p < 0.001). The TLR rate
did not differ for PCB angioplasty of paclitaxel-eluting stent
and non–paclitaxel-eluting stent restenosis (8.3% vs. 10.8%,
p ¼ 0.46). In de novo lesions (small vessels), the TLR rate
was low and did not differ between PCB angioplasty with
and without additional BMS implantation (p ¼ 0.31).
Conclusions PCB angioplasty in an all-comers, prospec-
tive, multicenter registry was safe and conﬁrmed in a large
population the low TLR rates seen in randomized clinical
trials. PCB angioplasty was more effective in BMS reste-
nosis compared with DES restenosis, with no difference
regarding the type of DES (44).Percutaneous Treatment of Patent Foramen Ovale
and Atrial Septal Defects
Percutaneous treatment of inter-atrial septal defects has
undergone exponential growth in the past 2 decades.
Improved percutaneous devices and interventional tech-
niques with low complication rates make this procedure an
attractive therapeutic option for congenital atrial septal
defects (ASD). Although indications for catheter-based
ASD closure are well-documented, those for catheter-
based patent foramen ovale (PFO) closure are still
evolving. Results from 2 randomized clinical trials question
the beneﬁt of percutaneous PFO closure, but concern has
also been raised about the efﬁcacy of the device used in those
trials. This review will focus on the anatomy, associated
syndromes, detection, and data for percutaneous closure of
both PFOs and ASDs. Percutaneous treatment of inter-
atrial septal defects has opened new areas of research,
because unexpected associations have been uncovered.
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complication rates make this procedure an attractive thera-
peutic option for congenital atrial septal defects (ASD). In
the United States, the rates of annual percutaneous patent
foramen ovale (PFO) and ASD closures have increased
nearly 50-fold over the past decade. Although indications for
catheter-based ASD closures are well-documented by many
society guidelines, those for catheter-based PFO closure are
still evolving. The results of 2 recent randomized clinical
trials raise questions about the utility of percutaneous PFO
closure. This review will focus on the anatomy, physiology,
associated syndromes, detection, and data for percutaneous
closure of both PFOs and ASDs (45).Effect of Cardiac Resynchronization Therapy on
the Risk of First and Recurrent Ventricular
Tachyarrhythmic Events in MADIT-CRT
Objectives This study aimed to evaluate the effect of
cardiac resynchronization therapy with a deﬁbrillator (CRT-
D) on the risks of ﬁrst and recurrent ventricular tachyar-
rhythmic events (VTEs) in the MADIT-CRT.
Background Reverse remodeling associated with CRT-D
therapy was suggested to reduce arrhythmic risk. However,
the effect of the device on the risk of recurrent VTEs among
patients who experience a ﬁrst arrhythmic event has not been
investigated.
Methods The CRT-D versus deﬁbrillator-only risks for
ﬁrst and subsequent fast VTEs (>180 beats/min) were
assessed by Cox proportional hazards and Andersen-Gill
proportional intensity regression modeling, respectively, in
efﬁcacy analyses recognizing active device-type during
follow-up.
Results Multivariate analysis showed that CRT-D was
associated with a signiﬁcant 29% (p ¼ 0.003) reduction
in the risk of a ﬁrst VTE, with a pronounced effect
among patients with left bundle branch block (LBBB)
(hazard ratio [HR]: 0.58; p < 0.001) and no signiﬁcant
effect among non-LBBB patients (HR: 1.05; p ¼ 0.82, p
for the difference ¼ 0.02). Patients with LBBB who
experienced a ﬁrst VTE had no change in the risk of
subsequent VTEs with CRT-D (HR: 0.98; p ¼ 0.85).
In contrast, the risk of recurrent VTEs with CRT-D was
signiﬁcantly increased among non-LBBB patients (HR:
3.62; p ¼ 0.002, p for the difference ¼ 0.009). Recurrent
VTEs increased the risk of subsequent heart failure or
death.
Conclusions In MADIT-CRT, active treatment with
CRT-D was associated with a signiﬁcant reduction in the
risk of life-threatening VTEs. However, our ﬁndings
suggest that CRT-D does not reduce the risk of subsequent
VTEs in patients who experience a ﬁrst arrhythmic event
and may increase subsequent arrhythmic risk in non-LBBB
patients. (Multicenter Automatic Deﬁbrillator Implantation
With Cardiac Resynchronization Therapy [MADIT-CRT];
NCT00180271) (46).Left Main Percutaneous Coronary Intervention
The introduction of drug-eluting stents and advances in
catheter techniques have led to increasing acceptance of
percutaneous coronary intervention (PCI) as a viable alter-
native to coronary artery bypass graft (CABG) for unpro-
tected left main disease. Current guidelines state that it is
reasonable to consider unprotected left main PCI in patients
with low to intermediate anatomic complexity who are at
increased surgical risk. Data from randomized trials
involving patients who are candidates for either treatment
strategy provide novel insight into the relative safety and
efﬁcacy of PCI for this lesion subset. Herein, we review the
current data comparing PCI with CABG for left main
disease, summarize recent guideline recommendations, and
provide an update on technical considerations that may
optimize clinical outcomes in left main PCI. More than 30
years have passed since the ﬁrstdand faileddattempt at left
main percutaneous coronary intervention (PCI) by Andreas
Gruentzig. Given the low prevalence of this lesion subset,
robust data from dedicated randomized controlled trials
(RCTs) comparing PCI with coronary artery bypass graft
(CABG) are lacking, and CABG remains the traditional
standard for the treatment of left main obstruction according
to society guidelines (1). The introduction of drug-eluting
stents (DES), combined with a culture within interven-
tional cardiology that promotes shared experience through
prompt dissemination of new techniques and outcomes, has
led to a rapid evolution in the percutaneous approach to left
main disease and broad clinical adoption of PCI that out-
paces current guidelines. Herein, we summarize these
guidelines, review the current state of observational and
RCT data that pertain to left main intervention, and provide
an update on technical considerations that may optimize
clinical outcomes in left main PCI (47).Factors Contributing to the Lower Mortality With
Ticagrelor Compared With Clopidogrel in Patients
Undergoing Coronary Artery Bypass Surgery
Objectives This study investigated the differences in
speciﬁc causes of post–coronary artery bypass graft surgery
(CABG) deaths in the PLATO (Platelet Inhibition and
Patient Outcomes) trial.
Background In the PLATO trial, patients assigned to
ticagrelor compared with clopidogrel and who underwent
CABG had signiﬁcantly lower total and cardiovascular
mortality.
Methods In the 1,261 patients with CABG performed
within 7 days after stopping study drug, reviewers blinded to
treatment assignment classiﬁed causes of death into
subcategories of vascular and nonvascular, and speciﬁcally
identiﬁed bleeding or infection events that either caused or
subsequently contributed to death.
Results Numerically more vascular deaths occurred in the
clopidogrel versus the ticagrelor group related to myocardial
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sudden death (9 vs. 3), and bleeding, including hemorrhagic
stroke (7 vs. 2). Clopidogrel was also associated with an
excess of nonvascular deaths related to infection (8 vs. 2).
Among factors directly causing or contributing to death,
bleeding and infections were more common in the clopi-
dogrel group compared with the ticagrelor group (infections:
16 vs. 6, p < 0.05, and bleeding: 27 vs. 9, p < 0.01, for
clopidogrel and ticagrelor, respectively).
Conclusions The mortality reduction with ticagrelor versus
clopidogrel following CABG in the PLATO trial was
associated with fewer deaths from cardiovascular, bleeding,
and infection complications. (Platelet Inhibition and Patient
Outcomes [PLATO]; NCT00391872) (48).The Problem With Asymptomatic Cerebral Embolic
Complications in Vascular Procedures: What If
They Are Not Asymptomatic?
Cerebral embolic events related to carotid and cardiac
disease have been known for decades. Recently, cerebral
embolic events have become a focus of clinical impor-
tance as complications of vascular procedures. Further,
the development of new technologies and procedures has
increased the overall clinical signiﬁcance. Although the
relative safety of these procedures is usually deﬁned by
acute stroke risk, it is also becoming clear that far more
subclinical events are occurring. Recent reports provided
substantial evidence of memory loss, cognitive decline,
and dementia related to these so-called silent infarcts.
Literature reports of magnetic resonance imaging events
lead to an estimate of as many as 600,000 patients with
new brain injury each year in the United States alone.
Given the magnitude of the numbers involved, the
impact of accelerated cognitive loss and premature
senescence in a vulnerable at-risk population could well
be signiﬁcant.
Cerebral embolic events related to carotid and cardiac
disease have been known for decades and have formed
a central part of clinical stroke research and management.
More recently, cerebral embolic events have become a focus
of clinical importance as complications of vascular proce-
dures. Surgical and endovascular procedures, both neuro-
interventional and cardiac, are associated with embolic
risks, and the development of new technologies and
procedures has increased the overall clinical signiﬁcance.
Although the relative safety of these procedures is usually
deﬁned by the acute stroke risk, it is also becoming clear
that far more subclinical events are occurring. Although the
fundamental issues of the nature of the embolic particles,
precise mechanisms of cerebral injury, and effective
prevention remain debated and unclear, recent reports have
provided substantial evidence of memory loss, cognitive
decline, and dementia related to these so-called silent
infarcts (49).Pre-procedural Risk Quantiﬁcation for Carotid
Stenting Using the CAS Score: A Report From the
NCDR CARE Registry
Objectives We developed and internally validated a risk
score to predict in-hospital stroke or death after carotid
artery stenting (CAS).
Background A tool that accurately assesses CAS risk could
aid clinical decision making and improve patient selection.
Methods Patients undergoing CAS without acute evolving
stroke from April 2005 through June 2011 as part of the
NCDR Carotid Artery Revascularization and Endarterec-
tomy (CARE) Registry were included. In-hospital stroke or
death was modeled using logistic regression with 35 candi-
date variables. Internal validation was achieved with boot-
strapping, and model discrimination and calibration were
assessed.
Results A total of 271 (2.4%) primary endpoint events
occurred during 11,122 procedures. Independent predictors
of stroke or death included impending major surgery,
previous stroke, age, symptomatic lesion, atrial ﬁbrillation,
and absence of previous ipsilateral carotid endarterectomy.
The model was well calibrated with moderate discriminatory
ability (C-statistic: 0.71) overall, and within symptomatic
(C-statistic: 0.68) and asymptomatic (C-statistic: 0.72)
subgroups. The inclusion of available angiographic variables
did not improve model performance (C-statistic: 0.72,
integrated discrimination improvement 0.001; p ¼ 0.21).
The NCDR CAS score was developed to support
prospective risk quantiﬁcation.
Conclusions The NCDR CAS score, comprising 6 clinical
variables, predicts in-hospital S/D after CAS. This tool may
be useful to assist clinicians in evaluating optimal manage-
ment, share more accurate pre-procedural risks with
patients, and improve patient selection for CAS (50).Trends in Permanent Pacemaker Implantation in
the United States From 1993 to 2009: Increasing
Complexity of Patients and Procedures
Objectives This study sought to deﬁne contemporary
trends in permanent pacemaker use by analyzing a large
national database.
Background The Medicare National Coverage Determi-
nation for permanent pacemaker, which emphasized single-
chamber pacing, has not changed signiﬁcantly since 1985.
We sought to deﬁne contemporary trends in permanent
pacemaker use by analyzing a large national database.
Methods We queried the Nationwide Inpatient Sample to
identify permanent pacemaker implants between 1993 and
2009 using the International Classiﬁcation of Diseases-
Ninth Revision-Clinical Modiﬁcation procedure codes for
dual-chamber (DDD), single-ventricular (VVI), single-atrial
(AAI), or biventricular (BiV) devices. Annual permanent
pacemaker implantation rates and patient demographics
were analyzed.
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received permanent pacemakers in the United States.
Overall use increased by 55.6%. By 2009, DDD use
increased from 62% to 82% (p < 0.001), whereas single-
chamber ventricular pacemaker use fell from 36% to 14%
(p ¼ 0.01). Use of DDD devices was higher in urban,
nonteaching hospitals (79%) compared with urban teaching
hospitals (76%) and rural hospitals (72%). Patients with
private insurance (83%) more commonly received DDD
devices than Medicaid (79%) or Medicare (75%) recipients
(p < 0.001). Patient age and Charlson comorbidity index
increased over time. Hospital charges ($2011) increased
45.3%, driven by the increased cost of DDD devices.
Conclusions There is a steady growth in the use of
permanent pacemakers in the United States. Although
DDD device use is increasing, whereas single-chamber
ventricular pacemaker use is decreasing. Patients are
becoming older and have more medical comorbidities. These
trends have important health care policy implications (51).Pilot Trial of Cryoplasty or Conventional Balloon
Post-Dilation of Nitinol Stents for
Revascularization of Peripheral Arterial Segments:
The COBRA Trial
Objectives The purpose of this study is to compare post-
dilation strategies of nitinol self-expanding stents implan-
ted in the superﬁcial femoral artery of diabetic patients with
peripheral arterial disease.
Background Endovascular treatment of superﬁcial femoral
artery disease with nitinol self-expanding stents is associated
with high rates of in-stent restenosis in patients with dia-
betes mellitus.
Methods We conducted a prospective, multicenter,
randomized, controlled clinical trial of diabetic patients to
investigate whether post-dilation of superﬁcial femoral artery
nitinol self-expanding stents using a cryoplasty balloon
reduces restenosis compared to a conventional balloon.
Inclusion criteria included diabetes mellitus, symptomatic
peripheral arterial disease, and superﬁcial femoral artery
lesions requiring implantation of stents >5 mm in diameter
and >60 mm in length. Primary endpoint was binary
restenosis at 12 months, deﬁned as 2.5-fold increase in
peak systolic velocity by duplex ultrasonography.
Results Seventy-four patients, with 90 stented superﬁcial
femoral artery lesions, were randomly assigned to post-
dilation using cryoplasty (n ¼ 45 lesions) or conventional
balloons (n ¼ 45 lesions). Mean lesion length was 148  98
mm, mean stented length was 190  116 mm, mean stent
diameter was 6.1  0.4 mm, and 50% of the lesions were
total occlusions. Post-dilation balloon diameters were
5.23  0.51 mm versus 5.51  0.72 mm in the cryoplasty
and conventional balloon angioplasty groups, respectively
(p ¼ 0.02). At 12 months, binary restenosis was signiﬁcantly
lower in the cryoplasty group (29.3% vs. 55.8%, p ¼ 0.01;
odds ratio: 0.36, 95% conﬁdence interval: 0.15 to 0.89).Conclusions Among diabetic patients undergoing
implantation of nitinol self-expanding stents in the super-
ﬁcial femoral artery, post-dilation with cryoplasty balloon
reduced binary restenosis compared to conventional balloon
angioplasty. (Study Comparing Two Methods of Expanding
Stents Placed in Legs of Diabetics With Peripheral Vascular
Disease [COBRA]; NCT00827853) (52).Double Antiplatelet Therapy After Drug-Eluting
Stent Implantation: Risk Associated With
Discontinuation Within the First Year
Objectives The goal of this study was to assess the risk
associated with double antiplatelet therapy (DAT) discon-
tinuation, and speciﬁcally, temporary discontinuation, during
the ﬁrst year after drug-eluting stent (DES) implantation.
Background Doubts remain about the risk of temporary
DAT discontinuation within 1 year after DES implantation.
Methods A total of 1,622 consecutive patients undergoing
DES implantation at 29 hospitals were followed up at 3, 6,
9, and 12 months to record the 1-year antiplatelet therapy
discontinuation (ATD) rate, the number of days without
DAT, and the rate of 1-year major cardiac events. Cox
regression was used to analyze the association between ATD
considered as a time-dependent covariate and 1-year cardiac
events.
Results One hundred seventy-two (10.6%) patients inter-
rupted at least 1 antiplatelet drug during the ﬁrst year after
DES implantation, although only 1 during the ﬁrst month.
Most (n ¼ 111, 64.5%) interrupted DAT temporarily
(median: 7 days; range: 5 to 8.5): 79 clopidogrel (31
temporarily), 38 aspirin (27 temporarily), and 55 both drugs
(53 temporarily). Discontinuation was followed by acute
coronary syndrome in 7 (4.1%; 95% conﬁdence interval
[CI]: 1.7 to 8.2), a similar rate of major cardiac events to that
in patients without ATD (n ¼ 80; 5.5%; 95% CI: 4.4 to 6.8;
p ¼ 0.23). ATD was not independently associated with 1-
year major cardiac events (hazard ratio: 1.32 [95% CI:
0.56 to 3.12]).
Conclusions ATD within the ﬁrst year and beyond the
ﬁrst month after DES is not exceptional, is usually tempo-
rary, and does not appear to have a large impact on risk (53).A New Strategy for Discontinuation of Dual
Antiplatelet Therapy: The RESET Trial (REal Safety
and Efﬁcacy of 3-month dual antiplatelet Therapy
following Endeavor zotarolimus-eluting stent
implantation)
Objectives The goal of this study was to evaluate shorter
duration (3 months) dual antiplatelet therapy (DAPT) after
drug-eluting stent (DES) implantation.
Background There have been few published reports of
prospective randomized clinical studies comparing the
safety and efﬁcacy of shorter duration DAPT after DES
implantation.
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coronary artery stenosis into 2 groups according to DAPT
duration and stent type: 3-month DAPT following
Endeavor zotarolimus-eluting stent (E-ZES) implantation
(E-ZESþ3-month DAPT, n ¼ 1,059) versus 12-month
DAPT following the other DES implantation (standard
therapy, n ¼ 1,058). We hypothesized that the E-ZESþ3-
month DAPT would be noninferior to the standard therapy
for the primary composite endpoint (cardiovascular death,
myocardial infarction, stent thrombosis, target\vessel revas-
cularization, or bleeding) at 1 year.
Results The primary endpoint occurred in 40 (4.7%)
patients assigned to E-ZESþ3-month DAPT compared
with 41 (4.7%) patients assigned to the standard therapy
(difference: 0.0%; 95% conﬁdence interval [CI]: 2.5 to 2.5;
p ¼ 0.84; p < 0.001 for noninferiority). The composite rates
of any death, myocardial infarction, or stent thrombosis were
0.8% and 1.3%, respectively (difference: 0.5%; 95%
CI: 1.5 to 0.5; p ¼ 0.48). The rates of stent thrombosis
were 0.2% and 0.3%, respectively (difference: 0.1%; 95%
CI: 0.5 to 0.3; p ¼ 0.65) without its further occurrence
after cessation of clopidogrel in the E-ZESþ3-month
DAPT group. The rates of target vessel revascularization
were 3.9% and 3.7%, respectively (difference: 0.2%; 95%
CI: 2.3 to 2.6; p ¼ 0.70).
Conclusions E-ZESþ3-month DAPT was noninferior to
the standard therapy with respect to the occurrence of the
primary endpoint. (REal Safety and Efﬁcacy of a 3-month
dual antiplatelet Therapy following E-ZES implantation
[RESET]; NCT01145079) (54).Updated Standardized Endpoint Deﬁnitions for
Transcatheter Aortic Valve Implantation: The Valve
Academic Research Consortium-2 Consensus
Document
Objectives The aim of the current Valve Academic
Research Consortium (VARC)-2 initiative was to revisit the
selection and deﬁnitions of transcatheter aortic valve
implantation (TAVI) clinical endpoints to make them more
suitable to the present and future needs of clinical trials. In
addition, this document is intended to expand the under-
standing of patient risk stratiﬁcation and case selection.
Background A recent study conﬁrmed that VARC deﬁ-
nitions have already been incorporated into clinical and
research practice and represent a new standard for consis-
tency in reporting clinical outcomes of patients with symp-
tomatic severe aortic stenosis (AS) undergoing TAVI.
However, as the clinical experience with this technology has
matured and expanded, certain deﬁnitions have become
unsuitable or ambiguous.
Methods and Results Two in-person meetings (held in
September 2011 in Washington, DC, USA, and in
February 2012 in Rotterdam, the Netherlands) involving
VARC study group members, independent experts
(including surgeons, interventional and non-interventionalcardiologists, imaging specialists, neurologists, geriatric
specialists, and clinical trialists), the US Food and Drug
Administration (FDA), and industry representatives,
provided much of the substantive discussion from which
this VARC-2 consensus manuscript was derived. This
document provides an overview of risk assessment and
patient stratiﬁcation that need to be considered for accurate
patient inclusion in studies. Working groups were assigned
to deﬁne the following clinical endpoints: mortality, stroke,
myocardial infarction, bleeding complications, acute kidney
injury, vascular complications, conduction disturbances and
arrhythmias, and a miscellaneous category including rele-
vant complications not previously categorized. Furthermore,
comprehensive echocardiography recommendations are
provided for the evaluation of prosthetic valve (dys)func-
tion. Deﬁnitions for the quality of life assessments are also
reported. These endpoints formed the basis for several
recommended composite endpoints.
Conclusions This VARC-2 document has provided
further standardization of endpoint deﬁnitions for studies
evaluating the use of TAVI, which will lead to improved
comparability and interpretability of the study results,
supplying an increasingly growing body of evidence with
respect to TAVI and/or surgical aortic valve replacement.
This initiative and document can furthermore be used as
a model during current endeavors of applying deﬁnitions to
other transcatheter valve therapies (for example, mitral valve
repair) (55).Cost-Effectiveness and Clinical Effectiveness of
Catheter-Based Renal Denervation for Resistant
Hypertension
Objectives The purpose of this study was to assess cost-
effectiveness and long-term clinical beneﬁts of renal dener-
vation in resistant hypertensive patients.
Background Resistant hypertension affects 12% of hyper-
tensive persons. In the Symplicity HTN-2 randomized
controlled trial, catheter-based renal denervation (RDN)
lowered systolic blood pressure by 32  23 mm Hg from
178  18 mm Hg at baseline.
Methods A state-transition model was used to predict the
effect of RDN and standard of care on 10-year and lifetime
probabilities of stroke, myocardial infarction, all coronary
heart disease, heart failure, end-stage renal disease, and
median survival. We adopted a societal perspective and
estimated an incremental cost-effectiveness ratio in U.S.
dollars per quality-adjusted life-year, both discounted at 3%
per year. Robustness and uncertainty were evaluated using
deterministic and probabilistic sensitivity analyses.
Results Renal denervation substantially reduced event
probabilities (10-year/lifetime relative risks: stroke 0.70/
0.83; myocardial infarction 0.68/0.85; all coronary heart
disease 0.78/0.90; heart failure 0.79/0.92; end-stage renal
disease 0.72/0.81). Median survival was 18.4 years for
RDN versus 17.1 years for standard of care. The discounted
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quality-adjusted life-year. Findings were relatively insensi-
tive to variations in input parameters except for systolic
blood pressure reduction, baseline systolic blood pressure,
and effect duration. The 95% credible interval for incre-
mental cost-effectiveness ratio was cost-saving to $31,460
per quality-adjusted life-year.
Conclusions The model suggests that catheter-based renal
denervation, over a wide range of assumptions, is a cost-
effective strategy for resistant hypertension that might
result in lower cardiovascular morbidity and mortality (56).Clinical and Angiographic Outcomes of Patients
Treated With Everolimus-Eluting Stents or First-
Generation Paclitaxel-Eluting Stents for
Unprotected Left Main Disease
Objectives The goal of this study was to compare the
outcomes of patients treated with everolimus-eluting stents
(EES) with outcomes of patients treated with ﬁrst-
generation paclitaxel-eluting stents (PES) for unprotected
left main disease (ULMD).
Background No data exist about the comparison of these
2 types of stents in ULMD.
Methods The primary endpoint of the study was a 1-year
composite of cardiac death, nonfatal myocardial infarction,
target vessel revascularization, and stroke (MACE).
Secondary endpoints were 1-year target vessel failure (TVF)
and 9-month angiographic in-segment restenosis >50%.
Results From 2004 to 2010, a total of 390 patients underwent
ULMD percutaneous coronary intervention (224 received
PES and 166 EES). The 1-year MACE rate was 21.9% in the
PES group and 10.2% in the EES group (p¼ 0.002). TVF rate
was 20.5% in the PES group and 7.8% in the EES group
(p < 0.001). The in-segment restenosis rate was 5.2% in the
EES group and 15.6% in the PES group (p ¼ 0.002). EES
and EuroSCORE were the only variables related to the risk
of MACE. EES (odds ratio: 0.32; p ¼ 0.007) was also inde-
pendently related to the risk of restenosis.
Conclusions EES implantation for ULMD is associated
with a reduced incidence of 1-year MACE, TVF, and
restenosis as compared with PES implantation (57).Reduction in Mortality as a Result of Direct
Transport From the Field to a Receiving Center for
Primary Percutaneous Coronary Intervention
Objectives This study sought to determine whether
mortality complicating ST-segment elevation myocardial
infarction (STEMI) was impacted by the design of transport
systems.
Background It is recommended that regions develop
systems to facilitate rapid transfer of STEMI patients to
centers equipped to perform primary percutaneous coronary
intervention (PCI), yet the impact on mortality from the
design of such systems remains unknown.Methods Within the framework of a citywide system where
all STEMI patients are referred for primary PCI, we
compared patients referred directly from the ﬁeld to a PCI
center to patients transported beforehand from the ﬁeld to
a non–PCI-capable hospital. The primary outcome was all-
cause mortality at 180 days.
Results A total of 1,389 consecutive patients with STEMI
were assessed by the emergency medical services (EMS) and
referred for primary PCI: 822 (59.2%) were referred directly
from the ﬁeld to a PCI center, and 567 (40.8%) were
transported to a non–PCI-capable hospital ﬁrst. Death at
180 days occurred in 5.0% of patients transferred directly
from the ﬁeld, and in 11.5% of patients transported from the
ﬁeld to a non–PCI-capable hospital (p < 0.0001. After
adjusting for baseline characteristics in a multivariable
logistic regression model, mortality remained lower among
patients referred directly from the ﬁeld to the PCI center
(odds ratio: 0.52, 95% conﬁdence interval: 0.31 to 0.88, p ¼
0.01). Similar results were obtained by using propensity
score methods for adjustment.
Conclusions A STEMI system allowing EMS to transport
patients directly to a primary PCI center was associated with
a signiﬁcant reduction in mortality. Our results support the
concept of STEMI systems that include pre-hospital referral
by EMS (58).Electrocardiographic Q-Wave “Remodeling” in
Reperfused ST-Segment Elevation Myocardial
Infarction: Validation Study With CMR
Objectives The aim of this study was to evaluate the
evolution in Q-wave expression during the ﬁrst 5 years after
a primary, successfully reperfused ST-segment elevation
myocardial infarction (MI), using cardiac magnetic reso-
nance (CMR) for infarct location, and to depict changes in
infarct size and left ventricular remodeling over time.
Background In the absence of QRS confounders, abnormal
Q waves are usually diagnostic of myocardial necrosis. It is
hypothesized that Q-wave regression after MI could be
related to smaller infarct sizes. Late gadolinium enhance-
ment accurately depicts MI of any age.
Methods Forty-six MI patients underwent electrocardiog-
raphy and CMR at 1 week (baseline), 4 months, 1 year, and
5 years post-infarction. Conventional CMR parameters were
analyzed, and infarct presence, location, and size were
assessed using late gadolinium enhancement CMR. Infarct
locations were anterior or nonanterior (inferior and/or
lateral), using late gadolinium enhancement CMR as
a reference. For each time point, patients were classiﬁed as
having a diagnostic/nondiagnostic electrocardiogram (ECG)
using the European Society of Cardiology/American
College of Cardiology Foundation/American Heart Asso-
ciation/World Heart Federation consensus criteria for
previous Q-wave infarct.
Results At baseline, 11 patients (23%) did not meet
the criteria for Q-wave MI. Non–Q-wave infarcts were
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anterior Q-wave infarcts (n ¼ 17) were correctly localized,
whereas in 7 of 19 nonanterior Q-wave infarcts, the location
or extent of the infarct was misjudged by electrocardiography.
At 4-month/1-year follow-up, in 10 patients (3 anterior/7
nonanterior), the ECG became nondiagnostic. The ECG
remained nondiagnostic at 5-year follow-up. A cutoff infarct
size of 6.2% at 1 year yielded a sensitivity of 89% and a spec-
iﬁcity of 74% to predict the presence or absence of Q waves.
Conclusions The incidence of nondiagnostic ECGs for
previous MI using the current European Society of Cardi-
ology/American College of Cardiology Foundation/Amer-
ican Heart Association/World Heart Federation criteria is
substantial and increases with time post-infarction from 23%
immediately post-infarction to 44% at 5-year follow-up (59).Patterns and Predictors of Stress Testing Modality
After Percutaneous Coronary Stenting: Data From
the NCDR
Objectives We evaluated temporal trends and geographic
variation in choice of stress testing modality after percuta-
neous coronary intervention (PCI), as well as associations
between modality and procedure use after testing.
Background Stress testing is frequently performed
post-PCI, but the choices among available modalities
(electrocardiography only, nuclear, or echocardiography;
pharmacological or exercise stress) and consequences of
such choices are not well characterized.
Methods CathPCI Registry data were linked with iden-
tiﬁable Medicare claims to capture stress testing use between
60 and 365 days post-PCI and procedures within 90 days
after testing. Testing rates and modality used were modeled
on the basis of patient, procedure, and PCI facility factors,
calendar quarter, and Census Divisions using Poisson and
logistic regression. Post-test procedure use was assessed
using Gray’s test.
Results Among 284,971 patients, the overall stress testing
rate after PCI was 53.1 per 100 person-years. Testing rates
declined from 59.3 in quarter 1 (2006) to 47.1 in quarter 4
(2008), but the relative use of modalities changed little.
Among exercise testing recipients, adjusted proportions
receiving electrocardiography-only testing varied from 6.8%
to 22.8% across Census Divisions; and among exercise
testing recipients having an imaging test, the proportion
receiving echocardiography (versus nuclear) varied from
9.4% to 34.1%. Post-test procedure use varied among
modalities; exercise electrocardiography-only testing was
associated with more subsequent stress testing (13.7% vs.
2.9%; p < 0.001), but less catheterization (7.4% vs. 14.1%;
p < 0.001) than imaging-based tests.
Conclusions Modest reductions in stress testing after PCI
occurring between 2006 and 2008 cannot be ascribed to
trends in use of any single modality. Additional research
should assess whether this trend represents better patient
selection for testing or administrative policies (e.g., restrictedaccess for patients with legitimate testing needs). Geo-
graphic variation in utilization of stress modalities and
differences in downstream procedure use among modalities
suggest a need to identify optimal use of the different test
modalities in individual patients (60).
Comparative Effectiveness of Drug-Eluting Versus
Bare-Metal Stents in Elderly Patients Undergoing
Revascularization of Chronic Total Coronary
Occlusions: Results From the National
Cardiovascular Data Registry, 2005–2008
Objectives This study sought to investigate the long-term
effectiveness of drug-eluting stents (DES) versus bare-
metal stents (BMS).
Background Improved recanalization techniques have
increased interest in percutaneous coronary intervention
(PCI) for chronic total coronary occlusion (CTO). The
long-term effectiveness of DES and BMS is not known.
Methods We used data from 10,261 stable patients
age 65 years at 889 U.S. hospitals who underwent CTO
PCI from January 1, 2005, to December 31, 2008, in the
NCDR (National Cardiovascular Data Registry) CathPCI
Registry with linked Medicare inpatient claims for follow-
up. Patient and procedural characteristics, and 30-month
death, myocardial infarction, revascularization, and hospi-
talization for bleeding were evaluated by stent type.
Outcomes following stenting were adjusted and compared
using propensity score matching.
Results DES were used for CTO PCI in 8,218 (80%) and
BMS in 2,043 (20%). DES patients were younger (74.0 vs.
75.5 years, p < 0.001), had longer lesions (18.8 vs. 16.5 mm,
p < 0.001), received more stents (2 stents in 45.7% vs.
37.9%, p < 0.001), and underwent multivessel PCI (18.9%
vs. 15.1%, p< 0.001). DES implantation was associated with
a lower hazard of mortality (hazard ratio [HR]: ¼ 0.72, 95%
conﬁdence interval [CI]: 0.60 to 0.86, p < 0.001), a similar
hazard for myocardial infarction (HR: 0.85, 95% CI: 0.61 to
1.19, p¼ 0.35), and subsequent revascularization (HR: 0.94,
95% CI: 0.79 to 1.12, p ¼ 0.48), including PCI (HR: 0.98,
95% CI: 0.83 to 1.19, p ¼ 0.87) and coronary artery bypass
grafting (HR: 0.71, 95% CI: 0.46 to 1.10, p ¼ 0.12).
Hospitalization for bleeding was also similar for DES versus
BMS (HR: 0.92; 95% CI: 0.61 to 1.39, p ¼ 0.70).
Conclusions Compared with BMS, DES use in stable
patients undergoing CTO PCI was associated with lower
mortality, as well as similar myocardial infarction and repeat
revascularization rates without an increase in subsequent
bleeding requiring hospitalization (61).
Evaluation of Efﬁcacy and Dose Response of
Different Paclitaxel-Coated Balloon Formulations
in a Novel Swine Model of Iliofemoral In-Stent
Restenosis
Objectives The authors aimed to validate a novel iliofe-
moral in-stent restenosis (ISR) model for the efﬁcacy
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familial hypercholesterolemic swine (FHS).
Background Most of the validation work regarding PCB
technologies has been performed in the coronary territory of
juvenile domestic swine. Although invaluable for safety
evaluation, this model is not suited for the evaluation of the
efﬁcacy of peripheral PCB technologies.
Methods Twenty-four iliofemoral segments in 12 FHS
underwent balloon injury and self-expanding stent place-
ment. After 21 days, the resulting ISR lesions were treated
with either 1 mg/mm2 dose (n ¼ 8), or 3 mg/mm2 dose (n ¼
8) PCB (Cotavance, Bayer Pharma AG/MEDRAD, Indi-
anola, Pennsylvania), or with an identical uncoated control
balloon (n ¼ 8).
Results At termination (28 days after treatment), the
percent diameter stenosis by quantitative vascular analysis in
the control group was higher (31.2  13.7%) compared with
the 1 mg/mm2 (19.3  14.0%, 38% reduction) and 3 mg/
mm2 (8.6  10.7%, 72% reduction) PCB groups. Intra-
vascular ultrasound analysis showed 36% (1 mg/mm2 dose,
p ¼ 0.04) and 55% (3 mg/mm2 dose, p < 0.01) reductions in
neointimal volume stenosis. In the histological analysis, the
control group showed the highest degree of percent area
stenosis (65  14.3%). The reductions in percent area
stenosis was 13.2% (p ¼ 0.5) and 26% (p ¼ 0.04) in the
1 mg/mm2 and 3 mg/mm2 dose groups, respectively.
Conclusions The FHS model of iliofemoral ISR demon-
strated a dose-dependent effect on the inhibition of
neointimal proliferation of a clinically validated PCB tech-
nology. This model represents a positive step toward the
efﬁcacy evaluation of PCB in the peripheral vascular
territory (62).Predictors of Early, Late, and Very Late Stent
Thrombosis After Primary Percutaneous Coronary
Intervention With Bare-Metal and Drug-Eluting
Stents for ST-Segment Elevation Myocardial
Infarction
Objectives The purpose of this study was to evaluate the
frequency and predictors of stent thrombosis (ST) after
stenting for ST-segment elevation myocardial infarction
(STEMI).
Background Stent thrombosis remains a major concern
with STEMI patients treated with primary percutaneous
coronary intervention.
Methods Consecutive patients (N ¼ 1,640) undergoing
stenting for STEMI were prospectively enrolled in our
database and followed for 1 to 15 years. Bare-metal stents
were implanted from 1995 to 2002, and drug-eluting and
bare-metal stents were implanted from 2003 to 2009. Stent
thrombosis was deﬁned as deﬁnite or probable.
Results Our population had a high risk proﬁle, including
a high incidence of Killip class III to IV (11.5%) and
STEMI due to ST (10.2%). Stent thrombosis occurred in
124 patients, including 42 with early ST (0 to 30 days), 35with late ST (31 days to 1 year), and 47 with very late ST
(>1 year). The frequency of ST was 2.7% at 30 days, 5.2% at
1 year, and 8.3% at 5 years. Independent predictors of early
or late ST were STEMI due to ST (hazard ratio [HR]: 4.38,
95% conﬁdence interval [CI]: 2.27 to 8.45), small stent size
(HR: 2.44, 95% CI: 1.49 to 4.00), Killip class III to IV (HR:
2.39, 95% CI: 1.30 to 4.40), and reperfusion time 2 h
(HR: 2.09, 95% CI: 1.03 to 4.24). Drug-eluting stent was
the only independent predictor of very late ST (HR: 3.73,
95% CI: 1.81 to 7.88).
Conclusions Stent thrombosis after primary percutaneous
coronary intervention is relatively frequent and continues to
increase out to 5 years. New strategies are needed to prevent
ST in STEMI patients, and targeted therapies are needed in
patients identiﬁed at highest risk (63).Open Versus Endovascular Stent Graft Repair of
Abdominal Aortic Aneurysms A Meta-Analysis of
Randomized Trials
Objectives This study sought to evaluate the short-,
intermediate-, and longer-term outcomes after endovascular
versus open repair of abdominal aortic aneurysms (AAA),
including both AAA-related and all-cause mortality.
Background Endovascular stent graft placement for AAA
has gained broad acceptance as an alternative to open
surgical repair due to a lower perioperative morbidity and
mortality. The intermediate- and long-term all-cause and
aneurysm-related mortality vary among studies. Thus, we
sought to perform a meta-analysis of open versus endovas-
cular repair for treating AAA.
Methods Electronic databases were queried for identiﬁca-
tion of prospective, randomized trials of open surgery versus
endovascular stent graft repair of AAA. A total of 10 pub-
lished papers reporting on 6 studies at different follow-up
intervals were identiﬁed; they involved 2,899 patients with
AAA repair procedures, of whom, 1,470 underwent endo-
vascular stent graft AAA exclusion and 1,429 were treated
by open AAA repair.
Results At 30 days, the pooled relative risk of all-cause
mortality was lower in the endovascular group (relative risk
[RR]: 0.35, 95% conﬁdence interval [CI]: 0.19 to 0.64) than
in the open surgery group. At intermediate follow-up, the
all-cause mortality had a nonsigniﬁcant difference (RR:
0.78, 95% CI: 0.57 to 1.08), the AAA-related mortality was
signiﬁcantly lower (RR: 0.46, 95% CI: 0.28 to 0.74) and
reintervention rates were higher (RR: 1.48, 95% CI: 1.06 to
2.08) in the endovascular group than in the open surgery
group. At long-term follow-up, there was no signiﬁcant
difference in all-cause mortality (RR: 0.99, 95% CI: 0.85 to
1.15) or AAA-related mortality (RR: 1.58, 95% CI: 0.20 to
12.74), whereas the signiﬁcant difference in the rate of
reinterventions persisted (RR: 2.54, 95% CI: 1.58 to 4.08).
Conclusions In patients randomized to open or endovas-
cular AAA repair, all-cause perioperative mortality, as well
as AAA-related mortality at short- and intermediate-term
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stent graft placement. This was associated with greater
reintervention in the endovascular group noted at interme-
diate follow-up. Long-term survival appears to converge
between the 2 groups (64).
Spontaneous Coronary Artery Dissection:
Long-Term Follow-Up of a Large Series of Patients
Prospectively Managed With a “Conservative”
Therapeutic Strategy
Objectives This study sought to assess the long-term clinical
outcome of patients with spontaneous coronary artery
dissection (SCD) managed with a conservative strategy.
Background SCD is a rare, but challenging, clinical entity.
Methods A prospective protocol, including a conservative
management strategy, was followed. Revascularization was
only considered in cases with ongoing/recurrent ischemia.
Inﬂammatory/immunologic markers were systematically
obtained.
Results Forty-ﬁve consecutive patients (incidence 0.27%)
were studied during a 6-year period. Of these, 27 patients
(60%) had “isolated” SCD (I-SCD), and 18 had SCD
associated with coronary artery disease (A-SCD). Age was
53  11 years, and 26 patients were female. Most patients
presented with an acute myocardial infarction. SCD had
a diffuse angiographic pattern (length: 31  23 mm). In 11
patients, the diagnosis was conﬁrmed by intracoronary
imaging techniques. Sixteen patients (35%) required revas-
cularization during initial admission. One patient died after
surgery, but no additional patient experienced recurrent
myocardial infarction. No signiﬁcant inﬂammatory/immu-
nologic abnormalities were detected. At follow-up (median
730 days), only 3 patients presented with adverse events (1
died of congestive heart failure, and 2 required revasculari-
zation). No patient experienced a myocardial infarction or
died suddenly. Event-free survival was similar (94% and
88%, respectively) in patients with I-SCD and A-SCD.
Notably, at angiographic follow-up, spontaneous “disap-
pearance” of the SCD image was found in 7 of 13 (54%)
patients.
Conclusions In this large prospective series of consecutive
patients with SCD, a “conservative” therapeutic strategy
provided excellent long-term prognosis. Clinical outcome
was similar in patients with I-SCD and A-SCD. The
natural history of SCD includes spontaneous healing with
complete resolution (65).
2-Year Patient-Related Versus Stent-Related
Outcomes: The SORT OUT IV (Scandinavian
Organization for Randomized Trials With Clinical
Outcome IV) Trial
Objectives There are limited head-to-head randomized
data on patient-related versus stent-related outcomes for
everolimus-eluting stents (EES) and sirolimus-eluting stents
(SES).Background In the SORT OUT IV (Scandinavian Orga-
nization for Randomized Trials With Clinical Outcome IV)
trial, comparing the EES with the SES in patients with
coronary artery disease, the EES was noninferior to the SES
at 9 months.
Methods The primary endpoint was a composite: cardiac
death, myocardial infarction (MI), deﬁnite stent thrombosis,
or target vessel revascularization. Safety and efﬁcacy
outcomes at 2 years were further assessed with speciﬁc focus
on patient-related composite (all death, all MI, or any
revascularization) and stent-related composite outcomes
(cardiac death, target vessel MI, or symptom-driven target
lesion revascularization). A total of 1,390 patients were
assigned to receive the EES, and 1,384 patients were
assigned to receive the SES.
Results At 2 years, the composite primary endpoint
occurred in 8.3% in the EES group and in 8.7% in the SES
group (hazard ratio [HR]: 0.94, 95% conﬁdence interval
[CI]: 0.73 to 1.22). The patient-related outcome: 15.0% in
the EES group versus 15.6% in the SES group, (HR: 0.95,
95% CI: 0.78 to 1.15), and the stent-related outcome: 5.2%
in the EES group versus 5.3% in the SES group (HR: 0.97,
95% CI: 0.70 to 1.35) did not differ between groups. Rate of
deﬁnite stent thrombosis was lower in the EES group (0.2%
vs. 0.9%, (HR: 0.23, 95% CI: 0.07 to 0.80).
Conclusions At 2-year follow-up, the EES was found to be
noninferior to the SES with regard to both patient-related
and stent-related clinical outcomes. (The SORT OUT IV
TRIAL [SORT OUT IV]; NCT00552877) (66).A Randomized Comparison of Pulmonary Vein
Isolation With Versus Without Concomitant Renal
Artery Denervation in Patients With Refractory
Symptomatic Atrial Fibrillation and Resistant
Hypertension
Objectives The aim of this prospective randomized study
was to assess the impact of renal artery denervation in
patients with a history of refractory atrial ﬁbrillation (AF)
and drug-resistant hypertension who were referred for
pulmonary vein isolation (PVI).
Background Hypertension is the most common cardio-
vascular condition responsible for the development and
maintenance of AF. Treating drug-resistant hypertension
with renal denervation has been reported to control blood
pressure, but any effect on AF is unknown.
Methods Patients with a history of symptomatic parox-
ysmal or persistent AF refractory to2 antiarrhythmic drugs
and drug-resistant hypertension (systolic blood pressure
>160 mm Hg despite triple drug therapy) were eligible for
enrolment. Consenting patients were randomized to PVI
only or PVI with renal artery denervation. All patients were
followed 1 year to assess maintenance of sinus rhythm and
to monitor changes in blood pressure.
Results Twenty-seven patients were enrolled, and 14 were
randomized to PVI only, and 13 were randomized to PVI
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signiﬁcant reductions in systolic (from 181  7 to 156 
5, p < 0.001) and diastolic blood pressure (from 97  6 to
87  4, p < 0.001) were observed in patients treated with
PVI with renal denervation without signiﬁcant change in the
PVI only group. Nine of the 13 patients (69%) treated with
PVI with renal denervation were AF-free at the 12-month
post-ablation follow-up examination versus 4 (29%) of the
14 patients in the PVI-only group (p ¼ 0.033).
Conclusions Renal artery denervation reduces systolic and
diastolic blood pressure in patients with drug-resistant
hypertension and reduces AF recurrences when combined
with PVI. (Combined Treatment of Resistant Hypertension
and Atrial Fibrillation; NCT01117025) (67).Vascular Complications After Transcatheter Aortic
Valve Replacement: Insights From the PARTNER
(Placement of AoRTic TraNscathetER Valve) Trial
Objectives This study sought to identify incidence,
predictors, and impact of vascular complications (VC) after
transfemoral (TF) transcatheter aortic valve replacement
(TAVR).
Background VC after TF-TAVR are frequent and may be
associated with unfavorable prognosis.
Methods From the randomized controlled PARTNER
(Placement of AoRTic TraNscathetER Valve) trial, a total
of 419 patients (177 from cohort B [inoperable] and 242
from cohort A [operable high-risk]) were randomly assigned
to TF-TAVR and actually received the designated treat-
ment. First-generation Edwards-Sapien valves and delivery
systems were used, via a 22- or 24-F sheath. The 30-day
rates of major and minor VC (modiﬁed Valve Academic
Research Consortium deﬁnitions), predictors, and effect on
1-year mortality were assessed.
Results Sixty-four patients (15.3%) had major VC and 50
patients (11.9%) had minor VC within 30 days of the
procedure. Among patients with major VC, vascular
dissection (62.8%), perforation (31.3%), and access-site
hematoma (22.9%) were the most frequent modes of
presentation. Major VC, but not minor VC, were associ-
ated with signiﬁcantly higher 30-day rates of major
bleeding, transfusions, and renal failure requiring dialysis,
and with a signiﬁcantly higher rate of 30-day and 1-year
mortality. The only identiﬁable independent predictor of
major VC was female gender (hazard ratio [HR]: 2.31
[95% conﬁdence interval (CI): 1.08 to 4.98], p ¼ 0.03).
Major VC (HR: 2.31 [95% CI: 1.20 to 4.43], p ¼ 0.012),
and renal disease at baseline (HR: 2.26 [95% CI: 1.34 to
3.81], p ¼ 0.002) were identiﬁed as independent predic-
tors of 1-year mortality.
Conclusions Major VC were frequent after TF-TAVR in
the PARTNER trial using ﬁrst-generation devices and were
associated with high mortality. However, the incidence and
impact of major VC on 1-year mortality decreased with
lower-risk populations (68).Early Anticoagulation of Bioprosthetic Aortic
Valves in Older Patients: Results From the Society
of Thoracic Surgeons Adult Cardiac Surgery
National Database
Objectives The aim of this study was to evaluate the risks
and beneﬁts of short-term anticoagulation in patients
receiving aortic valve bioprostheses.
Background Patients receiving aortic valve bioprostheses
have an elevated early risk of thromboembolic events;
however, the risks and beneﬁts of short-term anticoagulation
have been debated with limited evidence.
Methods Our cohort consisted of 25,656 patients 65
years of age receiving aortic valve bioprostheses at 797
hospitals within the Society of Thoracic Surgeons Adult
Cardiac Surgery Database (2004 to 2006). The associated
3-month incidences of death or readmission for embolic
(cerebrovascular accident, transient ischemic attack, and
noncerebral arterial thromboembolism) or bleeding events
were compared across discharge anticoagulation strategies
with propensity methods.
Results In this cohort (median age, 77 years), the 3 most
common discharge anticoagulation strategies included:
aspirin-only (49%), warfarin-only (12%), and warfarin plus
aspirin (23%). Among those receiving aspirin-only, 3-month
adverse events were low (death, 3.0%; embolic events, 1.0%;
bleeding events, 1.0%). Relative to aspirin-only, those
treated with warfarin plus aspirin had a lower adjusted risk of
death (relative risk [RR]: 0.80, 95% conﬁdence interval [CI]:
0.66 to 0.96) and embolic event (RR: 0.52, 95% CI: 0.35 to
0.76) but a higher risk of bleeding (RR: 2.80, 95% CI: 2.18
to 3.60). Relative to aspirin-only, warfarin-only patients had
a similar risk of death (RR: 1.01, 95% CI: 0.80 to 1.27),
embolic events (RR: 0.95, 95% CI: 0.61 to 1.47), and
bleeding (RR: 1.23, 95% CI: 0.85 to 1.79). These results
were generally consistent across patient subgroups.
Conclusions Death and embolic events were relatively rare
in the ﬁrst 3 months after bioprosthetic aortic valve
replacement. Compared with aspirin-only, aspirin plus
warfarin was associated with a reduced risk of death and
embolic events, but at the cost of an increased bleeding
risk (69).
Sex Differences in Mortality After Transcatheter
Aortic Valve Replacement for Severe Aortic
Stenosis
Objectives The aim of this study was to examine sex
differences in outcome after transcatheter aortic valve
replacement (TAVR) with real-world data from 2 large
centers in Canada.
Background Transcatheter aortic valve replacement is an
effective alternative to surgical valve replacement in symp-
tomatic patients with severe aortic stenosis, but the impact of
sex on outcomes remains unclear. The PARTNER (Place-
ment of Aortic Transcatheter Valves) 1A trial demonstrated
greater beneﬁt of TAVR over surgery in women, but
JACC Vol. 62, No. 18, 2013 The Editors
October 29, 2013:e245–e437 JACC Topic Collection: Interventional Cardiology
e271whether this was due to the poorer surgical outcome of
women or better TAVR outcome, compared with men, is
unknown.
Methods Consecutive patients (n ¼ 641) undergoing
TAVR in Vancouver and Quebec City, Canada, were
evaluated. Differences in all-cause mortality were examined
with Kaplan-Meier estimates, adjusted logistic regression,
and proportional hazards models.
Results Women comprised 51.3% of the cohort. Balloon-
expandable valves were used in 97% of cases, with trans-
apical approach in 51.7 % women and 38.1% men. Women
had more major vascular complications (12.4% vs. 5.4%, p ¼
0.003) and borderline signiﬁcantly more major/life-
threatening bleeds (21.6% vs. 15.8%, p ¼ 0.08). At base-
line, women had higher aortic gradients and worse renal
function but better ejection fractions. Men had more
comorbidities: prior myocardial infarction, prior revascular-
ization, and chronic obstructive pulmonary disease. The
adjusted odds ratio for 30-day all-cause mortality favored
women, 0.39 (95% conﬁdence interval: 0.19 to 0.80; p ¼
0.01), and this beneﬁt persisted for 2 years, hazard ratio 0.60
(95% conﬁdence interval: 0.41 to 0.88; p ¼ 0.008).
Conclusions Female sex is associated with better short-
and long-term survival after TAVR. Added to the
PARTNER 1A ﬁndings, these results suggest TAVR might
be the preferred treatment option for elderly women with
symptomatic severe aortic stenosis (70).The Impact of Frailty Status on Survival After
Transcatheter Aortic Valve Replacement in Older
Adults With Severe Aortic Stenosis: A Single-
Center Experience
Objectives This study sought to evaluate the impact of
frailty in older adults undergoing transcatheter aortic valve
replacement (TAVR) for symptomatic aortic stenosis.
Background Frailty status impacts prognosis in older adults
with heart disease; however, the impact of frailty on prog-
nosis after TAVR is unknown.
Methods Gait speed, grip strength, serum albumin, and
activities of daily living status were collected at baseline and
used to derive a frailty score among patients who underwent
TAVR procedures at a single large-volume institution. The
cohort was dichotomized on the basis of median frailty score
into frail and not frail groups. The impact of frailty on
procedural outcomes (stroke, bleeding, vascular complica-
tions, acute kidney injury, and mortality at 30 days) and
1-year mortality was evaluated.
Results Frailty status was assessed in 159 subjects who
underwent TAVR (age 86  8 years, Society of Thoracic
Surgery Risk Score 12  4). Baseline frailty score was not
associated with conventionally ascertained clinical variables
or Society of Thoracic Surgery score. Although high frailty
score was associated with a longer post-TAVR hospital stay
when compared with lower frailty score (9  6 days vs. 6  5
days, respectively, p ¼ 0.004), there were no signiﬁcantcrude associations between frailty status and procedural
outcomes, suggesting adequacy of the standard selection
process for identifying patients at risk for periprocedural
complications after TAVR. Frailty status was independently
associated with increased 1-year mortality (hazard ratio: 3.5,
95% conﬁdence interval: 1.4 to 8.5, p ¼ 0.007) after TAVR.
Conclusions Frailty was not associated with increased
periprocedural complications in patients selected as candi-
dates to undergo TAVR but was associated with increased
1-year mortality after TAVR. Further studies will evaluate
the independent value of this frailty composite in older
adults with aortic stenosis (71).Coronary Endothelial Dysfunction Distal to Stent
of First-Generation Drug-Eluting Stents
Objectives This study sought to evaluate the relationship
between coronary endothelial function and neointimal
coverage after drug-eluting stent (DES) implantation.
Background The mechanisms of endothelial dysfunction
after DES implantation remain to be fully elucidated. We
hypothesized that poor neointimal coverage after DES
implantation may be associated with endothelial dysfunction
distal to the stent site.
Methods Sixty-six stable angina patients treated with
a ﬁrst-generation DES were enrolled. At 9-month follow-
up, coronary endothelial function was evaluated with intra-
coronary infusion of incremental doses of acetylcholine
(108, 107, and 106 mol/l) and nitroglycerin (200 mg).
Vascular responses at the segments proximal and distal to
the stent site were angiographically and quantitatively
measured. At the same time, the degree of neointimal
coverage was evaluated using coronary angioscopy and
classiﬁed into 4 grades: 0 (no coverage) to 3 (full coverage).
Results We divided the subjects into poor-coverage
(grades 0 to 1, n ¼ 33) and good-coverage (grades 2 to 3,
n ¼ 33) groups. Acetylcholine induced dose-dependent
coronary vasoconstrictions in both groups. At the segment
distal to the stent, the magnitude of vasoconstriction to
acetylcholine in the poor-coverage group was signiﬁcantly
greater than in the good-coverage group (p < 0.001),
whereas vasomotor responses proximal to the stent and
vasodilation by nitroglycerine were similar between the 2
groups.
Conclusions Coronary endothelial dysfunction distal to the
stent was associated with poor neointimal coverage after
DES implantation (72).Conformational Pulsatile Changes of the Aortic
Annulus: Impact on Prosthesis Sizing by Computed
Tomography for Transcatheter Aortic Valve
Replacement
Objectives This study sought to investigate pulsatile
changes of the aortic annulus and their impact on prosthesis
selection by computed tomography (CT).
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a prerequisite for transcatheter aortic valve replacement.
Methods A total of 110 patients with severe aortic
stenosis (mean age: 82.9  8 years, mean aortic valve area:
0.69  0.18 cm2) underwent electrocardiogram-gated CT.
Aortic annulus dimensions were planimetrically quantiﬁed
as area-derived diameter (DA ¼ 2 U(CSA/p), where
CSA is the cross-sectional area) and perimeter-derived
diameter (DP ¼ P/p, where P is the length of the
perimeter) in 5% increments of the RR interval. Hypo-
thetical prosthesis sizing was based on DA and DP (23-
mm prosthesis for <22 mm; 26 mm: 22 to 25 mm; 29
mm: >25 mm) and compared between maximum and
traditional cardiac CT reconstruction phases at 35% and
75% of RR. Agreement for prosthesis selection was calcu-
lated by k statistics.
Results DA and DP were increased and eccentricity was
reduced during systole, with DA-MAX and DP-MAX
most often observed at 20% of RR. DP was consistently
larger than DA. Average net differences were 2.0  0.6
mm and 1.7  0.5 mm by DA-MIN versus DA-MAX
and DP-MIN versus DP-MAX. Agreement for pros-
thesis sizing was found in 93 of 110 patients (k ¼ 0.75)
by DA-75% and in 80 of 110 patients (k ¼ 0.53) by DA-
MAX compared with DA-35%; and in 94 of 110 patients
(k ¼ 0.73) by DP-75% and in 93 of 110 patients
(k ¼ 0.73) by DP-MAX compared with DP-35%. With
sizing by DA-75% or DP-75%, nominal prosthesis
diameter was smaller than DA-MAX or DP-MAX in 15
and 6 patients respectively.
Conclusions Aortic annulus morphology exhibits confor-
mational pulsatile changes throughout the cardiac cycle
due to deformation and stretch. These changes affect
prosthesis selection. Prosthesis selection by diastolic
perimeter- or area-derived dimensions harbors the risk of
undersizing (73).Long-Term Vascular Healing in Response to
Sirolimus- and Paclitaxel-Eluting Stents: An Optical
Coherence Tomography Study
Objectives This study sought to assess stent strut coverage,
malapposition, protrusion, and coronary evaginations as
markers of healing 5 years after implantation of sirolimus-
eluting stents (SES) and paclitaxel-eluting stents (PES),
by optical coherence tomography (OCT).
Background Early-generation drug-eluting stents have
been shown to delay vascular healing.
Methods A total of 88 event-free patients with 1 randomly
selected lesion were suitable for ﬁnal OCT analysis 5 years
after drug-eluting stent implantation. The analytical
approach was based on a hierarchical Bayesian random-
effects model.
Results OCT analysis was performed at 5 years in 41
SES lesions with 6,380 struts, and in 47 PES lesions with
6,782 struts. A total of 196 struts were uncovered in SES(1.5%) compared with 185 struts in PES lesions (1.0%,
95% credibility interval [CrI]: 0.5 to 1.6; p ¼ 0.32).
Malapposed struts were present in 1.2% of SES compared
with 0.7% of PES struts (0.7%, 95% CrI: 0.03 to 1.6; p ¼
0.23). Protruding struts were more frequent among SES
(n ¼ 114; 0.8%) than PES lesions (n ¼ 24; 0.1%, 95%
CrI: 0.3 to 1.3; p < 0.01). Coronary evaginations were
more common among SES- than PES-treated lesions (17
vs. 7 per 100 cross sections, p ¼ 0.003). During extended
clinical follow-up, 2 patients suffered from very late stent
thrombosis showing a high degree of malapposition,
protrusion, and coronary evaginations at the time of OCT
investigation.
Conclusions Early-generation drug-eluting stents show
a similar degree of strut coverage and malapposition at 5
years of follow-up. Despite an overall low degree of
uncovered and malapposed struts in event-free patients,
some lesions show a clustering of these characteristics,
indicating a heterogeneous healing response, which may be
the source for very late adverse events (74).Association Between Periprocedural Bleeding and
Long-Term Outcomes Following Percutaneous
Coronary Intervention in Older Patients
Objectives The authors sought to describe the association
between post-procedural bleeding and long-term recurrent
bleeding, major adverse cardiac events (MACE), and
mortality among older patients undergoing percutaneous
coronary intervention (PCI).
Background Bleeding complications after PCI are associ-
ated with an increased risk for acute morbidity and long-
term mortality, but the association of these bleeding
complications with other events is unknown.
Methods Patients entered into the National Cardiovas-
cular Data Registry (NCDR) CathPCI Registry (n ¼
461,311; 946 sites) from January 2004 to December 2008
were linked with claims from the Centers for Medicare
& Medicaid Services and grouped according to in-
hospital post-PCI bleeding. The association between
post-PCI bleeding and 1-, 12-, and 30-month read-
mission for bleeding, MACE, and all-cause mortality was
examined with Cox regression that included patient
and procedural characteristics using no bleeding as the
reference.
Results Overall, 3.1% (n ¼ 14,107) of patients experienced
post-PCI bleeding. Patients who bled were older, more
often female, had more medical comorbidities, less often
received bivalirudin, and more often underwent PCI via the
femoral approach. After adjustment, bleeding after the index
procedure was signiﬁcantly associated with readmission for
bleeding (adjusted hazard ratios [95% conﬁdence interval]: 1
month, 1.54 [1.42 to 1.67]; 12 months, 1.52 [1.40 to 1.66];
30 months, 1.29 [1.11 to 1.50]), MACE (1 month, 1.11
[1.07 to 1.15]; 12 months, 1.17 [1.13 to 1.21]; 30 months,
1.12 [1.06 to 1.19]) and all-cause mortality (1 month, 1.32
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1.22 [1.15 to 1.30]).
Conclusions Post-PCI bleeding complications are associ-
ated with an increased risk for short- and long-term recur-
rent bleeding, MACE, and all-cause mortality. These data
underscore the prognostic importance of periprocedural
bleeding and the need for identifying strategies to
reduce long-term bleeding risk among patients undergoing
PCI (75).Association Between Angiographic Complications
and Clinical Outcomes Among Patients With Acute
Coronary Syndrome Undergoing Percutaneous
Coronary Intervention: An EARLY ACS (Early
Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment
Elevation Acute Coronary Syndrome) Angiographic
Substudy
Objectives The goal of this analysis was to determine the
association between intraprocedural complications and
clinical outcomes among patients with high-risk non–ST-
segment elevation acute coronary syndrome (NSTEACS)
undergoing percutaneous coronary intervention (PCI).
Background Among patients undergoing PCI for
NSTEACS, the relationship between intraprocedural
complications and clinical outcomes, independent of
epicardial and myocardial perfusion, has not been well
characterized.
Methods The EARLY ACS (Early Glycoprotein IIb/IIIa
Inhibition in Non–ST-Segment Elevation Acute Coronary
Syndrome) trial enrolled 9,406 patients with high-risk
NSTEACS undergoing an early invasive strategy. Of
these, 1,452 underwent angiographic assessment in an
independent core laboratory and did not have a myocardial
infarction (MI) between enrollment and angiography.
We assessed the relationship between abrupt closure, loss
of side branch(es), distal embolization, and no-reﬂow
phenomenon and 30-day clinical outcomes in these
patients.
Results Of the patients, 166 (11.4%) experienced an
intraprocedural complication. Baseline clinical characteristics
were similar between patients who did and did not have
complications. The 30-day composite of death or MI was
signiﬁcantly higher among patients with an intraprocedural
complication (28.3% vs. 7.8%, odds ratio [OR]: 4.68, 95%
conﬁdence interval [CI]: 3.2 to 7.0, p< 0.001). Individually,
both mortality (3.0% vs. 0.9%, OR: 3.60, 95% CI: 1.2 to
10.5, p ¼ 0.019) and MI (27.1% vs. 7.4%, OR: 4.66, 95%
CI: 3.1 to 7.0, p < 0.001) were signiﬁcantly increased. After
adjusting for differences in post-PCI epicardial and
myocardial perfusion, the association with 30-day death or
MI remained signiﬁcant.
Conclusions Among high-risk NSTEACS patients
undergoing an invasive strategy, the incidence of intra-
procedural complications is high, and the occurrence of these
complications is associated with worse clinical outcomesindependent of epicardial and myocardial perfusion.
(Early Glycoprotein IIb/IIIa Inhibition in Patients With
Non–ST-segment Elevation Acute Coronary Syndrome
[EARLY ACS]; NCT00089895) (76).IVUS Detection of Vasa Vasorum Blood Flow
Distribution in Coronary Artery Vessel Wall
There is an increased body of evidence to suggest that
the vasa vasorum play a major role in the progression
and complications of vulnerable plaque leading to acute
coronary syndrome. We propose that detecting changes
in the ﬂow in the vascular wall by intravascular ultra-
sound signals can quantify the presence of vasa vasorum.
The results obtained in a porcine model of atheroscle-
rosis suggest that intravascular ultrasound-based esti-
mates of blood ﬂow in the arterial wall can be
used in vivo in a clinical research setting to establish the
density of vasa vasorum as an indicator of plaque
vulnerability (77).Risk of Stroke With Coronary Artery Bypass Graft
Surgery Compared With Percutaneous Coronary
Intervention
Objectives This study sought to determine whether coro-
nary artery bypass graft (CABG) surgery is associated with
an increased risk of stroke compared with percutaneous
coronary intervention (PCI).
Background Some, but not all, randomized trials have re-
ported increased rates of stroke with CABG compared with
PCI. However, all these studies were powered insufﬁciently
to examine differences in the risk of stroke reliably.
Methods We performed a meta-analysis of 19 trials in
which 10,944 patients were randomized to CABG versus
PCI. The primary end point was the 30-day rate of stroke.
We also determined the rate of stroke at the midterm
follow-up and investigated whether there was an interaction
between revascularization type and the extent of coronary
artery disease on the relative risk of stroke.
Results The 30-day rate of stroke was 1.20% after CABG
compared with 0.34% after PCI (odds ratio: 2.94, 95%
conﬁdence interval: 1.69 to 5.09, p < 0.0001). Similar
results were observed after a median follow-up of 12.1
months (1.83% vs. 0.99%, odds ratio: 1.67, 95% conﬁdence
interval: 1.09 to 2.56, p ¼ 0.02). The extent of coronary
artery disease (single vessel vs. multivessel vs. left main) did
not affect the relative increase in the risk of stroke observed
with CABG compared with PCI at either 30 days (p ¼
0.57 for interaction) or midterm follow-up (p ¼ 0.08 for
interaction). Similar results were observed when the
outcomes in 33,980 patients from 27 observational studies
were analyzed.
Conclusions Coronary revascularization by CABG
compared with PCI is associated with an increased risk of
stroke at 30 days and at the mid-term follow-up (78).
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HAS-BLED Bleeding Risk–Prediction Scores in
Patients With Atrial Fibrillation Undergoing
Anticoagulation: The AMADEUS (Evaluating the
Use of SR34006 Compared to Warfarin or
Acenocoumarol in Patients With Atrial Fibrillation)
Study
Objectives The objective of this study was to compare the
predictive performance of bleeding risk–estimation tools in
a cohort of patients with atrial ﬁbrillation (AF) undergoing
anticoagulation.
Background Three bleeding risk–prediction schemes have
been derived for and validated in patients with AF:
HEMORR2HAGES (Hepatic or Renal Disease, Ethanol
Abuse, Malignancy, Older Age, Reduced Platelet Count or
Function, Re-Bleeding, Hypertension, Anemia, Genetic
Factors, Excessive Fall Risk and Stroke), ATRIA (Anti-
coagulation and Risk Factors in Atrial Fibrillation), and
HAS-BLED (Hypertension, Abnormal Renal/Liver Func-
tion, Stroke, Bleeding History or Predisposition, Labile
International Normalized Ratio, Elderly, Drugs/Alcohol).
The relative predictive values of these bleeding scores have
not previously been compared.
Methods We analyzed the dataset from the AMADEUS
(Evaluating the Use of SR34006 Compared to Warfarin or
Acenocoumarol in Patients With Atrial Fibrillation) trial,
a multicenter, randomized, open-label noninferiority study
that compared ﬁxed-dose idraparinux with adjustable-dose
oral vitamin K antagonist therapy in patients with AF.
The principal safety outcome was any clinically relevant
bleeding event, which was a composite of major bleeding
plus clinically relevant nonmajor bleeding.
Results The HAS-BLED score performed best in pre-
dicting any clinically relevant bleeding, reﬂected both in net
reclassiﬁcation improvement (10.3% and 13% improvement
compared with HEMORR2HAGES and ATRIA, respec-
tively) and receiver-operating characteristic (ROC) analyses
(c-indexes: 0.60 vs. 0.55 and 0.50 for HAS-BLED vs.
HEMORR2AGES and ATRIA, respectively). Using
decision-curve analysis, the HAS-BLED score demon-
strated superior performance compared with ATRIA and
HEMORR2HAGES at any threshold probability for clin-
ically relevant bleeding. HAS-BLED was the only score that
demonstrated a signiﬁcant predictive performance for
intracranial hemorrhage (c-index: 0.75; p ¼ 0.03). An
ATRIA score >3 was not signiﬁcantly associated with the
risk for any clinically relevant bleeding on Cox regression or
on ROC analysis (c-index: 0.50; p ¼ 0.87).
Conclusions All 3 tested bleeding risk–prediction scores
demonstrated only modest performance in predicting any
clinically relevant bleeding, although the HAS-BLED score
performed better than the HEMORR2HAGES and
ATRIA scores, as reﬂected by ROC analysis, reclassiﬁcation
analysis, and decision-curve analysis. Only HAS-BLED
demonstrated a signiﬁcant predictive performance forintracranial hemorrhage. Given its simplicity, the HAS-
BLED score may be an attractive method for the estima-
tion of oral anticoagulant–related bleeding risk for use in
clinical practice, supporting recommendations in interna-
tional guidelines (79).
Pre-Hospital Electrocardiography by Emergency
Medical Personnel: Effects on Scene and Transport
Times for Chest Pain and ST-Segment Elevation
Myocardial Infarction Patients
Objectives This study sought to measure the impact of pre-
hospital (PH) electrocardiography (ECG) on scene-to-
hospital time for patients with chest pain of cardiac origin
and those with ST-segment elevation myocardial infarction
(STEMI).
Background Pre-hospital ECG decreases door-to balloon
(D2B) time for STEMI patients. However, obtaining a PH
ECG might prolong scene time. We investigated the impact
of obtaining a PH ECG on both scene and transport times
for patients with chest pain suspected of cardiac origin.
Methods City of San Diego Emergency Medical System
runsheets of patients with chest pain from January 2003 to
April 2008 were analyzed. The scene times and transport
times were compared before (from January 2003 to
December 2005) and after (from January 2006 to April
2008) implementation of the PH ECG. Among patients
with a PH ECG, median scene times and transport times
were compared in patients with and without STEMI.
Results There were 21,742 patients evaluated for chest pain
during the study period. Implementation of PH ECG
resulted in minimal increases in median scene time (19 min,
10 s vs. 19 min, 28 s, p ¼ 0.002) and transport time (13 min,
16 s vs. 13 min, 28 s, p ¼ 0.007). However, compared with
chest pain patients, in STEMI patients (n ¼ 303), shorter
median scene time (17 min, 51 s vs. 19 min, 31 s, p <
0.001), transport time (12 min, 34 s vs. 13 min, 31 s, p ¼
0.006), and scene-to-hospital time was observed (30 min, 45
s vs. 33 min, 29 s, p < 0.001).
Conclusions Obtaining a PH ECG for patients with chest
pain minimally prolongs scene and transport times. Further,
for STEMI patients, both scene times and transport times
are actually reduced leading to a potential reduction in total
ischemic time (80).
Indirect Comparisons of New Oral Anticoagulant
Drugs for Efﬁcacy and Safety When Used for
Stroke Prevention in Atrial Fibrillation
Objectives This study sought to perform an indirect
comparison analysis of dabigatran etexilate (2 doses), rivar-
oxaban, and apixaban for their relative efﬁcacy and safety
against each other.
Background Data for warfarin compared against the new
oral anticoagulants (OACs) in large phase III clinical trials
of stroke prevention in atrial ﬁbrillation (AF) are now
available for the oral direct thrombin inhibitor, dabigatran
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BID), and the oral Factor Xa inhibitors, rivaroxaban and
apixaban. A “head-to-head” direct comparison of drugs is
the standard method for comparing different treatments, but
in the absence of such head-to-head direct comparisons,
another alternative to assess the relative effect of different
treatment interventions would be to perform indirect
comparisons, using a common comparator. Nonetheless, any
inter-trial comparison is always fraught with major difﬁ-
culties, and an indirect comparison analysis has many limi-
tations, especially with the inter-trial population differences
and thus, should not be overinterpreted.
Methods Indirect comparison analysis was performed using
data from the published trials.
Results There was a signiﬁcantly lower risk of stroke and
systemic embolism (by 26%) for dabigatran (150 mg BID)
compared with rivaroxaban, as well as hemorrhagic stroke
and nondisabling stroke. There were no signiﬁcant differ-
ences for apixaban versus dabigatran (both doses) or rivar-
oxaban; or rivaroxaban versus dabigatran 110 mg BID in
preventing stroke and systemic embolism. For ischemic
stroke, there were no signiﬁcant differences between the new
OACs. Major bleeding was signiﬁcantly lower with apix-
aban compared with dabigatran 150 mg BID (by 26%) and
rivaroxaban (by 34%), but not signiﬁcantly different from
dabigatran 110 mg BID. There were no signiﬁcant differ-
ences between apixaban and dabigatran 110 mg BID in
safety endpoints. Apixaban also had lower major or clinically
relevant bleeding (by 34%) compared with rivaroxaban.
When compared with rivaroxaban, dabigatran 110 mg BID
was associated with less major bleeding (by 23%) and
intracranial bleeding (by 54%). There were no signiﬁcant
differences in myocardial infarction events between the
dabigatran (both doses) and apixaban.
Conclusions Notwithstanding the limitations of an indi-
rect comparison study, we found no profound signiﬁcant
differences in efﬁcacy between apixaban and dabigatran
etexilate (both doses) or rivaroxaban. Dabigatran 150 mg
BID was superior to rivaroxaban for some efﬁcacy
endpoints, whereas major bleeding was signiﬁcantly lower
with dabigatran 110 mg BID or apixaban. Only a head-to-
head direct comparison of the different new OACs would
fully answer the question of efﬁcacy/safety differences
between the new drugs for stroke prevention in AF (81).Sirolimus-Eluting Stents for Treatment of
Infrapopliteal Arteries Reduce Clinical Event Rate
Compared to Bare-Metal Stents
Objectives The study investigated the long-term clinical
impact of sirolimus-eluting stents (SES) in comparison with
bare-metal stents (BMS) in treatment of focal infrapopliteal
lesions.
Background There is evidence that SES reduce the risk of
restenosis after percutaneous infrapopliteal artery revascu-
larization. No data from randomized trials are availableconcerning the clinical impact of this ﬁnding during long-
term follow-up.
Methods The study extended the follow-up period of
a prospective, randomized, multicenter, double-blind trial
comparing polymer-free SES with placebo-coated BMS in
the treatment of focal infrapopliteal de novo lesions. The
main study endpoint was the event-free survival rate deﬁned
as freedom from target limb amputation, target vessel
revascularization, myocardial infarction, and death.
Secondary endpoints include amputation rates, target vessel
revascularization, and changes in Rutherford-Becker class.
Results The trial included 161 patients. The mean target
lesion length was 31  9 mm. Thirty-ﬁve (23.3%) patients
died during a mean follow-up period of 1,016  132 days.
The event-free survival rate was 65.8% in the SES group and
44.6% in the BMS group (log-rank p ¼ 0.02). Amputation
rates were 2.6% and 12.2% (p ¼ 0.03), and target vessel
revascularization rates were 9.2% and 20% (p ¼ 0.06),
respectively. The median (interquartile range) improvement
in Rutherford-Becker class was –2 (–3 to –1) in the SES
group and –1 (–2 to 0) in the BMS group, respectively (p ¼
0.006).
Conclusions Long-term event-free survival, amputation
rates, and changes in Rutherford-Becker class after treat-
ment of focal infrapopliteal lesions are signiﬁcantly improved
with SES in comparison with BMS. (YUKON-Drug-
Eluting Stent Below the Knee - Randomised Double-Blind
Study [YUKON-BTX]; NCT00664963) (82).Treatment of Atrial Fibrillation by the Ablation of
Localized Sources: CONFIRM (Conventional
Ablation for Atrial Fibrillation With or Without
Focal Impulse and Rotor Modulation) Trial
Objectives We hypothesized that human atrial ﬁbrillation
(AF) may be sustained by localized sources (electrical rotors
and focal impulses), whose elimination (focal impulse and
rotor modulation [FIRM]) may improve outcome from AF
ablation.
Background Catheter ablation for AF is a promising
therapy, whose success is limited in part by uncertainty in
the mechanisms that sustain AF. We developed a compu-
tational approach to map whether AF is sustained by several
meandering waves (the prevailing hypothesis) or localized
sources, then prospectively tested whether targeting patient-
speciﬁc mechanisms revealed by mapping would improve
AF ablation outcome.
Methods We recruited 92 subjects during 107 consecutive
ablation procedures for paroxysmal or persistent (72%) AF.
Cases were prospectively treated, in a 2-arm 1:2 design, by
ablation at sources (FIRM-guided) followed by conventional
ablation (n ¼ 36), or conventional ablation alone (n ¼ 71;
FIRM-blinded).
Results Localized rotors or focal impulses were detected in
98 (97%) of 101 cases with sustained AF, each exhibiting
2.1  1.0 sources. The acute endpoint (AF termination or
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cases versus 20% of FIRM-blinded cases (p < 0.001).
FIRM ablation alone at the primary source terminated AF
in a median 2.5 min (interquartile range: 1.0 to 3.1 min).
Total ablation time did not differ between groups (57.8 
22.8 min vs. 52.1  17.8 min, p ¼ 0.16). During a median
273 days (interquartile range: 132 to 681 days) after a single
procedure, FIRM-guided cases had higher freedom from
AF (82.4% vs. 44.9%; p < 0.001) after a single procedure
than FIRM-blinded cases with rigorous, often implanted,
electrocardiography monitoring. Adverse events did not
differ between groups.
Conclusions Localized electrical rotors and focal impulse
sources are prevalent sustaining mechanisms for human AF.
FIRM ablation at patient-speciﬁc sources acutely terminated
or slowed AF, and improved outcome. These results offer
a novel mechanistic framework and treatment paradigm for
AF. (Conventional Ablation for Atrial Fibrillation With or
Without Focal Impulse and Rotor Modulation
[CONFIRM]; NCT01008722) (83).Transcatheter Aortic Valve Replacement With the
St. Jude Medical Portico Valve: First-in-Human
Experience
Objectives The purpose of this study was to demonstrate
the feasibility and procedural outcomes with a new self-
expanding and repositionable transcatheter heart valve.
Background Transcatheter aortic valve replacement is
a viable option for selected patients with severe symp-
tomatic aortic stenosis. However, suboptimal prosthesis
positioning may contribute to paravalvular regurgitation,
atrioventricular conduction block, and mitral or coronary
compromise.
Methods The repositionable Portico valve (St. Jude
Medical, Minneapolis, Minnesota) was implanted in 10
patients with severe aortic stenosis utilizing percutaneous
femoral arterial access. Patients underwent transthoracic
and transesophageal echocardiography and multidetector
computed tomography before and after valve implantation.
Clinical and echocardiographic follow-up was obtained at
30 days.
Results Device implantation was successful in all patients.
Prosthesis recapture and repositioning was performed in 4
patients. Intermittent prosthetic leaﬂet dysfunction in 1
patient required implantation of a second transcatheter valve.
There was 1 minor stroke. At 30-day follow-up, echocar-
diographic mean transaortic gradient was reduced from 44.9
 16.7 mm Hg to 10.9  3.8 mm Hg (p < 0.001), and
valve area increased from 0.6  0.1 cm2 to 1.3  0.2 cm2
(p < 0.001). Paravalvular regurgitation was mild or less in 9
patients (90%) and moderate in 1 patient (10%). There were
no major strokes, major vascular complications, major
bleeds, or deaths. No patient required pacemaker implan-
tation. All patients were in New York Heart Association
functional class II or less.Conclusions Transcatheter aortic valve replacement with
the repositionable Portico transcatheter heart valve is
feasible, with good short-term clinical and hemodynamic
outcomes (84).Kissing Balloon Inﬂation in Percutaneous Coronary
Interventions
Bifurcation lesions are the most frequently approached
complex coronary lesions in everyday interventional practice.
Bifurcations complexity relies essentially on their very
speciﬁc anatomy that is imperfectly handled by current
coronary devices and, despite dedicated techniques and
drug-eluting stents, percutaneous coronary interventions
directed toward the treatment of bifurcations are technically
demanding and require proper execution. Kissing balloon
(KB) inﬂation was the ﬁrst speciﬁc bifurcation technique to
have been developed for percutaneous bifurcation interven-
tions and continues to currently play an important role.
Indeed, KB has been proposed to optimize stent apposition,
improve side branch access while correcting stent deforma-
tion or distortion. Over the years, the KB technique has been
deeply investigated by many different methods, from bench
testing and computer simulations to in vivo intravascular
imaging and clinical studies, producing a large amount of
data pointing out the beneﬁts and limitations of the tech-
nique. We sought to provide here a comprehensive overview
of all those aspects (85).Vascular Closure Device Failure in Contemporary
Practice
Objectives The goal of this study was to assess the
frequency and predictors of vascular closure device (VCD)
deployment failure, and its association with vascular
complications of 3 commonly used VCDs.
Background VCDs are commonly used following percu-
taneous coronary intervention on the basis of studies
demonstrating reduced time to ambulation, increased
patient comfort, and possible reduction in vascular compli-
cations as compared with manual compression. However,
limited data are available on the frequency and predictors of
VCD failure, and the association of deployment failure with
vascular complications.
Methods From a de-identiﬁed dataset provided by
Massachusetts Department of Health, 23,813 consecutive
interventional coronary procedures that used either
a collagen plug–based (n ¼ 18,533), a nitinol clip–based
(n ¼ 2,284), or a suture-based (n ¼ 2,996) VCD between
June 2005 and December 2007 were identiﬁed. The authors
deﬁned VCD failure as unsuccessful deployment or failure to
achieve immediate access site hemostasis.
Results Among 23,813 procedures, the VCD failed in 781
(3.3%) procedures (2.1% of collagen plug–based, 6.1% of
suture-based, 9.5% of nitinol clip–based VCDs). Patients
with VCD failure had an excess risk of “any” (7.7% vs. 2.8%;
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(5.8% vs. 2.1%; p < 0.001) vascular complications compared
with successful VCD deployment. In a propensity score–
adjusted analysis, when compared with collagen plug–based
VCD (reference odds ratio [OR] ¼ 1.0), nitinol clip–based
VCD had 2-fold increased risk (OR: 2.0, 95% conﬁdence
interval [CI]: 1.8 to 2.3, p < 0.001) and suture-based VCD
had 1.25-fold increased risk (OR: 1.25, 95% CI: 1.2 to 1.3,
p < 0.001) for VCD failure. VCD failure was a signiﬁcant
predictor of subsequent vascular complications for both
collagen plug–based VCD and nitinol clip–based VCD, but
not for suture-based VCD.
Conclusions VCD failure rates vary depending upon the
type of VCD used and are associated with signiﬁcantly
higher vascular complications as compared with deployment
successes (86).The Recanalization of Chronic Total Occlusion
Leads to Lumen Area Increase in Distal Reference
Segments in Selected Patients: An Intravascular
Ultrasound Study
Objectives This study sought to investigate the extent of
and factors related to lumen and vessel area change in
coronary arteries after total occlusion (TO) recanalization.
Background TO of a coronary artery promotes negative
remodeling in distal reference segments. Recanalization can
restore blood ﬂow, potentially leading to positive vascular
remodeling.
Methods From March 2005 to June 2008, 58 consecutive
patients with de novo TO lesions of at least 1-month
duration were enrolled. We performed intravascular ultra-
sound after successful percutaneous coronary intervention
and at the 6-month follow-up, and we quantiﬁed changes in
the distal reference segments.
Results At the 6-month follow-up, there was a signiﬁcant
increase in the mean lumen diameter (þ0.21 mm, p ¼
0.001), the mean external elastic membrane diameter (þ0.13
mm, p ¼ 0.010), the lumen area (þ0.87 mm2, p < 0.001),
and the external elastic membrane area (þ0.85 mm2, p ¼
0.001) in the distal reference segments and an increase in the
left ventricular ejection fraction (þ2.77%, p ¼ 0.010).
Overall, 40 of 58 patients (69%) showed lumen area
increase; these patients had increase in lumen diameter by
0.40  0.34 mm (p < 0.001) and increase in incomplete
stent apposition rate (p ¼ 0.006). A TO duration of longer
than 3 months (odds ratio [OR]: 14.8; 95% conﬁdence
interval [CI]: 1.28 to 172.8, p ¼ 0.032), a poor collateral
ﬂow (OR: 12.0; 95% CI: 1.92 to 74.2, p¼ 0.008), and statin
use (OR: 7.4; 95% CI: 1.03 to 53.6, p ¼ 0.047) were
independent predictors of lumen area increase.
Conclusions Recanalization of TO led to lumen area
increase in two-thirds of the patients. Independent predictors
of lumen area increase were occlusion duration, a poor
collateral ﬂow, and statin use. These factors could be used
as guides in choosing the optimal stent size duringpercutaneous coronary intervention to TO lesions and
optimal medical therapy during follow-up (87).Radiation Dose Reduction in the Invasive
Cardiovascular Laboratory: Implementing a Culture
and Philosophy of Radiation Safety
Objectives This paper investigates the effects of sustained
practice and x-ray system technical changes on the radiation
dose administered to adult patients during invasive cardio-
vascular procedures.
Background It is desirable to reduce radiation dose asso-
ciated with medical imaging to minimize the risk of adverse
radiation effects to both patients and staff. Several clinical
practice and technical changes to elevate radiation awareness
and reduce patient radiation dose were implemented under
the guidance of a cardiovascular invasive labs radiation safety
committee. Practice changes included: intraprocedure radi-
ation dose announcements; reporting of procedures for
which the air-kerma exceeded 6,000 mGy, including
procedure air-kerma in the clinical report; and establishing
compulsory radiation safety training for fellows. Technical
changes included establishing standard x-ray imaging
protocols, increased use of x-ray beam spectral ﬁlters,
reducing the detector target dose for ﬂuoroscopy and
acquisition imaging, and reducing the ﬂuoroscopy frame rate
to 7.5 s1.
Methods Patient- and procedure-speciﬁc cumulative skin
dose was calculated from air-kerma values and evaluated
retrospectively over a period of 3 years. Data were catego-
rized to include all procedures, percutaneous coronary
interventions, coronary angiography, noncardiac vascular
angiography and interventions, and interventions to treat
structural heart disease. Statistical analysis was based on
a comparison of the cumulative skin dose for procedures
performed during the ﬁrst and last quarters of the 3-year
study period.
Results A total of 18,115 procedures were performed by 27
staff cardiologists and 65 fellows-in-training. Considering
all procedures, the mean cumulative skin dose decreased
from 969 to 568 mGy (40% reduction) over 3 years.
Conclusions This work demonstrates that a philosophy of
radiation safety, implemented through a collection of sus-
tained practice and x-ray system changes, can result in
a signiﬁcant decrease in the radiation dose administered to
patients during invasive cardiovascular procedures (88).Reduction in Treatment Times Through Formalized
Data Feedback: Results From a Prospective
Multicenter Study of ST-Segment Elevation
Myocardial Infarction
Objectives This study sought to evaluate the effect of
systematic data analysis and standardized feedback on
treatment times and outcome in a prospective multicenter
trial.
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ment times in ST-segment elevation myocardial infarction
(STEMI).
Methods Over a 15-month period, 1,183 patients pre-
senting with STEMI were enrolled. Six primary percuta-
neous coronary intervention hospitals in Germany and 29
associated nonpercutaneous coronary intervention hospitals
participated. Data from patient contact to balloon inﬂation
were collected and analyzed. Pre-deﬁned quality indicators,
including the percentage of patients with pre-announced
STEMI, direct handoff in the catheterization laboratory,
contact-to-balloon time <90 min, door-to-balloon
time <60 min, and door-to-balloon time <30 min were
discussed with staff on a quarterly basis.
Results Median door-to-balloon time decreased from 71 to
58 min and contact-to-balloon time from 129 to 103 min
between the ﬁrst and the ﬁfth quarter (p < 0.05 for both).
Contributing were shorter stays in the emergency depart-
ment, more direct handoffs from ambulances to the cathe-
terization laboratory (from 22% to 38%, p < 0.05), and
a slight increase in the number of patients transported
directly to the percutaneous coronary intervention facility
(primary transport). One-year mortality was reduced in the
total group of patients and in the subgroup of patients with
primary transport (p < 0.05). The sharpest fall in mortality
was observed in patients with primary transport and TIMI
(Thrombolysis In Myocardial Infarction) risk score 3 (n ¼
521) with a decrease in 30-day mortality from 23.1% to
13.3% (p < 0.05) and in 1-year mortality from 25.6% to
16.7% (p < 0.05).
Conclusions Formalized data feedback is associated with
a reduction in treatment times for STEMI and with an
improved prognosis, which is most pronounced in high-risk
patients. (Feedback Intervention and Treatment Times in
ST-Elevation Myocardial Infarction [FITT-STEMI];
NCT00794001) (89).Impact of Paravalvular Leakage on Outcome in
Patients After Transcatheter Aortic Valve
Implantation
Objectives The aim of this study was to evaluate the
performance of the aortic regurgitation (AR) index as a new
hemodynamic parameter in an independent transcatheter
aortic valve implantation (TAVI) cohort and validate its
application.
Background Increasing evidence associates more-than-
mild periprosthetic aortic regurgitation (periAR) with
increased mortality and morbidity; therefore precise evalua-
tion of periAR after TAVI is essential. The AR index has
been proposed recently as a simple and reproducible indi-
cator for the severity of periAR and predictor of associated
mortality.
Methods The severity of periAR was evaluated by echo-
cardiography, angiography, and periprocedural measurement
of the dimensionless AR index ¼ ([diastolic bloodpressure  left ventricular end-diastolic pressure]/systolic
blood pressure)  100. A cutoff value of 25 was used to
identify patients at risk.
Results One hundred twenty-two patients underwent
TAVI by use of either the Medtronic CoreValve (Med-
tronic, Minneapolis, Minnesota) (79.5%) or the Edwards-
SAPIEN bioprosthesis (Edwards Lifesciences, Irvine, Cal-
ifornia) (20.5%). The AR index decreased stepwise from
29.4  6.3 in patients without periAR (n ¼ 26) to 28.0 
8.5 with mild periAR (n ¼ 76), 19.6  7.6 with moderate
periAR (n ¼ 18), and 7.6  2.6 with severe periAR (n ¼ 2)
(p < 0.001). Patients with AR index <25 had a signiﬁcantly
increased 1-year mortality rate compared with patients with
AR index 25 (42.3% vs. 14.3%; p < 0.001). Even in
patients with none/mild periAR, the 1-year mortality risk
could be further stratiﬁed by an AR index <25 (31.3% vs.
14.3%; p ¼ 0.04).
Conclusions The validity of the AR index could be
conﬁrmed in this independent TAVI cohort and provided
prognostic information that was complementary to the
severity of AR (90).Stem Cell–Based Transcatheter Aortic Valve
Implantation: First Experiences in a Pre-Clinical
Model
Objectives This study sought to investigate the combina-
tion of transcatheter aortic valve implantation and a novel
concept of stem cell-based, tissue-engineered heart valves
(TEHV) comprising minimally invasive techniques for both
cell harvest and valve delivery.
Background TAVI represents an emerging technology for
the treatment of aortic valve disease. The used bioprostheses
are inherently prone to calciﬁc degeneration and recent
evidence suggests even accelerated degeneration resulting
from structural damage due to the crimping procedures. An
autologous, living heart valve prosthesis with regeneration
and repair capacities would overcome such limitations.
Methods Within a 1-step intervention, trileaﬂet TEHV,
generated from biodegradable synthetic scaffolds, were
integrated into self-expanding nitinol stents, seeded with
autologous bone marrow mononuclear cells, crimped and
transapically delivered into adult sheep (n ¼ 12). Planned
follow-up was 4 h (Group A, n ¼ 4), 48 h (Group B, n ¼ 5)
or 1 and 2 weeks (Group C, n ¼ 3). TEHV functionality
was assessed by ﬂuoroscopy, echocardiography, and
computed tomography. Post-mortem analysis was per-
formed using histology, extracellular matrix analysis, and
electron microscopy.
Results Transapical implantation of TEHV was successful
in all animals (n ¼ 12). Follow-up was complete in all
animals of Group A, three-ﬁfths of Group B, and two-
thirds of Group C (1 week, n ¼ 1; 2 weeks, n ¼ 1).
Fluoroscopy and echocardiography displayed TEHV func-
tionality demonstrating adequate leaﬂet mobility and
coaptation. TEHV showed intact leaﬂet structures with
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structural damage. Histology and extracellular matrix dis-
played a high cellularity indicative for an early cellular
remodeling and in-growth after 2 weeks.
Conclusions We demonstrate the principal feasibility of
a transcatheter, stem cell–based TEHV implantation into
the aortic valve position within a 1-step intervention. Its
long-term functionality proven, a stem cell–based TEHV
approach may represent a next-generation heart valve
concept (91).
Transradial Versus Transfemoral Artery Approach
for Coronary Angiography and Percutaneous
Coronary Intervention in the Extremely Obese
Objectives This study sought to evaluate the safety and
efﬁcacy of transradial versus transfemoral access for coronary
angiography and percutaneous coronary intervention in
patients with a body mass index 40 kg/m2.
Background Coronary angiography is most commonly
performed via femoral artery access; however, the optimal
approach in extremely obese (EO) patients remains unclear.
Methods Between January 2007 and August 2010, a cohort
of consecutive EO patients who underwent coronary angi-
ography was identiﬁed in our center’s registry of angiography
and percutaneous coronary intervention procedures. Of
21,103 procedures, 564 (2.7%) were performed in unique
EO patients: 203 (36%) via the transradial approach; and
361 (64%) via the transfemoral approach.
Results The primary outcome, a combined endpoint of
major bleeding, access site complications, and nonaccess site
complications, occurred in 7.5% of the transfemoral group
and 2.0% of the transradial group (odds ratio [OR]: 0.30,
95% conﬁdence interval [CI]: 0.10 to 0.88, p ¼ 0.029), an
endpoint driven by reductions in major bleeding (3.3% vs.
0.0%, OR: 0.12, 95% CI: 0 to 0.71, p ¼ 0.015), as well as
access site injuries (4.7% vs. 0.0%, OR: 0.08, 95% CI: 0 to
0.48, p ¼ 0.002). There were no differences in nonaccess
site complications (1.7% vs. 2.0%, OR: 1.50, 95% CI: 0.41
to 5.55), but transradial access procedures were associated
with an increase in procedure time and patient radiation
dose (p < 0.05).
Conclusions Transfemoral access for coronary angiography
and percutaneous coronary intervention was associated with
more bleeding and access site complications when compared
with a transradial approach. Important reductions in
procedural associated morbidity may be possible with
a transradial approach in EO patients (92).
3-Year Clinical Outcomes in the Randomized SORT
OUT III Superiority Trial Comparing Zotarolimus-
and Sirolimus-Eluting Coronary Stents
Objectives This study sought to examine the 3-year clinical
outcomes in patients treated with the Endeavor (Medtronic,
Santa Rosa, California) zotarolimus-eluting stent (ZES) or
the Cypher (Cordis, Johnson & Johnson, Warren, NewJersey) sirolimus-eluting stent (SES) in routine clinical
practice.
Background The long-term clinical outcome in patients
treated with ZES in comparison with SES is unclear.
Methods The authors randomized 2,332 patients to ZES
(n ¼ 1,162) or SES (n ¼ 1,170) implantation. Endpoints
included major adverse cardiac events (MACE), a composite
of cardiac death, myocardial infarction, or target vessel
revascularization; the individual endpoints of MACE; and
deﬁnite stent thrombosis.
Results At 3-year follow-up, the MACE rate was higher in
patients treated with ZES than in patients treated with SES
(148 [12.9%] vs. 116 [10.1%]; hazard ratio [HR]: 1.33, 95%
conﬁdence interval [CI]: 1.04 to 1.69; p ¼ 0.022). Target
vessel revascularization was more frequent in the ZES group
compared with the SES group (103 [9.1%] vs. 76 [6.7%];
HR: 1.40, 95% CI: 1.04 to 1.89; p ¼ 0.025), whereas the
occurrence of myocardial infarction (3.8% vs. 3.3%) and
cardiac death (2.8% vs. 2.8%) did not differ signiﬁcantly.
Although the rate of deﬁnite stent thrombosis was similar at
3-year follow-up (1.1% vs. 1.4%), very late (12 to 36
months) deﬁnite stent thrombosis occurred in 0 (0%)
patients in the ZES group versus 12 (1.1%) patients in the
SES group (p ¼ 0.0005).
Conclusions Although the 3-year MACE rate is higher in
patients treated with ZES versus SES, our data highlight
a late safety problem concerning deﬁnite stent thrombosis
with the use of SES. This ﬁnding underscores the impor-
tance of long-term follow-up in head-to-head comparisons
of drug-eluting stents. (Randomized Clinical Comparison of
the Endeavor and the Cypher Coronary Stents in Non-
selected Angina Pectoris Patients [SORT OUT III];
NCT00660478) (93).Coronary Vasomotor Control in Obesity and Morbid
Obesity: Contrasting Flow Responses With
Endocannabinoids, Leptin, and Inﬂammation
Objectives This study sought to investigate abnormalities
in coronary circulatory function in 2 different disease entities
of obese (OB) and morbidly obese (MOB) individuals
and to evaluate whether these would differ in severity
with different proﬁles of endocannabinoids, leptin, and
C-reactive protein (CRP) plasma levels.
Background There is increasing evidence that altered
plasma levels of endocannabinoids, leptin, and CRP may
affect coronary circulatory function in OB and MOB.
Methods Myocardial blood ﬂow (MBF) responses to cold
pressor test from rest and during pharmacologically induced
hyperemia were measured with N-13 ammonia positron
emission tomography/computed tomography. Study partic-
ipants (n ¼ 111) were divided into 4 groups based on their
body mass index (BMI) (kg/m2): 1) control group (BMI: 20
to 24.9, n ¼ 30); 2) overweight group (BMI: 25 to 29.9, n ¼
31), 3) OB group (BMI: 30 to 39.9, n ¼ 25); and 4) MOB
group (BMI 40, n ¼ 25).
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endothelium-related MBF response (DMBF) progressively
declined in overweight and OB groups when compared with
the control group [median: 0.19 (interquartile range [IQR]
0.08, 0.27) and 0.11 (0.03, 0.17) vs. 0.27 (0.23, 0.38) ml/g/
min; p  0.01, respectively], whereas it did not differ
signiﬁcantly between OB and MOB groups [median: 0.11
(IQR: 0.03, 0.17) and 0.09 (–0.01, 0.19) ml/g/min;
p ¼ 0.93]. Compared with control subjects, hyperemic MBF
subjects comparably declined in the overweight, OB, and
MOB groups [median: 2.40 (IQR 1.92, 2.63) vs. 1.94 (1.65,
2.30), 2.05 (1.67, 2.38), and 2.14 (1.78, 2.76) ml/g/min;
p  0.05, respectively]. In OB individuals, DMBF was
inversely correlated with increase in endocannabinoid
anandamide (r ¼ –0.45, p ¼ 0.044), but not with leptin (r ¼
–0.02, p ¼ 0.946) or with CRP (r ¼ –0.33, p ¼ 0.168).
Conversely, there was a signiﬁcant and positive correlation
among DMBF and elevated leptin (r ¼ 0.43, p ¼ 0.031) and
CRP (r ¼ 0.55, p ¼ 0.006), respectively, in MOB indi-
viduals that was not observed for endocannabinoid anan-
damide (r ¼ 0.07, p ¼ 0.740).
Conclusions Contrasting associations of altered coronary
endothelial function with increases in endocannabinoid
anandamide, leptin, and CRP plasma levels identify and
characterize OB and MOB as different disease entities
affecting coronary circulatory function (94).Assessment of Myocardial Scarring Improves Risk
Stratiﬁcation in Patients Evaluated for Cardiac
Deﬁbrillator Implantation
Objectives We tested whether an assessment of myocardial
scarring by cardiac magnetic resonance imaging (MRI)
would improve risk stratiﬁcation in patients evaluated for
implantable cardioverter-deﬁbrillator (ICD) implantation.
Background Current sudden cardiac death risk stratiﬁca-
tion emphasizes left ventricular ejection fraction (LVEF);
however, most patients suffering sudden cardiac death have
a preserved LVEF, and many with poor LVEF do not
beneﬁt from ICD prophylaxis.
Methods One hundred thirty-seven patients undergoing
evaluation for possible ICD placement were prospectively
enrolled and underwent cardiac MRI assessment of LVEF
and scar. The pre-speciﬁed primary endpoint was death or
appropriate ICD discharge for sustained ventricular
tachyarrhythmia.
Results During a median follow-up of 24 months the
primary endpoint occurred in 39 patients. Whereas the rate
of adverse events steadily increased with decreasing LVEF,
a sharp step-up was observed for scar size >5% of left
ventricular mass (hazard ratio [HR]: 5.2; 95% conﬁdence
interval [CI]: 2.0 to 13.3). On multivariable Cox
proportional hazards analysis, including LVEF and
electrophysiological-study results, scar size (as a continuous
variable or dichotomized at 5%) was an independent
predictor of adverse outcome. Among patients with LVEF>30%, those with signiﬁcant scarring (>5%) had higher risk
than those with minimal or no (5%) scarring (HR: 6.3;
95% CI: 1.4 to 28.0). Those with LVEF >30% and signif-
icant scarring had risk similar to patients with LVEF 30%
(p ¼ 0.56). Among patients with LVEF 30%, those with
signiﬁcant scarring again had higher risk than those with
minimal or no scarring (HR: 3.9; 95% CI: 1.2 to 13.1).
Those with LVEF 30% and minimal scarring had risk
similar to patients with LVEF >30% (p ¼ 0.71).
Conclusions Myocardial scarring detected by cardiac MRI
is an independent predictor of adverse outcome in patients
being considered for ICD placement. In patients with
LVEF >30%, signiﬁcant scarring (>5% LV) identiﬁes
a high-risk cohort similar in risk to those with LVEF 30%.
Conversely, in patients with LVEF 30%, minimal or no
scarring identiﬁes a low-risk cohort similar to those with
LVEF >30% (95).Second-Generation Everolimus-Eluting Stents
Versus First-Generation Sirolimus-Eluting Stents in
Acute Myocardial Infarction1-Year Results of the
Randomized XAMI (XienceV Stent vs. Cypher Stent
in Primary PCI for Acute Myocardial Infarction)
Trial
Objectives The goal of this study was to compare the
efﬁcacy and safety of second-generation everolimus-eluting
stents (EES) with ﬁrst-generation sirolimus-eluting stents
(SES) in primary percutaneous coronary intervention (PCI)
for acute myocardial infarction (AMI).
Background Drug-eluting stents (DES) in AMI are still
feared for possible late and very late stent thrombosis (ST).
Newer-generation DES, with more hemocompatible poly-
mers and improved healing, may show promise regarding
increased efﬁcacy of DES with improved safety. However,
no randomized trials in AMI are available.
Methods A total of 625 patients with AMI were
randomized (2:1) to receive EES or SES in the XAMI
(XienceV Stent vs Cypher Stent in Primary PCI for Acute
Myocardial Infarction) trial. Primary endpoint was major
adverse cardiac events (MACE) at 1 year consisting of
cardiac death, nonfatal AMI, or any target vessel revascu-
larization. The study was powered for noninferiority of
EES. Secondary endpoints comprised ST rates and MACE
rate up to 3 years.
Results The MACE rate was 4.0% for EES and 7.7% for
SES; the absolute difference was 3.7% (95% conﬁdence
interval:8.28 to0.03; p¼ 0.048) and relative risk was 0.52
(95% conﬁdence interval: 0.27 to 1.00). One-year cardiac
mortality was low at 1.5% for EES versus 2.7% for SES (p ¼
0.36), and 1-year incidence of deﬁnite and/or probable ST
was 1.2% for EES versus 2.7% for SES (p ¼ 0.21).
Conclusions In this all-comer, randomized, multicenter
AMI trial, second-generation EES was noninferior to SES,
and superiority for MACE was suggested. ST rate in EES at
1-year was low, but long-term follow-up and larger studies
JACC Vol. 62, No. 18, 2013 The Editors
October 29, 2013:e245–e437 JACC Topic Collection: Interventional Cardiology
e281will have to show whether very late ST rates will also be
improved in newer DES. (XienceV Stent vs Cypher Stent in
Primary PCI for Acute Myocardial Infarction [XAMI];
NTR1123) (96).
Mortality Beneﬁt With Prasugrel in the TRITON–
TIMI 38 Coronary Artery Bypass Grafting Cohort:
Risk-Adjusted Retrospective Data Analysis
Objectives The objective of this study was to characterize
the bleeding, transfusion, and other outcomes of patients
related to the timing of prasugrel or clopidogrel withdrawal
before coronary artery bypass grafting (CABG).
Background There is little evidence to guide clinical deci-
sion making regarding the use of prasugrel in patients who
may need urgent or emergency CABG. Experience with
performing CABG in the presence of clopidogrel has raised
concern about perioperative bleeding complications that are
unresolved.
Methods A subset of the TRITON–TIMI 38 study (Trial
to Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition with Prasugrel–Thrombolysis
In Myocardial Infarction 38), in which patients with acute
coronary syndrome were randomized to treatment with
aspirin and either clopidogrel or prasugrel, underwent isolated
CABG (N ¼ 346). A supplemental case report form was
designed and administered, and the data combined with the
existing TRITON–TIMI 38 database. Baseline imbalances
were corrected for using elements of the European System for
Cardiac Operative Risk Evaluation and The Society of
Thoracic Surgeons predictive algorithm.
Results A signiﬁcantly higher mean 12-h chest tube blood
loss (655  580 ml vs. 503  378 ml; p ¼ 0.050) was
observed with prasugrel compared with clopidogrel, without
signiﬁcant differences in red blood cell transfusion (2.1 U vs.
1.7 U; p ¼ 0.442) or the total donor exposure (4.4 U vs. 3.0
U; p ¼ 0.463). All-cause mortality was signiﬁcantly reduced
with prasugrel (2.31%) compared with 8.67% with clopi-
dogrel (adjusted odds ratio: 0.26; p ¼ 0.025).
Conclusions Despite an increase in observed bleeding,
platelet transfusion, and surgical re-exploration for bleeding,
prasugrel was associated with a lower rate of death after
CABG compared with clopidogrel. (A Comparison of
Prasugrel [CS-747] and Clopidogrel in Acute Coronary
Syndrome Subjects Who Are to Undergo Percutaneous
Coronary Intervention; NCT00097591) (97).
Prognostic Value of a High On-Clopidogrel
Treatment Platelet Reactivity in Bivalirudin Versus
Abciximab Treated Non–ST-Segment Elevation
Myocardial Infarction PatientsISAR-REACT 4
(Intracoronary Stenting and Antithrombotic
Regimen: Rapid Early Action for Coronary
Treatment-4) Platelet Substudy
Objectives The ISAR-REACT 4 (Intracoronary Stenting
and Antithrombotic Regimen: Rapid Early Action forCoronary Treatment-4) platelet substudy aimed to deter-
mine the relevance of high on-clopidogrel treatment platelet
reactivity (HPR) in non–ST-segment elevation myocardial
infarction patients that received abciximab with unfractio-
nated heparin (UFH) or bivalirudin during percutaneous
coronary intervention (PCI).
Background In patients undergoing PCI, HPR has been
linked to a higher risk for ischemic events. The inﬂuence of
HPR on clinical outcomes may differ with regard to the
adjunctive antithrombotic treatment administered. In
ISAR-REACT 4, bivalirudin treatment showed similar
efﬁcacy proﬁles as compared to abciximab with UFH. The
impact of HPR on clinical outcomes in abciximab with
UFH versus bivalirudin treated non–ST-segment elevation
myocardial infarction patients has never been investigated
speciﬁcally.
Methods A total of 564 patients (274 in abciximab/UFH
group vs. 290 in bivalirudin group) were enrolled in this
study. Presence or absence of HPR following clopidogrel
loading was determined by platelet function testing on
a Multiplate analyzer (Verum Diagnostica, Munich,
Germany). Per study group and stratiﬁed in HPR and no-
HPR patients, the 30-day incidence of a combined efﬁ-
cacy endpoint (death, myocardial infarction, urgent target
vessel revascularization) was determined.
Results For abciximab with UFH, the incidence of the
efﬁcacy endpoint was similar in HPR versus no-HPR
patients (9.4% vs. 6.7%; odds ratio: 1.4; 95% conﬁdence
interval: 0.6 to 3.5; p ¼ 0.43). For bivalirudin, the incidence
of the efﬁcacy endpoint was signiﬁcantly higher in HPR
versus no-HPR patients (22.0% vs. 5.0%; odds ratio: 5.4;
95% conﬁdence interval: 2.4 to 12.1; p < 0.0001).
Conclusions For patients with a risk proﬁle similar to the
subjects enrolled in this platelet substudy, the impact of
HPR on clinical outcomes may depend on the type of
adjunctive antithrombotic therapy used during PCI. Further
investigations are warranted to clarify whether assessment of
platelet function may help tailoring antithrombotic therapy
during PCI. (Randomized Comparison of Abciximab Plus
Heparin With Bivalirudin in Acute Coronary Syndrome
[ISAR-REACT 4]; NCT00373451) (98).Prognostic Utility of Neutrophil Gelatinase-
Associated Lipocalin in Predicting Mortality and
Cardiovascular Events in PatientsWith ST-Segment
Elevation Myocardial Infarction Treated With
Primary Percutaneous Coronary Intervention
Objectives The aim of this study was to investigate the
prognostic role of neutrophil gelatinase–associated lipocalin
(NGAL) in a large population of patients with ST-segment
elevation myocardial infarction.lipocalin (NGAL) in a large
population of patients with ST-segment elevation myocar-
dial infarction.
Background NGAL is a glycoprotein released by damaged
renal tubular cells and is a sensitive maker of both clinical
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demonstrated that NGAL is also stored in granules of
mature neutrophils, and recent data suggest that NGAL
may also be involved in the development of atherosclerosis.
NGAL is signiﬁcantly increased in patients with myocardial
infarction compared with patients with stable coronary artery
disease and healthy subjects. However, the prognostic value
of NGAL has never been studied in patients with myocar-
dial infarction.
Methods We included 584 consecutive ST-segment
elevation myocardial infarction patients admitted to the
heart center of Gentofte University Hospital, Denmark, and
treated with primary percutaneous coronary intervention,
from September 2006 to December 2008. Blood samples
were drawn immediately before primary percutaneous
coronary intervention. Plasma NGAL levels were measured
using a time-resolved immunoﬂuorometric assay. The
endpoints were all-cause mortality (n ¼ 69) and the
combined endpoints (n ¼ 116) of major adverse cardiac
events (MACE) deﬁned as cardiovascular mortality and
admission due to recurrent myocardial infarction or heart
failure. The median follow-up time was 23 months (inter-
quartile range, 20 to 24 months).
Results Patients with high NGAL (>75th percentile) had
increased risk of all-cause mortality and MACE compared
with patients with low NGAL (log-rank test, p < 0.001).
After adjustment for confounding risk factors chosen by
backward elimination by Cox regression analysis, high
NGAL remained an independent predictor of all-cause
mortality and MACE (hazard ratio: 2.00; 95% conﬁ-
dence interval: 1.16 to 3.44; p ¼ 0.01 and hazard ratio:
1.51; 95% conﬁdence interval: 1.00 to 2.30; p ¼ 0.05,
respectively).
Conclusions High plasma NGAL independently predicts
all-cause mortality and MACE in ST-segment elevation
myocardial infarction patients treated with primary percu-
taneous coronary intervention (99).Ticagrelor Versus Prasugrel in Acute Coronary
Syndrome Patients With High On-Clopidogrel
Platelet Reactivity Following Percutaneous
Coronary Intervention: A Pharmacodynamic Study
Objectives The study aimed to compare the antiplatelet
action of ticagrelor with prasugrel in acute coronary
syndrome (ACS) patients with high on-treatment platelet
reactivity (HTPR) while on clopidogrel after percutaneous
coronary intervention (PCI).
Background Newer P2Y12 inhibitors like prasugrel and
ticagrelor provide stronger platelet inhibition compared with
clopidogrel. Both agents are efﬁcacious in patients with
HTPR while on clopidogrel, but direct comparison between
them has not yet been reported.
Methods In a prospective, single-center, single-blind study,
44 (of 139 screened, 31.7%) ACS patients with HTPR
while on clopidogrel 24 h post-PCI were randomized toeither ticagrelor 90 mg twice daily or prasugrel 10 mg once
daily for 15 days with a crossover directly to the alternate
treatment for another 15 days. HTPR was deﬁned as platelet
reactivity units (PRU) 235 as assessed by the VerifyNow
P2Y12 function assay.
Results The primary endpoint of platelet reactivity at the
end of the 2 treatment periods was lower for ticagrelor (32.9
PRU, 95% conﬁdence interval [CI]: 18.7 to 47.2) compared
with prasugrel (101.3 PRU, 95% CI: 86.8 to 115.7) with
a least squares mean difference of –68.3 PRU (95% CI:
–88.6 to –48.1; p < 0.001). The secondary endpoint of
HTPR rate was 0% for ticagrelor and 2.4% for prasugrel
(1 of 42, p ¼ 0.5). No patient exhibited a major bleeding
event at either treatment group.
Conclusions In patients with ACS exhibiting HTPR while
on clopidogrel 24 h post-PCI, ticagrelor produces a signiﬁ-
cantly higher platelet inhibition compared with prasugrel.
(Ticagrelor Versus Prasugrel in Acute Coronary Syndromes
After Percutaneous Coronary Intervention; NCT01360437)
(100).Impact of Ischemia-Guided Revascularization With
Myocardial Perfusion Imaging for Patients With
Multivessel Coronary Disease
Objectives The aim of this study was to evaluate the impact
of ischemia-guided (IG) revascularization.
Background The importance of IG revascularization has
not been well-determined.
Methods The outcomes of IG revascularization, in which
revascularization was performed in the matched coronary
artery with the perfusion abnormality on myocardial perfu-
sion image (MPI), were retrospectively compared with those
of non-IG revascularization in a registry of 5,340 patients
with multivessel coronary disease comprising 2,587 percu-
taneous coronary interventions (PCIs) with drug-eluting
stents and 2,753 coronary artery bypass graft (CABG)
surgeries after adjustment with inverse-probability-
of-treatment weighting.
Results The MPI was performed in 42.3% of patients, and
IG revascularization was performed in 17.3%, including
12.4% in PCI and 21.8% in CABG patients (p < 0.001).
The incidence of major adverse cardiac and cerebrovascular
events (MACCE) including death, myocardial infarction,
stroke, or repeat revascularization was signiﬁcantly lower in
the IG than in the non-IG group (16.2% vs. 20.7%; adjusted
hazard ratio [aHR]: 0.73; 95% conﬁdence interval [CI]: 0.60
to 0.88; p ¼ 0.001), primarily driven by the lower repeat
revascularization rate (9.9% vs. 22.8%; aHR: 0.66; 95% CI:
0.49 to 0.90; p ¼ 0.009). Subgroup analysis showed that IG
reduced the risk of MACCE in PCI (17.4% vs. 22.8%;
aHR: 0.59; 95% CI: 0.43 to 0.81; p ¼ 0.001) but not in
CABG (16.0% vs. 18.5%; aHR: 0.87; 95% CI: 0.67 to 1.14;
p ¼ 0.31) patients.
Conclusions Ischemia-guided revascularization with MPI,
particularly in PCI-treated patients, seems to decrease the
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with multivessel disease (101).
Hybrid Thoracoscopic Surgical and Transvenous
Catheter Ablation of Atrial Fibrillation
Objectives The purpose of this study was to evaluate the
feasibility, safety, and clinical outcomes up to 1 year in
patients undergoing combined simultaneous thoracoscopic
surgical and transvenous catheter atrial ﬁbrillation (AF)
ablation.
Background The combination of the transvenous endo-
cardial approach with the thoracoscopic epicardial approach
in a single AF ablation procedure overcomes the limitations
of both techniques and should result in better outcomes.
Methods A cohort of 26 consecutive patients with AF who
underwent hybrid thoracoscopic surgical and transvenous
catheter ablation were followed, with follow-up of up to 1
year.
Results Twenty-six patients (42% with persistent AF)
underwent successful hybrid procedures. There were no
complications. The mean follow-up period was 470  154
days. In 23% of the patients, the epicardial lesions were not
transmural, and endocardial touch-up was necessary. One-
year success, deﬁned according to the Heart Rhythm
Society, European Heart Rhythm Association, and Euro-
pean Cardiac Arrhythmia Society consensus statement for
the catheter and surgical ablation of AF, was 93% for
patients with paroxysmal AF and 90% for patients with
persistent AF. Two patients underwent catheter ablation for
recurrent AF or left atrial ﬂutter after the hybrid procedure.
Conclusions A combined transvenous endocardial and
thoracoscopic epicardial ablation procedure for AF is feasible
and safe, with a single-procedure success rate of 83% at 1
year (102).
Radial Artery and Saphenous Vein Patency More
Than 5 Years After Coronary Artery Bypass
Surgery: Results From RAPS (Radial Artery
Patency Study)
Objectives The purpose of this study was to present radial
and saphenous vein graft (SVG) occlusion results more than
5 years following coronary artery bypass surgery.
Background In the RAPS (Radial Artery Patency Study)
study, complete graft occlusion was less frequent in radial
artery compared with SVG 1 year post-operatively while
functional occlusion (Thrombolysis In Myocardial Infarc-
tion ﬂow grade 0, 1, 2) was similar.
Methods A total of 510 patients <80 years of age under-
going primary isolated nonemergent coronary artery bypass
grafting with 3-vessel disease were initially enrolled in 9
Canadian centers. Target vessels for the radial artery and
study SVG were the right and circumﬂex coronary arteries,
which had >70% proximal stenosis. Within-patient
randomization was performed; the radial artery was
randomized to either the right or circumﬂex territory and thestudy SVG was used for the other territory. The primary
endpoint was functional graft occlusion by invasive angiog-
raphy at least 5 years following surgery. Complete graft
occlusion by invasive angiography or computed tomography
angiography was a secondary endpoint.
Results A total of 269 patients underwent late angiography
(234 invasive angiography, 35 computed tomography angi-
ography) at a mean of 7.7  1.5 years after surgery. The
frequency of functional graft occlusion was lower in radial
arteries compared with SVGs (28 of 234 [12.0%] vs. 46 of
234 [19.7%]; p ¼ 0.03 by McNemar’s test). The frequency
of complete graft occlusion was also signiﬁcantly lower in
radial compared with SVGs (24 of 269 [8.9%] vs. 50 of 269
[18.6%]; p ¼ 0.002).
Conclusions Radial arteries are associated with reduced
rates of functional and complete graft occlusion compared
with SVGs more than 5 years following surgery. (Multi-
centre Radial Artery Patency Study: 5 Year Results;
NCT00187356) (103).Long-Term Prognosis Following Resuscitation From
Out of Hospital Cardiac Arrest: Role of
Percutaneous Coronary Intervention and
Therapeutic Hypothermia
Objectives The aim of the study was to assess the inﬂuence
of percutaneous coronary intervention (PCI) and therapeutic
hypothermia (TH) on long-term prognosis.
Background Although hospital care consisting of TH
and/or PCI in particular patients resuscitated following
out-of-hospital cardiac arrest (OHCA) can improve survival
to hospital discharge, there is little evidence regarding how
these therapies may impact long-term prognosis.
Methods We performed a cohort investigation of all
persons >18 years of age who suffered nontraumatic OHCA
and were resuscitated and discharged alive from the hospital
between January 1, 2001, and December 31, 2009, in
a metropolitan emergency medical service (EMS) system.
We reviewed EMS and hospital records, state death certif-
icates, and the national death index to determine clinical
characteristics and vital status. Survival analyses were con-
ducted using Kaplan-Meier estimates and multivariable Cox
regression. Analyses of TH were restricted to those patients
who were comatose at hospital admission.
Results Of the 5,958 persons who received EMS-
attempted resuscitation, 1,001 (16.8%) were discharged
alive from the hospital. PCI was performed in 384 of 1,001
(38.4%), whereas TH was performed in 241 of 941 (25.6%)
persons comatose at hospital admission. Five-year survival
was 78.7% among those treated with PCI compared with
54.4% among those not receiving PCI and 77.5% among
those treated with TH compared with 60.4% among those
not receiving TH (both p < 0.001). After adjustment for
confounders, PCI was associated with a lower risk of death
(hazard ratio [HR]: 0.46 [95% conﬁdence interval [CI]: 0.34
to 0.61]; p < 0.001). Likewise, TH was associated with
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p ¼ 0.04).
Conclusions The ﬁndings suggested that effects of acute
hospital interventions for post-resuscitation treatment
extend beyond hospital survival and can positively inﬂuence
prognosis following the arrest hospitalization (104).Clinical Application of Cardiovascular
Pharmacogenetics
Pharmacogenetics primarily uses genetic variation to identify
subgroups of patients who may respond differently to
a certain medication. Since its ﬁrst description, the ﬁeld of
pharmacogenetics has expanded to study a broad range of
cardiovascular drugs and has become a mainstream research
discipline. Three principle classes of pharmacogenetic
markers have emerged: 1) pharmacokinetic; 2) pharmaco-
dynamic; and 3) underlying disease mechanism. In the realm
of cardiovascular pharmacogenetics, signiﬁcant advances
have identiﬁed markers in each class for a variety of thera-
peutics, some with a potential for improving patient
outcomes. While ongoing clinical trials will determine if
routine use of pharmacogenetic testing may be beneﬁcial, the
data today support pharmacogenetic testing for certain
variants on an individualized, case-by-case basis. Our
primary goal is to review the association data for the major
pharmacogenetic variants associated with commonly used
cardiovascular medications: antiplatelet agents, warfarin,
statins, beta-blockers, diuretics, and antiarrhythmic drugs.
In addition, we highlight which variants and in which
contexts pharmacogenetic testing can be implemented by
practicing clinicians. The pace of genetic discovery has
outstripped the generation of the evidence justifying its
clinical adoption. Until the evidentiary gaps are ﬁlled,
however, clinicians may choose to target therapeutics to
individual patients whose genetic Background indicates that
they stand to beneﬁt the most from pharmacogenetic testing
(105).Everolimus-Eluting Stent Implantation for
Unprotected Left Main Coronary Artery
StenosisThe PRECOMBAT-2 (Premier of
Randomized Comparison of Bypass Surgery versus
Angioplasty Using Sirolimus-Eluting Stent in
Patients with Left Main Coronary Artery Disease)
Study
Objectives This study sought to evaluate the safety and
efﬁcacy of second-generation drug-eluting stents (DES) for
patients with unprotected left main coronary artery
(ULMCA) stenosis.
Background The clinical beneﬁt of second-generation
DES for ULMCA stenosis has not been determined.
Methods The authors assessed 334 consecutive patients
who received everolimus-eluting stents (EES) for ULMCA
stenosis between 2009 and 2010. The 18-month incidencerates of major adverse cardiac or cerebrovascular events
(MACCE), including death, myocardial infarction (MI),
stroke, or ischemia-driven target vessel revascularization
(TVR), were compared with those of a randomized study
comparing patients who received sirolimus-eluting stents
(SES) (n ¼ 327) or coronary artery bypass grafts (CABG)
(n ¼ 272).
Results EES (8.9%) showed a comparable incidence of
MACCE as SES (10.8%; adjusted hazard ratio [aHR] of
EES: 0.84; 95% conﬁdence interval [CI]: 0.51 to 1.40;
p ¼ 0.51) and CABG (6.7%, aHR of EES: 1.40; 95% CI:
0.78 to 2.54; p ¼ 0.26). The composite incidence of death,
MI, or stroke also did not differ among patients receiving
EES (3.3%), SES (3.7%; aHR of EES: 0.63; 95% CI: 0.27
to 1.47; p ¼ 0.29), and CABG (4.8%; aHR of EES: 0.67;
95% CI: 0.29 to 1.54; p ¼ 0.34). However, the incidence of
ischemia-driven TVR in the EES group (6.5%) was higher
than in the CABG group (2.6%, aHR of EES: 2.77; 95%
CI: 1.17 to 6.58; p ¼ 0.02), but comparable to SES (8.2%,
aHR of EES: 1.14; 95% CI: 0.64 to 2.06; p ¼ 0.65).
Angiographic restenosis rates were similar in the SES and
EES groups (13.8% vs. 9.2%, p ¼ 0.16).
Conclusions Second-generation EES had a similar
18-month risk of MACCE for ULMCA stenosis as ﬁrst-
generation SES or CABG. (Evaluation of Outcomes of
EES Implantation for Unprotected Left Main Coronary
Artery Stenosis [PRECOMBAT-2]; NCT01348022)
(106).Drug-Eluting Stent for Left Main Coronary Artery
DiseaseThe DELTA Registry: A Multicenter Registry
Evaluating Percutaneous Coronary Intervention
Versus Coronary Artery Bypass Grafting for Left
Main Treatment
Objectives The aim of this study was to compare, in a large
all-comers registry, major adverse cardiac and cerebrovas-
cular events (MACCE) after percutaneous coronary inter-
vention (PCI) with ﬁrst-generation drug-eluting stents
(DES) versus coronary artery bypass grafting (CABG) in
unprotected left main coronary artery (ULMCA) stenosis.
Background Percutaneous coronary intervention with DES
implantation in ULMCA has been shown to be a feasible
and safe approach at midterm clinical follow-up.
Methods All consecutive patients with ULMCA stenosis
treated by PCI with DES versus CABG were analyzed in
this multinational registry. A propensity score analysis was
performed to adjust for baseline differences in the overall
cohort.
Results In total 2,775 patients were included: 1,874 were
treated with PCI versus 901 with CABG. At 1,295 (inter-
quartile range: 928 to 1,713) days, there were no differences,
at the adjusted analysis, in the primary composite endpoint
of death, cerebrovascular accidents, and myocardial infarc-
tion (MI) (adjusted hazard ratio [HR]: 1.11; 95% conﬁ-
dence interval [CI]: 0.85 to 1.42; p ¼ 0.47), mortality
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composite endpoint of death and MI (adjusted HR: 1.25;
95% CI: 0.95 to 1.64; p ¼ 0.11). An advantage of CABG
over PCI was observed in the composite secondary endpoint
of MACCE (adjusted HR: 1.64; 95% CI: 1.33 to 2.03; p <
0.0001), driven exclusively by the higher incidence of target
vessel revascularization with PCI.
Conclusions In our multinational all-comers registry, no
difference was observed in the occurrence of death, cere-
brovascular accidents, and MI between PCI and CABG. An
advantage of CABG over PCI was observed in the incidence
of MACCE, driven by the higher incidence of target vessel
revascularization with PCI (107).Time Course of Endothelium-Dependent and
-Independent Coronary Vasomotor Response to
Coronary Balloons and Stents: Comparison of Plain
and Drug-Eluting Balloons and Stents
Objectives This study sought to determine the time
dependency of the endothelium-dependent and -independent
vascular responses after percutaneous coronary intervention
(PCI) with drug-eluting (DEB) or plain balloons, bare-metal
(BMS), and drug-eluting (DES) stents, or controls.
Background Long-term endothelial dysfunction after DES
implantation is associated with delayed healing and late
thrombosis.
Methods Domestic pigs underwent PCI using DEB or
plain balloon, BMS, or DES. The dilated and stented
segments, and the proximal reference segments of stents and
control arteries were explanted at 5-h, 24-h, 1-week, and
1-month follow-up (FUP). Endothelin-induced vasocon-
striction and endothelium-dependent and -independent
vasodilation of the arterial segments were determined
in vitro and were related to histological results.
Results DES- and BMS-treated arteries showed proneness
to vasoconstriction 5 h post-PCI. The endothelium-
dependent vasodilation was profoundly (p < 0.05) impaired
early after PCI (9.8  3.7%, 13.4  9.2%, 5.7  5.3%, and
7.6  4.7% using plain balloon, DEB, BMS, and DES,
respectively), as compared with controls (49.6  9.5%), with
slow recovery. In contrast to DES, the endothelium-related
vasodilation of vessels treated with plain balloon, DEB, and
BMS was increased at 1 month, suggesting enhanced
endogenous nitric oxide production of the neointima. The
endothelium-independent (vascular smooth muscle–related)
vasodilation decreased signiﬁcantly at 1 day, with slow
normalization during FUP. All PCI-treated vessels exhibited
imbalance between vasoconstriction–vasodilation, which was
more pronounced in DES- and BMS-treated vessels. No
correlation between histological parameters and vasomotor
function was found, indicating complex interactions between
the healing neoendothelium and smooth muscle post-PCI.
Conclusions Coronary arteries treated with plain balloon,
DEB, BMS, and DES showed time-dependent loss
of endothelial-dependent and -independent vasomotorfunction, with imbalanced contraction/dilation capacity
(108).
Radiation Exposure During Percutaneous Coronary
Interventions and Coronary Angiograms Performed
by the Radial Compared With the Femoral Route
Objectives This study aimed to compare radiation exposure
of patients undergoing percutaneous coronary interventions
(PCI) and coronary angiograms (CAG) accessed by the
femoral route with the radial route (operator’s choice).
Background There are limited and contradictory data on
the radiation exposure of patients during PCI and CAG
performed by the radial route compared with the femoral
route.
Methods Data on the radiation exposure of patients from
3,973 PCI and CAG procedures between June 22, 2004,
and December 31, 2008, were prospectively collected and
analyzed. A prediction model was made for radiation
exposure (dose-area product in Gy$cm2) based upon the
femoral access group, and the group of radial performed
procedures was compared to assess differences between
observed and expected radiation exposure.
Results Median exposures of patients undergoing a PCI via
the femoral route (n ¼ 2,309) was 75 (interquartile range
[IQR]: 44 to 135) Gy$cm2 compared with 72 (IQR: 42 to
134) Gy$cm2 for radial performed procedures (n ¼ 1,212)
(p ¼ 0.30). Median exposure for CAGs was 44 (IQR: 31 to
69) Gy$cm2 and 40 (IQR: 25 to 65) Gy$cm2 for, respec-
tively, femoral (n ¼ 314) and radial performed procedures
(n ¼ 138), (p ¼ 0.31). Also, the observed radiation exposure
in patients undergoing radial PCI or CAGs was not higher
than the expected exposure of patients as predicted by the
femoral access-based prediction model (71.5  2.3 Gy$cm2
vs. 79.9  1.8 Gy$cm2).
Conclusions The study shows that even after correction for
the complexity of the procedures, selected procedures per-
formed by the radial route are not associated with higher
radiation exposure of patients than selected procedures
performed by the femoral route (109).
Serious Infection After Acute Myocardial
Infarction: Incidence, Clinical Features, and
Outcomes
Objectives The aim of this study was to address the
knowledge gap using the APEX-AMI (Assessment of
Pexelizumab in Acute Myocardial Infarction) trial database.
We also assessed the association between serious infections
and 90-day death or death/myocardial infarction (MI).
Background Little is known about the incidence, location,
etiological organisms, and outcomes of infection in patients
with ST-segment elevation myocardial infarction (STEMI)
treated with primary percutaneous coronary intervention.
Methods We analyzed data from 5,745 STEMI patients
enrolled in the APEX-AMI trial. Detailed information on
infection was collected for all patients. We described
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of infection. Cox proportional hazards models were used to
assess 90-day outcomes among patients with and without
infections after adjusting for associated clinical variables and
with infection as a time-dependent covariate.
Results Overall, 138 patients developed a serious infection
(2.4%), most of whom presented with a single-site infection.
The median (25th, 75th percentile) time until diagnosis of
infection was 3 (1, 6) days. The most commonly identiﬁed
organism was Staphylococcus aureus, and the main location of
infection was the bloodstream. These patients had more
comorbidities and lower procedural success at index percu-
taneous coronary intervention than those without infections.
Serious infection was associated with signiﬁcantly higher
rates of 90-day death (adjusted hazard ratio: 5.6; 95%
conﬁdence interval: 3.8 to 8.4) and death or MI (adjusted
hazard ratio: 4.9; 95% conﬁdence interval: 3.4 to 7.1).
Conclusions Infections complicating the course of
patients with STEMI were uncommon but associated with
markedly worse 90-day clinical outcomes. Mechanisms for
early identiﬁcation of these high-risk patients as well as
design of strategies to reduce their risk of infection are
warranted. (Pexelizumab in Conjunction With Angio-
plasty in Acute Myocardial Infarction [APEX-AMI];
NCT00091637) (110).Implantation of a Drug-Eluting Stent With
a Different Drug (Switch Strategy) in Patients With
Drug-Eluting Stent Restenosis: Results From
a Prospective Multicenter Study (RIBS III
[Restenosis Intra-Stent: Balloon Angioplasty
Versus Drug-Eluting Stent])
Objectives This study sought to assess the effectiveness of
a strategy of using drug-eluting stents (DES) with
a different drug (switch) in patients with DES in-stent
restenosis (ISR).
Background Treatment of patients with DES ISR remains
a challenge.
Methods The RIBS-III (Restenosis Intra-Stent: Balloon
Angioplasty Versus Drug-Eluting Stent) study was
a prospective, multicenter study that aimed to assess results
of coronary interventions in patients with DES ISR. The use
of a different DES was the recommended strategy. The
main angiographic endpoint was minimal lumen diameter at
9-month follow-up. The main clinical outcome measure was
a composite of cardiac death, myocardial infarction, and
target lesion revascularization.
Results This study included 363 consecutive patients with
DES ISR from 12 Spanish sites. The different-DES
strategy was used in 274 patients (75%) and alternative
therapeutic modalities (no switch) in 89 patients (25%).
Baseline characteristics were similar in the 2 groups,
although lesion length was longer in the switch group. At
late angiographic follow-up (77% of eligible patients,
median: 278 days) minimal lumen diameter was larger (1.86 0.7 mm vs. 1.40  0.8 mm, p ¼ 0.003) and recurrent
restenosis rate lower (22% vs. 40%, p ¼ 0.008) in the
different-DES group. At the last clinical follow-up (99% of
patients, median: 771 days), the combined clinical endpoint
occurred less frequently (23% vs. 35%, p ¼ 0.039) in the
different-DES group. After adjustment using propensity
score analyses, restenosis rate (relative risk: 0.41, 95%
conﬁdence interval [CI]: 0.21 to 0.80, p ¼ 0.01), minimal
lumen diameter (difference: 0.41 mm, 95% CI: 0.19 to 0.62,
p ¼ 0.001), and the event-free survival (hazard ratio: 0.56,
95% CI: 0.33 to 0.96, p ¼ 0.038) remained signiﬁcantly
improved in the switch group.
Conclusions In patients with DES ISR, the implantation
of a different DES provides superior late clinical and
angiographic results than do alternative interventional
modalities (111).Renal Sympathetic Denervation Using an Irrigated
Radiofrequency Ablation Catheter for the
Management of Drug-Resistant Hypertension
Objectives This study sought to assess whether renal
sympathetic denervation (RSDN) can be achieved using an
off-the-shelf saline-irrigated radiofrequency ablation (RFA)
catheter typically employed for cardiac tissue ablation.
Background RSDN using a specialized solid-tip RFA
catheter has recently been demonstrated to safely reduce
systemic blood pressure in patients with refractory hyper-
tension. For cardiac tissue ablation, RFA technology has
evolved from nonirrigated to saline-irrigated ablation elec-
trodes to improve both safety and effectiveness.
Methods Ten patients with resistant hypertension under-
went renal angiography, followed by bilateral RSDN with
a saline-irrigated RFA catheter. Ambulatory blood pressure
recordings (24 h) were obtained at baseline, 1, 3, and 6
months after the procedure. Repeat renal angiography was
performed during follow-up to assess for arterial stenosis or
aneurysm. In 5 patients, pre- and post-procedural serum
measures of renal function and sympathetic activity were
obtained: aldosterone; metanephrine; normetanephrine;
plasma renin activity; and creatinine.
Results Over a 6-month period: 1) the systolic/diastolic
blood pressure decreased by 21/11 mm Hg; 2) all
patients experienced a decrease in systolic blood pressure of
at least 10 mm Hg (range 10 to 40 mm Hg); 3) there was no
evidence of renal artery stenosis or aneurysm at repeat
angiography; and 4) there was a signiﬁcant decrease in
metanephrine (12  4, p ¼ 0.003), normetanephrine
(18  4, p ¼ 0.0008), and aldosterone levels (60  33
ng/l, p ¼ 0.02) at 3 months. There was no signiﬁcant
change in plasma renin activity (0.2 mg/l/hod, p ¼ 0.4).
There was no signiﬁcant change in serum creatinine (1
mmol/l, p ¼ 0.4).
Conclusions These data provide the proof-of-principle
that RSDN can be performed using an off-the-shelf
saline-irrigated RFA catheter (112).
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Percutaneous Coronary Intervention With
Intravascular Ultrasound and Fractional Flow
Reserve: The Current State of Evidence
Percutaneous coronary intervention (PCI) is an evolving
indication for the treatment of unprotected left main coro-
nary arterial (UMLCA) stenoses in selected individuals.
Intravascular ultrasound (IVUS)-guided PCI within the
epicardial coronary tree has been shown to improve acute
procedural results and subsequent clinical outcomes. Simi-
larly, fractional ﬂow reserve (FFR) is rapidly gaining popu-
larity as a means to guide the coronary interventionalist to
embark upon a “physiological-based” revascularization
strategy. In light of the emergence of PCI for ULMCA
stenoses, the lack of randomized trials has meant that there
are no systematic guidelines that advocate the routine use of
these adjunctive imaging techniques to optimize procedural
and clinical outcomes. Given the potential dire clinical
consequences of procedural failure during ULMCA PCI, in
this review we systematically address the current level of
evidence for the use of FFR and IVUS during the assess-
ment for and undertaking of PCI for ULMCA stenoses. In
lieu of the current available level of evidence, we recommend
the use of FFR for the assessment of (angiographic inde-
terminate) isolated ostial or midshaft left main coronary
arterial (LMCA) stenoses in patients who are considered
more appropriate candidates for coronary arterial bypass
grafting. In those patients with distal/bifurcation LMCA
lesions and in those with diffuse/distal coronary arterial
disease, we strongly recommend the liberal use of IVUS.
Furthermore, in those patients considered likely candidates
for ULMCA PCI, IVUS remains crucial for assessing the
degree of lumen compromise and the extent, distribution,
and morphology of plaque as well as for the immediate
postprocedural quantiﬁcation of stent deployment (113).Meta-Analysis of Transcatheter Closure Versus
Medical Therapy for Patent Foramen Ovale in
Prevention of Recurrent Neurological Events After
Presumed Paradoxical Embolism
Objectives In this study, a meta-analysis of observational
studies was performed to compare the rate of recurrent
neurological events (RNE) between transcatheter closure
and medical management of patients with cryptogenic
stroke/transient ischemic attack (TIA) and concomitant
patent foramen ovale (PFO).
Background A signiﬁcant controversy surrounds the
optimal strategy for treatment of cryptogenic stroke/TIA
and coexistent PFO.
Methods We conducted a MEDLINE search with stan-
dard search terms to determine eligible studies.
Results Adjusted incidence rates of RNE were 0.8 (95%
conﬁdence interval [CI]: 0.5 to 1.1) events and 5.0 (95% CI:
3.6 to 6.9) events/100 person-years (PY) in the transcatheterclosure and medical management arms, respectively. Meta-
analysis of the limited number of comparative studies and
meta-regression analysis suggested that the transcatheter
closure might be superior to the medical therapy in
prevention of RNE after cryptogenic stroke. Comparison of
the anticoagulation and antiplatelet therapy subgroups of the
medical arm yielded a signiﬁcantly lower risk of RNE within
patients treated with anticoagulants. Device-related
complications were encountered at the rate of 4.1 (95%
CI: 3.2 to 5.0) events/100 PY, with atrial arrhythmias being
the most frequent complication. After transcatheter closure,
RNE did not seem to be related to the pre-treatment shunt
size or the presence of residual shunting in the follow-up
period. Signiﬁcant beneﬁt of transcatheter PFO closure
was apparent in elderly patients, patients with concomitant
atrial septal aneurysm, and patients with thrombophilia.
Conclusions Rates of RNE with transcatheter closure and
medical therapy in patients presenting with cryptogenic
stroke or TIA were estimated at 0.8 and 5.0 events/100 PY.
Further randomized controlled trials are needed to conclu-
sively compare these 2 management strategies (114).Ischemia Change in Stable Coronary Artery
Disease Is an Independent Predictor of Death and
Myocardial Infarction
Objectives The aim of this study was to evaluate the
independent prognostic signiﬁcance of ischemia change in
stable coronary artery disease (CAD).
Background Recent randomized trials in stable CAD have
suggested that revascularization does not improve outcomes
compared with optimal medical therapy (MT). In contrast,
the nuclear substudy of the COURAGE (Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation)
trial found that revascularization led to greater ischemia
reduction and suggested that this may be associated with
improved unadjusted outcomes. Thus, the effects of MT
versus revascularization on ischemia change and its indepen-
dent prognostic signiﬁcance requires further investigation.
Methods From the Duke Cardiovascular Disease and
Nuclear Cardiology Databanks, 1,425 consecutive patients
with angiographically documented CAD who underwent 2
serial myocardial perfusion single-photon emission
computed tomography scans were identiﬁed. Ischemia
change was calculated for patients undergoing MT alone,
percutaneous coronary intervention, or coronary artery
bypass grafting. Patients were followed for a median of 5.8
years after the second myocardial perfusion scan. Cox
proportional hazards regression modeling was used to
identify factors independently associated with the primary
outcome of death or myocardial infarction (MI). Formal risk
reclassiﬁcation analyses were conducted to assess whether
the addition of ischemia change to traditional predictors
resulted in improved risk classiﬁcation for death or MI.
Results More MT patients (15.6%) developed 5%
ischemia worsening compared with those undergoing
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bypass grafting (6.7%) (p < 0.001). After adjustment for
established predictors, 5% ischemia worsening remained
a signiﬁcant independent predictor of death or MI (hazard
ratio: 1.634; p ¼ 0.0019) irrespective of treatment arm.
Inclusion of 5% ischemia worsening in this model resulted
in signiﬁcant improvement in risk classiﬁcation (net reclas-
siﬁcation improvement: 4.6%, p ¼ 0.0056) and model
discrimination (integrated discrimination improvement:
0.0062, p ¼ 0.0057).
Conclusions In stable CAD, ischemia worsening is an
independent predictor of death or MI, resulting in signiﬁ-
cantly improved risk reclassiﬁcation when added to previ-
ously known predictors (115).Role of Echocardiography in Percutaneous Mitral
Valve Interventions
Intraprocedural imaging continues to evolve in parallel with
advances in percutaneous mitral valve interventions. This
didactic review uses several illustrations and rich intra-
procedural videos to further describe and demonstrate the
role of the most up-to-date echocardiographic and advanced
imaging technologies in the patient selection and intra-
procedural guidance of percutaneous mitral valve interven-
tions. We will focus on 3 interventions: 1) percutaneous
balloon mitral valvuloplasty for mitral stenosis; 2) trans-
catheter edge-to-edge repair of mitral valve regurgitation;
and 3) transcatheter closure of periprosthetic mitral
regurgitation. In addition, we discuss potential pitfalls of
3-dimensional transesophageal echocardiography and show
examples of this technique (116).OCT Findings in Patients With Recanalization of
Organized Thrombi in Coronary Arteries
Objectives The purpose of this study was to determine the
angiographic and optical coherence tomographic (OCT)
characteristics of coronary lesions with recanalized thrombi.
Background Although spontaneous recanalization of
thrombi has been reported pathologically, it is rarely
recognized in clinical practice.
Methods Based on histopathologic features, recanalization
of thrombi was deﬁned by characteristics on OCT.
Results Recanalization of thrombi was identiﬁed in 6
patients (3 male, 3 female; median age 63 years; age range 54
to 72 years). Based on symptoms, 3 patients were diagnosed
with unstable angina; 2 were diagnosed with stable angina;
and 1, who had mitral stenosis and huge left atrial thrombi,
was diagnosed with post-infarct angina. All had normal
serum concentrations of cardiac markers at admission.
Angiography showed irregular linear ﬁlling defects and
haziness. Two patients with near total occlusion had
Thrombolysis In Myocardial Infarction (TIMI) ﬂow grade 1
and collaterals, whereas 4 patients had TIMI ﬂow grade 3
and no collaterals. All patients showed OCT ﬁndingsconsistent with recanalized thrombi, which consisted of
signal-rich, high backscattered septa that divided the lumen
into multiple small cavities communicating with each other.
These structures, which had smooth inner borders, created
a “Swiss cheese” appearance. Percutaneous coronary inter-
vention was performed in 5 patients with angiographic slow
ﬂow or inducible-ischemia as documented by invasive or
noninvasive stress tests. The remaining 1 patient with
restored coronary ﬂow underwent mitral valve surgery and
left atrial thrombectomy.
Conclusions OCT provided details on the characteristics
of the organization of thrombi in both chronic total occlu-
sion and subtotal narrowing. Coronary lesions containing
recanalized thrombi were characterized by multiple small
channels, with most showing functional signiﬁcance (117).Clinical Outcomes After Transcatheter Aortic Valve
Replacement Using Valve Academic Research
Consortium Deﬁnitions: A Weighted Meta-Analysis
of 3,519 Patients From 16 Studies
Objectives This study sought to perform a weighted meta-
analysis to determine the rates of major outcomes after
transcatheter aortic valve replacement (TAVR) using Valve
Academic Research Consortium (VARC) deﬁnitions and to
evaluate their current use in the literature.
Background Recently, the published VARC deﬁnitions
have helped to add uniformity to reporting outcomes after
TAVR.
Methods A comprehensive search of multiple electronic
databases from January 1, 2011, through October 12,
2011, was conducted using predeﬁned criteria. We included
studies reporting at least 1 outcome using VARC
deﬁnitions.
Results A total of 16 studies including 3,519 patients met
inclusion criteria and were included in the analysis. The
pooled estimate rates of outcomes were determined
according to VARC’s deﬁnitions: device success, 92.1%
(95% conﬁdence interval [CI]: 88.7% to 95.5%); all-cause
30-day mortality, 7.8% (95% CI: 5.5% to 11.1%); myocar-
dial infarction, 1.1% (95% CI: 0.2% to 2.0%); acute kidney
injury stage II/III, 7.5% (95% CI: 5.1% to 11.4%); life-
threatening bleeding, 15.6% (95% CI: 11.7% to 20.7%);
major vascular complications, 11.9% (95% CI: 8.6% to
16.4%); major stroke, 3.2% (95% CI: 2.1% to 4.8%); and
new permanent pacemaker implantation, 13.9% (95% CI:
10.6% to 18.9%). Medtronic CoreValve prosthesis use was
associated with a signiﬁcant higher rate of new permanent
pacemaker implantation compared with the Edwards pros-
thesis (28.9% [95% CI: 23.0% to 36.0%] vs. 4.9% [95% CI:
3.9% to 6.2%], p < 0.0001). The 30-day safety composite
endpoint rate was 32.7% (95% CI: 27.5% to 38.8%) and the
1-year total mortality rate was 22.1% (95% CI: 17.9% to
26.9%).
Conclusions VARC deﬁnitions have already been used by
the TAVR clinical research community, establishing a new
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the VARC deﬁnitions are needed based on evolving TAVR
clinical experiences (118).First Results of the DEB-AMI (Drug Eluting Balloon
in Acute ST-Segment Elevation Myocardial
Infarction) TrialA Multicenter Randomized
Comparison of Drug-Eluting Balloon Plus Bare-
Metal Stent Versus Bare-Metal Stent Versus Drug-
Eluting Stent in Primary Percutaneous Coronary
Intervention With 6-Month Angiographic,
Intravascular, Functional, and Clinical Outcomes
Objectives The goal of this study was to compare
angiographic, intravascular imaging, and functional
parameters, as well as the clinical outcomes of patients
treated with drug-eluting balloon (DEB) plus bare-metal
stent (BMS) versus BMS versus drug-eluting stent
(DES) for ST-segment elevated acute myocardial infarction
(STEMI).
Background Concerns remain regarding the long-term
safety of DES in STEMI. DEB could provide an attrac-
tive alternative in order to achieve potentially similar
effectiveness but limiting the long-term hazards related to
late-acquired stent malapposition and thus stent thrombosis.
Methods In this randomized, international, 2-center,
single-blinded, 3-arm study, STEMI patients were ran-
domly assigned to group A: BMS; group B: DEB plus
BMS; or group C: DES after successful thrombus aspi-
ration. The primary endpoint was 6-month angiographic
in-stent late-luminal loss. Secondary endpoints were in-
stent binary restenosis, major adverse cardiac events
(MACE: cardiac death, myocardial infarction, target vessel
revascularization). In a subgroup of patients, stent (mal)
apposition (by optical coherence tomography) and
endothelial function (by acetylcholine infusion) was
assessed.
Results Overall, 150 patients were randomized. Procedural
success was achieved in 96.7%. In groups A, B, and C,
respectively, late-luminal loss was 0.74  0.57 mm, 0.64 
0.56 mm, and 0.21  0.32 mm (p < 0.01); binary restenosis
was 26.2%, 28.6%, and 4.7% (p ¼ 0.01); and MACE rates
were 23.5%, 20.0%, and 4.1% (p ¼ 0.02), respectively. The
median percentage [25th to 75th interquartile range] of
uncovered and malapposed stent struts per lesion was 0 [0 to
0.35], 2.84 [0 to 6.63], and 5.21 [3.25 to 14.5] (p < 0.01).
Signiﬁcant paradoxical vasoconstriction was seen in groups
B and C.
Conclusions In STEMI patients, DEB followed by BMS
implantation failed to show angiographic superiority to
BMS only. Angiographic results of DES were superior to
both BMS and DEB. Moreover, DEB before implantation
induced more uncovered and malapposed stent struts than
BMS, but less than after DES. (Drug-Eluting Balloon in
Acute Myocardial Infarction [DEB-AMI]; NCT00856765)
(119).Recovery of Platelet Function After
Discontinuation of Prasugrel or Clopidogrel
Maintenance Dosing in Aspirin-Treated Patients
With Stable Coronary Disease: The Recovery Trial
Objectives The goal of this study was to assess the offset of
the antiplatelet effects of prasugrel and clopidogrel.
Background Guidelines recommend discontinuing clopi-
dogrel at least 5 days and prasugrel at least 7 days before
surgery. The pharmacodynamic basis for these recommen-
dations is limited.
Methods Aspirin-treated patients with coronary artery
disease were randomly assigned to either prasugrel 10 mg or
clopidogrel 75 mg daily for 7 days. Platelet reactivity was
measured before study drug administration and for up to 12
days during washout. The primary endpoint was the
cumulative proportion of patients returning to baseline
reactivity after study drug discontinuation.
Results A total of 56 patients were randomized; 54 were
eligible for analysis. Platelet reactivity was lower 24 h after
the last dose of prasugrel compared with clopidogrel. After
prasugrel, 75% of patients returned to baseline reactivity by
washout day 7 compared with day 5 after clopidogrel.
Recovery time was dependent on the level of platelet reac-
tivity before study drug exposure and the initial degree of
platelet inhibition after study drug discontinuation but not
on treatment assignment.
Conclusions Recovery time after thienopyridine discon-
tinuation depends on the magnitude of on-treatment
platelet inhibition, resulting, on average, in a more delayed
recovery with prasugrel compared with clopidogrel. The
offset of prasugrel was consistent with current guidelines
regarding the recommended waiting period for surgery after
discontinuation. (Prasugrel/Clopidogrel Maintenance Dose
Washout Study; NCT01014624) (120).The New York State Cardiac Registries: History,
Contributions, Limitations, and Lessons for Future
Efforts to Assess and Publicly Report Healthcare
Outcomes
In 1988, the New York State Health Commissioner was
confronted with hospital-level data demonstrating very large,
multiple-year, interhospital variations in short-term
mortality and complications for cardiac surgery. The
concern with the extent to which these differences were due
to variations in patients’ pre-surgical severity of illness versus
hospitals’ quality of care led to the development of clinical
registries for cardiac surgery in 1989 and for percutaneous
coronary interventions in 1992 in New York. In 1990, the
Department of Health released hospitals’ risk-adjusted
cardiac surgery mortality rates for the ﬁrst time, and
shortly thereafter, similar data were released for hospitals
and physicians for percutaneous coronary interventions,
cardiac valve surgery, and pediatric cardiac surgery (only
hospital data). This practice is still ongoing. The purpose of
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including changes or purported changes that have occurred
since the public release of cardiac data. These changes
include decreases in risk-adjusted mortality, cessation of
cardiac surgery in New York by low-volume and high-
mortality surgeons, out-of-state referral or avoidance of
cardiac surgery/angioplasty for high-risk patients, alteration
of contracting choices by insurance companies, and modi-
ﬁcations in market share of cardiac hospitals. Evidence
related to these impacts is reviewed and critiqued. This
communication also includes a summary of numerous
studies that used New York’s cardiac registries to examine
a variety of policy issues regarding the choice and use of
cardiac procedures, the comparative effectiveness of
competing treatment options, and the examination of the
relationship among processes, structures, and outcomes of
cardiac care (121).A Randomized Trial of Prasugrel Versus
Clopidogrel in Patients With High Platelet
Reactivity on Clopidogrel After Elective
Percutaneous Coronary Intervention With
Implantation of Drug-Eluting Stents: Results of the
TRIGGER-PCI (Testing Platelet Reactivity In
Patients Undergoing Elective Stent Placement on
Clopidogrel to Guide Alternative Therapy With
Prasugrel) Study
Objectives This study sought to investigate the efﬁcacy,
safety, and antiplatelet effect of prasugrel as compared with
clopidogrel in patients with high on-treatment platelet
reactivity (HTPR) after elective percutaneous coronary
intervention (PCI).
Background The extent to which prasugrel can correct
HTPR and improve clinical outcomes in patients under-
going elective PCI is unknown.
Methods Stable coronary artery disease (CAD) patients
with HTPR (>208 P2Y12 reaction units [PRU] by the
VerifyNow test) after elective PCI with at least 1 drug-
eluting stent (DES) were randomly assigned to either pra-
sugrel 10 mg daily or clopidogrel 75 mg daily. Platelet
reactivity of the patients on the study drug was reassessed at
3 and 6 months. The study was stopped prematurely for
futility because of a lower than expected incidence of the
primary endpoint.
Results In 212 patients assigned to prasugrel, PRU
decreased from 245 (225 to 273) (median [interquartile
range]) at baseline to 80 (42 to 124) at 3 months, whereas in
211 patients assigned to clopidogrel, PRU decreased from
249 (225 to 277) to 241 (194 to 275) (p< 0.001 vs. prasugrel).
The primary efﬁcacy endpoint of cardiac death or myocardial
infarction at 6 months occurred in no patient on prasugrel
versus 1 on clopidogrel. The primary safety endpoint of non–
coronary artery bypass graft Thrombolysis In Myocardial
Infarction major bleeding at 6 months occurred in 3 patients
(1.4%) on prasugrel versus 1 (0.5%) on clopidogrel.Conclusions Switching from clopidogrel to prasugrel in
patients with HTPR afforded effective platelet inhibition.
However, given the low rate of adverse ischemic events after
PCI with contemporary DES in stable CAD, the clinical
utility of this strategy could not be demonstrated. (Testing
platelet Reactivity In patients underGoing elective stent
placement on clopidogrel to Guide alternative thErapy with
pRasugrel [TRIGGER-PCI]; NCT00910299) (122).Quantiﬁcation and Impact of Untreated Coronary
Artery Disease After Percutaneous Coronary
Intervention: The Residual SYNTAX (Synergy
Between PCI With Taxus and Cardiac Surgery)
Score
Objectives The purpose of this study was to quantify the
extent and complexity of residual coronary stenoses
following percutaneous coronary intervention (PCI) and to
evaluate its impact on adverse ischemic outcomes.
Background Incomplete revascularization (IR) after PCI is
common, and most studies have suggested that IR is asso-
ciated with a worse prognosis compared with complete
revascularization (CR). However, formal quantiﬁcation of
the extent and complexity of residual atherosclerosis after
PCI has not been performed.
Methods The baseline Synergy Between PCI With Taxus
and Cardiac Surgery (SYNTAX) score (bSS) from 2,686
angiograms from patients with moderate- and high-risk
acute coronary syndrome (ACS) undergoing PCI enrolled
in the prospective ACUITY (Acute Catheterization and
Urgent Intervention Triage Strategy) trial was determined.
The SS after PCI was also assessed, generating the “residual”
SS (rSS). Patients with rSS >0 were deﬁned as having IR
and were stratiﬁed by rSS tertiles, and their outcomes were
compared to the CR group.
Results The bSS was 12.8  6.7, and after PCI the rSS
was 5.6  2.2. Following PCI, 1,084 patients (40.4%) had
rSS ¼ 0 (CR), 523 (19.5%) had rSS >0 but 2, 578
(21.5%) had rSS >2 but 8, and 501 patients (18.7%) had
rSS >8. Age, insulin-treated diabetes, hypertension,
smoking, elevated biomarkers or ST-segment deviation, and
lower ejection fraction were more frequent in patients with
IR compared with CR. The 30-day and 1-year rates of
ischemic events were signiﬁcantly higher in the IR group
compared with the CR group, especially those with high
rSS. By multivariable analysis, rSS was a strong independent
predictor of all ischemic outcomes at 1 year, including all-
cause mortality (hazard ratio: 1.05, 95% conﬁdence
interval: 1.02 to 1.09, p ¼ 0.006).
Conclusions The rSS is useful to quantify and risk-
stratify the degree and complexity of residual stenosis
after PCI. Speciﬁcally, rSS >8.0 after PCI in patients with
moderate- and high-risk ACS is associated with a poor
30-day and 1-year prognosis. (Comparison of Angio-
max Versus Heparin in Acute Coronary Syndromes;
NCT00093158) (123).
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in Patients With ST-Segment Elevation Myocardial
Infarction
Objectives This study aimed to determine whether post-
conditioning at the time of percutaneous coronary inter-
vention could reduce reperfusion-induced myocardial edema
in patients with acute ST-segment elevation myocardial
infarction (STEMI).
Background Myocardial edema is a reperfusion injury with
potentially severe consequences. Post-conditioning is a car-
dioprotective therapy that reduces infarct size after reperfu-
sion, but no previous studies have analyzed the impact of
this strategy on reperfusion-induced myocardial edema in
humans.
Methods Fifty patients with STEMI were randomly
assigned to either a control or post-conditioned group.
Cardiac magnetic resonance imaging was performed within
48 to 72 h after admission. Myocardial edema was measured
by T2-weighted sequences, and infarct size was determined
by late gadolinium enhancement sequences and creatine
kinase release.
Results The post-conditioned and control groups were
similar with respect to ischemia time, the size of the area at
risk, and the ejection fraction before percutaneous coronary
intervention. As expected, post-conditioning was associated
with smaller infarct size (13  7 g/m2 vs. 21  14 g/m2;
p ¼ 0.01) and creatine kinase peak serum level (median
[interquartile range]: 1,695 [1,118 to 3,692] IU/l vs. 3,505
[2,307 to 4,929] IU/l; p ¼ 0.003). At reperfusion, the extent
of myocardial edema was signiﬁcantly reduced in the post-
conditioned group as compared with the control group
(23  16 g/m2 vs. 34  18 g/m2; p ¼ 0.03); the relative
increase in T2W signal intensity was also signiﬁcantly lower
(p ¼ 0.02). This protective effect was conﬁrmed after
adjustment for the size of the area at risk.
Conclusions This randomized study demonstrated that
post-conditioning reduced infarct size and edema in
patients with reperfused STEMI. (Post Cond No Reﬂow;
NCT01208727) (124).In-Stent Neoathero: sclerosis: A Final Common
Pathway of Late Stent Failure
Percutaneous coronary intervention with stenting is the most
widely performed procedure for the treatment of symp-
tomatic coronary disease, and drug-eluting stents (DES)
have minimized the limitations of bare-metal stents (BMS).
Nevertheless, there remain serious concerns about late
complications such as in-stent restenosis and late stent
thrombosis. Although in-stent restenosis of BMS was
considered as a stable condition with an early peak of intimal
hyperplasia, followed by a regression period beyond 1 year,
recent studies have reported that one-third of patients with
in-stent restenosis of BMS presented with acute coro-
nary syndrome that is not regarded as clinically benign.Furthermore, both clinical and histologic studies of DES
have demonstrated evidence of continuous neointimal
growth during long-term follow-up, which is designated as
“late catch-up” phenomenon. Here, we present emerging
evidence of de novo neoatherosclerosis based on histology,
angioscopy, and intravascular images that provide a new
insight for the mechanism of late stent failure. In-stent
neoatherosclerosis is an important substrate for late stent
failure for both BMS and DES, especially in the extended
phase. In light of the rapid progression in DES, early
detection of neoatherosclerosis may be beneﬁcial to
improving long-term outcome of patients with DES
implants (125).Optimal Treatment of Patients Surviving
Out-of-Hospital Cardiac Arrest
Interest in post-resuscitation care has risen with the devel-
opment of treatment modalities that can affect long-term
survival rates even when begun after the systematic
ischemia/reperfusion insult associated with cardiac arrest.
Mild therapeutic hypothermia has become the foundation
for improvement of neurologically favorable survival after
cardiac arrest. Reperfusion therapy, speciﬁcally early percu-
taneous coronary intervention, is becoming an important
adjunct to therapeutic hypothermia. Identifying which post–
cardiac arrest patient had an occluded or unstable coronary
vessel is difﬁcult because such events are not reliably pre-
dicted by precedent symptoms or standard electrocardio-
graphic analysis. Increasing clinical experience suggests that
resuscitated cardiac arrest victims without an obvious
noncardiac etiology should undergo emergency coronary
angiography and, where indicated, percutaneous coronary
intervention. If comatose, they should receive concurrent
therapeutic hypothermia. Such an approach can double
long-term survival rates among those successfully resusci-
tated after out-of-hospital cardiac arrest (126).Safety of Coronary Reactivity Testing in Women
With No Obstructive Coronary Artery Disease:
Results From the NHLBI-Sponsored WISE
(Women’s Ischemia Syndrome Evaluation) Study
Objectives This study evaluated the safety of coronary
reactivity testing (CRT) in symptomatic women with evi-
dence of myocardial ischemia and no obstructive coronary
artery disease (CAD).
Background Microvascular coronary dysfunction (MCD)
in women with no obstructive CAD portends an adverse
prognosis of a 2.5% annual major adverse cardiovascular
event (MACE) rate. The diagnosis of MCD is established
by invasive CRT, yet the risk of CRT is unknown.
Methods The authors evaluated 293 symptomatic women
with ischemia and no obstructive CAD, who underwent
CRT at 3 experienced centers. Microvascular function was
assessed using a Doppler wire and injections of adenosine,
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CRT-related serious adverse events (SAEs), adverse events
(AEs), and follow-up MACE (death, nonfatal myocardial
infarction [MI], nonfatal stroke, or hospitalization for heart
failure) were recorded.
Results CRT-SAEs occurred in 2 women (0.7%) during
the procedure: 1 had coronary artery dissection, and 1
developed MI associated with coronary spasm. CRT-AEs
occurred in 2 women (0.7%) and included 1 transient air
microembolism and 1 deep venous thrombosis. There was
no CRT-related mortality. In the mean follow-up period of
5.4 years, the MACE rate was 8.2%, including 5 deaths
(1.7%), 8 nonfatal MIs (2.7%), 8 nonfatal strokes (2.7%),
and 11 hospitalizations for heart failure (3.8%).
Conclusions In women undergoing CRT for suspected
MCD, contemporary testing carries a relatively low risk
compared with the MACE rate in these women. These
results support the use of CRT by experienced operators for
establishing deﬁnitive diagnosis and assessing prognosis in
this at-risk population. (Women’s Ischemia Syndrome
Evaluation [WISE]; NCT00832702) (127).Risk Proﬁle and 3-Year Outcomes From the
SYNTAX Percutaneous Coronary Intervention and
Coronary Artery Bypass Grafting Nested Registries
Objectives The aim of this study was to evaluate the use of
percutaneous coronary intervention (PCI) and coronary
artery bypass grafting (CABG) in “real-world” patients
unsuitable for the alternative treatment.
Background No data are available on the risk proﬁle and
outcomes of patients that can only undergo PCI or CABG.
Methods In the SYNTAX (Synergy between PCI with
TAXUS and Cardiac Surgery) trial, a multidisciplinary
Heart Team reached a consensus on whether PCI and
CABG could result in clinical equipoise; if so, the patient
was randomized. If not, the patient was enrolled in
a CABG-ineligible PCI registry or PCI-ineligible CABG
registry. A proportion (60%) of patients in the CABG
registry was randomly assigned to be followed up for 5 years.
No statistical comparisons were performed between
randomized and registry patients. Major adverse cardiac or
cerebrovascular event (MACCE) rates are presented as
observational only.
Results A total of 3,075 patients were treated in the
SYNTAX trial; 198 (6.4%) and 1,077 (35.0%) patients were
included in PCI and CABG registries, respectively. The
main reason for inclusion in the CABG registry was too
complex coronary anatomy (70.9%), and the main reason for
inclusion in the PCI registry was too high-risk for surgery
(70.7%). Three-year MACCE was 38.0% after PCI and
16.4% after CABG. Stratiﬁcation by SYNTAX score ter-
ciles demonstrated a step-wise increase of MACCE rates in
both PCI and CABG registries.
Conclusions The SYNTAX Heart Team concluded that
PCI and CABG remained the only treatment options for6.4% and 35.0% of patients, respectively. Inoperable patients
with major comorbidities that underwent PCI had high
MACCE rates. In patients not suitable for PCI, surgical
results were excellent. (SYNTAX Study: TAXUS Drug-
Eluting Stent Versus Coronary Artery Bypass Surgery
for the Treatment of Narrowed Arteries, NCT00114972)
(128).Contemporary Incidence and Predictors of Stent
Thrombosis and Other Major Adverse Cardiac
Events in the Year After XIENCE V Implantation:
Results From the 8,061-Patient XIENCE V United
States Study
Objectives The aim of this study was to identify predictors
of clinical events after XIENCE V (Abbott Vascular, Santa
Clara, California) stenting.
Background The XIENCE V USA (XIENCE V Ever-
olimus Eluting Coronary Stent System [EECSS] USA
Post-Approval) study is a prospective, multicenter, Food and
Drug Administration-required post-approval study to
examine safety and effectiveness in real-world settings. After
an initial 5,062 patients, 2,999 more were included as part
of the DAPT (Dual Antiplatelet Therapy) trial (total
n ¼ 8,061).
Methods One-year clinical events, including stent throm-
bosis (ST), cardiac death/myocardial infarction (MI), target
lesion failure, and target lesion revascularization, were
adjudicated according to Academic Research Consortium
criteria, with ST and cardiac death/MI as primary and co-
primary endpoints. Demographic, clinical, and procedural
variables were assessed by multivariable analysis. A time-
dependent covariate assessed the association between
DAPT usage and ST.
Results Roughly 61% were off-label; 85.6% remained on
DAPT without interruption through 1 year. Incidences of
deﬁnite/probable ST, cardiac death/MI, target lesion failure,
and target lesion revascularization were 0.80% (95% conﬁ-
dence interval [CI]: 0.61% to 1.03%), 7.1% (95% CI: 6.51%
to 7.68%), 8.9% (95% CI: 8.30% to 9.60%), and 4.3% (95%
CI: 3.82% to 4.75%), respectively. Several independent
clinical and angiographic predictors were identiﬁed for
each outcome. Predictors of ST included DAPT inter-
ruption 30 days (hazard ratio [HR]: 8.63, 95% CI: 2.69 to
27.73, p ¼ 0.0003), renal insufﬁciency (HR: 3.72, 95% CI:
1.71 to 8.09, p ¼ 0.0009), and total stent length (HR: 1.30,
95% CI: 1.16 to 1.47, p < 0.0001). A DAPT interruption
>30 days was not predictive of ST.
Conclusions In this large, real-world population,
XIENCE V demonstrated low event rates at 1 year, with
several independent predictors. Early DAPT interruption
(30 days) was the most potent predictor of ST, whereas
delayed interruption (>30 days) was not predictive.
(XIENCE V Everolimus Eluting Coronary Stent System
[EECSS] USA Post-Approval Study; NCT00676520)
(129).
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Plaque Characteristics and Slow-Flow
Phenomenon During Percutaneous Coronary
Intervention
Objectives This study sought to identify whether
computed tomographic angiographic (CTA) plaque char-
acteristics are associated with slow-ﬂow phenomenon (SF)
during percutaneous coronary intervention (PCI).
Background SF during PCI is associated with myocardial
damage and prolonged hospitalization. Intracoronary ultra-
sound–veriﬁed large echolucent lesions have been reported
to predict SF.
Methods The authors evaluated pre-PCI CTA plaque
characteristics in 40 consecutive patients (male/female, 31/9;
age, 69  10 years) with stable angina pectoris who devel-
oped SF during PCI; patients with 600 Agatston coronary
artery calcium score were not included. They were compared
with 40 age-, sex-, and culprit coronary artery–matched
patients (male/female, 31/9; age, 69  9 years) who
underwent PCI during the same period and did not develop
SF. Plaque characteristics, including vascular remodeling,
plaque consistency, including low-attenuation plaques rep-
resenting lipid-rich lesions and high-attenuation plaque
patterns of calcium deposition, were analyzed.
Results Calcium deposition in the perimeter of a plaque, or
circumferential plaque calciﬁcation (CPC), was signiﬁcantly
more frequent in the SF group (25 of 40, 63%) than the no-
SF group (2 of 40, 5.0%) (p < 0.001). Presence of CPC on
CTA was conﬁrmed at the same location in the non-
enhanced CT during Agatston coronary artery calcium score
calculation. The positive remodeling index was signiﬁcantly
higher (1.5 [1.3 to 1.8] vs. 1.2 [1.0 to 1.5]; p < 0.001) and
plaque density signiﬁcantly lower (23.5 [9.5 to 40] HU vs.
45 [29 to 86] HU; p ¼ 0.001) in the SF group. The
conditional logistic regression analysis revealed that CPC,
plaque density, and dyslipidemia were the predictors of SF,
with CPC being the strongest (odds ratio: 79; 95% conﬁ-
dence interval: 8 to 783, p < 0.0001).
Conclusions CTA-veriﬁed CPC with low-attenuation
plaque and positive remodeling were determinants of SF
during PCI. If CTA ﬁndings are available in patients
undergoing PCI, the interventionists should be aware of the
likelihood of SF (130).
Vascular Response of the Segments Adjacent to
the Proximal and Distal Edges of the ABSORB
Everolimus-Eluting Bioresorbable Vascular
Scaffold: 6-Month and 1-Year Follow-Up
Assessment: A Virtual Histology Intravascular
Ultrasound Study From the First-in-Man ABSORB
Cohort B Trial
Objectives This study sought to investigate in vivo the
vascular response at the proximal and distal edges of
the second-generation ABSORB everolimus-eluting bio-
resorbable vascular scaffold (BVS).Background The edge vascular response after implantation
of the BVS has not been previously investigated.
Methods The ABSORB Cohort B trial enrolled 101
patients and was divided into B1 (n ¼ 45) and B2 (n ¼ 56)
subgroups. The adjacent (5-mm) proximal and distal vessel
segments to the implanted ABSORB BVS were investigated
at either 6 months (B1) or 1 year (B2) with virtual histology
intravascular ultrasound (VH-IVUS) imaging.
Results At the 5-mm proximal edge, the only signiﬁcant
change was modest constrictive remodeling at 6 months (D
vessel cross-sectional area: 1.80% [3.18; 1.30], p <
0.05), with a tendency to regress at 1 year (D vessel cross-
sectional area: 1.53% [7.74; 2.48], p ¼ 0.06). The
relative change of the ﬁbrotic and ﬁbrofatty (FF) tissue areas
at this segment were not statistically signiﬁcant at either
time point. At the 5-mm distal edge, a signiﬁcant increase in
the FF tissue of 43.32% [19.90; 244.28], (p < 0.05) 1-year
post-implantation was evident. The changes in dense
calcium need to be interpreted with caution since the
polymeric struts are detected as “pseudo” dense calcium
structures with the VH-IVUS imaging modality.
Conclusions The vascular response up to 1 year after
implantation of the ABSORB BVS demonstrated some
degree of proximal edge constrictive remodeling and distal
edge increase in FF tissue resulting in nonsigniﬁcant plaque
progression with adaptive expansive remodeling. This
morphological and tissue composition behavior appears to
not signiﬁcantly differ from the behavior of metallic drug-
eluting stents at the same observational time points (131).The Effect of Patent Foramen Ovale Closure on
Visual Aura Without Headache or Typical Aura With
Migraine Headache
Objectives The aim of this study was to assess the preva-
lence of right-to-left (R to L) shunt in patients with visual
aura and evaluate the effect of shunt closure on resolution of
aura.
Background Right-to-left shunting is associated with
migraine headache (MH) with aura. Some patients present
with visual aura without headaches. It is unclear whether
visual aura without headache is a form of migraine or
a transient neurologic dysfunction.
Methods Of patients referred to the University of Cal-
ifornia, Los Angeles for suspected patent foramen ovale
(PFO), 225 had visual aura with or without MH. Patients
were assessed for a shunt and evaluated for MH and/or
visual aura. They were divided into 3 groups: 1) visual aura
associated with MH; 2) visual aura unrelated in time to MH;
and 3) visual aura without MH. The frequency of R to L
shunt was compared with a control group of 200 patients.
Eighty patients underwent PFO closure. Residual shunts,
MH, and visual aura were reassessed after 3 and 12 months.
Results The prevalence of R to L shunt in Groups A, B,
and C was 96%, 72%, and 67%, respectively, versus 18% in
the control group (p < 0.0001). The frequency of shunting
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all 3 groups compared with control subjects. Twelve months
after PFO closure, symptoms of aura were resolved in 52%,
75%, and 80% of patients in Groups A, B, and C, respec-
tively (p ¼ NS).
Conclusions The similar distribution of R to L shunting in
all 3 patient groups and the correlation between PFO closure
and improvement of aura suggests a similar pathophysiology
between the presence of PFO and the visual aura
phenomenon, whether or not headache is present in the
symptom complex (132).A Global Risk Approach to Identify Patients With
Left Main or 3-Vessel Disease Who Could Safely
and Efﬁcaciously Be Treated With Percutaneous
Coronary Intervention: The SYNTAX Trial at 3 Years
Objectives The aim of this study was to assess the addi-
tional value of the Global Riskda combination of the
SYNTAX Score (SXscore) and additive EuroSCOREdin
the identiﬁcation of a low-risk population, who could safely
and efﬁcaciously be treated with coronary artery bypass graft
surgery (CABG) or percutaneous coronary intervention
(PCI).
Background PCI is increasingly acceptable in appropriately
selected patients with left main stem or 3-vessel coronary
artery disease.
Methods Within the SYNTAX Trial (Synergy between
PCI with TAXUS and Cardiac Surgery Trial), all-cause
death and major adverse cardiac and cerebrovascular events
(MACCE) were analyzed at 36 months in low (GRCLOW)
to high Global Risk groups, with Kaplan-Meier, log-rank,
and Cox regression analyses.
Results Within the randomized left main stem pop-
ulation (n ¼ 701), comparisons between GRCLOW
groups demonstrated a signiﬁcantly lower mortality with
PCI compared with CABG (CABG: 7.5%, PCI: 1.2%,
hazard ratio [HR]: 0.16, 95% conﬁdence interval [CI]:
0.03 to 0.70, p ¼ 0.0054) and a trend toward reduced
MACCE (CABG: 23.1%, PCI: 15.8%, HR: 0.64, 95%
CI: 0.39 to 1.07, p ¼ 0.088). Similar analyses within the
randomized 3-vessel disease population (n ¼ 1,088)
demonstrated no statistically signiﬁcant differences in
mortality (CABG: 5.2%, PCI: 5.8%, HR: 1.14, 95% CI:
0.57 to 2.30, p ¼ 0.71) or MACCE (CABG: 19.0%,
PCI: 24.7%, HR: 1.35, 95% CI: 0.95 to 1.92,
p ¼ 0.10). Risk-model performance and reclassiﬁcation
analyses demonstrated that the EuroSCOREdwith the
added incremental beneﬁt of the SXscore to form the
Global Riskdenhanced the risk stratiﬁcation of all PCI
patients.
Conclusions In comparison with the SXscore, the Global
Risk, with a simple treatment algorithm, substantially
enhances the identiﬁcation of low-risk patients who
could safely and efﬁcaciously be treated with CABG or
PCI (133).Pathology of Drug-Eluting Versus Bare-Metal
Stents in Saphenous Vein Bypass Graft Lesions
Objectives The purpose of this study was to assess the
pathological responses of atherosclerotic saphenous vein
bypass grafts (SVBGs) to drug-eluting stents (DES) versus
bare-metal stents (BMS).
Background Repeat bypass surgery is typically associated
with a high rate of morbidity and mortality. Percutaneous
coronary interventions have emerged as the preferred treat-
ment; however, only limited data are available on SVBGs
pathological responses to DES and BMS.
Methods Formalin-ﬁxed SVBG of >2 years duration (n ¼
31) were collected to histologically characterize advanced
atherosclerotic lesions in native SVBG. In a separate group,
SVBGs treated with DES (n ¼ 9) and BMS (n ¼ 9) for
>30 days duration were assessed for morphological and
morphometric changes.
Results Necrotic core lesions were identiﬁed in 25% of
SVBG sections, and plaque rupture with luminal thrombosis
was observed in 6.3% of histological sections (32% [10 of
31] vein grafts examined). Morphometry of DES demon-
strated reduction in neointimal thickening versus BMS
(0.13 mm [interquartile range: 0.06 to 0.16 mm] vs. 0.30
mm [interquartile range: 0.20 to 0.48 mm], p ¼ 0.004).
DES lesions also showed greater delayed healing charac-
terized by increased peristrut ﬁbrin deposition, higher
percentage of uncovered struts, and less endothelialization
compared with BMS. Stent fractures (DES 56% vs. BMS
11%, p ¼ 0.045) and late stent thrombosis (DES 44% vs.
BMS 0%, p ¼ 0.023) were more common in DES versus
BMS.
Conclusions Advanced SVBG atherosclerotic lesions are
characterized by large hemorrhagic necrotic cores. Stenting
of such lesions is associated with delayed vascular healing
and late thrombosis particularly following DES implanta-
tion, which may help explain the higher rates of cardiovas-
cular events observed in SVBG stenting as compared with
native coronary arteries (134).
Inﬂuence of Genetic Polymorphisms on the Effect
of High- and Standard-Dose Clopidogrel After
Percutaneous Coronary Intervention: The GIFT
(Genotype Information and Functional Testing)
Study
Objectives This study sought to evaluate the inﬂuence of
single nucleotide polymorphisms (SNPs) on the pharma-
codynamic effect of high- or standard-dose clopidogrel after
percutaneous coronary intervention (PCI).
Background There is a lack of prospective, multicenter data
regarding the effect of different genetic variants on clopi-
dogrel pharmacodynamics over time in patients undergoing
PCI.
Methods The GRAVITAS (Gauging Responsiveness with
A VerifyNow assay–Impact on Thrombosis And Safety)
trial screened patients with platelet function testing after
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reactivity (OTR) to either high- or standard-dose clopi-
dogrel; a cohort of patients without high OTR were also
followed. DNA samples obtained from 1,028 patients were
genotyped for 41 SNPs in 17 genes related to platelet
reactivity. After adjusting for clinical characteristics, the
associations between the SNPs and OTR using linear
regression were evaluated.
Results CYP2C19*2 was signiﬁcantly associated with OTR
at 12 to 24 h (R2 ¼ 0.07, p ¼ 2.2  1015), 30 days (R2 ¼
0.10, p ¼ 1.3  107), and 6 months after PCI (R2 ¼ 0.07,
p ¼ 1.9  1011), whereas PON1, ABCB1 3435 C/T, and
other candidate SNPs were not. Carriers of 1 and 2 reduced-
function CYP2C19 alleles were signiﬁcantly more likely to
display persistently high OTR at 30 days and 6 months,
irrespective of treatment assignment. The portion of the risk
of persistently high OTR at 30 days attributable to reduced-
function CYP2C19 allele carriage was 5.2% in the patients
randomly assigned to high-dose clopidogrel.
Conclusions CYP2C19, but not PON1 or ABCB1, is
a signiﬁcant determinant of the pharmacodynamic effects of
clopidogrel, both early and late after PCI. In patients with
high OTR identiﬁed by platelet function testing, the
CYP2C19 genotype provides limited incremental informa-
tion regarding the risk of persistently high reactivity
with clopidogrel 150-mg maintenance dosing. (Genotype
Information and Functional Testing Study [GIFT];
NCT00992420) (135).Appropriateness of Coronary Revascularization for
Patients Without Acute Coronary Syndromes
Objectives The purpose of this study was to determine
appropriateness of percutaneous coronary intervention (PCI)
and coronary artery bypass graft (CABG) surgery performed
in New York for patients without acute coronary syndrome
(ACS) or previous CABG surgery.
Background The American College of Cardiology Foun-
dation (ACCF) and 6 other societies recently published joint
appropriateness criteria for coronary revascularization.
Methods Data from patients who underwent CABG
surgery and PCI without acute coronary syndrome or
previous CABG surgery in New York in 2009 and 2010
were used to assess appropriateness and to examine the
variation across hospitals in inappropriateness ratings.
Results Of the 8,168 patients undergoing CABG surgery in
New York without ACS/prior CABG who could be rated,
90.0% were appropriate for revascularization, 1.1% were
inappropriate, and 8.6% were uncertain. Of the 33,970 PCI
patients eligible for rating, 28% lacked sufﬁcient information
to be rated. Of the patients who could be rated, 36.1% were
appropriate, 14.3% were inappropriate, and 49.6% were
uncertain. A total of 91% of the patients undergoing PCI who
were classiﬁed as inappropriate had 1- or 2-vessel disease
without proximal left anterior descending artery disease and
had no or minimal anti-ischemic medical therapy.Conclusions For patients without ACS/prior CABG, only
1% of patients undergoing CABG surgery who could be
rated were found to be inappropriate for the procedure
according to the ACCF appropriateness criteria, but 14% of
the PCI patients who could be rated were found to be
inappropriate, and 28% lacked enough noninvasive test
information to be rated (136).
Impact of Coronary Plaque Composition on Cardiac
Troponin Elevation After Percutaneous Coronary
Intervention in Stable Angina Pectoris: A
Computed Tomography Analysis
Objectives The authors used multidetector computed
tomography (MDCT) to study the relation between culprit
plaque characteristics and cardiac troponin T (cTnT)
elevation after percutaneous coronary intervention (PCI).
Background Percutaneous coronary intervention is often
complicated by post-procedural myocardial necrosis man-
ifested by elevated cardiac biomarkers.
Methods Stable angina patients (n ¼ 107) with normal
pre-PCI cTnT levels underwent 64-slice MDCT before
PCI to evaluate plaque characteristics of culprit lesions.
Patients were divided into 2 groups according to presence
(group I, n ¼ 36) or absence (group II, n ¼ 71) of post-PCI
cTnT elevation 3 times the upper limit of normal (0.010
ng/ml) at 24 h after PCI.
Results Computed tomography attenuation values were
signiﬁcantly lower in group I than in group II (43.0 [26.5 to
75.7] HU vs. 94.0 [65.0 to 109.0] HU, p < 0.001).
Remodeling index was signiﬁcantly greater in group I than
in group II (1.20  0.18 vs. 1.04  0.15, p < 0.001). Spotty
calciﬁcation was observed signiﬁcantly more frequently in
group I than in group II (50% vs. 11%, p < 0.001).
Multivariate analysis showed presence of positive remodel-
ing (remodeling index >1.05; odds ratio: 4.54; 95% conﬁ-
dence interval: 1.36 to 15.9; p ¼ 0.014) and spotty
calciﬁcation (odds ratio: 4.27; 95% conﬁdence interval: 1.30
to 14.8; p ¼ 0.016) were statistically signiﬁcant independent
predictors for cTnT elevation. For prediction of cTnT
elevation, the presence of all 3 variables (CT attenuation
value <55 HU; remodeling index >1.05, and spotty calci-
ﬁcation) showed a high positive predictive value of 94%,
and their absence showed a high negative predictive value
of 90%.
Conclusions MDCT may be useful in detecting which
lesions are at high risk for myocardial necrosis after
PCI (137).
Temporal Trends in and Factors Associated With
Bleeding Complications Among Patients
Undergoing Percutaneous Coronary Intervention: A
Report From the National Cardiovascular Data
CathPCI Registry
Objectives The purpose of this study was to examine
temporal trends in post-percutaneous coronary intervention
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angina (UA)/non–ST-segment elevation myocardial infarc-
tion (NSTEMI), and ST-segment elevation myocardial
infarction (STEMI).
Background The impact of bleeding avoidance strategies
on post-PCI bleeding rates over time is unknown.
Methods Using the CathPCI Registry, we examined
temporal trends in post-PCI bleeding from 2005 to 2009
among patients with elective PCI (n ¼ 599,524), UA/
NSTEMI (n ¼ 836,103), and STEMI (n ¼ 267,632). We
quantiﬁed the linear time trend in bleeding using 3
sequential logistic regression models: 1) clinical factors; 2)
clinical þ vascular access strategies (femoral vs. radial, use of
closure devices); and 3) clinical, vascular strategies þ
antithrombotic treatments (anticoagulant  glycoprotein
IIb/IIIa inhibitor [GPI]). Changes in the odds ratio for time
trend in bleeding were compared using bootstrapping and
converted to risk ratio.
Results An approximate 20% reduction in post-PCI
bleeding was seen (elective PCI: 1.4% to 1.1%; UA/
NSTEMI: 2.3% to 1.8; STEMI: 4.9% to 4.5%). Radial
approach remained low (<3%), and closure device use
increased marginally from 44% to 49%. Bivalirudin use
increased (17% to 30%), whereas any heparin þ GPI
decreased (41% to 28%). There was a signiﬁcant 6% to 8%
per year reduction in annual bleeding risk in UA/NSTEMI
and elective PCI, but not in STEMI. Antithrombotic
strategies were associated with roughly half of the reduction
in annual bleeding risk: change in risk ratio from 7.5% to 4%
for elective PCI, and 5.7% to 2.8% for UA/NSTEMI (both
p <0.001).
Conclusions The nearly 20% reduction in post-PCI
bleeding over time was largely due to temporal changes in
antithrombotic strategies. Further reductions in bleeding
complications may be possible as bleeding avoidance strat-
egies evolve, especially in STEMI (138).Intraprocedural Thrombotic Events During
Percutaneous Coronary Intervention in Patients
With Non–ST-Segment Elevation Acute Coronary
Syndromes Are Associated With Adverse
Outcomes: Analysis From the ACUITY (Acute
Catheterization and Urgent Intervention Triage
Strategy) Trial
Objectives The purpose of this study was to assess the
prognostic impact of intraprocedural thrombotic events
(IPTE) during percutaneous coronary intervention (PCI).
Background Ischemic complications of PCI are infrequent
but prognostically important. How often these events are
a consequence of intraprocedural complications is unknown,
with only limited data assessing the occurrence and impor-
tance of IPTE.
Methods A total of 3,428 patients who underwent PCI for
non–ST-segment elevation acute coronary syndrome in the
ACUITY (Acute Catheterization and Urgent InterventionTriage Strategy) trial underwent detailed frame-by-frame
core laboratory angiographic analysis. An IPTE, deﬁned as
the development of new or increasing thrombus, abrupt
vessel closure, no reﬂow, slow reﬂow, or distal embolization
at any time during the procedure, occurred in 121 patients
(3.5%).
Results Patients with IPTE had higher in-hospital, 30-
day, and 1-year major adverse cardiac event rates than
patients without IPTE (25.6% vs. 6.3% in-hospital, 30.6%
vs. 9.3% at 30 days, and 37.0% vs. 20.5% at 1 year; p <
0.0001 for each). An IPTE was strongly associated with Q-
wave myocardial infarction and out-of-laboratory deﬁnite/
probable stent thrombosis (in-hospital 3.3% vs. 0.5%, p ¼
0.006; 30 days 5.8% vs. 1.3%, p < 0.0001; and 1 year 6.7%
vs. 2.0%, p ¼ 0.0002). Unplanned revascularization, target
vessel revascularization, and major bleeding not associated
with coronary artery bypass graft surgery were also increased
among patients with IPTE, as was overall 30-day mortality
(3.3% vs. 0.7%, p ¼ 0.002). Moreover, IPTE was an
independent predictor of 30-day and 1-year composite
death/myocardial infarction, stent thrombosis, and major
adverse cardiac events.
Conclusions Although infrequent among patients under-
going early PCI for moderate and high-risk non–ST-
segment elevation acute coronary syndrome, IPTE was
strongly associated with subsequent adverse outcomes
including death, myocardial infarction, and stent thrombosis
(139).Spotty Calciﬁcation as a Marker of Accelerated
Progression of Coronary Atherosclerosis: Insights
From Serial Intravascular Ultrasound
Objectives The purpose of this study was to determine
atheroma progression in patients with spotty calciﬁcation.
Background Although extensively calciﬁed atherosclerotic
lesions have been proposed to be clinically quiescent, the
presence of spotty calciﬁcation within plaque has been re-
ported to be associated with an increased incidence of
ischemic cardiovascular events. The relationship between
spotty calciﬁcation and disease progression has not been
investigated.
Methods A total of 1,347 stable patients with angiographic
coronary artery disease underwent serial evaluation of
atheroma burden with intravascular ultrasound imaging.
Patients with spotty calciﬁcation were identiﬁed based on
the presence of lesions (1 to 4 mm in length) containing an
arc of calciﬁcation of <90. Clinical characteristics and
disease progression were compared between patients with
spotty calciﬁcation (n ¼ 922) and those with no calciﬁcation
(n ¼ 425).
Results Patients with spotty calciﬁcation were older (age
56 years vs. 54 years; p ¼ 0.001), more likely to be male
(68% vs. 54%; p ¼ 0.01), and have a history of diabetes
mellitus (30% vs. 24%; p ¼ 0.01) and myocardial infarction
(28% vs. 20%; p ¼ 0.004), and have lower on-treatment
JACC Vol. 62, No. 18, 2013 The Editors
October 29, 2013:e245–e437 JACC Topic Collection: Interventional Cardiology
e297high-density lipoprotein cholesterol levels (48  16 mg/dl
vs. 51  17 mg/dl; p ¼ 0.001). Patients with spotty
calciﬁcation demonstrated a greater percent atheroma
volume (PAV) (36.0  7.6% vs. 29.0  8.5%; p < 0.001)
and total atheroma volume (174.6  71.9 mm3 vs. 133.9 
64.9 mm3; p < 0.001). On serial evaluation, spotty calci-
ﬁcation was associated with greater progression of PAV
(þ0.43  0.07% vs. þ0.02  0.11%; p ¼ 0.002).
Although intensive low-density lipoprotein cholesterol and
blood pressure lowering therapy slowed disease progres-
sion, these efﬁcacies were attenuated in patients with
spotty calciﬁcation.
Conclusions The presence of spotty calciﬁcation is asso-
ciated with more extensive and diffuse coronary atheroscle-
rosis and accelerated disease progression despite use of
medical therapies (140).Metabolomic Proﬁle of Human Myocardial
Ischemia by Nuclear Magnetic Resonance
Spectroscopy of Peripheral Blood Serum: A
Translational Study Based on Transient Coronary
Occlusion Models
Objectives The aim of this study was to investigate the
metabolomic proﬁle of acute myocardial ischemia (MIS)
using nuclear magnetic resonance spectroscopy of peripheral
blood serum of swine and patients undergoing angioplasty
balloon–induced transient coronary occlusion.
Background Biochemical detection of MIS is a major
challenge. The validation of novel biosignatures is of utmost
importance.
Methods High-resolution nuclear magnetic resonance
spectroscopy was used to proﬁle 32 blood serum metabolites
obtained (before and after controlled ischemia) from swine
(n ¼ 9) and patients (n ¼ 20) undergoing transitory MIS in
the setting of planned coronary angioplasty. Additionally,
blood serum of control patients (n ¼ 10) was sequentially
proﬁled. Preliminary clinical validation of the developed
metabolomic biosignature was undertaken in patients with
spontaneous acute chest pain (n ¼ 30).
Results Striking differences were detected in the blood
proﬁles of swine and patients immediately after MIS. MIS
induced early increases (10 min) of circulating glucose,
lactate, glutamine, glycine, glycerol, phenylalanine, tyrosine,
and phosphoethanolamine; decreases in choline-containing
compounds and triacylglycerols; and a change in the
pattern of total, esteriﬁed, and nonesteriﬁed fatty acids.
Creatine increased 2 h after ischemia. Using multivariate
analyses, a biosignature was developed that accurately
detected patients with MIS both in the setting of
angioplasty-related MIS (area under the curve 0.94) and in
patients with acute chest pain (negative predictive value
95%).
Conclusions This study reports, to the authors’ knowledge,
the ﬁrst metabolic biosignature of acute MIS developed
under highly controlled coronary ﬂow restriction. Metabolicproﬁling of blood plasma appears to be a promising
approach for the early detection of MIS in patients (141).
Transfemoral Aortic Valve Replacement With the
Edwards SAPIEN and Edwards SAPIEN XT
Prosthesis Using Exclusively Local Anesthesia and
Fluoroscopic Guidance: Feasibility and 30-Day
Outcomes
Objectives The authors report the feasibility and 30-day
outcomes of transfemoral aortic valve replacement
(TAVR), using the Edwards SAPIEN (Edwards Life-
sciences, Irvine, California) and Edwards SAPIEN XT
(Edwards Lifesciences) prosthesis, implanted using exclu-
sively local anesthesia and ﬂuoroscopic guidance.
Background Transfemoral TAVR is often managed with
general anesthesia. However, a simpliﬁed percutaneous
approach using local anesthesia has become more popular
because it offers multiple advantages in an elderly and fragile
population.
Methods Between May 2006 and January 2011, the
authors prospectively evaluated 151 consecutive patients
(logistic EuroSCORE: 22.8  11.8%) who underwent
TAVR (SAPIEN: n ¼ 78, SAPIEN XT: n ¼ 73) using
only local anesthesia and ﬂuoroscopic guidance. The primary
endpoint was a combination of all-cause mortality, major
stroke, life-threatening bleeding, stage 3 acute kidney injury
(AKI), periprocedural myocardial infarction (MI), major
vascular complication, and repeat procedure for valve-related
dysfunction at 30 days.
Results Transarterial femoral approach was surgical in all
SAPIEN procedures and percutaneous in 97.3% of
SAPIEN XT, using the ProStar vascular closure device, and
was well tolerated in all cases. Conversion to general anes-
thesia was required in 3.3% (SAPIEN cases) and was related
to complications. Vasopressors were required in 5.5%.
Procedural success was 95.4%. The combined-safety
endpoint was reached in 15.9%, including overall mortality
(6.6%), major stroke (2.0%), life-threatening bleeding
(7.9%), stage 3 AKI (0.7%), periprocedural MI (1.3%),
major vascular complication (7.9%), and repeat procedure for
valve-related dysfunction (2.0%) at 30 days. A permanent
pacemaker was required in 5.3%.
Conclusions This single-center, prospective registry
demonstrated the feasibility and safety of a simpliﬁed
transfemoral TAVR performed using only local anesthesia
and ﬂuoroscopic guidance in high surgical risk patients with
severe aortic stenosis (142).
Percutaneous Management of Vascular
Complications in Patients Undergoing
Transcatheter Aortic Valve Implantation
Objectives This study sought to investigate the feasibility
and safety of percutaneous management of vascular
complications after transcatheter aortic valve implantation
(TAVI).
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frequent and outcomes after percutaneous management of
these adverse events not well established.
Methods Between August 2007 and July 2010, 149
patients underwent transfemoral TAVI using a percutaneous
approach. We compared outcomes of patients undergoing
percutaneous management of vascular complications with
patients free from vascular complications and performed
duplex ultrasonography, ﬂuoroscopy, and multislice com-
puted tomography during follow-up.
Results A total of 27 patients (18%) experienced vascular
complications consisting of incomplete arteriotomy closure
(n ¼ 19, 70%), dissection (n ¼ 3, 11%), arterial perforation
(n ¼ 3, 11%), arterial occlusion (n ¼ 1, 4%), and pseu-
doaneurysm (n ¼ 1, 4%). Percutaneous stent graft implan-
tation was successful in 21 of 23 (91%) patients, whereas 2
patients were treated by manual compression, 2 patients
underwent urgent surgery, and 2 patients required delayed
surgery. Rates of major adverse cardiac events at 30 days
were similar among patients undergoing percutaneous
management of vascular complications and those without
vascular complications (9% vs. 8%, p ¼ 1.00). After
a median follow-up of 10.9 months, imaging showed no
evidence of hemodynamically signiﬁcant stenosis (mean
peak velocity ratio: 1.2  0.4). Stent fractures were observed
in 4 stents (22%, type I [6%], type II [16%]) and were
clinically silent in all cases.
Conclusions Vascular complications after TAVI can be
treated percutaneously as a bailout procedure with a high
rate of technical success, and clinical outcomes are compa-
rable to patients without vascular complications. Stent
patency is high during follow-up, although stent fractures
require careful scrutiny (143).Predictive Factors, Efﬁcacy, and Safety of Balloon
Post-Dilation After Transcatheter Aortic Valve
Implantation With a Balloon-Expandable Valve
Objectives This study sought to evaluate the predictive
factors, effects, and safety of balloon post-dilation (BPD) for
the treatment of signiﬁcant paravalvular aortic regurgitation
(AR) after transcatheter aortic valve implantation (TAVI).
Background Very few data exist on BPD after TAVI with
a balloon-expandable valve.
Methods A total of 211 patients who underwent TAVI
with a balloon-expandable valve were included. BPD was
performed after TAVI if paravalvular AR 2 was identiﬁed
by transesophageal echocardiography. Clinical events and
echocardiographic data were prospectively recorded, and
median follow-up was 12 (6 to 24) months.
Results BPD was performed in 59 patients (28%), leading
to a reduction in at least 1 degree of AR in 71% of patients,
with residual AR <2 in 54% of the patients. The predictors
of the need for BPD were the degree of valve calciﬁcation
and transfemoral approach, with valve calciﬁcation volume
>2,200 and >3,800 mm3 best determining the need for anda poor response to BPD, respectively. Patients who under-
went BPD had a higher incidence of cerebrovascular events
at 30 days (11.9% vs. 2.0%, p ¼ 0.006), with most (83%)
events within the 24 h after the procedure occurring in
patients who had BPD. No signiﬁcant changes in valve area
or AR degree were observed at follow-up in BPD and no-
BPD groups.
Conclusions BPD was needed in about one-fourth of the
patients undergoing TAVI with a balloon-expandable valve
and was successful in about one-half of them. A higher
degree of valve calciﬁcation and transfemoral approach
predicted the need for BPD. BPD was not associated with
any deleterious effect on valve function at mid-term follow-
up, but a higher rate of cerebrovascular events was observed
in patients who had BPD (144).Evaluation of Multidimensional Geriatric
Assessment as a Predictor of Mortality and
Cardiovascular Events After Transcatheter Aortic
Valve Implantation
Objectives This study evaluated Multidimensional Geri-
atric Assessment (MGA) as predictor of mortality and major
adverse cardiovascular and cerebral events (MACCE) after
transcatheter aortic valve implantation (TAVI).
Background Currently used global risk scores do not reli-
ably estimate mortality and MACCE in these patients.
Methods This prospective cohort comprised 100 consec-
utive patients 70 years undergoing TAVI. Global risk
scores (Society of Thoracic Surgeons [STS] score, Euro-
SCORE) and MGA-based scores (cognition, nutrition,
mobility, activities of daily living [ADL], and frailty index)
were evaluated as predictors of all-cause mortality and
MACCE 30 days and 1 year after TAVI in regression
models.
Results In univariable analyses, all predictors were signiﬁ-
cantly associated with mortality and MACCE at 30 days
and 1 year, except for the EuroSCORE at 30 days and
instrumental ADL at 30 days and 1 year. Associations of
cognitive impairment (odds ratio [OR]: 2.98, 95% conﬁ-
dence interval [CI]: 1.07 to 8.31), malnutrition (OR: 6.72,
95% CI: 2.04 to 22.17), mobility impairment (OR: 6.65,
95% CI: 2.15 to 20.52), limitations in basic ADL (OR:
3.63, 95% CI: 1.29 to 10.23), and frailty index (OR: 3.68,
95% CI: 1.21 to 11.19) with 1-year mortality were similar
compared with STS score (OR: 5.47, 95% CI: 1.48 to
20.22) and EuroSCORE (OR: 4.02, 95% CI: 0.86 to
18.70). Similar results were found for 30-day mortality and
MACCE. Bivariable analyses, including STS score or
EuroSCORE suggested independent associations of MGA-
based scores (e.g., OR of frailty index: 3.29, 95% CI: 1.06 to
10.15, for 1-year mortality in a model including
EuroSCORE).
Conclusions This study provides evidence that risk
prediction can be improved by adding MGA-based infor-
mation to global risk scores. Larger studies are needed for
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models (145).Need for Permanent Pacemaker as a Complication
of Transcatheter Aortic Valve Implantation and
Surgical Aortic Valve Replacement in Elderly
Patients With Severe Aortic Stenosis and Similar
Baseline Electrocardiographic Findings
Objectives The aim of this study was to compare the
incidence and predictive factors of complete atrioventricular
block (AVB) and permanent pacemaker implantation (PPI)
after transcatheter aortic valve implantation (TAVI) versus
surgical aortic valve replacement (SAVR).
Background No data exist on the need for PPI after TAVI
versus SAVR in patients with similar baseline electrocar-
diographic (ECG) ﬁndings.
Methods A total of 411 patients with severe aortic
stenosis (AS) and no prior pacemaker who underwent
TAVI with the balloon-expandable Edwards valve
(Edwards Lifesciences, Irvine, California) were matched
(1:1) with 411 elderly patients with severe AS who
underwent isolated SAVR on the basis of baseline ECG
ﬁndings. The incidence, reasons, and predictive factors for
PPI within 30 days after the procedure were compared
between groups.
Results Mean age was similar in both groups (p ¼ 0.11),
and the TAVI group had a higher Society of Thoracic
Surgeons score (p < 0.001). The rate of new PPI was higher
after TAVI (7.3%) compared with SAVR (3.4%), p ¼
0.014. Complete AVB and severe symptomatic bradycardia,
respectively, were the reasons for PPI in the TAVI (5.6%
and 1.7%, respectively) and SAVR (2.7% and 0.7%,
respectively) groups (p ¼ 0.039 for complete AVB, p ¼ NS
for symptomatic bradycardia). The presence of baseline
right bundle branch block was the only variable associated
with PPI in the TAVI group (odds ratio: 8.61, 95% conﬁ-
dence interval: 3.14 to 23.67, p < 0.0001), whereas no
variable was found in the SAVR group.
Conclusions Transcatheter aortic valve implantation was
associated with a higher rate of complete AVB and PPI
compared with SAVR in elderly patients with severe AS and
similar baseline ECG ﬁndings. The presence of baseline
right bundle branch block correlated with the need for PPI
in the TAVI group (146).Multicenter Evaluation of Edwards SAPIEN
Positioning During Transcatheter Aortic Valve
Implantation With Correlates for Device Movement
During Final Deployment
Objectives This study sought to evaluate the exact location
of Edwards SAPIEN (Edwards Lifesciences, Irvine, Cal-
ifornia) devices in different stages of implantation and to
quantify possible operator-independent device movement
during ﬁnal deployment.Background Accurate device positioning during trans-
catheter aortic valve implantation is crucial in order to
achieve optimal results.
Methods This multicenter study consisted of 68 procedures
with reliable pacemaker capture. Device positions were
assessed using ﬂuoroscopic images and the C-THV system
(Paieon Medical, Rosh Ha’Ayin, Israel).
Results The location after implantation was signiﬁcantly
higher than in the ﬁnal stage of rapid pacing: 16.7  16.3%
of device height below the plane of the lower sinus border
versus 32.6  13.8%, p < 0.0001. Operator-independent
device-center upper movement during ﬁnal deployment
was 2  1.43 mm, range: 1.3 to 4.6 mm. Device move-
ment was asymmetrical, occurring more in the lower part of
the device than in its upper part (3.2  1.4 mm vs. 0.75 
1.5 mm, p < 0.001), resulting in device shortening.
Multivariate analysis revealed that moderate and severe
aortic valve calciﬁcation had 49% higher upward movement
than mild calciﬁcation (p ¼ 0.03), and aortic sinus volume
was negatively correlated with movement size (r ¼ 0.35,
p ¼ 0.005). This movement was independent of device
version (SAPIEN vs. SAPIEN XT), procedural access
(transfemoral vs. transapical), and interventricular septum
width.
Conclusions The ﬁnal Edwards SAPIEN position is
mostly aortic in relation to the lower sinus border. There is
an operator-independent upward movement of the device
center during the ﬁnal stage of implantation. Anticipated
upward movement of the device should inﬂuence its posi-
tioning before ﬁnal deployment (147).Distribution of Calcium in the Ascending Aorta in
Patients Undergoing Transcatheter Aortic Valve
Implantation and Its Relevance to the Transaortic
Approach
Objectives This study sought to identify how many
patients suitable for transcatheter aortic valve implantation
(TAVI) would have a contraindication for the transaortic
(TAo) approach due to ascending aortic calciﬁcation.
Background TAo is an emerging approach for implanta-
tion of the Sapien valve through the ascending aorta. A
“porcelain aorta” is often considered a contraindication for
the TAo approach. This may not always be true, as the TAo
procedure requires a small calcium-free area for the purse-
string suture, usually in the upper outer quadrant of the
distal ascending aorta, identiﬁed as the “TAo zone.”
Methods A total of 237 patients underwent TAVI between
February 2008 and June 2011. Multislice computed
tomography scans (MSCT) were analyzed for distribution of
calcium with special attention to the TAo zone. Each
MSCT was interrogated in cross section and three dimen-
sional (3D) reconstructions. Correlation between the
calcium distribution on MSCT and the 3D reconstruction
with the clinical ﬁndings was sought in patients undergoing
the TAo procedure.
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the aortic arch (n ¼ 154, 64.9%) and aortic root (n ¼ 220,
92.8%). Of the 237 patients, only 1 patient had diffuse
calciﬁcation in the ascending aorta, including the TAo zone,
thus precluding a TAo procedure. MSCT and 3D recon-
struction data in the 33 patients who underwent a TAo
procedure, including 6 who were identiﬁed as having
porcelain aorta preoperatively, correlated very well with the
absence of calcium in the TAo zone during surgery. There
were no post-procedure neurological events in this group.
Conclusions Conventionally deﬁned porcelain aorta should
not be considered a contraindication for performing TAVI
by the TAo approach (148).Structural Integrity of Balloon-Expandable Stents
After Transcatheter Aortic Valve Replacement:
Assessment by Multidetector Computed
Tomography
Objectives This study sought to evaluate the structural
integrity of balloon-expandable stents used in transcatheter
aortic valve replacement.
Background Underexpansion, deformation, or fracture of
stent frames may affect transcatheter heart valve (THV)
function and durability.
Methods Patients >1 year after transcatheter aortic valve
replacement underwent multidetector computed tomog-
raphy. Geometry of the stent frame was assessed for circu-
larity; eccentricity; minimum and maximum external
diameter; and expansion at the inﬂow, mid-stent, and
outﬂow levels, as well as for stent fracture. THV non-
circularity was deﬁned as stent eccentricity >10% (1 –
minimum diameter/maximum diameter) and THV
underexpansion when expansion <90% (multidetector
computed tomography derived external valve area/nominal
external valve area). Echocardiography was performed after
implantation and annually.
Results Fifty patients underwent multidetector computed
tomography at an average of 2.5  0.9 years after
transcatheter aortic valve replacement (35 Sapien, 8 Sapien
XT, and 7 Cribier-Edwards valves [all Edwards Life-
sciences, Irvine, California). The mean external diameter
for the 23- and 26-mm valves was 23.3  0.9 mm and
25.9  0.9 mm, respectively. Circularity was present in
96% (48 of 50) and median eccentricity was 2.0%
(interquartile range: 1.2% to 3.0%). Mean THV expansion
was 104.1  7.4%, which increased from stent inﬂow to
outﬂow (100.8  7.6% vs. 108.1  6.9%, p < 0.001).
Stent fracture was not observed. Underexpanded valves
(8% [4 of 50]) and noncircular valves (4% [2 of 50])
demonstrated stable hemodynamic function on annual
echocardiography.
Conclusions Balloon-expandable aortic valves have excel-
lent rates of circularity with low eccentricity and maintain
full expansion without stent fracture at an average 2.5 years
after implantation (149).Transcatheter Valve-In-Valve Implantation for
Failed Balloon-Expandable Transcatheter Aortic
Valves
Objectives This study sought to evaluate outcomes after
implantation of a second transcatheter heart valve (THV-in-
THV) for acute THV failure.
Background Aortic regurgitation after transcatheter aortic
valve replacement (TAVR) may be valvular due to prosthetic
leaﬂet dysfunction or paravalvular due to poor annular
sealing.
Methods Patients undergoing aortic balloon-expandable
TAVR at 3 centers were prospectively evaluated at base-
line, intraprocedurally, at hospital discharge, and annually.
Results Of 760 patients undergoing TAVR, 21 (2.8%)
received a THV-in-THV implant due to acute, severe
regurgitation. Aortic regurgitation was paravalvular in 18
patients and transvalvular in the remaining 3 patients.
THV-in-THV implantation was technically successful in 19
patients (90%) and unsuccessful in 2 patients (10%), who
subsequently underwent open heart surgery. Mortality at 30
days and 1 year was 14.3% and 24%, respectively. After
successful THV-in-THV, mean aortic valve gradient fell
from 37  12 mm Hg to 13  5 mm Hg (p < 0.01); aortic
valve area increased from 0.64  0.14 cm2 to 1.55  0.27
cm2 (p < 0.01); and paravalvular aortic regurgitation was
none in 4 patients, mild in 13 patients, and moderate in 2
patients. At 1-year follow-up, 1 patient had moderate and
the others had mild or no paravalvular leaks. The mean
transvalvular gradient was 15  4 mm Hg, which was higher
than in patients undergoing conventional TAVR (11  4
mm Hg, p ¼ 0.02).
Conclusions THV-in-THV implantation is feasible and
results in satisfactory short- and mid-term outcomes (150).
Factors Predicting and Having an Impact on the
Need for a Permanent Pacemaker After CoreValve
Prosthesis Implantation Using the New Accutrak
Delivery Catheter System
Objectives The purpose of this study was to evaluate the
need for a permanent pacemaker after transcatheter aortic
valve implantation with the CoreValve prosthesis (Med-
tronic, Inc., Minneapolis, Minnesota) using the new
Accutrak delivery system (Medtronic, Inc.).
Background The need for a permanent pacemaker is
a recognized complication after transcatheter aortic valve
implantation with the CoreValve prosthesis.
Methods Between April 23, 2008 and May 31, 2011, 195
consecutive patients with symptomatic aortic valve stenosis
underwent transcatheter aortic valve implantation using the
self-expanding CoreValve prosthesis. In 124 patients, the
traditional delivery system was used, and in 71 patients, the
Accutrak delivery system was used.
Results There were no signiﬁcant differences in baseline
electrocardiographic characteristics between the traditional
system and the Accutrak patients: PR interval: 153 46 mm
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22 (20.2%) versus 8 (12.7%), p ¼ 0.21; right bundle
branch block: 21 (19.3%) versus 8 (12.7%), p ¼ 0.26. The
depth of the prosthesis in the left ventricular outﬂow tract was
greater with the traditional system than with the Accutrak
system (9.6  3.2 mm vs. 6.4  3 mm, p < 0.001) and
the need for a permanent pacemaker was higher with tradi-
tional system than with Accutrak (35.1% vs. 14.3%,
p ¼ 0.003). The predictors of the need for a pacemaker were
the depth of the prosthesis in the left ventricular outﬂow tract
(hazard ratio [HR]: 1.2, 95% conﬁdence interval [CI]: 1.08
to 1.34, p < 0.001), pre-existing right bundle branch
block (HR: 3.5, 95% CI: 1.68 to 7.29, p ¼ 0.001), and use
of the traditional system (HR: 27, 95% CI: 2.81 to 257,
p ¼ 0.004).
Conclusions The new Accutrak delivery system was asso-
ciated with less deep prosthesis implantation in the left
ventricular outﬂow tract, which could be related to the lower
rate of permanent pacemaker requirement (151).Pathology of Transcatheter Valve Therapy
Objectives This study sought to report on the pathology of
transcatheter aortic valves explanted at early and late time
points after transcatheter aortic valve implantation.
Background Information on pathological ﬁndings
following transcatheter aortic valve implantation is scarce,
particularly late after transcatheter aortic valve implantation.
Methods This study included 20 patients (13 men, median
age 80 years [interquartile range: 72 to 84] years) with
previous transcatheter aortic valve implantation with a valve
explanted at autopsy (n ¼ 17) or surgery (n ¼ 3) up to 30
months after implantation (10 transapical and 10 trans-
femoral procedures).
Results Structural valve degeneration was not seen,
although ﬁbrous tissue ingrowth was observed at later time
points with minimal effects on cusp mobility in 1 case.
Minor alterations in valve conﬁguration or placement were
observed in up to 50% of cases, but they were not accom-
panied by substantial changes in valve function or reliably
associated with chest compressions. Vascular or myocardial
injury was common, especially within 30 days of trans-
catheter aortic valve implantation (about 69%), with the
latter associated with left coronary ostial occlusion by calci-
ﬁed native aortic valve tissue in 2 cases. Mild to severe
myocardial amyloidosis was present in nearly 33% of cases
and likely played a role in the poor outcome of 3 patients.
Endocarditis, migration of the valve, and embolization
during the procedure led to surgical valve removal.
Conclusions Structural degeneration was not seen and
minor alterations of valve conﬁguration or placement did not
affect valve function and were not reliably caused by chest
compressions. Vascular or myocardial injury is very common
early after transcatheter aortic valve implantation and
myocardial amyloidosis represents a relatively frequent
potentially signiﬁcant comorbid condition (152).Transcatheter Aortic Valve Implantation in
Patients With Low-Flow, Low-Gradient Aortic
Stenosis
Objectives The purpose of this study was to evaluate the
efﬁcacy and outcome of transcatheter aortic valve implan-
tation (TAVI) in patients with low-ﬂow, low-gradient aortic
stenosis (LG-AS).
Background Patients with LG-AS have a poor prognosis
with medical treatment and a high risk for surgical aortic
valve replacement.
Methods Between January 2009 and June 2010, a total of
1,302 patients underwent TAVI for severe AS and were
prospectively included in the multicenter German TAVI
registry.
Results LG-AS was present in 149 patients (11.4%; mean
age: 80.2  6.3 years). In this subgroup, the EuroSCORE
was signiﬁcantly higher (26.8  16.6 vs. 20.0  13.3; p <
0.0001) compared with patients with high-gradient AS
(HG-AS). The procedural success rate (LG-AS: 95.3% vs.
HG-AS: 97.5%; p ¼ 0.13) and the rate of TAVI-associated
complications were comparable in both groups (new pace-
maker: 27.0% vs. 28.1%; p ¼ 0.76; cerebrovascular events:
3.4% vs. 3.1%, p ¼ 0.83). However, post-operative low-
output syndrome occurred more frequently in the LG-AS-
group (LG-AS: 14.9% vs. HG-AS: 5.7%, p < 0.0001),
and mortality at 30 days and 1 year was signiﬁcantly higher
in this subgroup (LG-AS: 12.8% and 36.9% vs. HG-AS:
7.4% and 18.1%; p < 0.001 and p < 0.0001, respectively).
Post-operative New York Heart Association functional class
improved, and self-assessed quality of life increased signiﬁ-
cantly, demonstrating a substantial beneﬁt in the LG-AS
group at 30 days and 1 year after TAVI.
Conclusions In high-risk patients with LG-AS, TAVI is
associated with a signiﬁcantly higher mortality at 30 days
and at 1 year. However, long-term survivors beneﬁt from
TAVI with functional improvement and a signiﬁcantly
increased quality of life. Therefore, in view of the poor
prognosis with medical treatment, TAVI should be
considered an option in high-risk patients with LG-AS
(153).
Direct Percutaneous Access Technique for
Transaxillary Transcatheter Aortic Valve
Implantation: “The Hamburg Sankt Georg
Approach”
Objectives This study questioned whether transaxillary
transcatheter aortic valve implantation (TAVI) is feasible as
a true percutaneous approach using percutaneous closure
devices.
Background Transaxillary TAVI is gaining increasing
acceptance as an alternative to the transfemoral route;
however, the access has always been done via surgical cut-
down so far.
Methods Between August 2010 and September 2011,
a total of 24 high-risk patients with severe aortic valvular
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direct puncture of the axillary artery without surgical cut-
down. For safety reasons and as a target for the puncture,
a wire was advanced via the ipsilateral brachial artery.
Moreover, a balloon was placed into the subclavian artery via
the femoral artery for temporary vessel blockade before
percutaneous vessel closure. Vascular closure was performed
using either the ProStar XL system (Abbott Vascular
Devices, Redwood City, California) or 2 ProGlide systems
(Abbott Vascular Devices).
Results The true percutaneous approach was successfully
completed in all patients (14 left and 8 right axillary artery
cases). Overall mortality at 30 days was 8.3%. Acute vascular
closure device success was achieved in 17 patients (71%).
Vascular closure device success rate was 100% for the Pro-
Glide device and 37% for the ProStar device, respectively.
Seven patients (29%) with failing closure devices were
treated by endovascular stent graft implantation without the
need for surgical repair. For the last 12 treated patients,
direct closure was achieved in 11 patients.
Conclusions Direct puncture of the axillary artery for
TAVI is feasible and safe if a wire is placed into the
subclavian artery via the ipsilateral brachial artery (154).Impact of Aortic Regurgitation After Transcatheter
Aortic Valve Implantation: Results From the
REVIVAL Trial
Objectives Understanding the severity of aortic regurgita-
tion (AR) after transcatheter aortic valve implantation, its
impact on left ventricular (LV) structure and function, and
the structural factors associated with worsening AR could
lead to improvements in patient selection, implantation
technique, and valve design.
Background Initial studies in patients at high risk of
surgical aortic valve replacement have reported both central
valvular and paravalvular AR after transcatheter aortic valve
implantation.
Methods Transthoracic echocardiograms were quantiﬁed
from 95 patients in the REVIVAL (TRanscatheter
EndoVascular Implantation of VALves) trial. Transthoracic
echocardiograms were obtained before implantation of the
Edwards-Sapien valve (Edwards Lifesciences, Irvine, Cal-
ifornia) and thereafter at selected intervals. Measurements
included LV internal diameters and volumes, ejection
fraction, aortic valve area, and the degree of aortic regur-
gitation. Measures of degree of native leaﬂet mobility,
thickness, and calciﬁcation, as well as left ventricular
outﬂow tract, aortic annulus, and aortic root diameters were
also made.
Results Eighty-four patients remained after 11 were
excluded; 26 (29.8%) died over a period of 3 years. At 24
h post-implantation, 75% had some degree of AR, mostly
paravalvular. By 1 year, the mean AR grade increased
slightly, but not signiﬁcantly (1.1  0.8 to 1.3  0.9),
and all measures of LV structure and function improved(LV ejection fraction, 50.7  16.1% to 59.4  14.0%).
Native aortic leaﬂet calciﬁcation and annulus diameter
correlated signiﬁcantly with the severity of AR at 1 year
(p < 0.05).
Conclusions AR after transcatheter aortic valve implanta-
tion is frequent but is rarely more than mild. Although AR
progresses, it is not associated with a harmful impact on LV
structure and function over the ﬁrst year. Native valve
calciﬁcation and aortic annulus diameter inﬂuence the
degree of AR at 6 months (155).High Platelet Reactivity on Clopidogrel Therapy
Correlates With Increased Coronary
Atherosclerosis and Calciﬁcation: A Volumetric
Intravascular Ultrasound Study
Objectives This study sought to evaluate the relationship
between platelet reactivity and atherosclerotic burden in
patients undergoing percutaneous coronary intervention
(PCI) with pre-intervention volumetric intravascular ultra-
sound (IVUS) imaging.
Background Atherosclerosis progresses by the pathologic
sequence of subclinical plaque rupture, thrombosis, and
healing. In this setting, increased platelet reactivity may lead
to more extensive arterial thrombosis at the time of plaque
rupture, leading to a more rapid progression of the disease.
Alternatively, abnormal vessel wall biology with advanced
atherosclerosis is known to enhance platelet reactivity.
Therefore, it is possible that by either mechanism, increased
platelet reactivity may be associated with greater athero-
sclerotic burden.
Methods This study included patients who underwent PCI
with pre-intervention IVUS imaging and platelet reactivity
functional assay (P2Y12 reaction units) performed >16 h
after PCI, after the stabilization of clopidogrel therapy
(administered before PCI). Platelet reactivity >230 P2Y12
reaction units deﬁned high on-treatment platelet reactivity
(HPR).
Results Among 335 patients (mean age 65.0 years, 71%
men), there were 109 patients with HPR (32.5%) and 226
without HPR (67.5%), with HPR being associated with
diabetes and chronic renal insufﬁciency. By IVUS analysis,
patients with HPR had signiﬁcantly greater target lesion
calcium lengths, calcium arcs, and calcium indexes.
Furthermore, patients with HPR tended to have longer
lesions and greater volumetric dimensions, indicating higher
plaque volume, larger total vessel volume, and also greater
luminal volume, despite similar plaque burden. By multi-
variate analysis controlling for baseline clinical variables,
HPR was the single consistent predictor of all IVUS
parameters examined, including plaque volume, calcium
length, and calcium arc.
Conclusions Increased platelet reactivity on clopidogrel
treatment, deﬁned as >230 P2Y12 reaction units, is associ-
ated with greater coronary artery atherosclerotic disease
burden and plaque calciﬁcation (156).
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Early After Ventricular Tachycardia Ablation to
Predict Risk of Late Recurrence
Objectives The goal of this study was to evaluate the ability
of noninvasive programmed stimulation (NIPS) after
ventricular tachycardia (VT) ablation to identify patients at
high risk of recurrence.
Background Optimal endpoints for VT ablation are not
well deﬁned.
Methods Of 200 consecutive patients with VT and struc-
tural heart disease undergoing ablation, 11 had clinical VT
inducible at the end of ablation and 11 recurred spontane-
ously. Of the remaining 178 patients, 132 underwent NIPS
through their implantable cardioverter-deﬁbrillator 3.1 
2.1 days after ablation. At 2 drive cycle lengths, single,
double, and triple right ventricular extrastimuli were deliv-
ered to refractoriness. Clinical VT was deﬁned by compar-
ison with 12-lead electrocardiograms and stored implantable
cardioverter-deﬁbrillator electrograms from spontaneous VT
episodes. Patients were followed for 1 year.
Results Fifty-nine patients (44.7%) had no VT inducible
at NIPS; 49 (37.1%) had inducible nonclinical VT only;
and 24 (18.2%) had inducible clinical VT. Patients with
inducible clinical VT at NIPS had markedly decreased 1-
year VT-free survival compared to those in whom no VT
was inducible (<30% vs. >80%; p ¼ 0.001), including
33% recurring with VT storm. Patients with inducible
nonclinical VT only, had intermediate 1-year VT-free
survival (65%).
Conclusions When patients with VT and structural heart
disease have no VT or nonclinical VT only inducible at the
end of ablation or their condition is too unstable to undergo
ﬁnal programmed stimulation, NIPS should be considered
in the following days to further deﬁne risk of recurrence. If
clinical VT is inducible at NIPS, repeat ablation may be
considered because recurrence over the following year is
high (157).
Heparanase Regulates Thrombosis in Vascular
Injury and Stent-Induced Flow Disturbance
Objectives The purpose of this study was to examine the
role of heparanase in controlling thrombosis following
vascular injury or endovascular stenting.
Background The use of endovascular stents are a common
clinical intervention for the treatment of arteries occluded
due to vascular disease. Both heparin and heparan sulfate are
known to be potent inhibitors of thrombosis. Heparanase is
the major enzyme that degrades heparan sulfate in
mammalian cells. This study examined the role of hepar-
anase in controlling thrombosis following vascular injury and
stent-induced ﬂow disturbance.
Methods This study used mice overexpressing human
heparanase and examined the time to thrombosis using
a laser-induced arterial thrombosis model in combination
with vascular injury. An ex vivo system was used toexamine the formation of thrombus to stent-induced ﬂow
disturbance.
Results In the absence of vascular injury, wild type and
heparanase overexpressing (HPA Tg) mice had similar times
to thrombosis in a laser-induced arterial thrombosis model.
However, in the presence of vascular injury, the time to
thrombosis was dramatically reduced in HPA Tg mice. An
ex vivo system was used to ﬂow blood from wild type and
HPA Tg mice over stents and stented arterial segments from
both animal types. These studies demonstrate markedly
increased thromboses on stents with blood isolated from
HPA Tg mice in comparison to blood from wild type
animals. We found that blood from HPA Tg animals had
markedly increased thrombosis when applied to stented
arterial segments from either wild type or HPA Tg mice.
Conclusions Taken together, this study’s results indicate
that heparanase is a powerful mediator of thrombosis in the
context of vascular injury and stent-induced ﬂow disturbance
(158).Coronary Arterial 18F-Sodium Fluoride Uptake: A
Novel Marker of Plaque Biology
Objectives With combined positron emission tomography
and computed tomography (CT), we investigated coronary
arterial uptake of 18F-sodium ﬂuoride (18F-NaF) and 18F-
ﬂuorodeoxyglucose (18F-FDG) as markers of active plaque
calciﬁcation and inﬂammation, respectively.
Background The noninvasive assessment of coronary artery
plaque biology would be a major advance particularly in the
identiﬁcation of vulnerable plaques, which are associated
with speciﬁc pathological characteristics, including micro-
calciﬁcation and inﬂammation.
Methods We prospectively recruited 119 volunteers (72 
8 years of age, 68% men) with and without aortic valve
disease and measured their coronary calcium score and 18F-
NaF and 18F-FDG uptake. Patients with a calcium score of
0 were used as control subjects and compared with those
with calciﬁc atherosclerosis (calcium score >0).
Results Inter-observer repeatability of coronary 18F-NaF
uptake measurements (maximum tissue/background ratio)
was excellent (intra-class coefﬁcient 0.99). Activity was
higher in patients with coronary atherosclerosis (n ¼ 106)
versus control subjects (1.64  0.49 vs. 1.23  0.24; p ¼
0.003) and correlated with the calcium score (r ¼ 0.652, p <
0.001), although 40% of those with scores >1,000 displayed
normal uptake. Patients with increased coronary 18F-NaF
activity (n ¼ 40) had higher rates of prior cardiovascular
events (p ¼ 0.016) and angina (p ¼ 0.023) and higher
Framingham risk scores (p ¼ 0.011). Quantiﬁcation of
coronary 18F-FDG uptake was hampered by myocardial
activity and was not increased in patients with atheroscle-
rosis versus control subjects (p ¼ 0.498).
Conclusions 18F-NaF is a promising new approach for the
assessment of coronary artery plaque biology. Prospective
studies with clinical outcomes are now needed to assess
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marker of plaque vulnerability, recent plaque rupture, and
future cardiovascular risk. (An Observational PET/CT
Study Examining the Role of Active Valvular Calciﬁcation
and Inﬂammation in Patients With Aortic Stenosis;
NCT01358513) (159).Prolongation of QTc and Risk of Stroke: The
REGARDS (REasons for Geographic and Racial
Differences in Stroke) Study
Objectives The purpose of this study was to examine the
association between prolongation of QT interval corrected
for heart rate (QTc) with incident stroke.
Background Unlike cardiovascular morbidity and mor-
tality, little is known about the relationship between QTc
and risk of stroke.
Methods A total of 27,411 participants age 45 years and
older without previous stroke from the REGARDS
(REasons for Geographic and Racial Differences in Stroke)
study were included in this analysis. QTc was calculated
using Framingham formula (QTcFram). Stroke cases were
identiﬁed and adjudicated during up to 8.2 years of follow-
up (median, 5.1 years).
Results The risk of incident stroke in study participants
with prolonged QTcFram was almost 3 times the risk in those
with normal QTcFram (hazard ratio [HR] [95% conﬁdence
interval (CI)]: 2.88 [2.12 to 3.92], p < 0.0001). After
adjustment for demographics (age, race, and sex), traditional
stroke risk factors (antihypertensive medication use, systolic
blood pressure, current smoking, diabetes, left ventricular
hypertrophy, atrial ﬁbrillation, and previous cardiovascular
disease), warfarin use, aspirin use, QRS duration and use of
QTc-prolonging drugs, the risk of stroke remained signiﬁ-
cantly high (HR [95% CI]: 1.67 [1.16 to 2.41], p ¼ 0.0061)
and was consistent across several subgroups of REGARDS
study participants. Similar results were obtained when the
risk of stroke was estimated per 1-SD increase in QTcFram,
(HR [95% CI]: 1.12 [1.03 to 1.21], p ¼ 0.0053 in
multivariable-adjusted model) and when other QTc
correction formulas including those of Hodge, Bazett, and
Fridericia were used.
Conclusions QTc prolongation is associated with a signif-
icantly increased risk of incident stroke independent of
traditional stroke risk factors. Examining the risk of stroke
associated with QTc-prolonging drugs may be warranted
(160).New Oral Anticoagulants in Atrial Fibrillation and
Acute Coronary Syndromes: ESC Working Group on
ThrombosisdTask Force on Anticoagulants in
Heart Disease Position Paper
Until recently, vitamin K antagonists were the only avail-
able oral anticoagulants, but with numerous limitations
that prompted the introduction of new oral anticoagulantstargeting the single coagulation enzymes thrombin (dabi-
gatran) or factor Xa (apixaban, rivaroxaban, and edoxaban)
and given in ﬁxed doses without coagulation monitoring.
Here we review the pharmacology and the results of
clinical trials with these new agents in stroke prevention in
atrial ﬁbrillation and secondary prevention after acute
coronary syndromes, providing perspectives on their future
incorporation into clinical practice. In phase III trials in
atrial ﬁbrillation, compared with warfarin, dabigatran
etexilate 150 mg B.I.D. reduced the rates of stroke/
systemic embolism without any difference in major
bleeding; dabigatran etexilate 110 mg B.I.D. had similar
efﬁcacy with decreased bleeding; apixaban 5 mg B.I.D.
reduced stroke, systemic embolism, and mortality as well
as major bleeding; and rivaroxaban 20 mg Q.D. was
noninferior to warfarin for stroke and systemic embolism
without a difference in major bleeding. All these agents
reduced intracranial hemorrhage. Edoxaban is currently
being evaluated in a further large phase III trial. Apixaban
and rivaroxaban were evaluated in phase III trials for
prevention of recurrent ischemia in patients with acute
coronary syndromes who were mostly receiving dual anti-
platelet therapy, with conﬂicting results on efﬁcacy but
consistent results for increased major bleeding. Overall, the
new oral anticoagulants are poised to replace vitamin K
antagonists for many patients with atrial ﬁbrillation and
may have a role after acute coronary syndromes. Although
convenient to administer and manage, they present chal-
lenges that need to be addressed (161).A Randomized Controlled Trial in Second-
Generation Zotarolimus-Eluting Resolute Stents
Versus Everolimus-Eluting Xience V Stents in Real-
World Patients: The TWENTE Trial
Objectives The aim of this study was to compare the safety
and efﬁcacy of Resolute zotarolimus-eluting stents (ZES)
(Medtronic Cardiovascular, Santa Rosa, California) with
Xience V everolimus-eluting stents (EES) (Abbott Vascular
Devices, Santa Clara, California) at 1-year follow-up.
Background Only 1 randomized trial previously compared
these stents.
Methods This investigator-initiated, patient-blinded,
randomized noninferiority study had limited exclusion
criteria (acute ST-segment elevation myocardial infarctions
not eligible). Patients (n ¼ 1,391; 81.4% of eligible pop-
ulation) were randomly assigned to ZES (n ¼ 697) or EES
(n ¼ 694). Liberal use of stent post-dilation was encouraged.
Cardiac biomarkers were systematically assessed. The
primary endpoint was target vessel failure (TVF),
a composite of cardiac death, myocardial infarction not
clearly attributable to non-target vessels, and clinically
indicated target-vessel revascularization. An external inde-
pendent research organization performed clinical event
adjudication (100% follow-up data available). Analysis was
by intention-to-treat.
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and “off-label” feature in 77% of patients. Of the lesions,
70% were type B2/C; the post-dilation rate was very high
(82%). In ZES and EES, TVF occurred in 8.2% and 8.1%,
respectively (absolute risk-difference 0.1%; 95% conﬁdence
interval: 2.8% to 3.0%, pnoninferiority ¼ 0.001). There was
no signiﬁcant between-group difference in TVF compo-
nents. The deﬁnite-or-probable stent thrombosis rates were
relatively low and similar for ZES and EES (0.9% and 1.2%,
respectively, p ¼ 0.59). Deﬁnite stent thrombosis rates were
also low (0.58% and 0%, respectively, p ¼ 0.12). In EES,
probable stent thrombosis beyond day 8 was observed only
in patients not adhering to dual antiplatelet therapy.
Conclusions Resolute ZES were noninferior to Xience V
EES in treating “real-world” patients with a vast majority of
complex lesions and “off-label” indications for drug-eluting
stents, which were implanted with liberal use of post-
dilation. (The Real-World Endeavor Resolute Versus
XIENCE V Drug-Eluting SteNt Study: Head-to-head
Comparison of Clinical Outcome After Implantation of
Second Generation Drug-eluting Stents in a Real World
Scenario; NCT01066650) (162).A Randomized, Multicenter, Single-Blinded Trial
Comparing Paclitaxel-Coated Balloon Angioplasty
With Plain Balloon Angioplasty in Drug-Eluting
Stent Restenosis: The PEPCAD-DES Study
Objectives This study sought to deﬁne the impact of
paclitaxel-coated balloon angioplasty for treatment of drug-
eluting stent restenosis compared with uncoated balloon
angioplasty alone.
Background Drug-coated balloon angioplasty is associated
with favorable results for treatment of bare-metal stent
restenosis.
Methods In this prospective, single-blind, multicenter,
randomized trial, the authors randomly assigned 110 patients
with drug-eluting stent restenoses located in a native coronary
artery to paclitaxel-coated balloon angioplasty or uncoated
balloon angioplasty. Dual antiplatelet therapy was prescribed
for 6 months. Angiographic follow-up was scheduled at 6
months. The primary endpoint was late lumen loss. The
secondary clinical endpoint was a composite of cardiac death,
myocardial infarction attributed to the target vessel, or target
lesion revascularization.
Results There was no difference in patient baseline char-
acteristics or procedural results. Angiographic follow-up rate
was 91%. Treatment with paclitaxel-coated balloon was
superior to balloon angioplasty alone with a late loss of 0.43
 0.61 mm versus 1.03  0.77 mm (p < 0.001), respec-
tively. Restenosis rate was signiﬁcantly reduced from 58.1%
to 17.2% (p < 0.001), and the composite clinical endpoint
was signiﬁcantly reduced from 50.0% to 16.7% (p < 0.001),
respectively.
Conclusions Paclitaxel-coated balloon angioplasty is
superior to balloon angioplasty alone for treatment ofdrug-eluting stent restenosis. (PEPCAD DES–Treatment
of DES-In-Stent Restenosis With SeQuent Please
Paclitaxel Eluting PTCA Catheter [PEPCAD-DES];
NCT00998439) (163).
The PROFI Study (Prevention of Cerebral
Embolization by Proximal Balloon Occlusion
Compared to Filter Protection During Carotid
Artery Stenting): A Prospective Randomized Trial
Objectives The objective of this study was to compare the
cerebral embolic load of ﬁlter-protected versus proximal
balloon–protected carotid artery stenting (CAS).
Background Randomized trials comparing ﬁlter-protected
CAS with carotid endarterectomy revealed a higher peri-
procedural stroke rate after CAS. Proximal balloon occlusion
may be more effective in preventing cerebral embolization
during CAS than ﬁlters.
Methods Patients undergoing CAS with cerebral embolic
protection for internal carotid artery stenosis were randomly
assigned to proximal balloon occlusion or ﬁlter protection.
The primary endpoint was the incidence of new cerebral
ischemic lesions assessed by diffusion-weighted magnetic
resonance imaging. Secondary endpoints were the number
and volume of new ischemic lesions and major adverse
cardiovascular and cerebral events (MACCE).
Results Sixty-two consecutive patients (mean age: 71.7
years, 76.4% male) were randomized. Compared with ﬁlter
protection (n ¼ 31), proximal balloon occlusion (n ¼ 31)
resulted in a signiﬁcant reduction in the incidence of new
cerebral ischemic lesions (45.2% vs. 87.1%, p ¼ 0.001).
The number (median [range]: 2 [0 to 13] vs. 0 [0 to 4],
p ¼ 0.0001) and the volume (0.47 [0 to 2.4] cm3 vs. 0 [0
to 0.84] cm3, p ¼ 0.0001) of new cerebral ischemic lesions
were signiﬁcantly reduced by proximal balloon occlusion.
Lesions in the contralateral hemisphere were found in
29.0% and 6.5% of patients (ﬁlter vs. balloon occlusion,
respectively, p ¼ 0.047). The 30-day MACCE rate was
3.2% and 0% for ﬁlter versus balloon occlusion, respec-
tively (p ¼ NS).
Conclusions In this randomized trial of patients under-
going CAS, proximal balloon occlusion as compared with
ﬁlter protection signiﬁcantly reduced the embolic load to the
brain (164).
A Multicenter Randomized Trial Comparing
Amphilimus- With Paclitaxel-Eluting Stents in De
Novo Native Coronary Artery Lesions
Objectives This study sought to demonstrate the non-
inferiority of polymer-free amphilimus-eluting stents (Cre8,
CID, Saluggia, Italy) versus permanent-polymer paclitaxel-
eluting stents (Taxus Liberté, Boston Scientiﬁc, Natick,
Massachusetts) in de novo percutaneous coronary
intervention.
Background Although the efﬁcacy of the drug-eluting
stent has been well established, the risk-beneﬁt balance is
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uncertain.
Methods Patients undergoing percutaneous coronary in-
tervention for de novo lesions were randomly assigned 1:1 to
Cre8 or Taxus Liberté stents. Primary endpoint was 6-
month angiographic in-stent late lumen loss (LLL) within
a noninferiority scope. Six-month intravascular ultrasound
was performed in 20% of the patients. All patients will be
clinically followed up to 5 years.
Results Out of 323 patients enrolled, 162 received Cre8
and 161 Taxus Liberté stents. In-stent LLL was signiﬁ-
cantly lower in Cre8 group (0.14  0.36 mm vs.
0.34  0.40 mm, p noninferiority <0.0001, p superi-
ority <0.0001). Clinical endpoints (cardiac death, myo-
cardial infarction, target lesion revascularization, and stent
thrombosis) up to 12 months did not differ signiﬁcantly
between the groups.
Conclusions The Cre8 stent in de novo lesions showed
signiﬁcantly lower in-stent LLL at 6 months than the Taxus
Liberté stent did, with a trend toward better 12-month
clinical safety and efﬁcacy results. (International Random-
ized Comparison Between DES Limus Carbostent and
Taxus Drug-Eluting Stents in the Treatment of De Novo
Coronary Lesions [NEXT]; NCT01373502) (165).Cross-Sectional Computed Tomographic
Assessment Improves Accuracy of Aortic Annular
Sizing for Transcatheter Aortic Valve Replacement
and Reduces the Incidence of Paravalvular Aortic
Regurgitation
Objectives In an effort to deﬁne the gold standard for
annular sizing for transcatheter aortic valve replacement
(TAVR), we sought to critically analyze and compare the
predictive value of multiple measures of the aortic annulus
for post-TAVR paravalvular (PV) regurgitation and then
assess the impact of a novel cross-sectional computed
tomographic (CT) approach to annular sizing.
Background Recent studies have shown clear discrep-
ancies between conventional 2-dimensional (2D) echo-
cardiographic and CT measurements. In terms of aortic
annular measurement for TAVR, such ﬁndings have
lacked the outcome analysis required to inform clinical
practice.
Methods The discriminatory value of multiple CT
annular measures for post-TAVR PV aortic regurgitation
was compared with 2D echocardiographic measures.
TAVR outcomes with device selection according to aortic
annular sizing using a traditional 2D transesophageal
echocardiography–guided or a novel CT-guided approach
were also studied.
Results In receiver-operating characteristic models, cross-
sectional CT parameters had the highest discriminatory
value for post-TAVR PV regurgitation: This was with the
area under the curve for [maximal cross-sectional diameter
minus prosthesis size] of 0.82 (95% conﬁdence interval: 0.69to 0.94; p < 0.001) and that for [circumference-derived
cross-sectional diameter minus prosthesis size] of 0.81
(95% conﬁdence interval: 0.7 to 0.94; p < 0.001). In
contrast, traditional echocardiographic measures were non-
discriminatory in relation to post-TAVR PV aortic regur-
gitation. The prospective application of a CT-guided
annular sizing approach resulted in less PV aortic regurgi-
tation of grade worse than mild after TAVR (7.5% vs.
21.9%; p ¼ 0.045).
Conclusions Our data lend strong support to 3-
dimensional cross-sectional measures, using CT as the
new gold standard for aortic annular evaluation for TAVR
with the Edwards SAPIEN device (166).Impact of Metabolic Syndrome on Procedural
Outcomes in Patients With Atrial Fibrillation
Undergoing Catheter Ablation
Objectives The aim of this study was to investigate impact
of metabolic syndrome (MS) on outcomes of catheter
ablation in patients with atrial ﬁbrillation (AF) in terms of
recurrence and quality of life (QoL).
Background MS, a proinﬂammatory state with hyperten-
sion, diabetes, dyslipidemia, and obesity, is presumed to be
a close associate of AF.
Methods In this prospective study, 1,496 consecutive
patients with AF undergoing ﬁrst ablation (29% with
paroxysmal AF, 26% with persistent AF, and 45% with
long-standing persistent AF) were classiﬁed into those with
MS (group 1; n ¼ 485) and those without MS (group 2;
n ¼ 1,011). Patients were followed for recurrence and
QoL. The Medical Outcomes Study SF-36 Health Survey
was used to assess QoL at baseline and 12 month after
ablation.
Results After 21  7 months of follow-up, 189 patients
in group 1 (39%) and 319 in group 2 (32%) had
arrhythmia recurrence (p ¼ 0.005). When stratiﬁed by AF
type, patients with nonparoxysmal AF in group 1 failed
more frequently compared with those in group 2 (150
[46%] vs. 257 [35%], p ¼ 0.002); no difference existed in
the subgroup with paroxysmal AF (39 [25%] vs. 62 [22%],
p ¼ 0.295). Group 1 patients had signiﬁcantly lower
baseline scores on all SF-36 Health Survey subscales. At
follow-up, both mental component summary (D5.7  2.5,
p < 0.001) and physical component summary (D9.1 
3.7, p < 0.001) scores improved in group 1, whereas only
mental component summary scores (D4.6  2.8, p ¼
0.036) were improved in group 2. In the subgroup
with nonparoxysmal AF, MS, sex, C-reactive protein 0.9
mg/dl, and white blood cell count were independent
predictors of recurrence.
Conclusions Baseline inﬂammatory markers and the pres-
ence of MS predicted higher recurrence after single-catheter
ablation only in patients with nonparoxysmal AF. Addi-
tionally, signiﬁcant improvements in QoL were observed in
the post-ablation MS population (167).
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Multidetector Computed Tomography Predicts
Moderate or Severe Paravalvular Regurgitation
After Transcatheter Aortic Valve Replacement:
A Multicenter Retrospective Analysis
Objectives This study sought to analyze multidetector
computed tomography (MDCT) 3-dimensional aortic
annular dimensions for the prediction of paravalvular aortic
regurgitation (PAR) following transcatheter aortic valve
replacement (TAVR).
Background Moderate or severe PAR after TAVR is
associated with increased morbidity and mortality.
Methods A total of 109 consecutive patients underwent
MDCT pre-TAVR with a balloon expandable aortic valve.
Differences between transcatheter heart valve (THV) size
and MDCT measures of annular size (mean diameter, area,
and circumference) were analyzed concerning prediction of
PAR. Patients with THV malposition (n ¼ 7) were
excluded. In 50 patients, MDCT was repeated after
TAVR to assess THV eccentricity (1 – short diameter/long
diameter) and expansion (MDCT measured THV area/
nominal THV area).
Results Moderate or severe PAR (13 of 102) was associated
with THV undersizing (THV diameter – mean diameter ¼
–0.7  1.4 mm vs. 0.9  1.8 mm for trivial to mild PAR,
p < 0.01). The difference between THV size and MDCT
annular size was predictive of PAR (mean diameter: area
under the curve [AUC]: 0.81, 95% conﬁdence interval [CI]:
0.68 to 0.88; area: AUC: 0.80, 95% CI: 0.65 to 0.90;
circumference: AUC: 0.76, 95% CI: 0.59 to 0.91). Annular
eccentricity was not associated with PAR (AUC: 0.58, 95%
CI: 0.46 to 0.75). We found that 35.3% (36 of 102) and
45.1% (46 of 102) of THVs were undersized relative to the
MDCT mean diameter and area, respectively. THV over-
sizing relative to the annular area was not associated with
THV eccentricity or underexpansion (oversized vs. under-
sized THVs; expansion: 102.7 5.3% vs. 106.1 5.6%, p¼
0.03; eccentricity: median: 1.7% [interquartile range: 1.4% to
3.0%] vs. 1.7% [interquartile range: 1.1% to 2.7%], p¼ 0.28).
Conclusions MDCT-derived 3-dimensional aortic annular
measurements are predictive of moderate or severe PAR
following TAVR. Oversizing of THVs may reduce the risk
of moderate or severe PAR (168).
A Randomized, 2-Period, Crossover Design Study
to Assess the Effects of Dexlansoprazole,
Lansoprazole, Esomeprazole, and Omeprazole on
the Steady-State Pharmacokinetics and
Pharmacodynamics of Clopidogrel in Healthy
Volunteers
Objectives The aim of this study was to assess the effects of
different proton pump inhibitors (PPIs) on the steady-state
pharmacokinetics and pharmacodynamics of clopidogrel.
Background Metabolism of clopidogrel requires cyto-
chrome P450s (CYPs), including CYP2C19. However,PPIs may inhibit CYP2C19, potentially reducing the
effectiveness of clopidogrel.
Methods A randomized, open-label, 2-period, crossover
study of healthy subjects (n ¼ 160, age 18 to 55 years,
homozygous for CYP2C19 extensive metabolizer genotype,
conﬁned, standardized diet) was conducted. Clopidogrel 75
mg with or without a PPI (dexlansoprazole 60 mg, lanso-
prazole 30 mg, esomeprazole 40 mg, or, as a positive control
to maximize potential interaction and demonstrate assay
sensitivity, omeprazole 80 mg) was given daily for 9 days.
Pharmacokinetics and pharmacodynamics were assessed on
days 9 and 10. Pharmacodynamic end-points were
vasodilator-stimulated phosphoprotein P2Y12 platelet reac-
tivity index, maximal platelet aggregation to 5 and 20 mmol/l
adenosine diphosphate, and VerifyNow P2Y12 platelet
response units.
Results Pharmacokinetic and pharmacodynamic responses
with omeprazole demonstrated assay sensitivity. The area
under the curve for clopidogrel active metabolite decreased
signiﬁcantly with esomeprazole but not with dexlansoprazole
or lansoprazole. Similarly, esomeprazole but not dexlanso-
prazole or lansoprazole signiﬁcantly reduced the effect of
clopidogrel on vasodilator-stimulated phosphoprotein
platelet reactivity index. All PPIs decreased the peak plasma
concentration of clopidogrel active metabolite (omeprazole
> esomeprazole > lansoprazole > dexlansoprazole) and
showed a corresponding order of potency for effects on
maximal platelet aggregation and platelet response units.
Conclusions Generation of clopidogrel active metabolite
and inhibition of platelet function were reduced less by the
coadministration of dexlansoprazole or lansoprazole with
clopidogrel than by the coadministration of esomeprazole or
omeprazole. These results suggest that the potential of PPIs
to attenuate the efﬁcacy of clopidogrel could be minimized
by the use of dexlansoprazole or lansoprazole rather than
esomeprazole or omeprazole. (A Study of the Effects of
Multiple Doses of Dexlansoprazole, Lansoprazole, Ome-
prazole or Esomeprazole on the Pharmacokinetics and
Pharmacodynamics of Clopidogrel in Healthy Participants;
NCT00942175) (169).Provoked Exercise Desaturation in Patent
Foramen Ovale and Impact of Percutaneous
Closure
Objectives This study was designed to assess the prevalence
of provoked exercise desaturation (PED) in patients with
patent foramen ovale (PFO) referred for cardiovascular
evaluation and to evaluate the impact of PFO closure.
Background Platypnea orthodeoxia syndrome is a rare,
mechanistically obscure consequence of PFO that results in
oxygen desaturation during postural changes. In our clinical
experience, however, it is far less common than desaturation
during exercise.
Methods This was a single-center prospective study of
50 patients with newly diagnosed PFO. Each patient
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saturation with pulse oximetry during postural changes and
stair climbing exercise. Provoked exercise desaturation was
deﬁned as a desaturation of at least 8% from baseline
to <90%. All patients who underwent closure were reeval-
uated 3 months after the procedure. Those with baseline
PED were similarly reassessed for desaturation at follow-up.
Results Mean age of the cohort was 46  17 years, 74%
were female, 30% had migraines, and 48% had experienced
a cerebrovascular event. Seventeen patients (34%) demon-
strated PED. Provoked exercise desaturation patients
seemed demographically similar to non-PED patients. Ten
PED patients underwent PFO closure (2 surgical, and 8
percutaneous). Drop in oxygen saturation was improved by
an average of 10.1  4.2% after closure (p < 0.001), and
New York Heart Association functional class improved by
a median of 1.5 classes (interquartile range: 0.75 to 2.00,
p ¼ 0.008).
Conclusions One-third of patients referred for assessment
of PFO experience oxygen desaturation during stair exercise.
Closure of PFO seems to ameliorate this phenomenon and
improve functional status (170).Successful Recanalization of Chronic Total
Occlusions Is Associated With Improved Long-Term
Survival
Objectives This study investigated the impact of proce-
dural success on mortality following chronic total occlusion
(CTO) percutaneous coronary intervention (PCI) in a large
cohort of patients in the drug-eluting stent era.
Background Despite advances in expertise and technolo-
gies, many patients with CTO are not offered PCI.
Methods A total of 6,996 patients underwent elective PCI
for stable angina at a single center (2003 to 2010), 836
(11.9%) for CTO. All-cause mortality was obtained to 5
years (median: 3.8 years; interquartile range: 2.0 to 5.4 years)
and stratiﬁed according to successful chronic total occlusion
(sCTO) or unsuccessful chronic total occlusion (uCTO)
recanalization. Major adverse cardiac events (MACE)
included myocardial infarction (MI), urgent revasculariza-
tion, stroke, or death.
Results A total of 582 (69.6%) procedures were successful.
Stents were implanted in 97.0% of successful procedures
(mean: 2.3  0.1 stents per patient, 73% drug-eluting). Prior
revascularization was more frequent among uCTO patients:
coronary artery bypass grafting (CABG) (16.5% vs. 7.4%;
p < 0.0001), PCI (36.0% vs. 21.2%; p < 0.0001). Baseline
characteristics were otherwise similar. Intraprocedural
complications, including coronary dissection, were more
frequent in unsuccessful cases (20.5% vs. 4.9%; p < 0.0001),
but did not affect in-hospital MACE (3% vs. 2.1%; p ¼
NS). All-cause mortality was 17.2% for uCTO and 4.5% for
sCTO at 5 years (p < 0.0001). The need for CABG was
reduced following sCTO (3.1% vs. 22.1%; p < 0.0001).
Multivariate analysis demonstrated that procedural successwas independently predictive of mortality (hazard ratio
[HR]: 0.32 [95% conﬁdence interval (CI): 0.18 to 0.58]),
which persisted when incorporating a propensity score (HR:
0.28 [95% CI: 0.15 to 0.52]).
Conclusions Successful CTO PCI is associated with
improved survival out to 5 years. Adoption of techniques and
technologies to improve procedural success may have an
impact on prognosis (171).
Relationship Between Fractional Flow Reserve and
Angiographic and Intravascular Ultrasound
Parameters in Ostial Lesions: Major Epicardial
Vessel Versus Side Branch Ostial Lesions
Objectives This study sought to assess the relationship of
coronary angiography, intravascular ultrasound (IVUS) and
fractional ﬂow reserve (FFR) between major epicardial vessel
(MV) and side branch (SB) ostial lesions.
Background Evaluation of ostial lesions is clinically very
important. However, anatomical parameters have limitations
in the prediction of the functional signiﬁcance of coronary
stenoses.
Methods IVUS and FFR measurement were performed in
93 lesions (MV: 38, SB: 55). Optimal angiographic and
IVUS criteria and their diagnostic accuracy for functionally
signiﬁcant stenoses (FFR 0.8) were assessed.
Results In MV ostial lesions, FFR had correlation with
angiographic percent diameter stenosis (r ¼ –0.68, p <
0.001), minimum lumen area (MLA) by IVUS (r ¼ 0.55,
p < 0.001), percent plaque burden (r ¼ –0.42, p ¼ 0.011),
and percent area stenosis (r ¼ –0.49, p ¼ 0.003). Mean-
while, FFR had no correlation with angiographic percent
diameter stenosis (r ¼ –0.067, p ¼ 0.635) and weak
correlation with MLA (r ¼ 0.30, p ¼ 0.026) in SB ostial
lesions. In MV ostial lesions, best cutoff value of angio-
graphic percent diameter stenosis, MLA, percent plaque
burden, and percent area stenosis to determine the func-
tional signiﬁcance was 53%, 3.5 mm2, 70%, and 50%.
However, a statistically signiﬁcant cutoff value of percent
diameter stenosis and MLA could not be found in SB ostial
lesions.
Conclusions The relations between angiographic/IVUS
parameters and FFR were different between MV and SB
ostial lesions. Angiographic and IVUS parameters had poor
diagnostic accuracy in predicting the functional signiﬁcance
of SB ostial lesions. (Main Branch Versus Side Branch
Ostial Lesion; NCT01335659) (172).
Use of a Novel Crossing and Re-Entry System in
Coronary Chronic Total Occlusions That Have
Failed Standard Crossing Techniques: Results of
the FAST-CTOs (Facilitated Antegrade Steering
Technique in Chronic Total Occlusions) Trial
Objectives This study sought to examine the efﬁcacy and
safety of 3 novel devices to recanalize coronary chronic total
occlusions (CTOs).
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(PCI) of CTOs improves clinical outcome in appropriately
selected patients. CTO PCI success, however, remains
suboptimal.
Methods A new crossing catheter and re-entry system was
evaluated in a prospective, multicenter, single-arm trial of
CTO lesions refractory to standard PCI techniques. The
primary efﬁcacy endpoint was the frequency of true lumen
guidewire placement distal to the CTO (technical success).
Results Enrollment included 147 patients with 150 CTOs.
The mean lesion length was 41  17 mm. A crossing
catheter crossed 56 lesions into the distal true lumen, and
a re-entry catheter facilitated tapered-wire cannulation of the
distal lumen in 59 CTOs initially crossed subintimally (77%
technical success). Success in the ﬁrst 75 CTOs was 67%,
rising to 87% in the last 75 CTOs. Mean ﬂuoroscopy and
procedure times were 45  16 min and 90  12 min,
respectively, each signiﬁcantly shorter than in historical
controls (p < 0.0001 for both). Coronary perforation
occurred in 14 cases (9.3%), requiring treatment in 3 cases
(prolonged balloon inﬂation, with additional coil emboli-
zation in 1 case). No tamponade or hemodynamic instability
occurred. Six patients had periprocedural non–ST-segment
elevation myocardial infarction. No emergency surgery, ST-
segment elevation myocardial infarction, or cardiac reinter-
vention occurred. Two deaths occurred within 30 days,
neither as a direct result of the procedure. The 30-day major
adverse cardiac event rate was 4.8%.
Conclusions In CTOs failing standard techniques, use of
a new crossing and re-entry system results in a high success
rate without increasing complications (173).Risk Factors and Outcomes of Post-Procedure
Heart Blocks After Transcatheter Device Closure
of Perimembranous Ventricular Septal Defect
Objectives The aim of this study was to analyze the risk
factors and mid-term outcomes associated with post-
procedure heart blocks (PPHBs) after transcatheter closure
of perimembranous ventricular septal defect (pmVSD).
Background The development of heart blocks remains
a major challenge for transcatheter closure of pmVSD.
Methods Transcatheter closure of pmVSD was carried out
in 228 patients. Electrocardiography and 24-h Holter
monitoring were performed before the procedure, within 1
week after the procedure, then 1, 3, 6, and 12 months, and
every year thereafter.
Results Thirty-three patients (14.5%) who received trans-
catheter closure of pmVSD developed PPHBs. PPHBs
included right bundle branch block (57.6%), left bundle
branch block (24.2%), and atrioventricular block (18.2%).
High-degree atrioventricular blocks occurred in 4 patients
and recovered to normal conduction after intravenous
administration of hydrocortisone. PPHBs recovered to
normal conduction in 21 patients by the time of hospital
discharge. Compared with the patients without PPHBs, thepatients suffering PPHBs were characterized by a signiﬁ-
cantly longer distance between the aortic valve and the defect
(DAVD), a shorter distance from the lower rim of the defect
to the septal leaﬂet of the tricuspid valve (DLRD-SLTV),
and a larger diameter difference between the occluder and
ventricular septal defect (DDOV). The earlier the PPHBs
developed after the procedure, the more difﬁcult the recovery
to normal conduction.
Conclusions The outcome of PPHBs after transcatheter
closure of pmVSD was satisfactory, as most patients recov-
ered to normal conduction. Measurements of DLRD-
SLTV, DAVD, and DDOV may be useful in predicting
the incidence of PPHBs (174).A Percutaneous Treatment Algorithm for Crossing
Coronary Chronic Total Occlusions
Coronary chronic total occlusions (CTOs) are frequently
identiﬁed during coronary angiography and remain the most
challenging lesion group to treat. Patients with CTOs are
frequently left unrevascularized due to perceptions of high
failure rates and technical complexity even if they have
symptoms of coronary disease or ischemia. In this review,
the authors describe a North American contemporary
approach for percutaneous coronary interventions for CTO.
Two guide catheters are placed to facilitate seamless tran-
sition between antegrade wire–based, antegrade dissection
re-entry–based, and retrograde (wire or dissection re-entry)
techniques, the “hybrid” interventional strategy. After dual
coronary injection is performed, 4 angiographic parameters
are assessed: 1) clear understanding of location of the
proximal cap using angiography or intravascular ultraso-
nography; 2) lesion length; 3) presence of branches, as well
as size and quality of the target vessel at the distal cap; and 4)
suitability of collaterals for retrograde techniques. On the
basis of these 4 characteristics, an initial strategy and rank
order hierarchy for technical approaches is established.
Radiation exposure, contrast utilization, and procedure time
are monitored throughout the procedure, and thresholds are
established for intraprocedural strategy conversion to maxi-
mize safety, efﬁciency, and effectiveness (175).Nobori Stent Shows Less Vascular Inﬂammation
and Early Recovery of Endothelial Function
Compared With Cypher Stent
Objectives The current study sought to examine inﬂam-
mation at the stented segments of Nobori (Terumo
Corporation, Tokyo, Japan) and Cypher (Cordis, Miami,
Florida) drug-eluting stents (DES), as well as free radical
production and endothelial function of the adjacent non-
stented segments in a pig coronary model.
Background Nobori is a novel DES, incorporating a bio-
limus A9-eluting biodegradable polymer coated only on the
abluminal surface of the stent. These unique features may
favorably affect inﬂammation and endothelial function, as
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clinical data on direct comparison of the various genera-
tions of DES are not available.
Methods A total of 18 DES were implanted in pig coro-
nary arteries and subsequently explanted at 1 month. Stented
segments were assessed by angiography and histology.
Ex vivo vasomotor function and superoxide production in
segments proximal and distal to the stent were determined.
The vasoconstriction, endothelial-dependent relaxation, and
endothelial-independent relaxation of proximal and distal
nonstented segments were measured.
Results Histological evaluation revealed lower inﬂamma-
tory response with Nobori than with Cypher DES. There is
trend for lower angiographic percentage diameter stenosis in
Nobori versus Cypher groups (p ¼ 0.054). There was
increased endothelium-dependent relaxation, decreased
endothelin-1–mediated contraction, and less superoxide
production in the vessel segments proximal and distal to
Nobori versus Cypher stents.
Conclusions Our data show signiﬁcantly lower inﬂamma-
tory response in the stented segments, and rapid recovery of
endothelial function of peristent segments in the Nobori
group compared with Cypher DES group at 1 month in
porcine coronary artery model (176).Maximal Hyperemia in the Assessment of
Fractional Flow ReserveIntracoronary Adenosine
Versus Intracoronary Sodium Nitroprusside Versus
Intravenous Adenosine: The NASCI (Nitroprussiato
Versus Adenosina nelle Stenosi Coronariche
Intermedie) Study
Objectives This study sought to compare increasing doses
of intracoronary (IC) adenosine or IC sodium nitroprusside
versus intravenous (IV) adenosine for fractional ﬂow reserve
(FFR) assessment.
Background Maximal hyperemia is the critical prerequisite
for FFR assessment. Despite IV adenosine currently repre-
senting the recommended approach, IC administration of
adenosine or other coronary vasodilators constitutes a valu-
able alternative in everyday practice. However, it is surpris-
ingly unclear which IC strategy allows the achievement of
FFR values comparable to IV adenosine.
Methods Fifty intermediate coronary stenoses (n ¼ 45)
undergoing FFR measurement were prospectively and
consecutively enrolled. Hyperemia was sequentially induced
by incremental boli of IC adenosine (ADN) (60 mg ADN60,
300 mg ADN300, 600 mg ADN600), by IC sodium nitro-
prusside (NTP) (0.6 mg/kg bolus) and by IV adenosine
infusion (IVADN) (140 mg/kg/min). FFR values, symp-
toms, and development of atrioventricular block were
recorded.
Results Incremental doses of IC adenosine and NTP
were well tolerated and associated with fewer symptoms
than IVADN. Intracoronary adenosine doses (0.881 
0.067, 0.871  0.068, and 0.868  0.070 with ADN60,ADN300, and ADN600, respectively) and NTP (0.892 
0.072) induced a signiﬁcant decrease of FFR compared
with baseline levels (p < 0.001). Notably, ADN600 only
was associated with FFR values similar to IVADN (0.867
 0.072, p ¼ 0.28). Among the 10 patients with FFR
values 0.80 with IVADN, 5 were correctly identiﬁed
also by ADN60, 6 by ADN300, 7 by ADN600, and
6 by NTP.
Conclusions Intracoronary adenosine, at doses higher than
currently suggested, allows obtaining FFR values similar to
IV adenosine. Intravenous adenosine, which remains the
gold standard, might thus be reserved for those lesions with
equivocal FFR values after high (up to 600 mg) IC adenosine
doses (177).Differences in Neointimal Thickness Between the
Adluminal and the Abluminal Sides of Malapposed
and Side-Branch Struts in a Polylactide
Bioresorbable Scaffold: Evidence In Vivo About the
Abluminal Healing Process
Objectives The goal of this study was to describe the
neointimal healing on the abluminal side (ABL) of mal-
apposed (ISA) struts and nonapposed side-branch (NASB)
struts in terms of coverage by optical coherence tomog-
raphy (OCT) and in comparison with the adluminal side
(ADL).
Background The neointimal healing on the ABL of ISA
and NASB struts has never to our knowledge been explored
in vivo and could be involved in the correction of acute
malapposition. The bioresorbable vascular scaffold (BVS) is
made of a translucent polymer that enables imaging of the
ABL with OCT.
Methods Patients enrolled in the ABSORB B (ABSORB
Clinical Investigation Cohort B) study were treated with
implantation of a BVS and imaged with OCT at 6 months.
Thickness of coverage on the ADL and ABL of ISA and
NASB struts was measured by OCT.
Results Twenty-eight patients were analyzed; 114 (2.4%)
struts were malapposed or at side branches. In 76 ISA
struts (89.4%) and 29 NASB struts (100%), the thickness
of ABL coverage was >30 mm. Coverage was thicker on
the ABL than on the ADL side (101 vs. 71 mm; 95%
conﬁdence interval [CI] of the difference: 20 to 40 mm).
In 70 struts (60.7%, 95% CI: 50.6% to 70.0%), the neo-
intimal coverage was thicker on the ABL, versus only 20
struts (18.5%, 95% CI: 11.6% to 28.1%) with thicker
neointimal coverage on the ADL side (odds ratio: 3.35,
95% CI: 2.22 to 5.07).
Conclusions Most of the malapposed and side-branch
struts are covered on the ABL side 6 months after BVS
implantation, with thicker neointimal coverage than on the
ADL side. The physiological correction of acute malap-
position involves neointimal growth from the strut to the
vessel wall or bidirectional. (ABSORB Clinical Investiga-
tion, Cohort B [ABSORB B]; NCT00856856) (178).
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Transcatheter Aortic Valve Replacement
The advent of transcatheter aortic valve replacement
(TAVR) is one of the most widely anticipated advances in
the care of patients with severe aortic stenosis. This
procedure is unique in many ways, one of which is the
need for a multimodality imaging team-based approach
throughout the continuum of the care of TAVR patients.
Pre-procedural planning, intra-procedural implantation
optimization, and long-term follow-up of patients under-
going TAVR require the expert use of various imaging
modalities, each of which has its own strengths and
limitations. Divided into 3 sections (pre-procedural,
intraprocedural, and long-term follow-up), this review
offers a single source for expert opinion and evidence-
based guidance on how to incorporate the various
modalities at each step in the care of a TAVR patient.
Although much has been learned in the short span of time
since TAVR was introduced, recommendations are offered
for clinically relevant research that will lead to reﬁnement
of best practice strategies for incorporating multimodality
imaging into TAVR patient care (179).Feasibility and Safety of Dabigatran Versus
Warfarin for Periprocedural Anticoagulation in
Patients Undergoing Radiofrequency Ablation for
Atrial Fibrillation: Results From a Multicenter
Prospective Registry
Objectives The purpose of this study was to evaluate the
feasibility and safety of periprocedural dabigatran during
atrial ﬁbrillation (AF) ablation.
Background AF ablation requires optimal periprocedural
anticoagulation for minimizing bleeding and thromboem-
bolic complications. The safety and efﬁcacy of dabigatran as
a periprocedural anticoagulant for AF ablation are unknown.
Methods We performed a multicenter, observational study
from a prospective registry including all consecutive patients
undergoing AF ablation in 8 high-volume centers in the
United States. All patients receiving dabigatran therapy who
underwent AF ablation on periprocedural dabigatran, with
the dose held on the morning of the procedure, were
matched by age, sex, and type of AF with an equal number
of patients undergoing AF ablation with uninterrupted
warfarin therapy over the same period.
Results A total of 290 patients, including 145 taking per-
iprocedural dabigatran and an equal number of matched
patients taking uninterrupted periprocedural warfarin, were
included in the study. The mean age was 60 years with 79%
being male and 57% having paroxysmal AF. Both groups
had a similar CHADS2 score, left atrial size, and left
ventricular ejection fraction. Three thromboembolic
complications (2.1%) occurred in the dabigatran group
compared with none in the warfarin group (p ¼ 0.25). The
dabigatran group had a signiﬁcantly higher major bleedingrate (6% vs. 1%; p ¼ 0.019), total bleeding rate (14% vs. 6%;
p ¼ 0.031), and composite of bleeding and thromboembolic
complications (16% vs. 6%; p ¼ 0.009) compared with the
warfarin group. Dabigatran use was conﬁrmed as an inde-
pendent predictor of bleeding or thromboembolic compli-
cations (odds ratio: 2.76, 95% conﬁdence interval: 1.22 to
6.25; p ¼ 0.01) on multivariate regression analysis.
Conclusions In patients undergoing AF ablation, peri-
procedural dabigatran use signiﬁcantly increases the risk of
bleeding or thromboembolic complications compared with
uninterrupted warfarin therapy (180).Functional Measurement of Coronary Stenosis
Fractional ﬂow reserve (FFR) is considered nowadays as the
gold standard for invasive assessment of physiologic stenosis
signiﬁcance and an indispensable tool for decision making in
coronary revascularization. Use of FFR in the catheterization
laboratory accurately identiﬁes which lesions should be
stented and improves the outcome in most elective clinical
and angiographic conditions. Recently, FFR has been
upgraded to a class IA classiﬁcation in multivessel percuta-
neous coronary intervention in the guidelines on coronary
revascularization of the European Society of Cardiology. In
this state-of-the-art paper, the basic concept of FFR and its
application, characteristics, and use in several subsets of
patients are discussed from a practical point of view (181).Morphometric Assessment of Coronary Stenosis
Relevance With Optical Coherence Tomography: A
Comparison With Fractional Flow Reserve and
Intravascular Ultrasound
Objectives The study sought to assess the diagnostic efﬁ-
ciency of optical coherence tomography (OCT) in identi-
fying hemodynamically severe coronary stenoses as
determined by fractional ﬂow reserve (FFR). Concomitant
OCT and intravascular ultrasound (IVUS) area measure-
ments were performed in a subgroup of patients to compare
the diagnostic efﬁciency of both techniques.
Background The value of OCT to determine stenosis
severity remains unsettled.
Methods Sixty-one stenoses with intermediate angio-
graphic severity were studied in 56 patients. Stenoses were
labeled as severe if FFR 0.80. OCT interrogation was
performed in all cases, with concomitant IVUS imaging in
47 cases.
Results Angiographic stenosis severity was 50.9  8%
diameter stenosis with 1.28  0.3 mm minimal lumen
diameter. FFR was 0.80 in 28 (45.9%) stenoses. An overall
moderate diagnostic efﬁciency of OCT was found (area
under the curve [AUC]: 0.74; 95% conﬁdence interval [CI]:
0.61 to 0.84), with sensitivity/speciﬁcity of 82%/63% asso-
ciated with an optimal cutoff value of 1.95 mm2. Compar-
ison of the results in patients with simultaneous IVUS and
OCT imaging revealed no signiﬁcant differences in the
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0.83) and IVUS (AUC. 0.63; 95% CI: 0.47 to 0.77;
p ¼ 0.19). Sensitivity/speciﬁcity for IVUS was 67%/65% for
an optimal cutoff value of 2.36 mm2. In the subgroup of
small vessels (reference diameter <3 mm) OCT showed
a signiﬁcantly better diagnostic efﬁciency (AUC: 0.77; 95%
CI: 0.60 to 0.89) than IVUS (AUC: 0.63; 95% CI: 0.46 to
0.78) to identify functionally signiﬁcant stenoses (p ¼ 0.04).
Conclusions OCT has a moderate diagnostic efﬁciency in
identifying hemodynamically severe coronary stenoses.
Although OCT seems slightly superior to IVUS for this
purpose (particularly in vessels <3 mm), its low speciﬁcity
precludes its use as a substitute of FFR for functional
stenosis assessment (182).Consensus Standards for Acquisition,
Measurement, and Reporting of Intravascular
Optical Coherence Tomography Studies: A Report
From the International Working Group for
Intravascular Optical Coherence Tomography
Standardization and Validation
Objectives The purpose of this document is to make the
output of the International Working Group for Intravas-
cular Optical Coherence Tomography (IWG-IVOCT)
Standardization and Validation available to medical and
scientiﬁc communities, through a peer-reviewed publica-
tion, in the interest of improving the diagnosis and treat-
ment of patients with atherosclerosis, including coronary
artery disease.
Background Intravascular optical coherence tomography
(IVOCT) is a catheter-based modality that acquires
images at a resolution of w10 mm, enabling visualization
of blood vessel wall microstructure in vivo at an unprec-
edented level of detail. IVOCT devices are now
commercially available worldwide, there is an active user
base, and the interest in using this technology is growing.
Incorporation of IVOCT in research and daily clinical
practice can be facilitated by the development of uniform
terminology and consensus-based standards on use of the
technology, interpretation of the images, and reporting of
IVOCT results.
Methods The IWG-IVOCT, comprising more than 260
academic and industry members from Asia, Europe, and the
United States, formed in 2008 and convened on the topic of
IVOCT standardization through a series of 9 national and
international meetings.
Results Knowledge and recommendations from this group
on key areas within the IVOCT ﬁeld were assembled to
generate this consensus document, authored by the Writing
Committee, composed of academicians who have partici-
pated in meetings and/or writing of the text.
Conclusions This document may be broadly used as
a standard reference regarding the current state of the
IVOCT imaging modality, intended for researchers and
clinicians who use IVOCT and analyze IVOCT data (183).Mechanical Aortic Valve Replacement in Young
Women Planning on Pregnancy: Maternal and Fetal
Outcomes Under Low Oral Anticoagulation, a Pilot
Observational Study on a Comprehensive Pre-
Operative Counseling Protocol
Objectives This pilot prospective observational study
aimed to evaluate the maternal and fetal outcomes of preg-
nancies under low-dose oral anticoagulation therapy after
aortic mechanical replacement.
Background Need for valve replacement is still an issue for
young women with native valve disease who are planning on
future pregnancy. Choice of replacement device is a chal-
lenging clinical task.
Methods A comprehensive pre-operative counseling
protocol to guide choice of replacement device was de-
veloped. The pre-operative anticoagulation trial to deter-
mine the warfarin daily dosage needed to reach target
international normalized ratio (INR) represented the main
stem of such protocol. Pregnancies on low-dose anti-
coagulation therapy (target INR: 1.5 to 2.5) were allowed
in a highly selected subset of mechanical aortic valve
recipients.
Results Twenty-two patients of 40 originally referred for
native valve disease surgery requiring valve replacement,
safely underwent the pre-operative anticoagulation chal-
lenge. No maternal or fetal complications were detected in
16 pregnancies under low oral anticoagulation. Patterns of
warfarin daily dosage and induced INRs were characterized
during pregnancy.
Conclusions In this small sample observational study,
a pre-operative anticoagulation therapy trial helped young
women scheduled for valve replacement to acquire complete
information as to the choice of prosthetic device. In selected
third-generation mechanical aortic prosthesis recipients,
low-dose anticoagulation therapy seems safe and feasible for
both mother and fetus. Further studies are needed to validate
this approach (184).
Randomized Trial of Optimal Treatment Strategies
for In-Stent Restenosis After Drug-Eluting Stent
Implantation
Objectives The purpose of this study is to compare the
efﬁcacy of the treatment strategies for in-stent restenosis
(ISR) of drug-eluting stents (DES) according to the
morphologic pattern of restenosis.
Background Optimal treatment strategies for ISR within
DES have not been adequately addressed yet.
Methods Patients with ISR of DES were randomized
according to the lesion length to compare outcomes of
sirolimus-eluting stent (SES) versus cutting balloon angio-
plasty for focal type (10 mm) and SES versus everolimus-
eluting stent (EES) for diffuse type (>10 mm). The primary
endpoint was in-segment late loss at 9 months. Overall 162
patients, 96 with focal ISR and 66 with diffuse ISR, were
enrolled.
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cantly higher in the cutting balloon group (n ¼ 48) than in
the SES group (n ¼ 48; 0.25 mm, interquartile range
[IQR]: 0.01 to 0.68 mm vs. 0.06 mm, IQR: 0.08 to 0.17
mm; p ¼ 0.04). Consequently, in-segment restenosis rate
tended to be higher in the cutting balloon group than in the
SES group (20.7% vs. 3.1%, p ¼ 0.06) with comparable
incidences of the composite of death, myocardial infarction,
or target vessel revascularization at 12 months of clinical
follow up (6.3% vs. 6.3%, p > 0.99). In 66 cases of diffuse
ISR, in-segment late loss (0.11 mm, IQR: 0.02 to 0.30
mm; vs. 0.00 mm, IQR: 0.08 to 0.25 mm; p ¼ 0.64), in-
segment restenosis rate (5.0% vs. 14.3%, p ¼ 0.32), and the
composite incidence of death, myocardial infarction, or
target lesion revascularization (9.6% vs. 8.8%, p > 0.99) did
not differ between SES group (n ¼ 32) and EES group (n ¼
34).
Conclusions For lesions of focal DES restenosis, repeat
implantation of SES is more effective in reducing late
luminal loss and subsequent restenosis rate than cutting
balloon angioplasty. For diffuse DES restenosis, implanta-
tion of SES or EES is comparably effective in terms of
angiographic and clinical outcomes (185).Current Perspectives on Coronary Chronic Total
Occlusions: The Canadian Multicenter Chronic
Total Occlusions Registry
Objectives The purpose of this study was to determine the
prevalence, clinical characteristics, and management of
coronary chronic total occlusions (CTOs) in current
practice.
Background There is little evidence in contemporary
literature concerning the prevalence, clinical characteristics,
and treatment decisions regarding patients who have coro-
nary CTOs identiﬁed during coronary angiography.
Methods Consecutive patients undergoing nonurgent
coronary angiography with CTO were prospectively iden-
tiﬁed at 3 Canadian sites from April 2008 to July 2009.
Patients with previous coronary artery bypass graft surgery or
presenting with acute ST-segment elevation myocardial
infarction were excluded. Detailed baseline clinical, angio-
graphic, electrocardiographic, and revascularization data
were collected.
Results Chronic total occlusions were identiﬁed in 1,697
(18.4%) patients with signiﬁcant coronary artery disease
(>50% stenosis in 1 coronary artery) who were undergoing
nonemergent angiography. Previous history of myocardial
infarction was documented in 40% of study patients, with
electrocardiographic evidence of Q waves corresponding to
the CTO artery territory in only 26% of cases. Left
ventricular function was normal in >50% of patients with
CTO. Half the CTOs were located in the right coronary
artery. Almost half the patients with CTO were treated
medically, and 25% underwent coronary artery bypass graft
surgery (CTO bypassed in 88%). Percutaneous coronaryintervention was done in 30% of patients, although CTO
lesions were attempted in only 10% (with 70% success rate).
Conclusions Chronic total occlusions are common in
contemporary catheterization laboratory practice. Prospec-
tive studies are needed to ascertain the beneﬁts of treatment
strategies of these complex patients (186).Platelet Biology and Response to Antiplatelet
Therapy in Women: Implications for the
Development and Use of Antiplatelet
Pharmacotherapies for Cardiovascular Disease
Women are underrepresented in cardiovascular studies, even
as their preponderance in the aging population steadily
increases. Although concerns have been raised about the
differential beneﬁt of antiplatelet medications for women,
the propensity for increased bleeding among women has also
been recognized. A better understanding of the factors
contributing to the observed sex-related differences in
platelet biology is warranted. These factors include differ-
ences in the frequency and expression of genetic poly-
morphisms affecting platelet responsiveness to agonists
(with and without antiplatelet therapies), which might be
obtained through population-based studies and in large
controlled clinical trials; inﬂammatory marker levels and
their inﬂuence on atherothrombotic risk, and the role of
speciﬁc hormones in mediating platelet activation and
function. Knowledge gained about these mechanistic factors
might inform the development of sex-speciﬁc antith-
rombotic treatment regimens that confer optimized safety
and efﬁcacy (187).Histopathologic Characterization of Chronic
Radiofrequency Ablation Lesions for Pulmonary
Vein Isolation
Objectives This study describes the histopathologic and
electrophysiological ﬁndings in patients with recurrence of
atrial ﬁbrillation (AF) after pulmonary vein (PV) isolation
who underwent a subsequent surgical maze procedure.
Background The recovery of PV conduction is commonly
responsible for recurrence of AF after catheter-based PV
isolation.
Methods Twelve patients with recurrent AF after acutely
successful catheter-based antral PV isolation underwent
a surgical maze procedure. Full-thickness surgical biopsy
specimens were obtained from the PV antrum in areas of
visible endocardial scar. Before biopsy, intraoperative
epicardial electrophysiological recordings were taken from
each PV using a circular mapping catheter.
Results Twenty-two PVs were biopsied from the 12
patients 8  11 months after ablation. Eleven of the 22
specimens (50%) revealed transmural scar, and 11 (50%)
showed viable myocardium with or without scar. Each
biopsy specimen demonstrated evidence of injury, most
commonly endocardial thickening (n ¼ 21 [95%]) and
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(32%) showed conduction block at surgery. Transmural scar
was more likely to be seen in the biopsy specimens from the
PVs with conduction block than in specimens from the PVs
showing reconnection. However, viable myocardium alone
or mixed with scar was seen in 2 specimens from PVs with
conduction block.
Conclusions PVs showing electrical reconnection after
catheter-based antral ablation frequently reveal anatomic
gaps or nontransmural lesions at the sites of catheter abla-
tion. Nontransmural lesions are noted in some PVs with
persistent conduction block, suggesting that lesion geometry
may inﬂuence PV conduction. The histological ﬁndings
show that nontransmural ablation can produce a dynamic
cellular substrate with features of reversible injury. Delayed
recovery from injury may explain late recurrences of AF after
PV isolation (188).The Clinical Impact of Incomplete Left Atrial
Appendage Closure With the Watchman Device in
Patients With Atrial Fibrillation: A PROTECT AF
(Percutaneous Closure of the Left Atrial
Appendage Versus Warfarin Therapy for
Prevention of Stroke in Patients With Atrial
Fibrillation) Substudy
Objectives The purpose of this study was to investigate the
frequency and clinical impact of incomplete left atrial
appendage (LAA) sealing and consequent peri-device
residual blood ﬂow in patients undergoing percutaneous
LAA closure with the Watchman device (Atritech, Inc.,
Plymouth, Minnesota).
Background During percutaneous LAA closure for stroke
prophylaxis, the geometric variability of the LAA ostium
may result in an incomplete seal of the LAA. On the one
hand, this could enhance thrombus formation and emboli-
zation of thrombi around the device into the circulation; on
the other hand, the relatively small size of these leaks may
preclude clinically relevant embolizations.
Methods Patients randomly assigned to device implantation
in the PROTECT AF (Percutaneous Closure of the Left
Atrial Appendage Versus Warfarin Therapy for Prevention
of Stroke in Patients With Atrial Fibrillation) trial were
analyzed. Transesophageal echocardiography was performed
at 45 days, 6 months, and 12 months. Per the study protocol,
patients discontinued warfarin therapy if the 45-day Trans-
esophageal echocardiogram revealed either minimal or no
peri-device ﬂow (jet 5 mm width). The impact of peri-
device ﬂow severity, deﬁned as minor, moderate, or major
(<1 mm, 1 mm to 3 mm, >3 mm, respectively) on the
composite primary efﬁcacy endpoint (stroke, systemic
embolism, and cardiovascular death) is expressed as hazard
ratio (HR) with 95% conﬁdence interval (CI).
Results Transesophageal echocardiography follow-up
revealed that 32.0% of implanted patients had at least
some degree of peri-device ﬂow at 12 months. The HR ofthe primary efﬁcacy endpoint per 1 mm larger per-device
ﬂow was 0.84 (95% CI: 0.62 to 1.14; p ¼ 0.256).
Compared to patients with no peri-device ﬂow, the HRs
were 0.85 (95% CI: 0.11 to 6.40), 0.83 (95% CI: 0.33 to
2.09), and 0.48 (95% CI: 0.11 to 2.09) for minor, moderate,
and major peri-device ﬂow, respectively (p ¼ 0.798).
Compared to patients with no peri-device ﬂow who dis-
continued warfarin, the HR for patients with any peri-device
ﬂow and continuing warfarin was 0.63 (95% CI: 0.14 to
2.71; p ¼ 0.530).
Conclusions These data indicate that residual peri-device
ﬂow into the LAA after percutaneous closure with the
Watchman device was common, and is not associated with
an increased risk of thromboembolism. This ﬁnding should
be interpreted with caution as the low event rate decreases
the conﬁdence of this conclusion (189).Prasugrel Versus Tiroﬁban Bolus With or Without
Short Post-Bolus Infusion With or Without
Concomitant Prasugrel Administration in Patients
With Myocardial Infarction Undergoing Coronary
Stenting: The FABOLUS PRO (Facilitation through
Aggrastat By drOpping or shortening Infusion Line
in patients with ST-segment elevation myocardial
infarction compared to or on top of PRasugrel
given at loading dOse) Trial
Objectives The authors sought to compare the effect on
inhibition of platelet aggregation (IPA) of prasugrel therapy
versus tiroﬁban bolus with or without a post-bolus short
drug infusion in ST-segment elevation myocardial infarction
(STEMI) patients.
Background The degree and rapidity of IPA after prasugrel
alone with or without concomitant glycoprotein IIb/IIIa
inhibition in STEMI patients is unknown.
Methods A total of 100 STEMI patients randomly
received prasugrel 60 mg versus 25 mg/kg tiroﬁban bolus
with or without post-bolus 2-h infusion of tiroﬁban, with or
without concomitant prasugrel. IPA at light transmission
aggregometry was performed throughout 24 h. The primary
endpoint was IPA stimulated with 20 mmol/l adenosine
diphosphate (ADP) at 30 min.
Results At 30 min, patients in the prasugrel group showed
a signiﬁcantly lower IPA to 20 mmol/l ADP stimulation as
compared with tiroﬁban-treated patients (36  35 vs. 87 
31, p < 0.0001). Similarly, patients taking prasugrel showed
a suboptimal degree of platelet inhibition for at least 2 h
compared with tiroﬁban patients. Post-bolus tiroﬁban
infusion was necessary to maintain a high level of IPA
beyond 1 h after bolus administration if concomitant clo-
pidogrel was given, whereas the bolus-only tiroﬁban and
concomitant prasugrel led to the higher and more consistent
IPA levels after both ADP and thrombin receptor-activating
peptide stimuli than either therapy alone.
Conclusions Our study shows that prasugrel administra-
tion leads to a suboptimal IPA for at least 2 h in STEMI
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only of glycoprotein IIb/IIIa inhibitor, obviates the need of
post-bolus infusion and almost completely abolishes residual
variability of IPA after treatment. (Facilitation through
Aggrastat By drOpping or shortening Infusion Line in
patients with ST-segment elevation myocardial infarction
compared to or on top of PRasugrel given at loading dOse
[The FABOLUS PRO trial]; NCT01336348) (190).
Long-Term Follow-Up After Treatment of Coronary
In-Stent Restenosis With a Paclitaxel-Coated
Balloon Catheter
Objectives This study presents long-term clinical follow-
up, including binary restenosis rate and major adverse
cardiovascular events, of the PACCOCATH-ISR (Treat-
ment of In-Stent Restenosis by Paclitaxel Coated PTCA
Balloons) I and II trial.
Background The PACCOCATH-ISR trial was a ﬁrst-in-
human study with a drug-coated balloon catheter and the
ﬁrst study for the treatment of coronary ISR with a drug-
coated balloon. So, far no long-term follow-up data have
been presented.
Methods This study enrolled 108 patients in a randomized,
double-blinded multicenter trial on the efﬁcacy and safety of
a paclitaxel-coated balloon (3 mg/mm2 balloon surface;
PACCOCATH [Bayer AG, Germany]) compared with an
uncoated balloon. The main inclusion criteria were a diam-
eter stenosis of 70% and <30-mm length with a vessel
diameter of 2.5 to 3.5 mm. The primary endpoint was
angiographic late lumen loss in-segment after 6 months.
Combined antiplatelet therapy was continued only for
1 month followed by treatment with aspirin alone.
Results During a follow-up of 5.4  1.2 years, the clinical
event rate was signiﬁcantly reduced in patients treated with
the drug-coated balloon (major adverse cardiovascular
events: 59.3% vs. 27.8%, p ¼ 0.009), which was mainly
driven by the reduction of target lesion revascularization
from 38.9% to 9.3% (p ¼ 0.004).
Conclusions Treatment of coronary ISR with paclitaxel-
coated balloon catheters is safe and persistently reduces
repeat revascularization during long-term follow-up. The
initial results were sustained over the 5-year period. (Treat-
ment of In-Stent Restenosis by Paclitaxel Coated PTCA
Balloons [PACCOCATH ISR I]; NCT00106587. Treat-
ment of In-Stent Restenosis by Paclitaxel Coated PTCA
Balloons [PACCOCATH ISR II]; NCT00409981) (191).
A Therapeutic Window for Platelet Reactivity for
Patients Undergoing Elective Percutaneous
Coronary Intervention: Results of the ARMYDA-
PROVE (Antiplatelet therapy for Reduction of
MYocardial Damage during Angioplasty–Platelet
Reactivity for Outcome Validation Effort) Study
Objectives This study sought to validate the ability of
the VerifyNow P2Y12 assay (Accumetrics, San Diego,California) in predicting both ischemic and bleeding events
after elective percutaneous coronary intervention (PCI).
Background High and low levels of platelet reactivity are
associated with ischemic and bleeding events, respectively,
after PCI.
Methods A total of 732 patients on dual antiplatelet
therapy undergoing elective PCI were recruited. Platelet
reactivity was measured before PCI. The primary endpoint
was the 30-day incidence of net adverse clinical events
(NACE), deﬁned as the occurrence of ischemic or bleeding
events, in relation to P2Y12 reaction unit (PRU)
distribution.
Results At receiver-operating characteristic curve analysis,
PRU values could signiﬁcantly discriminate between
patients with and without bleeding events (area under the
curve [AUC]: 0.72; 95% conﬁdence interval [CI]: 0.65 to
0.80; p < 0.0001) and those with and without ischemic
events (AUC: 0.68; 95% CI: 0.61 to 0.76; p < 0.0001). The
optimal cutoffs for bleeding (PRU 178) and ischemic
events (PRU 239) were used to deﬁne 3 groups: low
platelet reactivity (LPR) (LPR ¼ PRU 178), normal
platelet reactivity (NPR) (NPR ¼ PRU 179 to 238), and
high platelet reactivity (HPR) (HPR ¼ PRU 239). The
incidence of NACE was 14.1% in the LPR group, 7.8% in
the NPR group (p ¼ 0.025 vs. LPR group), and 15.4% in
the HPR group (p ¼ 0.005 vs. NPR group). At multivariate
analysis, PRU values in the NPR group were an independent
predictor of reduced risk of 30-day NACE (odds ratio: 0.47,
95% CI: 0.27 to 0.81).
Conclusions A therapeutic window for platelet reactivity
measured with the VerifyNow P2Y12 assay can be identiﬁed
using speciﬁc thresholds that deﬁne a group of patients at
lower risk for both ischemic and bleeding events. Adjunctive
measures may be beneﬁcial in patients with higher or lower
platelet reactivity in order to improve clinical outcomes after
PCI (192).Cigarette Smoking Is Associated With a Dose-
Response Effect in Clopidogrel-Treated Patients
With Diabetes Mellitus and Coronary Artery
Disease: Results of a Pharmacodynamic Study
Objectives This study sought to assess the presence of
a dose-response effect of cigarette smoking and its impact on
high on-treatment platelet reactivity (HPR) in patients with
diabetes mellitus treated with clopidogrel.
Background Cigarette smoking is an inducer of cyto-
chrome P450 1A2, a hepatic enzyme involved in clopidogrel
metabolism. If cigarette smoking is associated with a dose-
response effect on pharmacodynamic measures in
clopidogrel-treated patients is unknown.
Methods A total of 134 type 2 diabetes mellitus patients on
maintenance aspirin and clopidogrel therapy were studied.
Patients were divided into 3 groups according to cotinine
levels: <3 ng/ml (nonsmokers), 3 to 199 ng/ml (light
smokers), and 200 ng/ml (heavy smokers). Platelet
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VerifyNow P2Y12 assay (Accumetrics, San Diego, Cal-
ifornia), and vasodilator-stimulated phosphoprotein. Rates
of HPR were deﬁned using established cutoff values.
Results A dose-response effect was observed for all phar-
macodynamic parameters tested. Serum cotinine levels were
inversely associated with platelet reactivity as assessed by
light transmittance aggregometry using 5 and 20 mmol/l
adenosine diphosphate (p < 0.0001 for all). Accordingly,
platelet disaggregation increased with levels of serum coti-
nine (p < 0.0001). Similar results were found with P2Y12
reaction units (p < 0.0001) and inhibition of platelet
aggregation (p ¼ 0.005) as deﬁned by VerifyNow P2Y12
testing, and platelet reactivity index (p ¼ 0.002) as assessed
by vasodilator-stimulated phosphoprotein. Higher serum
cotinine levels were signiﬁcantly associated with lower rates
of HPR, as deﬁned according to various pharmacodynamic
cutoff measures.
Conclusions Cigarette smoking is associated with a dose-
response effect on clopidogrel-induced antiplatelet effects
and lower rates of HPR in diabetes mellitus patients (193).Comparison of Drug-Eluting and Bare-Metal Stents
for Primary Percutaneous Coronary Intervention
With or Without Abciximab in ST-Segment
Elevation Myocardial Infarction: DEBATER: The
Eindhoven Reperfusion Study
Objectives The goal of this study was to demonstrate
superiority of sirolimus-eluting stents (SES) over bare-metal
stents (BMS) and of abciximab over no abciximab in
primary percutaneous coronary intervention (PCI).
Background Drug-eluting stents (DES) are increasingly
used in primary PCI, but the recommendations for use in
primary PCI are based on a few randomized controlled trials
with selected patients. The usefulness of abciximab in
primary PCI is not established.
Methods Nine hundred seven patients referred to the
Catharina Hospital were randomized to SES or BMS, and
to abciximab or no abciximab in a prospective, randomized,
open 2  2 factorial trial with blinded evaluation. Primary
endpoint was major adverse cardiac and cerebrovascular
events (MACCE), deﬁned as the composite of death,
myocardial infarction (MI), stroke, repeat revascularization,
and bleeding at 1 year (stent arm) and the composite of
death, target vessel MI, target vessel revascularization
(TVR), and bleeding at 30 days (abciximab arm).
Results At 1 year, the rate of MACCE was lower in the
SES arm (16.5% vs. 25.8%, p ¼ 0.001), mainly driven by
less repeat revascularization (9.8% vs. 16.8%; p ¼ 0.003)
and without inﬂuencing the cumulative incidence of death
and MI (5.2% vs. 5.8%; p ¼ 0.68). At 30 days, the rate of
the composite of death, target vessel MI, TVR, and
bleeding was lower in the abciximab arm (8.2% vs. 12.4%,
p ¼ 0.04), mainly driven by less TVR due to less stent
thrombosis (1.2% vs.7.4%, p < 0.001). However, bleedingcomplications occurred more frequently in the abciximab
group (5.7% vs. 2.8%, p ¼ 0.03).
Conclusions Primary PCI with SES reduces adverse events
at 1 year, mainly by reduction of repeat revascularization,
whereas abciximab reduces early stent thrombosis, at the
expense of more bleeding complications. (Comparison of
Drug Eluting and Bare Metal Stents With or Without
Abciximab in ST Elevation Myocardial Infarction
[DEBATER]; NCT00986050) (194).
Clinical Evaluation of a Paclitaxel-Eluting Balloon
for Treatment of Femoropopliteal Arterial Disease:
12-Month Results From a Multicenter Italian
Registry
Objectives This study evaluated the use of a paclitaxel-
eluting balloon (PEB) for treatment of femoropopliteal
arterial disease.
Background Conventional balloon angioplasty and stent-
ing in this setting is associated with high restenosis rates
within 12 months. Recent data suggest that PEB use may
reduce restenosis. Twelve-month outcomes following PEB
use with provisional stenting are described.
Methods This prospective registry enrolled patients
(Rutherford class 2 to 4) with reference vessel diameter of 3
to 7 mm and lesion/occlusion length 15 cm. Endpoints
included primary patency rate, target lesion revasculariza-
tion, and changes in Rutherford class and ankle-brachial
index. Walking capacity, absolute claudication distance,
and quality of life were also assessed.
Results The registry enrolled 105 patients. Baseline ankle-
brachial index was 0.56  0.15. Baseline Rutherford clas-
siﬁcation was class 2 or 3 for most patients (91.5%). Most
lesions were located in the superﬁcial femoral artery (77.1%).
Mean lesion length was 76.3  38.3 mm; 29.8% of lesions
were total occlusions. The device was successfully used in all
patients and only 12.3% of lesions required stenting. At 12-
month follow-up, 92 of 105 patients (87.6%) were evaluable;
the primary patency rate was 83.7%; the target lesion
revascularization rate was 7.6%; 85.6% of patients were
Rutherford class 0 or 1; and mean ankle-brachial index was
0.86  0.15. Quality of life and absolute claudication
distance showed signiﬁcant improvement from baseline to
12-month follow-up.
Conclusions PEB treatment of femoropopliteal arterial
disease resulted in consistent clinical improvement across
multiple endpoints with a low rate of stenting and target
lesion revascularization (195).
Impact of Sex on Clinical and Angiographic
Outcomes Among Patients Undergoing
Revascularization With Drug-Eluting Stents
Objectives The goal of this study was to investigate sex-
based differences in long-term clinical and angiographic
outcomes after coronary revascularization with drug-eluting
stents (DES).
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graphic outcomes following revascularization with DES is
not well established.
Methods Individual patient data from 3 all-comers
randomized DES trials (SIRTAX, LEADERS, RESO-
LUTE All-Comers) were pooled. Of 5,011 patients, 4,885
(97.5%) completed 2-year follow-up (1,164 women, 3,721
men). Protocol-mandated angiographic follow-up was
available for 1,561 lesions (351 among women, 1,210 among
men). The primary endpoint was the composite of cardiac
death and myocardial infarction (MI) at 2 years.
Results At baseline, women, as compared with men, were
older, more frequently had diabetes, obesity, and hyperten-
sion, less frequently had smoking habits, previous MI, and
previous surgical revascularization, and had a smaller refer-
ence diameter of the target vessel as well as a lower
SYNTAX score. After adjustment for baseline differences,
women and men had a similar risk of cardiac death or MI
(odds ratio [OR]: 1.13, 95% conﬁdence interval [CI]: 0.82
to 1.56, p ¼ 0.44), cardiac death (OR: 1.04, 95% CI: 0.61 to
1.80, p ¼ 0.87), and MI (OR: 1.07, 95% CI: 0.75 to 1.53,
p ¼ 0.71) at 2 years. Similarly, risks of target lesion revas-
cularization (OR: 1.09, 95% CI: 0.77 to 1.54, p ¼ 0.62),
target vessel revascularization (OR: 0.88, 95% CI: 0.63 to
1.22, p ¼ 0.43), and deﬁnite or probable stent thrombosis
(OR: 0.73, 95% CI: 0.38 to 1.38, p ¼ 0.33) were compa-
rable for women and men. Follow-up angiography showed
no differences in terms of in-stent late loss (0.18  0.54 mm
vs. 0.20  0.99 mm, p ¼ 0.76) and in-segment binary
restenosis (8.5% vs. 8.5%, p ¼ 0.76).
Conclusions The unrestricted use of DES is associated
with similar long-term safety and efﬁcacy among women
and men with coronary artery disease. (Sirolimus-Eluting
Versus Paclitaxel-Eluting Stents for Coronary Revasculari-
zation [SIRTAX]; NCT00297661, LEADERS Trial
Limus Eluted From A Durable Versus ERodable Stent
Coating [LEADERS]; NCT00389220, RESOLUTE-III
All-comers Trial: A Randomized Comparison of a Zotar-
olimus-Eluting Stent With an Everolimus-Eluting Stent
for Percutaneous Coronary Intervention [RESOLUTE All-
Comers]; NCT00617084) (196).Transcatheter Mitral Valve-in-Valve Implantation in
Patients With Degenerated Bioprostheses
Objectives This study reports the results of a series of
transapical mitral valve-in-valve implantations and aims to
offer guidance on technical aspects of the procedure.
Background Mitral valve reoperations due to failing bio-
prostheses are associated with high morbidity and mortality.
Transcatheter techniques may evolve as complementary
approaches to surgery in these high-risk patients.
Methods Six patients (age 75  15 years) received trans-
apical implantation of a balloon-expandable pericardial heart
valve into a degenerated bioprosthesis (range 27 to 31 mm)
in mitral position at our institution. All patients wereconsidered high risk for surgical valve replacement (logistic
EuroSCORE: 33  15%) after evaluation by an interdisci-
plinary heart team. Procedural and clinical outcomes were
analyzed.
Results Implantation was successful in all patients with
reduction of mean transvalvular gradients from 11.3  5.2
mm Hg to 5.5  3.6 mm Hg (p ¼ 0.016) and median
regurgitation from grade 3.0 (interquartile range [IQR]: 2.7
to 3.1) to 0 (IQR: 0 to 1.0, p ¼ 0.033) with trace para-
valvular regurgitation remaining in 2 patients. Apical
bleeding occurred in 2 patients requiring rethoracotomy in 1
and resuscitation in a second patient, the latter of whom
died on postoperative day 6. In the remaining patients,
median New York Heart Association functional class
improved from 3.0 (IQR: 3.0 to 3.5) to 2.0 (IQR: 1.5 to 2.0,
p ¼ 0.048) over a median follow-up of 70 (IQR: 25.5 to
358) days.
Conclusions With acceptable results in a high-risk pop-
ulation, transapical mitral valve-in-valve implantation can be
considered as a complementary approach to reoperative
mitral valve surgery in select patients (197).Different Prognostic Signiﬁcance of High On-
Treatment Platelet Reactivity as Assessed by the
Verify: Now P2Y12 Assay After Coronary Stenting
in Patients With and Without Acute Myocardial
Infarction
Objectives This study compared the prognostic role of
high on-treatment platelet reactivity (HTPR) in predicting
thrombotic events in a Korean population undergoing
percutaneous coronary intervention (PCI) in the acute
myocardial infarction (AMI) and non-AMI setting.
Background The prognostic signiﬁcance and optimal
cutoff of HTPR might differ according to a given clinical
condition, such as AMI and ethnicity.
Methods On-treatment platelet reactivity was measured
with a VerifyNow P2Y12 assay (Accumetrics, San Diego,
California) in 1,226 patients (824 men; age 65  10 years),
including 413 AMI cases, 12 to 24 h after PCI between
March 2008 and March 2010. The prevalence of cardio-
vascular (CV) events deﬁned as a composite of death from
CV causes, nonfatal myocardial infarction, or stent throm-
bosis at 1-year follow-up were compared according to
HTPR between patients with and without AMI.
Results The optimal cutoff for HTPR was 272 IU of the
P2Y12 reaction unit (PRU) (area under the curve: 0.708;
95% conﬁdence interval [CI]: 0.607 to 0.809, p ¼ 0.03),
which was the upper-tertile threshold. Among AMI
patients, 1-year CV events occurred more frequently in
patients with versus without HTPR (n ¼ 14 [8.8%] vs. n ¼
1 [0.4%], p < 0.001), whereas there was no difference in the
composite endpoint on the basis of HTPR in patients
without AMI (n ¼ 7 [2.8%] vs. n ¼ 8 [1.4%], p ¼ 0.193).
Conclusions Increased residual platelet reactivity is related
to post-discharge CV events in subjects with AMI, whereas
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in patients with stable coronary disease after PCI (198).
Renal Denervation for Hypertension
Systemic hypertension is a major burden to the individual
and society. Its association with major adverse cardiac and
cerebral events and favorable effects of antihypertensive
therapy are undisputed. However, despite multidrug
therapy, blood pressures are frequently suboptimally
controlled. Moreover, adverse drug effects often interfere
with patients’ lifestyles and affect compliance. Therefore,
alternative treatment strategies have been explored. Most
recently, attention has been redirected to the sympathetic
nervous system (SNS) in the pathogenesis of hypertension.
In addition, interruption of the renal SNS in humans with
resistant hypertension has been studied with promising
results. The following review provides an overview of the
anatomy and physiology of the renal SNS, the rational for
manipulating the SNS, and the results of therapeutic renal
sympathetic denervation (199).
Incidence of Overall Bleeding in Patients Treated
With Intra-Aortic Balloon Pump During
Percutaneous Coronary Intervention: 12-Year
Milan Experience
Objectives This study aims to report a “real-world” expe-
rience of in hospital complications and clinical outcome of
a large cohort of consecutive patients who underwent
percutaneous coronary intervention (PCI) with intra-aortic
balloon pump counterpulsation (IABP) support, from
a tertiary care center over a 12-year period.
Background The incidence of vascular complications in
patients treated with PCI and IABP is expected to be
higher due to simultaneous puncture of femoral arteries,
larger IABP sheath size, and longer duration of IABP
therapy.
Methods A total of 360 consecutive patients (mean age of
65.9  11.2 years; 80.6% male) who required an IABP
support during percutaneous PCI were classiﬁed into 3
groups: Urgent: 133 patients (36.9%) admitted with acute
coronary syndrome in whom IABP therapy was started
before urgent PCI; Emergent: 56 patients (15.6%) in whom
emergent IABP insertion was required to manage hypo-
tension during PCI; and Elective: 171 patients (47.5%) with
stable angina pectoris in whom IABP was inserted before
elective PCI. Overall bleeding was deﬁned according to the
newest the Bleeding Academic Research Consortium
(BARC) deﬁnition criteria.
Results BARC bleeding occurred in 68 patients (19%),
with the highest incidence noted in the Urgent group
(31.1%), in comparison with the Emergent (26.8%) and
Elective (7%) groups, p < 0.0001. Bleeding related to the
IABP access site was 7.5%, which accounted for 82% of
any access site–related bleeding. It was signiﬁcantlyhigher in the Urgent group (12.8%) compared with the
Elective (4.1%) and Emergent (5.4%) groups. At multi-
variate analysis, IABP treatment duration and renal
impairment were the only independent predictors of
BARC bleeding.
Conclusions Bleeding related to the IABP access site was
signiﬁcantly higher in the Urgent group and accounted for
more than two-thirds of overall access site–related bleeding.
IABP treatment duration and renal impairment were inde-
pendent predictors of overall bleeding (200).Residual Plaque Burden in Patients With Acute
Coronary Syndromes After Successful
Percutaneous Coronary Intervention
Objectives The aim of this study was to characterize and
evaluate the clinical impact of untreated atherosclerotic
disease after percutaneous coronary intervention (PCI) in
patients with acute coronary syndromes (ACS).
Background Residual atherosclerotic disease after successful
PCI may predispose future major adverse cardiovascular
events (MACE). Compared with intravascular ultrasound
(IVUS), angiography underestimates the presence and
severity of coronary artery disease.
Methods Following successful PCI of all clinically signif-
icant lesions in 697 patients with ACS, 3-vessel grayscale
and radiofrequency IVUS was performed. Lesions were
prospectively characterized, and patients were followed for
a median of 3.4 years. A total of 3,229 untreated lesions
(4.89  1.98 lesions/patient) were identiﬁed by IVUS, with
mean plaque burden (PB) of 49.6  4.2%.
Results By angiography these nonculprit lesions were
mild, with mean diameter stenosis of 38.9  15.3%. At
least 1 lesion with a PB 70% (PB70 lesion) was found in
220 (33%) patients. By multivariable analysis, a history of
prior PCI and angiographic 3-vessel disease were inde-
pendent predictors of PB70 lesions. Patients with PB70
lesions had greater total percent plaque volume, normal-
ized PB, ﬁbroatheromas, thin-cap ﬁbroatheromas, and
normalized volumes of necrotic core and dense calcium.
Patients with PB70 lesions had greater 3-year rates of
MACE due to untreated nonculprit lesions (20.8% vs.
7.7%, p < 0.0001). Among imaged nonculprit lesions, the
proportion of PB70 lesions causing MACE was signiﬁ-
cantly greater than non-PB70 lesions (8.7% vs. 1.0%, p <
0.0001).
Conclusions After successful PCI of all angiographically
signiﬁcant lesions, overall untreated atherosclerotic burden
remains high, and PB70 lesions are frequently present in the
proximal and mid-coronary tree. Patients with PB70 lesions
have greater atherosclerosis throughout the coronary tree,
have more thin-cap ﬁbroatheromas, and are at increased risk
for future cardiovascular events. (PROSPECT: An Imaging
Study in Patients With Unstable Atherosclerotic Lesions;
NCT00180466) (201).
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Necrotic Core–Rich Plaques in Nonculprit Lesions
of Patients Presenting With Acute Coronary
Syndromes
Objectives In this substudy of the PROSPECT (Providing
Regional Observations to Study Predictors of Events in the
Coronary Tree) study, we examined the longitudinal
distribution of atherosclerotic plaque burden, virtual
histology–intravascular ultrasound (VH-IVUS) character-
ized necrotic core (NC) content and VH–thin-cap ﬁbroa-
theroma (TCFA) distribution in nonculprit lesions of
patients presenting with acute coronary syndromes.
Background Previous analyses suggested that vulnerable
plaques and acute myocardial infarction may occur more
frequently in the proximal than the distal coronary tree.
Methods A total of 4,234 proximal, mid, and distal 30-
mm-long segments of each epicardial coronary artery were
compared with each other and to the left main coronary
artery (LMCA).
Results Combining IVUS data from all 3 arteries, there
was a gradient in plaque burden from the proximal (42.4%)
to mid (37.6%) to distal (32.6%) 30-mm-long segments
(p < 0.0001). Overall, 67.4% of proximal, 41.0% of mid,
and 29.7% of distal 30-mm-long segments contained at least
1 lesion (plaque burden >40%). Proportion of NC, however,
was similar in the proximal and mid 30-mm-long segments
of all arteries (10.3% [interquartile range (IQR): 4.8% to
16.7%] vs. 10.6% [IQR: 5.0% to 18.1%], p ¼ 0.25), but less
in the distal 30-mm-long segment (9.1% [IQR: 3.7% to
17.8%], p ¼ 0.03 compared with the proximal segment and
p ¼ 0.003 compared with the mid segment). Overall, 17.3%
of proximal, 11.5% of mid, and 9.1% of distal 30-mm-long
segments had at least 1 lesion that was classiﬁed as VH-
TCFA (p < 0.0001). Comparing the LMCA with the
combined cohort of proximal left anterior descending, left
circumﬂex, and right coronary artery 30-mm-long segments:
1) plaque burden was less (35.4% [IQR: 28.8% to 43.5%] vs.
40.9% [IQR: 33.3% to 48.0%], p < 0.0001); 2) fewer
LMCAs contained at least 1 lesion (17.5%, p < 0.0001); 3)
there was less NC (6.5% [IQR: 2.9% to 12.2%] vs. 9.3%
[IQR: 4.3% to 15.9%], p < 0.0001); and 4) LMCAs rarely
contained a VH-TCFA (1.8%, p < 0.0001).
Conclusions The current analysis appears to conﬁrm that
lesions that are responsible for acute coronary events (large,
plaque burden–rich in NC) are somewhat more likely to be
present in the proximal than the distal coronary tree, except
for the LMCA (202).Plaque Composition and Clinical Outcomes in
Acute Coronary Syndrome Patients With Metabolic
Syndrome or Diabetes
Objectives The goal of this study was to characterize the
extent and composition of coronary atherosclerosis in
patients with diabetes mellitus or the metabolic syndrome(Met Syn) presenting with acute coronary syndromes
(ACS).
Background Diabetes and Met Syn patients have increased
rates of major adverse cardiac events (MACE), yet
a systematic description of nonculprit lesions for these high-
risk groups is incomplete.
Methods In the PROSPECT (Providing Regional
Observations to Study Predictors of Events in the Coronary
Tree) study, ACS patients underwent 3-vessel quantitative
coronary angiography, grayscale, and radiofrequency intra-
vascular ultrasound after successful percutaneous coronary
intervention (PCI). Subsequent MACE (cardiac death or
arrest, myocardial infarction, or rehospitalization for
unstable or progressive angina) were adjudicated to the
originally treated culprit versus untreated nonculprit lesions
in 3 patient groups: 1) diabetes; 2) Met Syn; and 3) neither.
Median length of follow-up was 3.4 years.
Results Of 673 patients, 119 (17.7%) had diabetes and 239
(35.5%) had Met Syn. The cumulative 3-year MACE rate
was 29.4% in patients with diabetes, 21.3% with Met Syn,
and 17.4% with neither (p ¼ 0.03). MACE adjudicated to
untreated nonculprit lesions occurred in 18.7%, 11.7%, and
9.7% of patients, respectively (p ¼ 0.06). Nonculprit lesions
in diabetes and Met Syn patients were longer and had
greater plaque burden, smaller lumen areas, with greater
necrotic core and calcium content. Diabetes and Met Syn
patients with future MACE had greater necrotic core and
calciﬁcation compared with the normal cardiometabolic
group.
Conclusions In this PCI ACS population, patients with
diabetes and Met Syn had higher 3-year MACE rates.
Lesion length, plaque burden, necrotic core, and calcium
content were signiﬁcantly greater among nonculprit lesions
of patients with diabetes and Met Syn, but only necrotic core
and calcium were signiﬁcantly greater in the nonculprit
lesions of patients with a future MACE in this exploratory
analysis (203).Natural History of Coronary Atherosclerosis by
Multislice Computed Tomography
Objectives This study sought to analyze the natural history
of coronary atherosclerosis by multislice computed tomog-
raphy (MSCT) and assess the serial changes in coronary
plaque burden, lumen dimensions, and arterial remodeling.
Background MSCT can comprehensively assess coronary
atherosclerosis by combining lumen and plaque size
parameters.
Methods Thirty-two patients with acute coronary
syndromes underwent 64-slice computed tomography
angiography after percutaneous coronary intervention at
baseline and after a median of 39 months. All patients
received contemporary medical treatment. All available
coronary segments in every subject were analyzed. The
progression of atherosclerosis per segment and per patient
was assessed by means of change in percent atheroma
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(TAVnorm), and percent change in TAV (% change in
TAV). Serial coronary remodeling was also assessed.
Measures of lumen stenosis included percent diameter
stenosis (%DS), minimum lumen diameter (MLD), percent
area stenosis (%AS), and minimum lumen area (MLA). For
each patient, the mean of all matched segments was calcu-
lated at the 2 time points. Clinical events at follow-up were
documented.
Results The PAV did not change signiﬁcantly (0.15 
3.64%, p ¼ 0.72). The mean change in TAVnorm was
47.36  143.24 mm3 (p ¼ 0.071), and the % change in
TAV was 6.7% (p ¼ 0.029). The MLD and MLA increased
by 0.15 mm (0.09 to 0.24, p ¼ 0.039) and 0.52 mm2
(0.38 to 1.04, p ¼ 0.034) respectively, which was
accompanied by vessel enlargement, with 53% of the
patients showing expansive positive remodeling. Patients
with clinical events had a larger TAVnorm at baseline
(969.72 mm3 vs. 810.77 mm3, p ¼ 0.010).
Conclusions MSCT can assess the progression of coronary
atherosclerosis and may be used for noninvasive monitoring
of pharmacological interventions in coronary artery disease.
(PROSPECT: An Imaging Study in Patients With
Unstable Atherosclerotic Lesions; NCT00180466) (204).Relationship Between Palpography and Virtual
Histology in Patients With Acute Coronary
Syndromes
Objectives The purpose of this study was to correlate
adverse events at long-term follow-up in patients after an
acute coronary syndrome with coronary plaque characteris-
tics derived from simultaneous evaluation of their mechan-
ical and compositional properties using virtual histology
(intravascular ultrasound virtual histology) and palpography.
Background Fibroatheroma is the plaque morphology with
the highest risk of causing adverse cardiac events. Palpog-
raphy can potentially assess the local mechanical plaque
properties with the possibility of identifying ﬁbroatheroma
with the highest risk of rupture.
Methods A total of 114 patients with acute coronary
syndrome from the PROSPECT (Providing Regional
Observations to Study Predictors of Events in the Coronary
Tree) trial underwent a single ultrasound imaging investi-
gation of their 3 coronary vessels with the co-registration of
intravascular ultrasound virtual histology and palpography.
Major adverse cardiac events (MACE) (cardiac death,
cardiac arrest, myocardial infarction, or unstable or
progressive angina) were collected up to a median follow-up
of 3.4 years and adjudicated to originally treated culprit
versus untreated nonculprit lesions.
Results In total, 488 necrotic core–rich plaques were iden-
tiﬁed and subclassiﬁed as thin-cap ﬁbroatheroma (n ¼ 111),
calciﬁed thick-cap ﬁbroatheroma (n¼ 213), and noncalciﬁed
thick-cap ﬁbroatheroma (n ¼ 164) and matched to their co-
registered palpography data. A total of 16 MACE,adjudicated to untreated nonculprit lesions, were recorded at
follow-up. In patients in whom MACE developed, ﬁbroa-
theroma were larger (plaque area 10.0 mm2 [range: 8.4 to
11.6 mm2] vs. 8.2 mm2 [range: 7.7 to 8.8 mm2] (p ¼ 0.03)
compared with patients who were MACE free. By palpog-
raphy, the maximum and the density strain values did not
differ between the varying subtypes of ﬁbroatheroma of
patients with or without MACE during follow-up.
Conclusions In acute coronary syndromes, patients treated
with stents and contemporary pharmacotherapy, palpog-
raphy did not provide additional diagnostic information for
the identiﬁcation of ﬁbroatheroma with a high risk of
rupture and MACE during long-term follow-up. (Providing
Regional Observations to Study Predictors of Events in
the Coronary Tree [PROSPECT]: An Imaging Study
in Patients With Unstable Atherosclerotic Lesions;
NCT00180466) (205).Adverse Cardiovascular Events Arising From
Atherosclerotic Lesions With and Without
Angiographic Disease Progression
Objectives The aim of this study was to use angiography
and grayscale and intravascular ultrasound–virtual histology
to assess coronary lesions that caused events during a median
follow-up period of 3.4 years.
Background Vulnerable plaque-related events are assumed
to be the result of substantial progression of insigniﬁcant
lesions.
Methods In the PROSPECT (Providing Regional
Observations to Study Predictors of Events in the Coronary
Tree) study, 697 patients with acute coronary syndromes
underwent treatment of all culprit lesions followed by
3-vessel imaging to assess the natural history of culprit and
untreated nonculprit (NC) lesions. Future adverse cardio-
vascular events adjudicated to NC lesions were divided into
those with versus without substantial lesion progression
(SLP) (20% angiographic diameter stenosis increase).
Results NC lesion events occurred in 72 patients, 44 (61%)
with and 28 (39%) without SLP. Myocardial infarctions
(n ¼ 6) occurred only in patients with SLP. Conversely,
patients without SLP presented only with unstable or
increasing angina requiring rehospitalization. Lesions with
versus without SLP occurred later (median time to event 401
vs. 223 days, p ¼ 0.07); were less severe at baseline (median
diameter stenosis 26.4% vs. 53.8%, p < 0.0001) but more
severe at the time of the event (mean diameter stenosis
73.8% vs. 56%, p < 0.0001); and had comparable baseline
median plaque burden (68.7% vs. 70.1%, p ¼ 0.17),
minimum luminal area (3.7 vs. 4.0 mm2, p ¼ 0.60), and
intravascular ultrasound–virtual histology phenotype (83.3%
vs. 90.9%, p ¼ 0.68; classiﬁed as ﬁbroatheromas at baseline).
Conclusions NC lesions responsible for future cardiovas-
cular events showed angiographic increase during 3.4 years
of follow-up, whereas SLP underlay many but not all of
them. NC events due to lesions with SLP were
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time course but were otherwise indistinguishable from NC
events that were not associated with SLP (206).Plaque Composition by Intravascular Ultrasound
and Distal Embolization After Percutaneous
Coronary Intervention
Distal embolization after percutaneous coronary intervention
occurs in 15% to 70% of patients, depending on the sensitivity
of the diagnostic modality used, and is associated with a poor
prognosis after elective and primary percutaneous coronary
intervention. It has been hypothesized that imaging of the
plaque composition can identify coronary artery lesions that
are predisposed to causing distal embolization. This review
report aims to summarize all currently available published
data on the use of assessment of atherosclerotic plaque
composition by virtual histology intravascular ultrasound
(VH-IVUS) to predict the occurrence of distal embolization.
A systematic review of the literature was performed. We
searchedMedline, ISIWeb of Knowledge, and the Cochrane
Library from January 2002 until March 2011. When a study
was found to be relevant, the manuscript was obtained and
reviewed. A total of 11 studies were identiﬁed investigating
the relationship between plaque composition assessed by
VH-IVUS and distal embolization. Although all studies used
the same equipment to perform and analyze VH-IVUS, there
was considerable heterogeneity in patient characteristics,
outcome deﬁnitions, and reporting of VH-IVUS ﬁndings.
Nevertheless, the necrotic core plaque componentdeither by
itself or as a constituent of a VH thin cap ﬁbroatheromadwas
associated with distal embolization in all but 2 of the 11
reviewed studies. Therefore, identiﬁcation of lesions with
large amounts of necrotic core on VH-IVUS could identify
lesions that might beneﬁt from the selective use of embolic
protection devices (207).Deﬁnitions and Methodology for the Grayscale and
Radiofrequency Intravascular Ultrasound and
Coronary Angiographic Analyses
Objectives In a prospective study of the natural history of
coronary atherosclerosis using angiography and grayscale
and radiofrequency intravascular ultrasound (IVUS)–virtual
histology (VH), larger plaque burden, smaller luminal area,
and plaque composition thin-cap ﬁbroatheroma emerged as
independent predictors of future adverse cardiovascular
events.
Background The methodology for IVUS-VH classiﬁcation
for an in vivo natural history study and the prospective image
mapping by angiography and grayscale and IVUS-VH have
not been established.
Methods All culprit and nonculprit lesions (deﬁned
as 30% angiographic visual diameter stenoses) were
analyzed. Three epicardial vessels as well as all 1.5-mm-
diameter side branches were divided into 29 CASS(Coronary Artery Surgery Study) segments. Each CASS
segment was then subdivided into 1.5-mm-long subseg-
ments, and dimensions were analyzed. All grayscale and
IVUS-VH slices from the proximal 6 to 8 cm of the 3
coronary arteries were analyzed, with lesions deﬁned as
having more than 3 consecutive slices with 40% plaque
burden categorized as: 1) VH thin-cap ﬁbroatheroma; 2)
thick-cap ﬁbroatheroma; 3) pathological intimal thickening;
4) ﬁbrotic plaque; or 5) ﬁbrocalciﬁc plaque. The locations of
angiographic and grayscale and IVUS-VH lesions were
recorded in relation to the corresponding coronary artery
ostium and nearby side branches.
Results The 3-year cumulative rate of major adverse
cardiovascular events was 20.4%. Events were adjudicated to
culprit lesions in 12.9% of patients and to nonculprit lesions
in 11.6%. On multivariate analysis, nonculprit lesions asso-
ciated with recurrent events were characterized by a plaque
burden 70% (hazard ratio: 5.03; 95% conﬁdence interval:
2.51 to 10.11; p < 0.0001), a minimal luminal area 4.0
mm2 (hazard ratio: 3.21; 95% conﬁdence interval: 1.61 to
6.42; p ¼ 0.001), and IVUS-VH phenotype of a thin-cap
ﬁbroatheroma (hazard ratio: 3.35; 95% conﬁdence interval:
1.77 to 6.36; p < 0.001).
Conclusions Three-vessel multimodality coronary artery
imaging was feasible and allowed the identiﬁcation of lesion-
level predictors for future events in this natural history study
(208).Characteristics and Clinical Signiﬁcance of
Angiographically Mild Lesions in Acute Coronary
Syndromes
Objectives The aim of this study was to assess whether
residual nonculprit (NC) lesions, deﬁned as visual diameter
stenosis 30% after successful percutaneous coronary
intervention, affect the rate of future events in patients with
acute coronary syndromes.
Background In patients with acute coronary syndromes,
approximately one-half of recurrent events after percuta-
neous coronary intervention arise from untreated lesions.
Methods Patients enrolled in PROSPECT (Providing
Regional Observations to Study Predictors of Events in the
Coronary Tree) were divided into 3 groups: those with no
NC lesions, 1 NC lesion, or 2 NC lesions. Time to events
for major adverse cardiac events was estimated up to 3 years.
Results Among 697 patients, 13.3% had no NC lesions,
19.7% had 1 NC lesion, and 67.0% had 2 NC lesions. The
median diameter stenoses of the NC lesions in the latter 2
groups were 36.7% (interquartile range: 31.0% to 43.4%)
and 37.4% (interquartile range: 32.0% to 46.5%), respec-
tively (p ¼ 0.22). At least 1 thin-cap ﬁbroatheroma was
present in one-half the patients in each group. At 3 years,
the incidence of major adverse cardiac events was 8.5%,
15.2%, and 24.3%, respectively (p ¼ 0.0009). NC lesion–
related events occurred in 0%, 5.0%, and 15.9% of patients,
respectively (p < 0.0001). Of 105 NC lesion–related clinical
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from angiographically evident baseline NC lesions (of which
36 had diameter stenosis >50%), while the other 32 arose
from normal or near normal segments.
Conclusions Residual NC lesions are common after
percutaneous coronary intervention for acute coronary
syndromes and portend a higher rate of recurrent ischemic
events within 3 years, especially when angiographically more
severe. Conversely, the absence of NC lesions by angiog-
raphy is highly predictive of freedom from events not related
to the originally treated culprit lesion(s) (209).
ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT
2012 Appropriate Use Criteria for Coronary
Revascularization Focused Update: A Report of the
American College of Cardiology Foundation
Appropriate Use Criteria Task Force, Society for
Cardiovascular Angiography and Interventions,
Society of Thoracic Surgeons, American
Association for Thoracic Surgery, American Heart
Association, American Society of Nuclear
Cardiology, and the Society of Cardiovascular
Computed Tomography
The American College of Cardiology Foundation (ACCF),
Society for Cardiovascular Angiography and Interventions,
Society of Thoracic Surgeons, and the American Association
for Thoracic Surgery, along with key specialty and subspe-
cialty societies, conducted an update of the appropriate use
criteria (AUC) for coronary revascularization frequently
considered. In the initial document, 180 clinical scenarios
were developed to mimic patient presentations encountered
in everyday practice and included information on symptom
status, extent of medical therapy, risk level as assessed by
noninvasive testing, and coronary anatomy. This update
provides a reassessment of clinical scenarios the writing
group felt to be affected by signiﬁcant changes in the
medical literature or gaps from prior criteria. The method-
ology used in this update is similar to the initial document,
and the deﬁnition of appropriateness was unchanged. The
technical panel scored the clinical scenarios on a scale of 1 to
9. Scores of 7 to 9 indicate that revascularization is
considered appropriate and likely to improve patients’ health
outcomes or survival. Scores of 1 to 3 indicate revasculari-
zation is considered inappropriate and unlikely to improve
health outcomes or survival. Scores in the mid-range (4 to 6)
indicate a clinical scenario for which the likelihood that
coronary revascularization will improve health outcomes or
survival is uncertain.
In general, as seen with the prior AUC, the use of
coronary revascularization for patients with acute coronary
syndromes and combinations of signiﬁcant symptoms and/
or ischemia is appropriate. In contrast, revascularization of
asymptomatic patients or patients with low-risk ﬁndings on
noninvasive testing and minimal medical therapy are viewed
less favorably. The technical panel felt that based on recentstudies, coronary artery bypass grafting remains an appro-
priate method of revascularization for patients with high
burden of coronary artery disease (CAD). Additionally,
percutaneous coronary intervention may have a role in
revascularization of patients with high burden of CAD. The
primary objective of the appropriate use criteria is to improve
physician decision making and patient education regarding
expected beneﬁts from revascularization and to guide future
research (210).Prognostic Value of Myocardial Viability by
Delayed-Enhanced Magnetic Resonance in
Patients With Coronary Artery Disease and Low
Ejection Fraction: Impact of Revascularization
Therapy
Objectives The purpose of this study was to evaluate the
impact of myocardial viability assessment by delayed-
enhanced cardiac magnetic resonance (DE-CMR) and of
revascularization therapy on survival in patients with coro-
nary artery disease (CAD) and low ejection fraction (EF).
Background Prior studies have shown that DE-CMR
predicts recovery of left ventricular (LV) dysfunction after
revascularization.
Methods The authors prospectively evaluated survival of
144 consecutive patients (130 males, age 65  11 years) with
CAD and LV dysfunction (EF: 24  7%) undergoing DE-
CMR. Eighty-six patients underwent complete revasculari-
zation of dysfunctional myocardium (79 coronary artery
bypass grafting, 7 percutaneous coronary intervention),
whereas 58 patients remained under medical treatment.
Results Over the 3-year median follow-up, 49 patients
died. Three-year survival was signiﬁcantly worse in medi-
cally treated patients with dysfunctional viable than with
nonviable myocardium (48% vs. 77% survival, p ¼ 0.02).
By contrast, in revascularized patients, survival was similar
whether myocardium was viable or not (88% and 71%
survival, respectively, p ¼ NS). Hazard of death of viable
myocardium remaining under medical treatment versus
complete revascularization was 4.56 (95% conﬁdence
interval [CI]: 1.93 to 10.8). Cox multivariate analysis
indicated that interaction of revascularization and viability
provided signiﬁcant additional value (chi-square test ¼
13.1, p ¼ 0.004) to baseline predictors of survival (New
York Heart Association functional class, wall motion score,
and peripheral artery disease). More importantly, in 43
pairs of propensity score–matched patients, hazard of
death (hazard ratio: 2.5 [95% CI: 1.1 to 6.1], p ¼ 0.02)
remained signiﬁcantly higher for medically treated patients
rather than for those with fully revascularized viable
myocardium.
Conclusions Without revascularization, presence of
dysfunctional viable myocardium by DE-CMR is an inde-
pendent predictor of mortality in patients with ischemic LV
dysfunction. This observation may be useful for pre-
operative selection of patients for revascularization (211).
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After Successful Chronic Total Occlusion
Recanalization
Objectives The aim of our study was to assess coronary
vasomotion after successful revascularization of chronic total
occlusion (CTO).
Background It is largely unknown whether the recovery of
anterograde ﬂow after CTO recanalization with drug-
eluting stent implantation affects vascular function in distal
coronary segments.
Methods One hundred consecutive CTOs successfully
treated with drug-eluting stents underwent coronary diam-
eter measurement after intracoronary nitroglycerin injection
5, 20, and 35 mm distal to the stented coronary segment
using 3-dimensional quantitative coronary angiography. In
a subgroup of 14 patients, coronary vasomotion was tested in
distal segments: incremental atrial pacing for endothelium-
dependent cases; and intracoronary nitroglycerin injection
for endothelium-independent cases. In another subgroup of
13 patients, distal vessels were assessed by intracoronary
ultrasounds.
Results Vessel diameters signiﬁcantly increased at follow-
up as compared to baseline values (2.0  0.52 mm vs.
2.25  0.50 mm, 1.76  0.49 mm vs. 2.05  0.58 mm, 1.54
 0.53 mm vs. 2.04  0.58 mm, at each segment analyzed;
p < 0.001). At baseline, distal segments failed to respond to
both endothelium-dependent and -independent stimuli. At
follow-up, atrial pacing induced vasoconstriction, whereas
nitroglycerine administration resulted in signiﬁcant vasodi-
lation (p < 0.05). Intracoronary ultrasounds failed to show
changes of the cross-sectional area of distal segments at
follow-up angiography.
Conclusions Recanalization of CTO is followed by
a hibernation of vascular wall at distal coronary segments
that fail to respond to endothelium-dependent and -inde-
pendent stimuli. Distal vessel diameter increases over time in
the absence of positive remodeling and in spite of persistent
endothelial dysfunction. This severe impairment of vaso-
motor tone after CTO reopening suggests that intracoronary
ultrasound assessment is of paramount importance for the
selection of stent size (212).
Role of AV Nodal Ablation in Cardiac
Resynchronization in Patients With Coexistent
Atrial Fibrillation and Heart FailureA Systematic
Review
Objectives The aim of this study was to systematically
review the medical literature to evaluate the impact of AV
nodal ablation in patients with heart failure and coexistent
atrial ﬁbrillation (AF) receiving cardiac resynchronization
therapy (CRT).
Background CRT has a substantial evidence base in
patients in sinus rhythm with signiﬁcant systolic dysfunc-
tion, symptomatic heart failure, and prolonged QRS
duration. The role of CRT is less well established in AFpatients with coexistent heart failure. AV nodal ablation
has recently been suggested to improve outcomes in this
group.
Methods Electronic databases and reference lists through
September 15, 2010, were searched. Two reviewers inde-
pendently evaluated citation titles, abstracts, and articles.
Studies reporting the outcomes after AV nodal ablation in
patients with AF undergoing CRT for symptomatic heart
failure and left ventricular dyssynchrony were selected. Data
were extracted from 6 studies, including 768 CRT-AF
patients, composed of 339 patients who underwent AV
nodal ablation and 429 treated with medical therapy aimed
at rate control alone.
Results AV nodal ablation in CRT-AF patients was
associated with signiﬁcant reductions in all-cause mortality
(risk ratio: 0.42 [95% conﬁdence interval: 0.26 to 0.68]),
cardiovascular mortality (risk ratio: 0.44 [95% conﬁdence
interval: 0.24 to 0.81]), and improvement in mean New
York Heart Association functional class (risk ratio: –0.52
[95% conﬁdence interval: –0.87 to –0.17]).
Conclusions AV nodal ablation was associated with
a substantial reduction in all-cause mortality and cardio-
vascular mortality and with improvements in New York
Heart Association functional class compared with medical
therapy in CRT-AF patients. Randomized controlled trials
are warranted to conﬁrm the efﬁcacy and safety of AV nodal
ablation in this patient population (213).Prognostic Value of Myocardial Contrast Delayed
Enhancement With 64-Slice Multidetector
Computed Tomography After Acute Myocardial
Infarction
Objectives This study evaluated the clinical value of
myocardial contrast delayed enhancement (DE) with mul-
tidetector computed tomography (MDCT) for predicting
clinical outcome after acute myocardial infarction (AMI).
Background Although some studies have described the use
of MDCT for assessment of myocardial viability after AMI,
clinical experience remains limited.
Methods In 102 patients with ﬁrst AMI, 64-slice MDCT
without iodine reinjection was performed immediately
following successful percutaneous coronary intervention
(PCI). We measured the size of myocardial contrast DE on
MDCT and compared it with clinical outcome. Primary
composite cardiac events were cardiac death or hospitaliza-
tion for worsening heart failure.
Results Among the 102 patients (24  10 months follow-
up), 19 patients experienced primary composite cardiac
events (cardiac death, n ¼ 7; heart failure, n ¼ 12). Kaplan-
Meier analysis showed higher risk of cardiac events for
patients in the third tertile of myocardial contrast DE size
(36 g) than for those in the other 2 tertiles (p < 0.0001).
Multivariable Cox proportional hazards regression analysis
indicated that myocardial contrast DE size (adjusted
hazard ratio [HR] for tertile 3 vs. 1: 16.1, 95% conﬁdence
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3 vs. 2: 5.06, 95% CI: 1.25 to 22.7, p ¼ 0.039) was
a signiﬁcant independent predictor for cardiac events after
adjustment for Thrombolysis In Myocardial Infarction
risk score, left ventricular ejection fraction, total defect
score on single-photon emission CT with technetium
tetrofosmin, and transmural extent of myocardial contrast
DE on MDCT.
Conclusions Myocardial contrast DE size on MDCT
immediately after primary PCI may provide promising
information for predicting clinical outcome in patients with
AMI (214).Characteristics and Long-Term Outcomes of
Percutaneous Revascularization of Unprotected
Left Main Coronary Artery Stenosis in the United
StatesA Report From the National Cardiovascular
Data Registry, 2004 to 2008
Objectives This study sought to assess percutaneous
coronary intervention (PCI) for unprotected left main
coronary artery (ULMCA) stenosis in routine U.S. clinical
practice.
Background Percutaneous coronary intervention for
ULMCA stenosis is controversial; however, current use and
outcomes of ULMCA PCI in routine U.S. clinical practice
have not been described.
Methods We evaluated 5,627 patients undergoing
ULMCA PCI at 693 centers within the National Cardio-
vascular Data Registry Catheterization Percutaneous Coro-
nary Intervention Registry for temporal trends in PCI use
(2004 to 2008), patient characteristics, and in-hospital
mortality. Thirty-month mortality and composite major
adverse events (death, myocardial infarction, and revascu-
larization) with drug-eluting versus bare-metal stents were
compared using inverse probability weighted (IPW) hazard
ratios (HRs) in a nonrandomized Medicare-linked (age 65
years) patient cohort (n ¼ 2,765).
Results ULMCA PCI was performed in 4.3% of patients
with ULMCA stenosis. Unadjusted in-hospital mortality
rates ranged from 2.9% for elective cases to 45.1% for
emergent/salvage cases. By 30 months, 57.9% of the elderly
ULMCA PCI population experienced death, myocardial
infarction, or revascularization, and 42.7% died. Patients
receiving drug-eluting stents (versus bare-metal stents) had
a lower 30-month mortality (IPW HR: 0.84, 95% conﬁ-
dence interval [CI]: 0.73 to 0.96), but the composite of
major adverse events were similar (IPW HR: 0.95, 95% CI:
0.84 to 1.06).
Conclusions In the United States, ULMCA PCI is per-
formed in <5% of patients with ULMCA disease and is
generally reserved for those at high procedural risk. Adverse
events are common in elderly patients and are related to
patient and procedural characteristics, including stent type
(215).Sex-Related Differences in Clinical Presentation
and Outcome of Transcatheter Aortic Valve
Implantation for Severe Aortic Stenosis
Objectives The purpose of this study was to clarify the
impact of sex-related differences in transcatheter aortic valve
implantation (TAVI) for high-risk patients with severe
aortic stenosis.
Background Although TAVI is becoming a mature tech-
nique, the impact of sex differences remains unclear.
Methods The TAVI patients were included prospectively
in a dedicated database from October 2006. The propor-
tion of women (n ¼ 131) was similar to that of men (n ¼
129). The Edwards valve (85.4%) and CoreValve (14.6%)
were used through the transfemoral (65.0%), subclavian
(3.1%), or transapical (31.9%) approach. All events were
deﬁned according to Valve Academic Research Consor-
tium criteria.
Results Age was similar (83.1  6.3 years), but women
had less coronary and peripheral disease, less previous
cardiac surgery, higher ejection fraction, and lower Euro-
SCORE (European System for Cardiac Operative Risk
Evaluation [22.3  9.0% vs. 26.2  13.0%, p ¼ 0.005]).
Minimal femoral size (7.74  1.03 mm vs. 8.55  1.34
mm, p < 0.001), annulus size (20.9  1.4 vs. 22.9  1.7
mm, p < 0.001), and valve size (23.9  1.6 mm vs. 26.3
 1.5 mm, p < 0.001) were smaller in women. Device
success was similar (90.8% vs. 88.4%, p ¼ 0.516) despite
more frequent iliac complications (9.0% vs. 2.5%, p ¼
0.030). Residual mean aortic pressure gradient (11.6  4.9
vs. 10.9  4.9, p ¼ 0.279) was also similar. The 1-year
survival rate was higher for women, 76% (95% conﬁ-
dence interval: 72% to 80%), than for men, 65% (95%
conﬁdence interval: 60% to 69%); and male sex (hazard
ratio: 1.62, 95% conﬁdence interval: 1.03 to 2.53, p ¼
0.037) was identiﬁed as a predictor of midterm mortality
by Cox regression analysis.
Conclusions Female sex is associated with better baseline
clinical characteristics and improved survival, and is identi-
ﬁed as a predictor of midterm survival after TAVI (216).Impact of Statin Therapy on Plaque Characteristics
as Assessed by Serial OCT, Grayscale and
Integrated Backscatter–IVUS
Objectives The purpose of this study was to evaluate the
effect of statin treatment on coronary plaque composition
and morphology by optical coherence tomography (OCT),
grayscale and integrated backscatter (IB) intravascular
ultrasound (IVUS) imaging.
Background Although previous studies have demonstrated
that statins substantially improve cardiac mortality, their
precise effect on the lipid content and ﬁbrous cap thickness
of atherosclerotic coronary lesions is less clear. While IVUS
lacks the spatial resolution to accurately assess ﬁbrous cap
thickness, OCT lacks the penetration of IVUS. We used
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comprehensively assess the impact of pitavastatin on plaque
characteristics.
Methods Prospective serial OCT, grayscale and IB-IVUS
of nontarget lesions was performed in 42 stable angina
patients undergoing elective coronary intervention. Of
these, 26 received 4 mg pitavastatin after the baseline
study; 16 subjects who refused statin treatment were
followed with dietary modiﬁcation alone. Follow-up
imaging was performed after a median interval of 9
months.
Results Grayscale IVUS revealed that in the statin-treated
patients, percent plaque volume index was signiﬁcantly
reduced over time (48.5  10.4%, 42.0  11.1%; p ¼
0.033), whereas no change was observed in the diet-only
patients (48.7  10.4%, 50.4  11.8%; p ¼ NS). IB-
IVUS identiﬁed signiﬁcant reductions in the percentage
lipid volume index over time (34.9  12.2%, 28.2  7.5%;
p ¼ 0.020); no change was observed in the diet-treated
group (31.0  10.7%, 33.8  12.4%; p ¼ NS). While
OCT demonstrated a signiﬁcant increase in ﬁbrous cap
thickness (140  42 mm, 189  46 mm; p ¼ 0.001), such
changes were not observed in the diet-only group (140  35
mm, 142  36 mm; p ¼ NS). Differences in the changes in
the percentage lipid volume index (6.8  8.0% vs. 2.8 
9.9%, p ¼ 0.031) and ﬁbrous cap thickness (52  32 mm vs.
2  22 mm, p < 0.001) over time between the pitavastatin
and diet groups were highly signiﬁcant.
Conclusions Statin treatment induces favorable plaque
morphologic changes with an increase in ﬁbrous cap thick-
ness, and decreases in both percentage plaque and lipid
volume indexes (217).
Percutaneous Coronary Intervention Use in the
United States: Deﬁning Measures of
Appropriateness
Appropriate utilization of percutaneous coronary inter-
vention (PCI) and medical therapy is deservedly a national
healthcare policy priority for the United States. Because
PCI is both common and costly, appraisal of appropri-
ateness is warranted. The initial appropriate use criteria
(AUC) have been developed for coronary revascularization
procedures and investigators recently reported the appro-
priateness for the approximately 500,000 PCI procedures
performed at centers participating in the National
Cardiovascular Data Registry. The AUC have broad
implications for both healthcare providers and our patients
and will be used as the basis for indications, referral
patterns, treatment options, physician education, shared
decision-making, and reimbursement for years to come.
While we acknowledge the importance of thoughtfully
assessing appropriateness for all medical procedures
including PCI, there are a number of concerns with the
current AUC and methods used to report appropriateness
that warrant expanded commentary (218).Principles of Percutaneous Paravalvular Leak
Closure
Paravalvular regurgitation affects 5% to 17% of all surgically
implanted prosthetic heart valves. Patients who have para-
valvular regurgitation can be asymptomatic or present with
hemolysis or heart failure, or both. Reoperation is associated
with increased morbidity and is not always successful
because of underlying tissue friability, inﬂammation, or
calciﬁcation. Comprehensive echocardiographic imaging
with transthoracic and real-time 3-dimensional trans-
esophageal echocardiography is key for characterizing the
defect location, size, and shape. For paramitral defects, an
antegrade transseptal approach can usually be guided by
biplane ﬂuoroscopy, and real-time 3-dimensional trans-
esophageal echocardiography can usually be performed
successfully. Alternative approaches to paramitral defects
include retrograde transaortic cannulation or transapical
access and retrograde cannulation. For oblong or crescentic
defects, the simultaneous or sequential deployment of 2
smaller devices, as opposed to 1 large device, results in
a higher degree of procedural success and safety because the
risk of impingement on the prosthetic leaﬂets is minimized.
Most para-aortic defects can be approached in a retrograde
manner and closed with a single device. With careful
anatomical assessment, procedural planning, and procedural
execution, successful closure rates of 90% or more should be
attainable with a low risk of device impingement on the
prosthetic valve or embolization (219).Long-Term Comparison of Everolimus- and
Sirolimus-Eluting Stents in Patients With Acute
Coronary Syndromes
Objectives The goal of this study was to compare the long-
term clinical outcome between everolimus-eluting stent
(EES) and sirolimus-eluting stent (SES) in patients with
acute coronary syndromes (ACS).
Background EES have not been directly compared with
SES in ACS patients to date.
Methods Between 2004 and 2009, 1,746 consecutive ACS
patients (ST-segment elevation ACS [STE-ACS]: 33.5%;
non–ST-segment elevation ACS [NSTE-ACS]: 66.5%)
were treated with EES (n ¼ 903) or SES (n ¼ 843). Using
propensity score matching, clinical outcome was compared
among 705 matched pairs of ACS patients treated with EES
and SES.
Results Through 3 years, the primary endpointdthe
composite of death, myocardial infarction (MI), and target
vessel revascularization (TVR)doccurred in 13.8% of EES-
and 17.7% of SES-treated ACS patients (hazard ratio [HR]:
0.72, 95% conﬁdence interval [CI]: 0.54 to 0.95, p ¼ 0.02).
The difference in favor of EES was driven by a lower risk of
TVR (5.7% vs. 8.8%, HR: 0.65, 95% CI: 0.43 to 0.98, p ¼
0.04) and a trend toward a lower risk of MI (2.1% vs. 3.3%,
HR: 0.56, 95% CI: 0.29 to 1.12, p ¼ 0.10). The risk of
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0.14) showed no difference between EES and SES. The
treatment effect in favor of EES for the primary endpoint
was similar for patients with STE-ACS (16.4% vs. 18.5%,
HR: 0.80, 95% CI: 0.50 to 1.27) and NSTE-ACS (12.4%
vs. 17.3%; HR: 0.67, 95% CI: 0.47 to 0.96; pfor interaction ¼
0.56) and across major subgroups. Deﬁnite (0.4% vs. 1.8%,
p ¼ 0.03), and deﬁnite or probable stent thrombosis (3.4%
vs. 6.1%, p ¼ 0.02) were less frequent among EES- than
SES-treated ACS patients.
Conclusions Among patients with ACS, the unrestricted
use of EES is associated with improved clinical outcome
compared with SES during long-term follow-up to 3 years.
Notably, the risk of stent thrombosis was lower among
EES-treated ACS patients (220).Timing of Angiography With a Routine Invasive
Strategy and Long-Term Outcomes in Non–
ST-Segment Elevation Acute Coronary Syndrome:
A Collaborative Analysis of Individual Patient Data
From the FRISC II (Fragmin and Fast
Revascularization During Instability in Coronary
Artery Disease), ICTUS (Invasive Versus
Conservative Treatment in Unstable Coronary
Syndromes), and RITA-3 (Intervention Versus
Conservative Treatment Strategy in Patients With
Unstable Angina or Non-ST Elevation Myocardial
Infarction) Trials
Objectives This study sought to investigate long-term
outcomes after early or delayed angiography in patients
with non–ST-segment elevation acute coronary syndrome
(nSTE-ACS) undergoing a routine invasive management.
Background The optimal timing of angiography in patients
with nSTE-ACS is currently a topic for debate.
Methods Long-term follow-up after early (within 2 days)
angiography versus delayed (within 3 to 5 days) angiography
was investigated in the FRISC-II (Fragmin and Fast
Revascularization During Instability in Coronary Artery
Disease), ICTUS (Invasive Versus Conservative Treatment
in Unstable Coronary Syndromes), and RITA-3 (Interven-
tion Versus Conservative Treatment Strategy in Patients
With Unstable Angina or Non-ST Elevation Myocardial
Infarction) (FIR) nSTE-ACS patient-pooled database. The
main outcome was cardiovascular death or myocardial
infarction up to 5-year follow-up. Hazard ratios (HR) were
calculated with Cox regression models. Adjustments were
made for the FIR risk score, study, and the propensity of
receiving early angiography using inverse probability
weighting.
Results Of 2,721 patients originally randomized to the
routine invasive arm, consisting of routine angiography and
subsequent revascularization if suitable, 975 underwent
early angiography and 1,141 delayed angiography. No
difference was observed in 5-year cardiovascular death
or myocardial infarction in unadjusted (HR: 1.06, 95%conﬁdence interval [CI]: 0.79 to 1.42, p ¼ 0.61) and
adjusted (HR: 0.93, 95% CI: 0.75 to 1.16, p ¼ 0.54) Cox
regression models.
Conclusions In the FIR database of patients presenting
with nSTE-ACS, the timing of angiography was not
related to long-term cardiovascular mortality or myo-
cardial infarction. (Invasive Versus Conservative Treat-
ment in Unstable Coronary Syndromes [ICTUS];
ISRCTN82153174. Intervention Versus Conservative
Treatment Strategy in Patients With Unstable Angina or
Non-ST Elevation Myocardial Infarction [the Third
Randomised Intervention Treatment of Angina Trials
(RITA-3)]; ISRCTN07752711) (221).Functional Assessment of Jailed Side Branches in
Coronary Bifurcation Lesions Using Fractional Flow
Reserve
Objectives This study was designed to assess the functional
signiﬁcance of side branches after stent implantation in main
vessels using fractional ﬂow reserve (FFR).
Background Little is known about the functional signiﬁ-
cance of side branches after stent implantation in main
vessels in coronary bifurcation lesions.
Methods Between May 2007 and January 2011, 230 side
branches in 230 patients after stent implantation in main
vessels were assessed by FFR and were consecutively
enrolled.
Results Median FFR at the side branch was 0.91
(interquartile range: 0.85 to 0.95). There was a negative
correlation between the diameter stenosis (DS) by quan-
titative coronary angiography (QCA) and FFR of side
branch (r ¼ 0.21, p ¼ 0.002), but only 41 (17.8%) side
branches were functionally signiﬁcant after stent implan-
tation in the main vessel. Among 67 side branches with
>50% DS by QCA, 19 (28.4%) had FFR 0.80, and
among 163 side branches with 50% DS by QCA, 22
(13.5%) had FFR 0.80 after stent implantation in main
vessels. On the basis of receiver-operating characteristic
curves, the optimal cutoff value of DS by QCA of the side
branch was 54.9%, and the area under the curve was 0.64
(95% conﬁdence interval [CI]: 0.58 to 0.71, p < 0.001)
with a 41.5% sensitivity, an 83.1% speciﬁcity, a 34.7%
positive predictive value, an 86.3% negative predictive
value, and a 75.7% accuracy. Multivariate binary logistic
regression analysis identiﬁed DS by QCA (odds ratio
[OR]: 1.04, 95% CI: 1.02 to 1.06, p ¼ 0.001) and
reference vessel diameter (OR: 0.28, 95% CI: 0.10 to 0.77,
p ¼ 0.014) before stent implantation as independent
predictors of the side branches with FFR 0.80 after stent
implantation.
Conclusions Most side branch lesions do not have
functional signiﬁcance after stent implantation in the
main vessel, and quantitative coronary angiography is
unreliable in assessing the functional severity of these
lesions (222).
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Coronary Intervention-Related Ischemic Stroke
Objectives This study sought to determine whether
procedural factors during percutaneous coronary interven-
tion (PCI) are associated with the occurrence of ischemic
stroke or transient ischemic attack (PCI-stroke).
Background Stroke is a devastating complication of PCI.
Demographic predictors are nonmodiﬁable. Whether PCI-
stroke is associated with procedural factors, which may be
modiﬁable, is unknown.
Methods We performed a single-center retrospective study
of 21,497 PCI hospitalizations between 1994 and 2008. We
compared procedural factors from patients who suffered an
ischemic stroke or transient ischemic attack related to PCI
(n ¼ 79) and a control group (n ¼ 158), and matched them
2:1 based on a predicted probability of stroke developed
from a logistic regression model.
Results PCI-stroke procedures involved the use of more
catheters (median: 3 [quarter (Q) 1, Q3: 3, 4] vs. 3 [Q1, Q3:
2, 3], p < 0.001), greater contrast volumes (250 ml vs. 218
ml, p ¼ 0.006), and larger guide caliber (median: 7-F [Q1,
Q3: 6, 8] vs. 6-F [Q1, Q3: 6, 8], p < 0.001). The number of
lesions attempted (1.7  0.8 vs. 1.5  0.8, p ¼ 0.14) and
stents placed (1.4  1.2 vs. 1.2  1.1, p ¼ 0.35) were similar
between groups, but PCI-stroke patients were more likely to
have undergone rotational atherectomy (10% vs. 3%, p ¼
0.029). Overall procedural success was lower in the PCI-
stroke group compared with controls (71% vs. 85%, p ¼
0.017). Evaluation of the entire PCI population revealed no
difference in the rate of PCI-stroke between radial and
femoral approaches (0.4% vs. 0.4%, p ¼ 0.78).
Conclusions Ischemic stroke related to PCI is associated
with potentially modiﬁable technical parameters. Careful
procedural planning is warranted, particularly in patients at
increased risk (223).
Clinical Presentation, Management, and Outcomes
of Angiographically Documented Early, Late, and
Very Late Stent Thrombosis
Objectives The aim of this study was to describe differ-
ences in treatment and in-hospital mortality of early, late,
and very late stent thrombosis (ST).
Background Early, late, and very late ST may differ in
clinical presentation, management, and in-hospital
outcomes.
Methods We analyzed deﬁnite (angiographically docu-
mented) ST cases identiﬁed from February 2009 to June
2010 in the CathPCI Registry. We stratiﬁed events by
timing of presentation: early (1 month), late (1 to 12
months), or very late (12 months) following stent
implantation. Multivariable logistic regression modeling was
performed to compare in-hospital mortality for each type of
ST after adjusting for baseline comorbidities.
Results During the study period, 7,315 ST events were
identiﬁed in 7,079 of 401,662 patients (1.8%) presentingwith acute coronary syndromes. This ST cohort consisted
of 1,391 patients with early ST (19.6%), 1,370 with late
ST (19.4%), and 4,318 with very late ST (61.0%). Subjects
with early ST had a higher prevalence of black race and
diabetes, whereas subjects with very late ST had a higher
prevalence of white race and a lower prevalence of prior
myocardial infarction or diabetes. In-hospital mortality was
signiﬁcantly higher in early ST (7.9%) compared with late
(3.8%) and very late ST (3.6%, p < 0.001). This lower
mortality for late and very late ST persisted after multi-
variable adjustment (odds ratio: 0.53 [95% conﬁdence
interval (CI): 0.36 to 0.79] and 0.58 [95% CI: 0.43 to
0.79], respectively).
Conclusions Signiﬁcant differences exist in the presenta-
tion and outcomes of early, late, and very late ST. Among
patients with acute coronary syndromes who are undergoing
percutaneous coronary intervention for angiographically
documented ST, early ST is associated with the highest in-
hospital mortality (224).Endothelial and Smooth Muscle Cells Dysfunction
Distal to Recanalized Chronic Total Coronary
Occlusions and the Relationship With the
Collateral Connection Grade
Objectives This study sought to assess the vascular func-
tion in patients with chronic total coronary occlusions
(CTO) immediately after successful percutaneous recanali-
zation and its relation with the pre-existing collateral
circulation.
Background CTOs represent a long-acting occlusion of
a coronary vessel, in which the progressively developed
collateral circulation may limit ischemia and symptoms.
However, it is unknown if the coronary segment distal to the
occlusion has a preserved vascular function.
Methods We prospectively enrolled 19 consecutive patients,
after percutaneous coronary intervention of a CTO. Luminal
diameter, measured by quantitative coronary angiography,
and coronary blood ﬂow at level of epicardial coronary artery
distal to the treated CTO was assessed before and after
administration of acetylcholine (Ach), adenosine, and nitro-
glycerin (NTG). Collaterals were assessed angiographically
by grading of Rentrop and of collateral connections (CC1:
threadlike continuous connection; CC2: side branch–like
connection).
Results Overall, Ach and adenosine caused coronary artery
vasoconstriction (p ¼ 0.001 and p ¼ 0.004, respectively),
whereas NTG failed to induce vasodilation (p ¼ 0.084).
Coronary blood ﬂow signiﬁcantly decreased with Ach (p ¼
0.005), signiﬁcantly increased with NTG (p ¼ 0.035), and
did not change with adenosine (p ¼ 0.470). Patients with
CC2 collaterals (n ¼ 8) had less vasoconstriction response
and reduction in coronary blood ﬂow after Ach (p ¼ 0.005
and p ¼ 0.008, respectively), and better vasomotor response
to NTG (p ¼ 0.029) than patients with CC1 collaterals
(n ¼ 11).
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dysfunction is present in the distal segments of successfully
recanalized CTOs, and that seems to be more pronounced
in the presence of a low grading of collateral circulation
(225).
Patient Safety and Outcomes From Live Case
Demonstrations of Interventional Cardiology
Procedures
Objectives The goal of this study was to examine the safety
and results of interventional procedures performed during
the broadcast of live case demonstrations.
Background Professional meetings using live case demon-
strations to present cutting-edge technology are considered
a valuable educational resource. There is an ongoing
discussion on whether patients who are treated during live
case demonstrations are exposed to a higher risk.
Methods Between 1998 and 2010, 101 patients were
treated during live transmissions from a single center in 15
invasive-cardiology conferences. Technical success was
deﬁned as the ability to effectively perform the planned
procedure without any major complication. The primary
endpoint of the study was the composite occurrence of
death, myocardial infarction, or stroke.
Results The interventional procedures included coronary
(n ¼ 66), carotid (n ¼ 15), peripheral (n ¼ 1), valvular (n ¼
2), congenital heart disease (n ¼ 12), and complex electro-
physiological mapping and ablation interventions (n ¼ 7). In
4 cases, the intended procedure was not done. The proce-
dure was technically successful in 95%. In 5 cases, the
procedure was unsuccessful because of the inability to cross
a chronic total occlusion. There were no deaths during the
hospital stay, and the composite primary endpoint occurred
in 2 patients: a minor stroke following an atrial ﬁbrillation
ablation and a rise in serum troponin levels after percuta-
neous coronary intervention. These results were no different
from those of 66 matched controls who underwent proce-
dures performed by the same operators but not as live case
demonstrations (relative risk: 0.32; 95% conﬁdence interval:
0.02 to 3.62, p ¼ 0.62).
Conclusions In this consecutive series of interventional
cardiology procedures that were performed by expert oper-
ators during live demonstration courses, the procedural and
30-day clinical outcomes were similar to those found in daily
practice and to those that have been reported in the
contemporary published data. These results suggest that
broadcasting live case demonstrations in selected patients
from selected centers may be safe (226).
Protective Effect of Telmisartan Against
Endothelial Dysfunction After Coronary Drug-
Eluting Stent Implantation in Hypertensive
Patients
Objectives The aim of this prospective, randomized study
was to evaluate the effects of telmisartan, compared with thecalcium-channel blocker amlodipine, on endothelial func-
tion after coronary drug-eluting stent (DES) implantation in
hypertensive patients.
Background DES implantation impairs local endothelial
function, which may be associated with future cardiovascular
events. Telmisartan, which has unique peroxisome pro-
liferator-activated-receptor-gamma–mediated effects in
addition to its renin-angiotensin system–inhibition effects,
has favorable effects on endothelial function.
Methods Fifty-one hypertensive patients with coronary
artery stenosis but without coronary artery spasm, treated
with a sirolimus-eluting stent, were randomly assigned to
either the telmisartan (25 cases) or amlodipine (26 cases)
treatment groups. At baseline and at 3 months after DES
implantation, endothelium-dependent and -independent
vasomotion were evaluated by quantitative coronary angi-
ography under the condition of medication withdrawal. The
mean luminal diameter of a 20-mm coronary segment,
beginning 5 mm distal to the stent, was measured before and
after infusion of intracoronary acetylcholine (107, 106
mol/l) and then again after infusion of nitroglycerin.
Results Blood pressure was comparable between groups at
baseline and after 3 months. Vasoconstriction after acetyl-
choline infusion at 3 months (impaired endothelial function)
was less pronounced in the telmisartan group than in the
amlodipine group (p < 0.0001), although there was no
signiﬁcant difference between the 2 groups before DES
implantation. The response to nitroglycerin did not differ
between groups before or at 3 months after DES
implantation.
Conclusions Telmisartan, compared with amlodipine,
signiﬁcantly ameliorated endothelial dysfunction after DES
implantation in terms of vasoconstriction induced by
acetylcholine (227).No Evidence of “Obesity Paradox” After Treatment
With Drug-Eluting Stents in a Routine Clinical
Practice: Results From the Prospective
Multicenter German DES.DE (German Drug-Eluting
Stent) Registry
Objectives The aim of this study was to compare clinical
outcomes among unselected patients stratiﬁed in categories
of body mass index, who underwent percutaneous coronary
intervention (PCI) with either sirolimus-eluting or
paclitaxel-eluting stents.
Background Overweight and obesity are often considered
risk factors for cardiovascular events. However, recent
studies have associated obesity with better outcomes after
PCI with bare-metal stents. Data from routine clinical
practice using drug-eluting stents (DES) focusing on this
“obesity paradox” are not available.
Methods We used data from DES.DE (German Drug-
Eluting Stent) registry to compare in-hospital and 1-year
outcomes among unselected patients undergoing PCI with
DES implantation. Primary endpoints were the rate of
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(deﬁned as the composite of death, myocardial infarction,
and stroke) and target vessel revascularization (TVR).
Results Between October 2005 and 2006, 1,436 normal
weight, 2,839 overweight, and 1,531 obese patients treated
with DES were enrolled at 98 sites. Baseline clinical
parameters were more severe in overweight and obese
patients; 1-year follow-up comparison between groups
revealed similar rates of all-cause death (3.3% vs. 2.4% vs.
2.4%; p ¼ 0.17), MACCE (7.1% vs. 5.6% vs. 5.5%; p ¼
0.09), and TVR in survivors (10.9% vs. 11.7% vs. 11.6%;
p ¼ 0.56) in normal weight individuals compared with
overweight or obese patients. Such results persisted after
risk-adjustment for heterogeneous baseline characteristics of
groups and were independent of the types of DES.
Conclusions DES.DE revealed no evidence of “obesity
paradox” in a routine clinical practice using DES (228).True Percutaneous Approach for Transfemoral
Aortic Valve Implantation Using the Prostar XL
Device: Impact of Learning Curve on Vascular
Complications
Objectives The purpose of this study was to evaluate the
incidence of vascular complications and the predictors of
Prostar failure for a “true percutaneous approach” in trans-
femoral transcatheter aortic valve implantation (TAVI).
Background Safety and efﬁcacy of a true percutaneous
approach in transfemoral-TAVI has not been described in
a large prospective cohort.
Methods Among 264 patients included in our prospec-
tive TAVI database (October 2006 to December 2010),
transfemoral-TAVI was performed in 170 patients. True
percutaneous approach was performed in 142 consecutive
patients since March 2008. Successful closure with Prostar
was deﬁned as adequate hemostasis without Prostar-
related vascular complications. We compared the inci-
dence of vascular complications in our early and late
experience.
Results Patients were 83.0  7.2 years old and with
a EuroSCORE of 24.0  11.6%. The Edwards valve
(Edwards Lifesciences, Irvine, California) (18- to 24-F) was
used in 109 cases and the CoreValve (Medtronic, Minne-
apolis, Minnesota) (18-F) in 31. The sheath outer diameter
to minimal femoral diameter ratio (SFAR) was 0.96  0.14.
Successful closure was achieved in 90.7%, and was signiﬁ-
cantly increased (95.7% vs. 85.7%, p ¼ 0.047) in the late
experience group. Cross-over to surgery was required in
3.6%. Vascular complications occurred in 20.0%, and were
signiﬁcantly lower in the late experience group (11.4% vs.
28.6%, p ¼ 0.012). Major vascular complications (2.9% vs.
14.3%, p ¼ 0.018) were decreased in the late experience
group. Early experience (hazard ratio [HR]: 3.66, 95%
conﬁdence interval [CI]: 1.04 to 13.89, p ¼ 0.047) and
SFAR (HR: 110.80, 95% CI: 1.15 to 10,710.73, p ¼ 0.044)
predicted Prostar failure by univariate analysis.Conclusions Experience reduced major vascular complica-
tions in a true percutaneous approach for transfemoral-
TAVI. Further application of this less invasive strategy is
feasible and may be beneﬁcial, in this high-risk patient
cohort (229).Silent Ischemia: Clinical Relevance
Myocardial ischemia can occur without overt symptoms. In
fact, asymptomatic (or silent) ST-segment depression during
ambulatory electrocardiogram monitoring occurs more often
than symptomatic ST-segment depression in patients with
coronary artery disease. Initial studies documented that silent
ischemia provided independent prediction of adverse
outcomes in patients with known and unknown coronary
artery disease. The ACIP (Asymptomatic Cardiac Ischemia
Pilot Study) enrolled patients in the 1990s and found that
revascularization was better than medical therapy in reducing
silent ischemic episodes and possibly cardiovascular (CV)
events. However, the more recent COURAGE (Clinical
Outcomes Utilizing Revascularization and Aggressive Drug
Evaluation) trial found similar CV event rates between
patients treated with optimal medical therapy alone and those
treated with optimal medical therapy plus percutaneous
revascularization. Therefore, in the current era, medical
therapy appears to be as effective as revascularization in
suppressing symptomatic ischemia and preventing CV
events. COURAGE was not designed to evaluate changes in
the frequency of silent ischemia. Therefore, silent ischemia
may persist despite current-era treatment and might still
identify patients with increased risk of CV events. Also, silent
ischemia is likely to occur frequently in heart transplant
patients with denervated hearts and coronary allograft vas-
culopathy, and future study aimed at improving the
management of silent ischemia in this population is war-
ranted. Additionally, future research is warranted to study the
effect of newer medical therapies such as ranolazine or
selected use of revascularization (for example, guided by
fractional ﬂow reserve) in those patients with persistent silent
ischemia despite optimal current-era medical therapy (230).Survival in Patients With Poorly Compressible Leg
Arteries
Objectives This study sought to compare survival of
patients with poorly compressible arteries (PCA) to those
with a normal ankle-brachial index (ABI) and those with
peripheral arterial disease (PAD).
Background Limited data are available regarding survival
in patients with PCA identiﬁed in the clinical setting by
noninvasive lower extremity arterial evaluation.
Methods We conducted a historical cohort study of
consecutive patients who underwent outpatient, noninvasive
lower extremity arterial evaluation at the Mayo Clinic,
Rochester, Minnesota, from January 1998 through
December 2007, and who were followed for a mean duration
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normal, PAD was deﬁned as a resting or post-exercise
ABI 0.90, and PCA deﬁned as an ABI 1.4 and/or an
ankle systolic blood pressure >255 mm Hg. Patients were
followed for all-cause mortality through September
30, 2009.
Results Of 16,493 individuals (mean age 67.8  13.0 years,
59% male); 29% had normal ABI, 54% had PAD, and 17%
had PCA. During follow-up (mean duration 5.8  3.1
years), 4,365 patients (26%) died. The percent alive at the
end of the study period was 88%, 70%, and 60% for normal
ABI, PAD, and PCA, respectively. After adjustment for
age, sex, cardiovascular risk factors, comorbid conditions,
and medication use, the hazard ratios (95% conﬁdence
intervals) of death associated with PCA were 2.0 (1.8 to 2.2)
and 1.3 (1.2 to 1.4) compared with the normal ABI and
PAD groups, respectively.
Conclusions Patients identiﬁed by noninvasive vascular
testing to have poorly compressible leg arteries have poor
survival, worse than those with a normal ABI or those with
PAD (231).Improvements in Transcatheter Aortic Valve
Implantation Outcomes in Lower Surgical Risk
Patients: A Glimpse Into the Future
Objectives The purpose of this study was to investigate the
evolution of patient selection criteria for transcatheter aortic
valve implantation (TAVI) and its impact on clinical
outcomes.
Background Anecdotal evidence suggests that patient
selection for TAVI is shifting toward lower surgical risk
patients. The extent of this shift and its impact on clinical
outcomes, however, are currently unknown.
Methods We conducted a single-center study that sub-
categorized TAVI patients into quartiles (Q1 to Q4) deﬁned
by enrollment date. These subgroups were subsequently
examined for differences in baseline characteristics and
30-day and 6-month mortality rate. The relationship
between quartiles and mortality rate was examined using
unadjusted and adjusted (for baseline characteristics) Cox
proportional hazard models.
Results Each quartile included 105 patients (n ¼ 420).
Compared with Q4 patients, Q1 patients had higher logistic
EuroSCORES (25.4  16.1% vs. 17.8  12.0%, p <
0.001), higher Society of Thoracic Surgeons scores (7.1 
5.5% vs. 4.8  2.6%, p > 0.001), and higher median N-
terminal pro–B-type natriuretic peptide levels (3,495 vs.
1,730 ng/dl, p < 0.046). From Q1 to Q4, the crude 30-day
and 6-month mortality rate decreased signiﬁcantly from
11.4% to 3.8% (unadjusted hazard ratio [HR]: 0.33; 95%
conﬁdence interval [CI]: 0.11 to 1.01; p ¼ 0.053) and from
23.5% to 12.4% (unadjusted HR: 0.49; 95 CI: 0.25 to 0.95;
p ¼ 0.07), respectively. After adjustment for baseline char-
acteristics, there were no signiﬁcant differences between Q1
and Q4 in 30-day mortality rate (adjusted HR ratio: 0.29;95% CI: 0.08 to 1.08; p ¼ 0.07) and 6-month mortality rate
(HR: 0.67; 95% CI: 0.25 to 1.77; p ¼ 0.42).
Conclusions The results of this study demonstrate an
important paradigm shift toward the selection of lower
surgical risk patients for TAVI. Signiﬁcantly better clinical
outcomes can be expected in lower than in higher surgical
risk patients undergoing TAVI (232).Hypothermia Therapy: Neurological and Cardiac
Beneﬁts
Due to its protective effect on the brain and the myocar-
dium, hypothermia therapy (HT) has been extensively
studied in cardiac arrest patients with coma as well as in
patients presenting with acute myocardial infarction (MI).
In the setting of cardiac arrest, randomized studies have
shown that HT decreases mortality and improves neuro-
logical outcomes. Subsequent guidelines have therefore
recommended cooling (32C to 34C) for 12 to 24 h in
unconscious adult patients with spontaneous circulation after
out-of-hospital cardiac arrest due to ventricular ﬁbrillation.
Observational studies have also conﬁrmed the feasibility of
this therapy in clinical practice and support its early appli-
cation in patients with nonventricular ﬁbrillation cardiac
arrest and in post-resuscitation circulatory shock. In patients
with acute MI, available clinical evidence does not yet
support HT as the standard of care, because no study to date
has shown a clear net beneﬁt in such a cohort. After a brief
review of the mechanisms of action for HT, we provide
a review of the clinical evidence, cooling techniques, and
potential adverse effects associated with HT in the setting of
post-cardiac arrest patient and acute MI (233).Percutaneous Coronary Intervention and Drug-
Eluting Stent Use Among Patients ‡85 Years of
Age in the United States
Objectives This study assessed the comparative effective-
ness of drug-eluting stents (DES) versus bare-metal stents
(BMS) among patients 85 years of age.
Background Despite an aging population, little is known
about the comparative effectiveness of DES versus BMS
among patients age 85 years undergoing percutaneous
coronary intervention (PCI).
Methods We examined 471,006 PCI patients age 65
years at 947 hospitals in the National Cardiovascular Data
Registry between 2004 and 2008 and linked to Medicare
claims data. Long-term outcomes (median follow-up 640.8
 423.5 days) were compared between users of DES and
BMS.
Results Patients age 85 years comprise an increasing
proportion of PCIs performed among elderly subjects, yet
rates of DES use declined the most in this age group.
Compared with BMS, use of DES was associated with lower
mortality: age 85 years, 29% versus 38% (adjusted hazard
ratio [HR]: 0.80 [95% conﬁdence interval (CI): 0.77 to
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CI: 0.75 to 0.79]); and age 65 to 74 years, 10% versus 16%
(HR: 0.73 [95% CI: 0.71 to 0.75]). However, the adjusted
mortality difference narrowed with increasing age
(pinteraction <0.001). In contrast, the adjusted HR for
myocardial infarction rehospitalization associated with DES
use was signiﬁcantly lower with increasing age: age 85
years, 9% versus 12% (HR: 0.77 [95% CI: 0.71 to 0.83]); age
75 to 84 years, 7% versus 9% (HR: 0.81 [95% CI: 0.77 to
0.84]); and age 65 to 74 years, 7% versus 8% (HR: 0.84
[95% CI: 0.80 to 0.88]) (pinteraction <0.001).
Conclusions In this national study of older patients
undergoing PCI, declines in DES use were most
pronounced among those aged 85 years, yet lower adverse-
event rates associated with DES versus BMS use were
observed (234).Incidence, Predictive Factors, and Prognostic
Value of New-Onset Atrial Fibrillation Following
Transcatheter Aortic Valve Implantation
Objectives This study sought to evaluate the incidence,
predictive factors, and prognostic value of new-onset atrial
ﬁbrillation (NOAF) following transcatheter aortic valve
implantation (TAVI).
Background Very few data exist on the occurrence of
NOAF following TAVI.
Methods A total of 138 consecutive patients with no prior
history of atrial ﬁbrillation (AF) underwent TAVI with
a balloon-expandable valve. Patients were on continuous
electrocardiogram monitoring until hospital discharge, and
NOAF was deﬁned as any episode of AF lasting >30 s. All
clinical, echocardiographic, procedural, and follow-up data
were prospectively collected.
Results NOAF occurred in 44 patients (31.9%) at
a median time of 48 h (interquartile range: 0 to 72 h)
following TAVI. The predictive factors of NOAF were left
atrial (LA) size (odds ratio [OR]: 1.21 for each increase in 1
mm/m2, 95% conﬁdence interval [CI]: 1.09 to 1.34, p <
0.0001) and transapical approach (OR: 4.08, 95% CI: 1.35
to 12.31, p ¼ 0.019). At 30-day follow-up, NOAF was
associated with a higher rate of stroke/systemic embolism
(13.6% vs. 3.2%, p ¼ 0.021, p ¼ 0.047 after adjustment for
baseline differences between groups), with no differences in
mortality rate between groups (NOAF: 9.1%, no-NOAF:
6.4%, p ¼ 0.57). At a median follow-up of 12 months
(interquartile range: 5 to 20 months), a total of 27 patients
(19.6%) had died, with no differences between the NOAF
(15.9%) and no-NOAF (21.3%) groups, p ¼ 0.58. The
cumulative rate of stroke and stroke/systemic embolism at
follow-up were 13.6% and 15.9%, respectively, in the
NOAF group versus 3.2% in the no-NOAF group (p ¼
0.039, adjusted p ¼ 0.037 for stroke; p ¼ 0.020, adjusted
p ¼ 0.023 for stroke/systemic embolism).
Conclusions NOAF occurred in about one-third of the
patients with no prior history of AF undergoing TAVI andits incidence was increased in patients with larger LA size
and those undergoing transapical TAVI. NOAF was asso-
ciated with a higher rate of stroke/systemic embolism, but
not a higher mortality, at 30 days and at 1-year follow-up
(235).Percutaneous Aortic Valve Replacement: Vascular
Outcomes With a Fully Percutaneous Procedure
Objectives The aim of this study was to evaluate vascular
complications in a consecutive patient population under-
going transfemoral percutaneous aortic valve replacement
(PAVR) applying current Valve Academic Research
Consortium deﬁnitions.
Background Vascular complications have been the major
cause of mortality and morbidity associated with PAVR.
Both open surgical and fully percutaneous access site strat-
egies have been advocated.
Methods All patients undergoing transfemoral PAVR
during ﬁscal years 2009 and 2010 were prospectively eval-
uated at baseline, after the procedure, and at 30 days.
Results PAVR was performed in 137 consecutive patients.
All but 1 patient underwent planned arteriotomy closure
using a percutaneous pre-closure technique. Smaller sheaths,
rigorous angiographic and computed tomographic screening
and patient selection, and percutaneous vascular repair
techniques were increasingly used over this period. From
2009 to 2010, major vascular complications decreased from
8% to 1% (p ¼ 0.06), minor vascular complications
decreased from 24% to 8% (p < 0.01), major bleeds fell from
14% to 1% (p < 0.01), and unplanned surgery decreased
from 28% to 2% (p < 0.01). A minimal artery diameter
smaller than the external sheath diameter, moderate or
severe calciﬁcation, and peripheral vascular disease were
associated with higher vascular complication rates.
Conclusions Vascular complications occur more often if
the minimal artery diameter is smaller than the external
sheath diameter, in the presence of moderate or severe
calciﬁcation, and in patients with peripheral vascular disease.
With careful patient selection, advanced interventional
techniques, and a fully percutaneous procedure, marked
reductions in vascular and bleeding complications can be
achieved (236).Procedural Complications, Rehospitalizations, and
Repeat Procedures After Catheter Ablation for
Atrial Fibrillation
Objectives The purpose of this study was to estimate rates
and identify predictors of inpatient complications and 30-
day readmissions, as well as repeat hospitalization rates for
arrhythmia recurrence following atrial ﬁbrillation (AF)
ablation.
Background AF is the most common clinically signiﬁcant
arrhythmia and is associated with increased morbidity and
mortality. Radiofrequency or cryotherapy ablation of AF is
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procedural outcomes in large general populations are limited.
Methods Using data from the California State Inpatient
Database, we identiﬁed all adult patients who underwent
their ﬁrst AF ablation from 2005 to 2008. We used multi-
variable logistic regression to identify predictors of compli-
cations and/or 30-day readmissions and Kaplan-Meier
analyses to estimate rates of all-cause and arrhythmia
readmissions.
Results Among 4,156 patients who underwent an initial
AF ablation, 5% had periprocedural complications, most
commonly vascular, and 9% were readmitted within 30 days.
Older age, female, prior AF hospitalizations, and less
hospital experience with AF ablation were associated with
higher adjusted risk of complications and/or 30-day read-
missions. The rate of all-cause hospitalization was 38.5% by
1 year. The rate of readmission for recurrent AF, atrial
ﬂutter, and/or repeat ablation was 21.7% by 1 year and
29.6% by 2 years.
Conclusions Periprocedural complications occurred in 1 of
20 patients undergoing AF ablation, and all-cause and
arrhythmia-related rehospitalizations were common. Older
age, female sex, prior AF hospitalizations, and recent
hospital procedure experience were associated with a higher
risk of complications and/or 30-day readmission after AF
ablation (237).Classiﬁcation and Clinical Impact of Restenosis
After Femoropopliteal Stenting
Objectives The purpose of this study was to investigate the
relationship between angiographic patterns of in-stent
restenosis (ISR) after femoropopliteal (FP) stenting and
the frequency of refractory ISR.
Background In-stent restenosis after FP stenting is an
unsolved problem. The incidence and predictors of refrac-
tory restenosis remain unclear.
Methods This study was a multicenter, retrospective
observational study. From September 2000 to December
2009, 133 restenotic lesions after FP artery stenting were
classiﬁed by angiographic pattern: class I included focal
lesions (50 mm in length), class II included diffuse lesions
(>50 mm in length), and class III included totally occluded
ISR. All patients were treated by balloon angioplasty for at
least 60 s. Recurrent ISR or occlusion was deﬁned as ISR or
occlusion after target lesion revascularization. Restenosis was
deﬁned as >2.4 of the peak systolic velocity ratio by duplex
scan or >50% stenosis by angiography.
Results Sixty-four percent of patients were male, 67% had
diabetes mellitus, and 24% underwent hemodialysis. Class I
pattern was found in 29% of the limbs, class II in 38%, and
class III in 33%. Mean follow-up period was 24  17
months. All-cause death occurred in 14 patients; bypass
surgery was performed in 11 limbs, and major amputation
was performed in 1 limb during the follow-up. Kaplan-
Meier survival curves showed that the rate of recurrent ISRat 2 years was 84.8% in class III patients compared with
49.9% in class I patients (p < 0.0001) and 53.3% in class II
patients (p ¼ 0.0003), and the rate of recurrent occlusion at
2 years was 64.6% in class III patients compared with 15.9%
in class I patients (p < 0.0001) and 18.9% in class II patients
(p < 0.0001).
Conclusions Restenotic patterns after FP stenting are
important predictors of recurrent ISR and occlusion (238).Ex Vivo Assessment of Vascular Response to
Coronary Stents by Optical Frequency Domain
Imaging
Objectives This study sought to examine the capability of
optical frequency domain imaging (OFDI) to characterize
various morphological and histological responses to stents
implanted in human coronary arteries.
Background A precise assessment of vascular responses to
stents may help stratify the risk of future adverse events in
patients who have been treated with coronary stents.
Methods Fourteen human stented coronary segments with
implant duration 1 month from 10 hearts acquired at
autopsy were interrogated ex vivo by OFDI and intravascular
ultrasound (IVUS). Comparison with histology was assessed
in 134 pairs of images where the endpoints were to investi-
gate: 1) accuracy of morphological measurements; 2) detec-
tion of uncovered struts; and 3) characterization of neointima.
Results Although both OFDI and IVUS provided a good
correlation of neointimal area with histology, the correlation
of minimum neointimal thickness was inferior in IVUS
(R2 ¼ 0.39) as compared with OFDI (R2 ¼ 0.67). Similarly,
IVUS showed a weak correlation of the ratio of uncovered to
total stent struts per section (RUTSS) (R2 ¼ 0.24), whereas
OFDI maintained superiority (R2 ¼ 0.66). In a more
detailed analysis by OFDI, identiﬁcation of individual
uncovered struts demonstrated a sensitivity of 77.9% and
speciﬁcity of 96.4%. Other important morphological features
such as ﬁbrin accumulation, excessive inﬂammation
(hypersensitivity), and in-stent atherosclerosis were charac-
terized by OFDI; however, the similarly dark appearance of
these tissues did not allow for direct visual discrimination.
The quantitative analysis of OFDI signal reﬂections from
various in-stent tissues demonstrated distinct features of
organized thrombus and accumulation of foamy
macrophages.
Conclusions The results of the present study reinforce the
potential of OFDI to detect vascular responses that may be
important for the understanding of long-term stent perfor-
mance, and indicate the capability of this technology to serve
as a diagnostic indicator of clinical success (239).The Retrograde Technique for Recanalization of
Chronic Total Occlusions: A Step-by-Step Approach
Chronic total occlusion recanalization still represents
the ﬁnal frontier in percutaneous coronary intervention.
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recently become an essential complement to the classical
antegrade approach. In experienced hands, the retrograde
technique currently has a high success rate with a low
complication proﬁle, despite frequent utilization in the most
anatomically and clinically complex patients. Since its initial
description, important changes have occurred that make the
technique faster and more successful. We propose a step-by-
step approach of the technique as practiced at experienced
centers in North America. Because the technique can vary
substantially, we describe the different alternatives to each
step and offer what we perceived to be the most efﬁcient
techniques (240).
Contemporary Use and Effectiveness of
N-Acetylcysteine in Preventing Contrast-Induced
Nephropathy Among Patients Undergoing
Percutaneous Coronary Intervention
Objectives The aim of this study was to examine the use of
and outcomes associated with use of N-acetylcysteine
(NAC) in real-world practice.
Background The role of NAC in the prevention of
contrast-induced nephropathy (CIN) is controversial,
leading to widely varying recommendations for its use.
Methods Use of NAC was assessed in consecutive patients
undergoing nonemergent percutaneous coronary interven-
tion from 2006 to 2009 in the Blue Cross Blue Shield of
Michigan Cardiovascular Consortium, a large multicenter
quality improvement collaborative. We examined the overall
prevalence of NAC use in these patients and then used
propensity matching to link its use with clinical outcomes,
including CIN, nephropathy-requiring dialysis, and death.
Results Of the 90,578 percutaneous coronary interventions
performed during the study period, NAC was used in
10,574 (11.6%) procedures, with its use steadily increasing
over the study period. Patients treated with NAC were
slightly older and more likely to have baseline renal insuf-
ﬁciency and other comorbidities. In propensity-matched,
risk-adjusted models, we found no differences in outcomes
between patients treated with NAC and those not receiving
NAC for CIN (5.5% vs. 5.5%, p ¼ 0.99), nephropathy-
requiring dialysis (0.6% vs. 0.6%, p ¼ 0.69), or death
(0.6% vs. 0.8%, p ¼ 0.15). These ﬁndings were consistent
across many prespeciﬁed subgroups.
Conclusions Use of NAC is common and has steadily
increased over the study period but does not seem to be
associated with improved clinical outcomes in real-world
practice (241).
Examination of the In Vivo Mechanisms of Late
Drug-Eluting Stent Thrombosis: Findings From
Optical Coherence Tomography and Intravascular
Ultrasound Imaging
Objectives This study investigated the role of uncovered
stent struts on late stent thrombosis (LST) after drug-eluting stent (DES) implantation with optical coherence
tomography (OCT).
Background Autopsy studies have identiﬁed delayed heal-
ing and lack of endothelialization of DES struts as the
hallmarks of LST. DES strut coverage has not previously
been examined in vivo in patients with LST.
Methods We studied 54 patients, including 18 with DES
LST (median 615 days after implant) undergoing emergent
percutaneous coronary interventions and 36 matched DES
control subjects undergoing routine repeat OCT and
intravascular ultrasound (IVUS) who did not experience
LST for 3 years. Thrombus aspiration was performed
during emergent percutaneous coronary intervention before
OCT and IVUS assessment.
Results By OCT, patients with LSTdcompared with
control subjectsdhad a higher percentage of uncovered
(median [interquartile range]) (12.27 [5.50 to 23.33] vs.
4.14 [3.00 to 6.22], p < 0.001) and malapposed (4.60 [1.85
to 7.19] vs. 1.81 [0.00 to 2.99], p < 0.001) struts. The mean
neointimal thickness was similar in the 2 groups (0.23 
0.17 mm vs. 0.17  0.09 mm, p ¼ 0.28). By IVUS, stent
expansion was comparable in the 2 groups, although positive
remodeling was increased in patients with LST (mean vessel
cross-section area 19.4  5.8 mm2 vs. 15.1  4.6 mm2, p ¼
0.003). Thrombus aspiration demonstrated neutrophils and
eosinophils in most cases. By multivariable analysis, the
length of segment with uncovered stent struts by OCT and
the remodeling index by IVUS were independent predictors
of LST.
Conclusions In this in vivo case-controlled study, the
presence of uncovered stent struts as assessed by OCT and
positive vessel remodeling as imaged by IVUS were associ-
ated with LST after DES (242).Quantifying the Learning Curve in the Use of
a Novel Vascular Closure Device: An Analysis of
the NCDR (National Cardiovascular Data Registry)
CathPCI Registry
Objectives This study sought to quantify the learning curve
for the safety and effectiveness of a newly introduced
vascular closure device through evaluation of the NCDR
(National Cardiovascular Data Registry) CathPCI clinical
outcomes registry.
Background The impact of learning on the clinical
outcomes complicates the assessment of the safety and
efﬁcacy during the early experience with newly introduced
medical devices.
Methods We performed a retrospective analysis of the
relationship between cumulative institutional experience and
clinical device success, deﬁned as device deployment success
and freedom from any vascular complications, for the Star-
Close vascular closure device (Abbott Vascular, Redwood
City, California). Generalized estimating equation modeling
was used to develop risk-adjusted clinical success predictions
that were analyzed to quantify learning curve rates.
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StarClose deployment, between January 1, 2006, and
December 31, 2007, with overall clinical success increasing
from 93% to 97% during the study period. The learning
curve was triphasic, with an initial rapid learning phase,
followed by a period of declining rates of success, followed
ﬁnally by a recovery to a steady-state rate of improved device
success. The rates of learning were inﬂuenced positively by
diagnostic (vs. percutaneous coronary intervention) proce-
dure use and teaching status and were affected inversely by
annual institutional volume.
Conclusions An institutional-level learning curve for the
initial national experience of StarClose was triphasic, likely
indicating changes in patient selection and expansion of
number of operators during the initial phases of device
adoption. The rate of learning was inﬂuenced by several
institutional factors, including overall procedural volume,
utilization for percutaneous coronary intervention proce-
dures, and teaching status (243).The Sirolimus-Eluting Cypher Select Coronary
Stent for the Treatment of Bare-Metal and Drug-
Eluting Stent Restenosis: Insights From the
e-SELECT (Multicenter Post-Market Surveillance)
Registry
Objectives This study sought to compare the 1-year safety
and efﬁcacy of Cypher Select or Cypher Select Plus (Cordis
Corporation, Bridgewater, New Jersey) sirolimus-eluting
stents (SES) with the treatment of bare-metal stents
(BMS) and drug-eluting stent (DES) in-stent restenosis
(ISR) in nonselected, real-world patients.
Background There is paucity of consistent data on DES for
the treatment of ISR, especially, DES ISR.
Methods The e-SELECT (Multicenter Post-Market
Surveillance) registry is a Web-based, multicenter and
international registry encompassing virtually all subsets of
patients and lesions treated with at least 1 SES during the
period from 2006 to 2008. We enrolled in this pre-speciﬁed
subanalysis all patients with at least 1 clinically relevant BMS
or DES ISR treated with SES. Primary endpoint was major
adverse cardiac events and stent thrombosis rate at 1 year.
Results Of 15,147 patients enrolled, 1,590 (10.5%) pre-
sented at least 1 ISR (BMS group, n ¼ 1,235, DES group,
n ¼ 355). Patients with DES ISR had higher incidence of
diabetes (39.4% vs. 26.9%, p < 0.001), renal insufﬁciency
(5.8% vs. 2.3%, p ¼ 0.003), and prior coronary artery bypass
graft (20.5% vs. 11.8%, p < 0.001). At 1 year, death (1.4%
for BMS vs. 2.1% for DES, p ¼ 0.3) and myocardial
infarction (2.4% for BMS and 3.3% for DES, p ¼ 0.3) rates
were similar, whereas ischemia-driven target lesion revas-
cularization and deﬁnite/probable late stent thrombosis were
higher in patients with DES ISR (6.9% vs. 3.1%, p ¼ 0.003,
and 1.8% vs. 0.5%, p ¼ 0.04, respectively).
Conclusions Use of SES for either BMS or DES ISR
treatment is safe and associated with low target lesionrevascularization recurrence and no apparent safety concern
(244).Angiographic Stent Thrombosis at Coronary
Bifurcations: Short- and Long-Term Prognosis
Objectives This study sought to describe the presentation,
management, and outcomes of patients presenting with
angiographic deﬁnite stent thrombosis (ST) at coronary
bifurcations.
Background The development of drug-eluting stents has
made it increasingly feasible to treat bifurcation lesions
percutaneously. However, ST at coronary bifurcations may
be associated with greater mortality than ST elsewhere.
Methods We analyzed a multicenter California registry
comprising all cases of angiographic deﬁnite ST at 5
academic hospitals from 2005 to 2010. Stenting was deﬁned
as occurring at a bifurcation if the main vessel stent crossed
a side branch 2.0 mm in diameter (provisional single-stent
approach), or if there was a prior 2-stent bifurcation
approach.
Results Among 173 cases of angiographic deﬁnite ST, we
identiﬁed 20 cases of ST at coronary bifurcations. Nine of 20
bifurcation ST (45%) occurred with a stent present in both
the parent and branch vessel. Eight cases had thrombus
present in both the parent and side branch vessels. In-
hospital mortality was much higher for subjects with bifur-
cation ST than ST at a nonbifurcation site (20% vs. 2%, p <
0.0001). During a median follow-up of 2.3 years, ST at
a coronary bifurcation was associated with increased long-
term mortality (hazard ratio [HR]: 3.3, 95% conﬁdence
interval [CI]: 1.4 to 7.7, p ¼ 0.007) and a signiﬁcantly
higher risk for major adverse cardiovascular events (HR: 2.2,
95% CI: 1.04 to 4.8, p ¼ 0.04) relative to ST at a non-
bifurcation site.
Conclusions ST at coronary bifurcations is associated with
a higher in-hospital and long-term mortality than ST at
nonbifurcation lesions. (Stent Thrombus in Acute Coronary
Syndromes; NCT00931502) (245).Transcatheter Aortic Valve Implantation:
Assessing the Learning Curve
Objectives The aim of this study was to assess the learning
curve for the implantation of the percutaneous aortic valve
via the transfemoral route.
Background Transcutaneous aortic valve insertion is
a fundamentally new procedure for the treatment of aortic
valve stenosis. The number of cases needed to gain proﬁ-
ciency with concomitant ease and familiarity (i.e., the
“learning curve”) with the procedure is unknown.
Methods We performed a retrospective analysis of the ﬁrst
44 consecutive patients who underwent transcatheter aortic
valve implantation as part of the PARTNER (Placement of
Aortic Transcatheter Valves) trial at our institution between
November 2008 and May 2011.
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(interquartile range: 77 to 87 years) and a median Society of
Thoracic Surgery risk score of 9.6. Pre-procedural assess-
ment of the aortic valve revealed a mean gradient of 53.5
mm Hg, mean aortic valve area of 0.7 mm2, and a median
ejection fraction of 59.5%. Patients were divided into tertiles
based on sequence. Signiﬁcant decreases in median contrast
volume (180 to 160 to 130 ml, p ¼ 0.003), valvuloplasty to
valve deployment time (12.0 to 11.6 to 7.0 min, p < 0.001)
and ﬂuoroscopy times, from 26.1 to 17.2 and 14.3 min
occurred from tertiles 1 to 3, p < 0.001. Signiﬁcant
decreases in radiation doses were also seen across the 3
tertiles, p < 0.001. The 30-day mortality for the entire
cohort was 11%.
Conclusions Experience accumulated over 44 transfemoral
aortic valve implantations led to signiﬁcant decreases in
procedural times, radiation, and contrast volumes. Our data
show increasing proﬁciency with evidence of plateau after
the ﬁrst 30 cases. More studies are needed to conﬁrm these
ﬁndings (246).Percutaneous Edge-to-Edge Mitral Valve Repair in
High-Surgical-Risk Patients: Do We Hit the Target?
Objectives This study sought to assess the feasibility and
safety of percutaneous edge-to-edge mitral valve (MV)
repair in patients with an unacceptably high operative risk.
Background MV repair for mitral regurgitation (MR) can
be accomplished by use of a clip that approximates the free
edges of the mitral leaﬂets.
Methods All patients were declined for surgery because of
a high logistic EuroSCORE (>20%) or the presence of
other speciﬁc surgical risk factors. Transthoracic echocardi-
ography was performed before and 6 months after the
procedure. Differences in New York Heart Association
(NYHA) functional class, quality of life (QoL) using the
Minnesota questionnaire, and 6-min walk test (6-MWT)
distances were reported.
Results Fifty-ﬁve procedures were performed in 52 patients
(69.2% male, age 73.2  10.1 years, logistic EuroSCORE
27.1  17.0%). In 3 patients, partial clip detachment
occurred; a second clip was placed successfully. One patient
experienced cardiac tamponade. Two patients developed
inguinal bleeding, of whom 1 needed surgery. Six patients
(11.5%) died during 6-month follow-up (5 patients as
a result of progressive heart failure and 1 noncardiac death).
The MR grade before repair was 3 in 100%; after 6
months, a reduction in MR grade to 2 was present in 79%
of the patients. Left ventricular (LV) end-diastolic diameter,
LV ejection fraction, and systolic pulmonary artery pressure
improved signiﬁcantly. Accompanied improvements in
NYHA functional class, QoL index, 6-MWT distances, and
log N-terminal pro–B-type natriuretic peptide were
observed.
Conclusions In a high-risk population, MR reduction can
be achieved by percutaneous edge-to-edge valve repair,resulting in LV remodeling with improvement of functional
capacity after 6 months (247).
Kissing Balloon or Sequential Dilation of the Side
Branch and Main Vessel for Provisional Stenting of
Bifurcations: Lessons From Micro-Computed
Tomography and Computational Simulations
Objectives This study sought to evaluate post-dilation
strategies in bifurcation stenting.
Background In bifurcation stenting practice, it is still
controversial how post-dilation should be performed and
whether the kissing balloon (KB) technique is mandatory
when only the main vessel (MV) receives a stent.
Methods A series of drug-eluting stents (DES) (n ¼ 26)
were deployed in a coronary bifurcation model following
a provisional approach. After the deployment of the stent in
the MV, post-dilation with the KB technique was compared
with a 2-step, sequential post-dilation of the side branch
(SB) and MV without kissing.
Results The percentage of the SB lumen area free of stent
struts was similar after KB (79.1  8.7%) and after the 2-
step sequence (74.4  11.6%, p ¼ 0.25), a considerable
improvement compared with MV stenting only without
dilation of the stent at the SB ostium (30.8  7.8%, p <
0.0001). The rate of strut malapposition in the ostium was
21.3  9.2% after KB and 24.9  10.4% after the 2-step
sequence, respectively, a signiﬁcant reduction compared
with a simple SB dilation (55.3  16.8%, p < 0.0001) or
MV stenting only (47.0  8.5%, p < 0.0005). KB created
a signiﬁcant elliptical overexpansion of the MV lumen,
inducing higher stress concentration proximal to the SB. KB
also led to a higher risk of incomplete stent apposition at the
proximal stent edge (30.7  26.4% vs. 2.8  9.6% for 2-
step, p ¼ 0.0016).
Conclusions Sequential 2-step post-dilation of the SB and
MV may offer a simpler and more efﬁcient alternative to
ﬁnal KB technique for provisional stenting of bifurcations
(248).
Transradial Versus Transfemoral Intervention for
Acute Myocardial Infarction: A Propensity Score-
Adjusted and -Matched Analysis From the REAL
(REgistro regionale AngiopLastiche dell’Emilia-
Romagna) Multicenter Registry
Objectives This study sought to assess whether transradial
intervention, by minimizing access-site bleeding and
vascular events, improves outcomes in patients with ST-
segment elevation myocardial infarction compared with the
transfemoral approach.
Background Bleeding and consequent blood product
transfusions have been causally associated with a higher
mortality rate in patients with myocardial infarction under-
going coronary angioplasty.
Methods We identiﬁed all adults undergoing percuta-
neous intervention for acute myocardial infarction in
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residents, between January 1, 2003, and July 30, 2009, at 12
referral hospitals using a region-mandated database of
percutaneous coronary intervention procedures. Differences
in the risk of death at 2 years between patients undergoing
transfemoral versus transradial intervention, assessed on an
intention-to-treat basis, were determined from vital statistics
records and compared based on propensity score adjustment
and matching.
Results A total of 11,068 patients were treated for acute
myocardial infarction (8,000 via transfemoral and 3,068 via
transradial route). According to analysis of matched pairs,
the 2-year, risk-adjusted mortality rates were lower for the
transradial than for the transfemoral group (8.8% vs. 11.4%;
p ¼ 0.0250). The rate of vascular complications requiring
surgery or need for blood transfusion were also signiﬁcantly
decreased in the transradial group (1.1% vs. 2.5%, p ¼
0.0052).
Conclusions In patients undergoing angioplasty for acute
myocardial infarction, transradial treatment is associated
with decreased 2-year mortality rates and a reduction in the
need for vascular surgery and/or blood transfusion compared
with transfemoral intervention (249).Prevention of Contrast Nephropathy by
Furosemide With Matched Hydration: The MYTHOS
(Induced Diuresis With Matched Hydration
Compared to Standard Hydration for Contrast
Induced Nephropathy Prevention) Trial
Objectives This study investigated the effect of
furosemide-forced diuresis and intravenous saline infusion
matched with urine output, using a novel dedicated devi-
ce designed for contrast-induced nephropathy (CIN)
prevention.
Background CIN is a frequent cause of acute kidney injury
associated with increased morbidity and mortality.
Methods A total of 170 consecutive patients with chronic
kidney disease (CKD) undergoing coronary procedures
were randomized to either furosemide with matched
hydration (FMH group, n ¼ 87) or to standard intrave-
nous isotonic saline hydration (control group; n ¼ 83). The
FMH group received an initial 250-ml intravenous bolus
of normal saline over 30 min followed by an intravenous
bolus (0.5 mg/kg) of furosemide. Hydration infusion rate
was automatically adjusted to precisely replace the patient’s
urine output. When a urine output rate >300 ml/h was
obtained, patients underwent the coronary procedure.
Matched ﬂuid replacement was maintained during the
procedure and for 4 h post-treatment. The deﬁnition of
CIN was a 25% or 0.5 mg/dl rise in serum creatinine
over baseline.
Results In the FMH group, no device- or therapy-related
complications were observed. Four (4.6%) patients in the
FMH group developed CIN versus 15 (18%) controls (p ¼
0.005). A lower incidence of cumulative in-hospital clinicalcomplications was also observed in FMH-treated patients
than in controls (8% vs. 18%; p ¼ 0.052).
Conclusions In patients with CKD undergoing coronary
procedures, furosemide-induced high urine output with
matched hydration signiﬁcantly reduces the risk of CIN and
may be associated with improved in-hospital outcome.
(Induced Diuresis With Matched Hydration Compared to
Standard Hydration for Contrast Induced Nephropathy
Prevention [MYTHOS]; NCT00702728) (250).
The Leipzig Prospective Vascular Ultrasound
Registry in Radial Artery Catheterization: Impact
of Sheath Size on Vascular Complications
Objectives This study investigated the impact of sheath
size on the rate of radial artery occlusions (RAO) (primary
objective) and other access site complications (hemorrhage,
pseudoaneurysm, arteriovenous ﬁstula) as secondary Objec-
tives after transradial coronary catheterization.
Background The number of vascular access complications
in the published data ranges from 5% to 38% after trans-
radial catheterization.
Methods Between November 2009 and August 2010, 455
patients 65.3  10.9 years of age (62.2% male) with trans-
radial access with 5-F (n ¼ 153) or 6-F (n ¼ 302) arterial
sheaths were prospectively recruited. Duplex sonography was
obtained in each patient before discharge. Patients with
symptomatic RAO were treated with low-molecular-weight
heparin (LMWH), and a follow-up was performed.
Results The incidence of access site complications was
14.4% with 5-F sheaths compared with 33.1% with 6-F
sheaths (p < 0.001). Radial artery occlusion occurred in
13.7% with 5-F sheaths compared with 30.5% with 6-F
sheaths (p < 0.001). There was no difference between
groups with regard to hemorrhage, pseudoaneurysms, or
arteriovenous ﬁstulas. Female sex, larger sheath size,
peripheral arterial occlusive disease, and younger age inde-
pendently predicted RAO in multivariate analysis. In total,
42.5% of patients with RAO were immediately symptom-
atic; another 7% became symptomatic within a mean of 4
days. Of patients with RAO, 59% were treated with
LMWH. The recanalization rates were signiﬁcantly higher
in patients receiving LMWH compared with conventional
therapy (55.6% vs. 13.5%, p < 0.001) after a mean of 14
days.
Conclusions The incidence of RAO by vascular ultrasound
was higher than expected from previous data, especially in
patients who underwent the procedure with larger sheaths
(251).
A Point-of-Care Platelet Function Assay and
C-Reactive Protein for Prediction of Major
Cardiovascular Events After Drug-Eluting Stent
Implantation
Objectives This study sought to investigate clinical utility
of on-site platelet function test and C-reactive protein
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intervention (PCI).
Background Data on long-term prognostic value of high
on-treatment platelet reactivity (HTPR) on clopidogrel after
PCI are limited. As a distinct biological pathway, CRP has
been suggested to be associated with post-PCI athero-
thrombotic events.
Methods We evaluated 2,849 patients who received drug-
eluting stents (DES) and had post-PCI VerifyNow P2Y12
assays (Accumetrics, San Diego, California) performed.
Among them, baseline CRP measurement was available in
2,546 patients. The primary endpoint was a composite
of all-cause death, nonfatal myocardial infarction, stent
thrombosis, and stroke.
Results During follow-up (median, 2.2 years), the occur-
rence of the primary endpoint did not signiﬁcantly differ
among patients with and without HTPR (2.8% vs. 2.4% at 2
years; hazard ratio [HR]: 1.33, 95% conﬁdence interval
[CI]: 0.88 to 2.01; p ¼ 0.18). By contrast, patients with
elevated CRP levels were at signiﬁcantly higher risk for the
primary endpoint, as compared with those with nonelevated
CRP levels (5.6% vs. 1.7% at 2 years; HR: 2.81, 95% CI:,
1.83 to 4.31; p < 0.001). The VerifyNow test had no
incremental usefulness to classify long-term risk. However,
the incorporation of CRP into a model with conventional
clinical and procedural risk factors signiﬁcantly improved the
C-statistic for the prediction of the primary endpoint (0.729
to 0.759; p ¼ 0.03).
Conclusions We failed to identify that HTPR measured by
VerifyNow P2Y12 assay was signiﬁcantly associated with
long-term atherothrombotic risks in patients receiving DES.
However, elevated CRP levels were signiﬁcantly associated
with worse outcomes and had incremental predictive values
over conventional risk factors (252).Impact of Body Weight and Extreme Obesity on the
Presentation, Treatment, and In-Hospital
Outcomes of 50,149 Patients With ST-Segment
Elevation Myocardial Infarction: Results From the
NCDR (National Cardiovascular Data Registry)
Objectives The aim of this study was to assess the impact
of extreme (class III) obesity (body mass index [BMI] 40
kg/m2) on care and outcomes in patients with ST-segment
elevation myocardial infarction (STEMI).
Background Although its prevalence is increasing rapidly,
little is known about the impact of extreme obesity on
STEMI presentation, treatments, complication rates, and
outcomes.
Methods The relationship between BMI and baseline
characteristics, treatment patterns, and risk-adjusted in-
hospital outcomes was quantiﬁed for 50,149 patients with
STEMI from the National Cardiovascular Data Registry
(NCDR) ACTION Registry–GWTG.
Results The proportions of patients with STEMI by
BMI category were as follows: underweight (BMI <18.5kg/m2) 1.6%, normal weight (18.5 kg/m2 BMI <25 kg/
m2) 23.5%, overweight (25 kg/m2 BMI <30 kg/m2)
38.7%, class I obese (30 kg/m2 BMI <35 kg/m2) 22.4%,
class II obese (35 kg/m2 BMI <40 kg/m2) 8.7%, and
class III obese 5.1%. Extreme obesity was associated with
younger age at STEMI presentation (median age 55 years
for class III obese vs. 66 years for normal weight); a higher
prevalence of diabetes, hypertension, and dyslipidemia;
a lower prevalence of smoking; and less extensive coronary
artery disease and higher left ventricular ejection fraction.
Process-of-care measures were similar across BMI cate-
gories, including the extremely obese. Using class I obesity
as the referent, risk-adjusted in-hospital mortality rates
were signiﬁcantly higher only for class III obese patients
(adjusted odds ratio: 1.64; 95% conﬁdence interval: 1.32
to 2.03).
Conclusions Patients with extreme obesity present with
STEMI at younger ages and have less extensive coronary
artery disease, better left ventricular systolic function, and
similar processes and quality of care. Despite these advan-
tages, extreme obesity remains independently associated
with higher in-hospital mortality (253).Percutaneous Radiofrequency Septal Reduction
for Hypertrophic Obstructive Cardiomyopathy in
Children
Objectives The aim of this study was to assess the efﬁcacy
of radiofrequency catheter ablation (RFCA) in the treatment
of hypertrophic obstructive cardiomyopathy in children.
Background Hypertrophic obstructive cardiomyopathy is
an uncommon cause of left ventricular outﬂow tract
obstruction in children. In symptomatic patients, open heart
surgical myectomy has hitherto been the only therapeutic
option.
Methods In 32 children, at a median age of 11.1 (range 2.9
to 17.5) years and weight of 31 (15 to 68) kg, ablation of the
hypertrophied septum was performed using a cool-tip
ablation catheter via a femoral arterial approach. The
median number of lesions was 27 (10 to 63) and ﬂuoroscopic
time was 24 (12 to 60) min.
Results The majority of patients demonstrated an imme-
diate decrease in the catheter pullback gradient (mean 78.5
 26.2 mm Hg pre-RFCA versus mean 36.1  16.5 mm Hg
post-RFCA, p < 0.01) and a further reduction in the Doppler
echocardiographic gradient (mean 96.9  27.0 mm Hg
pre-RFCA versus 32.7  27.1 mm Hg post-RFCA,
p < 0.01) at follow-up. One patient died due to a paradox-
ical increase in left ventricular outﬂow tract obstruction, and
another had persistent atrioventricular block that required
permanent pacing. Six patients required further procedures
(surgery, pacing, or further RFCA) during a median follow-
up of 48 (3 to 144) months.
Conclusions The preliminary results of RFCA for septal
reduction in children with hypertrophic cardiomyopathy
are promising and merit further evaluation (254).
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a Clinical Problem
Objectives Standardized bench-top compression and
elongation testing was undertaken to assess the longitudinal
strength of contemporary stents. Insights gained may
improve clinical stent choice and deployment techniques,
and facilitate future stent design improvements.
Background The hoops of coronary stents provide radial
support, and connectors hold hoops together. Strut material,
shape, and thickness, along with connector number and
conﬁguration, provide the balance between stent ﬂexibility and
longitudinal integrity. Longitudinal distortion manifests as
length change, strut overlap, strut separation, malapposition,
and luminal obstruction. These may predispose to restenosis
and stent thrombosis, obstruct passage of devices, be mis-
interpreted as strut fracture, and require additional stenting.
Methods The force required to compress and to elongate 7
contemporary stents was measured with an Instron universal
testing machine (Norwood, Massachusetts). Stents deployed
in a silicone phantom damaged by a balloon or guide
catheter were imaged by microcomputed tomography to
understand better the appearances and effects of longitudinal
distortion.
Results Stents with 2 connectors (Boston Scientiﬁc
[Natick, Massachusetts] Omega and Medtronic [Santa
Rosa, California] Driver) required signiﬁcantly less force to
be compressed up to 5 mm and elongated by 1 mm than
designs with more connectors. The 6-connector Cypher
Select required signiﬁcantly more force to be elongated 5
mm than other designs.
Conclusions Stents with 2 connectors between hoops have
less longitudinal strength when exposed to compressing or
elongating forces than those with more connectors. This
independent, standardized study may assist stent selection in
clinical situations where longitudinal integrity is important,
and may aid future design improvements.Stent longitudinal
strength, the resistance to shortening or elongation, appears
related to the number of connectors between hoops. Using
a standardized testing protocol, designs with 2 connectors were
more likely to shorten or elongate than those with more
connectors. Distortion may be recognized clinically as
bunching or separation of struts, and may be confused with
strut fracture. Without post-dilation or further stent deploy-
ment, the patient may be at increased risk for adverse clinical
events. A stent design change ensuring 3 connectors, especially
at the proximal end of a stent, should increase longitudinal
integrity, but perhaps at the expense of stent ﬂexibility (255).A New Era of Prospective Real-World Safety
Evaluation: Primary Report of XIENCE V USA
(XIENCE V Everolimus Eluting Coronary Stent
System Condition-of-Approval Post-Market Study)
The XIENCE V USA (XIENCE V Everolimus
Eluting Coronary Stent System Condition-of-ApprovalPost-Market Study) sought to evaluate the safety of
everolimus-eluting coronary stent systems in a real-world
population with a total of 5,054 participants (1,875
standard-risk; 3,179 extended-risk). At 1 year, the rate of
Academic Research Consortium-deﬁned deﬁnite and
probable stent thrombosis was 0.84%, and the composite
rate of cardiac death and Academic Research Consortium-
deﬁned myocardial infarction was 6.5%. Consistent safety
outcomes between the matched standard-risk cohorts from
the XIENCE V USA study and the SPIRIT IV randomized
trial (Clinical Evaluation of the XIENCE V Everolimus
Eluting Coronary Stent System in the Treatment of Subjects
With de Novo Native Coronary Artery Lesions) suggest that
this study affords a reliable benchmark for understanding the
safety of everolimus-eluting coronary stent systems in real-
world clinical practice.
Objectives The XIENCE V USA (XIENCE V Ever-
olimus Eluting Coronary Stent System Condition-of-
Approval Post-Market study) sought to: 1) evaluate the
safety of everolimus-eluting coronary stent systems
(EECSS) in a contemporary cohort of real-world subjects;
and 2) prospectively test the quality of event reporting with
analysis of matched patients from the randomized SPIRIT
IV (Clinical Evaluation of the XIENCE V Everolimus
Eluting Coronary Stent System in the Treatment of Subjects
With de Novo Native Coronary Artery Lesions) trial.
Background Randomized trials have demonstrated the
safety and efﬁcacy of EECSS in selected “standard-risk”
patients.
Methods The XIENCE V USA trial was a prospective,
multicenter, single-arm study in unselected patients. The
primary endpoint was Academic Research Consortium
(ARC)-deﬁned deﬁnite and probable stent thrombosis (ST);
the co-primary endpoint was the composite of cardiac death
and myocardial infarction at 1 year. Secondary analyses
included: 1) stratiﬁcation by standard-risk and extended-risk
cohorts; and 2) late ST after dual antiplatelet therapy
interruption.
Results Of 5,054 participants (1,875 standard-risk; 3,179
extended-risk), 4,958 (98.1%) reached 1-year follow-up.
The rate of ARC-deﬁned deﬁnite and probable ST was
0.84% (95% conﬁdence interval [CI]: 0.60% to 1.14%) in
the overall population and 0.33% (95% CI: 0.12% to
10.72%) and 1.14% (95% CI: 0.80% to 11.58%) in the
standard-risk and extended-risk cohorts, respectively. No
late ST was observed after dual antiplatelet therapy inter-
ruption in either cohort after 6 months. The composite rate
of cardiac death and ARC-deﬁned myocardial infarction was
6.5% (95% CI: 5.79% to 17.17%) in the overall population,
3.8% (95% CI: 2.98% to 14.78%) in the standard-risk
cohort, and 8.0% (95% CI: 7.09% to 19.02%) in the
extended-risk cohort.
Conclusions This study comprehensively reports ST rates
for EECSS in a contemporary real-world population. The
absence of ST after dual antiplatelet therapy interruption
beyond 6 months in standard-risk and high-risk patients is
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standard-risk cohorts from the XIENCE V USA study and
the SPIRIT IV randomized trial suggest that this study
affords a reliable benchmark for understanding the safety
of EECSS in the context of real-world clinical practice.
(XIENCE V Everolimus Eluting Coronary Stent System
[EECSS] USA Post-Approval Study; NCT00676520)
(256).A High-Risk Period for Cerebrovascular Events
Exists After Transcatheter Aortic Valve
Implantation
Objectives This study assesses if there exists a high-risk
period for cerebrovascular events (CeV)after transcatheter
aortic valve implantation (TAVI).
Background Even though acute strokes after TAVI have
been described, it is uncertain if stroke rates continue to
remain high in the early months after TAVI. Furthermore,
the optimal dose and duration of thromboprophylaxis is
unclear.
Methods Patients who underwent TAVI were evaluated at
baseline, at discharge, at 1 and 6 months, and yearly. Risk
factors for CeV events, procedural details, and antith-
rombotic therapy were recorded. Outcomes assessed were
CeV events and death. The timing of such events, predic-
tors, and impact on survival were analyzed.
Results A total of 253 patients were assessed. Median age
was 85 years. The median Society of Thoracic Surgeons
score was 8.1% (interquartile range [IQR]: 5.5% to 12.0%).
Risk factors included smoking (47%), hypertension (70%),
dyslipidemia (66%), and diabetes mellitus (25%). Twenty-
three percent had known cerebrovascular disease and 39%
had atrial ﬁbrillation. Median follow-up was 455 days (IQR:
160 to 912 days) at which time 23 patients experienced
a CeV event. The incidence was highest in the ﬁrst 24 h but
remained high for 2 months. In-hospital mortality rate after
a CeV event was 21%. A prior history of CeV disease was an
independent predictor of an event (hazard ratio: 4.23, 95%
CI: 1.60 to 11.11, p ¼ 0.004).
Conclusions The incidence of CeV events is highest within
24 h of TAVI, but this risk may remain elevated for up to 2
months. A prior history of cerebrovascular disease is an
independent predictor. This may have implications for
patient selection and antithrombotic strategies (257).30-Day Readmission for Patients Undergoing
Percutaneous Coronary Interventions in New York
State
Objectives This study sought to report percutaneous
coronary intervention (PCI) 30-day readmission rates,
identify the impact of staged (planned) readmissions on
overall readmission rates, determine the signiﬁcant predic-
tors of unstaged readmissions after PCI, and specify the
reasons for readmissions.Background Hospital readmissions occur frequently and
incur substantial costs. PCI are among the most common
and costly procedures, and little is known about the nature
and extent of readmissions for PCI.
Methods We retrospectively analyzed 30-day readmissions
after PCI using the nation’s largest statewide PCI registry to
identify 40,093 New York State patients who underwent
PCI between January 1, 2007, and November 30, 2007.
Demographic variables, pre-procedural risk factors,
complications of PCI, and length of stay were considered as
potential predictors of readmission, and reasons for read-
mission were identiﬁed from New York’s administrative
database using principal diagnoses.
Results A total of 15.6% of all PCI patients were read-
mitted within 30 days, and 20.6% of these readmissions
were staged. Among unstaged readmissions, the most
common reasons for readmission were chronic ischemic
heart disease (22.5%), chest pain (10.8%), and heart failure
(8.2%). A total of 2,015 patients (32.2% of readmissions)
underwent a repeat PCI. Thirteen demographic and diag-
nostic risk factors, as well as longer lengths of stay, were all
associated with higher readmission rates.
Conclusions Future efforts to reduce readmissions should
be directed toward the recognition of patients most at risk,
and the reasons they are readmitted. Staging also should be
examined from a cost-effectiveness standpoint as a function
of patients’ unique risk factors (258).
Serial In Vivo Intravascular Ultrasound-Based
Echogenicity Changes of Everolimus-Eluting
Bioresorbable Vascular Scaffold During the First
12 Months After Implantation: Insights From the
ABSORB B Trial
Because the bioresorption of the ABSORB bioresorbable
vascular scaffold (Abbott Vascular, Santa Clara, California) is
characterized by a diminishing gray-level intensity of the
struts over time, the evaluation of quantitative changes in
hyperechogenicity can be useful to follow the in vivo degra-
dation of the scaffold.Whereas the ﬁrst ABSORB generation
showed at 6 months a 50% reduction in hyperechogenicity,
the second ABSORB generation (1.1), designed to prolong
the duration of luminal scaffolding, showed a 15% and 20%
reduction in hyperechogenicity at 6 and 12 months, respec-
tively, compared with post-implantation. These ﬁndings
conﬁrm the value of the manufacturing changes and suggest
a slower degradation rate of the scaffold.
Objectives This study sought to investigate quantitative
and homogeneity differential echogenicity changes of the
ABSORB scaffold (1.1) during the ﬁrst year after
implantation.
Background The imaging of the ABSORB bioresorbable
vascular scaffold degradation by intravascular ultrasound
(IVUS) has previously demonstrated diminishing gray-level
intensity of the struts over time that can be evaluated by
IVUS-based differential echogenicity. The ﬁrst generation
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echogenicity at 6 months and restoration of the pre-
ABSORB implantation values at 2 years. The second
generation of ABSORB (1.1), investigated in the ABSORB
B trial, was modiﬁed to prolong the duration of luminal
scaffolding.
Methods A total of 63 patients were examined by IVUS
immediately post-implantation and at 6-month (Cohort B1,
n ¼ 28) or 12-month (Cohort B2, n ¼ 35) follow-up.
IVUS-based tissue composition analysis software was used
to quantify changes in hyperechogenicity over time in the
scaffolded regions. Relative changes in hyperechogenicity
were calculated as: 100  (% hyperechogenicity at
follow-up  % hyperechogenicity at baseline)/% hyper-
echogenicity at baseline.
Results At 6- and 12-month follow-up, there was a 15%
(from 22.58  9.77% to 17.42  6.69%, p ¼ 0.001) and
20% (from 23.51  8.57% to 18.25  7.19%, p < 0.001)
reduction in hyperechogenicity, respectively, compared
with post-implantation values. No difference in hyper-
echogenicity changes were observed between the proximal,
medial, or distal part of the scaffolded segment.
Conclusions Quantitative differential echogenicity changes
of the ABSORB scaffold (1.1) during the ﬁrst 12 months
after implantation are lower compared with those previously
observed with its ﬁrst generation (1.0), conﬁrming the value
of the manufacturing changes and suggesting a slower
degradation rate of the scaffold (259).Intracoronary Optical Diagnostics: Current Status,
Limitations, and Potential
Optical coherence tomography (OCT), is a novel intravas-
cular imaging modality analogous to intravascular ultrasound
but uses light instead of sound. This review details the
background, development, and status of current investiga-
tion using OCT, and discusses advantages, limitations, and
likely future developments. It provides indications for
possible future clinical use, and places OCT in the context of
current intravascular imaging in what is a rapidly changing
ﬁeld of investigation (260).Carotid Artery Stenting in Acute Stroke
Objectives The purpose of this study is to demonstrate the
technical success of carotid artery stenting in acute extra-
cranial internal carotid artery (ICA) occlusion as well as the
beneﬁt in clinical outcome.
Background Stroke caused by acute occlusion of the ICA is
associated with a signiﬁcant level of morbidity and mortality.
For this type of lesion, treatment with standard intravenous
thrombolysis alone leads to a good clinical outcome in only
17% of the cases, with a death rate as high as 55%.
Recanalization of the occluded ICA can lead to an
improvement in acute symptoms of stroke, prevent possible
deterioration, and reduce long-term stroke risk. At present,there is no consensus treatment for patients with acute
ischemic stroke presenting with severe clinical symptoms
due to atherosclerotic occlusion of the extracranial ICA.
Methods Carotid artery stenting was performed in 22
patients with acute atherosclerotic extracranial ICA occlu-
sion within 6 h of stroke symptom onset. In 18 patients,
there was an additional intracranial occlusion at the level of
the terminal segment of the ICA (n ¼ 4) and at the level of
the middle cerebral artery (n ¼ 14). Intracranial occlusions
were either treated with the Penumbra system or the Soli-
taire stent–based recanalization system, or a combination of
mechanical recanalization and intra-arterial thrombolysis.
Recanalization results were assessed by angiography imme-
diately after the procedure. The neurologic status was eval-
uated before and after the treatment with a follow-up as long
as 90 days using the National Institutes of Health Stroke
Scale and the modiﬁed Rankin Scale.
Results Successful revascularization of extracranial ICA
with acute stent implantation was achieved in 21 patients
(95%). There was no acute stent thrombosis. After
successful recanalization of the origin of the ICA, the
intracranial recanalization with Thrombolysis In Myocar-
dial Infarction ﬂow grade 2/3 was achieved in 11 of the 18
patients (61%). The overall recanalization rate (extracranial
and intracranial) was 14 of 22 patients (63%). Nine
patients (41%) had a modiﬁed Rankin Scale score of 2 at
90 days. The mortality rate was 13.6% at 90 days.
Conclusions Carotid artery stenting in acute atheroscle-
rotic extracranial ICA occlusion with severe stroke symp-
toms is feasible, safe, and useful within the ﬁrst 6 h after
symptom onset (261).CHADS2 and CHA2DS2-VASc Scores in the
Prediction of Clinical Outcomes in Patients With
Atrial Fibrillation After Catheter Ablation
Objectives This study aimed to evaluate whether
CHADS2 and CHA2DS2-VASc scores are useful for risk
stratiﬁcation in patients after catheter ablation of atrial
ﬁbrillation (AF).
Background AF is associated with increased risk of
cardiovascular events. However, limited data are available on
the predictors of adverse events in patients with AF after
catheter ablation.
Methods A total of 565 patients with AF who underwent
catheter ablation were enrolled in the study. The clinical
endpoint was occurrence of thromboembolic events
(ischemic stroke, transient ischemic attack, peripheral
embolism, or pulmonary embolisms) or death during follow-
up after catheter ablation.
Results During a follow-up of 39.2  22.6 months, 27
patients (4.8%) experienced adverse events. Both the
CHADS2 and CHA2DS2-VASc scores were useful
predictors of events in separate multivariate models. The
areas under the receiver-operator characteristic curves based
on the CHADS2 and CHA2DS2-VASc scores in predicting
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difference did not reach statistical signiﬁcance (p ¼ 0.116),
the CHA2DS2-VASc score could be used to further stratify
the patients with CHADS2 scores of 0 or 1 into 2 groups
with different event rates (7.1% vs. 1.1%, p ¼ 0.003) at
a cutoff value of 2.
Conclusions The CHADS2 and CHA2DS2-VASc scores
are useful predictors of adverse events after catheter ablation
of AF (262).Alcohol Septal Ablation for the Treatment of
Hypertrophic Obstructive Cardiomyopathy: A
Multicenter North American Registry
Objectives The purpose of the study is to identify the
predictors of clinical outcome (mortality and survival
without repeat septal reduction procedures) of alcohol septal
ablation for the treatment of patients with hypertrophic
obstructive cardiomyopathy.
Background Alcohol septal ablation is used for treatment
of medically refractory hypertrophic obstructive cardiomy-
opathy patients with severe outﬂow tract obstruction.
The existing literature is limited to single-center results, and
predictors of clinical outcome after ablation have not been
determined. Registry results can add important data.
Methods Hypertrophic obstructive cardiomyopathy
patients (N ¼ 874) who underwent alcohol septal ablation
were enrolled. The majority (64%) had severe obstruction at
rest, and the remaining had provocable obstruction. Before
ablation, patients had severe dyspnea (New York Heart
Association [NYHA] functional class III or IV: 78%) and/or
severe angina (Canadian Cardiovascular Society angina class
III or IV: 43%).
Results Signiﬁcant improvement (p < 0.01) occurred after
ablation (w5% in NYHA functional classes III and IV, and
8 patients in Canadian Cardiovascular Society angina class
III). There were 81 deaths, and survival estimates at 1, 5,
and 9 years were 97%, 86%, and 74%, respectively. Left
anterior descending artery dissections occurred in 8 patients
and arrhythmias in 133 patients. A lower ejection fraction at
baseline, a smaller number of septal arteries injected with
ethanol, a larger number of ablation procedures per patient,
a higher septal thickness post-ablation, and the use beta-
blockers post-ablation predicted mortality.
Conclusions Variables that predict mortality after ablation,
include baseline ejection fraction and NYHA functional
class, the number of septal arteries injected with ethanol,
post-ablation septal thickness, beta-blocker use, and the
number of ablation procedures (263).Safety and Efﬁcacy of Antiplatelet and
Antithrombotic Therapy in Acute Coronary
Syndrome Patients With Chronic Kidney Disease
Chronic kidney disease (CKD) is prevalent and affects an
ever-increasing proportion of patients presenting with acutecoronary syndrome (ACS). Patients with CKD have
a higher risk of ACS and signiﬁcantly higher mortality, and
are also predisposed to increased bleeding complications.
Antiplatelet and antithrombotic drugs form the bedrock of
management of patients with ACS. Most randomized trials
of these drugs exclude patients with CKD, and current
guidelines for management of these patients are largely
based on these trials. We aim to review the safety and efﬁ-
cacy of these drugs in patients with CKD presenting with
ACS (264).Stroke Associated With Surgical and
Transcatheter Treatment of Aortic Stenosis: A
Comprehensive Review
Stroke is a potential complication of treating patients with
aortic stenosis via surgical aortic valve replacement (AVR),
transcatheter aortic valve replacement (TAVR), and balloon
aortic valvuloplasty. Because there are limited and hetero-
geneous data on the incidence, risk factors, and outcomes of
stroke among patients being treated for aortic stenosis, we
performed a comprehensive review of the literature. The risk
of stroke after AVR in the general population is approxi-
mately 1.5%, and the risk is increased (to approximately 2%
to 4%) in older and higher-risk patients. Strokes were re-
ported in 1.5% to 6% of patients treated with TAVR, and in
the only randomized trial of AVR versus TAVR, there was
an increased risk of 30-day strokes (minor and major strokes
and transient ischemic attacks) with TAVR (5.5% vs. 2.4%,
p ¼ 0.04) (265).Multimodality Imaging in Transcatheter Aortic
Valve Implantation and Post-Procedural Aortic
Regurgitation: Comparison Among Cardiovascular
Magnetic Resonance, Cardiac Computed
Tomography, and Echocardiography
Objectives The purpose of this study was to determine
imaging predictors of aortic regurgitation (AR) after trans-
catheter aortic valve implantation (TAVI) and the agree-
ment and reproducibility of cardiovascular magnetic
resonance (CMR), cardiac computed tomography (CCT),
and transthoracic echocardiography (TTE) in aortic root
assessment.
Background The optimal imaging strategy for planning
TAVI is unclear with a paucity of comparative multi-
modality imaging data. The association between aortic root
morphology and outcomes after TAVI also remains
incompletely understood.
Methods A total of 202 consecutive patients assessed by
CMR, CCT, and TTE for TAVI were studied. Agreement
and variability among and within imaging modalities was
assessed by Bland-Altman analysis. Postoperative AR was
assessed by TTE.
Results Of the 202 patients undergoing TAVI assessment
with both CMR and TTE, 133 also underwent CCT. Close
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dimensions of the aortic annulus (bias, 0.4 mm; 95% limits
of agreement: 5.7 to 5.0 mm), and similarly for sinus of
Valsalva, sinotubular junction, and ascending aortic
measures. Agreement between TTE-derived measures and
either CMR or CCT was less precise. Intraobserver and
interobserver variability were lowest with CMR. The pres-
ence and severity of AR after TAVI were associated with
larger aortic valve annulus measurements by both CMR
(p ¼ 0.03) and CCT (p ¼ 0.04) but not TTE-derived
measures (p ¼ 0.10). Neither CCT nor CMR measures of
annulus eccentricity, however, predicted AR after TAVI
(p ¼ 0.33 and p ¼ 0.78, respectively).
Conclusions In patients undergoing imaging assessment
for TAVI, the presence and severity of AR after TAVI were
associated with larger aortic annulus measurements by both
CMR and CCT, but not TTE. Both CMR and CCT
provide highly reproducible information in the assessment of
patients undergoing TAVI (266).Long-Term Outcomes After Transcatheter Aortic
Valve Implantation in High-Risk Patients With
Severe Aortic Stenosis: The U.K. TAVI (United
Kingdom Transcatheter Aortic Valve Implantation)
Registry
Objectives The objective was to deﬁne the characteristics
of a real-world patient population treated with transcatheter
aortic valve implantation (TAVI), regardless of technology
or access route, and to evaluate their clinical outcome over
the mid to long term.
Background Although a substantial body of data exists in
relation to early clinical outcomes after TAVI, there are few
data on outcomes beyond 1 year in any notable number of
patients.
Methods The U.K. TAVI (United Kingdom Transcatheter
Aortic Valve Implantation) Registry was established to
report outcomes of all TAVI procedures performed within
the United Kingdom. Data were collected prospectively on
870 patients undergoing 877 TAVI procedures up until
December 31, 2009. Mortality tracking was achieved in
100% of patients with mortality status reported as of
December 2010.
Results Survival at 30 days was 92.9%, and it was 78.6%
and 73.7% at 1 year and 2 years, respectively. There was
a marked attrition in survival between 30 days and 1 year. In
a univariate model, survival was signiﬁcantly adversely
affected by renal dysfunction, the presence of coronary artery
disease, and a nontransfemoral approach; whereas left
ventricular function (ejection fraction <30%), the presence
of moderate/severe aortic regurgitation, and chronic
obstructive pulmonary disease remained the only indepen-
dent predictors of mortality in the multivariate model.
Conclusions Midterm to long-term survival after TAVI
was encouraging in this high-risk patient population,although a substantial proportion of patients died within the
ﬁrst year (267).Impact of Platelet Reactivity on Clinical Outcomes
After Percutaneous Coronary Intervention: A
Collaborative Meta-Analysis of Individual
Participant Data
Objectives The purpose of the study was to systemati-
cally evaluate the signiﬁcance of platelet reactivity on
clopidogrel treatment on adverse cardiovascular events
using a collaborative meta-analysis using patient-level data
for the VerifyNow P2Y12 assay (Accumetrics, San Diego,
California).
Background Clinical evidence has been controversial
regarding the inﬂuence of clopidogrel on treatment platelet
reactivity and ischemic outcomes.
Methods MEDLINE, Scopus, and the Cochrane library
databases were searched through January 2010. A database
containing individual patient-level time-to-event data was
generated from identiﬁed studies. The primary outcome of
interest was a composite of death, myocardial infarction
(MI), or stent thrombosis. Secondary outcomes included
the incidence of: 1) death; 2) MI; and 3) stent
thrombosis.
Results A total of 6 studies with 3,059 patients was
included. In each study, clopidogrel responsiveness was
assessed using the same point-of-care assay after percu-
taneous coronary intervention. The primary endpoint
occurred more frequently in higher quartiles of P2Y12
reaction unit (PRU) values: quartile I, 5.8%; quartile II,
6.9%; quartile III, 10.9%; quartile IV, 15.8% (p < 0.001).
Taking quartile I as referent, the hazard ratios (HRs)
for the primary endpoint were as follows: quartile II, HR:
1.13 (95% conﬁdence interval [CI]: 0.72 to 1.78;
p ¼ 0.60); quartile III, HR: 1.82 (95% CI: 1.20 to 2.75;
p ¼ 0.005); quartile IV, HR: 2.62 (95% CI: 1.78 to
3.87; p < 0.001). On a continuous scale, every 10-U
increase in PRU was associated with a signiﬁcantly
higher rate of the primary endpoint (HR: 1.04; 95% CI:
1.03 to 1.06; p < 0.0001). According to receiver-
operating characteristic curve analysis, a PRU value of
230 appeared to best predict death, MI, or stent
thrombosis (p < 0.001). A PRU value 230 was asso-
ciated with a higher rate of the composite primary
endpoint (HR: 2.10; 95% CI: 1.62 to 2.73; p < 0.0001),
as well as the individual endpoints of death (HR: 1.66;
95% CI: 1.04 to 2.68; p ¼ 0.04), MI (HR: 2.04; 95%
CI: 1.51 to 2.76; p < 0.001), and stent thrombosis (HR:
3.11; 95% CI: 1.50 to 6.46; p ¼ 0.002).
Conclusions In this collaborative meta-analysis, the level of
on-treatment platelet reactivity according to the P2Y12 assay
is associated with long-term cardiovascular events after
percutaneous coronary intervention, including death, MI,
and stent thrombosis (268).
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e343Carotid Revascularization Immediately Before
Urgent Cardiac Surgery: Practice Patterns
Associated With the Choice of Carotid Artery
Stenting or Endarterectomy: A Report From the
CARE (Carotid Artery Revascularization and
Endarterectomy) Registry
Objectives We describe characteristics associated with use
of endarterectomy (CEA) versus stenting (CAS) in patients
before urgent cardiac surgery.
Background The optimal modality of carotid revasculari-
zation preceding cardiac surgery is unknown.
Methods Retrospective evaluation of the CARE (Carotid
Artery Revascularization and Endarterectomy) registry from
January 2005 to April 2010 was performed on patients
undergoing CEA or CAS preceding urgent cardiac surgery
within 30 days. Baseline characteristics were compared, and
multivariate adjustment was performed.
Results Of 451 patients who met study criteria, 255
underwent CAS and 196 underwent CEA. Both procedures
increased over time to a similar degree (p ¼ 0.18). Patients
undergoing CAS had more frequent history of peripheral
artery disease (38.2% vs. 26.5%, p < 0.01), neck surgery
(5.5% vs. 1.0%, p ¼ 0.01), neck radiation (4.3% vs. 1.0%,
p ¼ 0.04), left-main coronary disease (34.8% vs. 23.5%, p <
0.01), neurological events (45.8% vs. 31.3%, p < 0.01),
carotid intervention (20.8% vs. 7.6%, p < 0.01), and higher
baseline creatinine (1.3 vs. 1.1 mg/dl, p ¼ 0.02). The target
carotid arteries of CAS patients were more likely to be
symptomatic in the 6 months before revascularization and
have restenosis from prior CEA. Patients undergoing CAS
had a lower American Society of Anesthesiology grade.
Midwest hospitals were less likely to perform CAS than
CEA, whereas in the other regions CAS was more common
(p < 0.01). Non-Caucasian race, a history of heart failure,
previous carotid procedures, prior stroke, left main coronary
artery stenosis, lower American Society of Anesthesiology
grade, and teaching hospital were independent predictors of
patients who would receive CAS.
Conclusions Carotid artery stenting and CEA have
increased among patients undergoing urgent cardiac surgery.
Patients who underwent CAS had more vascular disease but
lower acute pre-surgical risk. Signiﬁcant regional variation in
procedure selection exists (269).
Carotid Artery Stenting and Cardiac Surgery in
Symptomatic Patients
Objectives The purpose of this study was to evaluate
the feasibility and safety of the combined outcome of carotid
artery stenting (CAS) and coronary artery bypass graft
(CABG) surgery in neurologically symptomatic patients.
Background The risk of perioperative stroke in patients
undergoing CABG who report a prior history of transient
ischemic attack or stroke has been associated with a 4-fold
increased risk as compared to the risk for neurologically
asymptomatic patients. It seems appropriate to offerprophylactic carotid endarterectomy to neurologically
symptomatic patients who have signiﬁcant carotid artery
disease and are scheduled for CABG. The CAS-CABG
outcome for symptomatic patients remains underreported,
notwithstanding randomized data supporting CAS for high-
risk patients.
Methods In a prospective, single-center study, the peri-
procedural and long-term outcomes of 57 consecutive
patients who underwent CAS before cardiac surgery were
analyzed.
Results The procedural success rate of CAS was 98%. The
combined death, stroke, and myocardial infarction rate was
12.3%. The death and major stroke rate from time of CAS
to 30 days after cardiac surgery was 3.5%. The myocardial
infarction rate from time of CAS to 30 days after cardiac
surgery was 1.5%.
Conclusions This is the ﬁrst single-center study reporting
the combined outcome of CAS-CABG in symptomatic
patients. The periprocedural complication rate and long-
term results of the CAS-CABG strategy in this high-risk
population support the reliability of this approach. In such
a high-risk population, this strategy might offer a valuable
alternative to the combined surgical approach; however,
a large randomized trial is clearly warranted (270).
Contemporary Clinical Applications of Coronary
Intravascular Ultrasound
Intravascular ultrasound (IVUS) provides valuable informa-
tion on the coronary vascular lumen and wall and has been
an important tool in the cardiac catheterization laboratory
for over 2 decades. The major utility of IVUS relates to
optimizing stent deployment, particularly in complex
lesions. In percutaneous coronary intervention with bare-
metal stents, IVUS guidance reduces restenosis. In percu-
taneous coronary intervention with drug-eluting stents,
IVUS guidance may reduce rates of stent thrombosis with
little affect on restenosis. The beneﬁt of IVUS guidance is
most important in complex lesion subsets, such as left main
and bifurcation lesions, where studies suggest that IVUS
guidance may reduce mortality. Whereas IVUS luminal area
measurements have been used to assess intermediate lesion
severity, recent studies have demonstrated that IVUS accu-
rately identiﬁes nonischemic lesions for which percutaneous
coronary intervention can be safely deferred, but cannot
accurately predict hemodynamically signiﬁcant lesions and
should not solely be used to justify revascularization. In the
current review, we focus on clinical applications of IVUS in
interventional cardiology (271).
Aortic Annulus Diameter Determination by
Multidetector Computed Tomography:
Reproducibility, Applicability, and Implications for
Transcatheter Aortic Valve Implantation
Objectives This study sought to determine the most
reproducible multidetector computed tomography (MDCT)
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methods to improve the applicability of these measurements
for transcatheter aortic valve implantation.
Background The reproducibility and applicability of
MDCT annular measurements to guide transcatheter aortic
valve implantation remain unclear.
Methods Annular measurements were performed in 50
patients planed for transcatheter aortic valve implantation in
multiple planes: basal ring (short- and long-axis, mean
diameter, area-derived diameter), coronal, sagittal, and 3-
chamber projections. A theoretical model was developed
taking into account the differences between the most
reproducible MDCT measurements and transesophageal
echocardiography to guide valve size choice.
Results The most reproducible measurements were the
area-derived diameter and basal ring average diameter (inter-
reader intraclass correlation coefﬁcient: 0.87 [95% conﬁ-
dence interval: 0.81 to 0.92] and 0.80 [95% conﬁdence
interval: 0.70 to 0.87]; respectively; intrareader >0.90 for all
readers). These were generally larger than transesophageal
echocardiography diameters (mean difference of 1.5  1.6
mm and 1.1  1.7 mm, respectively). When a strategy of
valve-sizing is undertaken using these CT measurements
using an echocardiographic sizing scale, a different THV
size would be selected in 44% and 40% of cases, respectively.
When adjusting the sizing cutoffs to account for the
differences in observed diameters, this was reduced to 10%
to 12% (p < 0.01 for both, respectively).
Conclusions The most reproducible MDCT measure-
ments of the annulus are the area-derived diameter and basal
ring average diameter, with derived values generally larger
than those obtained with echocardiography. If MDCT is
used for valve sizing, a strategy incorporating these differ-
ences may be important. MDCT using these easily derived
measurements may be ideally suited to sizing transcatheter
aortic valves as they account for the eccentricity of the aortic
annulus, are reproducible, and are noninvasive (272).Valve-in-Valve Transcatheter Aortic Valve
Implantation for Degenerated Bioprosthetic Heart
Valves
Objectives We sought to analyze outcomes of patients with
degenerated surgically implanted bioprosthetic heart valves
undergoing valve-in-valve (viv) transcatheter aortic valve
implantation (TAVI).
Background Redo cardiac surgery for degenerated bio-
prosthetic heart valves is associated with increased risks,
particular in elderly patients with comorbidities. For these
patients, TAVI may be an attractive, less invasive treatment
option.
Methods Data from 47 patients age 64 to 97 years (logistic
euroSCORE: 35.0  18.5%) undergoing transfemoral (n ¼
25) or transapical (n ¼ 22) viv-TAVI for failed bioprosthetic
aortic valves 113  65 months after initial surgery at 9
clinical sites in Germany and Switzerland were analyzed.Results Valve-in-valve TAVI was technically successful in
all patients, with 2 patients requiring bailout implantation of
a second TAVI prosthesis for severe regurgitation during the
procedure. There was 1 procedural death as the result of
low-output failure. Valvular function after viv-TAVI was
excellent with respect to valve competence, but increased
transvalvular gradients 20 mm Hg were noted in 44% of
patients. Vascular access complications occurred in 6 (13%)
patients, and 5 (11%) patients required new pacemaker
implantation after viv-TAVI. Renal failure requiring dialysis
occurred in 4 (9%) patients. Mortality at 30 days was 17% (1
procedural and 7 post-procedural deaths), with 3 of 8
fatalities the result of non–valve-related septic complications.
Conclusions Valve-in-valve TAVI can be performed with
high technical success rates, acceptable post-procedural
valvular function, and excellent functional improvement.
However, in these predominantly elderly high-risk patients
with multiple comorbidities, viv-TAVI was associated with
17% mortality, often because of septic complications arising
in the post-operative phase (273).Impact of Lesion Length and Vessel Size on
Clinical Outcomes After Percutaneous Coronary
Intervention With Everolimus- Versus Paclitaxel-
Eluting Stents: Pooled Analysis From the SPIRIT
(Clinical Evaluation of the XIENCE V Everolimus
Eluting Coronary Stent System) and COMPARE
(Second-generation everolimus-eluting and
paclitaxel-eluting stents in real-life practice)
Randomized Trials
Objectives The aim of this study was to investigate the
impact of reference vessel diameter (RVD) and lesion length
(LL) on the relative safety and efﬁcacy of everolimus-eluting
stents (EES) and paclitaxel-eluting stents (PES).
Background Lesion length and RVD are well-known
predictors of adverse events after percutaneous coronary
intervention.
Methods Patient-level data were pooled from the
randomized SPIRIT (Clinical Evaluation of the XIENCE
V Everolimus Eluting Coronary Stent System) II, III, IV
and COMPARE (Second-generation everolimus-eluting
and paclitaxel-eluting stents in real-life practice) trials.
Quantitative angiographic core laboratory data were available
for 6,183 patients randomized to EES (n ¼ 3,944) or PES
(n ¼ 2,239). Long lesions and small vessels were deﬁned as
LL >median (13.4 mm) and RVD median (2.65 mm),
respectively. Major adverse cardiac events (MACE) (con-
sisting of cardiac death, myocardial infarction, or ischemia-
driven target lesion revascularization) were assessed at 2
years, according to stent type in 3 groups: short lesions in
large vessels (group A, n ¼ 1,297); long lesions or small
vessels but not both (group B, n ¼ 2,981); and long lesions
in small vessels (group C, n ¼ 1,905).
Results The pooled 2-year MACE rates were 5.6%,
8.2%, and 10.4% in Groups A, B, and C, respectively
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lesion group and stent type (p ¼ 0.64), indicating lower
MACE with EES compared with PES regardless of LL and
RVD. However, the absolute difference was largest in
Groups B and C. In Group A, 2-year MACE rates were not
signiﬁcantly different between EES and PES (4.8% vs.
7.0%, respectively, p ¼ 0.11). In contrast, EES was associ-
ated with lower 2-year rates of MACE in Group B (6.6% vs.
11.2%, p < 0.01) and in Group C (9.1% vs. 12.7%, p ¼
0.008) as well as lower rates of myocardial infarction, target
lesion revascularization, and stent thrombosis. Multivariable
analysis conﬁrmed EES versus PES as an independent
predictor of freedom from MACE in Groups B and C.
Conclusions Patients with short lesions in large vessels
have low rates of MACE at 2 years after treatment with
either EES or PES. In higher-risk patients with long lesions
and/or small vessels, EES results in signiﬁcant improve-
ments in both clinical safety and efﬁcacy outcomes. (A
Clinical Evaluation of the XIENCE V Everolimus Eluting
Coronary Stent System in the Treatment of Patients With
de Novo Native Coronary Artery Lesions; NCT00180310;
SPIRIT III: A Clinical Evaluation of the Investigational
Device XIENCE V Everolimus Eluting Coronary Stent
System [EECSS] in the Treatment of Subjects With de
Novo Native Coronary Artery Lesions; NCT00180479;
SPIRIT IV Clinical Trial: Clinical Evaluation of the
XIENCE V Everolimus Eluting Coronary Stent System in
the Treatment of Subjects With de Novo Native Coronary
Artery Lesions; NCT00307047; A Randomized Controlled
Trial of Everolimus-eluting Stents and Paclitaxel-eluting
Stents for Coronary Revascularization in Daily Practice:
The COMPARE Trial; NCT01016041) (274).Fractional Flow Reserve in Unstable Angina and
Non–ST-Segment Elevation Myocardial Infarction:
Experience From the FAME (Fractional ﬂow reserve
versus Angiography for Multivessel Evaluation)
Study
Objectives The aim of this study was to study whether
there is a difference in beneﬁt of fractional ﬂow reserve
(FFR) guidance for percutaneous coronary intervention
(PCI) in multivessel coronary disease in patients with
unstable angina (UA) or non–ST-segment elevation
myocardial infarction (NSTEMI), compared with stable
angina (SA).
Background The use of FFR to guide PCI has been well
established for patients with SA. Its use in patients with UA
or NSTEMI has not been investigated prospectively.
Methods In the FAME (Fractional ﬂow reserve versus
Angiography for Multivessel Evaluation) study 1,005
patients with multivessel disease amenable to PCI were
included and randomized to either angiography-guided PCI
of all lesions 50% or FFR-guided PCI of lesions with an
FFR 0.80. Patients admitted for UA or NSTEMI with
positive troponin but total creatine kinase <1,000 U/l wereeligible for inclusion. We determined 2-year major adverse
cardiac event rates of these patients and compared it with
stable patients.
Results Of 1,005 patients, 328 had UA or NSTEMI.
There was no evidence for heterogeneity among the
subgroups for any of the outcome variables (all p values
>0.05). Using FFR to guide PCI resulted in similar risk
reductions of major adverse cardiac events and its compo-
nents in patients with UA or NSTEMI, compared with
patients with SA (absolute risk reduction of 5.1% vs. 3.7%,
respectively, p ¼ 0.92). In patients with UA or NSTEMI,
the number of stents was reduced without increase in
hospital stay or procedure time and with less contrast use, in
similarity to stable patients.
Conclusions The beneﬁt of using FFR to guide PCI in
multivessel disease does not differ between patients with UA
or NSTEMI, compared with patients with SA (275).Intravascular Ultrasound-Derived Predictors for
Fractional Flow Reserve in Intermediate Left Main
Disease
Objectives The aim of this study was to determine the best
intravascular ultrasound (IVUS) criteria for predicting
physiological signiﬁcance of left main (LM) stenosis with
fractional ﬂow reserve (FFR) as the standard.
Background For identifying signiﬁcant LM disease,
optimal cutoff of minimal lumen area (MLA) and its
accuracy remain debatable.
Methods We identiﬁed 55 patients (31 stable and 24
unstable angina) with an isolated LM lesion of 30% to 80%
angiographic diameter stenosis who underwent IVUS and
invasive physiological assessment before intervention.
Results The FFR at maximum hyperemia signiﬁcantly
correlated with IVUS-measured MLA within the LM
(r ¼ 0.623, p < 0.001), plaque burden (r ¼ 0.548,
p < 0.001), angiographic diameter stenosis (r ¼ 0.449,
p ¼ 0.002), and angiographic length of the lesion
(r ¼ 0.292, p ¼ 0.046). The FFR was signiﬁcantly
lower in 18 lesions with plaque rupture than 37 lesions
without plaque rupture (0.76  0.09 vs. 0.82  0.09,
p ¼ 0.018). The independent determinants of FFR as
a continuous variable were MLA (beta ¼ 0.598, p <
0.001) and plaque rupture (beta ¼ 0.255, p ¼ 0.038).
Furthermore, the MLA within the LM was the only
independent determinant for FFR <0.80 (adjusted odds
ratio: 0.312, p < 0.001) and for FFR <0.75 (adjusted
odds ratio: 0.196, p ¼ 0.001). The IVUS MLA value
within the LM that best predicted FFR <0.80 was <4.8
mm2 (89% sensitivity, 83% speciﬁcity). In addition, the
cutoff value of plaque burden to predict FFR <0.80
was 72% (73% sensitivity, 79% speciﬁcity). The best
cutoff values of the MLA and plaque burden for pre-
dicting FFR <0.75 were <4.1 mm2 (95% sensitivity,
83% speciﬁcity) and 76% (79% sensitivity, 80% speci-
ﬁcity), respectively.
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MLA <4.8 mm2 is a useful criterion for predicting
FFR <0.80 (276).
Long-Term Follow-Up After Fractional Flow
Reserve–Guided Treatment Strategy in Patients
With an Isolated Proximal Left Anterior
Descending Coronary Artery Stenosis
Objectives This study sought to evaluate the long-term
clinical outcome of patients with an angiographically inter-
mediate left anterior descending coronary artery (LAD)
stenosis in whom the revascularization strategy was based on
fractional ﬂow reserve (FFR).
Background When revascularization is based mainly on
angiographic guidance, a number of hemodynamically
nonsigniﬁcant stenoses will be revascularized.
Methods In 730 patients with a 30% to 70% isolated
stenosis in the proximal LAD and no signiﬁcant valvular
disease, FFR measurements were obtained to guide treat-
ment strategy. When FFR was 0.80, the patients (n ¼
564) were treated medically (medical group); when FFR
was <0.80, the patients (n ¼ 166) underwent a revasculari-
zation procedure (revascularization group; 13% coronary
artery bypass graft surgery and 87% percutaneous coronary
intervention). A 100% long-term clinical follow-up (median
follow-up: 40 months) was obtained. The 5-year survival of
the medical group was compared with that of a reference
population. For each patient, 4 controls were selected from
an age- and sex-matched control population.
Results The 5-year survival estimate was 92.9% in the
medical group versus 89.6% in the controls (p ¼ 0.74). The
mean diameter stenosis was signiﬁcantly smaller in the
medical than in the revascularization group (39  14% vs. 54
 13%, p < 0.0001), but there was a large overlap between
both groups. The 5-year event-free survival estimates (death,
myocardial infarction, and target vessel revascularization)
were 89.7% and 68.5%, respectively (p < 0.0001).
Conclusions Medical treatment of patients with a hemo-
dynamically nonsigniﬁcant stenosis (FFR 0.80) in the
proximal LAD is associated with an excellent long-term
clinical outcome with survival at 5 years similar to an age-
and sex-matched control population (277).
Transcatheter Valve-in-Valve Implantation Using
CoreValve Revalving System for Failed Surgical
Aortic Bioprostheses
Objectives The purpose of this study was to evaluate the
performance of CoreValve Revalving System (CRS) (Med-
tronic, Minneapolis, Minnesota) implantation in patients
with failed aortic bioprostheses.
Background Transcatheter aortic valve implantation with
the CRS is an effective option in high-risk patients with
severe aortic stenosis. It may be an option for patients with
a failed aortic bioprosthesis, especially when the risk of
a surgical redo is deemed prohibitive.Methods CRS “valve-in-valve” implantation was per-
formed in 25 high-risk patients with a failed bioprosthesis.
Their mean age was 82.4  3.2 years. New York Heart
Association functional classes III and IV were present in 21
and 4 patients, respectively. The logistic EuroSCORE was
31.5  14.8%, whereas the Society of Thoracic Surgeons
score was 8.2  4.2. Patients/prostheses were divided in type
A (mainly stenotic, n ¼ 9) and type B (mainly regurgitant,
n ¼ 16).
Results The implantation success rate was 100%. In group
A, the peak aortic gradient signiﬁcantly decreased from 77.6
 21.6 mm Hg to 34.6  19.4 mm Hg (p ¼ 0.001). In all
but 2 patients in group B, no signiﬁcant regurgitation was
observed post-implantation. No patients died during the
procedure. At 30 days, there were 3 deaths (12%), 2
myocardial infarctions (8%), and 3 atrioventricular blocks
requiring pacemaker implantation (12%). At a mean follow-
up of 6 months, there were another death (survival rate of
84%) and a pacemaker implantation (cumulative incidence
of 16%). New York Heart Association functional class
improved in all patients to I and II.
Conclusions CRS implantation was feasible and effective
regardless of the prevalent mode of failure. This ﬁnding may
signiﬁcantly affect the treatment of patients with a failed
bioprosthesis deemed at a prohibitive risk for surgical redo
(278).Safety and Efﬁcacy of Drug-Eluting Stents in Older
Patients With Chronic Kidney Disease: A Report
From the Linked CathPCI Registry–CMS Claims
Database
Objectives The purpose of this study was to determine the
safety and efﬁcacy of drug-eluting stents (DES) compared
with bare-metal stents (BMS) in older patients with chronic
kidney disease (CKD).
Background DES may be associated with late death and
myocardial infarction (MI) secondary to stent thrombosis.
However, data on outcomes in older patients with CKD are
limited.
Methods We estimated the glomerular ﬁltration rate
(GFR) of 283,593 patients 65 years of age and older
who underwent stent implantation between 2004 and
2007. In propensity-matched cohorts grouped by GFR,
the association between DES and BMS and the risk of
death, MI, revascularization, and major bleeding was
examined.
Results A total of 121,446 patients (42.8%) had CKD
(GFR <60 ml/min/1.73 m2). The 30-month mortality rate
for patients on long-term dialysis was 52.0%. In propensity-
matched pairs, placement of a DES compared with a BMS
in patients with normal renal function was associated with
signiﬁcant reductions in 30-month revascularization (hazard
ratio [HR]: 0.91; 95% conﬁdence interval [CI]: 0.86 to
0.95), MI (HR: 0.77; 95% CI: 0.71 to 0.83), and death
(HR: 0.73; 95% CI: 0.69 to 0.77), but no difference in
JACC Vol. 62, No. 18, 2013 The Editors
October 29, 2013:e245–e437 JACC Topic Collection: Interventional Cardiology
e347bleeding (HR: 0.89; 95% CI: 0.79 to 1.00). Lower MI and
mortality rates were also observed after DES compared with
BMS implantation in all CKD subgroups with the exception
of MI in the long-term dialysis group. Decreased rates of
revascularization did not extend to any subgroup of patients
with CKD.
Conclusions The safety of DES compared with BMS is
observed in all patients regardless of renal function and is
associated with reduced rates of MI and death in some
subsets of patients with CKD (279).Everolimus-Eluting Versus Sirolimus-Eluting
Stents in Patients Undergoing Percutaneous
Coronary Intervention: The EXCELLENT (Efﬁcacy of
Xience/Promus Versus Cypher to Reduce Late
Loss After Stenting) Randomized Trial
Objectives The goal of this study was to compare the
angiographic outcomes of everolimus-eluting stents (EES)
and sirolimus-eluting stents (SES) in a head-to-head
manner.
Background EES have been shown to be superior to
paclitaxel-eluting stents in inhibiting late loss (LL) and
clinical outcome. Whether EES may provide similar
angiographic and clinical outcomes compared with SES is
undetermined.
Methods This was a prospective, randomized, open-label,
multicenter trial to demonstrate the noninferiority of EES
compared with SES in preventing LL at 9 months. A total
of 1,443 patients undergoing percutaneous coronary inter-
vention were randomized 3:1 to receive EES or SES.
Routine follow-up angiography was recommended at 9
months. The primary endpoint was in-segment LL at 9
months, and major secondary endpoints included in-stent
LL at 9 months, target lesion failure, cardiac death,
nonfatal myocardial infarction, target lesion revasculariza-
tion, and stent thrombosis at 12 months. Data were
managed by an independent management center, and clin-
ical events were adjudicated by an independent adjudication
committee.
Results Clinical follow-up was available in 1,428 patients
and angiographic follow-up in 924 patients (1,215 lesions).
The primary endpoint of the study (in-segment LL at 9
months) was 0.11  0.38 mm and 0.06  0.36 mm for EES
and SES, respectively (p for noninferiority ¼ 0.0382). The
in-stent LL was also noninferior (EES 0.19  0.35 mm;
SES 0.15  0.34 mm; p for noninferiority ¼ 0.0121). The
incidence of clinical endpoints was not statistically different
between the 2 groups, including target lesion failure (3.75%
vs. 3.05%; p ¼ 0.53) and stent thrombosis (0.37% vs. 0.83%;
p ¼ 0.38).
Conclusions EES were noninferior to SES in inhibition of
LL after stenting, which was corroborated by similar rates of
clinical outcomes. (Efﬁcacy of Xience/Promus Versus
Cypher in Reducing Late Loss After Stenting [EXCEL-
LENT]; NCT00698607) (280).Hemodynamic and Clinical Impact of Prosthesis–
Patient Mismatch After Transcatheter Aortic Valve
Implantation
Objectives This study examined the mid-term hemody-
namic and clinical impact of prosthesis–patient mismatch
(PPM) in patients undergoing transcatheter aortic valve
implantation (TAVI) with balloon-expandable valves.
Background PPM can be observed after aortic valve
surgery. However, little is known about the incidence of
PPM in patients undergoing TAVI.
Methods Echocardiography and clinical assessment were
performed in 165 patients at baseline, before hospital
discharge, and at 6 months after TAVI. PPM was deﬁned as
an indexed effective oriﬁce area 0.85 cm2/m2.
Results Thirty patients (18.2%) showed PPM before
hospital discharge. At baseline, patients with PPM had
a larger body surface area (1.84  0.18 m2 vs. 1.73  0.18
m2, p ¼ 0.003) and a greater severity of aortic stenosis
(indexed valve area 0.35  0.09 cm2/m2 vs. 0.40  0.10
cm2/m2, p ¼ 0.005) than patients without PPM. Patients
with PPM demonstrated a slower and smaller reduction in
mean transaortic gradient, limited left ventricular (LV) mass
regression, and left atrial volume reduction over 6 months
compared with patients without PPM. LV ﬁlling pressure,
measured by E/e0, tended to remain elevated in patients with
PPM. Importantly, a higher proportion of patients with
PPM did not improve in New York Heart Association
functional class compared with patients without PPM
(36.7% vs. 1.5%, p < 0.001), although major adverse valve-
related and cardiovascular events did not differ between the
2 groups.
Conclusions PPM may be observed after TAVI and when
present may be accompanied by less favorable changes in
transvalvular hemodynamics, limited LV mass regression,
persistent elevated LV ﬁlling pressure, and less improvement
in clinical functional status (281).
Impact of In-Hospital Major Bleeding on Late
Clinical Outcomes After Primary Percutaneous
Coronary Intervention in Acute Myocardial
Infarction: The HORIZONS-AMI (Harmonizing
Outcomes With Revascularization and Stents in
Acute Myocardial Infarction) Trial
Objectives We aimed to investigate the long-term prog-
nosis of patients with in-hospital major bleeding (IHMB).
Background The effect of IHMB on the long-term prog-
nosis of patients undergoing primary percutaneous coronary
intervention (PCI) for ST-segment elevation myocardial
infarction is unknown.
Methods Primary PCI was performed in 3,345 (92.9%) of
3,602 patients in the HORIZONS-AMI (Harmonizing
Outcomes With Revascularization and Stents in Acute
Myocardial Infarction) trial; in-hospital protocol-deﬁned
non–coronary artery bypass graft–related major bleeding
developed in 231 (6.9%). We examined medication use at
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(composite of death, reinfarction, stroke, or ischemic target
vessel revascularization) at 3-year follow-up in patients with
and without IHMB.
Results At 3-year follow-up, patients with IHMB had
higher mortality (24.6% vs. 5.4%, p < 0.0001) and major
adverse cardiovascular events (40.3% vs. 20.5%, p < 0.0001).
The deleterious effect of major bleeding was observed within
1 month, between 1 month and 1 year, and between 1 and 3
years. IHMB was an independent predictor of mortality
(hazard ratio: 2.80; 95% conﬁdence interval: 1.89 to 4.16,
p < 0.0001) at 3-year follow up.
Conclusions Patients with IHMB after primary PCI have
signiﬁcantly increased 3-year rates of morbidity and
mortality. Further investigation is warranted to understand
the mechanisms underlying this relationship and to further
improve outcomes in patients with ST-segment myocardial
infarction. (Harmonizing Outcomes With Revascularization
and Stents in Acute Myocardial Infarction [HORIZONS-
AMI]; NCT00433966) (282).Comparative Effectiveness and Cost-Effectiveness
of Computed Tomography Screening for Coronary
Artery Calcium in Asymptomatic Individuals
Objectives The aim of this study was to assess the (cost-)
effectiveness of screening asymptomatic individuals at
intermediate risk of coronary heart disease (CHD) for
coronary artery calcium with computed tomography (CT).
Background Coronary artery calcium on CT improves
prediction of CHD.
Methods A Markov model was developed on the basis of
the Rotterdam Study. Four strategies were evaluated: 1)
current practice; 2) current prevention guidelines for
cardiovascular disease; 3) CT screening for coronary
calcium; and 4) statin therapy for all individuals. Asymp-
tomatic individuals at intermediate risk of CHD were
simulated over their remaining lifetime. Quality-adjusted life
years (QALYs), costs, and incremental cost-effectiveness
ratios were calculated.
Results In men, CT screening was more effective and more
costly than the other 3 strategies (CT vs. current
practice: þ0.13 QALY [95% conﬁdence interval (CI): 0.01
to 0.26], þ$4,676 [95% CI: $3,126 to $6,339]; CT vs.
statin therapy: þ0.04 QALY [95% CI: 0.02 to
0.13], þ$1,951 [95% CI: $1,170 to $2,754]; and CT vs.
current guidelines: þ0.02 QALY [95% CI: 0.04 to
0.09], þ$44 [95% CI: $441 to $486]). The incremental
cost-effectiveness ratio of CT calcium screening was
$48,800/QALY gained. In women, CT screening was more
effective and more costly than current practice (þ0.13
QALY [95% CI: 0.02 to 0.28], þ$4,663 [95% CI: $3,120
to $6,277]) and statin therapy (þ0.03 QALY [95%
CI: 0.03 to 0.12], þ$2,273 [95% CI: $1,475 to $3,109]).
However, implementing current guidelines was more
effective compared with CT screening (þ0.02 QALY [95%CI: 0.03 to 0.07]), only a little more expensive (þ$297
[95% CI: $8 to $633]), and had a lower cost per additional
QALY ($33,072/QALY vs. $35,869/QALY). Sensitivity
analysis demonstrated robustness of results in women but
considerable uncertainty in men.
Conclusions Screening for coronary artery calcium with
CT in individuals at intermediate risk of CHD is probably
cost-effective in men but is unlikely to be cost-effective in
women (283).Beneﬁt of Early Statin Therapy in Patients With
Acute Myocardial Infarction Who Have Extremely
Low Low-Density Lipoprotein Cholesterol
Objectives We investigated whether statin therapy could
be beneﬁcial in patients with acute myocardial infarction
(AMI) who have baseline low-density lipoprotein choles-
terol (LDL-C) levels below 70 mg/dl.
Background Intensive lipid-lowering therapy with a target
LDL-C value <70 mg/dl is recommended in patients with
very high cardiovascular risk. However, whether to use statin
therapy in patients with baseline LDL-C levels below 70
mg/dl is controversial.
Methods We analyzed 1,054 patients with AMI who had
baseline LDL-C levels below 70 mg/dl and survived at
discharge from the Korean Acute MI Registry between
November 2005 and December 2007. They were divided
into 2 groups according to the prescribing of statins at
discharge (statin group n ¼ 607; nonstatin group n ¼ 447).
The primary endpoint was the composite of 1-year major
adverse cardiac events, including death, recurrent MI, target
vessel revascularization, and coronary artery bypass grafting.
Results Statin therapy signiﬁcantly reduced the risk of the
composite primary endpoint (adjusted hazard ratio [HR]:
0.56; 95% conﬁdence interval [CI]: 0.34 to 0.89; p¼ 0.015).
Statin therapy reduced the risk of cardiac death (HR: 0.47;
95% CI: 0.23 to 0.93; p ¼ 0.031) and coronary revascular-
ization (HR: 0.45, 95% CI: 0.24 to 0.85; p ¼ 0.013).
However, there were no differences in the risk of the
composite of all-cause death, recurrent MI, and repeated
percutaneous coronary intervention rate.
Conclusions Statin therapy in patients with AMI with
LDL-C levels below 70 mg/dl was associated with improved
clinical outcome (284).Microembolization During Carotid Artery Stenting
in Patients With High-Risk, Lipid-Rich Plaque: A
Randomized Trial of Proximal Versus Distal
Cerebral Protection
Objectives The goal of this study was to compare the rate
of cerebral microembolization during carotid artery stenting
(CAS) with proximal versus distal cerebral protection in
patients with high-risk, lipid-rich plaque.
Background Cerebral protection with ﬁlters partially
reduces the cerebral embolization rate during CAS.
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embolization risk.
Methods Fifty-three consecutive patients with carotid
artery stenosis and lipid-rich plaque were randomized to
undergo CAS with proximal protection (MO.MA system,
n ¼ 26) or distal protection with a ﬁlter (FilterWire EZ, n¼
27). Microembolic signals (MES) were assessed by using
transcranial Doppler during: 1) lesion wiring; 2) pre-
dilation; 3) stent crossing; 4) stent deployment; 5) stent
dilation; and 6) device retrieval/deﬂation. Diffusion-
weighted magnetic resonance imaging was conducted
before CAS, after 48 h, and after 30 days.
Results Patients in the MO.MA group had higher
percentage diameter stenosis (89  6% vs. 86  5%, p ¼
0.027) and rate of ulcerated plaque (35% vs. 7.4%; p ¼
0.019). Compared with use of the FilterWire EZ,
MO.MA signiﬁcantly reduced mean MES counts (p <
0.0001) during lesion crossing (mean 18 [interquartile
range (IQR): 11 to 30] vs. 2 [IQR: 0 to 4]), stent crossing
(23 [IQR: 11 to 34] vs. 0 [IQR: 0 to 1]), stent deploy-
ment (30 [IQR: 9 to 35] vs. 0 [IQR: 0 to 1]), stent
dilation (16 [IQR: 8 to 30] vs. 0 [IQR: 0 to 1]), and total
MES (93 [IQR: 59 to 136] vs. 16 [IQR: 7 to 36]). The
number of patients with MES was higher with the Fil-
terWire EZ versus MO.MA in phases 3 to 5 (100% vs.
27%; p < 0.0001). By multivariate analysis, the type of
brain protection was the only independent predictor of
total MES number. No signiﬁcant difference was found in
the number of patients with new post-CAS embolic lesion
in the MO.MA group (2 of 14, 14%) as compared with
the FilterWire EZ group (9 of 21, 42.8%).
Conclusions In patients with high-risk, lipid-rich plaque
undergoing CAS, MO.MA led to signiﬁcantly lower
microembolization as assessed by using MES counts.
(Carotid Stenting in Patients With High Risk Carotid
Stenosis [“Soft Plaque”] [MOMA]; NCT01274676) (285).Evaluation of the Second Generation of
a Bioresorbable Everolimus-Eluting Vascular
Scaffold for the Treatment of De Novo Coronary
Artery Stenosis: 12-Month Clinical and Imaging
Outcomes
Objectives The aim of this study was to demonstrate that
the prevention of early scaffold area shrinkage of the
ABSORB BVS (Rev.1.1, Abbott Vascular, Santa Clara,
California) was sustained and not simply delayed by a few
months.
Background With improved scaffold design and modiﬁed
manufacturing process of its polymer, the second iteration of
ABSORB (BVS 1.1) has improved performance to prevent
a scaffold area reduction at 6 months.
Methods Fifty-six patients were enrolled and received 57
ABSORB scaffolds. Quantitative coronary angiography,
intravascular ultrasound (IVUS), analysis of radiofrequen-
cy backscattering, echogenicity and optical coherencetomography (OCT) were performed at baseline and at 12-
month follow-up.
Results Overall the scaffold area remained unchanged with
IVUS as well as with OCT, whereas the radiofrequency
backscattering and the echogenicity of the struts decreased
by 16.8% (p < 0.001) and 20% (p < 0.001), respectively;
more speciﬁcally, the strut core area on OCT decreased by
11.4% (p ¼ 0.003). Despite the absence of scaffold area loss,
pharmacological vasomotion was restored. On an intention-
to-treat basis, the angiographic late lumen loss amounted to
0.27  0.32 mm with an IVUS relative decrease in minimal
lumen area of 1.94% (p ¼ 0.12), without signiﬁcant changes
in mean lumen area. The OCT at follow-up showed that
96.69% of the struts were covered and that malapposition,
initially observed in 18 scaffolds was only detected at follow-
up in 4 scaffolds. Two patients experienced peri-procedural
and iatrogenic myocardial infarction, respectively, whereas 2
underwent repeat intervention, resulting in the major
adverse cardiac event rate of 7.1% (4 of 56).
Conclusions The 12-month performance of the second-
generation ABSORB bioresorbable everolimus-eluting
scaffold justiﬁes the conduct of a randomized trial against
current best standards. (A Clinical Evaluation of the Bio-
absorbable Everolimus Eluting Coronary Stent System
[BVS EECSS] in the Treatment of Patients With de Novo
Native Coronary Artery Lesions; NCT00856856) (286).Health-Related Quality of Life After Carotid
Stenting Versus Carotid Endarterectomy: Results
From CREST (Carotid Revascularization
Endarterectomy Versus Stenting Trial)
Objectives The purpose of this study was to compare
health-related quality of life (HRQOL) outcomes in patients
treated with carotid artery stenting (CAS) versus carotid
endarterectomy (CEA).
Background In CREST (Carotid Revascularization
Endarterectomy versus Stenting Trial), the largest
randomized trial of carotid revascularization to date, there
was no signiﬁcant difference in the primary composite
endpoint, but rates of stroke and myocardial infarction (MI)
differed between CAS and CEA. To help guide individu-
alized clinical decision making, we compared HRQOL
among patients enrolled in the CREST study. We also
performed exploratory analyses to evaluate the association
between periprocedural complications and HRQOL.
Methods We measured HRQOL at baseline, and after 2
weeks, 1 month, and 1 year among 2,502 patients randomly
assigned to either CAS or CEA in the CREST study. The
HRQOL was assessed using the Medical Outcomes Study
Short-Form 36 (SF-36) and 6 disease-speciﬁc scales
designed to study HRQOL in patients undergoing carotid
revascularization.
Results At both 2 weeks and 1 month, CAS patients had
better outcomes for multiple components of the SF-36, with
large differences for role physical function, pain, and the
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disease-speciﬁc scales, CAS patients reported less difﬁculty
with driving, eating/swallowing, neck pain, and headaches
but more difﬁculty with walking and leg pain (all p < 0.05).
However, by 1 year, there were no differences in any
HRQOL measure between CAS and CEA. In the explor-
atory analyses, periprocedural stroke was associated with
poorer 1-year HRQOL across all SF-36 domains, but per-
iprocedural MI or cranial nerve palsy were not.
Conclusions Among patients undergoing carotid revascu-
larization, CAS is associated with better HRQOL during the
early recovery period as compared with CEAdparticularly
with regard to physical limitations and paindbut these
differences diminish over time and are not evident after 1 year.
Although CAS and CEA are associated with similar overall
HRQOL at 1 year, event-speciﬁc analyses conﬁrm that stroke
has a greater and more sustained impact on HRQOL than
MI. (Carotid Revascularization Endarterectomy versus
Stenting Trial [CREST]; NCT00004732) (287).Outcome Comparison of 600- and 300-mg Loading
Doses of Clopidogrel in Patients Undergoing
Primary Percutaneous Coronary Intervention for
ST-Segment Elevation Myocardial Infarction:
Results From the ARMYDA-6 MI (Antiplatelet
therapy for Reduction of MYocardial Damage
during Angioplasty-Myocardial Infarction)
Randomized Study
Objectives The purpose of this study was to compare 600-
and 300-mg clopidogrel loading doses in patients with ST-
segment elevation myocardial infarction (STEMI).
Background Given the high thrombotic risk of patients
with STEMI, greater platelet inhibition may improve
outcome in those patients receiving percutaneous coronary
intervention (PCI). Although observational data suggest
that pretreatment with a 600-mg clopidogrel loading dose
may be more effective than the 300-mg regimen in primary
PCI, this hypothesis has never been tested in a randomized
study.
Methods A total of 201 patients undergoing primary PCI
for STEMI randomly received a 600-mg (n ¼ 103) or 300-
mg (n ¼ 98) clopidogrel loading dose before the procedure.
The primary endpoint was the evaluation of the infarct size,
deﬁned as the area under the curve of cardiac markers.
Results Infarct size was signiﬁcantly lower in the high-dose
regimen: median creatine kinase-myocardial band 2,070 ng/
ml (interquartile range [IQR]: 815 to 2,847 ng/ml) versus
3,049 ng/ml (IQR: 1,050 to 7,031 ng/ml) in the 300-mg
group, p ¼ 0.0001; troponin-I 255 ng/ml (IQR: 130 to
461 ng/ml) versus 380 ng/ml (IQR: 134 to 1,406 ng/ml),
p < 0.0001. In the 600-mg arm, Thrombolysis In
Myocardial Infarction ﬂow grade <3 after PCI was less
frequent (5.8% vs. 16.3%, p ¼ 0.031), left ventricular ejec-
tion fraction at discharge was improved (52.1  9.5% vs.
48.8  11.3%, p ¼ 0.026), 30-day major adversecardiovascular events were fewer (5.8% vs. 15%, p ¼ 0.049),
and bleeding/entry site complications were not increased
(secondary endpoints).
Conclusions In STEMI patients, pre-treatment with
a 600-mg clopidogrel loading dose before primary PCI was
associated with a reduction of the infarct size compared with
a 300-mg loading dose, as well as with improvement of
angiographic results, residual cardiac function, and 30-day
major adverse cardiovascular events; further studies are
warranted to evaluate impact of such strategy on survival
(288).
Dual Antiplatelet Therapy Duration and Clinical
Outcomes Following Treatment With Zotarolimus-
Eluting Stents
Objectives We sought to evaluate differences in late safety
outcomes relative to dual antiplatelet therapy (DAPT)
duration in patients treated with zotarolimus-eluting stents
(ZES).
Background Despite treatment recommendations for at
least 12 months of DAPT following drug-eluting stent
revascularization, device-speciﬁc outcomes relative to DAPT
duration are absent.
Methods Among 2,032 patients undergoing percutaneous
coronary revascularization with ZES in 5 trials, late safety
events were compared relative to DAPT duration for
patients with 6 months DAPT adherence and survival free
of major ischemic and bleeding events.
Results A total of 1,414 event-free patients on DAPT at 6
months were identiﬁed. Patient group comparisons relative
to DAPT included: 6 months versus 12 months, and 6
months versus 24 months. Through 3 years, risk-adjusted
ischemic event rates did not signiﬁcantly differ between
groups: 6 versus 12 months: death (2.7% vs. 2.2%),
myocardial infarction (MI, 0.3% vs. 1.1%), and deﬁnite/
probable stent thrombosis (ST, 0.3% vs. 0%); 6 versus 24
months: death (1.6% vs. 1.6%), MI (0.4% vs. 1.2%), and
deﬁnite/probable ST (0.1% vs. 0.2%). Composite events also
did not statistically vary between DAPT durations. In
multivariable analysis, 6-month versus longer DAPT dura-
tion was not associated with increased likelihood of
thrombotic events at 3-year follow-up. Major bleeding was
negligible across groups.
Conclusions Among patients treated with ZES, late-term
events of death, MI, stroke, and ST do not signiﬁcantly
differ between patients taking 6 months DAPT compared
with continuation beyond 1 year. These ﬁndings merit
further study to identify the appropriate duration of DAPT
according to speciﬁc drug-eluting stents (289).
Assessing the Temporal Course of Neointimal
Hyperplasia Formation After Different Generations
of Drug-Eluting Stents
Objectives This study sought to assess the temporal course
of neointimal hyperplasia (NIH) formation following
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stents (DES).
Background The amount of NIH following DES
implantation correlates with the potency of the anti-
proliferative drug, its kinetic release, as well as some indi-
vidual characteristics, as the presence of diabetes mellitus
(DM). Recently, some publications have suggested
a continuous growth of NIH following DES, which in some
cases, might result in late “catch-up.”
Methods Twenty-ﬁve patients with single, de novo lesions
were treated with sirolimus-eluting stents (SES) (n ¼ 12)
and biolimus-eluting stents (BES) (n ¼ 13) and underwent
intravascular ultrasound evaluation immediately after the
procedure and at 9-month and 5-year follow-ups. The
primary endpoint was the comparison of the percentage of
NIH obstruction between mid- and long-term follow-up.
Results Mean age was 59 years and 28% of patients had
DM. Overall, the percentage of NIH obstruction signiﬁ-
cantly increased from 9 months to 5 years (1.3% at ﬁrst
follow-up vs. 4.8% at second follow-up, p ¼ 0.002). There
was no signiﬁcant difference in the variation of vessel volume
(D ¼ 0.70 mm3/mm BES vs. D ¼ 0.18 mm3/mm SES,
p ¼ 0.56), lumen volume (D ¼ 0.40 mm3/mm BES vs.
D ¼ 0.05 mm3/mm SES, p ¼ 0.71), and percentage of
NIH obstruction (D ¼ 3.0% BES vs. D ¼ 3.8% SES, p ¼
0.55) among DES. However, diabetic patients had a marked
NIH increase along the years (NIH volume at second
follow-up: 10.15 mm3 DM vs. 5.11 mm3 non-DM, p ¼
0.028).
Conclusions The present serial intravascular ultrasound
assessment supports the occurrence of continuous NIH
growth following different generations of DES. These
ﬁndings seem to be particularly more pronounced among
patients with DM (290).Clinical Utility of Regadenoson for Assessing
Fractional Flow Reserve
Objectives The aim of this study was to evaluate the efﬁ-
cacy of regadenoson, in comparison with adenosine, for
assessing fractional ﬂow reserve (FFR) of intermediate
coronary artery stenoses (CAS).
Background Fractional ﬂow reserve is an established
invasive method for assessing the physiological signiﬁcance
of CAS. Regadenoson, a selective A2A receptor agonist, is an
approved hyperemic agent for pharmacological stress
imaging, but its role for measuring FFR is unknown.
Methods This prospective, single-center study enrolled 25
consecutive patients with intermediate CAS discovered
during elective angiography (25 lesions). In each patient,
FFR of the CAS was measured ﬁrst by IV adenosine (140
mg/kg/min), followed by IV regadenoson (400 mg bolus).
The intrapatient FFR correlation between adenosine and
regadenoson was evaluated.
Results The mean age was 63  11 years, and mean left
ventricular ejection fraction was 58  11%. Most patientswere male (52%) and had hypertension (84%) and dyslipi-
demia (84%), with 24% having diabetes mellitus and 20%
chronic obstructive pulmonary disease. The CAS was visu-
ally estimated during angiography (mean 58  9%) and
most often found in the left anterior descending coronary
artery (48%). A strong, linear correlation of FFR was noted
with adenosine and regadenoson (r ¼ 0.985, p < 0.001). A
hemodynamically signiﬁcant lesion (FFR 0.80) was
present in 52% with no reclassiﬁcation of signiﬁcance
between adenosine and regadenoson. No serious events
occurred with administration of either drug.
Conclusions Our results suggest that a single IV bolus of
regadenoson is as effective as an intravenous infusion of
adenosine for measuring FFR and, given its ease of use,
should be considered for FFR measurement in the cathe-
terization laboratory (291).Effects of Increasing Doses of Intracoronary
Adenosine on the Assessment of Fractional Flow
Reserve
Objectives The purpose of this study was to investigate the
effects of increasing dose of intracoronary adenosine on
fractional ﬂow reserve (FFR) measurement.
Backgrounds FFR is a validated method for the assessment
of the severity of coronary artery stenosis. It is based on the
change in the pressure gradient across the stenosis after the
achievement of maximal hyperemia of the coronary micro-
circulation that may be obtained by either intracoronary
bolus or intravenous infusion of adenosine. No study has
explored so far the effects of very high doses of intracoronary
adenosine on FFR.
Methods FFR was assessed in 46 patients with 50 inter-
mediate lesions during cardiac catheterization by pressure-
recording guidewire (PrimeWire, Volcano, San Diego,
California). FFR was calculated as the ratio of the distal
coronary pressure to the aortic pressure at hyperemia.
Increasing doses of adenosine were administrated (60, 120,
180, 360, and 720 mg) as intracoronary boluses. Exclusion
criteria were: 1) allergy to adenosine; 2) baseline bradycardia
(heart rate <50 beats/min); 3) hypotension (blood
pressure <90 mm Hg); and 4) refusal to provide signed
informed consent.
Results High doses of intracoronary adenosine were well
tolerated, with no major side effects. Increasing doses up to
720 mg progressively decreased FFR values and increased the
percentage of patients showing an FFR <0.75. Among
angiographic parameters, both percent stenosis and lesion
length were independently associated with lower FFR
values.
Conclusions This study shows that high doses of intra-
coronary adenosine (up to 720 mg) increased the sensitivity
of FFR in the detection of hemodynamically relevant
coronary stenoses. Furthermore, lesion length and stenosis
severity were independent angiographic determinants of
FFR (292).
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e352Comparison of Everolimus- and Sirolimus-Eluting
Stents in Patients With Long Coronary Artery
Lesions: A Randomized LONG-DES-III
(Percutaneous Treatment of LONG Native Coronary
Lesions With Drug-Eluting Stent-III) Trial
Objectives This study compared everolimus-eluting stents
(EES) and sirolimus-eluting stents (SES) for long coronary
lesions.
Background Outcomes remain relatively unfavorable for
stent-based coronary intervention of lesions with long
diseased segments.
Methods This randomized, multicenter, prospective trial
compared the use of long EES with SES in 450 patients
with long (25 mm) native coronary lesions. The primary
endpoint of the trial was in-segment late luminal loss at 9-
month angiographic follow-up.
Results The EES and SES groups had similar baseline
characteristics. Lesion length was 34.0  15.4 mm in the
EES group and 34.3  13.5 mm in the SES group (p ¼
0.85). Nine-month angiographic follow-up was performed
in 80% of the EES group and 81% of the SES group (p ¼
0.69). In-segment late loss as the primary study endpoint
was signiﬁcantly larger in the EES group than in the SES
group (0.17  0.41 mm vs. 0.09  0.30 mm, p for
noninferiority ¼ 0.96, p for superiority ¼ 0.04). The in-
segment binary restenosis rate was also higher in the EES
group than in the SES group (7.3% vs. 2.7%, p ¼ 0.046).
However, in-stent late loss (0.22  0.43 mm vs. 0.18  0.28
mm, p ¼ 0.29) and in-stent binary restenosis rate (3.9% vs.
2.7%, p ¼ 0.53) were similar among the 2 groups. The
incidence of any clinical outcomes (death, myocardial
infarction, stent thrombosis, target lesion revascularization,
and composite outcomes) was not statistically different
between the 2 groups.
Conclusions For patients with long native coronary artery
disease, EES implantation was associated with greater
angiographic in-segment late loss and higher rates of in-
segment restenosis compared with SES implantation.
However, clinical outcomes were both excellent and not
statistically different. (Percutaneous Treatment of LONG
Native Coronary Lesions With Drug-Eluting Stent-III
[LONG-DES-III]; NCT01078038) (293).Vascular Inﬂammation and Repair: Implications for
Re-Endothelialization, Restenosis, and Stent
Thrombosis
The cellular and molecular processes that control vascular
injury responses after percutaneous coronary intervention
involve a complex interplay among vascular cells and
progenitor cells that control arterial remodeling, neo-
intimal proliferation, and re-endothelialization. Drug-
eluting stents (DES) improve the efﬁcacy of percutaneous
coronary intervention by modulating vascular inﬂam-
mation and preventing neointimal proliferation andrestenosis. Although positive effects of DES reduce
inﬂammation and restenosis, negative effects delay re-
endothelialization and impair endothelial function.
Delayed re-endothelialization and impaired endothelial
function are linked to stent thrombosis and adverse clinical
outcomes after DES use. Compared with bare-metal
stents, DES also differentially modulate mobilization,
homing, and differentiation of vascular progenitor cells
involved in re-endothelialization and neointimal prolifer-
ation. The effects of DES on vascular inﬂammation and
repair directly impact clinical outcomes with these devices
and dictate requirements for extended-duration dual anti-
platelet therapy (294).Characterization of Clopidogrel Hypersensitivity
Reactions and Management With Oral Steroids
Without Clopidogrel Discontinuation
Objectives The purpose of this study was to characterize
clopidogrel hypersensitivity and describe its successful
management with oral steroids without clopidogrel
discontinuation.
Background Hypersensitivity reactions to clopidogrel are
poorly understood and present difﬁculty in management.
Methods Patients diagnosed with clopidogrel hypersensi-
tivity after percutaneous coronary intervention underwent
evaluation and received oral prednisone without clopidogrel
discontinuation. Cutaneous testing was performed after
completion of clopidogrel therapy for diagnosis and assess-
ment of cross-reactivity.
Results Sixty-two patients representing 1.6% of the
percutaneous coronary intervention population developed
clopidogrel hypersensitivity during the study period. The
mean age was 62  11 years, 71% of patients were male, and
35% reported prior adverse drug reaction. Clopidogrel
hypersensitivity manifested as generalized exanthema in
79%, localized skin reaction in 16%, and angioedema or
urticaria in 5% of patients. Biopsy of affected areas
demonstrated a lymphocyte-mediated delayed hypersensi-
tivity reaction. Complete resolution of hypersensitivity
reaction was observed in 61 patients (98%) with a short
course of oral prednisone. Cutaneous testing conﬁrmed
delayed hypersensitivity reaction to clopidogrel in 34 (81%)
and immediate hypersensitivity in 3 of 42 patients (7%)
tested. Allergenic cross-reactivity was observed for ticlopi-
dine in 10 (24%), prasugrel in 7 (17%), and both ticlopidine
and prasugrel in 3 patients (7%). Histological examination
showed lymphocyte-mediated hypersensitivity in abnormal
patch test areas.
Conclusions Clopidogrel hypersensitivity is manifested as
generalized exanthema and is caused by a lymphocyte-
mediated delayed hypersensitivity in most patients. This
can be managed with oral steroids without clopidogrel
discontinuation. Allergenic cross-reactivity with ticlopidine,
prasugrel, or both is present in a signiﬁcant number of
patients with clopidogrel hypersensitivity (295).
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Coronary Artery Bypass Graft Surgery in Left Main
Coronary Artery Disease: A Meta-Analysis of
Randomized Clinical Data
Objectives The purpose of this study was to determine the
safety and efﬁcacy of percutaneous coronary intervention
(PCI) compared with coronary artery bypass graft (CABG)
in patients with left main coronary artery (LMCA) disease.
Background Previous meta-analyses of PCI versus CABG
in LMCA disease mainly included nonprospective, obser-
vational studies. Several new randomized trials have recently
been reported.
Methods We identiﬁed 1,611 patients from 4 randomized
clinical trials for the present meta-analysis. The primary
endpoint was the 1-year incidence of major adverse cardiac
and cerebrovascular events (MACCE), deﬁned as death,
myocardial infarction (MI), target vessel revascularization
(TVR), or stroke.
Results PCI was associated with a nonsigniﬁcantly higher
1-year rate of MACCE compared with CABG (14.5% vs.
11.8%; odds ratio [OR]: 1.28; 95% conﬁdence interval [CI]:
0.95 to 1.72; p ¼ 0.11), driven by increased TVR (11.4% vs.
5.4%; OR: 2.25; 95% CI: 1.54 to 3.29; p < 0.001).
Conversely, stroke occurred less frequently with PCI (0.1%
vs. 1.7%; OR: 0.15; 95% CI: 0.03 to 0.67; p ¼ 0.013). There
were no signiﬁcant differences in death (3.0% vs. 4.1%; OR:
0.74; 95% CI: 0.43 to 1.29; p ¼ 0.29) or MI (2.8% vs. 2.9%;
OR: 0.98; 95% CI: 0.54 to 1.78; p ¼ 0.95).
Conclusions In patients with LMCA disease, PCI was
associated with nonsigniﬁcantly different 1-year rates of
MACCE, death, and MI, a lower risk of stroke, and
a higher risk of TVR compared with CABG (296).ACCF/AHA Methodology for the Development of
Quality Measures for Cardiovascular Technology: A
Report of the American College of Cardiology
Foundation/American Heart Association Task
Force on Performance Measures
Consistent with the growing national focus on healthcare
quality, the American College of Cardiology Foundation
(ACCF) and the American Heart Association (AHA) have
taken a leadership role over the past decade in developing
measures of the quality of cardiovascular care by convening
a joint ACCF/AHA Task Force on Performance
Measures. The Task Force is charged with identifying the
clinical topics appropriate for the development of perfor-
mance measures and with assembling writing committees
composed of clinical and methodological experts in
collaboration with appropriate subspecialty societies. The
Task Force has also created methodology documents that
offer guidance in the development of process, outcome,
composite, and efﬁciency measures. Cardiovascular
performance measures using existing ACCF/AHA
methodology are based on Class I or Class III guidelinesrecommendations, usually with Level A evidence. These
performance measures, based on evidence-based ACCF/
AHA guidelines, remain the most rigorous quality
measures for both internal quality improvement and public
reporting. However, many of the tools for diagnosis and
treatment of cardiovascular disease involve advanced tech-
nologies, such as cardiac imaging, for which there are often
no underlying guideline documents. Because these tech-
nologies affect the quality of cardiovascular care and also
have the potential to contribute to cardiovascular health
expenditures, there is a need for more critical assessment of
the use of technology, including the development of quality
and performance measures in areas in which guideline
recommendations are absent. The evaluation of quality in
the use of cardiovascular technologies requires consider-
ation of multiple parameters that differ from other
healthcare processes. The present document describes
methodology for development of 2 new classes of quality
measures in these situations, appropriate use measures and
structure/safety measures. Appropriate use measures are
based on speciﬁc indications, processes, or parameters of
care for which high level of evidence data and Class I or
Class III guideline recommendations may be lacking but
are addressed in ACCF appropriate use criteria documents.
Structure/safety measures represent measures developed to
address structural aspects of the use of healthcare tech-
nology (e.g., laboratory accreditation, personnel training,
and credentialing) or quality issues related to patient safety
when there are neither guidelines recommendations nor
appropriate use criteria. Although the strength of evidence
for appropriate use measures and structure/safety measures
may not be as strong as that for formal performance
measures, they are quality measures that are otherwise
rigorously developed, reviewed, tested, and approved in the
same manner as ACCF/AHA performance measures. The
ultimate goal of the present document is to provide
direction in deﬁning and measuring the appropriate
usedavoiding not only underuse but also overuse and
misusedand proper application of cardiovascular tech-
nology and to describe how such appropriate use measures
and structure/safety measures might be developed for the
purposes of quality improvement and public reporting. It is
anticipated that this effort will help focus the national
dialogue on the use of cardiovascular technology and away
from the current concerns about volume and cost alone to
a more holistic emphasis on value (297).Activation and Entrainment Mapping of
Hemodynamically Unstable Ventricular
Tachycardia Using a Percutaneous Left Ventricular
Assist Device
Objectives Our goal was to investigate the effects of
percutaneous left ventricular assist device (pLVAD) support
during catheter ablation of unstable ventricular tachycardia
(VT).
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unstable VT is being increasingly used, but there is little
available information on the potential hemodynamic
beneﬁts.
Methods Twenty-three consecutive procedures in 22
patients (ischemic, n ¼ 11) with structural heart disease and
hemodynamically unstable VT were performed with either
pLVAD support (n ¼ 10) or no pLVAD support (intra-
aortic balloon pump counterpulsation, n ¼ 6; no support,
n ¼ 7). Procedural monitoring included vital signs, left atrial
pressure, arterial blood pressure, cerebral perfusion/oximetry,
VT characteristics, and ablation outcomes.
Results The pLVAD group was maintained in VT
signiﬁcantly longer than the non-pLVAD group (66.7 min
vs. 27.5 min; p ¼ 0.03) and required fewer early termina-
tions of sustained VT for hemodynamic instability (1.0 vs.
4.0; p ¼ 0.001). More patients in the pLVAD group had at
least 1 VT termination during ablation than non-pLVAD
patients (9 of 10 [90%] vs. 5 of 13 [38%]; p ¼ 0.03).
There were no differences between groups in duration of
cerebral deoxygenation, hypotension or perioperative
changes in left atrial pressure, brain natriuretic peptide levels,
lactic acid, or renal function.
Conclusions In patients with scar-related VT undergoing
catheter ablation, pLVAD support was able to safely
maintain end-organ perfusion despite extended periods of
hemodynamically unstable VT. Randomized studies are
necessary to determine whether this enhanced ability to
perform entrainment and activation mapping will translate
into a higher rate of clinical success (298).Functional SYNTAX Score for Risk Assessment in
Multivessel Coronary Artery Disease
Objectives This study was aimed at investigating whether
a fractional ﬂow reserve (FFR)-guided SYNTAX score (SS),
termed “functional SYNTAX score” (FSS), would predict
clinical outcome better than the classic SS in patients with
multivessel coronary artery disease (CAD) undergoing
percutaneous coronary intervention (PCI).
Background The SS is a purely anatomic score based on
the coronary angiogram and predicts outcome after PCI in
patients with multivessel CAD. FFR-guided PCI improves
outcomes by adding functional information to the anatomic
information obtained from the angiogram.
Methods The SS was prospectively collected in 497
patients enrolled in the FAME (Fractional Flow Reserve
versus Angiography for Multivessel Evaluation) study. FSS
was determined by only counting ischemia-producing
lesions (FFR 0.80). The ability of each score to predict
major adverse cardiac events (MACE) at 1 year was
compared.
Results The 497 patients were divided into tertiles of risk
based on the SS. After determining the FSS for each patient,
32% moved to a lower-risk group as follows. MACE
occurred in 9.0%, 11.3%, and 26.7% of patients in the low-,medium-, and high-FSS groups, respectively (p < 0.001).
Only FSS and procedure time were independent predictors
of 1-year MACE. FSS demonstrated a better predictive
accuracy for MACE compared with SS (Harrell’s C of FSS,
0.677 vs. SS, 0.630, p ¼ 0.02; integrated discrimination
improvement of 1.94%, p < 0.001).
Conclusions Recalculating SS by only incorporating
ischemia-producing lesions as determined by FFR decreases
the number of higher-risk patients and better discriminates
risk for adverse events in patients with multivessel CAD
undergoing PCI. (Fractional Flow Reserve versus Angiog-
raphy for Multivessel Evaluation [FAME]; NCT00267774)
(299).Strain-Encoded Cardiac Magnetic Resonance
During High-Dose Dobutamine Stress Testing for
the Estimation of Cardiac Outcomes: Comparison
to Clinical Parameters and Conventional Wall
Motion Readings
Objectives The purpose of this study was to determine the
prognostic value of strain-encoded magnetic resonance
imaging (SENC) during high-dose dobutamine stress
cardiac magnetic resonance imaging (DS-MRI) compared
with conventional wall motion readings.
Background Detection of inducible ischemia by DS-MRI
on the basis of assessing cine images is subjective and
depends on the experience of the readers, which may
inﬂuence not only the diagnostic classiﬁcation but also the
risk stratiﬁcation of patients with ischemic heart disease.
Methods In all, 320 consecutive patients with suspected or
known coronary artery disease underwent DS-MRI, using
a standard protocol in a 1.5T MR scanner. Wall motion
abnormalities (WMA) and myocardial strain were assessed
at baseline and during stress, and outcome data including
cardiac deaths, nonfatal myocardial infarctions (“hard
events”), and revascularization procedures performed >90
days after the MR scans were collected.
Results Thirty-ﬁve hard events occurred during a 28  9
month follow-up period, including 10 cardiac deaths and 25
nonfatal myocardial infarctions, and 32 patients underwent
coronary revascularization. Using a series of Cox
proportional-hazards models, both resting and inducible
WMA offered incremental information for the assessment
of hard cardiac events compared to clinical variables (chi-
square ¼ 13.0 for clinical vs. chi-square ¼ 26.1 by adding
resting WMA, p < 0.001, vs. chi-square ¼ 39.3 by adding
inducible WMA, p < 0.001). Adding visual SENC or
quantitative strain rate reserve to this model further
improved the prediction of outcome (chi-square ¼ 50.7 vs.
chi-square ¼ 52.5, p < 0.001 for both). In a subset of
patients (n ¼ 175) who underwent coronary angiography,
SENC yielded signiﬁcantly higher sensitivity for coronary
artery disease detection (96% vs. 84%, p < 0.02), whereas
speciﬁcity and accuracy were not signiﬁcantly different (88%
vs. 94% and 93% vs. 88%, p ¼ NS for both).
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tiﬁcation of patients at high risk for future cardiac events and
revascularization procedures, beyond the assessment of
conventional atherogenic risk factors and resting or inducible
WMA on cine images. (Strain-Encoded Cardiac Magnetic
Resonance Imaging as an Adjunct for Dobutamine Stress
Testing; NCT00758654) (300).
Invasive Acute Hemodynamic Response to Guide
Left Ventricular Lead Implantation Predicts
Chronic Remodeling in Patients Undergoing
Cardiac Resynchronization Therapy
Objectives We evaluated the relationship between acute
hemodynamic response (AHR) and reverse remodeling
(RR) in cardiac resynchronization therapy (CRT).
Background CRT reduces mortality and morbidity in heart
failure patients; however, up to 30% of patients do not derive
symptomatic beneﬁt. Higher proportions do not remodel.
Multicenter trials have shown echocardiographic techniques
are poor at improving response rates. We hypothesized the
degree of AHR at implant can predict which patients
remodel.
Methods Thirty-three patients undergoing CRT (21
dilated and 12 ischemic cardiomyopathy) were studied. Left
ventricular (LV) volumes were assessed before and after
CRT. The AHR (maximum rate of left ventricular pressure
[LV-dP/dtmax]) was assessed at implant with a pressure wire
in the LV cavity. Largest percentage rise in LV-dP/dtmax
from baseline (atrial antibradycardia pacing or right
ventricular pacing with atrial ﬁbrillation) to dual-chamber
pacing (DDD)-LV was used to determine optimal coro-
nary sinus LV lead position. Reverse remodeling was deﬁned
as reduction in LV end systolic volume 15% at 6 months.
Results The LV-dP/dtmax increased signiﬁcantly from
baseline (801  194 mm Hg/s to 924  203 mm Hg/s, p <
0.001) with DDD-LV pacing for the optimal LV lead
position. The LV end systolic volume decreased from 186 
68 ml to 157  68 ml (p < 0.001). Eighteen (56%) patients
exhibited RR. There was a signiﬁcant relationship between
percentage rise in LV-dP/dtmax and RR for DDD-LV
pacing (p < 0.001). A similar relationship for AHR and
RR in dilated cardiomyopathy and ischemic cardiomyopathy
(p ¼ 0.01 and p ¼ 0.006) was seen.
Conclusions Acute hemodynamic response to LV pacing is
useful for predicting which patients are likely to remodel in
response to CRT both for dilated cardiomyopathy and
ischemic cardiomyopathy. Using AHR has the potential to
guide LV lead positioning and improve response rates (301).
Cardiorespiratory Response to Exercise After
Renal Sympathetic Denervation in Patients With
Resistant Hypertension
Objectives This study sought to investigate the effects of
interventional renal sympathetic denervation (RD) on
cardiorespiratory response to exercise.Background RD reduces blood pressure at rest in patients
with resistant hypertension.
Methods We enrolled 46 patients with therapy-resistant
hypertension as extended investigation of the Symplicity
HTN-2 (Renal Denervation With Uncontrolled Hyper-
tension) trial. Thirty-seven patients underwent bilateral RD
and 9 patients were assigned to the control group. Cardio-
pulmonary exercise tests were performed at baseline and 3-
month follow-up.
Results In the RD group, compared with baseline exami-
nation, blood pressure at rest and at maximum exercise after
3 months was signiﬁcantly reduced by 31 13/9 13 mmHg
(p < 0.0001) and by 21  20/5  14 mm Hg (p < 0.0001),
respectively. Achieved work rate increased by 5  13 W
(p ¼ 0.029) whereas peak oxygen uptake remained
unchanged. Blood pressure 2 min after exercise was signif-
icantly reduced by 29  17/8  15 mm Hg (p < 0.001 for
systolic blood pressure; p ¼ 0.002 for diastolic blood pres-
sure). Heart rate at rest decreased after RD (4  11 beats/
min; p ¼ 0.028), whereas maximum heart rate and heart rate
increase during exercise were not different. Heart rate
recovery improved signiﬁcantly by 4  7 beats/min after
renal denervation (p ¼ 0.009). In the control group, there
were no signiﬁcant changes in blood pressure, heart rate,
maximum work rate, or ventilatory parameters after 3
months.
Conclusions RD reduces blood pressure during exercise
without compromising chronotropic competence in patients
with resistant hypertension. Heart rate at rest decreased and
heart rate recovery improved after the procedure. (Renal
Denervation With Uncontrolled Hypertension; [Symplicity
HTN-2]; NCT00888433) (302).
10 Years of Intracoronary and Intramyocardial
Bone Marrow Stem Cell Therapy of the Heart: From
the Methodological Origin to Clinical Practice
Intracoronary and intramyocardial stem cell therapy aim at
the repair of compromised myocardium therebydas
a causal treatmentdpreventing ventricular remodeling and
improving overall performance. Since the ﬁrst-in-human
use of bone marrow stem cells (BMCs) after acute
myocardial infarction in 2001, a large number of clinical
studies have demonstrated their clinical beneﬁt: BMC
therapy can be performed with usual cardiac catheterization
techniques in the conscious patient as well as also easily
during cardiosurgical interventions. New York Heart
Association severity degree of patients as well as physical
activity improve in addition to (“on top” of) all other
therapeutic regimens. Stem cell therapy also represents an
ultimate approach in advanced cardiac failure. For acute
myocardial infarction and chronic ischemia, long-term
mortality after 1 and 5 years, respectively, is signiﬁcantly
reduced. A few studies also indicate beneﬁcial effects for
chronic dilated cardiomyopathy. The clinical use of autol-
ogous BMC therapy implies no ethical problems, when
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BMCs, there are no major stem cell-related side effects,
especially no cardiac arrhythmias and inﬂammation.
Various mechanisms of the stem cell action in the human
heart are discussed, for example, cell transdifferentiation,
cell fusion, activation of intrinsic cardiac stem cells, and
cytokine-mediated effects. New techniques allow point-of-
care cell preparations, for example, within the cardiac
intervention or operation theater, thereby providing short
preparation time, facilitated logistics of cell transport, and
reasonable cost effectiveness of the whole procedure. The 3
main indications are acute infarction, chronic ischemic
heart failure, and dilated cardiomyopathy. Future studies
are desirable to further elucidate the mechanisms of stem
cell action and to extend the current use of intracoronary
and/or intramyocardial stem cell therapy by larger and
presumably multicenter and randomized trials (303).Long-Term Outcome of Percutaneous Coronary
Intervention for Chronic Total Occlusions
Objectives The aim of this study was to evaluate long-term
clinical outcomes after percutaneous coronary intervention
(PCI) for chronic total occlusions (CTO).
Background Despite technical advancements, there is
a paucity of data on long-term outcomes after PCI of CTO.
Methods We evaluated long-term clinical outcomes in
1,791 patients who underwent PCI of 1,852 CTO at 3
tertiary care centers in the United States, South Korea, and
Italy between 1998 and 2007. Median follow-up was 2.9
years (interquartile range: 1.5 to 4.6 years).
Results Procedural success was obtained in 1,226 (68%)
patients. Stents were implanted in 1,160 patients (95%); 396
patients (34%) received bare-metal stents (BMS), and 764
patients (66%) received drug-eluting stents (DES). After
multivariable analysis, successful CTO PCI was an inde-
pendent predictor of a lower cardiac mortality (hazard ratio
[HR]: 0.40, 95% conﬁdence interval [CI]: 0.21 to 0.75, p <
0.01) and reduced need for coronary artery bypass graft
surgery (HR: 0.21, 95% CI: 0.13 to 0.40, p < 0.01); it also
correlated with a strong trend toward lower all-cause
mortality (HR: 0.63, 95% CI: 0.40 to 1.00, p ¼ 0.05) at
5-year follow-up. Among patients who underwent stent
implantation, treatment with DES rather than BMS resul-
ted in less target vessel revascularization at long-term follow-
up (17.2% vs. 31.1%, p < 0.01); deﬁnite/probable stent
thrombosis rates were similar (DES 1.7%, BMS 2.3%, p ¼
0.58). Within the DES subgroup, patients treated with
paclitaxel-eluting stents and sirolimus-eluting stents had
similar clinical outcomes.
Conclusions Successful CTO PCI is associated with
reduced long-term cardiac mortality and need for coronary
artery bypass graft surgery. Treatment of CTO with DES
rather than BMS is associated with a signiﬁcant reduction in
target vessel revascularization with similar rates of stent
thrombosis. Paclitaxel-eluting stents and sirolimus-elutingstents had similar long-term safety and efﬁcacy outcomes
(304).Characteristics and In-Hospital Outcomes of
Patients With Non–ST-Segment Elevation
Myocardial Infarction and Chronic Kidney Disease
Undergoing Percutaneous Coronary Intervention
Objectives This study sought to evaluate the characteris-
tics, therapies, and outcomes of patients with chronic kidney
disease (CKD) presenting with non–ST-segment elevation
myocardial infarction (NSTEMI) and managed with
percutaneous coronary intervention (PCI). This speciﬁc
population has not been evaluated previously.
Background Among patients with acute coronary
syndrome, the presence of renal dysfunction is associated
with an increased risk of death and major bleeding.
Methods We examined data on 40,074 NSTEMI patients
managed with PCI who were captured by the ACTION
(Acute Coronary Treatment and Intervention Outcomes
Network) registry. Patients were divided according to
baseline renal function in 4 groups: no CKD and CKD
stages 3, 4, and 5.
Results Overall, 31.1% (n ¼ 12,045) of patients with
NSTEMI undergoing PCI had CKD. Compared with
patients with normal renal function, CKD patients managed
with PCI had signiﬁcantly more history of myocardial
infarction, heart failure, and more 3-vessel coronary artery
disease. They received fewer antithrombotic therapies but
were treated more frequently with bivalirudin. In addition,
they had signiﬁcantly higher rates of in-hospital mortality
and major bleeding. CKD stage 4 was associated with the
highest risk of adverse events relative to no CKD. The
multivariable adjusted odds ratios of in-hospital mortality for
CKD stages 3, 4, and 5 relative to no CKD were 2.0, 2.8,
and 2.6, respectively (global p value <0.0001), and the
analogous adjusted odds ratios of major bleeding were 1.5,
2.8, and 1.8, respectively (global p value <0.0001).
Conclusions CKD patients presenting with NSTEMI and
managed with PCI have more comorbidities and receive
guideline-recommended therapies less frequently than do
patients without CKD. CKD is strongly associated with in-
hospital mortality and bleeding in NSTEMI patients
undergoing PCI (305).Time to Signiﬁcant Gradient Reduction Following
Septal Balloon Occlusion Predicts the Magnitude
of Final Gradient Response During Alcohol Septal
Ablation in Patients With Hypertrophic Obstructive
Cardiomyopathy
Objectives The purpose of this study was to investigate
whether a relationship exists between an acute reduction in
resting left ventricular outﬂow tract (LVOT) gradient with
balloon occlusion and the ﬁnal invasive gradient response
following alcohol septal ablation (ASA).
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surgery to reduce the basal septal thickness and decrease the
resting and/or provocable LVOT gradient in patients with
hypertrophic cardiomyopathy. Patients have a variable
gradient response to occlusion of the septal perforator artery
before ethanol infusion for ASA.
Methods From November 1998 to November 2008, 120
patients (mean age 60 years [range 16 to 87 years], 50%
women) with hypertrophic cardiomyopathy underwent ASA
at our institution. The resting LVOT gradient (peak systolic
left ventricle [LV] pressure – peak systolic aortic pressure)
was measured continuously during the ASA procedure. The
time to signiﬁcant LVOT gradient decrease (deﬁned as
>50% decrease from baseline) was recorded following
balloon occlusion of the dominant septal perforator coronary
artery, which was found to perfuse the basal septum based on
contrast echocardiographic studies.
Results The mean baseline resting LVOT gradient was 86
 43 mm Hg, and it decreased to 17  11 mm Hg
following ASA (80.2%). The mean time to signiﬁcant
gradient reduction was 3.6  2 min (range 25 s to 11 min).
The time to signiﬁcant LVOT gradient reduction strongly
correlated with the ﬁnal magnitude of gradient reduction
following ASA (r ¼ –0.81, p < 0.001).
Conclusions This study demonstrates a correlation
between the time to signiﬁcant LVOT gradient reduction
following septal perforator balloon occlusion and the
magnitude of ﬁnal gradient response after ASA (306).Long-Term Safety and Effectiveness of Drug-
Eluting Stents for the Treatment of Saphenous
Vein Grafts Disease: A Population-Based Study
Objectives The purpose of this study was to evaluate the
long-term safety and effectiveness of drug-eluting stents
(DES) for the treatment of saphenous vein graft (SVG)
disease.
Background DES are frequently implanted for SVG
interventions, but some studies have shown that they are not
effective in reducing target vessel revascularization (TVR)
over longer-term follow-up. Some studies suggest there is
increased mortality with DES compared with bare-metal
stents (BMS).
Methods We performed propensity score matching analysis
using a population-based cohort that included 709 well-
matched pairs (n ¼ 1,418) who received DES or BMS for
the treatment of SVG disease from 2003 to 2008. Outcomes
of interest included repeat TVR, myocardial infarction, and
death.
Results The mean age of the propensity-matched cohort
was 69 years, 50% had diabetes, and the mean age of SVG
was 10.6 years. At 4-year follow-up, the rate of repeat TVR
was 21% in the DES group and 27.6% in the BMS group
(p ¼ 0.004). DES implantation was associated with the
largest TVR reduction among patients with diabetes and
patients receiving longer stents (30 mm) and the numberof procedures needed to prevent a TVR at 4 years was 8 and
7, respectively. The composite rate of myocardial infarction
or death was not signiﬁcantly different between DES and
BMS at 4 years (27.8% vs. 32.6%, p ¼ 0.09).
Conclusions Implantation of DES in the treatment of SVG
disease is associated with substantial reduction of repeat
revascularization, without evidence of an increased risk of
myocardial infarction or death at longer-term follow-up (307).Surgical Candidacy and Selection Biases in
Nonemergent Left Main Stenting: Implications for
Observational Studies
Objectives This study sought to characterize reasons for
surgical ineligibility in patients undergoing nonemergent
unprotected left main (ULM) percutaneous coronary inter-
vention (PCI) and to assess the potential for these reasons to
confound comparative effectiveness studies of coronary
revascularization.
Background Although both PCI and coronary artery
bypass graft surgery are treatments for ULM disease, some
patients are not eligible for both treatments, which may
result in treatment selection biases.
Methods In 101 consecutive patients undergoing non-
emergent ULM PCI, mixed methods were used to deter-
mine the prevalence of treatment selection dictated by
surgical ineligibility and to identify the reasons cited for
avoiding coronary artery bypass graft surgery. We then
determined whether these reasons were captured by the
ACC–NCDR (American College of Cardiology–National
Cardiovascular Data Registry) Cath-PCI dataset to assess
the ability of this registry to account for biases in treatment
selection. Finally, the association of surgical eligibility with
long-term outcomes after ULM PCI was assessed.
Results Treatment selection was dictated by surgical ineli-
gibility in over half the ULM PCI cohort with the majority
having reasons for ineligibility not captured by the ACC–
NCDR. Surgical ineligibility was a signiﬁcant predictor of
mortality after adjustment for Society of Thoracic Surgeons
(hazard ratio [HR]: 5.4, 95% conﬁdence interval [CI]: 1.2 to
25), EuroSCORE (European System for Cardiac Operative
Risk Evaluation) (HR: 5.9, 95% CI: 1.3 to 27), or NCDR
mortality scores (HR: 6.2, 95% CI: 1.4 to 27).
Conclusions Surgical ineligibility dictating treatment
selection is common in patients undergoing nonemergent
ULM PCI, occurs on the basis of risk factors not captured
by the ACC–NCDR, and is independently associated with
worse long-term outcomes after adjusting for standard risk
scores (308).Fundamental Wire Technique and Current Standard
Strategy of Percutaneous Intervention for Chronic
Total Occlusion With Histopathological Insights
Currently, successful treatment of chronic total occlusion
(CTO) seems markedly improved, due to several new
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this improved success rate is often limited to procedures
performed by skilled, highly experienced operators. To
improve the overall success rate of percutaneous coronary
intervention of CTO from a worldwide perspective, a deeper
understanding of CTO histopathology might offer insights
into the development of new techniques and procedural
strategies. In this review, CTO histopathology and wire
techniques are discussed on the basis of the fundamental
concepts of antegrade and retrograde approaches. Although
details pertaining to wire manipulation are very difﬁcult to
explain objectively, we tried to describe this as best as
possible in this article. Finally, a systematic review of the
current standard CTO strategy is provided. Hopefully, this
article will enhance the understanding of this complex
procedure and, consequently, promote safe and effective
CTO-percutaneous coronary intervention for patients who
present with this challenging lesion subset (309).Long-Term Impact of Chronic Kidney Disease in
Patients With ST-Segment Elevation Myocardial
Infarction Treated With Primary Percutaneous
Coronary Intervention: The HORIZONS-AMI
(Harmonizing Outcomes With Revascularization
and Stents in Acute Myocardial Infarction) Trial
Objectives This study sought to investigate the impact of
chronic kidney disease (CKD) in patients undergoing
percutaneous coronary intervention (PCI) for ST-segment
elevation myocardial infarction (STEMI) with different
antithrombotic strategies.
Background CKD is associated with increased risk of
adverse ischemic and hemorrhagic events after primary PCI
for STEMI.
Methods HORIZONS-AMI (Harmonizing Outcomes
With Revascularization and Stents in Acute Myocardial
Infarction) trial was a multicenter, international, randomized
trial comparing bivalirudin monotherapy or heparin plus
a glycoprotein IIb/IIIa inhibitor (GPI) during primary PCI
in STEMI. CKD, deﬁned as creatinine clearance <60 ml/
min, was present at baseline in 554 of 3,397 patients
(16.3%). Patients were followed for 3 years. Net adverse
cardiac event (NACE) was deﬁned as the composite of
death, reinfarction, ischemia-driven target vessel revascu-
larization (TVR), stroke or non–coronary artery bypass
grafting (CABG)-related major bleeding.
Results Patients with CKD compared with patients without
had higher rates of NACE (41.4% vs. 23.8%, p < 0.0001),
death (18.7% vs. 4.4%, p < 0.0001), and major bleeding
(19.3% vs. 6.7%, p < 0.0001). Multivariable analysis identi-
ﬁed baseline creatinine as an independent predictor of death
at 3 years (hazard ratio: 1.51, 95% conﬁdence interval: 1.21 to
1.87, p < 0.001). Patients with CKD randomized to biva-
lirudin monotherapy versus heparin plus GPI had no signif-
icant difference in major bleeding (19.0% vs. 19.6%, p ¼
0.72) or death (19.0% vs. 18.4%, p ¼ 0.88) at 3 years. Inpatients with CKD, there was no difference in the rates of
TVR in bare-metal stents (BMS) versus drug-eluting stents
(DES) at 3 years (14.1% vs. 15.1%, p ¼ 0.8).
Conclusions STEMI patients with CKD have signiﬁcantly
higher rates of death and major bleeding compared with
those without CKD. In patients with CKD, there appears to
be no beneﬁt of bivalirudin compared with heparin þ GPI,
or DES versus BMS during primary PCI in improving
clinical outcomes (310).
Sirolimus-Eluting Coronary Stents in
Octogenarians: A 1-Year Analysis of the Worldwide
e-SELECT Registry
Objectives The aim of this study was to identify the
worldwide practice of Cypher Select (Cordis Corporation,
Bridgewater, New Jersey) or Cypher Select Plus sirolimus-
eluting stent (SES) in patients 80 years of age (octoge-
narian) and to identify clinical outcomes in this patient
population.
Background The use of drug-eluting stents in elderly
patients may have different features compared with younger
patients.
Methods Between 2006 and 2008, 15,147 patients from
320 hospitals in 56 countries were enrolled in a registry. Initial
implantation and follow-up outcome information obtained at
1-year follow-up in 675 octogenarian patients were compared
with those in 14,472 nonoctogenarian patients.
Results Octogenarians had signiﬁcantly more comorbid-
ities and had higher Charlson comorbidity index scores (1.5
 1.6 vs. 1.0  1.3, p< 0.001). Rates of cardiac death (3.3%
vs. 0.9%, p < 0.001), myocardial infarction (2.3% vs. 1.9%,
p ¼ 0.021), and deﬁnite or probable stent thrombosis (2.3%
vs. 0.9%, p ¼ 0.0002), and major bleeding (2.0% vs. 0.9%,
p ¼ 0.015) were signiﬁcantly higher in octogenarians at 1
year; however, there was no signiﬁcant difference in the rate
of target lesion revascularization between the 2 groups (3.2%
vs. 2.2%, p ¼ 0.12). In octogenarians, a high Charlson
comorbidity index was an independent predictor of death
and stent thrombosis up to 360 days from the index
procedure (hazard ratio: 1.3, 95% conﬁdence interval: 1.1 to
1.5, p < 0.001, and hazard ratio: 1.5, 95% conﬁdence
interval: 1.3 to 1.8, p < 0.001, respectively).
Conclusions Stenting with SES may be an effective thera-
peutic option in elderly patients, with acceptable rates of
complications and a very low rate of repeat revascularization as
demonstrated by this e-SELECT (A Multi-Center Post-
Market Surveillance Registry) subgroup analysis (311).
Impact of Intravascular Ultrasound Imaging on
Early and Late Clinical Outcomes Following
Percutaneous Coronary Intervention With
Drug-Eluting Stents
Objectives This study sought to assess the impact of
intravascular ultrasound (IVUS)-guided versus angiography-
guided drug-eluting stent (DES) implantation.
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the DES era. Therefore, we investigated the impact of IVUS
guidance on clinical outcomes in the MATRIX (Compre-
hensive Assessment of Sirolimus-Eluting Stents in Complex
Lesions) registry.
Methods The MATRIX registry prospectively enrolled
consecutive, unselected patients treated with sirolimus-
eluting stents (SES) (n ¼ 1,504); 631 patients (42%)
underwent IVUS-guided stenting, and 873 (58%) had only
angiographic guidance. We assessed 30-day, 1-year, and 2-
year rates of death/myocardial infarction (MI), major adverse
cardiac events (cardiac death, MI, or target vessel revascu-
larization), and deﬁnite/probable stent thrombosis in 548
propensity-score matched patient pairs.
Results After matching, baseline and angiographic char-
acteristics were similar in IVUS and no-IVUS groups.
Patients in the IVUS group had signiﬁcantly less death/MI
at 30 days (1.5% vs. 4.6%, p < 0.01), 1 year (3.3% vs. 6.5%,
p < 0.01), and 2 years (5.0% vs. 8.8%, p < 0.01). Patients in
the IVUS group had signiﬁcantly less major adverse cardiac
events at 30 days (2.2% vs. 4.8%, p ¼ 0.04) and numerically
less major adverse cardiac events at 1 year (9.1% vs. 13.5%,
p ¼ 0.07) and 2 years (12.9% vs. 16.7%, p ¼ 0.18). Rates of
MI were signiﬁcantly lower in the IVUS group at 30 days
(1.5% vs. 4.0%, p < 0.01), 1 year (1.8% vs. 4.8%, p < 0.01),
and 2 years (2.1% vs. 5.7%, p < 0.01).
Conclusions IVUS-guided stent implantation appears to
be associated with a reduction in both early and long-term
clinical events. Further investigation in randomized
controlled trials is warranted (312).Myocardium at Risk in ST-Segment Elevation
Myocardial Infarction: Comparison of T2-Weighted
Edema Imaging With the MR-Assessed Endocardial
Surface Area and Validation Against Angiographic
Scoring
Objectives The objective of this study was to assess the
area at risk (AAR) in ST-segment elevation myocardial
infarction with 2 different cardiac magnetic resonance
(CMR) imaging methods and to compare them with the
validated angiographic Alberta Provincial Project for
Outcome Assessment in Coronary Heart Disease Score
(APPROACH-score) in a large consecutive patient
cohort.
Background Edema imaging with T2-weighted CMR and
the endocardial surface area (ESA) assessed by late gadoli-
nium enhancement have been introduced as relatively new
methods for AAR assessment in ST-segment elevation
myocardial infarction. However, data on the utility and
validation of these techniques are limited.
Methods A total of 197 patients undergoing primary
percutaneous coronary intervention in acute ST-segment
elevation myocardial infarction were included. AAR
(assessed with T2-weighted edema imaging and the ESA
method), infarct size, and myocardial salvage (AAR minusinfarct size) were determined by CMR 2 to 4 days after
primary angioplasty. Angiographic AAR scoring was per-
formed by use of the APPROACH-score. All measure-
ments were done ofﬂine by blinded observers.
Results The AAR assessed by T2-weighted imaging
showed good correlation with the angiographic AAR (r ¼
0.87; p < 0.001), whereas the ESA showed only a moderate
correlation either to T2-weighted imaging (r ¼ 0.56; p <
0.001) or the APPROACH-score (r ¼ 0.44; p < 0.001).
Mean AAR by ESA (20.0  11.7% of left ventricular mass)
was signiﬁcantly (p < 0.001) smaller than the AAR assessed
by T2-weighted imaging (35.6  10.9% of left ventricular
mass) or the APPROACH-score (27.9  10.5% of left
ventricular mass) and showed a signiﬁcant negative depen-
dence on myocardial salvage index. In contrast, no depen-
dence of T2-weighted edema imaging or the APPROACH-
score on myocardial salvage index was seen.
Conclusions The AAR can be reliably assessed by T2-
weighted CMR, whereas assessment of the AAR by ESA
seems to be dependent on the degree of myocardial salvage,
thereby underestimating the AAR in patients with high
myocardial salvage such as aborted infarction. Thus,
assessment of the AAR with the ESA method cannot be
recommended. (Myocardial Salvage and Contrast Dye
Induced Nephropathy Reduction by N-Acetylcystein
[LIPSIA-N-ACC]; NCT00463749) (313).Physiological Basis for Angina and ST-Segment
Change: PET-Veriﬁed Thresholds of Quantitative
Stress Myocardial Perfusion and Coronary Flow
Reserve
Objectives This study aimed to determine the quantitative
low-ﬂow threshold for stress-induced perfusion defects with
severe angina and/or signiﬁcant ST-segment depression
during dipyridamole hyperemia.
Background Vasodilator stress reveals differences in
regional perfusion without ischemia in most patients.
However, in patients with a perfusion defect, angina, and/or
signiﬁcant ST-segment depression during dipyridamole
stress, quantitative absolute myocardial perfusion and coro-
nary ﬂow reserve (CFR) at the exact moment of deﬁnite
ischemia have not been established. Deﬁning these low-ﬂow
thresholds of angina or ST-segment changes may offer
insight into physiological disease severity in patients with
atherosclerosis.
Methods Patients underwent rest–dipyridamole stress
positron emission tomography (PET) with absolute ﬂow
quantiﬁcation in ml/min/g. Deﬁnite ischemia was deﬁned as
a new or worse perfusion defect during dipyridamole stress
with signiﬁcant ST-segment depression and/or severe
angina requiring pharmacological treatment. Indeterminate
clinical features required only 1 of these 3 abnormalities. The
comparison group included patients without prior myocar-
dial infarction, or angina or electrocardiographic changes
after dipyridamole.
The Editors JACC Vol. 62, No. 18, 2013
JACC Topic Collection: Interventional Cardiology October 29, 2013:e245–e437
e360Results In 1,674 sequential PET studies, we identiﬁed 194
(12%) with deﬁnite ischemia, 840 (50%) studies with no
ischemia, and 301 (18%) that were clinically indeterminate.
A vasodilator stress perfusion cutoff of 0.91 ml/min/g
optimally separated deﬁnite from no ischemia with an area
under the receiver-operator characteristic curve (AUC) of
0.98 and a CFR cutoff of 1.74 with an AUC ¼ 0.91,
reﬂecting excellent discrimination at the exact moment of
deﬁnite ischemia.
Conclusions Thresholds of low myocardial vasodilator
stress perfusion in ml/min/g and CFR sharply separate
patients with angina or ST-segment change from those
without these manifestations of ischemia during dipyr-
idamole stress with excellent discrimination. Stress ﬂow
below 0.91 ml/min/g in dipyridamole-induced PET perfu-
sion defects causes signiﬁcant ST-segment depression and/
or severe angina. However, when the worst vasodilator stress
ﬂow exceeds 1.12 ml/min/g, these manifestations of
ischemia occur rarely (314).Transcatheter Aortic Valve Implantation in
Patients With Severe Aortic Stenosis and Small
Aortic Annulus
Objectives Valve hemodynamics and clinical outcomes
among patients with a small aortic annulus who underwent
transcatheter aortic valve implantation (TAVI) were
examined.
Background The presence of a small aortic annulus may
complicate the surgical management of patients with severe
aortic stenosis (AS). TAVI is an alternative to aortic valve
replacement (AVR) in high-risk patients, but few data exist
on the results of TAVI in patients with a small aortic
annulus.
Methods Between 2007 and 2010, 35 patients (mean age
79.2  9.4 years) with severe AS and an aortic annulus
diameter <20 mm (mean 18.5  0.9 mm) underwent TAVI
with a 23-mm Edwards SAPIEN bioprosthesis (Edwards
Lifesciences, Inc., Irvine, California). Echocardiographic
parameters and clinical outcomes were assessed prior to
discharge and at 6, 12, and 24 months.
Results Procedural success was achieved in 34 patients
(97.1%). There was 1 in-hospital death. Peak and mean
transaortic gradients decreased from 76.3  33.0 mm Hg
and 45.2  20.6 mm Hg at baseline to 21.8  8.4 mm Hg
and 11.7  4.8 mm Hg post-procedure, respectively, both
p < 0.0001. Mean indexed effective oriﬁce area (IEOA)
increased from 0.35  0.10 cm2/m2 at baseline to 0.90 
0.18 cm2/m2 post-procedure, p< 0.0001. Severe prosthesis–
patient mismatch (IEOA <0.65 cm2/m2) occurred in 2
patients (5.9%). At a mean follow-up of 14  11 months,
gradients remained low and 30 of the 31 remaining survivors
were in New York Heart Association functional class I or II.
Conclusions In high-risk patients with severe AS and
a small aortic annulus, TAVI is associated with good post-
procedural valve hemodynamics and clinical outcomes.TAVI may provide a reasonable alternative to conventional
AVR in elderly patients with a small aortic annulus (315).
Renal Function-Based Contrast Dosing to Deﬁne
Safe Limits of Radiographic Contrast Media in
Patients Undergoing Percutaneous Coronary
Interventions
Objectives The aim of this study was to evaluate the
association between calculated creatinine clearance (CCC)-
based contrast dose and renal complications in patients
undergoing percutaneous coronary interventions (PCI).
Background Excess volumes of contrast media are associ-
ated with renal complications in patients undergoing cardiac
procedures. Because contrast media are excreted by the
kidney, we hypothesized that a dose estimation on the basis
of CCC would provide a simple strategy to deﬁne a safe dose
of contrast media.
Methods We assessed the association between CCC-based
contrast dose and the risk of contrast-induced nephropathy
(CIN) and need for in-hospital dialysis in 58,957 patients
undergoing PCI and enrolled in the BMC2 (Blue Cross
Blue Shield of Michigan Cardiovascular Consortium)
registry from 2007 to 2008. Patients receiving dialysis at the
time of the procedure were excluded.
Results The risk of CIN and nephropathy requiring dial-
ysis (NRD) was directly associated with increasing contrast
volume adjusted for renal function. The risk for CIN and
NRD approached signiﬁcance when the ratio of contrast
dose/CCC exceeded 2 (adjusted odds ratio [OR] for CIN:
1.16, 95% conﬁdence interval [CI]: 0.98 to 1.37, adjusted
OR for NRD: 1.72, 95% CI: 0.9 to 3.27) and was
dramatically elevated in patients exceeding a contrast to
CCC ratio of 3 (adjusted OR for CIN: 1.46, 95% CI: 1.27
to 1.66, adjusted OR for NRD: 1.89, 95% CI: 1.21 to 2.94).
Conclusions Our study supports the need for minimizing
contrast dose in patients with renal dysfunction. A contrast
dose on the basis of estimated renal function with a planned
contrast volume restricted to less than thrice and preferably
twice the CCC might be valuable in reducing the risk of
CIN and NRD (316).
Hospital Variability in the Rate of Finding
Obstructive Coronary Artery Disease at Elective,
Diagnostic Coronary Angiography
Objectives The purpose of this study was to describe
hospital variability in the rate of ﬁnding obstructive coronary
artery disease (CAD) at elective coronary angiography.
Background A recent national study found that obstructive
CAD was found in less than one-half of patients undergoing
elective coronary angiography.
Methods We performed a retrospective analysis of 565,504
patients without prior myocardial infarction or revasculari-
zation undergoing elective coronary angiography using
CathPCI Registry data from 2005 to 2008 to evaluate the
rate of ﬁnding obstructive CAD (any major epicardial vessel
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hospitals.
Results The rate of obstructive coronary disease found at
elective coronary angiography varied from 23% to 100%
among hospitals (median 45%; interquartile range: 39% to
52%), and were consistent from year to year and when
alternative deﬁnitions of coronary stenosis were applied.
Sites with lower rates of ﬁnding obstructive CAD were more
likely to perform procedures on younger patients, those with
low Framingham risk (33% in lowest yield quartile vs. 21%
in highest yield quartile, p < 0.0001); with no or atypical
symptoms (73% vs. 58%, p < 0.0001); and with a negative,
equivocal, or unperformed functional status assessment.
Hospitals with lower rates of ﬁnding obstructive CAD also
less frequently prescribed aspirin, beta-blockers, platelet
inhibitors, and statins (all p < 0.0001). The CAD rate was
lower at facilities with small-volume catheterization labora-
tories and was not associated with hospital ownership or
teaching program status.
Conclusions The rate of ﬁnding obstructive CAD at
elective coronary angiography varied considerably among
reporting centers and was associated with patient selection
and pre-procedure assessment strategies. This institutional
variation suggests that an important opportunity may exist
for quality improvement (317).The Effect of Age on Clinical Outcomes and Health
Status: BARI 2D (Bypass Angioplasty
Revascularization Investigation in Type 2
Diabetes)
Objectives The purpose of this study was to determine the
extent to which effectiveness of cardiac and diabetes treat-
ment strategies varies by patient age.
Background The impact of age on the effectiveness of
revascularization and hyperglycemia treatments has not been
thoroughly investigated.
Methods In the BARI 2D (Bypass Angioplasty Revascu-
larization Investigation in Type 2 Diabetes) trial, 2,368
patients with documented stable heart disease and type 2
diabetes were randomized to receive prompt revasculariza-
tion versus initial medical therapy with deferred revascular-
ization and insulin sensitization versus insulin provision for
hyperglycemia treatment. Patients were followed for an
average of 5.3 years. Cox regression and mixed models were
used to investigate the effect of age and randomized treat-
ment assignment on clinical and health status outcomes.
Results The effect of prompt revascularization versus
medical therapy did not differ by age for death (interaction
p ¼ 0.99), major cardiovascular events (interaction p ¼
0.081), angina (interaction p ¼ 0.98), or health status
outcomes. After intervention, participants of all ages had
signiﬁcant angina and health status improvement. Younger
participants experienced a smaller decline in health status
during follow-up than older participants (age by time
interaction p < 0.01). The effect of the randomizedglycemia treatment on clinical and health status outcomes
was similar for patients of different ages.
Conclusions Among patients with stable heart disease and
type 2 diabetes, the relative beneﬁcial effects of a strategy of
prompt revascularization versus initial medical therapy and
insulin-sensitizing versus insulin-providing therapy on
clinical endpoints, symptom relief, and perceived health
status outcomes do not vary by age. Health status improved
signiﬁcantly after treatment for all ages, and this improve-
ment was sustained longer among younger patients. (Bypass
Angioplasty Revascularization Investigation in Type 2
Diabetes [BARI 2D]; NCT00006305) (318).Prognostic Impact of Staged Versus “One-Time”
Multivessel Percutaneous Intervention in Acute
Myocardial Infarction: Analysis From the
HORIZONS-AMI (Harmonizing Outcomes With
Revascularization and Stents in Acute Myocardial
Infarction) Trial
Objectives The purpose of this study was to compare
a one-time primary percutaneous coronary intervention
(PCI) of the culprit and nonculprit lesions with PCI of only
the culprit lesion and staged nonculprit PCI at a later date in
patients with ST-segment elevation myocardial infarction
(STEMI) and multivessel disease.
Background In patients with STEMI and multivessel
disease, it is unknown whether it is safe or even desirable to also
treat the nonculprit vessel during the primary PCI procedure.
Methods In the HORIZONS-AMI (Harmonizing
Outcomes With Revascularization and Stents in Acute
Myocardial Infarction) trial, 668 of the 3,602 STEMI
patients enrolled (18.5%) underwent PCI of culprit and
nonculprit lesions for multivessel disease. Patients were
categorized into a single PCI strategy (n ¼ 275) versus
staged PCI (n ¼ 393). The endpoints analyzed included the
1-year rates of major adverse cardiovascular events and its
components, death, reinfarction, target-vessel revasculariza-
tion for ischemia, and stroke.
Results Single versus staged PCI was associated with higher
1-year mortality (9.2% vs. 2.3%; hazard ratio [HR]: 4.1, 95%
conﬁdence interval [CI]: 1.93 to 8.86, p < 0.0001), cardiac
mortality (6.2% vs. 2.0%; HR: 3.14, 95% CI: 1.35 to 7.27,
p ¼ 0.005), deﬁnite/probable stent thrombosis (5.7% vs.
2.3%; HR: 2.49, 95% CI: 1.09 to 5.70, p¼ 0.02), and a trend
toward greater major adverse cardiovascular events (18.1% vs.
13.4%; HR: 1.42, 95% CI: 0.96 to 2.1, p ¼ 0.08). The
mortality advantage favoring staged PCI was maintained in
a subgroup of patients undergoing truly elective multivessel
PCI. Also, the staged PCI strategy was independently asso-
ciated with lower all-cause mortality at 30 days and at 1 year.
Conclusions A deferred angioplasty strategy of nonculprit
lesions should remain the standard approach in patients with
STEMI undergoing primary PCI, as multivessel PCI may
be associated with a greater hazard for mortality and
stent thrombosis. (Harmonizing Outcomes With
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[HORIZONS-AMI]; NCT00433966) (319).
Culprit Vessel Only Versus Multivessel and Staged
Percutaneous Coronary Intervention for
Multivessel Disease in Patients Presenting With
ST-Segment Elevation Myocardial Infarction: A
Pairwise and Network Meta-Analysis
Objectives The purposes of this study were to investigate
whether, in patients with ST-segment elevation myocardial
infarction (STEMI) and multivessel disease (MVD),
percutaneous coronary intervention (PCI) should be
conﬁned to the culprit or also nonculprit vessels and, when
performing PCI for nonculprit vessels, whether it should
take place during primary PCI or staged procedures.
Background A signiﬁcant percentage of STEMI patients
have MVD. However, the best PCI strategy for nonculprit
vessel lesions is unknown.
Methods Pairwise and network meta-analyses were per-
formed on 3 PCI strategies for MVD in STEMI patients: 1)
culprit vessel only PCI strategy (culprit PCI), deﬁned as PCI
conﬁned to culprit vessel lesions only; 2) multivessel PCI
strategy (MV-PCI), deﬁned as PCI of culprit vessel as well
as 1 nonculprit vessel lesions; and 3) staged PCI strategy
(staged PCI), deﬁned as PCI conﬁned to culprit vessel, after
which 1 nonculprit vessel lesions are treated during staged
procedures. Prospective and retrospective studies were
included when research subjects were patients with STEMI
and MVD undergoing PCI. The primary endpoint was
short-term mortality.
Results Four prospective and 14 retrospective studies
involving 40,280 patients were included. Pairwise meta-
analyses demonstrated that staged PCI was associated with
lower short- and long-term mortality as compared with
culprit PCI and MV-PCI and that MV-PCI was associated
with highest mortality rates at both short- and long-term
follow-up. In network analyses, staged PCI was also
consistently associated with lower mortality.
Conclusions This meta-analysis supports current guide-
lines discouraging performance of multivessel primary PCI
for STEMI. When signiﬁcant nonculprit vessel lesions are
suitable for PCI, they should only be treated during staged
procedures (320).
Aspirin Extrusion From Human Platelets Through
Multidrug Resistance Protein-4–Mediated
Transport: Evidence of a Reduced Drug Action in
Patients After Coronary Artery Bypass Grafting
Objectives In this study we investigate: 1) the role of
multidrug resistance protein-4 (MRP4), an organic anion
unidirectional transporter, in modulating aspirin action on
human platelet cyclooxygenase (COX)-1; and 2) whether
the impairment of aspirin–COX-1 interaction, found in
coronary artery bypass grafting (CABG) patients, could be
dependent on MRP4-mediated transport.Background Platelets of CABG patients present a reduced
sensitivity to aspirin despite in vivo and in vitro drug
treatment. Aspirin is an organic anion and could be
a substrate for MRP4.
Methods Intracellular aspirin concentration and drug COX-1
activity, measured by thrombin-induced thromboxane B2
(TxB2) production, were evaluated in platelets obtained from
healthy volunteers (HV) and hematopoietic-progenitor cell
cultures reducing or not reducing MRP4-mediated transport.
Platelet MRP4 expression was evaluated, in platelets from HV
and CABG patients, by dot-blot or by immunogold-
electromicrographs or immunoﬂuorescence-microscopy
analysis.
Results Inhibition of MRP4-mediated transport by dipyr-
idamole or Mk-571 increases aspirin entrapment and its
in vitro effect on COX-1 activity (142.7  34.6 pg/108 cells
vs. 343.7  169.3 pg/108 cells TxB2-production). Platelets
derived from megakaryocytes transfected with MRP4 small
interfering ribonucleic acid have a higher aspirin entrapment
and drug COX-1 activity. Platelets from CABG patients
showed a high expression of MRP4 whose in vitro inhibition
enhanced aspirin effect on COX-1 (349  141 pg/108 cells
vs. 1,670  646 pg/108 cells TxB2-production).
Conclusions Aspirin is a substrate for MRP4 and can be
extruded from platelet through its transportation. Aspirin
effect on COX-1 is little-related to MRP4-mediated aspirin
transport in HV, but in CABG patients with MRP4 over-
expression, its pharmacological inhibition enhances aspirin
action in an efﬁcient way (321).Incidence of Asymptomatic Intracranial Embolic
Events After Pulmonary Vein Isolation:
Comparison of Different Atrial Fibrillation Ablation
Technologies in a Multicenter Study
Objectives We compared the safety of different devices by
screening for subclinical intracranial embolic events after
pulmonary vein isolation with either conventional irrigated
radiofrequency (RF) or cryoballoon or multielectrode phased
RF pulmonary vein ablation catheter (PVAC).
Background New devices speciﬁcally designed to facilitate
pulmonary vein isolation procedures have recently been
introduced.
Methods This prospective, observational, multicenter study
included patients with symptomatic atrial ﬁbrillation
referred for pulmonary vein isolation. Ablation was per-
formed using 1 of the 3 catheters. Strict periprocedural
anticoagulation, with intravenous heparin during ablation to
achieve an activated clotting time >300 s, was ensured in all
patients. Cerebral magnetic resonance imaging was per-
formed before and after ablation.
Results Seventy-four patients were included in the study:
27 in the irrigated RF group, 23 in the cryoballoon group,
and 24 in the PVAC group. Total procedure times were 198
 50 min, 174  35 min, and 124  32 min, respectively
(p < 0.001 for PVAC vs. irrigated RF and cryoballoon).
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patients before and after ablation. Post-procedure magnetic
resonance imaging detected a single new embolic lesion in 2
of 27 patients in the irrigated RF group (7.4%) and in 1 of
23 in the cryoballoon group (4.3%). However, in the PVAC
group 9 of 24 patients (37.5%) demonstrated 2.7  1.3 new
lesions each (p ¼ 0.003 for the presence of new embolic
events among the 3 groups).
Conclusions The PVAC is associated with a signiﬁcantly
higher incidence of subclinical intracranial embolic events.
Further study of the causes and signiﬁcance of these emboli
is required to determine the safety of the PVAC (322).
Transapical Transcatheter Aortic Valve
Implantation in the Presence of a Mitral Prosthesis
Objectives We review our experience with transapical
transcatheter aortic valve implantation (AVI) in patients
with functioning mitral prostheses, and describe the tech-
nical considerations.
Background Transcatheter AVI for aortic stenosis in
patients with mitral prostheses is technically challenging.
Methods Ten patients (7 mechanical and 3 bioprosthetic
mitral valves) received the Edwards SAPIEN balloon-
expandable valve (Edwards Lifesciences, Irvine, California)
during 2006 to 2010. All patients were declined conventional
surgery and prospectively followed. The mean patient age was
77.6  7.1 years (range: 67 to 88 years). The logistic Euro-
SCORE and the Society of Thoracic Surgeons–predicted
operative mortality were 30.3  18.6% (range: 11.4% to
70.4%), and 9.9  4.8% (range: 4.6% to 18.7%), respectively.
Results All valves were successfully implanted, with no 30-
day mortality or mitral prosthetic dysfunction. Nine patients
had none to mild residual aortic paravalvular leak. The
overall survival was 60% at a mean follow-up of 12.2  10.4
months (range: 2 to 33 months), with 4 nonvalve-related
deaths. Seven patients improved to New York Heart
Association functional class I to II. The mean transvalvular
gradient and effective oriﬁce area improved from 40.0 
17.4 mm Hg to 8.2  2.1 mm Hg, and 0.6  0.1 cm2 to 1.3
 0.2 cm2, respectively (p < 0.0001). The mitral bio-
prosthetic strut predisposes to device “shift” during deploy-
ment. An “unfavorable” mechanical mitral prosthetic cage or
pivot strut can also cause shifts. Balloon shifts during val-
vuloplasty warn of a high likelihood of prosthesis shift.
Conclusions This report details the technical lessons
learned thus far from our ﬁrst 10 patients. Excellent
procedural success and early outcomes in patients with
functioning mitral prosthesis can be achieved (323).
A Multicenter, Randomized Trial Comparing
Heparin/Warfarin and Acetylsalicylic Acid as
Primary Thromboprophylaxis for 2 Years After the
Fontan Procedure in Children
Objectives The purpose of this study was to compare
the safety and efﬁcacy of acetylsalicylic acid (ASA)and warfarin for thromboprophylaxis after the Fontan
procedure.
Background Fontan surgery is the deﬁnitive palliation for
children with single-ventricle physiology. Thrombosis is an
important complication; the optimal thromboprophylaxis
strategy has not been determined.
Methods We performed a multicenter international
randomized trial of primary prophylactic anticoagulation
after Fontan surgery. Patients were randomized to receive
for 2 years either ASA (5 mg/kg/day, no heparin phase) or
warfarin (started within 24 h of heparin lead-in; target
international normalized ratio: 2.0 to 3.0). Primary
endpoint (intention to treat) was thrombosis, intracardiac
or embolic (all events adjudicated). At 3 months and 2
years after the Fontan procedure, transthoracic and trans-
esophageal echocardiograms were obtained as routine
surveillance. Major bleeding and death were primary
adverse outcomes.
Results A total of 111 eligible patients were randomized
(57 to ASA, 54 to heparin/warfarin). Baseline character-
istics for each group were similar. There were 2 deaths
unrelated to thrombosis or bleeding. There were 13
thromboses in the heparin/warfarin group (3 clinical, 10
routine echo) and 12 thromboses in the ASA group (4
clinical, 8 routine echo). Overall freedom from thrombosis
2 years after Fontan surgery was 19%, despite thrombosis
prophylaxis. Cumulative risk of thrombosis was persistent
but varying and similar for both groups (p ¼ 0.45). Major
bleeding occurred in 1 patient in each group.
Conclusions There was no signiﬁcant difference between
ASA and heparin/warfarin as primary thromboprophylaxis
in the ﬁrst 2 years after Fontan surgery. The thrombosis rate
was suboptimal for both regimens, suggesting alternative
approaches should be considered. (International Multi
Centre Randomized Clinical Trial Of Anticoagulation In
Children Following Fontan Procedures; NCT00182104)
(324).Radiofrequency Ablation of Atrial Fibrillation in
Patients With Mechanical Mitral Valve Prostheses:
Safety, Feasibility, Electrophysiologic Findings,
and Outcomes
Objectives The purpose of this study was to evaluate the
feasibility, safety, and outcomes of radiofrequency ablation of
atrial ﬁbrillation (AF) in patients with mechanical mitral
valve replacement (MVR).
Background The role of ablative therapy in patients with
MVR is not yet established, with safety concerns and very
few outcome data.
Methods Between January 2003 and December 2008, we
followed up 81 patients with MVR undergoing ﬁrst-time
AF ablation (compared with 162 age- and sex-matched
controls). Arrhythmia recurrences were identiﬁed by symp-
toms with documentation, event monitoring, Holter moni-
toring, and electrocardiograms.
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under therapeutic international normalized ratio. No
entrapment of catheters or stroke occurred. There were no
differences in terms of procedure-related complications
between the groups (p ¼ NS). Patients with MVR had
larger atria (p < 0.0001), lower left ventricular ejection
fractions (p ¼ 0.0001), and more concomitant atrial ﬂutter
at baseline (p < 0.0001). Over a 24-month follow-up, they
had higher recurrence rates compared with controls (49.4%
vs. 27.7% after a single ablation, p ¼ 0.0006). The creation
of ﬂutter lines signiﬁcantly reduced recurrences in patients
with any history of atrial ﬂutter (16.7% vs. 60.9%, p ¼
0.009). At last follow-up, 82.7% of MVR patients had their
arrhythmia controlled (69.1% not receiving antiarrhythmic
drugs).
Conclusions Radiofrequency ablation is feasible and safe
for patients with MVR. It allowed restoration of sinus
rhythm in a substantial proportion of patients undergoing
ablation. An abnormal atrial substrate underlies recurrences
in these patients. The ablation procedure needs to be further
reﬁned with a focus on extra pulmonary vein triggers and
concomitant ﬂutters to improve outcomes (325).Association Between IVUS Findings and Adverse
Outcomes in Patients With Coronary Artery
Disease: The VIVA (VH-IVUS in Vulnerable
Atherosclerosis) Study
Objectives The purpose of this study was to determine
whether thin-capped ﬁbroatheromata (TCFA) identiﬁed by
virtual histology intravascular ultrasound (VH-IVUS) are
associated with major adverse cardiac events (MACE) on
individual plaque or whole patient analysis.
Background Post-mortem studies have identiﬁed TCFA as
the substrate for most myocardial infarctions. However, little
is known about the natural history of individual TCFA and
their link with MACE. VH-IVUS provides a method of
identifying plaques in vivo that are similar (although not
identical) to histologically deﬁned TCFA, and has been
validated in human atherectomy and post-mortem studies.
Methods One hundred seventy patients with stable angina
or troponin-positive acute coronary syndrome referred for
percutaneous coronary intervention (PCI) were prospectively
enrolled and underwent 3-vessel VH-IVUS pre-PCI and
also post-PCI in the culprit vessel. MACE consisted of
death, myocardial infarction, or unplanned revascularization.
Results In all, 30,372 mm of VH-IVUS were analyzed.
Eighteen MACE occurred in 16 patients over a median
follow-up of 625 days (interquartile range: 463 to 990 days);
1,096 plaques were classiﬁed, and 19 lesions resulted in
MACE (13 nonculprit lesions and 6 culprit lesions). Non-
culprit lesion factors associated with nonrestenotic MACE
included VHTCFA (hazard ratio [HR]: 7.53, p ¼ 0.038)
and plaque burden >70% (HR: 8.13, p ¼ 0.011).
VHTCFA (HR: 8.16, p ¼ 0.007), plaque burden >70%
(HR: 7.48, p < 0.001), and minimum luminal area <4 mm2(HR: 2.91, p ¼ 0.036) were associated with total MACE.
On patient-based analysis, the only factor associated with
nonrestenotic MACE was 3-vessel noncalciﬁed VHTCFA
(HR: 1.79, p ¼ 0.004).
Conclusions VH-IVUS TCFA was associated with non-
restenotic and total MACE on individual plaque analysis,
and noncalciﬁed VHTCFA was associated with non-
restenotic and total MACE on whole-patient analysis,
demonstrating that VH-IVUS can identify plaques at
increased risk of subsequent events. The preservation of the
association between VHTCFA and MACE despite various
analyses emphasizes its biological importance (326).The Pre-Hospital Fibrinolysis Experience in Europe
and North America and Implications for Wider
Dissemination
Objectives The primary objective of this report was to
describe the infrastructures and processes of selected Euro-
pean and North American pre-hospital ﬁbrinolysis (PHL)
programs. A secondary objective is to report the outcome
data of the PHL programs surveyed.
Background Despite its beneﬁt in reducing mortality in
patients with ST-segment elevation myocardial infarction,
PHL remained underused in North America. Examination
of existing programs may provide insights to help address
barriers to the implementation of PHL.
Methods The leading investigators of PHL research
projects/national registries were invited to respond to
a survey on the organization and outcomes of their afﬁliated
PHL programs.
Results PHL was successfully deployed in a wide range of
geographic territories (Europe: France, Sweden, Vienna,
England, and Wales; North America: Houston, Edmonton,
and Nova Scotia) and was delivered by healthcare profes-
sionals of varying expertise. In-hospital major adverse
outcomes were rare with mortality of 3% to 6%, reinfarction
of 2% to 5%, and stroke of <2%.
Conclusions Combining formal protocols for PHL for
some patients with direct transportation of others to
a percutaneous coronary intervention hospital for primary
percutaneous coronary intervention would allow for tailored
reperfusion therapy for patients with ST-segment elevation
myocardial infarction. Insights from a variety of interna-
tional settings may promote widespread use of PHL and
increase timely coronary reperfusion worldwide (327).Saphenous Vein Graft Intervention
Saphenous vein grafts are commonly used conduits for
surgical revascularization of coronary arteries but are asso-
ciated with poor long-term patency rates. Percutaneous
revascularization of saphenous vein grafts is associated with
worse clinical outcomes including higher rates of in-stent
restenosis, target vessel revascularization, myocardial
infarction, and death compared with percutaneous coronary
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protection devices is a Class I indication according to the
American College of Cardiology/American Heart Associa-
tion guidelines to decrease the risk of distal embolization,
no-reﬂow, and periprocedural myocardial infarction.
Nonetheless, these devices are underused in clinical practice.
Various pharmacological agents are available that may also
reduce the risk of or mitigate the consequences of no-reﬂow.
Covered stents do not decrease the rates of periprocedural
myocardial infarction and restenosis. Most available
evidence supports treatment with drug-eluting stents in this
high-risk lesion subset to reduce angiographic and clinical
restenosis, although large, randomized trials comparing
drug-eluting stents and bare-metal stents are needed (328).Impact of Pentoxify: lline on Platelet Function
Proﬁles in Patients With Type 2 Diabetes Mellitus
and Coronary Artery Disease on Dual Antiplatelet
Therapy With Aspirin and Clopidogrel
Objectives The aim of this study was to evaluate the impact
of the phosphodiesterase (PDE) inhibitor pentoxifylline on
platelet function proﬁles in patients receiving dual anti-
platelet therapy (DAPT).
Background Previous studies have shown that, in patients
receiving DAPT, the adjunctive use of a PDE inhibitor
enhances platelet inhibition, particularly in those presenting
with diabetes mellitus (DM). However, the pharmacody-
namic (PD) effects of the PDE inhibitor pentoxifylline on
platelet function proﬁles in DM patients receiving DAPT
are unknown.
Methods This was a prospective, randomized, double-
blind, parallel design study conducted in DM patients
with stable coronary artery disease receiving DAPT. Patients
were randomly assigned to either pentoxifylline 400 mg or
placebo 3 times daily for 14 days. The PD effects were
assessed by vasodilator-stimulated phosphoprotein phos-
phorylation assay, light transmittance aggregometry, Ver-
ifyNow P2Y12 assay (Accumetric, Inc., San Diego,
California), and multiple electrode aggregometry at baseline
and 14 days. The PD effects were also assessed according the
presence or absence of high on-treatment platelet reactivity
status.
Results A total of 40 patients were available for analysis. At
14 days, there were no differences in the P2Y12 reactivity
index as assessed by vasodilator-stimulated phosphoprotein
phosphorylation between treatment groups (primary
endpoint; p ¼ 0.93). Intra-group comparisons also failed to
show any differences between baseline and 14-day P2Y12
reactivity index assessment in the placebo and pentoxifylline
arms (p ¼ 0.61). There were no signiﬁcant inter- and intra-
group differences in all other PD measures. The PD effects
did not vary according the presence or absence of high on-
treatment platelet reactivity.
Conclusions Adjunctive treatment with pentoxifylline is
not associated with increased platelet inhibitory effects inDM patients with coronary artery disease receiving DAPT
(329).
Clinical Experience With Percutaneous Left
Ventricular Transapical Access for Interventions in
Structural Heart Defects: A Safe Access and
Secure Exit
Objectives This study sought to evaluate the safety of
percutaneous direct left ventricular access for interventional
procedures.
Background Experience with percutaneous access of the
left ventricle (LV) for interventional procedures has been
limited and associated with a high percentage of major
complications. We report our clinical experience with
percutaneous direct LV access for interventional procedures.
Methods Between March 2008 and December 2010, there
were 32 percutaneous transapical punctures in 28 consecu-
tive patients (16 males, mean age 68.2  10.8 years). The
delivery sheath sizes ranged from 5- to 12-F.
Results All transapical punctures were successfully per-
formed, and safe closure of the access sites was achieved.
Total procedural time was 153.6  49.4 min for procedures
converted from conventional approaches to a transapical
approach, 129.5  29.6 min for the transapical approach
with trans-septal rail support, and 109.3  41.4 min for the
planned transapical approach. Fluoroscopy time was 61.3 
26.1 min, 29.7  20.8 min, and 27.4  21.4 min, respec-
tively. Fluoroscopy time for closure of mitral paravalvular
leaks was reduced by 35%, from 42.6  29.9 min to 27.4 
15.6 min. Complications were observed in 2 patients (7.1%).
Conclusions With meticulous planning, transapical punc-
ture is safe. The transapical access provides a more direct
approach to the LV targets for intervention and leads to
a signiﬁcant decrease in the procedural and ﬂuoroscopy
times. Device closure of the direct LV access site is a reliable
and safe method of hemostasis. Placement of a closure
device should be considered if sheaths larger than 5-F are
used. Although we used this technique only for paravalvular
leak and LV pseudoaneurysm closure, it may have applica-
tion for other percutaneous structural heart interventions
(330).
Clinical Outcomes Using a New Crossover Balloon
Occlusion Technique for Percutaneous Closure
After Transfemoral Aortic Valve Implantation
Objectives This study sought to evaluate the technical
success and clinical outcomes of an adjunctive crossover
balloon occlusion technique (CBOT) combined with the
10-F Prostar percutaneous closure device (PCD) on the
incidence of vascular and bleeding complications in patients
after transfemoral transcatheter aortic valve implantation
(TAVI).
Background Vascular closure following large-vessel access
has most commonly been performed using a surgical cut-
down and repair procedure.
The Editors JACC Vol. 62, No. 18, 2013
JACC Topic Collection: Interventional Cardiology October 29, 2013:e245–e437
e366Methods Between November 2008 and September 2010,
58 consecutive patients with severe aortic stenosis underwent
TAVI via a retrograde femoral artery approach using the
Edwards-SAPIEN transcatheter valve. Among these
patients, 56 were treated with a CBOT using the “pre-close”
technique and the 10-F Prostar system. The technical
success of this new CBOT and the 30-day frequency of
clinical events, including all-cause mortality, major vascular
complications, and major bleeding (deﬁned according to
a modiﬁed version of the Valve Academic Research
Consortium criteria), were assessed.
Results Successful closure was obtained in all but 3 patients
(94.6%). The 30-day frequencies of mortality, major vascular
complications, and major bleeding were 7.1%, 14.3%, and
5.4% respectively. No deaths were directly related to access
site complications. Fourteen patients (25%) received at least
1 transfusion during the index hospitalization, of which 8
(57.1%) were not related to vascular complications. The
mean and median hospital lengths of stay were 7.8 and 6.0
days.
Conclusions This new percutaneous adjunctive CBOT
combined with the Prostar PCD resulted in controlled, safe,
and successful percutaneous closure in most patients after
TAVI (331).New Insights Into the Coronary Artery Bifurcation:
Hypothesis-Generating Concepts Utilizing
3-Dimensional Optical Frequency Domain Imaging
Coronary artery bifurcations are a common challenging
lesion subset accounting for approximately 10% to 20% of all
percutaneous coronary interventions. The provisional T-
stenting approach is generally recommended as the ﬁrst-line
management of most lesions. Carina shift is suggested to be
the predominant mechanism of side-branch pinching during
provisional T-stenting and has been indirectly inferred from
bench work and other intravascular imaging modalities.
Ofﬂine 3-dimensional (3D) reconstructions of patients
studied in the ﬁrst-in-man trial of the high-frequency (160
frames/s) Terumo optical frequency domain imaging system
were undertaken using volume-rendering software. Through
a series of 3D reconstructions, several novel hypothesis-
generating concepts are presented (332).2-Year Clinical Follow-Up From the Randomized
Comparison of Biolimus-Eluting Stents With
Biodegradable Polymer and Sirolimus-Eluting
Stents With Durable Polymer in Routine Clinical
Practice
Objectives This study sought to investigate safety and
efﬁcacy of biolimus-eluting stents (BES) with biodegradable
polymer as compared with sirolimus-eluting stents (SES)
with durable polymer through 2 years of follow-up.
Background BES with a biodegradable polymer provide
similar efﬁcacy and safety as SES with a durable polymer at 9months. Clinical outcomes beyond the period of biodegra-
dation of the polymer used for drug release and after
discontinuation of dual antiplatelet therapy are of particular
interest.
Methods A total of 1,707 patients were randomized to
unrestricted use of BES (n ¼ 857) or SES (n ¼ 850) in an
all-comers patient population.
Results At 2 years, BES remained noninferior compared
with SES for the primary endpoint, which was a composite
of cardiac death, myocardial infarction, or clinically indicated
target vessel revascularization (BES 12.8% vs. SES 15.2%,
hazard ratio [HR]: 0.84, 95% conﬁdence interval [CI]: 0.65
to 1.08, pnoninferiority < 0.0001, psuperiority ¼ 0.18). Rates of
cardiac death (3.2% vs. 3.9%, HR: 0.81, 95% CI: 0.49 to
1.35, p ¼ 0.42), myocardial infarction (6.3% vs. 5.6%, HR:
1.12, 95% CI: 0.76 to 1.65, p ¼ 0.56), and clinically indi-
cated target vessel revascularization (7.5% vs. 8.6%, HR:
0.86, 95% CI: 0.62 to 1.20, p ¼ 0.38) were similar for BES
and SES. The rate of deﬁnite stent thrombosis through 2
years was 2.2% for BES and 2.5% for SES (p ¼ 0.73). For
the period between 1 and 2 years, event rates for deﬁnite
stent thrombosis were 0.2% for BES and 0.5% for SES (p ¼
0.42). After discontinuation of dual antiplatelet therapy, no
very late deﬁnite stent thrombosis occurred in the BES
group.
Conclusions At 2 years of follow-up, the unrestricted use
of BES with a biodegradable polymer maintained a similar
safety and efﬁcacy proﬁle as SES with a durable polymer.
(Limus Eluted From a Durable Versus Erodable Stent
Coating [LEADERS]; NCT00389220) (333).Percutaneous Coronary Intervention in Native
Arteries Versus Bypass Grafts in Prior Coronary
Artery Bypass Grafting Patients: A Report From the
National Cardiovascular Data Registry
Objectives This study examined a large registry to deter-
mine the frequency, predictors, and outcomes of native
coronary artery versus bypass graft percutaneous coronary
intervention (PCI) in patients with prior coronary artery
bypass graft surgery (CABG).
Background The PCI target vessel and corresponding
outcomes in prior CABG patients are poorly studied.
Methods We analyzed the frequency and factors associated
with native versus bypass graft PCI in prior CABG patients
undergoing PCI between January 1, 2004, and June 30,
2009, in the National Cardiovascular Data Registry
(NCDR) CathPCI Registry. Generalized estimating equa-
tions logistic regression modeling was used to generate
independent variables associated with native versus bypass
graft PCI and in-hospital mortality.
Results During the study period, PCI in prior CABG
patients represented 17.5% of the total PCI volume
(300,902 of 1,721,046). The PCI target was a native coro-
nary artery in 62.5% and a bypass graft in 37.5%: saphenous
vein graft (SVG) (104,678 [34.9%]), arterial graft (7,517
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Compared with patients undergoing native coronary artery
PCI, those undergoing bypass graft PCI had higher-risk
characteristics and more procedural complications. On
multivariable analysis, several parameters (including graft
stenosis and longer interval from CABG) were associated
with performing native coronary PCI, and bypass graft PCI
was associated with higher in-hospital mortality (adjusted
odds ratio: 1.22, 95% conﬁdence interval: 1.12 to 1.32).
Conclusions Most PCIs performed in prior CABG
patients are done in native coronary artery lesions.
Compared with native coronary PCI, bypass graft PCI is
independently associated with higher in-hospital mortality
(334).Recovery of Microcirculation After Intracoronary
Infusion of Bone Marrow Mononuclear Cells or
Peripheral Blood Mononuclear Cells in Patients
Treated by Primary Percutaneous Coronary
Intervention: The Doppler Substudy of the Hebe
Trial
Objectives In the present substudy of the Hebe trial, we
investigated the effect of intracoronary bone marrow
mononuclear cell (BMMC) and peripheral blood mono-
nuclear cell (PBMC) therapy on the recovery of microcir-
culation in patients with reperfused ST-segment elevation
myocardial infarction (STEMI).
Background Several studies have suggested that cell
therapy enhances neovascularization after STEMI.
Methods Paired Doppler ﬂow measurements were available
for 23 patients in the BMMC group, 18 in the PBMC
group, and 19 in the control group. Coronary ﬂow was
assessed at 3 to 8 days after primary percutaneous coronary
intervention (PCI) and repeated at 4-month follow-up, with
intracoronary Doppler ﬂow measurements.
Results At baseline, the coronary ﬂow velocity reserve was
reduced in the infarct-related artery and improved over 4
months in all 3 groups. The increase of coronary ﬂow
velocity reserve did not signiﬁcantly differ between the 2
treatment groups and the control group (BMMC group:
2.0  0.5 to 3.1  0.7; PBMC group: 2.2  0.6 to 3.2 
0.8; control group: 2.0  0.5 to 3.4  0.9). Additionally,
the decrease in hyperemic microvascular resistance index
from baseline to 4-month follow-up was not statistically
different between the 2 treatment groups and the control
group.
Conclusions In STEMI patients treated with primary PCI
in the Hebe trial, adjuvant therapy with BMMCs or
PBMCs does not improve the recovery of microcirculation.
Therefore, our data do not support the hypothesis of
enhanced neovascularization after this mode of cell therapy.
(Multicenter, randomised trial of intracoronary infusion of
autologous mononuclear bone marrow cells or peripheral
mononuclear blood cells after primary percutaneous coronary
intervention [PCI]; ISRCTN95796863) (335).1-Year Outcome of TRIAS HR (TRI-Stent
Adjudication Study–High Risk of Restenosis): A
Multicenter, Randomized Trial Comparing Genous
Endothelial Progenitor Cell Capturing Stents With
Drug-Eluting Stents
Objectives This study sought to demonstrate the non-
inferiority of endothelial progenitor cell capturing stents
(ECS) relative to drug-eluting stents (DES) regarding target
lesion failure (TLF) and the composite of cardiac death,
myocardial infarction, and target lesion repeat revasculari-
zation within 1 year.
Background A “pro-healing” approach for prevention of
in-stent restenosis is theoretically favorable over the use of
cytotoxic/cytostatic drugs released from DES to treat coro-
nary artery disease. Promoting accelerated endothelialization
of the stent, ECS have shown promising results in studies
with patients carrying noncomplex lesions.
Methods We undertook an international, clinical trial in 26
centers planning to randomize 1,300 patients with stable
coronary artery disease and with a high risk of restenosis
between treatment, with either ECS or DES. After a routine
review with 50% of the patients enrolled, early cessation of
the trial was recommended by the data and safety moni-
toring board when TLF in the ECS population was higher
and treatment of new patients with an ECS would be
unreasonable.
Results At 1 year evaluating 304 patients receiving ECS
and 318 receiving DES, TLF occurred in 17.4% of the
ECS-treated patients and in 7.0% of the DES-treated
patients (p ¼ 0.98 for noninferiority).
Conclusions Within 1 year, inhibition of intimal hyper-
plasia by the ECS is not sufﬁciently strong to compete with
DES in terms of restenosis prevention in patients/lesions
with a high risk of restenosis. Furthermore, long-term
follow-up is pivotal to fully appreciate the clinical value of
ECS, including the effect on late intimal hyperplasia
regression (336).
Prognostic Implications of Nonobstructive
Coronary Plaques in Patients With Non–
ST-Segment Elevation Myocardial Infarction: A
Multidetector Computed Tomography Study
Objectives We sought to determine whether the amount of
noncalciﬁed plaque (NCP) in nonobstructive coronary
lesions as detected by multidetector computed tomography
(MDCT) was a predictor of future coronary events.
Background Patients presenting with non–ST-segment
elevation myocardial infarction (NSTEMI) frequently have
multiple coronary plaques, which may be detected with
MDCT.
Methods We included 312 consecutive patients presenting
with NSTEMI, who underwent 64-slice MDCT coronary
angiography and coronary artery calcium scoring before
invasive coronary angiography. All patients were treated
according to current guidelines based on an invasive
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composition and volume were performed by MDCT in all
nonobstructive coronary lesions. The endpoint was cardiac
death, acute coronary syndrome, or symptom-driven
revascularization.
Results After a median follow-up of 16 months, 23
patients had suffered a cardiac event. Age, male sex, and
diabetes mellitus were all associated with an increasing
amount of NCP. In a multivariate regression analysis for
events, the total amount of NCP in nonobstructive lesions
was independently associated with an increased hazard ratio
(1.18/100-mm3 plaque volume increase, p¼ 0.01). Contrary
to this, neither Agatston score nor the amount of calcium in
nonobstructive lesions was associated with an increased risk.
Conclusions Multidetector computed tomography plaque
imaging identiﬁed patients at increased risk of recurrent
coronary events after NSTEMI by measuring the total
amount of NCP in nonobstructive lesions. The amount of
calciﬁed plaque was not associated with an increased risk
(337).High On-Treatment Platelet Reactivity After
Prasugrel Loading Dose and Cardiovascular Events
After Percutaneous Coronary Intervention in Acute
Coronary Syndromes
Objectives The aim of this study was to investigate the
relationship between platelet reactivity (PR) after a loading
dose (LD) of prasugrel and thrombotic events.
Background Post-treatment PR has been shown to be
strongly associated with the occurrence of major adverse
cardiac events (MACE) after percutaneous coronary inter-
vention (PCI) in the clopidogrel era. Prasugrel is a new
P2Y12–adenosine diphosphate receptor with a higher
potency on PR.
Methods A prospective multicenter study included patients
who underwent successful PCI for acute coronary syndromes
and received prasugrel therapy. Vasodilator-stimulated
phosphoprotein (VASP) index was measured after the pra-
sugrel LD. High on-treatment PR was deﬁned as a VASP
index 50%. MACE included cardiovascular death,
myocardial infarction, and deﬁnite stent thrombosis at 1
month.
Results Three hundred one patients were enrolled. The
mean VASP index after 60 mg of prasugrel was 34.3 
23.1%. High on-treatment PR was observed in 76 patients
(25.2%). Patients experiencing thrombotic events after PCI
had signiﬁcantly higher VASP indexes compared with those
free of events (64.4  14.4% vs. 33.4  22.7%; range: 51%
to 64% and 5% to 47.6%, respectively; p ¼ 0.001). Kaplan-
Meier analysis comparing good responders and patients with
high on-treatment PR demonstrated a signiﬁcantly higher
rate of MACE in patients with suboptimal PR inhibition
(log-rank p< 0.001). Receiver-operating characteristic curve
analysis found a cutoff value of 53.5% of the VASP index to
predict thrombotic events at 1 month (r ¼ 0.86, p < 0.001).Patients with minor or major Thrombolysis In Myocardial
Infarction unrelated to coronary artery bypass grafting
bleeding and those without had similar VASP indexes (30 
17.8% vs. 34.3  23%, p ¼ 0.70).
Conclusions Despite the use of prasugrel, a signiﬁcant
number of patients undergoing PCI in the setting of acute
coronary syndromes do not achieve optimal PR inhibition.
Such patients have a higher risk for MACE after PCI (338).
Prospective Application of Pre-Deﬁned
Intravascular Ultrasound Criteria for Assessment
of Intermediate Left Main Coronary Artery Lesions:
Results From the Multicenter LITRO Study
Objectives This study is a prospective validation of 6 mm2
as a minimum lumen area (MLA) cutoff value for revascu-
larization of left main coronary artery (LMCA) lesions.
Background Lesions involving the LMCA are prognosti-
cally relevant. Angiography has important limitations in the
evaluation of LMCA lesions with intermediate severity. An
MLA of 6 mm2 assessed by intravascular ultrasound has
been proposed as a cutoff value to determine lesion severity,
but there are no large studies evaluating the prospective
application and safety of this approach.
Methods We have designed a multicenter, prospective
study. Consecutive patients with intermediate lesions in
unprotected LMCA were evaluated with intravascular
ultrasound. An MLA <6 mm2 was used as criterion for
revascularization.
Results A total of 354 patients were included in 22 centers.
LMCA revascularization was performed in 90.5% (152 of
168) of patients with an MLA <6 mm2 and was deferred in
96% (179 of 186) of patients with an MLA of 6 mm2 or
more. A large scatter was observed between both groups
regarding angiographic parameters. In a 2-year follow-up
period, cardiac death-free survival was 97.7% in the
deferred group versus 94.5% in the revascularized group
(p ¼ 0.5), and event-free survival was 87.3% versus 80.6%,
respectively (p ¼ 0.3). In the 2-year period, only 8 (4.4%)
patients in the deferred group required subsequent LMCA
revascularization, none with an infarction.
Conclusions Angiographic measurements are not reliable
in the assessment of intermediate LMCA lesions. An MLA
of 6 mm2 or more is a safe value for deferring revasculari-
zation of the LMCA, given the application of the clinical
and angiographic inclusion criteria used in this study (339).
A New Risk Scheme to Predict Warfarin-
Associated Hemorrhage: The ATRIA
(Anticoagulation and Risk Factors in Atrial
Fibrillation) Study
Objectives The purpose of this study was to develop a risk
stratiﬁcation score to predict warfarin-associated hemorrhage.
Background Optimal decision making regarding warfarin
use for atrial ﬁbrillation requires estimation of hemorrhage
risk.
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lation contributing 32,888 person-years of follow-up on
warfarin, obtaining data from clinical databases and vali-
dating hemorrhage events using medical record review. We
used Cox regression models to develop a hemorrhage risk
stratiﬁcation score, selecting candidate variables using
bootstrapping approaches. The ﬁnal model was internally
validated by split-sample testing and compared with 6
published hemorrhage risk schemes.
Results We observed 461 ﬁrst major hemorrhages during
follow-up (1.4% annually). Five independent variables were
included in the ﬁnal model and weighted by regression
coefﬁcients: anemia (3 points), severe renal disease (e.g.,
glomerular ﬁltration rate <30 ml/min or dialysis-dependent,
3 points), age 75 years (2 points), prior bleeding (1 point),
and hypertension (1 point). Major hemorrhage rates ranged
from 0.4% (0 points) to 17.3% per year (10 points).
Collapsed into a 3-category risk score, major hemorrhage
rates were 0.8% for low risk (0 to 3 points), 2.6% for
intermediate risk (4 points), and 5.8% for high risk (5 to 10
points). The c-index for the continuous risk score was 0.74
and 0.69 for the 3-category score, higher than in the other
risk schemes. There was net reclassiﬁcation improvement
versus all 6 comparators (from 27% to 56%).
Conclusions A simple 5-variable risk score was effective in
quantifying the risk of warfarin-associated hemorrhage in
a large community-based cohort of patients with atrial
ﬁbrillation (340).6-Month Clinical Outcomes Following Implantation
of the Bioresorbable Everolimus-Eluting Vascular
Scaffold in Vessels Smaller or Larger Than 2.5 mm
Objectives We investigated the 6-month clinical outcomes
after implantation of second-generation 3.0-mm bio-
resorbable everolimus-eluting vascular scaffolds (BVS) in
small coronary vessels (<2.5 mm).
Background BVS are a novel approach to treating coronary
lesions and are untested in small vessels.
Methods The ABSORB Cohort B Trial is a multicenter,
single-arm, prospective, open-label trial assessing the
performance of the second-generation BVS, in which 101
patients were enrolled. The pre-procedural reference vessel
diameter (RVD) was assessed by quantitative coronary
angiography during post hoc analysis. The vessel size was
overestimated, by visual assessment, in 41 patients before
implantation of 3.0-mm BVS in vessels with a pre-
procedural RVD <2.5 mm. The study population was
divided into 2 groups, group I (n ¼ 41) with RVD <2.5 mm
and group II (n ¼ 60) with RVD 2.5 mm. The composite
endpoint of ischemia-driven major adverse cardiac events,
deﬁned as ischemia-driven target lesion revascularization,
myocardial infarction, or cardiac death, was assessed. Of the
45 patients scheduled for 6-month coronary angiography, 42
patients had the procedure performed, with intravascular
ultrasound undertaken in 40 of these patients.Results At 6 months, no signiﬁcant differences in
ischemia-driven major adverse cardiac events (3 of 41 [7.3%]
cases vs. 2 of 60 [3.3%] cases; p ¼ 0.3933) were observed in
the small- and large-vessel groups, respectively. No cardiac
deaths or episodes of in-scaffold thromboses were seen.
Angiographic and intravascular ultrasound follow-up
demonstrated no differences in late lumen loss (0.16 
0.18 mm vs. 0.21  0.17 mm; p ¼ 0.3525) or percentage
lumen area stenosis (17.6  6.0% vs. 19.8  8.5%; p ¼
0.3643).
Conclusions The second-generation 3.0-mm BVS appears
to be safe in small vessels, with similar clinical and angio-
graphic outcomes compared with those of large vessels
(341).Epicardial Ablation of Rotors Suppresses
Inducibility of Acetylcholine-Induced Atrial
Fibrillation in Left Pulmonary Vein–Left Atrium
Preparations in a Beagle Heart Failure Model
Objectives The purpose of this study was to provide direct
evidences that rotor ablation suppresses atrial ﬁbrillation
(AF) inducibility.
Background Micro–re-entrant wavefronts have been sug-
gested to serve as sources of rapid activations during AF.
Whether AF inducibility is suppressed by elimination of
rotors remains unknown.
Methods We used optical mapping to study Langendorff-
perfused left pulmonary vein (PV)–left atrium (LA) prepa-
rations from 13 dogs with pacing-induced heart failure.
Atrial arrhythmias were induced by pacing and mapped
during acetylcholine infusion (1 mmol/l). Rotors were
identiﬁed from optical recordings. Epicardial ablation was
performed targeting the rotor anchoring sites in preparations
with sustained (>10 min) or incessant spontaneous AF.
Non-rotor ablation was performed in 4 preparations.
Repeated pacing was performed to test the AF inducibility
after ablation.
Results Sustained AF (n ¼ 12) and incessant spontaneous
AF (n ¼ 1) were induced after acetylcholine infusion.
Pulmonary vein focal discharge was found in 9 preparations
(9.2  4.2 beats/s), and rotor anchoring was found at the left
superior PV-LA junction in 13 preparations (9.1  4.6
beats/s) and at the ligament of Marshall-PV-LA junction in
1 preparation. Epicardial rotor ablation successfully inhibi-
ted the inducibility of sustained AF in 12 of 13 preparations
(p < 0.01), including 4 with the maximal dominant
frequency sites located on the PV-LA junctional rotor zones
(direct elimination of mother rotors). The longest AF
duration was shortened signiﬁcantly by rotor ablation
(Wilcoxon Z ¼ 3.60, p ¼ 0.002, n ¼ 13), but not by non-
rotor ablation (Wilcoxon Z ¼ 1.00, p ¼ 0.317, n ¼ 4).
Conclusions Epicardial ablation of the rotor anchoring
sites suppresses AF inducibility. The arrhythmogenicity at
the maximal dominant frequency sites is directly/indirectly
suppressed by the rotor ablation (342).
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e370Impact of Metabolic Syndrome and Diabetes on
Prognosis and Outcomes With Early Percutaneous
Coronary Intervention in the COURAGE (Clinical
Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation) Trial
Objectives Our purpose was to clarify the clinical utility of
identifying metabolic syndrome (MetS) in patients with
coronary artery disease (CAD).
Background It is uncertain whether MetS inﬂuences
prognosis in patients with CAD and whether the risk
associated with MetS exceeds the risk associated with the
sum of its individual components.
Methods In a post hoc analysis, we compared the incidence
of death or myocardial infarction (MI) in stable CAD
patients in the COURAGE (Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation) trial
according to the presence (þ) or absence () of MetS and
diabetes: Group A, MetS/diabetes; Group B, þMetS/
diabetes; Group C, MetS/þdiabetes; and Group
D, þMetS/þdiabetes. We explored which MetS compo-
nents best predicted adverse outcomes and whether MetS
had independent prognostic signiﬁcance beyond its indi-
vidual components.
Results Of 2,248 patients, 61% had MetS and 34% dia-
betes. Risk for death or MI increased from Group A (14%)
to Group D (25%, p < 0.001). Hypertension (hazard ratio
[HR]: 1.30; 95% conﬁdence interval [CI]: 0.98 to 1.71; p ¼
0.07), low high-density lipoprotein cholesterol (HR: 1.26;
95% CI: 1.03 to 1.55; p ¼ 0.03), and elevated glucose (HR:
1.17; 95% CI: 0.96 to 1.47; p ¼ 0.11) most strongly pre-
dicted death or MI. MetS was associated with an increased
risk of death or MI (unadjusted HR: 1.41; 95% CI: 1.15 to
1.73; p ¼ 0.001). However, after adjusting for its individual
components, MetS was no longer signiﬁcantly associated
with outcome (HR: 1.15; 95% CI: 0.79 to 1.68; p ¼ 0.46).
Allocation to initial percutaneous coronary intervention did
not affect the incidence of death or MI within any group.
Conclusions Among stable CAD patients in the
COURAGE trial, the presence of MetS identiﬁed increased
risk for death or MI, but MetS did not have independent
prognostic signiﬁcance after adjusting for its constituent
components. The addition of early percutaneous coronary
intervention to optimal medical therapy did not signiﬁcantly
reduce the risk of death or MI regardless of MetS or
diabetes status. (Clinical Outcomes Utilizing Revasculari-
zation and Aggressive Drug Evaluation [COURAGE];
NCT00007657) (343).Stroke Intervention: Catheter-Based Therapy for
Acute Ischemic Stroke
The majority (>80%) of the three-quarters of a million
strokes that will occur in the United States this year are
ischemic in nature. The treatment of acute ischemic stroke is
very similar to acute myocardial infarction, which requirestimely reperfusion therapy for optimal results. The majority
of patients with acute ischemic stroke do not receive any
form of reperfusion therapy, unlike patients with acute
myocardial infarction. Improving outcomes for acute stroke
will require patient education to encourage early presenta-
tion, an aggressive expansion of qualiﬁed hospitals, and
willing providers and early imaging strategies to match
patients with their best options for reperfusion therapy to
minimize complications (344).The Impact of Right Coronary Artery Chronic Total
Occlusion on Clinical Outcome of Patients
Undergoing Percutaneous Coronary Intervention
for Unprotected Left Main Disease
Objectives The aim of the present study was to investigate
whether right coronary artery chronic total occlusion (CTO)
carries prognostic implications in patients undergoing drug-
eluting stent–supported percutaneous coronary intervention
(PCI) for unprotected left main disease (ULMD).
Background No data exist on the prognostic implication of
CTO in patients undergoing PCI for ULMD.
Methods Prospective registry of consecutive patients
undergoing PCI for ULMD. Patients with ST-segment
elevation myocardial infarction were excluded. Primary
endpoints were 6-month and long-term cardiac mortality.
Results From January 2004 to December 2009, 330
patients underwent PCI for ULMD. Of the 330 patients, 78
(24%) had CTO of the right coronary artery, 22 (7%) had
CTO of the left anterior descending artery, and 16 (5%) had
CTO of the left circumﬂex artery. Patients with right
coronary artery CTO had a higher risk proﬁle compared
with patients without right coronary artery CTO. The 6-
month mortality rate was 12.8% in patients with right
coronary artery CTO, and 3.6% in patients without right
coronary artery CTO (p < 0.002), and the 3-year cardiac
survival rate was 76.4  6.8% and 89.7  2.7% (p < 0.003),
respectively. By multivariable analysis, the only 2 indepen-
dent predictors of 3-year cardiac mortality were right coro-
nary artery CTO (hazard ratio: 2.15, 95% conﬁdence
interval: 1.02 to 4.50; p ¼ 0.043) and EuroSCORE (hazard
ratio: 1.03, 95% conﬁdence interval: 1.02 to 1.05; p <
0.001).
Conclusions Right coronary artery CTO occurs frequently
and is a signiﬁcant predictor of mortality in patients with
ULMD undergoing PCI (345).Dark Regions of No-Reﬂow on Late Gadolinium
Enhancement Magnetic Resonance Imaging Result
in Scar Formation After Atrial Fibrillation Ablation
Objectives The aim of this study was to assess acute
ablation injuries seen on late gadolinium enhancement
(LGE) magnetic resonance imaging (MRI) immediately
post-ablation (IPA) and the association with permanent scar
3 months post-ablation (3moPA).
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ablation vary signiﬁcantly, in part because of limited infor-
mation about the location, extent, and permanence of
ablation injury at the time of procedure. Although the
amount of scar on LGE MRI months after ablation corre-
lates with procedure outcomes, early imaging predictors of
scar remain elusive.
Methods Thirty-seven patients presenting for atrial ﬁbril-
lation ablation underwent high-resolution MRI with a 3-
dimensional LGE sequence before ablation, IPA, and
3moPA using a 3-T scanner. The acute left atrial wall
injuries on IPA scans were categorized as hyperenhancing
(HE) or nonenhancing (NE) and compared with scar
3moPA.
Results Heterogeneous injuries with HE and NE regions
were identiﬁed in all patients. Dark NE regions in the left
atrial wall on LGE MRI demonstrate ﬁndings similar to the
“no-reﬂow” phenomenon. Although the left atrial wall
showed similar amounts of HE, NE, and normal tissue IPA
(37.7  13%, 34.3  14%, and 28.0  11%, respectively;
p ¼ NS), registration of IPA injuries with 3moPA scarring
demonstrated that 59.0  19% of scar resulted from NE
tissue, 30.6  15% from HE tissue, and 10.4  5% from
tissue identiﬁed as normal. Paired t-test comparisons were
all statistically signiﬁcant among NE, HE, and normal tissue
types (p < 0.001). Arrhythmia recurrence at 1-year follow-
up correlated with the degree of wall enhancement
3moPA (p ¼ 0.02).
Conclusions Radiofrequency ablation results in heteroge-
neous injury on LGE MRI with both HE and NE wall
lesions. The NE lesions demonstrate no-reﬂow character-
istics and reveal a better predictor of ﬁnal scar at 3 months.
Scar correlates with procedure outcomes, further high-
lighting the importance of early scar prediction (346).Impact of Diabetes Mellitus on the Safety and
Effectiveness of Bivalirudin in Patients With Acute
Myocardial Infarction Undergoing Primary
Angioplasty: Analysis From the HORIZONS-AMI
(Harmonizing Outcomes with RevasculariZatiON
and Stents in Acute Myocardial Infarction) Trial
Objectives We sought to evaluate the safety and efﬁcacy of
bivalirudin compared with glycoprotein IIb/IIIa inhibitors
(GPI) in diabetic patients with ST-segment elevation
myocardial infarction (STEMI) undergoing primary percu-
taneous coronary intervention (PCI).
Background Prior studies have demonstrated that GPI are
especially beneﬁcial in patients with diabetes with acute
coronary syndromes and/or those undergoing PCI.
Methods In the multicenter, prospective HORIZONS-
AMI (Harmonizing Outcomes with RevasculariZatiON
and Stents in Acute Myocardial Infarction) trial, 3,602
patients with STEMI were randomized to bivalirudin or
unfractionated heparin plus a GPI. Clinical outcomes were
analyzed at 30 days and 1 year in patients with diabetes.Results Diabetes mellitus was present in 593 patients
(16.5%). The rates of cardiac death were signiﬁcantly lower
in diabetic patients treated with bivalirudin compared with
heparin plus GPI (30 days: 2.1% vs. 5.5%, p ¼ 0.04; 1 year:
2.5% vs. 7.1%, p ¼ 0.01), and bivalirudin resulted in lower
30-day rates of stroke (0% vs. 2%, p ¼ 0.02). There were no
signiﬁcant differences among diabetic patients randomized
to bivalirudin versus heparin plus GPI in the 1-year rates of
major adverse cardiac events (14.2% vs. 16.2%, p ¼ 0.44),
major bleeding (8.7% vs. 10.7%, p ¼ 0.42), or stent
thrombosis (4.2% vs. 3.8%, p ¼ 0.85). By interaction
testing, the relative effects of bivalirudin compared with
heparin plus GPI were not signiﬁcantly different in patients
with and without diabetes.
Conclusions In patients with diabetes mellitus presenting
with STEMI undergoing primary PCI, anticoagulant
therapy with bivalirudin compared with heparin plus GPI is
safe and effective and might reduce cardiac mortality at 30
days and 1 year. (Harmonizing Outcomes With Revascu-
larization and Stents in Acute Myocardial Infarction;
NCT00433966) (347).Angiographic Geometric Changes of the Lumen
Arterial Wall After Bioresorbable Vascular
Scaffolds and Metallic Platform Stents at 1-Year
Follow-Up
Objectives The aim of this study was to compare the
angiographic changes in coronary geometry of the bio-
resorbable vascular scaffolds (BVS) and metallic platform
stent (MPS) between baseline and follow-up.
Background Coronary geometry changes after stenting
might result in wall shear stress changes and adverse events.
The BVS have better conformability, compared with MPS,
but still modify artery geometry. It is uncertain whether the
BVS resorption can restore the coronary anatomical
conﬁguration at midterm follow-up.
Methods All patients of the ABSORB (A Clinical Eval-
uation of the Bioabsorbable Everolimus Eluting Coronary
Stent System [BVS EECSS] in the Treatment of Patients
With de Novo Native Coronary Artery Lesions) and
SPIRIT (A Clinical Evaluation of the XIENCE V Ever-
olimus Eluting Coronary Stent System in the Treatment of
Patients With de Novo Native Coronary Artery Lesions)
trials treated with a single 3.0  18 mm device and imaged
at baseline and 6- to 12-month follow-up were eligible.
Coronary geometry changes were assessed with quantitative
angiography as changes in curvature and angulation.
Curvature and angulation changes between systole and
diastole were investigated to assess hinging movements of
the coronary artery.
Results One hundred sixty-one patients (86 BVS, and 75
MPS) were included. Baseline angiographic characteristics
were similar. From post-implantation to follow-up, curva-
ture increased 8.4% (p < 0.01) with BVS and decreased
1.9% (p ¼ 0.54) with MPS; p ¼ 0.01. Angulation increased
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p < 0.01. From pre-implantation to follow-up, BVS
decreased 3.4% the artery curvature (p ¼ 0.05) and 3.9% the
artery angulation (p ¼ 0.16), whereas MPS presented with
26.1% decrease in curvature (p < 0.01) and 26.9% decrease
in angulation (p < 0.01), being larger with MPS (p < 0.01,
both). Hinging movements in curvature from pre-
implantation to follow-up decreased 19.7% with BVS and
39.0% with MPS (p ¼ 0.27) and decreased 3.9% with BVS
and 26.9% with MPS in angulation (p < 0.01).
Conclusions At midterm follow-up, the BVS tended to
restore the coronary conﬁguration and the systo-diastolic
movements to those seen before implantation. The coro-
nary geometry remained similar to that seen at after
implantation with MPS. (A Clinical Evaluation of the
Bioabsorbable Everolimus Eluting Coronary Stent System
[BVS EECSS] in the Treatment of Patients With de Novo
Native Coronary Artery Lesions; NCT00856856) (348).Periprocedural and Short-Term Outcomes of
Transfemoral Transcatheter Aortic Valve
Implantation With the Sapien XT as Compared With
the Edwards Sapien Valve
Objectives The aim of this study was to analyze the short-
term outcomes after transcatheter aortic valve implantation
with the Edwards Sapien THV (ESV), compared with the
Sapien XT THV (SXT) (Edwards Lifesciences, Irvine,
California).
Background The SXT has been recently commercialized in
Europe, but there are no studies analyzing the efﬁcacy and
safety of SXT, compared with ESV.
Methods All consecutive patients (n ¼ 120) who under-
went transcatheter aortic valve implantation in our center via
the transfemoral approach with either ESV (n ¼ 66) or SXT
(n ¼ 54). Valve Academic Research Consortium endpoints
were used.
Results Mean age was 80  8 years, and mean Logistic-
European System for Cardiac Operative Risk Evaluation
was 24.9  17.0. The ilio-femoral artery minimal lumen
diameter was smaller in patients treated with the SXT
(7.27  1.09 mm vs. 7.94  1.08 mm, p ¼ 0.002).
Device success was high in both groups (96.3% vs. 92.4%,
p ¼ 0.45). Major vascular events were 3-fold lower in the
SXT group (11.1% vs. 33.3%, relative risk: 0.40, 95%
conﬁdence interval: 0.28 to 0.57; p ¼ 0.004). Life-
threatening and major bleeding events were not signiﬁ-
cantly different between groups (18.5% vs. 27.3% and
35.2% vs. 40.9%, respectively). The SXT group had
a lower 30-day Valve Academic Research Consortium
combined safety endpoint (20.4% vs. 45.5%; relative risk:
0.44, 95% conﬁdence interval: 0.24 to 0.80; p ¼ 0.004).
The 30-day mortality was 1.7% (n ¼ 2). At 30 days, mean
transaortic gradient was approximately 10 mm Hg in both
groups and the aortic regurgitation was mild-to-moderate
in 70.2% of SXT and 76.3% of ESV.Conclusions The new SXT valve has the same short-term
performance as the ESV but seems to be associated with
a lower risk of major vascular complications and thus has
a broader clinical application (349).Transcatheter Aortic Valve Implantation for Failing
Surgical Aortic Bioprosthetic Valve: From Concept
to Clinical Application and Evaluation (Part 1)
With an aging population, improvement in life expectancy,
and signiﬁcant increase in the use of bioprosthetic valves,
structural valve deterioration will become more and more
prevalent. The operative mortality for an elective redo aortic
valve surgery is reported to range from 2% to 7%, but this
percentage can increase to more than 30% in high-risk and
nonelective patients. Because transcatheter aortic valve
(TAV)-in-surgical aortic valve (SAV) implantation repre-
sents a minimally invasive alternative to conventional redo
surgery, it may prove to be safer and just as effective as redo
surgery. Of course, prospective comparisons with a large
number of patients and long-term follow-up are required to
conﬁrm these potential advantages. It is axiomatic that
knowledge of the basic construction and dimensions,
radiographic identiﬁcation, and potential failure modes of
SAV bioprostheses is fundamental in understanding key
principles involved in TAV-in-SAV implantation. The
goals of this paper are: 1) to review the classiﬁcation,
physical characteristics, and potential failure modes of
surgical bioprosthetic aortic valves; and 2) to discuss patient
selection and procedural techniques relevant to TAV-in-SAV
implantation (350).Transcatheter Aortic Valve Implantation for Failing
Surgical Aortic Bioprosthetic Valve: From Concept
to Clinical Application and Evaluation (Part 2)
Objectives This study sought to review the acute proce-
dural outcomes of patients who underwent transcatheter
aortic valve (TAV)–in–surgical aortic valve (SAV) implan-
tation at the German Heart Center, Munich, and to
summarize the existing literature on TAV-in-SAV
implantation (n ¼ 47).
Background There are several case reports and small case
series describing transcatheter aortic valve implantation for
a failing surgical aortic valve bioprosthesis (TAV-in-SAV
implantation).
Methods From January 2007 to March 2011, 20 out of 556
patients underwent a TAV-in-SAV implantation at the
German Heart Center Munich. Baseline characteristics and
clinical outcome data were prospectively entered into
a dedicated database.
Results The mean patient age was 75  13 years, and the
mean logistic European System for Cardiac Operative Risk
Evaluation and Society of Thoracic Surgeons’ Risk Model
scores were 27  13% and 7  4%, respectively. Of the 20
patients, 14 had stented and 6 had stentless surgical
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transapical route using a 23-mm Edwards Sapien prosthesis
(Edwards Lifesciences, Irvine, California). Successful
implantation of a TAV in a SAV with the patient leaving
the catheterization laboratory alive was achieved in 18 of 20
patients. The mean transaortic valve gradient was 20.0  7.5
mm Hg. None-to-trivial, mild, and mild-to-moderate par-
avalvular aortic regurgitation was observed in 10, 6, and 2
patients, respectively. We experienced 1 intraprocedural
death following pre-implant balloon aortic valvuloplasty
(“stone heart”) and 2 further in-hospital deaths due to
myocardial infarction.
Conclusions TAV-in-SAV implantation is a safe and
feasible treatment for high-risk patients with failing aortic
bioprosthetic valves and should be considered as part of the
armamentarium in the treatment of aortic bioprosthetic
valve failure (351).Prognostic Signiﬁcance of Coronary Thrombus in
Patients Undergoing Percutaneous Coronary
Intervention for Acute Coronary Syndromes: A
Subanalysis of the ACUITY (Acute Catheterization
and Urgent Intervention Triage strategY) Trial
Objectives The objective of this study is to investigate the
incidence and clinical implications of thrombus on baseline
angiography among patients presenting with non–ST-
segment elevation acute coronary syndromes (ACS) under-
going percutaneous coronary intervention (PCI).
Background Given current advances in the pharmacolog-
ical and mechanical treatment of ACS patients managed
with an early invasive strategy, the incidence and prognostic
importance of pre-procedural lesion thrombus is warranted.
Methods In the ACUITY (Acute Catheterization and
Urgent Intervention Triage strategY) trial, a total of 3,627
patients with moderate- and high-risk ACS undergoing
PCI had their baseline and ﬁnal post-PCI angiograms
analyzed by an independent angiographic core laboratory.
Results Patients with thrombus (n ¼ 530 [15%]) compared
with those without thrombus had higher rates of impaired
ﬁnal epicardial coronary ﬂow (ﬁnal Thrombolysis In
Myocardial Infarction [TIMI] ﬂow grade 3: 89.6% vs. 97.1%,
p < 0.0001). Thrombus was an independent predictor of 30
day death (odds ratio [OR]: 3.16 [95% conﬁdence interval
(CI): 1.20 to 8.37], p¼ 0.02), andmyocardial infarction (MI)
at 30 days (OR: 1.62 [95% CI: 1.17 to 2.24], p ¼ 0.003) and
at 1 year (OR: 1.56 [95% CI: 1.16 to 2.08], p ¼ 0.003).
Patients with thrombus had signiﬁcantly higher rates of stent
thrombosis (ST) compared with patients without thrombus
at 30 days (2.8% vs. 1.1%, p ¼ 0.002) and at 1 year (3.7% vs.
1.8%, p ¼ 0.003), and thrombus was an independent
predictor of ST at both 30 days (OR: 2.61 [95% CI: 1.38 to
4.91]) and 1 year (OR: 2.98 [95% CI: 1.64 to 5.42]).
Conclusions Pre-procedural thrombus was present in 15%
of moderate- and high-risk ACS patients undergoing PCIin the ACUITY trial. Baseline thrombus predicts increased
ischemic complications at 30 days including a 3-fold
increased risk of death as well as MI up to 1 year. Further
evaluation of adjunctive pharmacotherapy is needed in this
high-risk population (352).Optimal Intravascular Ultrasound Criteria and Their
Accuracy for Deﬁning the Functional Signiﬁcance
of Intermediate Coronary Stenoses of Different
Locations
Objectives We performed this study to determine the
optimal intravascular ultrasound (IVUS) criteria and to
evaluate their accuracy for deﬁning the functional signiﬁ-
cance of intermediate coronary stenoses in different locations
of the coronary tree.
Background Presence of myocardial ischemia is the most
important prognostic factor in patients with coronary artery
disease and is determined by both the lesion severity and the
amount of myocardium supplied.
Methods IVUS and fractional ﬂow reserve (FFR)
measurements were performed in 267 intermediate lesions
located at the proximal or mid part of major epicardial
coronary arteries. Optimal IVUS criteria and their diagnostic
accuracy for functionally signiﬁcant stenoses (FFR <0.8)
were assessed.
Results FFR was <0.8 in 88 lesions (33%). The deter-
minants of FFR were minimum lumen area (MLA) and
lesion location. The diagnostic accuracy of MLA was
highly variable according to the location of lesions. The
best cutoff value of MLA to deﬁne the functional signif-
icance was 3.0 mm2 (area under the curve [AUC]: 0.81,
95% conﬁdence interval [CI]: 0.68 to 0.91) for proximal
left anterior descending artery (LAD) lesions and 2.75
mm2 for mid-LAD lesions located before the second
diagonal branch (AUC: 0.76, 95% CI: 0.66 to 0.84).
However, the appropriate MLA to predict the functional
signiﬁcance of lesions could not be found in other
segments.
Conclusions When IVUS parameters are used to deter-
mine the functional signiﬁcance of lesions in patients with
intermediate coronary artery stenoses, different criteria
should be used according to lesion location. In segments or
vessels with anatomic variations, IVUS cannot be used for
functional assessment of a stenosis. (Comparison of Frac-
tional Flow Reserve and Intravascular Ultrasound;
NCT01133015) (353).Percutaneous Closure of Congenital Coronary
Artery Fistulae: Results and Angiographic
Follow-Up
Objectives This study sought to assess clinical and angio-
graphic outcomes in a series of 29 patients who underwent
transcatheter closure of coronary artery ﬁstulae (CAF).
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alternative to surgical closure, but the reported experience is
relatively limited.
Methods Medical records of all patients with CAF who
underwent transcatheter closure at the Mayo Clinic,
Rochester, Minnesota, between 1997 and 2010, were
reviewed. Patients with other complex cardiac lesions and
those requiring surgery were excluded.
Results Twenty-nine patients with CAF underwent 36
transcatheter closure procedures. The most were women
(55%), and the median age at the time of transcatheter
closure was 49 years. Twenty-three patients had a single
CAF. The most common presenting symptom was chest
pain (52%). Thirty devices were deployed antegrade into 1 or
more arterial feeders, 3 using an arteriovenous wire loop and
3 retrograde at the ﬁstulous connection. Successful closure
occurred immediately in all patients with no residual ﬂow in
89% and with trivial ﬂow in 11%. Four complications
occurred including 2 device migrations, 1 coronary spasm,
and 1 coronary thrombosis. A follow-up angiogram was
obtained in 18 (62%) patients with a median time to follow-
up angiography of 1.5 years. Ten patients (56%) of the 18
patients with follow-up angiography had no recanalization
of embolized vessel; 4 patients (22%) had trivial recanali-
zation, and 4 patients (22%) had large recanalization. A
repeat closure procedure was performed in all 4 patients of
the latter.
Conclusions Transcatheter closure of CAF is feasible
and should be considered in carefully selected patients.
Recanalization of the treated coronary ﬁstulae can occur, so
follow-up angiography or other imaging modality should be
performed in these patients (354).Feasibility of Transcatheter Aortic Valve
Implantation Without Balloon Pre-Dilation: A Pilot
Study
Objectives The purpose of this pilot study was to evaluate
the feasibility and safety of transcatheter aortic valve
implantation (TAVI) without balloon pre-dilation.
Background Balloon pre-dilation of the stenosed aortic
valve is currently believed to be a necessary step for valve
preparation before device placement in patients undergoing
TAVI and, therefore, is considered an obligatory part of the
procedure. However, clear evidence supporting this policy is
lacking. In contrast, pre-dilation might be responsible in
part for distal embolizations as well as atrioventricular
conduction disturbances seen during TAVI procedures.
Methods A total of 60 consecutive patients (mean age 80.1
 6.4 years, 53% female, mean logistic EuroScore 23.3 
15.2%) undergoing TAVI using the self-expanding Med-
tronic CoreValve prosthesis (Medtronic, Minneapolis,
Minnesota) have been prospectively enrolled at 13 interna-
tional centers.
Results Pre-procedural mean transaortic valve gradient was
47.8  15.5 mm Hg, mean effective oriﬁce area was 0.67 0.15 cm2. Technical success rate was 96.7% (58 of 60) of
patients. Post-dilation was performed in 16.7% (10 of 60) of
patients. Post-procedural mean valve gradient was 4.4  2.0
mm Hg. Circular and noncircular valve conﬁguration was
present in 41 and 19 cases (68.3% vs. 31.7%), respectively,
with similar effective oriﬁce areas (1.74  0.10 cm2 vs. 1.71
 0.22 cm2, p ¼ NS). In-hospital mortality, myocardial
infarction, stroke, and major vascular complications occurred
in 6.7% (4 of 60), 0%, 5%, and 10% of patients. There was
no valve embolization. New permanent pacing was needed
in 11.7% (7 of 60) of patients.
Conclusions Transcatheter aortic valve implantation
without balloon pre-dilation is feasible and safe, resulting in
similar acute safety and efﬁcacy as the current standard
approach of TAVI with pre-dilation (355).Impact of Drug Release Kinetics on Vascular
Response to Different Zotarolimus-Eluting Stents
Implanted in Patients With Long Coronary
Stenoses: The LongOCT Study (Optical Coherence
Tomography in Long Lesions)
Objectives We assessed the in vivo vascular response to
a new generation of zotarolimus-eluting stents (ZES) with
prolonged drug release (Resolute ZES-SR, Medtronic
Vascular, Santa Rosa, California) compared with ZES with
faster kinetics (Endeavor ZES-FR, Medtronic Vascular) by
optical coherence tomography.
Background Local drug release kinetics has been impli-
cated with antirestenosis efﬁcacy of drug-eluting stents.
However, the impact of different release kinetics on vascular
response of diseased human coronary arteries remains to be
investigated.
Methods The study population consisted of 43 patients
with long lesions in native coronary vessels treated with
multiple overlapping ZES. Twenty-one patients treated
with ZES-SR were compared with 22 patients treated with
ZES-FR from the ODESSA (Optical coherence tomog-
raphy for DES SAfety) study. The primary endpoint was in-
stent neointimal hyperplasia as assessed by optical coherence
tomography at 6-month follow-up. Coprimary endpoints
were the percentage of uncovered and malapposed struts.
Results Strut-level median neointimal thickness was 0.11
mm (interquartile range [IQR]: 0.07 to 0.15 mm) in ZES-
SR and 0.31 mm (IQR: 0.27 to 0.42 mm) in ZES-FR,
respectively (p < 0.001). The 6-month rate of uncovered
struts per patient was 7.38% (IQR: 3.06% to 12.72%) in
ZES-SR and 0.00% (IQR: 0.00% to 0.00%) in ZES-FR
(p < 0.001); rate of malapposed and uncovered struts was
1.47% (IQR: 0.32% to 4.23%) in ZES-SR and 0.00% (IQR:
0.00% to 0.00%) in ZES-FR (p < 0.001).
Conclusions This study demonstrated the impact of
different release kinetics on human in vivo vascular response
to ZES implantation. The new generation of ZES-SR
compared with ZES-FR had better suppression of the
neointimal response but higher proportion of uncovered and
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follow-up. (Optical Coherence Tomography in Long
Lesions [LongOCT]; NCT01133925) (356).Feasibility and Acute Efﬁcacy of Radiofrequency
Ablation of Cavotricuspid Isthmus–Dependent
Atrial Flutter Guided by Real-Time 3D TEE
Objectives The aim of this study was to evaluate the
feasibility and acute efﬁcacy of real-time 3-dimensional
transesophageal echocardiography (RT3DTEE)–guided
ablation of the cavotricuspid isthmus (CVTI).
Background The use of RT3DTEE to guide a trans-
catheter radiofrequency ablation procedure has never been
systematically investigated.
Methods Seventy consecutive patients with CVTI-
dependent atrial ﬂutter underwent CVTI ablation. Proce-
dural monitoring using RT3DTEE was assigned to patients
who requested general anesthesia for the procedure (n ¼ 21
[30%]). In the other 49 patients (the control group), the
procedures were monitored using the standard ﬂuoroscopic
approach. Procedural time was considered as skin-to-skin
electrophysiological procedure duration, not including
anesthesia preparation; adequate radiofrequency ablation
applications (with ﬁxed temperature and power settings)
were considered as lesions lasting  60 s.
Results RT3DTEE allowed visualization of the CVTI and
identiﬁed related structures in most patients (20 of 21);
anatomic features such as long CVTI (n ¼ 11), prominent
Eustachian ridge (n ¼ 9), prominent Eustachian valve (n ¼
6), septal recess (n ¼ 8), and pectinate muscles (n ¼ 10)
were frequent. Also, RT3DTEE allowed continuous visu-
alization of ablation catheter movement and contact.
Compared with the control group, RT3DTEE was equally
effective in achieving CVTI bidirectional block (100% in
both groups), and no complications occurred. RT3DTEE
shortened procedural time (median 73.0 min, interquartile
range [IQR] 60.0 to 90.0 min, vs. median 115.0 min, IQR
85.0 to 133.0 min, p < 0.001), reduced radiation exposure
(median ﬂuoroscopy time 4.2 min, IQR 3.1 to 8.4 min, vs.
median 19.3 min, IQR 12.9 to 36.4 min, p < 0.001; median
ﬂuoroscopy dose 575.4 cGy $ cm2, IQR 428.5 to 1,299.4
cGy $ cm2, vs. median 3,520.7 cGy $ cm2, IQR 1,700.0 to
6,709.0 cGy $ cm2, p < 0.001), and reduced the number of
radiofrequency applications to achieve bidirectional block
(median 7, IQR 6 to 10, vs. median 12, IQR 10 to 22, p ¼
0.007). A strong learning curve was detected by comparing
procedural data between the ﬁrst and last patients treated
using RT3DTEE.
Conclusions RT3DTEE-guided ablation of CVTI was
feasible, allowing real-time detailed morphological CVTI
characterization as well as continuous visualization of the
ablation catheter during radiofrequency ablation. This
approach entailed marked reductions in procedural time,
radiation exposure, and the number of radiofrequency
applications (357).Assessment of Coronary Atherosclerosis
Progression and Regression at Bifurcations Using
Combined IVUS and OCT
Objectives The aim of this study was to evaluate the
progression of atherosclerotic coronary plaques at bifurca-
tions, using combined intravascular ultrasound–virtual
histology (IVUS-VH) and optical coherence tomography
(OCT).
Background Pathological ﬁndings reveal that atheroscle-
rotic plaques characterized by the presence of large necrotic
cores (NCs) with ﬁbrous cap thicknesses < 65 mm are more
prone to rupture. Accuracy in the detection of high-risk
plaques could be improved by the combined use of IVUS-
VH and OCT.
Methods IVUS-VH and OCT are 2 imaging modalities
with different lateral resolutions and different depths of
penetration. To provide a precise matching of the images,
bifurcations were used as landmarks. IVUS-VH and OCT
were performed in 56 bifurcations from 24 patients at
baseline and at 6-month follow-up. All patients were treated
with standard medical therapy. Bifurcations were studied at
the proximal, in-bifurcation, and distal regions. Plaques were
classiﬁed according to their composition as assessed by
IVUS-VH and ﬁbrous cap thickness as quantiﬁed by OCT.
Results At baseline, 27 NC-rich plaques were found. At 6-
month follow-up, 22 (81%) did not show any signiﬁcant
change. Four new NC-rich lesions developed. At both time
points, percent NC was higher and the ﬁbrous cap was
thinner at the proximal bifurcation rim compared with the
distal. There were no signiﬁcant changes in percent NC and
ﬁbrous cap thickness in the 3 bifurcation regions between
baseline and follow-up examinations. No major cardiovas-
cular events due to bifurcation lesion progression were
observed.
Conclusions The combined use of IVUS-VH and OCT is
a reliable tool to serially assess plaque progression and
regression, and in the present study it was demonstrated to
be safe and feasible. At 6-month follow-up, in this post–
percutaneous coronary intervention patient population, most
high-risk plaques remained unchanged, retaining their
imaging classiﬁcations, nevertheless appearing to have
remained clinically silent (358).
Randomized Comparison of Everolimus- and
Paclitaxel-Eluting Stents: 2-Year Follow-Up From
the SPIRIT (Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System) IV Trial
Objectives We sought to determine whether the differ-
ences in outcomes present between everolimus-eluting stents
(EES) and paclitaxel-eluting stents (PES) in the SPIRIT
(Clinical Evaluation of the XIENCE V Everolimus Eluting
Coronary Stent System) IV trial at 1 year were sustained
with longer-term follow-up.
Background In the SPIRIT IV trial, patients undergoing
percutaneous coronary intervention who were randomized to
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target lesion failure (cardiac death, target vessel myocardial
infarction [MI], or ischemia-driven target lesion revascu-
larization [TLR]), with signiﬁcant reductions in the indi-
vidual rates of MI, TLR, and stent thrombosis.
Methods We prospectively randomized 3,687 patients with
up to 3 noncomplex previously untreated native coronary
artery lesions to EES versus PES at 66 U.S. sites. Follow-up
through 2 years is complete in 3,578 patents (97.0%).
Results Treatment with EES compared with PES reduced
the 2-year rates of TLF (6.9% vs. 9.9%, p ¼ 0.003), all MI
(2.5% vs. 3.9%, p ¼ 0.02), Q-wave MI (0.1% vs. 0.8%, p ¼
0.002), stent thrombosis (0.4% vs. 1.2%, p ¼ 0.008), and
ischemia-driven TLR (4.5% vs. 6.9%, p ¼ 0.004), with
nonsigniﬁcantly different rates of all-cause and cardiac
mortality. Between 1 year and 2 years, there were no
signiﬁcant differences in adverse event rates between the 2
stent types.
Conclusions In the large-scale, prospective, multicenter,
randomized SPIRIT IV trial, the beneﬁts of EES compared
with those of PES present at 1 year were sustained at 2 years.
(Clinical Evaluation of the XIENCE V Everolimus Eluting
Coronary Stent System; NCT01016041) (359).2-Year Follow-Up of a Randomized Controlled Trial
of Everolimus- and Paclitaxel-Eluting Stents for
Coronary Revascularization in Daily Practice:
COMPARE (Comparison of the everolimus eluting
XIENCE-V stent with the paclitaxel eluting TAXUS
LIBERTÉ stent in all-comers: a randomized open
label trial)
Objectives The purpose of this study was to compare the
safety and efﬁcacy of the Xience V (Abbott Vascular, Santa
Clara, California) everolimus-eluting stent (EES) with the
Taxus Liberté (Boston Scientiﬁc, Natick, Massachusetts)
paclitaxel-eluting stent (PES) at 2-year follow-up.
Background COMPARE (Comparison of the everolimus
eluting XIENCE-V stent with the paclitaxel eluting
TAXUS LIBERTÉ stent in all-comers: a randomized open
label trial) demonstrated a superior clinical outcome of EES
over PES at 1 year in all comers. Whether this superiority is
maintained after discontinuation, at 12 months, of dual
antiplatelet therapy is unclear.
Methods Patients undergoing percutaneous coronary inter-
vention with limited exclusion criteria were randomly allo-
cated to EES or PES. The 2-year pre-speciﬁed endpoints are
composites of safety and efﬁcacy and stent thrombosis.
Results Follow-up was completed in 1,795 of 1,800
patients (99.7%). The groups had similar baseline charac-
teristics. At 2 years, signiﬁcantly fewer EES patients took
dual antiplatelet therapy (11.4% vs. 15.4%, p ¼ 0.02). The
primary composite of all death, nonfatal myocardial infarc-
tion, and target vessel revascularization occurred in 9.0% of
EES patients and 13.7% of PES patients (relative risk [RR]:0.66; 95% conﬁdence interval [CI]: 0.50 to 0.86) driven by
a lower rate of myocardial infarction (3.9% vs. 7.5%; RR:
0.52; 95% CI: 0.35 to 0.77) and target vessel revasculari-
zation (3.2% vs. 8.0%; RR: 0.41; 95% CI: 0.27 to 0.62), in
parallel with a lower rate of deﬁnite or probable stent
thrombosis (0.9% vs. 3.9%; RR: 0.23; 95% CI: 0.11 to 0.49).
Differences signiﬁcantly increased between 1- and 2-year
follow-up for the primary composite endpoint (p ¼ 0.04),
target vessel revascularization (p ¼ 0.02), and deﬁnite or
probable stent thrombosis (p ¼ 0.02).
Conclusions The substantial clinical beneﬁt of the EES
over the PES with regard to measures of both safety and
efﬁcacy is maintained at 2 years in real-life practice with
an increasing beneﬁt in terms of safety and efﬁcacy
between 1 year and 2 years. Comparison of the everolimus
eluting XIENCE-V stent with the paclitaxel eluting
TAXUS LIBERTÉ stent in all-comers: a randomized
open label trial: The COMPARE Trial [COMPARE 1];
NCT01016041) (360).Bleeding Avoidance Strategies: Consensus and
Controversy
Bleeding complications after coronary intervention are
associated with prolonged hospitalization, increased hospital
costs, patient dissatisfaction, morbidity, and 1-year
mortality. Bleeding avoidance strategies is a term incorpo-
rating multiple modalities that aim to reduce bleeding and
vascular complications after cardiovascular catheterization.
Recent improvements in the rates of bleeding complications
after invasive cardiovascular procedures suggest that the
clinical community has successfully embraced speciﬁc strat-
egies and improved patient care in this area. There remains
controversy regarding the efﬁcacy, safety, and/or practicality
of 3 key bleeding avoidance strategies for cardiac catheteri-
zation and coronary intervention: procedural (radial artery
approach, safezone arteriotomy), pharmacological (multiple
agents), and technological (vascular closure devices)
approaches to improved access. In this paper, we address
areas of consensus with respect to selected modalities in
order to deﬁne the role of each strategy in current practice.
Furthermore, we focus on areas of controversy for selected
modalities in order to deﬁne key areas warranting cautious
clinical approaches and the need for future randomized
clinical trials in this area (361).Impact of Insulin Receptor Substrate-1 Genotypes
on Platelet Reactivity and Cardiovascular
Outcomes in Patients With Type 2 Diabetes
Mellitus and Coronary Artery Disease
Objectives The aim of this study was to assess the associ-
ation between genetic variants of the insulin receptor
substrate (IRS)-1 gene, platelet function, and long-term
outcomes in patients with type 2 diabetes mellitus (DM)
JACC Vol. 62, No. 18, 2013 The Editors
October 29, 2013:e245–e437 JACC Topic Collection: Interventional Cardiology
e377and stable coronary artery disease while on aspirin and clo-
pidogrel therapy.
Background The effects of pharmacogenetic determinants
on platelet function and cardiovascular outcomes in type
DM patients are unknown.
Methods The association between IRS-1 genetic variants,
platelet function, and the risk of major adverse cardiac events
(MACE) at 2 years was assessed in 187 patients with type 2
DM and stable coronary artery disease on maintenance
aspirin and clopidogrel therapy.
Results Seven tag single nucleotide polymorphisms were
selected. Individuals with high platelet reactivity were more
frequent among carriers of the C allele (GC and CC
genotypes; approximately 20% of population) of the
rs956115 marker (44.4% vs. 20.5%; odds ratio: 3.1, 95%
conﬁdence interval [CI]: 1.44 to 6.67; p ¼ 0.006). These
patients were at higher risk of MACE (28.0% vs. 10.9%;
hazard ratio: 2.90, 95% CI: 1.38 to 6.11; p ¼ 0.005). The C
allele carriers of the rs956115 marker were more commonly
associated with a hyperreactive platelet phenotype. This was
conﬁrmed in an external validation cohort of patients with
type 2 DM but not in an external validation cohort of
patients without DM. Carriers of the C allele of the
rs956115 marker also had a signiﬁcantly higher risk of
MACE compared with noncarriers (30.6% vs. 11.4%;
hazard ratio: 2.88, 95% CI: 1.35 to 6.14; p ¼ 0.006).
Conclusions Type 2 DM patients who are carriers of the C
allele of the rs956115 marker of the IRS-1 gene have
a hyperreactive platelet phenotype and increased risk of
MACE (362).Prospective Evaluation of On-Clopidogrel Platelet
Reactivity Over Time in Patients Treated With
Percutaneous Coronary Intervention: Relationship
With Gene Polymorphisms and Clinical Outcome
Objectives This study sought to investigate the evolving
pattern over time of on-clopidogrel platelet reactivity (PR)
and its relationship with genotype and clinical outcomes
after percutaneous coronary intervention.
Background Whether on-clopidogrel PR and role of
genotype differ over time is unknown.
Methods On-clopidogrel PR before percutaneous coronary
intervention, and 1 and 6 months thereafter via VerifyNow
P2Y12 (Accumetrics Inc., San Diego, California),
CYP2C19*2, *17, CYP3A5*3, and ABCB1 polymorphisms
were evaluated in 300 patients. Death, stroke, myocardial
infarction, and bleedings were assessed up to 1 year.
Results On-clopidogrel PR varied signiﬁcantly over time,
being higher at baseline than at 1 and 6 months after. From
baseline to 1 month, 83 of 300 patients varied their response
status. This was mainly due to baseline poor responders
becoming full responders (75 of 83). Genotype justiﬁes
roughly 18% of this trend. CYP2C19*2 and *17 inﬂuence on
PR was consistent over time, whereas that of ABCB1
appeared of greater impact at baseline. On-clopidogrel PR at1 month independently best predicts ischemic and bleeding
events. We found a therapeutic window (86 to 238 P2Y12
reactivity units) with a lower incidence of both ischemic and
bleeding complications. A risk score was created by
combining genotype (ABCB1 and CYP2C19*2), baseline
PR, and creatinine clearance to predict 1-month poor
responsiveness and 1-year poor prognosis.
Conclusions In patients at steady state for clopidogrel
undergoing percutaneous coronary intervention, PR
decreases from baseline to 1 month. Genotype inﬂuences
z18% of this trend. On-clopidogrel PR at 1 month is the
strongest predictor of adverse outcomes, and this can be
predicted by combining genotype to baseline phenotype and
clinical variables (363).Prognostic Value of the SYNTAX Score in Patients
With Acute Coronary Syndromes Undergoing
Percutaneous Coronary Intervention: Analysis
From the ACUITY (Acute Catheterization and
Urgent Intervention Triage StrategY) Trial
Objectives We sought to investigate the predictive value of
the SYNTAX (Synergy Between PCI With Taxus and
Cardiac Surgery) score (SS) for risk assessment of 1-year
clinical outcomes in patients with non–ST-segment eleva-
tion acute coronary syndromes undergoing percutaneous
coronary intervention (PCI).
Background In the SYNTAX trial, the SS was effective in
risk-stratifying patients with left main and triple-vessel
coronary disease, the majority of whom had stable
ischemic heart disease.
Methods The SS was determined in 2,627 patients with
non–ST-segment elevation acute coronary syndromes
undergoing PCI in the angiographic substudy of the
ACUITY (Acute Catheterization and Urgent Intervention
Triage StrategY) trial. Patients were stratiﬁed according to
tertiles of the SS: <7 (n ¼ 854), 7 and <13 (n ¼ 825),
and 13 (n ¼ 948).
Results Among patients in the ﬁrst, second, and third SS
tertiles, the 1-year rates of mortality were 1.5%, 1.6%, and
4.0%, respectively (p ¼ 0.0005); the cardiac mortality rates
were 0.2%, 0.9%, and 2.7%, respectively (p < 0.0001); the
myocardial infarction (MI) rates were 6.3%, 8.3%, and
12.9%, respectively (p < 0.0001); and the target vessel
revascularization (TVR) rates were 7.4%, 7.0%, and 9.8%,
respectively (p ¼ 0.02). By multivariable analysis, the SS was
an independent predictor of 1-year death (hazard ratio
[HR]: 1.04, 95% conﬁdence interval [CI]: 1.01 to 1.07; p ¼
0.005), cardiac death (HR: 1.06, 95% CI: 1.03 to 1.09; p ¼
0.0002), MI (HR: 1.03, 95% CI: 1.02 to 1.05; p < 0.0001),
and TVR (HR: 1.03, 95% CI: 1.02 to 1.05; p < 0.0001).
The SS affected death, cardiac death, and MI both within
the ﬁrst 30 days after PCI and between 30 days and 1 year,
whereas it affected TVR primarily within the ﬁrst 30 days.
The predictive value of an increased SS was consistent
among multiple pre-speciﬁed subgroups.
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acute coronary syndromes undergoing PCI, the SS is an
independent predictor of the 1-year rates of death, cardiac
death, MI, and TVR. (Comparison of Angiomax Versus
Heparin in Acute Coronary Syndromes [ACS];
NCT00093158) (364).
Effect of Switching Antithrombin Agents for
Primary Angioplasty in Acute Myocardial
Infarction: The HORIZONS-SWITCH Analysis
Objectives We investigated the outcomes of switching to
bivalirudin after initial administration of heparin in patients
with acute ST-segment elevation myocardial infarction
undergoing primary percutaneous coronary intervention.
Background Unfractionated heparin (UFH) is frequently
administered early in ST-segment elevation myocardial
infarction. Whether the beneﬁts of bivalirudin documented
in the HORIZONS-AMI (Harmonizing Outcomes With
Revascularization and Stents in Acute Myocardial Infarc-
tion) trial persist in patients previously administered UFH is
unknown.
Methods We analyzed the outcomes of the 2,357 patients
from HORIZONS-AMI treated with UFH before enroll-
ment according to their subsequent randomization to biva-
lirudin (switch group, n ¼ 1,178) or UFH plus
a glycoprotein IIb/IIIa inhibitor (control group, n ¼ 1,179).
Results At 30 days, major bleeding occurred in 7.6% of the
switch group versus 12.3% of the control group (p ¼
0.0001). Switch patients had lower 30-day rates of cardiac
mortality (1.6% vs. 2.9%, p ¼ 0.04). At 2-year follow-up,
switch patients experienced lower rates of major bleeding
(8.4% vs. 13.0%, p ¼ 0.0003), cardiac mortality (2.3% vs.
3.8%, p ¼ 0.04), and reinfarction (4.0% vs. 7.1%, p ¼
0.0002). Two-year rates of deﬁnite/probable stent throm-
bosis were similar in switch and control patients (3.1% vs.
4.3%, p ¼ 0.17).
Conclusions In ST-segment elevation myocardial infarc-
tion patients who receive early treatment with UFH,
switching to bivalirudin before primary percutaneous coro-
nary intervention results in reduced rates of major bleeding
and improved early and late cardiac survival (365).
NIRS and IVUS for Characterization of
Atherosclerosis in Patients Undergoing Coronary
Angiography
Objectives The aim of this study was to compare the
ﬁndings of near-infrared spectroscopy (NIRS), intravascular
ultrasound (IVUS) virtual histology (VH), and grayscale
IVUS obtained in matched coronary vessel segments of
patients undergoing coronary angiography.
Background Intravascular ultrasound VH has been devel-
oped to add tissue characterization to the grayscale IVUS
assessment of coronary plaques. Near-infrared spectroscopy
is a new imaging technique able to identify lipid core-
containing coronary plaques (LCP).Methods We performed NIRS and IVUS-VH pullbacks in
a consecutive series of 31 patients with a common region of
interest (ROI) between 2 side branches. For each ROI, we
analyzed the chemogram blocks by NIRS, plaque area and
plaque burden by grayscale IVUS, and tissue types by IVUS-
VH. The chemogram block is a summary metric of a 2-mm
vertical slice of the chemogram. The value ranges from 0 to 1
according to the presence of lipids and represents the
probability of LCP with a color scale from red (low proba-
bility) through orange and tan to yellow (high probability).
Results Plaque area (mm2) increases as percentage VH
derived-necrotic core (NC) content (4.6  2.7 vs. 7.4  3.5
vs. 8.6  3.4 vs. 7.9  3.3, grouped in percentage NC
quartiles, p < 0.001) and chemogram block probability color
bin thresholds increase (4.9  3.8 red, 7.3  3.6 orange, 8.1
 3.4 tan, and 8.7  3.4 yellow, p < 0.001). The correlation
between the block chemogram detection of lipid core and
percentage NC content by VH was weak (r ¼ 0.149).
Correction for the presence of calcium does not improve this
correlation.
Conclusions Larger plaque area by grayscale IVUS was
more often associated with either elevated percentage VH-
NC or LCP by NIRS; however, the correlation between
the detection of LCP by NIRS and necrotic core by VH is
weak (366).Plaque Characteristics of Thin-Cap Fibroatheroma
Evaluated by OCT and IVUS
Objectives The purpose of this study was to assess plaque
characteristics of optical coherence tomography (OCT)-
derived thin-cap ﬁbroatheroma (TCFA) by integrated
backscatter intravascular ultrasound (IB-IVUS).
Background Radiofrequency signal-derived IVUS tissue
characterization technology has become clinically available
and provided objective and quantitative plaque characteris-
tics of the coronary vessel wall. Integrated backscatter IVUS
is one of the tissue characterization methods that can
possibly provide quantitative plaque characteristics of the
OCT-derived TCFA.
Methods Eighty-one coronary lesions with plaque burden
>40% were selected and analyzed with both IB-IVUS and
OCT. The OCT-derived TCFA was deﬁned as a presence
of thin ﬁbrous cap (<65 mm) overlying a signal-poor lesion
with diffuse border representing a lipid-rich plaque. By
conventional gray-scale IVUS, external elastic membrane
(EEM) cross-sectional area (CSA), lumen CSA, plaque plus
media (PþM) CSA, plaque burden and remodeling index
were measured. By IB-IVUS, plaque characteristics were
further classiﬁed as ﬁbrosis, dense ﬁbrosis, calciﬁcation, or
lipid pool.
Results Optical coherence tomography identiﬁed 40
TCFAs (49%) and 41 non-TCFAs. The EEM CSA, PþM
CSA, plaque burden, and remodeling index were signiﬁ-
cantly larger in OCT-derived TCFA than non-TCFA. By
IB-IVUS, percentage lipid pool area (¼ lipid pool area/
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vs. 38.4  13.1%, p < 0.0001) and percentage ﬁbrosis area
(¼ ﬁbrosis area/PþM CSA  100) was signiﬁcantly lower
(34.6  11.4% vs. 50.5  8.7%, p < 0.0001) in OCT-
derived TCFA than non-TCFA. By receiver-operator
characteristic curve analysis, percentage lipid pool
area 55%, percentage ﬁbrosis area 41%, and remodeling
index 1.0 were predictors of OCT-derived TCFA.
Conclusions The OCT-derived TCFA had larger pla-
que burden and positive remodeling with predominant
lipid component and less ﬁbrous plaque assessed by IB-
IVUS (367).Impact of Bleeding on Mortality After
Percutaneous Coronary Intervention: Results From
a Patient-Level Pooled Analysis of the REPLACE-2
(Randomized Evaluation of PCI Linking Angiomax
to Reduced Clinical Events), ACUITY (Acute
Catheterization and Urgent Intervention Triage
Strategy), and HORIZONS-AMI (Harmonizing
Outcomes With Revascularization and Stents in
Acute Myocardial Infarction) Trials
Objectives This study sought to develop a risk score
predictive of bleeding in patients undergoing percutaneous
coronary intervention (PCI) and to investigate the impact of
bleeding on subsequent mortality.
Background Bleeding complications after PCI have been
independently associated with early and late mortality.
Methods This study represents a patient-level pooled
analysis including 17,034 patients undergoing PCI from 3
large, randomized trials of bivalirudin versus heparin plus
glycoprotein IIb/IIIa inhibitors, including the REPLACE-2
(Randomized Evaluation of PCI Linking Angiomax to
Reduced Clinical Events), ACUITY (Acute Catheterization
and Urgent Intervention Triage Strategy), and
HORIZONS-AMI (Harmonizing Outcomes With
Revascularization and Stents in Acute Myocardial Infarc-
tion) trials. We developed a risk score to predict non-
coronary artery bypass graft (CABG)–related TIMI
(Thrombolysis In Myocardial Infarction) major bleeding
and evaluated the impact of various types of bleeding on 1-
year mortality.
Results A non-CABG–related TIMI major bleed occurred
within 30 days in 267 patients (1.6%), and death occurred in
497 patients (2.9%) within 1 year. A risk score was devel-
oped to predict the bleeding risk of patients undergoing
PCI, consisting of 7 variables (serum creatinine, age, sex,
presentation, white blood cell count, cigarette smoking, and
randomized treatment). The TIMI major bleeding rates
increased by bleeding risk score groups: from 0.4% for those
in the lowest to 5.8% for those in the highest risk group.
Non-CABG–related TIMI major bleeding and the occur-
rence of myocardial infarction within 30 days
were independent predictors of subsequent mortality, with
respective hazard ratios of 4.2 and 2.9, each p < 0.001.Ranked in order of severity, TIMI major bleeding, blood
transfusion without TIMI bleed, TIMI minor bleeding
requiring blood transfusion, and TIMI minor bleeding not
requiring blood transfusion were independent predictors of
subsequent mortality with hazard ratios of 4.89, 2.91, 2.73,
and 1.66, respectively. Isolated hematomas were not
predictive of subsequent mortality.
Conclusions Non-CABG–related bleeding within 30 days
is strongly associated with an increased risk of subsequent
mortality at 1 year in patients undergoing PCI for all indi-
cations. A risk score was established to calculate the bleeding
risk for patients undergoing PCI, allowing therapeutic
decision making to minimize the incidence of bleeding
(368).Total Ischemic Time: The Correct Focus of
Attention for Optimal ST-Segment Elevation
Myocardial Infarction Care
Currently accepted standards for gauging quality of care in
the treatment of ST-segment elevation myocardial infarction
(STEMI) mainly focus on shortening the time to treatment
after the patient arrives at the hospital. But this narrow focus
fails to consider the substantial duration of myocardial
ischemia that exists prior to hospital arrival, and the large
number of deaths that occur during the pre-hospital period.
The time from symptom onset until reperfusion occurs is
one estimate of total ischemic time. Several experimental
studies and now human clinical studies have conﬁrmed that
infarct size and mortality are strongly correlated with the
total ischemic time, and much less so with its subintervals
like door-to-balloon time. This review will discuss the
importance of total ischemic time in STEMI (369).Validation of Minimal Luminal Area Measured by
Intravascular Ultrasound for Assessment of
Functionally Signiﬁcant Coronary Stenosis:
Comparison With Myocardial Perfusion Imaging
Objectives This study sought to evaluate the ability of
minimal luminal area (MLA) measured by intravascular
ultrasound (IVUS) to assess the functional signiﬁcance of
coronary artery disease.
Background The use of IVUS to determine the functional
signiﬁcance of coronary artery lesions remains a matter for
debate.
Methods From our prospective IVUS imaging database,
between July 2009 and April 2010, 170 coronary lesions in
150 patients who underwent stress myocardial single-photon
emission computed tomography (SPECT) performed
within 1 month of IVUS evaluation were identiﬁed and
analyzed. MLA and other parameters were measured by
IVUS and compared with the results of myocardial SPECT.
Results Overall, 45 lesions had positive SPECT, and 125
lesions had negative SPECT. The MLA of lesions with
positive SPECT was smaller than the MLA of those with
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0.001). By logistic regression analysis, MLA (odds ratio: 3.1
by decrease of 1 mm2, 95% conﬁdence interval [CI]: 1.75 to
5.5, p < 0.01) was an independent predictor of the positive
SPECT. Using receiver-operator characteristic curve anal-
ysis, the best cutoff value of MLA was 2.1 mm2 with an
86.7% sensitivity, a 50.4% speciﬁcity, a 38.6% positive
predictive value, and a 91.3% negative predictive value versus
lesions with a positive SPECT (area under the curve: 0.690,
95% CI: 0.615 to 0.759, p < 0.01).
Conclusions The best cutoff value of MLA measured by
IVUS to predict myocardial ischemia was 2.1 mm2. The
IVUS-measured MLA appeared to play a limited role in
detecting functionally signiﬁcant lesions assessed by
myocardial SPECT (370).Percutaneous Coronary Intervention of
Unprotected Left Main Coronary Artery Disease as
Culprit Lesion in Patients With Acute Myocardial
Infarction
Objectives This study sought to evaluate short- and long-
term outcomes of patients undergoing emergency percuta-
neous coronary intervention (PCI) for acute myocardial
infarction due to a culprit lesion in an unprotected left main
coronary artery.
Methods In this retrospective, 2-center, international
observational study, 5,261 patients were admitted between
February 2005 and December 2008 with acute myocardial
infarction and treated with PCI; of these, 1,277 were ST-
segment elevation myocardial infarction and 3,984 non–ST-
segment elevation myocardial infarction. We identiﬁed 48
patients among this cohort who underwent emergency PCI to
an unprotected left main coronary artery culprit lesion.
Results Mean age was 70  12.5 years, and 45% of the
patients presented with ST-segment elevation myocardial
infarction or new left bundle branch block. Cardiogenic shock
was present in 45%, and distal left main coronary artery
disease was present in 71% of patients. Angiographic proce-
dural success was achieved in 92% of patients. Overall in-
hospital mortality was 21%, due in all cases to refractory,
multiorgan failure. Twenty-ﬁve percent experienced major
adverse cardiac events, deﬁned as death, myocardial infarc-
tion, stent thrombosis, and target vessel revascularization. In
patients presenting in cardiogenic shock, in-hospital mortality
was 32%. At 1-year follow-up, in-hospital survivors had
a mortality rate of 10.5%, whereas 18.4% experienced
subsequent major adverse cardiac events. Long-term prog-
nosis was excellent in hospital survivors with a 1-year survival
rate of 89.5%.
Conclusions Patients with acute myocardial infarction and
thrombosis of the unprotected left main coronary artery are
a high-risk subgroup with a substantial mortality, particu-
larly if they present in cardiogenic shock. We demonstrate
that in these patients, PCI is a feasible treatment option
associated with reasonably good outcomes. Long-termprognosis is excellent in hospital survivors with an 89.5%
survival rate at 1 year (371).
Comparison of Titanium-Nitride-Oxide–Coated
Stents With Zotarolimus-Eluting Stents for
Coronary Revascularization: A Randomized
Controlled Trial
Objectives This study sought to compare the efﬁcacy of
passive stent coating with titanium-nitride-oxide (TiNO)
with drug-eluting stents releasing zotarolimus (ZES)
(Endeavor, Medtronic, Minneapolis, Minnesota).
Background Stent coating with TiNO has been shown to
reduce restenosis compared with bare-metal stents in
experimental and clinical studies.
Methods In an assessor-blind noninferiority study, 302
patients undergoing percutaneous coronary intervention
were randomized to treatment with TiNO or ZES. The
primary endpoint was in-stent late loss at 6 to 8 months, and
analysis was by intention to treat.
Results Both groups were well balanced with respect to
baseline clinical and angiographic characteristics. The TiNO
group failed to reach the pre-speciﬁed noninferiority margin
for the primary endpoint (in-stent late loss: 0.64  0.61 mm
vs. 0.47  0.48 mm, difference: 0.16, upper 1-sided 95%
conﬁdence interval [CI]: 0.26; pnoninferiority ¼ 0.54), and
subsequent superiority testing was in favor of ZES
(psuperiority ¼ 0.02). In-segment binary restenosis was lower
with ZES (11.1%) than with TiNO (20.5%; psuperiority ¼
0.04). A stratiﬁed analysis of the primary endpoint found
particularly pronounced differences between stents among
diabetic versus nondiabetic patients (0.90  0.69 mm vs.
0.39  0.38 mm; pinteraction ¼ 0.04). Clinical outcomes
showed a similar rate of death (0.7% vs. 0.7%; p ¼ 1.00),
myocardial infarction (5.3% vs. 6.7%; p ¼ 0.60), and major
adverse cardiac events (21.1% vs. 18.0%, hazard ratio: 1.19,
95% CI: 0.71 to 2.00; p ¼ 0.50) at 1 year. There were no
differences in rates of deﬁnite or probable stent thrombosis
(0.7% vs. 0%; p ¼ 0.51) at 1 year.
Conclusions Compared with TiNO, ZES was superior
with regard to late loss and binary restenosis. The concept of
passive stent coating with TiNO remains inferior to drug-
eluting stent technology in reducing restenosis. ([TIDE]
Randomized Trial Comparing Titan Stent With
Zotarolimus-Eluting Stent: NCT00492908) (372).
Randomized Comparison of Pre-Hospital–Initiated
Facilitated Percutaneous Coronary Intervention
Versus Primary Percutaneous Coronary
Intervention in Acute Myocardial Infarction Very
Early After Symptom Onset: The LIPSIA-STEMI Trial
(Leipzig Immediate Prehospital Facilitated
Angioplasty in ST-Segment Myocardial Infarction)
Objectives This multicenter trial sought to assess the
merits of facilitated percutaneous coronary intervention
(PCI) versus primary PCI in an ST-segment elevation
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distances in patients presenting early after symptom onset.
Background Facilitated PCI with ﬁbrinolysis might be
beneﬁcial in speciﬁc high-risk STEMI situations to prevent
myocardial necrosis expansion.
Methods Patients with STEMI (<3 h after symptom
onset) were randomized to either pre-hospital–initiated
facilitated PCI using tenecteplase (Group A; n ¼ 81) or
primary PCI (Group B; n ¼ 81) plus optimal antith-
rombotic comedication. The primary endpoint was infarct
size assessed by delayed-enhancement magnetic resonance
imaging. Secondary endpoints were microvascular obstruc-
tion and myocardial salvage, early ST-segment resolution,
and a composite of death, repeated myocardial infarctions,
and congestive heart failure within 30 days.
Results The median time from symptom onset to
randomization was 64 min (interquartile range [IQR]: 42 to
103 min) in Group A versus 55 min in Group B (IQR: 27 to
91 min; p ¼ 0.26). Despite better pre-interventional TIMI
(Thrombolysis In Myocardial Infarction) ﬂow in Group A
(71% vs. 35% TIMI ﬂow grade 2 or 3; p < 0.001), the
infarct size tended to be worse in Group A versus Group B
(17.9% of left ventricle [IQR: 8.4% to 35.0%] vs. 13.7%
[IQR: 7.5% to 24.0%]; p ¼ 0.10). There was also a strong
trend toward more early and late microvascular obstruction,
(p ¼ 0.06 and 0.09) and no difference in ST-segment
resolution (p ¼ 0.26). The combined clinical endpoint
showed a trend toward higher event rates in Group A
(19.8% vs. 13.6%; p ¼ 0.13, relative risk: 0.52, 95% conﬁ-
dence interval: 0.23 to 1.18).
Conclusions In STEMI patients presenting early after
symptom onset with relatively long transfer times, a ﬁbri-
nolytic-based facilitated PCI approach with optimal anti-
platelet comedication does not offer a beneﬁt over primary
PCI with respect to infarct size and tissue perfusion.
([LIPSIA-STEMI] The Leipzig Immediate Prehospital
Facilitated Angioplasty in ST-Segment Myocardial Infarc-
tion; NCT00359918) (373).
A Patient-Level Pooled Analysis Assessing the
Impact of the SYNTAX (Synergy Between
Percutaneous Coronary Intervention With Taxus
and Cardiac Surgery) Score on 1-Year Clinical
Outcomes in 6,508 Patients Enrolled in
Contemporary Coronary Stent Trials
Objectives This study sought to assess the impact of the
SYNTAX (Synergy Between Percutaneous Coronary
Intervention With Taxus and Cardiac Surgery) score
(SXscore) on clinical outcomes in patients undergoing
percutaneous coronary intervention.
Background The SXscore has been demonstrated to have an
ability to predict clinical outcomes in patients undergoing
percutaneous revascularization. Current studies are limited by
the relatively small number of patients in each SXscore group.
Methods Patient-level data from 7 contemporary coronary
stent trials were pooled by an independent academic researchorganization (Cardialysis, Rotterdam, the Netherlands).
Analysis was performed on a cohort of 6,508 patients treated
with drug-eluting stents and who had calculated SXscores.
Clinical outcomes in terms of death, myocardial infarction
(MI), repeat revascularization, and major adverse cardiac
events (MACE, a composite of death, MI, and repeat
revascularization) were subsequently stratiﬁed according to
SXscore quartiles: SXscoreQ1 8 (n ¼ 1,702); 8 <
SXscoreQ2 <15 (n ¼ 1,528); 15  SXscoreQ3 <23 (n ¼
1,620); and SXscoreQ4 23 (n ¼ 1,658).
Results One-year outcomes were available in 6,496 patients
(99.8%). At 1-year follow-up, all clinical outcomes including
mortality, MI, repeat revascularization, MACE, and deﬁnite
and any stent thrombosis were all signiﬁcantly higher in
patients in the highest SXscore quartile. Similar trends were
observed in a subgroup of 2,093 patients (32.2%) who
presented with an ST- or non–ST-segment elevation MI.
The rate of MACE among patients with an SXscore >32
and 32 was 24.9% and 14.0%, respectively (p < 0.001).
The SXscore was identiﬁed as an independent predictor of
all clinical outcomes including mortality, MACE, and stent
thrombosis (p < 0.001 for all).
Conclusions This study conﬁrms the consistent ability of
the SXscore to identify patients who are at highest risk of
adverse events (374).Clinical and Angiographic Predictors and
Prognostic Value of Failed Thrombus Aspiration in
Primary Percutaneous Coronary Intervention
Objectives This study sought to investigate which factors
are associated with failure of thrombus aspiration (TA) and
if this has prognostic implications.
Background The pathophysiological mechanism and clin-
ical beneﬁt of TA during primary percutaneous coronary
intervention for acute ST-segment elevation myocardial
infarction is still in debate.
Methods Between August 2001 and October 2007, TA
was attempted in 1,399 patients. Failure of TA was
deﬁned as the inability to reach and/or cross the occlusion
with the aspiration catheter for effective thrombus removal.
In addition, we analyzed patients in which no material
could be obtained. We examined baseline clinical and
angiographic variables related to failure of TA or to the
lack of aspirate. Follow-up on vital status was obtained at
1 year.
Results In 144 (10.3%) patients, the aspiration catheter
failed to cross the lesion. After multivariable adjustment,
marked proximal tortuosity (odds ratio [OR]: 2.88, 95%
conﬁdence interval [CI]: 1.92 to 4.31, p < 0.001), the
presence of a calciﬁed lesion (OR: 2.70, 95% CI: 1.77 to
4.13, p < 0.001), and a bifurcation lesion (OR: 1.97, 95%
CI: 1.15 to 3.37, p ¼ 0.013) were independent predictors of
failed TA. Age over 60 years and the circumﬂex as infarct-
related artery were associated with the lack of aspirate.
Mortality rates at 1 year were 6.2% in patients with failed
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CI: 0.49 to 1.95, p ¼ 0.95).
Conclusions The presence of marked proximal tortuosity
of the infarct-related artery, a calciﬁed lesion, and a bifur-
cation lesion are independent predictors of failure of
thrombus aspiration. We found that unsuccessful TA did
not affect 1-year mortality (375).
Safety of Contemporary Percutaneous Peripheral
Arterial Interventions in the Elderly: Insights From
the BMC2 PVI (Blue Cross Blue Shield of Michigan
Cardiovascular Consortium Peripheral Vascular
Intervention) Registry
Objectives This study sought to evaluate the effect of age
on procedure type, periprocedural management, and in-
hospital outcomes of patients undergoing lower-extremity
(LE) peripheral vascular intervention (PVI).
Background Surgical therapy of peripheral arterial disease
is associated with signiﬁcant morbidity and mortality in the
elderly. There are limited data related to the inﬂuence of
advanced age on the outcome of patients undergoing
percutaneous LE PVI.
Methods Clinical presentation, comorbidities, and in-
hospital outcomes of patients undergoing LE PVI in
a multicenter, multidisciplinary registry were compared
between 3 age groups: <70 years, between 70 and 80 years,
and 80 years (elderly group).
Results In our cohort, 7,769 patients underwent LE PVI.
The elderly patients were more likely to be female and to
have a greater burden of comorbidities. Procedural success
was lower in the elderly group (74.2% for age 80 years vs.
78% for age 70 to <80 years and 81.4% in patients age <70
years, respectively; p < 0.0001). Unadjusted rates of
procedure-related vascular access complications, post-
procedure transfusion, contrast-induced nephropathy,
amputation, and major adverse cardiac events were higher in
elderly patients. After adjustment for baseline covariates, the
elderly patients were more likely to experience vascular access
complications; however, advanced age was not found to be
associated with major adverse cardiac events, transfusion,
contrast-induced nephropathy, or amputation.
Conclusions Contemporary PVI can be performed in elderly
patients with high procedural and technical success with low
rates of periprocedural complications including mortality.
These ﬁndings may support the notion of using PVI as
a preferred revascularization strategy in the treatment of severe
peripheral arterial disease in the elderly population (376).
Primary Percutaneous Coronary Intervention for
Unprotected Left Main Disease in Patients With
Acute ST-Segment Elevation Myocardial Infarction:
The AMIS (Acute Myocardial Infarction in
Switzerland) Plus Registry Experience
Objectives This study sought to assess outcomes in patients
with ST-segment elevation myocardial infarctionundergoing primary percutaneous coronary intervention
(PCI) for unprotected left main (LM) disease.
Background Limited data are available on outcomes in
patients with ST-segment elevation myocardial infarction
undergoing LM PCI.
Methods Of 9,075 patients with ST-segment elevation
myocardial infarction enrolled in the AMIS (Acute
Myocardial Infarction in Switzerland) Plus registry between
2005 and June 30, 2010, 6,666 underwent primary PCI. Of
them, 348 (5.2%; mean age: 63.5  12.6 years) underwent
LM PCI, either isolated (n ¼ 208) or concomitant to PCI
for other vessel segments (n ¼ 140). They were compared
with 6,318 patients (94.8%; mean age: 61.9  12.5 years)
undergoing PCI of non-LM vessel segments only.
Results The LM patients had higher rates of cardiogenic
shock (12.2% vs. 3.5%; p < 0.001), cardiac arrest (10.6% vs.
6.3%; p < 0.01), in-hospital mortality (10.9% vs. 3.8%; p <
0.001), and major adverse cardiac and cerebrovascular events
(12.4% vs. 5.0%; p < 0.001) than non-LM PCI. Rates of
mortality and major adverse cardiac and cerebrovascular
events were highest for concurrent LM and non-LM PCI
(17.9% and 18.6%, respectively), intermediate for isolated
LM PCI (6.3% and 8.3%, respectively), and lowest for non-
LM PCI (3.8% and 5.0%, respectively). Rates of mortality
and major adverse cardiac and cerebrovascular events for LM
PCI were higher than for non-LM multivessel PCI (10.9%
vs. 4.9%, p < 0.001, and 12.4% vs. 6.4%, p < 0.001,
respectively). LM disease independently predicted in-
hospital death (odds ratio: 2.36; 95% conﬁdence interval:
1.34 to 4.17; p ¼ 0.003).
Conclusions Emergent LM PCI in the context of acute
myocardial infarction, even including 12% cardiogenic
shock, appears to have a remarkably high (89%) in-hospital
survival. Concurrent LM and non-LM PCI has worse
outcomes than isolated LM PCI (377).The V2 Transition Ratio: A New
Electrocardiographic Criterion for Distinguishing
Left From Right Ventricular Outﬂow Tract
Tachycardia Origin
Objectives We sought to develop electrocardiography
(ECG) criteria for distinguishing left ventricular outﬂow
tract (LVOT) from right ventricular outﬂow tract (RVOT)
origin in patients with idiopathic outﬂow tract ventricular
tachycardia (OTVT) and lead V3 R/S transition.
Background Several ECG criteria have been proposed for
differentiating left from right OTVT origin; ventricular
tachycardias (VTs) with left bundle branch block and V3
transition remain a challenge.
Methods We analyzed the surface ECG pattern of patients
with OTVT with a precordial transition in lead V3 who
underwent successful catheter ablation. Sinus and VT QRS
morphologies were measured in limb and precordial leads
with electronic calipers. The V2 and V3 transition ratios were
calculated by computing the percentage R-wave during VT
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rhythm (R/RþS)SR.
Results We retrospectively analyzed ECGs from 40 patients
(mean age 44  14 years, 21 female) with outﬂow tract
premature ventricular contractions (PVCs)/VT. Patients with
structural heart disease, paced rhythms, and bundle branch
block during sinus rhythm were excluded. The V2 transition
ratio was signiﬁcantly greater for LVOT PVCs compared
with RVOT PVCs (1.27  0.60 vs. 0.23  0.16; p < 0.001)
and was the only independent predictor of LVOT origin. In
21 prospective cases, a V2 transition ratio 0.60 predicted an
LVOT origin with 91% accuracy. A PVC precordial transi-
tion occurring later than the sinus rhythm transition excluded
an LVOT origin with 100% accuracy.
Conclusions The V2 transition ratio is a novel electrocar-
diographic measure that reliably distinguishes LVOT from
RVOT origin in patients with lead V3 precordial transition.
This measure might be useful for counseling patients and
planning an ablation strategy (378).The Impact of Patient and Lesion Complexity on
Clinical and Angiographic Outcomes After
Revascularization With Zotarolimus- and
Everolimus-Eluting Stents: A Substudy of the
RESOLUTE All Comers Trial (A Randomized
Comparison of a Zotarolimus-Eluting Stent With an
Everolimus-Eluting Stent for Percutaneous
Coronary Intervention)
Objectives The aim of this study was to investigate the
impact of patient and lesion complexity on outcomes with
newer-generation zotarolimus-eluting stents (ZES) and
everolimus-eluting stents (EES).
Background Clinical and angiographic outcomes of newer-
generation stents have not been described among complex
patients.
Methods Patients enrolled in the RESOLUTE All
Comers trial (A Randomized Comparison of a Zotarolimus-
Eluting Stent With an Everolimus-Eluting Stent for
Percutaneous Coronary Intervention) were stratiﬁed into
“complex” and “simple.”
Results Of 2,292 patients, 1,520 (66.3%) were complex
and treated with ZES (n ¼ 764) or EES (n ¼ 756). Event
rates were higher among complex patients, and results did
not differ between ZES and EES, regardless of complexity.
At 1 year, target lesion failure was 8.9% in ZES- and 9.7%
in EES-treated complex patients (p ¼ 0.66) and 6.8% in
ZES- and 5.7% in EES-treated simple patients (p ¼ 0.55).
Rates of cardiac death (1.3% vs. 2.2%, p ¼ 0.24), target-
vessel myocardial infarction (4.3% vs. 4.4%, p ¼ 0.90),
and clinically indicated target lesion revascularization (4.4%
vs. 4.0%, p ¼ 0.80) were similar for both stent types among
complex patients. Deﬁnite or probable stent thrombosis
occurred in 20 (1.3%) complex patients with no difference
between ZES (1.7%) and EES (0.9%, p ¼ 0.26). Angio-
graphic follow-up showed similar results for ZES and EESin terms of in-stent percentage diameter stenosis (22.2 
15.4% vs. 21.4  15.8%, p ¼ 0.67) and in-segment binary
restenosis (6.6% vs. 8.0%, p ¼ 0.82) in the complex group.
Conclusions In this all-comers randomized trial, major
adverse cardiovascular events were more frequent among
complex than simple patients. The newer-generation ZES
and EES proved to be safe and effective, regardless of
complexity, with similar clinical and angiographic outcomes
for both stent types through 1 year. (RESOLUTE-III All
Comers Trial: A Randomized Comparison of a Zotarolimus-
Eluting Stent With an Everolimus-Eluting Stent for Percu-
taneous Coronary Intervention; NCT00617084) (379).
Long-Term Comparison of Everolimus-Eluting and
Sirolimus-Eluting Stents for Coronary
Revascularization
Objectives This study sought to compare the unrestricted
use of everolimus-eluting stents (EES) with sirolimus-
eluting stents (SES) in patients undergoing percutaneous
coronary intervention.
Background It is unclear whether there are differences in
safety and efﬁcacy between EES and SES during long-term
follow-up.
Methods Using propensity score matching, clinical
outcome was compared among 1,342 propensity score–
matched pairs of patients treated with EES and SES. The
primary outcome was a composite of death, MI, and target
vessel revascularization.
Results The median follow-up was 1.5 years with
a maximum of 3 years. The primary outcome occurred in
14.9% of EES- and 18.0% of SES-treated patients up to 3
years (hazard ratio [HR]: 0.83, 95% conﬁdence interval
[CI]: 0.68 to 1.00, p ¼ 0.056). All-cause mortality (6.0% vs.
6.5%, HR: 0.92, 95% CI: 0.68 to 1.25, p ¼ 0.59) was
similar, risks of myocardial infarction (MI) (3.3% vs. 5.0%,
HR: 0.62, 95% CI: 0.42 to 0.92, p ¼ 0.017), and target
vessel revascularization (7.0% vs. 9.6%, HR: 0.75, 95% CI:
0.57 to 0.99, p ¼ 0.039) were lower with EES than SES.
Deﬁnite stent thrombosis (ST) (HR: 0.30, 95% CI: 0.12 to
0.75, p ¼ 0.01) was less frequent among patients treated
with EES. The reduced rate of MI with EES was explained
in part by the lower risk of deﬁnite ST and the corre-
sponding decrease in events associated with ST (HR: 0.25,
95% CI: 0.08 to 0.75, p ¼ 0.013).
Conclusions The unrestricted use of EES appears to be
associated with improved clinical long-term outcome
compared with SES. Differences in favor of EES are driven
in part by a lower risk of MI associated with ST (380).
Complexity of Atherosclerotic Coronary Artery
Disease and Long-Term Outcomes in Patients With
Unprotected Left Main Disease Treated With Drug-
Eluting Stents or Coronary Artery Bypass Grafting
Objectives The aim of this study was to compare treatment
effects of drug-eluting stents (DES) or coronary artery
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(LMCA) disease according to the complexity of athero-
sclerotic disease burden.
Background Limited information is available on the rela-
tionships between the extent of coronary atherosclerosis and
very long-term outcomes of surgical or percutaneous LMCA
revascularization.
Methods A total of 1,146 patients with unprotected
LMCA disease who received DES (n ¼ 645) or under-
went CABG (n ¼ 501) were evaluated. The extent of
atherosclerotic disease burden was measured using the
SYNTAX (Synergy Between PCI With Taxus and Cardiac
Surgery) score; a low-risk score was deﬁned as 22, an
intermediate-risk score as 23 to 32, and a high-risk score
as 33.
Results After multivariate adjustment with the inverse-
probability-of-treatment weighting method, the 5-year
risks for death (6.1% for DES vs. 16.2% for CABG;
hazard ratio [HR]: 0.52; 95% conﬁdence interval [CI]:
0.21 to 1.28; p ¼ 0.15) and the composite of death, Q-
wave myocardial infarction, or stroke (6.4% vs. 16.2%;
HR: 0.54; 95% CI: 0.22 to 1.34; p ¼ 0.18) favored DES
in patients with low-risk SYNTAX scores; in contrast, the
5-year risks for death (26.9% vs. 17.8%; HR: 1.46; 95%
CI: 0.92 to 2.30; p ¼ 0.11) and the composite outcome
(27.6% vs. 19.5%; HR: 1.36; 95% CI: 0.87 to 2.12; p ¼
0.18) favored CABG in patients with high-risk SYNTAX
scores (interaction p ¼ 0.047 for death, interaction p ¼
0.08 for composite outcome). Patients undergoing
CABG consistently had lower rates of target vessel
revascularization.
Conclusions According to the complexity of concomitant
coronary disease, there were differential treatment effects on
long-term mortality in patients with unprotected LMCA
disease who received DES or underwent CABG (381).Incidence, Predictive Factors, and Prognostic
Value of Myocardial Injury Following
Uncomplicated Transcatheter Aortic Valve
Implantation
Objectives This study sought to: 1) determine the inci-
dence, degree, and timing of the rise in serum cardiac
markers of myocardial injury associated with uncomplicated
transcatheter aortic valve implantation (TAVI); and 2)
evaluate the predictive factors and prognostic value of
myocardial injury associated with TAVI.
Background Very few data exist on the occurrence and
clinical relevance of myocardial injury during TAVI
procedures.
Methods A total of 101 patients who underwent successful
TAVI (transfemoral [TF] approach, n ¼ 38; transapical
[TA] approach, n ¼ 63) were included. Creatine kinase-MB
(CK-MB) and cardiac troponin T (cTnT) levels were
determined at baseline and at 6 to 12, 24, 48, and 72 h
following TAVI.Results TAVI was associated with some degree of
myocardial injury in 99% of the patients (TF: 97%, TA:
100%) as determined by a rise in cTnT (maximal value, 0.48
mg/l, interquartile range [IQR]: 0.24 to 0.82 mg/l) and in
77% of the patients (TF: 47%, TA: 95%) as determined by
a rise in CK-MB (maximal value, 18.6 mg/l; IQR: 11.0 to
27.4 mg/l). TA approach and baseline renal dysfunction were
associated with a higher increase in biomarkers of myocar-
dial injury (p < 0.01 for both). A larger myocardial injury
was associated with a smaller improvement of left ventricular
ejection fraction (LVEF) (p < 0.01). The degree of rise in
cTnT was an independent predictor of cardiac mortality at 9
 10 months of follow-up (hazard ratio: 1.14 per each
increase of 0.1 mg/l, 95% conﬁdence interval: 1.02 to 1.28,
p ¼ 0.028).
Conclusions TAVI was systematically associated with
some degree of myocardial injury, with TA approach and
baseline renal dysfunction determining a higher increase
in biomarkers of myocardial injury. A greater degree of
myocardial injury was associated with less improvement
in LVEF and a higher cardiac mortality at follow-up
(382).
Promoting Global Cardiovascular Health: Ensuring
Access to Essential Cardiovascular Medicines in
Low- and Middle-Income Countries
On May 13, 2010, a resolution passed at the United
Nations for a high-level meeting with heads of state on
noncommunicable chronic diseases (NCDs), catapulting
NCDs atop the political and health agendas. This meeting
on NCDs, slated for September 2011, provides the rare
political moment to commit to scaling up international,
regional, and national efforts to prevent and treat NCDs,
giving the issue the priority it deserves. An analogous
high-proﬁle meeting transpired in 2001 on human
immunodeﬁciency virus (HIV)/acquired immune deﬁ-
ciency syndrome (AIDS), effectively serving as the nucle-
ating event for a vigorous global and political movement
towards universal prevention and treatment. As was the
case at the HIV/AIDS meeting, a key priority area in the
new NCD movement remains ensuring universal access to
reliable, affordable essential medicines to prevent and treat
NCDs. The upcoming meeting, therefore, provides the
perfect opportunity to capitalize on the increased political
and social awareness of NCDs and to apply the lessons
learned from the HIV/antiretroviral experience in order to
improve access to essential medicines for NCDs. Social
mobilization and political advocacy, used in tandem with
technical solutions, is an important lesson from the HIV
experience, and will likely be important to ensure access to
essential medicines for NCDs, including cardiovascular
disease. Here, we use cardiovascular disease as a speciﬁc
case study to examine the issue, outlining early solutions
while drawing parallels and analogies to the HIV experi-
ence (383).
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e385Intraluminal Thrombus in Facilitated Versus
Primary Percutaneous Coronary Intervention: An
Angiographic Substudy of the ASSENT-4 PCI
(Assessment of the Safety and Efﬁcacy of a New
Treatment Strategy With Percutaneous Coronary
Intervention) Trial
Objectives This study investigated the occurrence of
intraluminal thrombus and its potential implications with
facilitated percutaneous coronary interventions (fPCIs).
Background The effect of fPCI on the presence and
consequences of intraluminal thrombus is unknown.
Methods Thrombolysis In Myocardial Infarction (TIMI)
ﬂow grade, frame count, and thrombus grade; distal embo-
lization; and slow ﬂow in the infarct-related artery were
assessed in a blinded fashion on coronary angiograms in
1,342 patients from the ASSENT-4 PCI (Assessment of
the Safety and Efﬁcacy of a New Treatment Strategy With
Percutaneous Coronary Intervention) trial. Residual TIMI
thrombus grade 2 and/or distal embolization and/or slow
ﬂow, reﬂecting thrombus burden (TB), following PCI were
correlated with ST-segment resolution, epicardial blood
ﬂow, and clinical outcome. The clinical composite endpoint
was death, congestive heart failure, or shock.
Results In the fPCI group, more TIMI ﬂow grade 2/3 in
the infarct-related artery at the ﬁrst angiogram (73.7% vs.
33.4%, p < 0.001) and a higher TB following PCI (19.7%
vs. 13.4%, p ¼ 0.002) were found in comparison with the
primary PCI group. Post-PCI TIMI thrombus grade was
signiﬁcantly associated with ST-segment resolution (p <
0.001) and TIMI frame count (p < 0.0001) in both groups.
In the fPCI group, the presence of post-PCI thrombus was
associated with a signiﬁcantly worse outcome at 90 days
(clinical composite endpoint: 32.1% vs. 18.6%, p ¼ 0.023).
Multivariable logistic regression showed that facilitation
with tenecteplase (p ¼ 0.005) and TB (odds ratio: 2.43, 95%
conﬁdence interval: 1.30 to 4.51, p ¼ 0.0052) were inde-
pendent predictors of 90-day mortality.
Conclusions In ASSENT-4 PCI, despite more patency,
residual TB was signiﬁcantly higher in fPCI patients and
was associated with less efﬁcient tissue reperfusion and
worse clinical outcomes. (A Trial Evaluating the Efﬁcacy
and Safety of Tenecteplase Together With Unfractionated
Heparin Prior to Early Percutaneous Coronary Intervention
[PCI] as Compared to Standard Primary PCI in Patients
With Acute Myocardial Infarction [ASSENT-4 PCI];
NCT00168792) (384).
The Incidence of Bradyarrhythmias and Clinical
Bradyarrhythmic Events in Patients With Acute
Coronary Syndromes Treated With Ticagrelor or
Clopidogrel in the PLATO (Platelet Inhibition and
Patient Outcomes) Trial: Results of the Continuous
Electrocardiographic Assessment Substudy
Objectives The aim of this study was to determine whether
ticagrelor increased the risk of ventricular pauses comparedwith clopidogrel and whether these pauses were associated
with any clinical bradycardic events in patients presenting
with acute coronary syndromes.
Background Ticagrelor, an oral reversibly binding P2Y12
inhibitor, provides more potent and consistent inhibition of
platelet aggregation than clopidogrel but in a phase II study
was associated with increased risk for ventricular pauses. A
prospective continuous electrocardiographic (cECG)
assessment was therefore performed within the PLATO
(Platelet Inhibition and Patient Outcomes) study comparing
ticagrelor and clopidogrel in patients hospitalized with acute
coronary syndromes.
Methods Patients in the cECG assessment had planned
7-day cECG recording initiated at the time of randomi-
zation (week 1), which was within 24 h of symptom onset,
and then repeated at 1 month after randomization during
the convalescent phase. The principal safety endpoint was
the incidence of ventricular pauses lasting at least 3 s.
Investigators also reported symptomatic bradycardic
adverse events during the entire study duration (median
277 days).
Results A total of 2,908 patients were included in the
cECG assessment, of whom 2,866 (98.5%) had week 1
recordings, 1,991 (68.4%) had 1-month recordings, and
1,949 (67.0%) had both. During the ﬁrst week after
randomization, ventricular pauses 3 s occurred more
frequently in patients receiving ticagrelor than clopidogrel
(84 [5.8%] vs. 51 [3.6%]; relative risk: 1.61; p ¼ 0.006). At 1
month, pauses 3 s occurred overall less frequently and were
similar between treatments (2.1% vs. 1.7%). Most were
ventricular pauses, and the greatest excess associated with
ticagrelor were asymptomatic, sinoatrial nodal in origin
(66%), and nocturnal. There were no differences between
ticagrelor and clopidogrel in the incidence of clinically re-
ported bradycardic adverse events, including syncope,
pacemaker placement, and cardiac arrest.
Conclusions In the PLATO cECG assessment, more
patients treated with ticagrelor compared with clopidogrel
had ventricular pauses, which were predominantly asymp-
tomatic, sinoatrial nodal in origin, and nocturnal and
occurred most frequently in the acute phase of acute coro-
nary syndromes. There were no apparent clinical conse-
quences related to the excess in ventricular pauses in patients
assigned to ticagrelor. (A Comparison of AZD6140 and
Clopidogrel in Patients With Acute Coronary Syndrome
[PLATO]; NCT00391872) (385).The Relationship Between Volumetric Plaque
Components and Classical Cardiovascular Risk
Factors and the Metabolic Syndrome: A 3-Vessel
Coronary Artery Virtual Histology–Intravascular
Ultrasound Analysis
Objectives The aim of this study was to analyze volumetric
plaque composition of the coronary arterial tree according to
the classical cardiovascular risk factors and metabolic
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sound (VH-IVUS).
Background It remains unclear how the cardiovascular risk
factors correlate with the histological components of coro-
nary plaques.
Methods “Whole vessel” VH-IVUS analysis was per-
formed in 189 vessels of 63 patients. The components of
atherosclerotic plaques were classiﬁed as ﬁbrous, ﬁbrofatty,
necrotic core (NC), and dense calcium. Quantitative
assessment of these plaque components and the presence of
VH-IVUS–derived thin-cap ﬁbroatheroma in the coronary
arterial trees were compared with cardiovascular risk factors.
Results There was a signiﬁcantly larger mean plaque-plus-
media burden in patients with diabetes mellitus (DM) (47 
5% vs. 39  7% in non-DM patients, p < 0.001) and MS
(47  4% vs. 39  7% in non-MS patients, p < 0.001). DM
patients had a signiﬁcantly larger %NC (17.8  5.6% vs.
12.5  6.1%, p ¼ 0.003) compared with non-DM patients;
and MS patients had a signiﬁcantly larger %NC (17.3 
5.8% vs. 12.8  6.2%, p ¼ 0.016) as compared to non-MS
patients. Finally, VH-IVUS–derived thin-cap ﬁbroather-
omas were more frequent in DM patients (3.4  2.0 vs. 2.1
 1.7 in non-DM patients, p ¼ 0.016) and in MS patients
(4.1  2.1 vs. 1.9  1.4 in non-MS patients, p ¼ 0.001).
Conclusions Three-vessel VH-IVUS analysis showed that
DM and MS patients, compared to patients without DM or
MS, had a larger plaque-plus-media burden, larger amount
of NC, and more frequent VH-IVUS–derived thin-cap
ﬁbroatheromas in coronary arterial trees, implying greater
plaque vulnerability in DM and MS patients (386).The Relationship Between Attenuated Plaque
Identiﬁed by Intravascular Ultrasound and No-
Reﬂow After Stenting in Acute Myocardial
Infarction: The HORIZONS-AMI (Harmonizing
Outcomes With Revascularization and Stents in
Acute Myocardial Infarction) Trial
Objectives The aim of this study was to understand the
impact of attenuated plaque on distal embolization during
stent implantation in patients with acute myocardial
infarction (AMI).
Background Attenuated plaques identiﬁed by grayscale
intravascular ultrasound (IVUS) might predict transient
deterioration in coronary ﬂow and/or no-reﬂow during
percutaneous coronary intervention (PCI).
Methods We analyzed clinical, angiographic, and IVUS
data from 364 patients (n ¼ 364 infarct-related arteries)
enrolled in the randomized HORIZONS-AMI (Harmo-
nizing Outcomes With Revascularization and Stents in
Acute Myocardial Infarction) trial. No-reﬂow was ﬁnal
Thrombolysis In Myocardial Infarction (TIMI) ﬂow
grade 2 in the absence of mechanical obstruction. Atten-
uated plaque was hypoechoic or mixed atheroma with
ultrasound attenuation without calciﬁcation. A mean
attenuation score was created by measuring the angle ofattenuation each 1 mm, scoring the angle as 1 to 4 (corre-
sponding to <90, 90 to 180, 180 to 270, or 270 to
360, respectively), summing the scores, and normalizing for
analysis length.
Results Overall, 284 (78.0%) patients had attenuated pla-
ques; no-reﬂow occurred in 37 (10.2%). Patients with no-
reﬂow had a higher mean attenuation score (median
[interquartile range] 2.2 [0.0 to 2.8] vs. 1.3 [0.7 to 1.8], p <
0.001), lower baseline left ventricular ejection fraction
(52.8% [43.2% to 61.5%] vs. 61.4% [52.2% to 68.1%], p ¼
0.002), and more baseline angiographic thrombus (89.2% vs.
74.1%, p ¼ 0.043) with no differences in post-PCI stent
expansion versus patients without no-reﬂow. Multivariate
analysis indicated that mean attenuation score was the
strongest predictor of no-reﬂow. The mean attenuation
score that best predicted no-reﬂow was 2 points (90 to
180, sensitivity of 81.5%, and speciﬁcity of 80.5%).
Conclusions Attenuated plaque was present in three-
quarters of patients with AMI. The amount of attenuated
plaque strongly correlated with no-reﬂow; the larger the
attenuated plaque, the greater the likelihood of no-reﬂow.
(Dual Arm Factorial Randomized Trial in Patients w/ST
Segment Elevation AMI to Compare the Results of Using
Anticoagulation With Either Unfractionated Heparin þ
Routine GP IIb/IIIa Inhibition or Bivalirudin þ Bail-out
GP IIb/IIIa Inhibition; and Primary Angioplasty with
stent implantation with Either a Slow Rate-release Pacli-
taxel-eluting Stent [TAXUS] or Uncoated Bare Metal
Stent [EXPRESS2]; NCT00433966) (387).Assessment of Echo-Attenuated Plaque by Optical
Coherence Tomography and its Impact on Post-
Procedural Creatine Kinase-Myocardial Band
Elevation in Elective Stent Implantation
Objectives This study examined morphological character-
istics of echo-attenuated plaques by optical coherence
tomography (OCT) and evaluated their inﬂuence on crea-
tine kinase-myocardial band (CK-MB) elevation after
percutaneous coronary intervention (PCI) in patients with
elective stent implantation.
Background Recent intravascular ultrasound studies have
described atherosclerotic plaques with echo attenuation
(EA) without associated bright echoes that are correlated
with no-reﬂow phenomenon after PCI.
Methods We studied 135 native de novo culprit coronary
lesions in 135 patients with normal pre-PCI CK-MB levels
(28 with unstable angina; 107 with stable angina) who
underwent intravascular ultrasound and OCT examinations
before elective stent implantation. The lesions were divided
into 2 groups based on the presence or absence of EA, and
OCT ﬁndings were compared. We then determined
predictors of post-PCI CK-MB elevation.
Results EA was found in 47 (34.8%) lesions and was
associated with the presence of OCT-derived thin-capped
ﬁbroatheroma, ruptured plaques, greater lipid content,
JACC Vol. 62, No. 18, 2013 The Editors
October 29, 2013:e245–e437 JACC Topic Collection: Interventional Cardiology
e387intravascular ultrasound–derived large reference and plaque
area, lesion eccentricity, and microcalciﬁcation. Elevated
CK-MB levels were observed in 36 (26.7%) lesions, and
signiﬁcantly more frequently in lesions with EA than
without. In multivariable analysis, EA (odds ratio [OR]:
3.49; 95% conﬁdence interval [CI]: 1.53 to 7.93; p ¼ 0.003)
and OCT-derived ruptured plaque (OR: 2.92; 95% CI: 1.21
to 7.06; p ¼ 0.017) were independent predictors of post-
PCI CK-MB elevation.
Conclusions Atherosclerotic plaques with EA were asso-
ciated with characteristics considered to be high risk or
unstable. OCT examination showed an additive predictive
value to the presence of EA for post-PCI CK-MB elevation
(388).Early and Long-Term Outcomes After Combined
Percutaneous Revascularization in Patients With
Carotid and Coronary Artery Stenoses
Objectives This study sought to evaluate the 30-day and
long-term clinical outcomes of patients with carotid
obstructive disease (COD) and concomitant coronary artery
disease (CAD) undergoing a combined percutaneous
revascularization, in 4 high-volume centers skilled for the
treatment of multilevel vascular disease.
Background The optimal management of patients with
COD and concomitant CAD remains controversial. A
variety of therapeutic strategies, including coronary artery
bypass grafting, alone or in combination with carotid artery
revascularization, have been reported.
Methods Between January 2006 and April 2010, 239
consecutive patients with COD (symptomatic carotid
stenosis in 20.5%) and concomitant CAD were treated
with staged or simultaneous carotid artery stenting and
percutaneous coronary intervention, and enrolled in this
prospective registry. The primary endpoint was the inci-
dence of major cardiac and cerebrovascular events,
including any death, myocardial infarction, or stroke
occurring between the ﬁrst revascularization procedure and
30 days after treatment of the second vascular territory
affected.
Results The incidence of the primary endpoint at 30
days was 4.2% (95% conﬁdence interval [CI]: 2.02 to
7.56). The rate of death, myocardial infarction, and stroke
at long-term follow-up (median 520 days) was 4.2%,
2.1%, and 3.8%, respectively. At long-term follow-up,
patients with previous cardiovascular disease had signiﬁ-
cantly higher rates of major cardiac and cerebrovascular
events than did patients with a ﬁrst clinical episode (17%
vs. 6%, hazard ratio: 3.34; 95% CI: 1.46 to 7.63; p ¼
0.004).
Conclusions In patients with COD and concomitant
CAD, a combined percutaneous treatment compares
favorably with previous surgical or hybrid experiences. Such
strategy may be particularly suited to complex patients at
high surgical risk (389).The Impact of Pravastatin Pre-Treatment on
Periprocedural Microcirculatory Damage in
Patients Undergoing Percutaneous Coronary
Intervention
Objectives This study evaluated the effect of pravastatin
pre-treatment on post-procedural index of microcirculatory
resistance (IMR) values that are introduced for assessing the
status of the microcirculation independently of the epicardial
area.
Background Pre-treatment with statins decreased the
incidence of cardiac enzyme increase after percutaneous
coronary intervention (PCI). However, 2 different etiolo-
gies, distal embolization of atheroma or ischemia caused by
side-branch occlusion, cannot be differentiated by measuring
cardiac enzyme levels.
Methods Eighty patients with stable angina were
randomly assigned to either pravastatin treatment (20 mg/
day, n ¼ 40) or no treatment (n ¼ 40) 4 weeks before
elective PCI. An intracoronary pressure/temperature
sensor-tipped guidewire was used. Thermodilution curves
were obtained during maximal hyperemia. The IMR was
calculated from the ratio of the mean distal coronary
pressure at maximal hyperemia to the inverse of mean
hyperemic transit time. Creatine kinase-myocardial band
and troponin I values were measured at baseline and at 8
and 24 h after PCI.
Results Post-PCI troponin I levels tended to be lower in
patients with pravastatin treatment (median: 0.13 [inter-
quartile range (IQR): 0.10 to 0.31] vs. 0.22 [IQR: 0.10 to
0.74] ng/ml, p ¼ 0.1). However, patients with pravastatin
treatment had signiﬁcantly lower IMR than did patients
without pravastatin treatment (median: 12.6 [IQR: 8.8 to
18.0] vs. 17.6 [IQR: 9.7 to 33.9], p ¼ 0.007). Multivariate
analysis revealed that the lack of pravastatin pre-treatment
was the only independent predictor of post-PCI impaired
IMR (p ¼ 0.03).
Conclusions Post-PCI measurement of the IMR
conﬁrmed that pre-treatment with pravastatin was associ-
ated with reduced microvascular dysfunction induced by
PCI regardless of side branch occlusions. These data suggest
that pre-treatment with statin is desired in patients under-
going elective PCI. (The Impact of Pravastatin Pretreatment
on Periprocedural Microcirculatory Damage After Percuta-
neous Coronary Intervention; UMIN000002885) (390).
Long-Term Safety and Efﬁcacy of Paclitaxel-Eluting
Stents: Final 5-Year Analysis From the TAXUS
Clinical Trial Program
Objectives These studies sought to evaluate the clinical
outcomes of the slow-release Taxus paclitaxel-eluting stent
(PES) versus an otherwise identical bare-metal stent (BMS).
Background Prior studies were not individually powered to
generate reliable estimates of low-frequency safety endpoints
or to characterize the long-term safety and efﬁcacy proﬁle of
PES.
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prospective, randomized, double-blind TAXUS I, II, IV,
and V trials were pooled for a patient-level analysis.
Results The study population comprised 2,797 randomized
patients (1,400 PES and 1,397 BMS). At the end of the 5-
year study period, PES compared with BMS signiﬁcantly
reduced the rate of ischemia-driven target lesion revasculari-
zation (12.3% vs. 21.0%, p < 0.0001), with consistent
reductions across high-risk subgroups and in patients with
and without routine angiographic follow-up. There were no
signiﬁcant differences between the stent types in the 1-year or
cumulative 5-year rates of death or myocardial infarction
(MI). However, cardiac death or MI between 1 and 5 years
was increased with PES (6.7% vs. 4.5%, p ¼ 0.01), as was
stent thrombosis (protocol deﬁnition: 0.9% vs. 0.2%, p ¼
0.007; ARC deﬁnition: 1.4% vs. 0.9%, p ¼ 0.18).
Conclusions In this pooled patient-level analysis from the
prospective, randomized, double-blind TAXUS trials, PES
compared with BMS resulted in a durable 47% reduction in
the 5-year rate of ischemia-driven target lesion revasculari-
zation in simple and complex lesions, with nonsigniﬁcant
differences in the cumulative 5-year rates of death or MI.
Between 1 and 5 years, however, the rates of cardiac death or
MI and protocol-deﬁned stent thrombosis were increased
with PES (391).Troponin T Levels and Infarct Size by SPECT
Myocardial Perfusion Imaging
Objectives To evaluate the relationship between serial
cardiac troponin T (cTnT) levels with infarct size and left
ventricular ejection fraction by gated single-photon emission
computed tomography myocardial perfusion imaging
(SPECT-MPI) in patients with acute myocardial infarction
(AMI).
Background Current guidelines recommend the use of
cTnT as the biomarker of choice for the diagnosis of AMI.
Data relating cTnT to SPECT-MPI in patients with AMI
are limited.
Methods A subset of patients with their ﬁrst AMI
participating in a community-based cohort of AMI in
Olmsted County, Minnesota, were prospectively studied.
Serial cTnT levels were evaluated at presentation, <12 h and
1, 2, and 3 days after onset of pain. Peak cTnT was deﬁned
as the maximum cTnT value.
Results A total of 121 patients (age, 61  13 years; 31%
women) with AMI underwent gated SPECT-MPI at
a median (25th percentile, 75th percentile) of 10 (5, 15) days
post-AMI. The type of infarct was non–ST-segment elevation
myocardial infarction in 61%, and 13% were anterior in
location. The median infarct size was 1% (0%, 11%) and the
median gated left ventricular ejection fraction was 54% (47%,
60%). Fifty-nine patients (49% of the population) had no
measurable infarction by SPECT-MPI. Independent predic-
tors of measurable SPECT-MPI infarct size included cTnT at
days 1, 2, and 3 and peak cTnT, but not at presentationor <12 h. In receiver-operator characteristic analysis, the area
under the curve was highest at day 3. Receiver-operator
characteristic analysis demonstrated a cutoff of 1.5 ng/ml for
peak cTnT for the detection of measurable infarct size.
Conclusions In a community-based cohort of patients with
their ﬁrst AMI, independent predictors of measurable
SPECT-MPI infarct size included cTnT at days 1, 2, and 3
and peak cTnT. In contrast, cTnT level at presentation
and <12 h was not an independent predictor of myocardial
infarction size as assessed by SPECT-MPI. Receiver-oper-
ator characteristic analysis demonstrated a cutoff value peak
cTnT of 1.5 ng/ml for the detection of measurable infarct
(392).
Clinical Evaluation of the Resolute Zotarolimus-
Eluting Coronary Stent System in the Treatment of
De Novo Lesions in Native Coronary Arteries: The
RESOLUTE US Clinical Trial
Objectives The RESOLUTE US (R-US) trial is
a prospective, observational study designed to evaluate the
clinical effectiveness of the Resolute zotarolimus-eluting
stent (R-ZES) in a U.S. population.
Background The R-ZES releases zotarolimus over a 6-
month period in order to achieve optimal clinical effective-
ness and safety.
Methods The R-US trial recruited patients with de novo
native coronary lesions suitable for 1- or 2-vessel treatment
with stents from 2.25 to 4.0 mm in diameter. In the main
analysis cohort (2.5- to 3.5-mm stents and single-lesion
treatment), the primary endpoint was 12-month target
lesion failure (TLF) deﬁned as the composite of cardiac
death, myocardial infarction (MI), and clinically-driven
target lesion revascularization (TLR), compared with data
from Endeavor zotarolimus-eluting stent (E-ZES) trials,
adjusting for baseline covariates through propensity scores.
Results Overall, 1,402 patients were enrolled with a mean
reference vessel diameter of 2.59  0.47 mm and diabetes
prevalence of 34.4%. In the main analysis cohort, TLF was
3.7% at 12 months compared with historical E-ZES results
(TLF ¼ 6.5%). The R-ZES met the 3.3% margin of non-
inferiority (rate difference ¼ 2.8%, upper 1-sided 95%
conﬁdence interval: 1.3%, p < 0.001). The overall TLF
rate was 4.7%, and rates of cardiac death, MI, and TLR were
0.7%, 1.4%, and 2.8%, respectively. The 12-month rate of
stent thrombosis was 0.1%.
Conclusions The R-ZES achieved a very low rate of
clinical restenosis while maintaining low rates of important
clinical safety events such as death, MI, and stent throm-
bosis at 1-year follow-up. (The Medtronic RESOLUTE US
Clinical Trial [R-US]; NCT00726453) (393).
Pericardial Fat Is Associated With Atrial Fibrillation
Severity and Ablation Outcome
Objectives The aim of this study was to characterize the
relationship between pericardial fat and atrial ﬁbrillation (AF).
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Pericardial fat has been hypothesized to exert local patho-
genic effects on nearby cardiac structures above and beyond
that of systemic adiposity.
Methods One hundred ten patients undergoing ﬁrst-time
AF ablation and 20 reference patients without AF under-
went cardiac magnetic resonance imaging for the quantiﬁ-
cation of periatrial, periventricular, and total pericardial fat
volumes using a previously validated technique. Together
with body mass index and body surface area, these were
examined in relation to the presence of AF, the severity of
AF, left atrial volume, and long-term AF recurrence after
ablation.
Results Pericardial fat volumes were signiﬁcantly associated
with the presence of AF, AF chronicity, and AF symptom
burden (all p values <0.05). Pericardial fat depots were also
predictive of long-term AF recurrence after ablation (p ¼
0.035). Finally, pericardial fat depots were also associated
with left atrial volume (total pericardial fat: r ¼ 0.46, p <
0.001). Importantly, these associations persisted after
multivariate adjustment and additional adjustment for body
weight. In contrast, however, systemic measures of adiposity,
such as body mass index and body surface area, were not
associated with these outcomes in multivariate-adjusted
models.
Conclusions Pericardial fat is associated with the presence
of AF, the severity of AF, left atrial volumes, and poorer
outcomes after AF ablation. These associations are both
independent of and stronger than more systemic measures of
adiposity. These ﬁndings are consistent with the hypothesis
of a local pathogenic effect of pericardial fat on the
arrhythmogenic substrate supporting AF (394).A Prospective, Randomized Evaluation of a Novel
Everolimus-Eluting Coronary Stent: The PLATINUM
(A Prospective, Randomized, Multicenter Trial to
Assess an Everolimus-Eluting Coronary Stent
System [PROMUS Element] for the Treatment of up
to Two De Novo Coronary Artery Lesions) Trial
Objectives We sought to evaluate the clinical outcomes
with a novel platinum chromium everolimus-eluting stent
(PtCr-EES) compared with a predicate cobalt chromium
everolimus-eluting stent (CoCr-EES) in patients under-
going percutaneous coronary intervention (PCI).
Background Randomized trials have demonstrated an
excellent safety and efﬁcacy proﬁle for the CoCr-EES. The
PtCr-EES uses the identical antiproliferative agent and
polymer but with a novel platinum chromium scaffold
designed for enhanced deliverability, vessel conformability,
side-branch access, radiopacity, radial strength, and fracture
resistance.
Methods A total of 1,530 patients undergoing PCI of 1 or
2 de novo native lesions were randomized at 132 worldwide
sites to CoCr-EES (n ¼ 762) or PtCr-EES (n ¼ 768). The
primary endpoint was the 12-month rate of target lesionfailure (TLF), the composite of target vessel-related cardiac
death, target vessel-related myocardial infarction (MI), or
ischemia-driven target lesion revascularization (TLR) in the
per-protocol population (patients who received 1 assigned
study stent), powered for noninferiority.
Results The 12-month rate of TLF in the per-protocol
population occurred in 2.9% versus 3.4% of patients
assigned to CoCr-EES versus PtCr-EES, respectively
(difference: 0.5%, 95% conﬁdence interval: 1.3% to 2.3%,
pnoninferiority ¼ 0.001, psuperiority ¼ 0.60). By intention-to-
treat, there were no signiﬁcant differences between CoCr-
EES and PtCr-EES in the 12-month rates of TLF (3.2%
vs. 3.5%, p ¼ 0.72), cardiac death or MI (2.5% vs. 2.0%, p ¼
0.56), TLR (1.9% vs. 1.9%, p ¼ 0.96), or Academic
Research Consortium deﬁnite or probable stent thrombosis
(0.4% vs. 0.4%, p ¼ 1.00).
Conclusions In this large-scale, prospective, single-blind
randomized trial, a novel PtCr-EES was noninferior to
the predicate CoCr-EES for TLF, with nonsigniﬁcant
differences in measures of safety and efﬁcacy through 12-
month follow-up after PCI. (A Prospective, Randomized,
Multicenter Trial to Assess an Everolimus-Eluting Coro-
nary Stent System [PROMUS Element] for the Treatment
of up to Two De Novo Coronary Artery Lesions:
NCT00823212) (395).2-Year Follow-Up of Patients Undergoing
Transcatheter Aortic Valve Implantation Using
a Self-Expanding Valve Prosthesis
Objectives The purpose of this study was to evaluate the
safety, device performance, and clinical outcome up to 2
years for patients undergoing transcatheter aortic valve
implantation (TAVI).
Background The role of TAVI in the treatment of calciﬁc
aortic stenosis evolves rapidly, but mid- and long-term
results are scarce.
Methods We conducted a prospective, multicenter, single-
arm study with symptomatic patients undergoing TAVI for
treatment of severe aortic valve stenosis using the 18-F
Medtronic CoreValve (Medtronic, Minneapolis, Minne-
sota) prosthesis.
Results In all, 126 patients (mean age 82 years, 42.9% male,
mean logistic European System for Cardiac Operative Risk
Evaluation score 23.4%) with severe aortic valve stenosis
(mean gradient 46.8 mm Hg) underwent the TAVI proce-
dure. Access was transfemoral in all but 2 cases with
subclavian access. Retrospective risk stratiﬁcation classiﬁed 54
patients as moderate surgical risk, 51 patients as high-risk
operable, and 21 patients as high-risk inoperable. The over-
all technical success rate was 83.1%. Thirty-day all-cause
mortality was 15.2%, without signiﬁcant differences in the
subgroups. At 2 years, all-cause mortality was 38.1%, with
a signiﬁcant difference between the moderate-risk group and
the combined high-risk groups (27.8% vs. 45.8%, p ¼ 0.04).
This difference was mainly attributable to an increased risk of
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risk groups. Hemodynamic results remained unchanged
during follow-up (mean gradient: 8.5  2.5 mm Hg at 30
days and 9.0  3.4 mm Hg at 2 years). Functional class
improved in 80% of patients and remained stable over time.
There was no incidence of structural valve deterioration.
Conclusions The TAVI procedure provides sustained
clinical and hemodynamic beneﬁts for as long as 2 years for
patients with symptomatic severe aortic stenosis at increased
risk for surgery (396).
Relation Between Hyperinsulinemia and Nonculprit
Plaque Characteristics in Nondiabetic Patients
With Acute Coronary Syndromes
Objectives We sought to assess whether hyperinsulinemia
is associated with percentage lipid and coronary plaque
burden in nondiabetic patients with acute coronary
syndromes (ACS).
Background Hyperinsulinemia carries an increased risk of
cardiovascular disease even in pre-diabetic patients, but the
precise mechanisms of its effects remain unclear.
Methods Nonculprit coronary lesions associated with mild-
to-moderate stenosis in 82 nondiabetic patients with ACS
were examined by integrated backscatter intravascular ultra-
sound (IB-IVUS), using a 40-MHz intravascular catheter.
Conventional IVUS and IB-IVUS measurements from the
worst 10-mm segment (1-mm intervals) were calculated. All
patients underwent a 75-g oral glucose tolerance test
(OGTT) to calculate the area under the insulin
concentration-time curve (AUC insulin) from 0 to 120 min.
Results Patients in the high tertile of AUC insulin had
a signiﬁcantly greater percentage lipid area and absolute lipid
volume than did patients in the intermediate and low tertiles
(tertile 3 vs. tertile 2 vs. tertile 1; 37.6  16.6% vs. 25.8 
11.9% vs. 27.5  14.7%, p < 0.01 by analysis of variance
[ANOVA], and 29.9  22.6 mm3 vs. 15.3  12.6 mm3 vs.
17.7  12.7 mm3, p < 0.01 by ANOVA, respectively) and
a smaller percentage ﬁbrosis area (55.0  11.5% vs. 61.7 
9.4% vs. 60.7  9.4%, p ¼ 0.03 by ANOVA). Multiple
regression analysis showed that the high tertile of AUC insulin
was independently associated with an increased percentage
lipid area (p < 0.05). On conventional IVUS analysis, external
elastic membrane cross-sectional area was signiﬁcantly
increased with greater plaque volume in patients in the high
tertile of AUC insulin (both p < 0.05 by ANOVA).
Conclusions Hyperinsulinemia is associated with an
increased lipid content and a greater plaque volume of
nonculprit intermediate lesions in nondiabetic patients with
ACS, suggesting that plaque vulnerability is increased in this
subgroup of patients (397).
Multidetector Computed Tomography in
Transcatheter Aortic Valve Implantation
Aortic stenosis is a common disorder. Aortic valve replace-
ment is indicated in symptomatic patients with severe aorticstenosis, as the prognosis of untreated patients is poor.
Nevertheless, many patients pose a prohibitively high
surgical risk and are not candidates for surgical valve
replacement. Transcatheter aortic valve implantation
(TAVI) is a novel method to treat selected high-risk patients
with aortic stenosis. Patient screening and anatomic
measurements of the aortic root are of great importance to
ensure procedural success and appropriate patient selection.
Multidetector computed tomography (CT) is playing an
increasingly important role in patient screening protocols
before TAVI, provides detailed anatomic assessment of the
aortic root and valve annulus, assesses the suitability of
iliofemoral access, and determines appropriate coaxial angles
to optimize the valve implantation procedure. Additionally,
CT is providing a greater understanding of medium-term
valve durability and integrity. This review outlines an
evolving role for CT angiography in support of a TAVI
program and describe step by step how CT can be used to
enhance the procedure and provide a practical guide for the
utilization of CT angiography in support of a transcatheter
aortic valve program (398).Synchronicity of LV Contraction as a Determinant
of LV Twist Mechanics: Serial Speckle-Tracking
Analyses in WPW Syndrome Before and After
Radiofrequency Catheter Ablation
Objectives This study set out to investigate the iso-
lated impact of synchronous patterns of left ventricular
(LV) contraction (i.e., LV synchronicity) on LV twist
behavior.
Background Although the relationships between LV
loading status/LV contractility and twist are well-
established, no data are available regarding the relation
between LV twist and LV synchronicity, without any
interference by changes in LV pre-load, afterload, and
contractility. Serial assessment of patients with Wolff-
Parkinson-White syndrome before and after radio-
frequency catheter ablation (RFCA) allows this to be
explored.
Method Of the 40 Wolff-Parkinson-White patients
initially screened, 34 were enrolled. Two-dimensional and
Doppler echocardiography along with speckle tracking-
derived LV twist mechanics, apical-basal rotation delay,
and left ventricular dyssynchrony index (LVdys) were ob-
tained before and after RFCA. The LVdys was deﬁned as
the maximal delay in time-to-peak radial strain of different
LV segments at the papillary muscle level.
Results Overall, no signiﬁcant changes were demonstrated
in LV volumes, systolic and diastolic function, and end-
systolic wall stress before versus after RFCA. After
RFCA, median value of LVdys was attenuated from 33.5
(interquartile range [IQR]: 14.0 to 84.3) to 14.0 (IQR: 11.5
to 21.8) (p ¼ 0.002), which was accompanied by a reduction
in apical-basal rotation delay from 9.7% (IQR: 3.5 to 23.7)
to 3.3% (IQR: 1.3 to 8.0) (p ¼ 0.004). In contrast, LV twist
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(IQR: 15.0 to 22.6) after RFCA (p ¼ 0.002). Delta LV
twist pre- to post-RFCA displayed a signiﬁcant inverse
correlation with changes in apical-basal rotation delay
(r ¼ 0.42, p ¼ 0.01) and Delta LVdys (r ¼ 0.39, p ¼
0.02).
Conclusions The LV synchronous contraction is signiﬁ-
cantly related to LV twist (399).Platelet Inhibition by Adjunctive Cilostazol Versus
High Maintenance-Dose Clopidogrel in Patients
With Acute Myocardial Infarction According to
Cytochrome P450 2C19 Genotype
Objectives The aim of this study was to assess the degree of
platelet inhibition by adjunctive cilostazol in patients with
acute myocardial infarction (AMI) according to hepatic
cytochrome P450 2C19 (CYP2C19) genotype.
Background Although adjunctive cilostazol intensiﬁes
platelet inhibition in AMI patients, it is not established
whether this regimen can be free from the effect of
CYP2C19 loss-of-function variants (*2/*3).
Methods We randomly assigned 126 AMI patients
with available CYP2C19 genotyping to receive adjunctive
cilostazol (triple group; n ¼ 64) or high maintenance-
dose (MD) clopidogrel of 150 mg/day (high-MD
group; n ¼ 62). Using conventional aggregometry and
VerifyNow (Accumetrics Inc., San Diego, California),
platelet reactivity was measured at pre-discharge and 30-
day follow-up. Primary endpoint was change in maximal
platelet aggregation (DAggmax) between pre-discharge
and 30-day follow-up. High on-treatment platelet
reactivity (HPR) was deﬁned as 20 mmol/l adenosine
diphosphate–induced maximal platelet aggregation
(Aggmax) >59%.
Results In noncarriers, despite numerically greater inhibi-
tion by adjunctive cilostazol, changes in platelet measures
and the rate of HPR did not signiﬁcantly differ between the
2 groups. In carriers, DAggmax after 5 and 20 mmol/l
adenosine diphosphate stimuli was signiﬁcantly higher in
the triple (n ¼ 39) versus high-MD group (n ¼ 38) (21.8 
13.9% vs. 9.0  13.3%, p < 0.001, and 24.2  17.2% vs. 7.7
 15.5%, p < 0.001, respectively). Likewise, changes in late
platelet aggregation and P2Y12 reaction unit were consis-
tently greater in the triple versus high-MD group. Fewer
patients in the triple group met the criteria of HPR at 30-
day follow-up than in the high-MD group (15.4% vs.
44.7%, p ¼ 0.005).
Conclusions Compared with high-MD clopidogrel,
adjunctive cilostazol signiﬁcantly enhances platelet
inhibition and reduces the rate of HPR, especially in
AMI patients with CYP2C19 loss-of-function variants.
(Adjunctive Cilostazol Versus High Maintenance-Dose
Clopidogrel in Acute Myocardial Infarction (AMI)
Patients According to CYP2C19 Polymorphism [ACCE-
LAMI2C19]; NCT00915733) (400).High Doses of Clopidogrel to Overcome Genetic
Resistance: The Randomized Crossover CLOVIS-2
(Clopidogrel and Response Variability
Investigation Study 2)
Objectives This study sought to determine whether the
pharmacokinetic (PK) and pharmacodynamic (PD)
responses to high or standard clopidogrel loading doses
(LDs) differ according to CYP2C19*2 allele.
Background CYP2C19 loss-of-function alleles are associ-
ated with reduced responsiveness to standard clopidogrel
doses.
Methods Young post-myocardial infarction patients
heterozygous (wild type [wt]/*2, n ¼ 43) or homozygous
(*2/*2, n ¼ 8) for the CYP2C19*2 genetic variant were
matched with patients not carrying the variant (wt/wt, n ¼
58). All patients were randomized to a 300- or 900-mg
clopidogrel LD. The relative reduction in residual platelet
aggregation (RR-RPA, %) and the area under the plasma
concentration time curve of active metabolite from baseline
to 6 h after loading (AUC0-6) were compared according to
both LD and CYP2C19*2 carriage.
Results The 300-mg LD led to a gene-dose effect for RR-
RPA (65.7%  35.9% in wt/wt vs. 48.0%  38.4% in
wt/*2 vs. 14.6%  32.4% in *2/*2; overall p value ¼ 0.003,
p ¼ 0.03 for wt/wt versus wt/*2, p ¼ 0.04 for wt/*2 versus
*2/*2) with minor effect in *2/*2 carriers. After the 900-mg
LD, the effect of the CYP2C19*2 variant on platelet inhi-
bition was fully compensated in wt/*2 carriers but not in *2/
*2 carriers (83.6%  25.8% in wt/wt vs.77.2%  26.9%
in wt/*2 vs. 29.5%  26.8% in *2/*2; overall p value ¼
0.0003, p ¼ 0.20 for wt/wt versus wt/*2, p < 0.001 for wt/*2
versus *2/*2). A similar pattern was observed for the active
metabolite AUC0-6 according to carriage of CYP2C19*2 for
both LDs. There was a signiﬁcant correlation between PK
and PD responses irrespective of the LD.
Conclusions Carriers of CYP2C19*2 display signiﬁcantly
lower responses to clopidogrel with a gene-dose effect.
Clopidogrel resistance can be overcome by increasing the
dose in heterozygous carriers but not in homozygous
carriers. (Clopidogrel and Response Variability Investigation
Study 2 [CLOVIS-2]; NCT00822666) (401).
Trends, Predictors, and Outcomes of
Cerebrovascular Events Related to Percutaneous
Coronary Intervention: A 16-Year Single-Center
Experience
Objectives We sought to determine trends, predictors, in-
hospital and long-term outcomes of cerebrovascular events
(CVE) related to percutaneous coronary intervention (PCI)
over a 16-year period.
Background Despite a temporal increase in patient risk
proﬁle and procedural complexity, rates of PCI-related
mortality and myocardial infarction have decreased.
Temporal trends, characterization, and outcomes after PCI-
related CVE in the contemporary era remain unknown.
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PCI hospitalizations in 19,165 unique patients, between
January 1, 1994, and December 31, 2009, and compared
those who suffered an in-hospital PCI-CVE with the
remaining control population who did not.
Results The incidence of CVE was 0.37% (n ¼ 89), of
which 22% were transient ischemic attacks. Temporal
analysis showed no signiﬁcant trend in incidence over 16
years (p ¼ 0.47). Multiple clinical and angiographic
predictors of PCI-CVE were identiﬁed. Multivariate logistic
regression analyses revealed age, female sex, myocardial
infarction within 7 days before PCI, and history of prior
CVE as independent predictors of PCI-CVE, with a 19-
fold increase in incidence in patients over 80 with a prior
CVE history. In-hospital mortality was 19% after PCI-CVE
versus 2% in controls (p < 0.001). Those who survived PCI-
CVE exhibited a markedly higher risk of mortality over the
subsequent 10 years (p < 0.001).
Conclusions The incidence of PCI-related CVE has
remained steady over a 16-year period, despite an increase in
the baseline risk proﬁle. Age and prior history of CVE were
the strongest independent demographic predictors. PCI-
CVE had a markedly adverse impact on early and late
outcomes (402).Randomized Comparison of a Polymer-Free
Sirolimus-Eluting Stent Versus a Polymer-Based
Paclitaxel-Eluting Stent in Patients With Diabetes
Mellitus: The LIPSIA Yukon Trial
Objectives The objective of the study was to assess non-
inferiority of the polymer-free sirolimus-eluting Yukon
Choice stent (Translumina GmbH, Hechingen, Germany)
compared with the polymer-based Taxus Liberté stent
(Boston Scientiﬁc, Natick, Massachusetts) with regard to
the primary endpoint, in-stent late lumen loss, at 9 months
in patients with diabetes mellitus.
Background The Yukon Choice stent has been evaluated
in several randomized controlled trials before, albeit to date,
there has been no trial that exclusively enrolled patients with
diabetes mellitus.
Methods Patients with diabetes mellitus undergoing percu-
taneous coronary intervention for clinically signiﬁcant de novo
coronary artery stenosis were randomized 1:1 to receive either
the polymer-free sirolimus-eluting Yukon Choice stent or the
polymer-based paclitaxel-eluting Taxus Liberté stent.
Results A total of 240 patients were randomized. Quanti-
tative coronary angiography was available for 79% of patients.
Mean in-stent late lumen loss was 0.63  0.62 mm for the
Yukon Choice stent and 0.45  0.60 mm for the Taxus
Liberté stent. Based on the pre-speciﬁed margin, the Yukon
Choice stent failed to show noninferiority for the primary
endpoint. During follow-up, there were no signiﬁcant differ-
ences between groups regarding death, myocardial infarction,
stent thrombosis, target lesion revascularization, target vessel
revascularization, or nontarget vessel revascularization.Conclusions Compared with the Taxus Liberté stent, the
polymer-free sirolimus-eluting Yukon Choice stent failed to
show noninferiority with regard to the primary endpoint, in-
stent late lumen loss, in patients with diabetes mellitus after
9-month follow-up. Both stents showed comparable clinical
efﬁcacy and safety. (Yukon Choice Versus Taxus Liberté in
Diabetes Mellitus; NCT00368953) (403).
First-in-Human Evaluation of a Novel Robotic-
Assisted Coronary Angioplasty System
Objectives We aimed to evaluate the safety and feasibility
of a robotic angioplasty system in delivery and manipulation
of coronary guidewires, balloons, and stents in patients
undergoing elective percutaneous coronary intervention
(PCI).
Background A remote-control, robotic-assisted angioplasty
system is under development to address some of the
procedural challenges and occupational hazards associated
with traditional PCI.
Methods Patients with coronary artery disease and clinical
indication for elective PCI were enrolled. The coronary
angioplasty procedure was performed with the CorPath 200
robotic system (Corindus, Inc., Natick, Massachusetts). The
system consists of a remote interventional cockpit and
a multicomponent bedside unit that enables the operator to
advance, retract, and rotate guidewires and rapid exchange
catheters. The primary endpoint was device clinical success
(30% residual stenosis) without in-hospital major adverse
cardiac events. Technical success was deﬁned as the ability of
the system to complete all the planned angioplasty steps on
the basis of procedural segments. Patients were followed up
to 30 days after angioplasty procedure.
Results A total of 8 patients were enrolled in the study.
The primary endpoint was achieved in all patients (100%).
The technical success of the robotic system was 97.9% in
completing 47 of 48 planned steps. There were no device- or
procedure-related complications and no in-hospital or 30-
day major adverse cardiac events. The operators rated the
robotic system performances as equal to or better than
manual procedures in 97.5% of the cases. The operator
radiation exposure was 97% lower than the levels found at
the standard table position.
Conclusions Early clinical experience with a robotic-
assisted angioplasty system demonstrated feasibility, safety,
and procedural effectiveness comparable to manual opera-
tion. In addition, the total operator exposure to radiation
was signiﬁcantly low. A larger study is warranted to verify
the safety and effectiveness of robotic-assisted percutaneous
coronary intervention (404).
Impact of Bleeding on Subsequent Early and Late
Mortality After Drug-Eluting Stent Implantation
Objectives The aim of this study was to assess the impact
of early and late bleeding on subsequent mortality after
drug-eluting stent (DES) implantation.
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bleeding after DES implantation.
Methods With a time-updated Cox model, the impact of
bleeding and myocardial infarction (MI) on 3-year mortality
was analyzed in 3,148 consecutive patients who underwent
DES implantation for coronary disease.
Results Bleeding, deﬁned according to STEEPLE (Safety
and Efﬁcacy of Enoxaparin in PCI Patients, an Interna-
tional Randomized Evaluation) minor or major criteria,
occurred in 6.5% of patients over 3 years. Patients with
bleeding were older; were more likely to be female; had
higher rates of diabetes mellitus, hypertension, and extensive
coronary disease and lower ventricular function; and
underwent more complex procedures than those without
bleeding. The 3-year adjusted hazard ratios (HRs) for
mortality were 5.81 (95% conﬁdence interval [CI]: 3.92 to
8.60; p < 0.001) for patients with bleeding and 2.53 (95%
CI: 1.62 to 3.96; p < 0.001) for patients with MI. When the
timings of events were separated, the HRs for mortality were
4.89 (95% CI: 3.08 to 7.78; p < 0.001) and 7.81 (95% CI:
4.39 to 13.89; p < 0.001) for patients with bleeding within
and after 30 days, respectively. By contrast, the HRs for
mortality were 1.85 (95% CI: 1.09 to 3.14, p ¼ 0.022) and
10.33 (95% CI: 4.91 to 21.75, p < 0.001) for patients with
MI within and after 30 days, respectively.
Conclusions Bleeding is closely associated with mortality
during both the early and late periods after DES implan-
tation. Therefore, in addition to carefully assessing bleeding
after stenting, evidence-based treatment should be imple-
mented to offer the best balance of beneﬁt and harm (405).The Prognostic Utility of the SYNTAX Score on
1-Year Outcomes After Revascularization With
Zotarolimus- and Everolimus-Eluting Stents: A
Substudy of the RESOLUTE All Comers Trial
Objectives This study assessed the ability of the SYNTAX
score (SXscore) to stratify risk in patients treated with
percutaneous coronary intervention (PCI) using
zotarolimus-eluting or everolimus-eluting stents.
Background The SXscore can identify patients treated with
PCI who are at highest risk of adverse events.
Methods The SXscore was calculated prospectively in
2,033 of the 2,292 patients enrolled in the RESOLUTE All
Comers study (RESOLUTE III All Comers Trial: A
Randomized Comparison of a Zotarolimus-Eluting Stent
With an Everolimus-Eluting Stent for Percutaneous Coro-
nary Intervention). Clinical outcomes in terms of a patient-
oriented composite endpoint (POCE) of all-cause death,
myocardial infarction (MI), and repeat revascularization;
the individual components of POCE; target lesion failure
(TLF) (a composite of cardiac death, target-vessel MI, and
clinically driven target lesion revascularization); and stent
thrombosis were subsequently stratiﬁed according to SXscore
tertiles: SXscoreLOW 9 (n ¼ 698), 9 <SXscoreMID 17
(n ¼ 676); SXscoreHIGH >17 (n ¼ 659).Results At 12-month follow-up, rates of POCE, MI,
repeat revascularization, TLF, and the composite of death/
MI were all signiﬁcantly higher in patients in the highest
SXscore tercile. Rates of stent thrombosis were all highest in
the SXscoreHIGH tertile (p > 0.05). After multivariate
adjustment, the SXscore was identiﬁed as an independent
predictor of POCE, MI, repeat revascularization, and TLF
(p < 0.05 for all). At 12-month follow-up, the SXscore,
ACEF score, and Clinical SXscore had C-statistics of 0.57,
0.78, and 0.67, respectively, for mortality and of 0.62, 0.56,
0.63, respectively, for POCE. No signiﬁcant between-stent
differences were observed for TLF or POCE in any of the
SXscore tertiles.
Conclusions The SYNTAX score is able to stratify risk
amongst an all-comers population treated with PCI with
second-generation drug-eluting stents (DES); however,
improvements can be made with the inclusion of clinical
variables. (RESOLUTE III All Comers Trial: A
Randomized Comparison of a Zotarolimus-Eluting Stent
With an Everolimus-Eluting Stent for Percutaneous
Coronary Intervention; NCT00617084) (406).Clopidogrel and Proton Pump Inhibitors: Inﬂuence
of Pharmacological Interactions on Clinical
Outcomes and Mechanistic Explanations
Dual antiplatelet therapy with aspirin and clopidogrel is
associated with a signiﬁcant reduction in vascular ischemic
events; however, gastrointestinal bleeding events are a major
concern in high-risk and older patients. Clinical practice
guidelines recommend combination therapy with proton
pump inhibitors (PPI) and dual antiplatelet therapy to
attenuate gastrointestinal bleeding risk. In addition, high
on-treatment platelet reactivity has been associated with
recurrent ischemic events. Whether or not the pharmaco-
logical interaction between clopidogrel and PPI, which
results in diminished antiplatelet effect, adversely inﬂuences
clinical efﬁcacy is highly controversial and the subject of
debate. Based on largely anecdotal post-hoc analyses, the
U.S. Federal Drug Administration’s and European Medi-
cines Agency’s recommendations discourage PPI use
(particularly omeprazole) in patients treated with clopidog-
rel. However, many American College of Cardiology/
American Heart Association/Society for Cardiovascular
Angiography and Interventions experts do not support
change in clinical practice guidelines recommendations
without adequately powered, prospective, randomized clin-
ical trial data (407).Prasugrel Overcomes High On-Clopidogrel Platelet
Reactivity Post-Stenting More Effectively Than
High-Dose (150-mg) Clopidogrel: The Importance of
CYP2C19*2 Genotyping
Objectives The primary aim of the study was to determine
the antiplatelet effects of prasugrel versus high-dose
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reactivity (HTPR) after percutaneous coronary intervention
(PCI) and, secondarily, their relation to cytochrome (CYP)
2C19*2 carriage.
Background High on-treatment platelet reactivity after
clopidogrel administration after PCI is linked to the loss-of-
function CYP2C19*2 allele and accompanied by an increased
risk of adverse events.
Methods We performed a prospective, randomized, single-
blind, crossover study of platelet inhibition by prasugrel 10
mg/day versus high-dose 150 mg/day clopidogrel in 71 (of
210 screened; 33.8%) post-PCI patients with HTPR.
Platelet function was assessed by the VerifyNow assay
(Accumetrics, San Diego, California), and real-time poly-
merase chain reaction genotyping was performed for
CYP2C19*2 carriage.
Results The primary endpoint of platelet reactivity
(measured in platelet reactivity units) at the end of the 2
treatment periods was lower after prasugrel compared with
clopidogrel (least-squares estimates 129.4, 95% conﬁdence
interval [CI]: 111.1 to 147.7 versus 201.7, 95% CI: 183.2 to
220.2; p < 0.001). The least-squares mean difference
between the 2 treatments was 122.9 (95% CI: 166.7
to 79.2, p < 0.001), and 47.5 (95% CI: 79.5 to 15.4,
p ¼ 0.004), in carriers and noncarriers of at least 1 mutant
allele, respectively. The HTPR rates were lower for prasugrel
than for clopidogrel, in all patients (7.5% vs. 35.8%, p <
0.001), in carriers (5.3% vs. 47.4%, p ¼ 0.007), and in
noncarriers (8.8% vs. 29.4%, p ¼ 0.005), respectively.
Conclusions In patients with HTPR after PCI, prasugrel is
more effective compared with high clopidogrel in reducing
platelet reactivity, particularly in CYP2C19*2 carriers. Gen-
otyping guidance might be helpful only in case an increased
clopidogrel maintenance dose is considered. (Prasugrel
Versus High Dose Clopidogrel in Clopidogrel Resistant
Patients Post Percutaneous Coronary Intervention (PCI);
NCT01109784) (408).Enhanced Prediction of Mortality After
Percutaneous Coronary Intervention by
Consideration of General and Neurological
Indicators
Objectives This study sought to improve methodology for
predicting post–percutaneous coronary intervention (PCI)
mortality.
Background Recently, an increased proportion of post-PCI
deaths caused by noncardiac causes has been suggested,
often in rapidly triaged patients resuscitated from sudden
cardiac death or presenting with cardiogenic shock. Older
risk adjustment algorithms may not adequately reﬂect these
issues.
Methods Consecutive patients undergoing PCI from 2000
to 2009 were randomly divided into training (n ¼ 8,966)
and validation (n ¼ 8,891) cohorts. The 2010 ACC-NCDR
(American College of Cardiology–National CardiovascularData Registry) mortality algorithm was applied to the
training cohort and its highest risk decile, separately. Vari-
ables describing general and neurological status at admission
were then tested for their additional predictive capability and
new algorithms developed. These were tested in the vali-
dation cohort, using receiver-operator characteristic curve,
Hosmer-Lemeshow, and reclassiﬁcation measures as prin-
cipal outcome measures.
Results In-hospital mortality was 1.0%, of which 52.2%
had noncardiac causes or major contributions. Baseline
model C-statistics for the total and upper decile training
cohorts were 0.904 and 0.830. The Aldrete score (address-
ing consciousness, respiration, skin color, muscle function,
and circulation) and neurology scores added incremental
information, resulting in improved validation cohort C-
statistics (entire group: 0.883 to 0.914, p < 0.001; high-risk
decile: 0.829 to 0.874, p < 0.001). Reclassiﬁcation of the
ACC-NCDR <90th and 90th risk percentiles by the new
score yielded improved mortality prediction (p < 0.001 and
p ¼ 0.033, respectively).
Conclusions Half of in-hospital deaths in this series were
of noncardiac causation. Prediction of in-hospital mortality
after PCI can be considerably improved over conventional
models by the inclusion of variables describing general and
neurological status (409).Stent Thrombosis and Bleeding Complications
After Implantation of Sirolimus-Eluting Coronary
Stents in an Unselected Worldwide Population:
A Report From the e-SELECT (Multi-Center Post-
Market Surveillance) Registry
Objectives The aim of this study was to ascertain the
1-year incidence of stent thrombosis (ST) and major
bleeding (MB) in a large, unselected population treated with
sirolimus-eluting stents (SES).
Background Stent thrombosis and MB are major potential
complications of drug-eluting stent implantation. Their
relative incidence and predisposing factors among large
populations treated worldwide are unclear.
Methods The SES were implanted in 15,147 patients
who were entered in a multinational registry. We an-
alyzed the incidence of: 1) deﬁnite and probable ST as
deﬁned by the Academic Research Consortium; and 2)
MB, with the STEEPLE (Safety and efﬁcacy of Enox-
aparin in PCI) deﬁnition, together with their relation to
dual antiplatelet therapy (DAPT) and to 1-year clinical
outcomes.
Results The mean age of the sample was 62  11 years,
30.4% were diabetic, 10% had a Charlson comorbidity
index 3, and 44% presented with acute coronary
syndrome or myocardial infarction. At 1 year, the reported
compliance with DAPT as recommended by the European
Society of Cardiology guidelines was 86.3%. Adverse event
rates were: ST 1.0%, MB 1.0%, mortality 1.7%, myocar-
dial infarction 1.9%, and target lesion revascularization
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and 4 correlates of MB. Advanced age and a high
Charlson index were associated with an increased risk of
both ST and MB. After ST, the 7-day and 1-year all-
cause mortality was 30% and 35%, respectively, versus
1.5% and 10% after MB. Only 2 of 13,749 patients
(0.015%) experienced both MB and ST during the entire
1-year follow-up period.
Conclusions In this worldwide population treated with 1
SES, the reported compliance with DAPT was good, and
the incidence of ST and MB was low. Stent thrombosis and
MB very rarely occurred in the same patient. (The e-
SELECT Registry: a Multicenter Post-Market Surveillance;
NCT00438919) (410).Composition of Coronary Thrombus in Acute
Myocardial Infarction
Objectives We sought to analyze the composition of
coronary thrombus in vivo in ST-segment elevation
myocardial infarction (STEMI) patients.
Background The dynamic process of intracoronary
thrombus formation in STEMI patients is poorly
understood.
Methods Intracoronary thrombi (n ¼ 45) were obtained by
thromboaspiration in 288 consecutive STEMI patients
presenting for primary percutaneous intervention, and
analyzed using high-deﬁnition pictures taken with a scan-
ning electron microscope. Plasma biomarkers (TnI, CRPus,
IL-6, PAI-1, sCD40 ligand, and TNF-a) and plasma ﬁbrin
clot viscoelastic properties were measured simultaneously on
peripheral blood.
Results Thrombi were mainly composed of ﬁbrin (55.9 
18%) with platelets (16.8  18%), erythrocytes (11.5 
9%), cholesterol crystals (5.2  8.4%), and leukocytes (1.3
 2.0%). The median ischemic time was 175 min
(interquartile range: 140 to 297). Ischemic time impacted
thrombi composition, resulting in a positive correlation
with intracoronary thrombus ﬁbrin content, r ¼ 0.38, p ¼
0.01, and a negative correlation with platelet content,
r ¼ 0.34, p ¼ 0.02. Thus, ﬁbrin content increased with
ischemic time, ranging from 48.4  21% (<3 h) up to
66.9  9% (>6 h) (p ¼ 0.02), whereas platelet content
decreased from 24.9  23% (<3 h) to 9.1  6% (>6 h)
(p ¼ 0.07). Soluble CD40 ligand was positively correlated
to platelet content in the thrombus (r ¼ 0.40, p ¼ 0.02)
and negatively correlated with ﬁbrin content (r ¼ 0.36;
p ¼ 0.04). Multivariate analysis indicated that ischemic
time was the only predictor of thrombus composition, with
a 2-fold increase of ﬁbrin content per ischemic hour
(adjusted odds ratio: 2.00 [95% conﬁdence interval: 1.03
to 3.7]; p ¼ 0.01).
Conclusions In acute STEMI, platelet and ﬁbrin contents
of the occlusive thrombus are highly dependent on ischemia
time, which may have a direct impact on the efﬁcacy of
drugs or devices used for coronary reperfusion (411).Incidence, Predictors, Treatment, and Long-Term
Prognosis of Patients With Restenosis After Drug-
Eluting Stent Implantation for Unprotected Left
Main Coronary Artery Disease
Objectives The aim of this study was to evaluate the
incidence, predictors, and long-term outcomes of patients
with in-stent restenosis (ISR) after percutaneous coronary
intervention (PCI) with drug-eluting stents (DES) for
unprotected left main coronary artery (LMCA) disease.
Background Few data on the clinical course and
management of patients experiencing restenosis after
DES treatment for unprotected LMCA disease have
appeared.
Methods Between February 2003 and November 2007,
509 consecutive patients with unprotected LMCA disease
underwent DES implantation, with 402 (80.1%) under-
going routine surveillance or clinically driven angiographic
follow-up. A major adverse cardiac event was deﬁned as the
composite of death, myocardial infarction (MI), or target-
lesion revascularization.
Results The overall incidence of angiographic ISR in
LMCA lesions was 17.6% (71 of 402 patients, 57 with
focal-type and 14 with diffuse-type ISR. Forty patients
(56.3%) underwent repeated PCI, 10 (14.1%) underwent
bypass surgery, and 21 (29.6%) were treated medically.
During long-term follow-up (a median of 31.7 months),
there were no deaths, 1 (2.2%) MI, and 6 (9.5%) repeated
target-lesion revascularization cases. The incidence of
major adverse cardiac event was 14.4% in the medical
group, 13.6% in the repeated PCI group, and 10.0% in the
bypass surgery group (p ¼ 0.91). Multivariate analysis
showed that the occurrence of DES-ISR did not affect the
risk of death or MI.
Conclusions The incidence of ISR was 17.7% after DES
stenting for LMCA. The long-term clinical prognosis of
patients with DES-ISR associated with LMCA stenting
might be benign, given that these patients were optimally
treated with the clinical judgment of the treating physician
(412).Severe Renal Impairment and Stroke Prevention in
Atrial Fibrillation: Implications for
Thromboprophylaxis and Bleeding Risk
The prevalence of atrial ﬁbrillation (AF) in end-stage renal
failure is high, with an increased risk of stroke among
these patients with AF compared with the AF population
without severe renal impairment. Many trials have shown
the net clinical beneﬁt of oral anticoagulation therapy for
primary and secondary prevention of stroke in patient
populations with AF. However, current stroke risk strati-
ﬁcation schemes are based on studies that have deliberately
excluded patients with severe renal impairment. Indeed,
there are no large randomized controlled trials that assess
the real risk/beneﬁt of full intensity anticoagulation in
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bleeding episodes in anticoagulated hemodialysis patients
with AF are high. These data are inﬂuenced by the lack of
appropriate monitoring, the difﬁculties in maintaining the
international normalized ratio target (variable between the
studies), and an inaccurate bleeding classiﬁcation. Thus,
the limited available data may be difﬁcult to apply to such
a heterogeneous patient population, characterized by both
an increased risk of bleeding and a hypercoagulability state,
as seen in the patient population with severe renal
impairment (413).The Pathology of Neoatherosclerosis in Human
Coronary Implants: Bare-Metal and Drug-Eluting
Stents
Objectives Human coronary bare-metal stents (BMS) and
drug-eluting stents (DES) from autopsy cases with implant
duration >30 days were examined for the presence of neo-
intimal atherosclerotic disease.
Background Neointimal atherosclerotic change (neo-
atherosclerosis) after BMS implantation is rarely reported
and usually occurs beyond 5 years. The incidence of
neoatherosclerosis after DES implantation has not been
reported.
Methods All available cases from the CVPath stent registry
(n ¼ 299 autopsies), which includes a total of 406
lesionsd197 BMS, 209 DES (103 sirolimus-eluting stents
[SES] and 106 paclitaxel-eluting stents [PES])dwith
implant duration >30 days were examined. Neo-
atherosclerosis was recognized as clusters of lipid-laden
foamy macrophages within the neointima with or without
necrotic core formation.
Results The incidence of neoatherosclerosis was signiﬁ-
cantly greater in DES lesions (31%) than BMS lesions
(16%; p < 0.001). The median stent duration with neo-
atherosclerosis was shorter in DES than BMS (DES, 420
days [interquartile range [IQR]: 361 to 683 days]; BMS,
2,160 days [IQR: 1,800 to 2,880 days], p < 0.001).
Unstable lesions characterized as thin-cap ﬁbroatheromas
or plaque rupture were more frequent in BMS (n ¼ 7, 4%)
than in DES (n ¼ 3, 1%; p ¼ 0.17), with relatively
shorter implant durations for DES (1.5  0.4 years)
compared to BMS (6.1  1.5 years). Independent deter-
minants of neoatherosclerosis identiﬁed by multiple logistic
regression included younger age (p < 0.001), longer
implant durations (p < 0.001), SES usage (p < 0.001),
PES usage (p ¼ 0.001), and underlying unstable plaques
(p ¼ 0.004).
Conclusions Neoatherosclerosis is a frequent ﬁnding in
DES and occurs earlier than in BMS. Unstable features
of neoatherosclerosis are identiﬁed for both BMS and
DES with shorter implant durations for the latter. The
development of neoatherosclerosis may be yet another
rare contributing factor to late thrombotic events (414).Can Differences in Corrected Coronary
Opaciﬁcation Measured With Computed
Tomography Predict Resting Coronary Artery Flow?
Objectives A proof-of-concept study was undertaken to
determine whether differences in corrected coronary opaci-
ﬁcation (CCO) within coronary lumen can identify arteries
with abnormal resting coronary ﬂow.
Background Although computed tomographic coronary
angiography can be used for the detection of obstructive
coronary artery disease, it cannot reliably differentiate
between anatomical and functional stenoses.
Methods Computed tomographic coronary angiography
patients (without history of revascularization, cardiac trans-
plantation, and congenital heart disease) who underwent
invasive coronary angiography were enrolled. Attenuation
values of coronary lumen were measured before and after
stenoses and normalized to the aorta. Changes in CCO were
calculated, and CCO differences were compared with severity
of coronary stenosis and Thrombolysis In Myocardial Infarc-
tion (TIMI) ﬂow at the time of invasive coronary angiography.
Results One hundred four coronary arteries (n ¼ 52, mean
age ¼ 60.0  9.5 years; men ¼ 71.2%) were assessed.
Compared with normal arteries, the CCO differences were
greater in arteries with computed tomographic coronary
angiography diameter stenoses 50%. Similarly, CCO
differences were greater in arteries with TIMI ﬂow grade <3
(0.406  0.226) compared with those with normal ﬂow
(TIMI ﬂow grade 3) (0.078  0.078, p < 0.001). With
CCO differences, abnormal coronary ﬂow (TIMI ﬂow
grade <3) was identiﬁed with a sensitivity and speciﬁcity,
positive predictive value, and negative predictive value of
83.3% (95% conﬁdence interval [CI]: 57.7 to 95.6%), 91.2%
(95% CI: 75.2% to 97.7%), 83.3% (95% CI: 57.7% to
95.6%), and 91.2% (95% CI: 75.2% to 97.7%), respectively.
Accuracy of this method was 88.5% with very good agree-
ment (kappa ¼ 0.75, 95% CI: 0.55 to 0.94).
Conclusions Changes in CCO across coronary stenoses
seem to predict abnormal (TIMI ﬂow grade <3) resting
coronary blood ﬂow. Further studies are needed to under-
stand its incremental diagnostic value and its potential to
measure stress coronary blood ﬂow (415).A Randomized, Double-Blind, Multicenter
Comparison Study of Triple Antiplatelet Therapy
With Dual Antiplatelet Therapy to Reduce
Restenosis After Drug-Eluting Stent Implantation
in Long Coronary Lesions: Results From the
DECLARE-LONG II (Drug-Eluting Stenting Followed
by Cilostazol Treatment Reduces Late Restenosis
in Patients with Long Coronary Lesions) Trial
Objectives The purpose of this study was to determine
whether cilostazol reduces intimal hyperplasia in patients
undergoing long zotarolimus-eluting stent implantation
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(length: 25 mm).
Background Restenosis after drug-eluting stent implanta-
tion remains a signiﬁcant clinical problem in long coronary
lesions.
Methods Patients (n ¼ 499) were assigned randomly to
triple (aspirin, clopidogrel, and cilostazol, triple group:
n ¼ 250) or dual antiplatelet therapy (aspirin and clo-
pidogrel and placebo, dual group: n ¼ 249) for 8
months after long zotarolimus-eluting stent implanta-
tion. The primary end point was in-stent late loss at the
8-month angiography according to the intention-to-treat
principle.
Results The 2 groups had similar baseline characteristics.
The in-stent (0.56  0.55 mm vs. 0.68  0.59 mm, p ¼
0.045) and in-segment (0.32  0.54 mm vs. 0.47  0.54
mm, p ¼ 0.006) late loss were signiﬁcantly lower in the
triple versus dual group, as were 8-month in-stent reste-
nosis (10.8% vs. 19.1%, p ¼ 0.016), in-segment restenosis
(12.2% vs. 20.0%, p ¼ 0.028), and 12-month ischemic-
driven target lesion revascularization (5.2% vs. 10.0%,
p ¼ 0.042) rates. At 12 months, major adverse cardiac
events including death, myocardial infarction, and
ischemic-driven target lesion revascularization tended to be
lower in the triple group than the dual group (7.2% vs.
12.0%, p ¼ 0.07). Percent intimal hyperplasia volume by
volumetric intravascular ultrasound analysis was reduced
from 27.1  13.2% for the dual group to 22.1  9.9% for
the triple group (p ¼ 0.017).
Conclusions Patients receiving triple antiplatelet therapy
after long zotarolimus-eluting stent implantation had
decreased extent of late luminal loss, percent intimal
hyperplasia volume, and angiographic restenosis, result-
ing in a reduced risk of 12-month target lesion revas-
cularization compared with patients receiving dual
antiplatelet therapy. (Triple Versus Dual Antiplatelet
Therapy after ABT578-Eluting Stent; NCT00589927)
(416).Clopidogrel–Drug Interactions
Multidrug therapy increases the risk for drug–drug inter-
actions. Clopidogrel, a prodrug, requires hepatic cyto-
chrome P450 (CYP) metabolic activation to produce the
active metabolite that inhibits the platelet P2Y12 adenosine
diphosphate (ADP) receptor, decreasing platelet activation
and aggregation processes. Atorvastatin, omeprazole, and
several other drugs have been shown in pharmacodynamic
studies to competitively inhibit CYP activation of clopi-
dogrel, reducing clopidogrel responsiveness. Conversely,
other agents increase clopidogrel responsiveness by
inducing CYP activity. The clinical implications of these
pharmacodynamic interactions have raised concern because
many of these drugs are coadministered to patients with
coronary artery disease. There are multiple challenges inproving that a pharmacodynamic drug–drug interaction is
clinically signiﬁcant. To date, there is no consistent
evidence that clopidogrel–drug interactions impact adverse
cardiovascular events. Statins and proton pump inhibitors
have been shown to decrease adverse clinical event rates
and should not be withheld from patients with appropriate
indications for therapy because of concern about potential
clopidogrel–drug interactions. Clinicians concerned about
clopidogrel–drug interactions have the option of
prescribing either an alternative platelet P2Y12 receptor
inhibitor without known drug interactions, or statin and
gastro-protective agents that do not interfere with clopi-
dogrel metabolism (417).Efﬁcacy of Post-Operative Clopidogrel Treatment
in Patients Revascularized With Coronary Artery
Bypass Grafting After Myocardial Infarction
Objectives The objective of this study was to examine the
clinical efﬁcacy of clopidogrel treatment on death and
recurrent myocardial infarction (MI) among MI patients
revascularized by coronary artery bypass graft surgery
(CABG).
Background The beneﬁt from post-operative clopidogrel in
CABG-treated MI patients is largely unknown.
Methods All patients admitted with ﬁrst-time MI between
2002 and 2006, treated with CABG within 180 days after
admission, were identiﬁed by nationwide administrative
registers. Clopidogrel treatment was determined by claimed
prescriptions after discharge from surgery. Risk of death or
recurrent MI, and of a combined end point of the 2, were
assessed by cumulative incidence and Cox proportional
hazards model. A propensity score-matched subgroup
analysis was done.
Results We included 3,545 patients, and of these, 957
(27.0%) were treated with clopidogrel after CABG. Mean
follow-up was 466  144 days. Among patients treated
with clopidogrel, 39 (4.1%) died or experienced a recur-
rent MI, whereas that occurred in 203 (7.8%) patients
without clopidogrel (log-rank p ¼ 0.0003). Hazard ratio
was 0.59 (95% conﬁdence interval [CI]: 0.42 to 0.85) for
patients treated with clopidogrel, with no-clopidogrel as
reference. By propensity score, of 945 patients with or
without clopidogrel treatment who were matched, death
or recurrent MI occurred in 38 (4.0%) patients with
clopidogrel and 57 (6.0%) without clopidogrel (log-rank
p ¼ 0.05). Corresponding hazard ratio was 0.67 (95%
CI: 0.44 to 1.00) for clopidogrel users, with no-
clopidogrel as reference.
Conclusions Among MI patients revascularized by
CABG, only 27% received clopidogrel after discharge.
Clopidogrel-treated patients had a lower risk of the
combined end point of death or recurrent MI. Focus on
discharge clopidogrel treatment of these patients should be
made (418).
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Inhibitors During Elective Coronary
Revascularization: A Meta-Analysis of Randomized
Trials Performed in the Era of Stents and
Thienopyridines
Objectives The purpose of this study was to investigate the
efﬁcacy and safety of glycoprotein IIb/IIIa inhibitors (GPIs)
during elective percutaneous coronary intervention (PCI).
Background Studies have documented that GPIs are useful
during PCI; however, much of this research was conducted
before the routine use of coronary stents and
thienopyridines.
Methods We searched the MEDLINE, Cochrane clinical
trials, and ClinicalTrials.gov databases from inception for
studies that randomly assigned patients undergoing elective
PCI to a GPI versus control. Trials were included if stents
and thienopyridines were used routinely and clinical
outcomes were reported. Outcomes were assessed within 30
days. A DerSimonian-Laird model was used to construct
random effects summary risk ratios (RRs) and 95% conﬁ-
dence intervals (CIs).
Results Our search yielded 22 studies with 10,123 patients.
The incidence of nonfatal myocardial infarction was 5.1%
with GPI versus 8.3% with control (RR: 0.66, 95% CI: 0.55
to 0.79, p < 0.0001). Major bleeding was 1.2% versus 0.9%
(RR: 1.37, 95% CI: 0.83 to 2.25, p ¼ 0.22), minor bleeding
was 3.0% versus 1.7% (RR: 1.70, 95% CI: 1.28 to 2.26, p <
0.0001), and mortality was 0.3% versus 0.5% (RR: 0.70, 95%
CI: 0.36 to 1.33, p ¼ 0.27), respectively.
Conclusions In the current era of elective PCI performed
with stents and thienopyridines, GPIs provide clinical
beneﬁt. These agents reduce nonfatal myocardial infarction
without a notable increase in major bleeding; however, they
increase the risk of minor bleeding. All-cause mortality is
not reduced (419).
Effects of Aspirin Responsiveness and Platelet
Reactivity on Early Vein Graft Thrombosis After
Coronary Artery Bypass Graft Surgery
Objectives The purpose of this study was to determine if an
incomplete response to or inadequate antiplatelet effect of
aspirin, or both, contribute to saphenous vein graft (SVG)
occlusion after coronary artery bypass graft (CABG) surgery.
Background Thrombosis is the predominant cause of early
SVG occlusion. Aspirin, which inhibits cyclooxygenase-1
activity and thromboxane generation in platelets, reduces
early SVG occlusion by one-half.
Methods Aspirin responsiveness and platelet reactivity were
characterized 3 days and 6 months after coronary artery
bypass graft surgery in 229 subjects receiving aspirin mon-
otherapy by platelet aggregation to arachidonic acid, aden-
osine diphosphate, collagen and epinephrine, Platelet
Function Analyzer-100 (Siemens Healthcare Diagnostics,
Newark, Delaware) closure time (CT) using collagen/
epinephrine agonist cartridge and collagen/adenosinediphosphate (CADP) agonist cartridge, VerifyNow Aspirin
assay (Accumetrics, Inc., San Diego, California), and urine
levels of 11-dehydro-thromboxane B2 (UTXB2). SVG
patency was determined 6 months after surgery by computed
tomography coronary angiography.
Results Inhibited arachidonic acid-induced platelet aggre-
gation, indicative of aspirin-mediated cyclooxygenase-1
suppression, occurred in 95% and >99% of subjects 3 days
and 6 months after surgery, respectively. Despite this, 73%
and 31% of subjects at these times had elevated UTXB2.
Among tested parameters, only UTXB2 and CADP CT
measured 6 months after surgery correlated with outcome.
By multivariate analysis, CADP CT of 88 s (odds ratio:
2.85, p ¼ 0.006), target vessel diameter of 1.5 mm (odds
ratio: 2.38, p ¼ 0.01), and UTXB2 of 450 pg/mg creati-
nine (odds ratio: 2.59, p ¼ 0.015) correlated with SVG
occlusion. CADP CT and UTXB2 in combination further
identiﬁed subjects at particularly high and low risk for SVG
occlusion.
Conclusions Aspirin-insensitive thromboxane generation
measured by UTXB2 and shear-dependent platelet hyper-
reactivity measured by Platelet Function Analyzer-
100 CADP CT are novel independent risk factors for
early SVG thrombosis after coronary artery bypass graft
surgery (420).The Valve-in-Valve Technique for Treatment of
Aortic Bioprosthesis Malposition: An Analysis of
Incidence and 1-Year Clinical Outcomes From the
Italian CoreValve Registry
Objectives We appraised the incidence and clinical
outcomes of patients who were treated with the valve-in-
valve (ViV) technique for hemodynamically destabilizing
paraprosthetic leak (PPL).
Background Device malpositioning causing severe PPL
after transcatheter aortic valve implantation is not an
uncommon ﬁnding. It occurs after release of the prosthesis,
leading to hemodynamic compromise. It can be managed
successfully in selected cases with implantation of a second
device inside the malpositioned primary prosthesis (ViV
technique).
Methods Consecutive patients (n ¼ 663) who underwent
transcatheter aortic valve implantation with the 18-F Cor-
eValve ReValving System (Medtronic, Inc., Minneapolis,
Minnesota) at 14 centers across Italy were included in this
prospective web-based registry. We identiﬁed patients treated
with the ViV technique for severe PPL and analyzed their
clinical and echocardiographic outcomes. Primary end points
were major adverse cerebrovascular and cardiac events and
prosthesis performance at the 30-day and midterm follow-up.
Results Overall procedural success was obtained in 650
patients (98.0%). The ViV technique was used in 24 (3.6%)
of 663 patients. The 30-day major adverse cerebrovascular
and cardiac event rates were 7.0% and 0% in patients
undergoing the standard procedure and ViV technique,
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0% in patients undergoing the standard procedure and ViV
technique, respectively (p ¼ 0.238). There was an
improvement in the mean transaortic gradient in all patients
without signiﬁcant difference between the 2 groups (from
52.1  17.1 mm Hg and 45.4  14.8 mm Hg [p ¼ 0.060]
to 10.1  4.2 mm Hg and 10.5  5.2 mm Hg, respectively
[p ¼ 0.838]). At 12 months, the major adverse cerebro-
vascular and cardiac event rates in the standard procedure
and ViV technique groups were 4.5% and 14.1%, respec-
tively (p ¼ 0.158), and the mortality rates were 4.5% versus
13.7%, respectively (p ¼ 0.230).
Conclusions This large, multicenter registry provides
important information about the feasibility, safety, and efﬁ-
cacy of the ViV technique with the third-generation Cor-
eValve ReValving System. The clinical and echocardiographic
end points compare favorably with those of patients under-
going the standard procedure. The ViV technique offers
a viable therapeutic option in patients with acute signiﬁcant
PPL without recourse to emergent surgery (421).Contrast-Enhanced C-Arm CT Evaluation of
Radiofrequency Ablation Lesions in the Left
Ventricle
Objectives The purpose of this study was to evaluate use of
cardiac C-arm computed tomography (CT) in the assess-
ment of the dimensions and temporal characteristics of
radiofrequency ablation (RFA) lesions. This imaging
modality uses a standard C-arm ﬂuoroscopy system rotating
around the patient, providing CT-like images during the
RFA procedure.
Background Both cardiac magnetic resonance (CMR) and
CT can be used to assess myocardial necrotic tissue. Several
studies have reported visualizing cardiac RFA lesions with
CMR; however, obtaining CMR images during interven-
tional procedures is not common practice. Direct visualiza-
tion of RFA lesions using C-arm CT during the procedure
may improve outcomes and circumvent complications
associated with cardiac ablation procedures.
Methods RFA lesions were created on the endocardial
surface of the left ventricle of 9 swine using a 7-F RFA
catheter. An electrocardiographically gated C-arm CT
imaging protocol was used to acquire projection images
during iodine contrast injection and after the injection every
5 min for up to 30 min, with no additional contrast.
Reconstructed images were analyzed ofﬂine. The mean and
SD of the signal intensity of the lesion and normal
myocardium were measured in all images in each time series.
Lesion dimensions and area were measured and compared in
pathologic specimens and C-arm CT images.
Results All ablation lesions (n ¼ 29) were visualized
and lesion dimensions, as measured on C-arm CT,
correlated well with postmortem tissue measurements (linear
dimensions: concordance correlation ¼ 0.87; area: concor-
dance correlation ¼ 0.90. Lesions were visualized asa perfusion defect on ﬁrst-pass C-arm CT images with
a signal intensity of 95 HU lower than that of normal
myocardium (95% conﬁdence interval: 111 HU to 79
HU). Images acquired at 1 and 5 min exhibited an
enhancing ring surrounding the perfusion defect in 24
lesions (83%).
Conclusions RFA lesion size, including transmurality, can
be assessed using electrocardiographically gated cardiac C-
arm CT in the interventional suite. Visualization of RFA
lesions using cardiac C-arm CT may facilitate the assess-
ment of adequate lesion delivery and provide valuable
feedback during cardiac ablation procedures (422).Global Risk Classiﬁcation and Clinical SYNTAX
(Synergy between Percutaneous Coronary
Intervention with TAXUS and Cardiac Surgery)
Score in Patients Undergoing Percutaneous or
Surgical Left Main Revascularization
Objectives The aim of this study was to investigate the
ability to predict cardiac mortality of the Global Risk
Classiﬁcation (GRC) and the Clinical SYNTAX (Synergy
between Percutaneous Coronary Intervention with TAXUS
and Cardiac Surgery) score (CSS) in left main (LM) patients
undergoing percutaneous coronary intervention (PCI) or
coronary artery bypass graft (CABG).
Background There is a renewed interest in combining
clinical and angiographic information to deﬁne the risk of
patients undergoing LM revascularization.
Methods The GRC and CSS were assessed in patients
undergoing LM PCI (n ¼ 400) or CABG (n ¼ 549).
Stand-alone clinical (ACEF [age, creatinine, ejection frac-
tion]), EuroSCORE (European System for Cardiac Oper-
ative Risk Evaluation) and angiographic (SYNTAX score)
risk scores were also investigated.
Results The GRC (Hosmer-Lemeshow statistic 0.357,
p ¼ 0.550; area under the curve 0.743) and the ACEF
(Hosmer-Lemeshow 0.426, p ¼ 0.514; area under the curve
0.741) showed the most balanced predictive characteristics
in the PCI and CABG cohorts, respectively. In PCI
patients, the CSS used fewer data to achieve similar
discrimination but poorer calibration than the GRC.
Propensity-adjusted outcomes were comparable between
PCI and CABG patients with low, intermediate, or high
EuroSCORE, ACEF, GRC, and CSS and those with low
or intermediate SYNTAX score. Conversely, in the group
with the highest SYNTAX score, the risk of cardiac
mortality was signiﬁcantly higher in PCI patients (hazard
ratio: 2.323, 95% conﬁdence interval: 1.091 to 4.945, p ¼
0.029).
Conclusions In LM patients undergoing PCI, combined
scores improve the discrimination accuracy of clinical or
angiographic stand-alone tools. In LM patients undergoing
CABG, the ACEF score has the best prognostic accuracy
compared with other stand-alone or combined scores. The
good predictive ability for PCI along with the poor
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preferable decision-making tool in LM disease (423).
Clinical Determinants of Radiation Dose in
Percutaneous Coronary Interventional Procedures:
Inﬂuence of Patient Size, Procedure Complexity,
and Performing Physician
Objectives The Objectives of this work were to establish
the primary clinical determinants of patient radiation dose
associated with percutaneous coronary interventional (PCI)
and to identify opportunities for dose reduction.
Background Use of X-ray imaging and associated radiation
dose is a necessary part of PCI. Potential adverse conse-
quences of radiation dose include skin radiation injury and
predicted increase in lifetime cancer risk.
Methods Cumulative skin dose (CSD) (measured in
gray [Gy] units) was selected as a measurement of pa-
tient radiation burden. Several patient-, disease-, and
treatment-related variables, including 15 performing
physicians, were analyzed in a multiple linear regression
statistical model with cumulative skin dose CSD as the
primary end point. The model results provide an estimate
of the relative CSD increase (decrease) attributable to
each variable.
Results Percutaneous coronary interventions performed
on 1,287 male and 540 female patients were included.
Median patient age was 68.6 years, median body mass
index was 29.7 kg/m2, and median weight was 88 kg.
Median CSD was 1.64 Gy per procedure for male and
1.15 Gy for female patients. Increasing body mass index,
patient sex, lesion complexity, lesion location, and per-
forming physician were signiﬁcantly associated with CSD.
Physicians who performed more procedures were associ-
ated with lower CSD.
Conclusions Several primary determinants of patient
radiation dose during PCI were identiﬁed. Along with
physician development of radiation-sparing methods and
skills, pre-procedure dose planning is proposed to help
minimize radiation dose for PCI (424).
Plasma High-Mobility Group Box 1 Levels Predict
Mortality After ST-Segment Elevation Myocardial
Infarction
Objectives We evaluated the potential association between
plasma high-mobility group box 1 (HMGB1) levels and
outcome in patients with ST-segment elevation myocardial
infarction (STEMI) treated with primary percutaneous
coronary intervention.
Background The positive effect of reperfusion after
STEMI may be compromised by ischemic/reperfusion
injury. HMGB1 is released by necrotic cells and, in pre-
clinical studies, has been implicated to play a role in
myocardial ischemic/reperfusion injury.
Methods The study included 141 STEMI patients, with
acute occlusion of the left anterior descending coronaryartery successfully treated with percutaneous coronary
intervention. Plasma HMGB1 levels were measured by
enzyme-linked immunoadsorbent assay at admission. Forty-
two healthy individuals served as control subjects.
Results After a median of 10 months of follow-up, 13
STEMI patients died. There were no signiﬁcant differ-
ences with regard to baseline variables between the group
of patients who survived and those who died. Baseline
HMGB1 levels were increased in STEMI patients when
compared with control subjects. Furthermore, the STEMI
patients who died had higher HMGB1 levels than those
who survived. After adjusting for age, sex, troponin I, and
creatine kinase-myocardial band, we found that a doubling
of HMGB1 concentrations increased the risk of mortality
by 75% (hazard ratio: 1.75; 95% conﬁdence interval: 1.1
to 2.8).
Conclusions Plasma HMGB1 levels are elevated in
STEMI patients compared with healthy control subjects.
Furthermore, after a follow-up period of 10 months,
plasma HMGB1 levels are shown to be independently
associated with increased mortality in STEMI patients
treated with PCI. These data suggest that plasma
HMGB1 may be used as a new prognostic biomarker in
STEMI patients (425).Radial Artery Access as a Predictor of Increased
Radiation Exposure During a Diagnostic Cardiac
Catheterization Procedure
Objectives We sought to determine whether radial artery
access is associated with increased radiation exposure
during cardiac catheterization and whether this relation-
ship differs between operators, after adjustment for clinical
and patient characteristics associated with greater radiation
exposure.
Background Although previous studies have demonstrated
a relationship between radial access and increased radiation
exposure to the patient during ﬂuoroscopy-guided cardiac
procedures, such studies did not account for differences in
operator technique or clustering of patients, procedure
complexity, or patient size. Those studies included data from
few operators.
Methods Data were collected prospectively on 5,954
diagnostic cardiac catheterizations performed at a tertiary
cardiac center. A multilevel regression analysis was used to
determine the relationship between radial artery access and
radiation exposure.
Results After adjustment for multiple factors, radial
access was associated with increased exposure (beta ¼
0.22, p < 0.0001) when compared with the use of
femoral access, as measured using the logarithmically
transformed air kerma (LogAK). On average, radial access
accounted for a 23% increase in measured AK. This was
consistent between operators. There were observed
differences in the mean LogAK between operators (p ¼
0.0158), as well as substantial variation in measured
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(p < 0.001).
Conclusions Radial artery access cardiac catheterization was
associated with increased radiation exposure to the patient
when compared with femoral access. The measured AK was
still far below the threshold for deterministic effects in most
patients studied. Observed variations in AK between and
within operators may point to better opportunities to reduce
exposure (426).Off-Hour Primary Percutaneous Coronary
Angioplasty Does Not Affect Outcome of
Patients With ST-Segment Elevation Acute
Myocardial Infarction Treated Within a Regional
Network for Reperfusion: The REAL (Registro
Regionale Angioplastiche dell’Emilia-Romagna)
Registry
Objectives This study aims to evaluate whether results
of “off-hours” and “regular-hours” primary angioplasty
(primary percutaneous coronary intervention [pPCI]) are
comparable in an unselected population of patients with ST-
segment elevation acute myocardial infarction treated within
a regional network organization.
Background Conﬂicting results exist on the outcome of
off-hours pPCI.
Methods We analyzed in-hospital and 1-year cardiac
mortality among 3,072 consecutive ST-segment elevation
myocardial infarction (STEMI) patients treated with pPCI
between January 1, 2004, and June 30, 2006, during regular-
hours (weekdays 8:00 AM to 8:00 PM) and off-hours
(weekdays 8:01 PM to 7:59 AM, weekends, and holidays)
within the STEMI Network of the Italian Region Emilia-
Romagna (28 hospitals: 19 spoke and 9 hub interventional
centers).
Results Fifty-three percent of patients were treated off-
hours. Baseline ﬁndings were comparable, although
regular-hours patients were older and had more inci-
dences of multivessel disease. Median pain-to-balloon
(195 min, interquartile range [IQR]: 140 to 285 vs.
186 min, IQR: 130 to 280 min; p ¼ 0.03) and door-to-
balloon time (88 min, IQR: 60 to 122 vs. 77 min, IQR:
48 to 116 min; p < 0.0001) were longer for off-hours
pPCI. However, unadjusted in-hospital (5.8% off-hours
vs. 7.2% regular-hours, p ¼ 0.11) and 1-year cardiac
mortality (8.4% off-hours vs. 10.3% regular-hours, p ¼
0.08) were comparable. At multivariate analysis, off-hours
pPCI did not predict an adverse outcome either for the
overall population (odds ratio [OR]: 0.70, 95% conﬁ-
dence interval [CI]: 0.49 to 1.01) or for patients directly
admitted to the interventional center (OR: 0.79, 95% CI:
0.52 to 1.20).
Conclusions When pPCI is performed within an efﬁcient
STEMI network focused on reperfusion, the clinical effec-
tiveness of either off-hours or regular-hours pPCI is
comparable (427).5-Year Follow-Up of Polytetraﬂuoroethylene-
Covered Stents Compared With Bare-Metal Stents
in Aortocoronary Saphenous Vein Grafts: The
Randomized BARRICADE (Barrier Approach to
Restenosis: Restrict Intima to Curtail Adverse
Events) Trial
Objectives We sought to evaluate the utility of the JOS-
TENT polytetraﬂuoroethylene (PTFE) stent-graft (Jomed
GmbH, Rangendingen, Germany) in patients with diseased
saphenous vein grafts (SVGs) undergoing percutaneous
coronary intervention (PCI).
Background Prior trials of the JOSTENT stent-graft did
not mandate high-pressure implantation or prolonged dual
antiplatelet therapy, and were limited by short-term follow-
up.
Methods A total of 243 patients at 47 centers with 1 to 2
discrete lesions in SVGs were prospectively randomized to
JOSTENT implantation (18 atm.) versus bare-metal
stents (BMS). The JOSTENT patients were treated with
aspirin indeﬁnitely and clopidogrel for 8 months. Routine
angiographic follow-up was performed at 8 months, and all
patients were followed for 5 years.
Results The primary end point of in-lesion binary reste-
nosis occurred in 31.8% of lesions treated with the JOS-
TENT versus 28.4% of lesions treated with BMS (relative
risk: 1.12, 95% conﬁdence interval [CI]: 0.72 to 1.75, p ¼
0.63). At 9 months, the major secondary end point of target
vessel failure (death, myocardial infarction, or clinically
driven target vessel revascularization) occurred in 32.2% of
patients treated with the JOSTENT versus 22.1% of
patients treated with BMS (hazard ratio: 1.54, 95% CI: 0.94
to 2.53, p ¼ 0.08). During long-term follow-up, signiﬁ-
cantly more events accrued in the JOSTENT arm such that
by 5 years target vessel failure had occurred in 68.3% of
JOSTENT patients versus 51.8% of BMS patients (hazard
ratio: 1.59, 95% CI: 1.13 to 2.23, p ¼ 0.007).
Conclusions The long-term prognosis for diseased SVGs
requiring PCI is dismal. The JOSTENT PTFE stent-graft
results in inferior outcomes compared with BMS, despite
high-pressure implantation and prolonged dual antiplatelet
therapy, a ﬁnding that becomes more evident with longer-
term follow-up (428).Acute Stroke Intervention
This review summarizes the current state-of-the-art
regarding the endovascular management of acute ischemic
stroke. Beginning with intravenous tissue plasminogen
activator, this paper traces the gradual shift of systemic
thrombolysis from a competing to complementary treatment
modality. Intra-arterial thrombolysis, mechanical throm-
bectomy with the Merci (Concentric Medical, Mountain
View, California) and Penumbra (Penumbra, Inc., Alameda,
California) systems, angioplasty, primary intracranial stent-
ing, and emerging stentriever devices are sequentially
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current endovascular stroke management and considers
future areas of progress and research (429).
5-Year Follow-Up of Coronary Revascularization in
Diabetic Patients With Multivessel Coronary Artery
Disease: Insights From ARTS (Arterial
Revascularization Therapy Study)-II and ARTS-I Trials
Objectives We compared the 5-year outcomes of diabetic
patients with multivessel disease treated with sirolimus-
eluting stents (SES), bare-metal stents (BMS), and coro-
nary artery bypass graft surgery (CABG) enrolled in the
ARTS (Arterial Revascularization Therapy Study) I and II
studies.
Background Diabetes is an established risk factor for major
adverse cardiac events after revascularization. Recent trials
suggest that revascularization with drug-eluting stents has
equivalent safety to CABG up to 2 years.
Methods The ARTS I and II studies included 367 diabetic
patients (SES: 159, CABG: 96, and BMS: 112) compared
with respect to 5-year clinical outcomes.
Results The rate of major adverse cardiovascular and
cerebrovascular events was signiﬁcantly higher in patients
treated with BMS (BMS 53.6% vs. CABG 23.4% vs. SES
40.5%; log-rank, p < 0.01 for SES vs. BMS and SES vs.
CABG). There was no signiﬁcant difference in mortality
among all 3 groups. There was, however, a statistically
signiﬁcant difference in the myocardial infarction rate
between BMS and CABG arms (BMS 11.0%, CABG
5.2%, SES 4.8%, p ¼ 0.04 for SES vs. BMS and p ¼ 0.76
for SES vs. CABG). The rate of repeat revascularization was
signiﬁcantly lower in patients treated with CABG compared
with SES (SES 33.2% vs. CABG 10.7%, p < 0.001).
Revascularization rate of patients treated with SES at 5 years
approached that of patients treated with BMS although
remained signiﬁcantly lower. This “catch-up” phenomenon
was not apparent in the nondiabetic population.
Conclusions At 5-year follow-up, CABG has comparable
safety and superior efﬁcacy compared with BMS and SES in
the treatment of diabetic patients with multivessel disease
(430).
Prospective Randomized Comparison of Sirolimus-
or Everolimus-Eluting Stent to Treat Bifurcated
Lesions by Provisional Approach
Objectives This study sought to compare the procedural
performance and the acute angiographic result on side-
branch ostium obtained using 2 different drug-eluting
stents (DES) to treat patients with bifurcated coronary
lesions.
Background Drug-eluting stents are routinely used in
percutaneous coronary interventions (PCI) of bifurcated
coronary lesions. Different DES types have major technical
differences that may inﬂuence the procedural and clinical
performance in bifurcation PCI.Methods Consecutive patients with bifurcated lesions
undergoing DES implantation using a systematic
provisional-stenting strategy were randomized to sirolimus-
eluting stent (SES) or everolimus-eluting stent (EES) before
intervention. The procedural details for PCI were prospec-
tively recorded to assess the occurrence of any trouble in the
side-branch (SB) management (primary end point). Post-
PCI angiographic result (primary end point: minimal
lumen diameter at SB ostium) was evaluated ofﬂine by 3-
dimensional reconstruction and quantitative coronary anal-
ysis. Clinical outcome was prospectively recorded up to 18
months to assess the occurrence of target bifurcation failure.
Results A total of 150 patients were enrolled in the study
(29% diabetics, 17% unprotected left main). The stent was
successfully implanted according to randomization in all
cases. Procedural performance was not signiﬁcantly different
between the 2 kinds of DES. Three-dimensional recon-
struction and quantitative coronary analysis showed similar
post-PCI results in the main vessel and better results in the
SB with EES than with SES (minimal lumen diameter at
SB ostium: 1.94  0.72 mm vs. 1.64  0.62 mm; p ¼
0.013). At 18 months, target bifurcation failure occurred in
7 (9.0%) of SES-treated patients versus 8 (10.7%) of EES
patients (p ¼ 0.57).
Conclusions In patients with bifurcated lesions treated by
provisional stenting technique, EES compared with SES is
associated with similar procedural performance and better 3-
dimensional reconstruction and quantitative coronary anal-
ysis result in the SB. Both DES are associated with low rates
of major adverse events and angiographic failure. (Sirolimus
Versus Everolimus-Eluting Stent Randomized Assessment
in Bifurcated Lesions and Clinical Signiﬁcance of Residual
Side-Branch Stenosis [SEA-SIDE]; NCT00697372) (431).Impact of Lesion Sets on Mid-Term Results of
Surgical Ablation Procedure for Atrial Fibrillation
Objectives The objective of this study was to evaluate the
effects of different lesion sets of ablation in patients
undergoing mitral surgery plus maze.
Background The role of lesion sets on outcome after maze
is poorly deﬁned.
Methods A total of 141 patients were prospectively fol-
lowed up. Two different lesion sets were prepared: 32
patients underwent a radiofrequency left atrial lesion set of
maze (“limited”), and 109 had combined left and right atrial
lesion sets of maze  ganglionic plexi isolation (“extensive”).
A longitudinal observational study assessed the role of
“extensive” versus “limited” ablation on atrial ﬁbrillation
(AF), New York Heart Association (NYHA) functional
class II/III, treatment with antiarrhythmic drugs, follow-up
recovery of the ratio of E- to A-wave (E/A), and survival
and time to hospitalization (overall and for heart failure).
Results The prevalence of AF over time was lower in the
“extensive” arm (adjusted relative risk [RR]: 0.10; 95%
conﬁdence interval [CI]: 0.03 to 0.31; p < 0.001), with
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months. The prevalence of patients in NYHA functional
class II/III over time was lower in the “extensive” arm
(adjusted RR: 0.11; 95% CI: 0.03 to 0.34; p < 0.001), with
signiﬁcant differences at any assessment (except the third
month). The differences in E/A recovery and use of anti-
arrhythmic drugs were less marked, with an RR of 1.55
(95% CI: 0.99 to 2.42; p ¼ 0.05) and RR of 0.76 (95% CI:
0.54 to 1.06; p ¼ 0.11), respectively, with a signiﬁcantly
lower prevalence of antiarrhythmic drugs in the “extensive”
ablation arm at 12, 18, and 24 months. Rates of hospitali-
zation for heart failure, overall hospitalization, and the
combined event death/hospitalization were lower in the
“extensive” arm (p ¼ 0.11, p ¼ 0.003, and p ¼ 0.002,
respectively).
Conclusions The addition of right-sided ablation improves
clinical and electrophysiologic results after maze procedure
(432).Improvement in Mortality Risk Prediction After
Percutaneous Coronary Intervention Through the
Addition of a “Compassionate Use” Variable to the
National Cardiovascular Data Registry Cath: PCI
Dataset: A Study From the Massachusetts
Angioplasty Registry
Objectives This study investigated the impact of adding
novel elements to models predicting in-hospital mortality
after percutaneous coronary interventions (PCIs).
Background Massachusetts mandated public reporting of
hospital-speciﬁc PCI mortality in 2003. In 2006, a physician
advisory group recommended adding to the prediction
models 3 attributes not collected by the National Cardio-
vascular Data Registry instrument. These “compassionate
use” (CU) features included coma on presentation, active
hemodynamic support during PCI, and cardiopulmonary
resuscitation at PCI initiation.
Methods From October 2005 through September 2007,
PCI was performed during 29,784 admissions in Massa-
chusetts nonfederal hospitals. Of these, 5,588 involved
patients with ST-segment elevation myocardial infarction or
cardiogenic shock. Cases with CU criteria identiﬁed were
adjudicated by trained physician reviewers. Regression
models with and without the CU composite variable (pres-
ence of any of the 3 features) were compared using areas
under the receiver-operator characteristic curves.
Results Unadjusted mortality in this high-risk subset was
5.7%. Among these admissions, 96 (1.7%) had at least 1 CU
feature, with 69.8% mortality. The adjusted odds ratio for
in-hospital death for CU PCIs (vs. no CU criteria) was 27.3
(95% conﬁdence interval: 14.5 to 47.6). Discrimination of
the model improved after including CU, with areas under
the receiver-operating characteristic curves increasing from
0.87 to 0.90 (p < 0.01), while goodness of ﬁt was preserved.
Conclusions A small proportion of patients at extreme risk
of post-PCI mortality can be identiﬁed using pre-proceduralfactors not routinely collected, but that heighten predictive
accuracy. Such improvements in model performance may
result in greater conﬁdence in reporting of risk-adjusted PCI
outcomes (433).
A Randomized Clinical Study Comparing Double
Kissing Crush With Provisional Stenting for
Treatment of Coronary Bifurcation Lesions:
Results From the DKCRUSH-II (Double Kissing
Crush versus Provisional Stenting Technique for
Treatment of Coronary Bifurcation Lesions) Trial
Objectives The present study aimed to investigate the
difference in major adverse cardiac events (MACE) at 12
months in patients with coronary bifurcation lesions after
double kissing double crush (DK crush) or provisional
stenting (PS) techniques.
Background Provisional side branch (SB) stenting is pref-
erable to DK crush because it has been associated with fewer
complications. It is unknown which strategy would provide
the best results.
Methods From April 2007 to June 2009, 370 unselected
patients with coronary bifurcation lesions from 7 Asian
centers were randomly assigned to either the DK or the PS
group. Additional SB stenting in PS was required if ﬁnal
results were suboptimal. The primary end point was the
occurrence of MACE at 12 months, including cardiac
death, myocardial infarction, or target vessel revasculariza-
tion (TVR). Secondary end point was the angiographic
restenosis at 8 months.
Results There were 3 procedural occlusions of SB in the PS
group. At 8 months, angiographic restenosis rates in the
main vessel and SB were signiﬁcantly different between the
DK (3.8% and 4.9%) and the PS groups (9.7% and 22.2%,
p ¼ 0.036 and p < 0.001, respectively). Additional SB
stenting in the PS group was required in 28.6% of lesions.
TVR was 6.5% in the DK group, occurring signiﬁcantly less
often than in the PS group (14.6%, p ¼ 0.017). There were
nonsigniﬁcant differences in MACE and deﬁnite stent
thrombosis between the DK (10.3% and 2.2%) and PS
groups (17.3%, and 0.5%, p ¼ 0.070 and p ¼ 0.372,
respectively).
Conclusions DK crush was associated with a signiﬁcant
reduction of TLR and TVR in this unselected patient
population. However, there was no signiﬁcant difference in
MACE between DK and the PS groups. (Randomized
Study on DK Crush Technique Versus Provisional Stenting
Technique for Coronary Artery Bifurcation Lesions;
ChicTR-TRC-00000015) (434).
Prevalence and Predictors of Concomitant Carotid
and Coronary Artery Atherosclerotic Disease
Objectives The purpose of this research was to evaluate the
relationship between coronary and carotid atherosclerotic
disease using current guidelines for the deﬁnition of carotid
artery stenosis (CAS).
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coronary and carotid atherosclerotic disease has varied
among studies due to differences in study populations and
methodologies used.
Methods We performed a retrospective analysis of
prospectively collected data obtained between January 2007
and May 2009 from consecutive patients undergoing same-
day coronary angiography and carotid Doppler studies.
Spearman correlations and multinomial logistic regression
models were used to identify independent correlates of CAS.
Results The study included 1,405 patients (age 65  11
years, 77.2% male), of whom 12.8% had signiﬁcant CAS
(peak systolic velocity [PSV] >125 cm/s) and 4.6% had
severe CAS (PSV >230 cm/s). Mild CAS (PSV <125 cm/s
and the presence of a sonographic atherosclerotic lesion) was
present in 58%. The severity of CAS and the extent of
coronary artery disease (CAD) were signiﬁcantly correlated
(r ¼ 0.255, p < 0.001). Independent predictors of severe
CAS deﬁned by PSV were the presence of left-main or 3-
vessel CAD, increasing age, a history of stroke, smoking
status, and diabetes mellitus.
Conclusions The degree of internal carotid artery (ICA)
stenosis is related to the extent of CAD, though the prev-
alence of clinically signiﬁcant ICA stenosis is lower in
speciﬁc CAD subsets than previously reported (435).High Versus Standard Clopidogrel Maintenance
Dose After Percutaneous Coronary Intervention
and Effects on Platelet Inhibition, Endothelial
Function, and Inﬂammation: Results of the
ARMYDA-150 mg (Antiplatelet Therapy for
Reduction of Myocardial Damage During
Angioplasty) Randomized Study
Objectives This study was done to compare effects of high
versus standard clopidogrel maintenance doses on platelet
inhibition, inﬂammation, and endothelial function in
patients undergoing percutaneous coronary intervention.
Background Previous data suggested that clopidogrel has
various biological actions in addition to antiplatelet effects.
Methods Fifty patients were randomly assigned 1 month
after intervention (T-0) to receive standard (75 mg/day; n ¼
25) or high (150 mg/day; n ¼ 25) clopidogrel maintenance
dose for 30 days (until T-1); at this time-point, cross-over
was performed, and the assigned clopidogrel maintenance
regimen was switched and continued for a further 30 days
(until T-2). Platelet reactivity (expressed as P2Y12 reaction
units by the point-of-care VerifyNow assay [Accumetrics,
San Diego, California]), endothelial function (evaluated by
ﬂow-mediated vasodilation), and high-sensitivity C-reactive
protein levels were measured at T-0, T-1, and T-2.
Results Patients in the 150-mg/day arm had higher platelet
inhibition (50  20% vs. 31  20% in the 75-mg/day group;
p < 0.0001), better ﬂow-mediated vasodilation (16.9 
12.6% vs. 7.9  7.5%; p ¼ 0.0001), and lower high-
sensitivity C-reactive protein levels (3.6  3.0 mg/l vs. 7.0 8.6 mg/l; p ¼ 0.016). Higher clopidogrel dose was
associated with decreased proportion of patients with P2Y12
reaction units 240 (12% vs. 32%; p ¼ 0.001), ﬂow-
mediated vasodilation <7% (16% vs. 58%; p ¼ 0.0003),
and high-sensitivity C-reactive protein levels >3 mg/l (46%
vs. 64%; p ¼ 0.07).
Conclusions For patients undergoing percutaneous coro-
nary intervention, the 150-mg/day clopidogrel maintenance
dose is associated with stronger platelet inhibition,
improvement of endothelial function, and reduction of
inﬂammation, compared with the currently recommended
75-mg/day regimen; those effects might have a role in the
clinical beneﬁt observed with clopidogrel and may provide
the rationale for using the higher maintenance regimen in
selected patients (436).Clinical Characteristics, Management, and
Outcomes of Patients Diagnosed With Acute
Pulmonary Embolism in the Emergency
Department: Initial Report of EMPEROR
(Multicenter Emergency Medicine Pulmonary
Embolism in the Real World Registry)
Objectives In a large U.S. sample, this study measured the
presentation features, testing, treatment strategies, and
outcomes of patients diagnosed with pulmonary embolism
(PE) in the emergency department (ED).
Background No data have quantiﬁed the demographics,
clinical features, management, and outcomes of outpatients
diagnosed with PE in the ED in a large, multicenter U.S.
study.
Methods Patients of any hemodynamic status were
enrolled from the ED after conﬁrmed acute PE or with
a high clinical suspicion prompting anticoagulation before
imaging for PE. Exclusions were inability to provide
informed consent (where required) or unavailability for
follow-up.
Results A total of 1,880 patients with conﬁrmed acute PE
were enrolled from 22 U.S. EDs. Diagnosis of PE was based
upon positive results of computerized tomographic pulmo-
nary angiogram in most cases (n ¼ 1,654 [88%]). Patients
represented both sexes equally, and racial and ethnic
composition paralleled the overall U.S. ED population.
Most (79%) patients with PE were employed, and one-third
were older than age 65 years. The mortality rate directly
attributed to PE was 20 in 1,880 (1%; 95% conﬁdence
interval [CI]: 0% to 1.6%). Mortality from hemorrhage was
0.2%, and the all-cause 30-day mortality rate was 5.4% (95%
CI: 4.4% to 6.6%). Only 3 of 20 patients with major PE that
ultimately proved fatal had systemic anticoagulation initiated
before diagnostic conﬁrmation, and another 3 of these 20
received a ﬁbrinolytic agent.
Conclusions Patients diagnosed with acute PE in U.S.
EDs have high functional status, and their mortality rate is
low. These registry data suggest that appropriate initial
medical management of ED patients with severe PE with
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for research to determine the appropriate threshold for
empiric treatment when PE is suspected before diagnostic
conﬁrmation (437).With the “Universal Deﬁnition,” Measurement of
Creatine Kinase-Myocardial Band Rather Than
Troponin Allows More Accurate Diagnosis of
Periprocedural Necrosis and Infarction After
Coronary Intervention
Objectives We aimed to assess the differential implica-
tions of creatine kinase-myocardial band (CK-MB)
and troponin measurement with the universal deﬁnition
of periprocedural injury after percutaneous coronary
intervention.
Background Differentiation between deﬁnitions of peri-
procedural necrosis and periprocedural infarction has prac-
tical, sociological, and research implications. Troponin is the
recommended biomarker, but there has been debate about
the recommended diagnostic thresholds.
Methods Thirty-two patients undergoing multivessel
percutaneous coronary intervention and late gadolinium
enhancement (LGE) cardiac magnetic resonance (CMR)
imaging in a prospective study had cardiac troponin I, CK-
MB, and inﬂammatory markers (C-reactive protein, serum
amyloid A, myeloperoxidase, tumor necrosis factor alpha)
measured at baseline, 1 h, 6 h, 12 h, and 24 h after the
procedure. Three “periprocedural injury” groups were
deﬁned with the universal deﬁnition: G1: no injury
(biomarker <99th percentile); G2: periprocedural necrosis
(1 to 3  99th percentile); G3: myocardial infarction (MI)
type 4a (>3  99th percentile). Differences in inﬂammatory
proﬁles were analyzed.
Results With CK-MB there were 17, 10, and 5 patients in
groups 1, 2, and 3, respectively. Patients with CK-MB–
deﬁned MI type 4a closely approximated patients with new
CMR-LGE injury. Groups deﬁned with CK-MB showed
progressively increasing percentage change in C-reactive
protein and serum amyloid A, reﬂecting increasing inﬂam-
matory response (p < 0.05). Using cardiac troponin I
resulted in 26 patients deﬁned as MI type 4a, but only
a small minority had evidence of abnormality on CMR-
LGE, and only 3 patients were deﬁned as necrosis. No
differences in inﬂammatory response were evident when
groups were deﬁned with troponin.
Conclusions Measuring CK-MB is more clinically rele-
vant for diagnosing MI type 4a, when applying the
universal deﬁnition. Current troponin thresholds are
oversensitive with the arbitrary limit of 3  99th percentile
failing to discriminate between periprocedural necrosis
and MI type 4a. (Myocardial Injury following Coronary
Artery bypass Surgery versus Angioplasty: a randomised
controlled trial using biochemical markers and cardiovas-
cular magnetic resonance imaging; ISRCTN25699844)
(438).Long-Term Prevention of Stroke: A Modern
Comparison of Current Carotid Stenting and
Carotid Endarterectomy
Objectives This study sought to evaluate long-term
outcomes of carotid stenting (CAS) versus carotid endar-
terectomy (CEA) based on physician-guided indications.
Background The issue regarding long-term outcome of
CAS versus CEA in patients with carotid stenosis is clini-
cally relevant but remains unsettled.
Methods Consecutive patients (71% men, mean age 71.3
years) treated by CEA (n ¼ 1,118) or CAS (n ¼ 1,084) after
a training phase were reviewed. Selection of treatment was
based on better-suitability characteristics (morphology and
clinical). Data were adjusted with propensity score analysis
and stratiﬁed by symptoms, age, and sex.
Results Thirty-day stroke/death rates were similar: 2.8% in
CAS and 2.0% in CEA (p ¼ 0.27). The risk was higher in
symptomatic (3.5%) versus asymptomatic (2.0%) patients
(p ¼ 0.04) but without signiﬁcant difference between CAS
and CEA groups. Five-year survival rates were 82.0% in
CAS and 87.7% in CEA (p ¼ 0.05). Kaplan-Meier esti-
mates of the composite of any periprocedural stroke/death
and ipsilateral stroke at 5 years after the procedure were
similar in all patients (4.7% vs. 3.7%; p ¼ 0.4) and the
subgroups of symptomatic (8.7% vs. 4.9%; p ¼ 0.7) and
asymptomatic (2.5% vs. 3.3%; p ¼ 0.2) patients in CEA
versus CAS, respectively. Cox analysis, adjusted by
propensity score, identiﬁed statin treatment (p ¼ 0.016) and
symptomatic disease (p ¼ 0.003) associated with the
composite end point. There were no sex- or age-related
signiﬁcant outcome differences.
Conclusions When physicians use their clinical judgment
to select the appropriate technique for carotid revasculari-
zation CAS can offer efﬁcacy and durability comparable to
CEA with beneﬁts persisting at 5 years (439).
Ticagrelor Versus Clopidogrel in Patients With
Acute Coronary Syndromes Undergoing Coronary
Artery Bypass Surgery: Results From the PLATO
(Platelet Inhibition and Patient Outcomes) Trial
Objectives The purpose of this study is to evaluate the
efﬁcacy and safety of ticagrelor and clopidogrel in patients
with acute coronary syndrome undergoing coronary artery
bypass graft surgery (CABG), as a post-randomization
strategy.
Background Ticagrelor is a novel, reversibly binding, oral,
direct-acting P2Y12-receptor antagonist. In the PLATO
(Platelet Inhibition and Patient Outcomes) trial, which
randomized 18,624 patients with acute coronary syndromes,
ticagrelor compared with clopidogrel signiﬁcantly reduced
the risk of the primary composite end point of cardiovascular
(CV) death, myocardial infarction, or stroke (hazard ratio
[HR]: 0.84; 95% conﬁdence interval [CI]: 0.77 to 0.92; p <
0.001). This report investigated the outcomes of patients
treated with CABG during the trial.
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randomization. The protocol recommended ticagrelor/
placebo to be withheld for 24 to 72 h and clopidogrel/
placebo for 5 days preoperatively. In all, 1,261 patients
underwent CABG and were receiving study drug
treatment <7 days before surgery. The statistical analysis
was based on events occurring from the CABG procedure
until the end of the study, excluding 3 patients with CABG
after study end.
Results In the 1,261 patient cohort, the relative reduction
of primary composite end point at 12 months (10.6% [66 of
629] with ticagrelor versus 13.1% [79 of 629] with clopi-
dogrel; HR: 0.84; 95% CI: 0.60 to 1.16; p ¼ 0.29) was
consistent with the results of the whole trial. Total mortality
was reduced from 9.7% (58 of 629) to 4.7% (29 of 629; HR:
0.49; 95% CI: 0.32 to 0.77; p < 0.01), CV death from 7.9%
(47 of 629) to 4.1% (25 of 629; HR: 0.52; 95% CI: 0.32 to
0.85; p < 0.01), and non-CV death numerically from 2.0%
to 0.7% (p ¼ 0.07). There was no signiﬁcant difference in
CABG-related major bleeding between the randomized
treatments.
Conclusions In the subgroup of patients undergoing
CABG within 7 days after the last study drug intake, tica-
grelor compared with clopidogrel was associated with
a substantial reduction in total and CV mortality without
excess risk of CABG-related bleeding (440).Endocardial Radiofrequency Ablation for
Hypertrophic Obstructive Cardiomyopathy: Acute
Results and 6 Months’ Follow-Up in 19 Patients
Objectives The purpose of this study was to examine the
efﬁcacy and safety of endocardial radiofrequency ablation of
septal hypertrophy (ERASH) for left ventricular outﬂow
tract (LVOT) gradient reduction in hypertrophic obstructive
cardiomyopathy (HOCM).
Background Anatomic variability of the vessels supplying
the obstructing septal bulge can limit the efﬁcacy of trans-
coronary ablation of septal hypertrophy in HOCM. Previous
studies showed that inducing a local contraction disorder
without reducing septal mass results in effective gradient
reduction. We examined an alternative endocardial approach
to transcoronary ablation of septal hypertrophy by using
ERASH.
Methods Nineteen patients with HOCM were enrolled; in
9 patients, the left ventricular septum was ablated, and in 10
patients, the right ventricular septum was ablated. Follow-up
examinations (echocardiography, 6-min walk test, bicycle
ergometry) were performed 3 days and 6 months after
ERASH.
Results After 31.2  10 radiofrequency pulses, a signiﬁcant
and sustained LVOT gradient reduction could be achieved
(62% reduction of resting gradients and 60% reduction of
provoked gradients, p ¼ 0.0001). The 6-min walking
distance increased signiﬁcantly from 412.9  129 m to
471.2  139 m after 6 months, p ¼ 0.019); and New YorkHeart Association functional class was improved from 3.0 
0.0 to 1.6  0.7 (p ¼ 0.0001). Complete atrioventricular
block requiring permanent pacemaker implantation occurred
in 4 patients (21%); 1 patient had cardiac tamponade.
Conclusions ERASH is a new therapeutic option in the
treatment of HOCM, allowing signiﬁcant and sustained
reduction of the LVOT gradient as well as symptomatic
improvement with acceptable safety by inducing a discrete
septal contraction disorder. It may be suitable for patients
not amenable to transcoronary ablation of septal hypertrophy
or myectomy (441).Genetic Warfarin Dosing: Tables Versus Algorithms
Objectives The aim of this study was to compare the
accuracy of genetic tables and formal pharmacogenetic
algorithms for warfarin dosing.
Background Pharmacogenetic algorithms based on
regression equations can predict warfarin dose, but they
require detailed mathematical calculations. A simpler alter-
native, recently added to the warfarin label by the U.S. Food
and Drug Administration, is to use genotype-stratiﬁed
tables to estimate warfarin dose. This table may potentially
increase the use of pharmacogenetic warfarin dosing in
clinical practice; however, its accuracy has not been
quantiﬁed.
Methods A retrospective cohort study of 1,378 patients
from 3 anticoagulation centers was conducted. Inclusion
criteria were stable therapeutic warfarin dose and complete
genetic and clinical data. Five dose prediction methods were
compared: 2 methods using only clinical information
(empiric 5 mg/day dosing and a formal clinical algorithm), 2
genetic tables (the new warfarin label table and a table based
on mean dose stratiﬁed by genotype), and 1 formal phar-
macogenetic algorithm, using both clinical and genetic
information. For each method, the proportion of patients
whose predicted doses were within 20% of their actual
therapeutic doses was determined. Dosing methods were
compared using McNemar’s chi-square test.
Results Warfarin dose prediction was signiﬁcantly more
accurate (all p < 0.001) with the pharmacogenetic algorithm
(52%) than with all other methods: empiric dosing (37%;
odds ratio [OR]: 2.2), clinical algorithm (39%; OR: 2.2),
warfarin label (43%; OR: 1.8), and genotype mean dose
table (44%; OR: 1.9).
Conclusions Although genetic tables predicted warfarin
dose better than empiric dosing, formal pharmacogenetic
algorithms were the most accurate (442).Randomized Comparison of Percutaneous
Coronary Intervention With Sirolimus-Eluting
Stents Versus Coronary Artery Bypass Grafting in
Unprotected Left Main Stem Stenosis
Objectives The purpose of this randomized study was to
compare sirolimus-eluting stenting with coronary artery
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main (ULM) coronary artery disease.
Background CABG is considered the standard of care for
treatment of ULM. Improvements in percutaneous coronary
intervention (PCI) with use of drug-eluting stents might
lead to similar results. The effectiveness of drug-eluting
stenting versus surgery has not been established in
a randomized trial.
Methods In this prospective, multicenter, randomized trial,
201 patients with ULM disease were randomly assigned to
undergo sirolimus-eluting stenting (n ¼ 100) or CABG
using predominantly arterial grafts (n ¼ 101). The primary
clinical end point was noninferiority in freedom from major
adverse cardiac events, such as cardiac death, myocardial
infarction, and the need for target vessel revascularization
within 12 months.
Results The combined primary end point was reached in
13.9% of patients after surgery, as opposed to 19.0% after
PCI (p ¼ 0.19 for noninferiority). The combined rates
for death and myocardial infarction were compara-
ble (surgery, 7.9% vs. stenting, 5.0%; noninferiority
p < 0.001), but stenting was inferior to surgery for
repeat revascularization (5.9% vs. 14.0%; noninferiority
p ¼ 0.35). Perioperative complications including 2 strokes
were higher after surgery (4% vs. 30%; p < 0.001).
Freedom from angina was similar between groups (p ¼
0.33).
Conclusions In patients with ULM stenosis, PCI with
sirolimus-eluting stents is inferior to CABG at 12-month
follow-up with respect to freedom from major adverse
cardiac events, which is mainly inﬂuenced by repeated
revascularization, whereas for hard end points, PCI results
are favorable. A longer follow-up is warranted. (Percuta-
neous Coronary Intervention [PCI] With Drug-Eluting
Stents [DES] Versus Coronary Artery Bypass Graft
[CABG] for Patients With Signiﬁcant Left Main Stenosis;
NCT00176397) (443).Long-Term Prognostic Value of Dobutamine Stress
CMR
Objectives The aim of this study was to assess the long-
term value of high-dose dobutamine cardiac magnetic
resonance (DCMR) for the prediction of cardiac events in
a large cohort of patients with known or suspected coronary
artery disease.
Background High-dose DCMR has been shown to be
a useful technique for diagnosis and intermediate-term
prognostic stratiﬁcation.
Methods Clinical data and DCMR results were analyzed in
1,463 consecutive patients undergoing DCMR between
2000 and 2004. Ninety-four patients were lost to follow-up.
The remaining 1,369 patients were followed up for a mean
of 44  24 months. Cardiac events, deﬁned as cardiac death
and nonfatal myocardial infarction, were related to clinical
and DCMR results.Results Three-hundred ﬁfty-two patients underwent early
revascularization (3 months of DCMR) and were
excluded from analysis. Of the remaining 1,017 patients,
301 patients (29.6%) experienced inducible wall motion
abnormalities (WMA). Forty-six cardiac events were re-
ported. In those with and without inducible WMA, the
proportion of patients with cardiac events was 8.0% versus
3.1%, respectively, p ¼ 0.001 (hazard ratio: 3.3; 95%
conﬁdence interval: 1.8 to 5.9 for the presence of inducible
WMA; p < 0.001). A DCMR without inducible WMA
carried an excellent prognosis, with a 6-year cardiac event-
free survival of 96.8%. In all 1,369 patients in the patient
group with stress-inducible WMA, those patients with
medical therapy demonstrated a trend to a higher cardiac
event rate (8.0%) than those with early revascularization
(5.4%) (p ¼ 0.234). Patients with normal DCMR and
medical therapy or early revascularization demonstrated
similar cumulative cardiac event rates (3.1% vs. 3.2%, p ¼
0.964).
Conclusions In a large cohort of patients, DCMR has an
added value for predicting cardiac events during long-term
follow-up, improving the differentiation between high-risk
and low-risk patients. Patients with inducible WMA and
following early revascularization, demonstrate lower cardiac
event rates than patients with medical therapy alone (444).Usefulness of TEE as the Primary Imaging
Technique to Guide Transcatheter Transapical
Aortic Valve Implantation
Objectives The aim of this study was to: 1) determine the
usefulness of transesophageal echocardiography (TEE) as
the primary technique to guide transapical (TA) trans-
catheter aortic valve implantation (TAVI); and 2) to
compare TEE with angiography as the primary imaging
modality for TA-TAVI guidance.
Background TEE has been routinely used as an adjunct to
angiography during TA-TAVI procedures, but very few data
exist on the use of TEE as the primary imaging technique
guiding TA-TAVI.
Methods One hundred consecutive high-risk patients
(mean age 79  9 years, mean logistic EuroSCORE:
25.8  17.6%) who underwent TA-TAVI in our center
were included. The Edwards valve was used in all cases,
and all procedures were performed in an operating room
without hybrid facilities. The TA-TAVI was primarily
guided by angiography in the ﬁrst 25 patients (A-TAVI
group) and by TEE in the last 75 patients (TEE-TAVI
group). Procedural, 30-day, and follow-up results were
evaluated.
Results No differences were observed between groups at
baseline except for a higher (p ¼ 0.001) prevalence of
moderate or severe mitral regurgitation in the TEE-TAVI
group. The procedure was successful in 97.3% and 100%
of the patients in the TEE-TAVI and A-TAVI groups,
respectively (p ¼ 1.0), and a lower contrast volume was used
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ml, p < 0.0001). There were no differences between groups
in the occurrence of valve malposition needing a second
valve (TEE-TAVI: 5.3%; A-TAVI: 4%; p ¼ 1.0) or valve
embolization (TEE-TAVI: 1.3%; A-TAVI: 4%; p ¼ 0.44).
The results regarding post-procedural valve hemodynamic
status and aortic regurgitation were similar between groups.
The survival rates at 30-day and 1-year follow-up were 87%
and 75% in the TEE-group and 88% and 84% in the A-
TAVI group, respectively (log-rank ¼ 0.49).
Conclusions TEE-TAVI was associated with similar acute
and midterm results as A-TAVI and signiﬁcantly reduced
contrast media use during the procedures. These results
suggest the feasibility and safety of performing TA-TAVI
procedures in an operating room without hybrid facilities,
but larger studies are needed to conﬁrm these ﬁndings (445).Quantiﬁcation of Coronary Arterial Stenoses by
Multidetector CT Angiography in Comparison With
Conventional Angiography: Methods, Caveats, and
Implications
Multidetector computed tomography (MDCT) is a rapidly
evolving technology for performing noninvasive coronary
angiography. Despite good sensitivity and speciﬁcity for
detecting signiﬁcant coronary artery disease in patients,
disagreement on individual coronary arterial stenosis
severity is common between MDCT and the current gold
standard, conventional angiography. The reasons for such
disagreement are numerous, but are at least partly inherent
to MDCT’s modest spatial and temporal resolution at
present. Less well acknowledged, however, is the fact that
MDCT and conventional angiography are fundamentally
different technologies, rendering good agreement on the
degree of lumen narrowing rather unrealistic, given both of
their respective limitations. Discrepant stenosis assessment
by MDCT and conventional angiography receives
remarkable attention, whereas its signiﬁcance for patient
outcome is less certain. On the other hand, the ability to
noninvasively assess coronary arterial plaque characteristics
and composition in addition to lumen obstruction shows
strong promise for improved risk assessment and may at
last enable us to move beyond mere coronary stenosis
assessment for the management of patients with coronary
artery disease (446).Noninvasive Evaluation of Coronary Reperfusion
by CT Angiography in Patients With STEMI
Objectives The aim of this study was to determine whether
64-slice multidetector computed tomography (MDCT) can
differentiate coronary reperfusion with Thrombolysis In
Myocardial Infarction (TIMI) ﬂow grade 3 from TIMI ﬂow
grade 2 after ST-segment elevation myocardial infarction
(STEMI).Background Multidetector computed tomography has
become a popular modality for noninvasive coronary artery
imaging. Recently, 64-slice MDCT has been applied to
evaluate coronary arteries in acute coronary artery disease.
Methods The presence or absence of distal reperfusion in
infarct-related arteries (IRA) was visualized with 64-slice
MDCT during the acute phase in 87 non–high-risk
patients after STEMI. To differentiate TIMI ﬂow grade 3
from TIMI ﬂow grade 2, we calculated the computed
tomography (CT) number ratio by dividing the CT number
of the contrast-enhanced coronary lumen at the most distal
IRA by that at the proximal site to the culprit lesion in
patients with reperfusion on MDCT. The MDCT ﬁndings
were compared with TIMI ﬂow grade with invasive coronary
angiography (ICA) performed 20  5 min later.
Results According to ICA, 58 patients had TIMI ﬂow
grade 0 or 1, 17 had TIMI ﬂow grade 2, and 12 had TIMI
ﬂow grade 3, whereas distal reperfusion was evident on
MDCT in 28 of the 29 patients with TIMI ﬂow grade 2
and absent in 55 of the 58 with TIMI ﬂow grade 1. The
CT number ratio was signiﬁcantly higher in TIMI ﬂow
grade 3 than in TIMI ﬂow grade 2 (0.64  0.11 vs. 0.37 
0.12; p < 0.0001). The sensitivity, speciﬁcity, and accuracy
of a diagnosis of TIMI ﬂow grade 3 on the basis of a CT
number ratio of 0.54 that was an optimal cutoff value
determined by receiver-operator characteristic curve analysis
were 92%, 97%, and 97%, respectively.
Conclusions Visualization of the IRA by 64-slice MDCT
enables noninvasive differentiation of angiographic TIMI
ﬂow grade 3 from TIMI ﬂow grade 2 coronary reperfusion
during the acute phase in patients with STEMI (447).Prospective Validation of Standardized,
3-Dimensional, Quantitative Coronary Computed
Tomographic Plaque Measurements Using
Radiofrequency Backscatter Intravascular
Ultrasound as Reference Standard in Intermediate
Coronary Arterial Lesions: Results From the
ATLANTA (Assessment of Tissue Characteristics,
Lesion Morphology, and Hemodynamics by
Angiography With Fractional Flow Reserve,
Intravascular Ultrasound and Virtual Histology, and
Noninvasive Computed Tomography in
Atherosclerotic Plaques) I Study
Objectives This study sought to determine the accuracy of
3-dimensional, quantitative measurements of coronary pla-
que by computed tomography angiography (CTA) against
intravascular ultrasound with radiofrequency backscatter
analysis (IVUS/VH).
Background Quantitative, 3-dimensional coronary CTA
plaque measurements have not been validated against IVUS/
VH.
Methods Sixty patients in a prospective study underwent
coronary X-ray angiography, IVUS/VH, and coronary
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after spatial coregistration on segmental and slice-by-slice
bases. Correlation, mean difference, and limits of agree-
ment were determined.
Results There was signiﬁcant correlation for all pre-
speciﬁed parameters by segmental and slice-by-slice anal-
yses (r ¼ 0.41 to 0.84; all p < 0.001). On a segmental basis,
CTA underestimated minimal lumen diameter by 21% and
overestimated diameter stenosis by 39%. Minimal lumen
area was overestimated on CTA by 27% but area stenosis
was only underestimated by 5%. Mean difference in non-
calciﬁed plaque volume and percent and calciﬁed plaque
volume and percent were 38%, 22%, 104%, and 64%. On
a slice-by-slice basis, lumen, vessel, noncalciﬁed-, and
calciﬁed-plaque areas were overestimated on CTA by 22%,
19%, 44%, and 88%. There was signiﬁcant correlation for
percentage of atheroma volume (0.52 vs. 0.54; r ¼ 0.51; p <
0.001). Compositional analysis suggested that high-density
noncalciﬁed plaque on CTA best correlated with ﬁbrous
tissue and low-density noncalciﬁed plaque correlated with
necrotic core plus ﬁbrofatty tissue by IVUS/VH.
Conclusions This is the ﬁrst validation that standardized,
3-dimensional, quantitative measurements of coronary pla-
que correlate with IVUS/VH. Mean differences are small,
whereas limits of agreement are wide. Low-density non-
calciﬁed plaque correlates with necrotic core plus ﬁbrofatty
tissue on IVUS/VH (448).Inﬂuence of Site and Operator Characteristics on
Carotid Artery Stent Outcomes: Analysis of the
CAPTURE 2 (Carotid ACCULINK/ACCUNET Post
Approval Trial to Uncover Rare Events) Clinical
Study
Objectives The aim of this study was to analyze the
CAPTURE 2 (Carotid ACCULINK/ACCUNET Post
Approval Trial to Uncover Rare Events) study for physician-
or site-related variables associated with differential outcomes
for carotid artery stenting (CAS).
Background The CAPTURE 2 trial is an ongoing,
prospective, nonrandomized, independently adjudicated,
multicenter clinical study enrolling high-surgical-risk
patients undergoing CAS.
Methods In this assessment of the CAPTURE 2 study, the
American Heart Association carotid endarterectomy guide-
line limits were used to deﬁne acceptable site and physician
CAS outcomes; therefore, the resulting population of non-
octogenarian, asymptomatic subjects in this analysis is
conﬁned to 3,388 (of the total 5,297) subjects treated at 180
U.S. hospitals by 459 operators between March 2006 and
January 2009.
Results The rates of death, stroke, and myocardial
infarction and death and stroke (DS) at 30 days were
3.5% and 3.3%, respectively, for the full CAPTURE 2
study cohort and 2.9% and 2.7%, respectively, for
the asymptomatic, nonoctogenarian subgroup. In thissubgroup, two-thirds of sites (118 of 180, 66%) had no
DS events. Within the remaining sites, an inverse rela-
tionship between event rates and hospital patient volume
as well as between event rates and individual operator
volume was observed. The DS rates trended lower
for interventional cardiologists compared with other
specialties.
Conclusions Outcomes from the largest prospectively
gathered, independently adjudicated, multicenter CAS
study indicate that CAS can be safely performed in
a variety of hospital settings by physicians with various
specialties. The most important determinant of perioper-
ative CAS outcomes was both site and operator CAS
volume. A threshold of 72 cases was found to be necessary
for consistently achieving a DS rate below 3% in this later-
phase single arm study; background era and non-study
operator experience will affect this determination.
(Second Phase of “Carotid RX ACCULINK/RX
ACCUNET Post-Approval Trial to Uncover Unantici-
pated or Rare Events”; NCT00302237) (449).Incidence, Prognostic Impact, and Inﬂuence of
Antithrombotic Therapy on Access and Nonaccess
Site Bleeding in Percutaneous Coronary
Intervention
Objectives The aim of this study was to evaluate the rela-
tive frequency of access and nonaccess site bleeding, the
association of these events with 1-year mortality, and the
impact of randomized antithrombotic therapy.
Background Post-percutaneous coronary intervention
(PCI) bleeding has been strongly associated with subsequent
mortality. The extent to which access versus nonaccess site
bleeding contributes to this poor prognosis and the role of
antithrombotic therapies remains poorly understood.
Methods The incidence and impact of Thrombolysis In
Myocardial Infarction (TIMI) major/minor 30-day bleeding
and randomized antithrombotic therapy were examined in
a combined dataset from the REPLACE-2 (Randomized
Evaluation in PCI Linking Angiomax to Reduced Clinical
Events), Acute Catheterization and Urgent Intervention
Triage Strategy (ACUITY), and HORIZONS-AMI
(Harmonizing Outcomes with Revascularization and
Stents in Acute Myocardial Infarction) trials in 17,393 PCI
patients.
Results The TIMI major/minor bleeding occurred in
5.3% of patients, 61.4% of which (3.3%) were nonaccess
site bleeds. After multivariable adjustment, TIMI
bleeding was associated with an increased risk of 1-year
mortality (hazard ratio [HR]: 3.17, 95% conﬁdence
interval [CI]: 2.51 to 4.00, p < 0.0001). The HR of
a nonaccess site bleed was approximately 2-fold that of an
access site bleed: HR: 3.94, 95% CI: 3.07 to 5.15, p <
0.0001 versus HR: 1.82, 95% CI: 1.17 to 2.83, p ¼
0.008, respectively. Randomization to bivalirudin versus
heparin þ a glycoprotein IIb/IIIa inhibitor resulted in
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and TIMI major bleeding, respectively (p < 0.0001 for
both), with signiﬁcant reductions in both access and
nonaccess site bleeding.
Conclusions Nonaccess site bleeding after PCI is common,
representing approximately two-thirds of all TIMI bleeding
events, and is associated with a 4-fold increase in 1-year
mortality. Use of bivalirudin rather than heparin þ a glyco-
protein IIb/IIIa inhibitor signiﬁcantly decreases both non-
access site as well as access site bleeding events by
approximately 40% (450).The SPIRIT V Study: A Clinical Evaluation of the
XIENCE V Everolimus-Eluting Coronary Stent
System in the Treatment of Patients With De Novo
Coronary Artery Lesions
Objectives The SPIRIT V (A Clinical Evaluation of the
XIENCE V Everolimus-Eluting Coronary Stent System in
the Treatment of Patients With De Novo Coronary Artery
Lesions) study is a post-market surveillance experience of
the XIENCE V (Abbott Vascular, Santa Clara, California)
everolimus-eluting stent (EES) in patients with higher-risk
coronary anatomy.
Background Previous pre-approval studies have shown the
safety and efﬁcacy of EES in highly selected groups of
patients.
Methods The SPIRIT V trial is a prospective, open label,
single arm, multicenter study. Two thousand seven
hundred patients with multiple de novo coronary artery
lesions suitable for treatment with a planned maximum of
4 EES were enrolled at 93 centers in Europe, Asia Paciﬁc,
Canada, and South Africa. Lesions had a reference vessel
diameter between 2.25 and 4.0 mm and a length of 28
mm by visual estimation. An independent clinical events
committee adjudicated all end point-related events. The
primary end point was the composite rate of all death,
myocardial infarction (MI), and target vessel revasculari-
zation at 30 days. Secondary end points included stent
thrombosis and acute success (clinical device and procedure
success).
Results At 30 days, the primary composite end point of
all death, MI, and target vessel revascularization was 2.7%.
At 1 year, rates of cardiac death, overall MI, and target
lesion revascularization were 1.1%, 3.5%, and 1.8%,
respectively. The cumulative rate of deﬁnite and probable
stent thrombosis was low at 0.66% at 1 year.
Conclusions Use of EES in patients with multiple,
complex de novo lesions yielded 1-year major adverse cardiac
events, stent thrombosis, and target lesion revascularization
rates that are comparable to those of the more controlled
SPIRIT II and SPIRIT III trialsdwhich included patients
with restricted inclusion/exclusion criteriadand other all-
comer population, physician-initiated studies like the
X-SEARCH (Xience Stent Evaluated At Rotterdam
Cardiology Hospital) and COMPARE (A RandomizedControlled Trial of Everolimus-eluting Stents and
Paclitaxel-eluting Stents for Coronary Revascularization in
Daily Practice) trials (451).The STAT-MI (ST-Segment Analysis Using Wireless
Technology in Acute Myocardial Infarction) Trial
Improves Outcomes
Objectives The goal of this study was to evaluate the
impact of the STAT-MI (ST-Segment Analysis Using
Wireless Technology in Acute Myocardial Infarction)
network on outcomes in the treatment of patients pre-
senting with ST-segment elevation myocardial infarction
(STEMI).
Background Shortening door-to-balloon (D2B) time
remains a national priority for the treatment of STEMI. We
previously reported a fully automated wireless network
(STAT-MI) for transmission of electrocardiograms (ECGs)
for suspected STEMI from the ﬁeld to offsite cardiologists,
allowing early triage with shortening of subsequent D2B
times. We now report the impact of the STAT-MI wireless
network on infarct size, length of hospital stay (LOS), and
mortality.
Methods A fully automated wireless network (STAT-MI)
was developed to enable automatic 12-lead ECG trans-
mission and direct communication between emergency
medical services personnel and offsite cardiologists that
facilitated direct triage of patients to the cardiac catheteri-
zation laboratory. Demographic, laboratory, and time
interval data of STAT-MI network patients were prospec-
tively collected over a 33-month period and compared with
concurrent control patients who presented with STEMI
through non–STAT-MI pathways.
Results From June 2006 through February 2009, 92
patients presented via the STAT-MI network, and 50
patients presented through non–STAT-MI pathways
(control group). Baseline clinical and demographic vari-
ables were similar in both groups. Overall, compared with
control subjects, STAT-MI patients had signiﬁcantly
shorter D2B times (63 [42 to 87] min vs. 119 [96 to
178] min, U ¼ 779.5, p < 0.00004), signiﬁcantly lower
peak troponin I (39.5 [11 to 120.5] ng/ml vs. 87.6 [38.4
to 227] ng/ml, U ¼ 889.5, p ¼ 0.005) and creatine
phosphokinase-MB (126.1 [37.2 to 280.5] ng/ml vs.
290.3 [102.4 to 484] ng/ml, U ¼ 883, p ¼ 0.001),
higher left ventricular ejection fractions (50% [35 to 55]
vs. 35% [25 to 52], U ¼ 1,075, p ¼ 0.004), and shorter
LOS (3 [2 to 4] days vs. 5.5 [3.5 to 10.5] days, U ¼
378, p < 0.001).
Conclusions A fully automated, ﬁeld-based, wireless
network that transmits ECGs automatically to offsite
cardiologists for the early evaluation and triage of patients
with STEMI shortens D2B times, reduces infarct size,
limits ejection fraction reduction, and shortens LOS
(452).
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Chronic Total Occlusion of Native Coronary Lesions
Within 30 Minutes: The J-CTO (Multicenter CTO
Registry in Japan) Score as a Difﬁculty Grading and
Time Assessment Tool
Objectives This study sought to establish a model for
grading lesion difﬁculty in interventional chronic total
occlusion (CTO) treatment.
Background Owing to uncertainty of success of the
procedure and difﬁculties in selecting suitable cases for
treatment, performance of interventional CTO remains
infrequent.
Methods Data from 494 native CTO lesions were
analyzed. To eliminate operator bias, the objective parameter
of successful guidewire crossing within 30 min was set as an
end point, instead of actual procedural success. All obser-
vations were randomly assigned to a derivation set and
a validation set at a 2:1 ratio. The J-CTO (Multicenter
CTO Registry of Japan) score was determined by assigning
1 point for each independent predictor of this end point and
summing all points accrued. This value was then used to
develop a model stratifying all lesions into 4 difﬁculty
groups: easy (J-CTO score of 0), intermediate (score of 1),
difﬁcult (score of 2), and very difﬁcult (score of 3).
Results The set end point was achieved in 48.2% of lesions.
Independent predictors included calciﬁcation, bending,
blunt stump, occlusion length >20 mm, and previously
failed lesion. Easy, intermediate, difﬁcult, and very difﬁcult
groups, stratiﬁed by J-CTO score, demonstrated stepwise,
proportioned, and highly reproducible differences in prob-
ability of successful guidewire crossing within 30 min
(87.7%, 67.1%, 42.4%, and 10.0% in the derivation set and
92.3%, 58.3%, 34.8%, and 22.2% in the validation set,
respectively). Areas under receiver-operator characteristic
curves were comparable (derivation: 0.82 vs. validation:
0.76).
Conclusions This model predicted the probability of
successful guidewire crossing within 30 min very well and
can be applied for difﬁculty grading (453).
Circadian Variation in Coronary Stent Thrombosis
Objectives We sought to determine the circadian, weekly,
and seasonal variation of coronary stent thrombosis.
Background Other adverse cardiovascular events such as
acute myocardial infarction are known to have higher inci-
dences during the early morning hours, Mondays, and
winter months.
Methods The Mayo Clinic Percutaneous Coronary Inter-
vention Registry was searched for patients admitted to our
center who underwent repeat percutaneous coronary interven-
tion in a previously stented coronary artery segment. Stent
thrombosis was conﬁrmed by angiographic review, and date and
time of symptom onset were obtained from medical records.
Results We identiﬁed 124 patients with deﬁnite stent
thrombosis and known date and time of symptom onset. Inthese patients, onset of stent thrombosis was signiﬁcantly
associated with time of day (p ¼ 0.006), with a peak inci-
dence around 7:00 AM. When patients were subdivided into
early stent thrombosis (0 to 30 days; n ¼ 49), late stent
thrombosis (31 to 360 days; n ¼ 30), and very late stent
thrombosis (>360 days; n ¼ 45), only early stent thrombosis
remained signiﬁcantly associated with time of day (p ¼
0.030). No association with the day of the week was found
(p ¼ 0.509); however, onset of stent thrombosis did follow
a signiﬁcant seasonal pattern, with higher occurrences in the
summer (p ¼ 0.036).
Conclusions Coronary stent thrombosis occurs more often
in the early morning hours. Early stent thrombosis follows
a circadian rhythm with a peak at 7:00 AM. This pattern was
not signiﬁcant in late and very late stent thrombosis.
Occurrences throughout the week were equally distributed,
but stent thrombosis was more likely to occur in the summer
months (454).Long-Term Outcomes After the Percutaneous
Treatment of Drug-Eluting Stent Restenosis
Objectives This study sought to evaluate the long-term
angiographic and clinical outcomes after the treatment of
drug-eluting stent in-stent restenosis (DES-ISR) based on
the angiographic pattern of restenosis.
Background Long-term outcomes after percutaneous
treatment of DES-ISR are unclear.
Methods This study performed a retrospective analysis of
481 consecutive de novo DES-ISR lesions (n ¼ 392) treated
percutaneously between August 2002 and July 2007. The
lesions were divided based on the pattern of restenosis: focal
(305; 63.4%), diffuse (120; 24.9%), and occlusive (56; 11.6%).
Results The majority (65%) of patients had angina or
ischemia on presentation and 13% had an acute coronary
syndrome. Angiographic follow-up after treatment of DES-
ISR was available in 65.5% of lesions. A second angio-
graphic restenosis occurred in 29.1% of the focal group,
45.8% (p ¼ 0.007) of the diffuse, and 65.6% (p < 0.0001) of
the occlusive. The pattern of DES-ISR predicted the pattern
of recurrence: occlusive reoccluded in 66.7%; diffuse
recurred as diffuse or occlusive in 57.9%; focal as focal in
67.2%. During a median follow-up of 2.97 years (inter-
quartile range: 2.37 to 3.89), major adverse cardiac events
occurred in 32.8% of patients with no signiﬁcant differences
among the focal, diffuse, and occlusive groups (30.9%,
38.7%, 31.1%; p ¼ 0.38). Diffuse restenosis was associated
with a signiﬁcantly higher target lesion revascularization rate
compared with focal (27.1% vs. 15.8%; p ¼ 0.008). A
disparity between restenosis (65.6%) and target lesion
revascularization (18.5%) rates for occlusive DES-ISR
suggests that as many recurrent restenoses were occlusive,
they were not retreated.
Conclusions DES-ISR identiﬁes a high-risk cohort that is
at an increased risk of events, in particular repeat revascu-
larization, during long-term follow-up. The initial pattern of
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restenosis or the need for subsequent reintervention (455).
Dynamic 3-Dimensional Stress Cardiac Magnetic
Resonance Perfusion Imaging: Detection of
Coronary Artery Disease and Volumetry of
Myocardial Hypoenhancement Before and After
Coronary Stenting
Objectives The aim of this study was to establish a new,
dynamic 3-dimensional cardiac magnetic resonance (3D-
CMR) perfusion scan technique exploiting data correlation
in k-space and time with sensitivity-encoding and to
determine its value for the detection of coronary artery
disease (CAD) and volumetry of myocardial hypoenhance-
ment (VOLUMEhypo) before and after percutaneous coro-
nary stenting.
Background Dynamic 3D-CMR perfusion imaging might
improve detection of myocardial perfusion deﬁcits and could
facilitate direct volumetry of myocardial hypoenhancement.
Methods In 146 patients with known or suspected CAD,
a 3.0-T CMR examination was performed including cine
imaging, 3D-CMR perfusion under adenosine stress and at
rest followed by delayed enhancement imaging. Quantitative
invasive coronary angiography deﬁned signiﬁcant CAD
(50% luminal narrowing). Forty-eight patients underwent
an identical repeat CMR examination after percutaneous
stenting of at least 1 coronary lesion. The 3D-CMR
perfusion scans were visually classiﬁed as pathologic if 1
segment showed an inducible perfusion deﬁcit in the
absence of delayed enhancement. The VOLUMEhypo was
measured by segmentation of the area of inducible hypo-
enhancement and normalized to left-ventricular myocardial
volume (%VOLUMEhypo).
Results The 3D-CMR perfusion resulted in a sensitivity,
speciﬁcity, and diagnostic accuracy of 91.7%, 74.3%, and
82.9%, respectively. Before and after coronary stenting, %
VOLUMEhypo averaged to 14.2  9.5% and 3.2  5.2%,
respectively, with a relative VOLUMEhypo reduction of 79.4
 25.4%. Intrareader and inter-reader reproducibility of
VOLUMEhypo measurements was high (Lin’s concordance
correlation coefﬁcient, 0.96 and 0.96, respectively).
Conclusions The 3D-CMR stress perfusion provided high
image quality and high diagnostic accuracy for the detection
of signiﬁcant CAD. The VOLUMEhypo measurements
were highly reproducible and allowed for the assessment of
the treatment effect achievable by percutaneous coronary
stenting (456).
Calcium-Channel Blockers Do Not Alter the Clinical
Efﬁcacy of Clopidogrel After Myocardial Infarction:
A Nationwide Cohort Study
Objectives The purpose of this study was to determine the
risk of adverse cardiovascular events associated with
concomitant use of clopidogrel and calcium-channel blockers
(CCBs) in patients with myocardial infarction (MI).Background CCBs inhibit a variety of cytochrome P-450
enzymes, some of which contribute to clopidogrel metabolic
activation. This interaction may diminish the efﬁcacy of
clopidogrel.
Methods All patients surviving 30 days after a ﬁrst-time
MI in the period 2000 to 2006 in Denmark were identi-
ﬁed by individual-level linkage of nationwide administrative
registers. The cohort was divided into patients treated with
and without clopidogrel and followed for 1 year after
discharge. The risk of a composite of cardiovascular death,
MI, or stroke and the risk of the individual components of
the composite end point and all-cause death associated with
CCBs were analyzed with multivariable Cox proportional
hazard models and in univariate propensity score-matched
models.
Results A total of 56,800 patients were included, of whom
24,923 were treated with clopidogrel and 13,380 with
CCBs. In the Cox analyses, the risk of the composite end
point associated with CCBs was increased in both patients
treated and not treated with clopidogrel, with a hazard ratio
of 1.15 (95% conﬁdence interval [CI]: 1.07 to 1.24) and
1.05 (95% CI: 1.01 to 1.11), respectively. The increased risk
was independent of clopidogrel use; the hazard rate ratio was
1.08 (95% CI: 0.99 to 1.18). Analyses of all additional
adverse end points and propensity score–matched models
provided similar results.
Conclusions The clinical efﬁcacy of clopidogrel in patients
with a recent MI is not modiﬁed by concomitant CCB
treatment. This potential drug interaction is unlikely to have
clinical signiﬁcance (457).Cardiovascular Mortality in Chronic Kidney
Disease Patients Undergoing Percutaneous
Coronary Intervention Is Mainly Related to
Impaired P2Y12 Inhibition by Clopidogrel
Objectives We sought to determine whether low platelet
response to the P2Y12 receptor antagonist clopidogrel as
assessed by vasodilator-stimulated phosphoprotein ﬂow
cytometry test (VASP-FCT) differentially affects
outcomes in patients with or without chronic kidney
disease (CKD) undergoing percutaneous coronary inter-
vention (PCI).
Background Although both CKD and impaired platelet
responsiveness to clopidogrel are strong predictors of
unfavorable outcome after PCI, the impact of their asso-
ciation is unknown. The platelet VASP-FCT assay is
speciﬁc for the P2Y12 ADP receptor pathway. In this test,
platelet activation is expressed as the platelet reactivity
index (PRI).
Methods Four-hundred forty unselected patients (CKD:
126, estimated glomerular ﬁltration rate [eGFR] <60 ml/
min/1.73 m2), no-CKD: 314 eGFR >60 ml/min/1.73 m2)
undergoing urgent (n ¼ 336) or planned (n ¼ 104) PCI
were prospectively enrolled. In each subgroup, patients were
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(R: PRI <61%) to clopidogrel.
Results At a mean follow-up of 9  2 months, all-cause
mortality, cardiac death, and possible stent thrombosis
were higher in CKD than in no-CKD patients. Within
the CKD group, the LR status was associated with higher
rates of all-cause mortality (25.5% vs. 2.8%, p < 0.001),
cardiac death (23.5% vs. 2.8%, p < 0.001), all stent
thrombosis (19.6% vs. 2.7%, p ¼ 0.003), and MACE
(33.3% vs. 12.3%, p ¼ 0.007). Conversely, in no-CKD
patients, the LR status did not affect outcomes. Multi-
variate analysis identiﬁed Killip class 3, drug-eluting
stent implantation, and the interaction between LR and
CKD (hazard ratio: 11.96, 95% conﬁdence interval: 1.22
to 116.82; p ¼ 0.033) as independent predictors of cardiac
death.
Conclusions In CKD patients, the presence of low platelet
response to clopidogrel is associated with worse outcomes
after PCI (458).Left Atrial Strain Predicts Reverse Remodeling
After Catheter Ablation for Atrial Fibrillation
Objectives The purpose of this study was to assess left atrial
(LA) strain during long-term follow-up after catheter
ablation for atrial ﬁbrillation and to ﬁnd predictors for LA
reverse remodeling.
Background The association between LA reverse remod-
eling and improvement in LA strain after catheter ablation
has not been investigated thus far.
Methods In 148 patients undergoing catheter ablation for
atrial ﬁbrillation, LA volumes and LA strain were assessed
with echocardiography at baseline and after a mean of 13.2
 6.7 months of follow-up. The study population was
divided according to LA reverse remodeling at follow-up:
responders were deﬁned as patients who exhibited 15% or
more reduction in maximum LA volume at long-term
follow-up. Left atrial systolic (LAs) strain was assessed
with tissue Doppler imaging.
Results At follow-up, 93 patients (63%) were classiﬁed as
responders, whereas 55 patients (37%) were nonresponders.
At baseline, LAs strain was signiﬁcantly higher in the
responders as compared with the nonresponders (19  8%
vs. 14  6%; p ¼ 0.001). Among the responders, a signiﬁ-
cant increase in LAs strain was noted from baseline to
follow-up (from 19  8% to 22  9%; p < 0.05), whereas
no change was noted among the nonresponders. LAs strain
at baseline was an independent predictor of LA reverse
remodeling (odds ratio: 1.813; 95% conﬁdence interval:
1.102 to 2.982; p ¼ 0.019).
Conclusions In the present study, 63% of the patients
exhibited LA reverse remodeling after catheter ablation for
atrial ﬁbrillation, with a concomitant improvement in LA
strain. LA strain at baseline was an independent predictor of
LA reverse remodeling (459).Door-to-Balloon Times Under 90 Min Can Be
Routinely Achieved for Patients Transferred for ST-
Segment Elevation Myocardial Infarction
Percutaneous Coronary Intervention in a Rural
Setting
Objectives The purpose of this study was to demonstrate
the feasibility of routine transfer of ST-segment elevation
myocardial infarction (STEMI) patients to achieve percu-
taneous coronary intervention (PCI) in less than 90 min
from presentation.
Background Many PCI hospitals have achieved routine
door-to-balloon times under 90 min for patients with
STEMI presenting directly to the hospital. However, few
patients transferred from a non-PCI center undergo PCI
within 90 min of presentation.
Methods Our rural PCI hospital implemented a program
in 2005 for rapid triage, transfer, and treatment of STEMI
patients and made additional improvements in 2006 and
2007. Intervals between milestones in the STEMI triage/
transfer/treatment process were assessed before and after
implementation of the program.
Results During the 5-year study period, 676 patients with
687 STEMIs were transferred from 19 community hospitals
and underwent PCI. Median door-to-balloon time
decreased from 189 min to 88 min (p < 0.001). The time
intervals reﬂecting efﬁciency of the referring hospitals,
transfer services, and PCI hospital all signiﬁcantly improved.
In 2008, median door-to-balloon times were <90 min for 6
of the 7 most frequently referring hospitals. Delays during
off-hours presentation in 2004 were abolished after the
program was implemented in 2005. In-hospital mortality
decreased from 6% before to 3% after implementation of the
program. In multivariate modeling, presentation before
initiation of the STEMI program predicted increased risk of
in-hospital mortality (odds ratio: 3.74, 95% conﬁdence
interval: 1.22 to 11.51, p ¼ 0.021).
Conclusions A program of rapid triage, transfer, and
treatment of STEMI patients presenting to non-PCI
hospitals can reduce in-hospital mortality and produce
progressive improvements in door-to-balloon time such that
median door-to-balloon times under 90 min are feasible
(460).
Multicenter Randomized Trial Evaluating the
Efﬁcacy of Cilostazol on Ischemic Vascular
Complications After Drug-Eluting Stent
Implantation for Coronary Heart Disease: Results
of the CILON-T (Inﬂuence of CILostazol-based triple
antiplatelet therapy ON ischemic complication
after drug-eluting stenT implantation) Trial
Objectives We aimed to test whether cilostazol has bene-
ﬁcial effects in the real-world patients treated with intra-
coronary drug-eluting stents (DES).
Background The addition of cilostazol on the conventional
dual antiplatelet therapy has been reported to reduce platelet
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neous coronary intervention in previous studies.
Methods In a randomized multicenter trial, we enrolled
960 patients who received DES. They were randomized to
receive either dual antiplatelet therapy (DAT) (aspirin and
clopidogrel) or triple antiplatelet therapy (TAT) (aspirin,
clopidogrel, and cilostazol) for 6 months. Primary end point
was the composite of cardiac death, nonfatal myocardial
infarction, ischemic stroke, or target lesion revascularization
(TLR). Secondary end points were P2Y12 reaction unit
(PRU) measured with the VerifyNow P2Y12 assay (Accu-
metrics, San Diego, California) at discharge and at 6 months
after the index procedure. All-cause death, stent thrombosis,
and each component of the primary end point at 6 months
were other secondary end points. Analysis was done on an
intention-to-treat basis.
Results At 6 months’ follow-up, there was no difference in
the primary end point between the 2 groups (8.5% in TAT
vs. 9.2% in DAT, p ¼ 0.74). In secondary end point anal-
ysis, the TAT group achieved lower PRU levels than the
DAT group both at discharge (206.6  90.3 PRU vs. 232.2
 80.3 PRU, p < 0.001) and at 6 months (210.7  87.9
PRU vs. 255.7  73.7 PRU, p < 0.001). In the Cox
proportional hazards analysis, lesion length (28 mm,
hazard ratio [HR]: 2.10, 95% conﬁdence interval [CI]: 1.25
to 3.52), and PRU level at discharge (every increase in tertile,
HR: 1.61, 95% CI: 1.16 to 2.25) were predictors of the
primary end point, but not the use of cilostazol (HR: 0.90,
95% CI: 0.54 to 1.52).
Conclusions Despite the greater reduction of platelet reac-
tivity by addition of cilostazol to conventional DAT, TAT did
not show superiority in reducing the composite of adverse
cardiovascular outcomes after DES implantation. (The Efﬁ-
cacy of CILostazol ON Ischemic Complications After
DES Implantation [CILON-T]; NCT00776828) (461).Standardized Endpoint Deﬁnitions for
Transcatheter Aortic Valve Implantation Clinical
Trials: A Consensus Report From the Valve
Academic Research Consortium
Objectives To propose standardized consensus deﬁnitions
for important clinical endpoints in transcatheter aortic valve
implantation (TAVI), investigations in an effort to improve
the quality of clinical research and to enable meaningful
comparisons between clinical trials. To make these
consensus deﬁnitions accessible to all stakeholders in TAVI
clinical research through a peer reviewed publication, on
behalf of the public health.
Background Transcatheter aortic valve implantation may
provide a worthwhile less invasive treatment in many
patients with severe aortic stenosis and since its introduction
to the medical community in 2002, there has been an
explosive growth in procedures. The integration of TAVI
into daily clinical practice should be guided by academic
activities, which requires a harmonized and structuredprocess for data collection, interpretation, and reporting
during well-conducted clinical trials.
Methods and Results The Valve Academic Research
Consortium established an independent collaboration
between Academic Research organizations and specialty
societies (cardiology and cardiac surgery) in the USA and
Europe. Two meetings, in San Francisco, California
(September 2009) and in Amsterdam, the Netherlands
(December 2009), including key physician experts, and
representatives from the U.S. Food and Drug Administra-
tion (FDA) and device manufacturers, were focused on
creating consistent endpoint deﬁnitions and consensus
recommendations for implementation in TAVI clinical
research programs. Important considerations in developing
endpoint deﬁnitions included: 1) respect for the historical
legacy of surgical valve guidelines; 2) identiﬁcation of
pathophysiological mechanisms associated with clinical
events; 3) emphasis on clinical relevance. Consensus criteria
were developed for the following endpoints: mortality,
myocardial infarction, stroke, bleeding, acute kidney injury,
vascular complications, and prosthetic valve performance.
Composite endpoints for TAVI safety and effectiveness
were also recommended.
Conclusions Although consensus criteria will invariably
include certain arbitrary features, an organized multidisci-
plinary process to develop speciﬁc deﬁnitions for TAVI
clinical research should provide consistency across studies
that can facilitate the evaluation of this new important
catheter-based therapy. The broadly based consensus
endpoint deﬁnitions described in this document may be
useful for regulatory and clinical trial purposes (462).Catheter Ablation for Atrial Fibrillation: Are
Results Maintained at 5 Years of Follow-Up?
Objectives This study describes 5-year follow-up results of
catheter ablation for atrial ﬁbrillation (AF).
Background Long-term efﬁcacy following catheter abla-
tion of AF remains unknown.
Methods A total of 100 patients (86 men, 14 women), age
55.7  9.6 years, referred to our center for a ﬁrst AF ablation
(63% paroxysmal; 3.5  1.4 prior ineffective antiarrhythmic
agents) were followed for 5 years. Complete success was
deﬁned as absence of any AF or atrial tachycardia recurrence
(clinical or by 24-h Holter monitoring) lasting 30 s.
Results Arrhythmia-free survival rates after a single cath-
eter ablation procedure were 40%, 37%, and 29% at 1, 2, and
5 years, respectively, with most recurrences over the ﬁrst 6
months. Patients with long-standing persistent AF experi-
enced a higher recurrence rate than those with paroxysmal or
persistent forms (hazard ratio [HR]: 1.9, 95% conﬁdence
interval [CI]: 1.0 to 3.5; p ¼ 0.0462). In all, 175 procedures
were performed, with a median of 2 per patient.
Arrhythmia-free survival following the last catheter ablation
procedure was 87%, 81%, and 63% at 1, 2, and 5 years,
respectively. Valvular heart disease (HR: 6.0, 95% CI: 2.0 to
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(HR: 34.0, 95% CI: 6.3 to 182.1; p < 0.0001) indepen-
dently predicted recurrences. Major complications (cardiac
tamponade requiring drainage) occurred in 3 patients (3%).
Conclusions In selected patients with AF, a catheter abla-
tion strategy with repeat intervention as necessary provides
acceptable long-term relief. Although most recurrences tran-
spire over the ﬁrst 6 to 12 months, a slow but steady decline
in arrhythmia-free survival is noted thereafter (463).
Association of Mortality With Years of Education in
Patients With ST-Segment Elevation Myocardial
Infarction Treated With Fibrinolysis
Objectives The purpose of this study was to examine the
association between lower socioeconomic status (SES), as
ascertained by years of education, and outcomes in patients
with acute ST-segment elevation myocardial infarction
(STEMI).
Background Previous studies have shown an inverse rela-
tionship between SES and coronary heart disease and
mortality. Whether a similar association between SES and
mortality exists in STEMI patients is unknown.
Methods We evaluated 11,326 patients with STEMI in
the GUSTO-III (Global Use of Strategies to Open
Occluded Coronary Arteries) trial study from countries that
enrolled >500 patients. We evaluated clinical outcomes
(adjusted using multivariate regression analysis) according to
the number of years of education completed.
Results One-year mortality was inversely related to years of
education and was 5-fold higher in patients with <8 years
compared with those with >16 years of education (17.5% vs.
3.5%, p < 0.0001). The strength of the relationship between
education and mortality varied among different countries.
Nonetheless, years of education remained an independent
correlate of mortality at day 7 (hazard ratio per year of
increase in education: 0.86; 95% conﬁdence interval: 0.83 to
0.88) and also between day 8 and 1 year (hazard ratio per
year of increase in education: 0.96; 95% conﬁdence interval:
0.94 to 0.98), even after adjustment for baseline character-
istics and country of enrollment.
Conclusions When the number of years of education was
used as a measure of SES, there was an inverse relationship
such that signiﬁcantly higher short-term and 1-year mortality
existed beyond that accounted for by baseline clinical vari-
ables and country of enrollment. Future studies should
account for and investigate the mechanisms underlying this
link between SES and cardiovascular disease outcomes (464).
Long-Term Comparison of Drug-Eluting Stents and
Coronary Artery Bypass Grafting for Multivessel
Coronary Revascularization: 5-Year Outcomes
From the Asan Medical Center-Multivessel
Revascularization Registry
Objectives We performed the long-term (5-year)
follow-up of a large cohort of patients who underwentdrug-eluting stent (DES) or coronary artery bypass graft
(CABG) surgery for multivessel revascularization.
Background Limited information is available on very long-
term outcomes after multivessel DES treatment relative to
CABG.
Methods We evaluated 3,042 patients with multivessel
disease who received DES (n ¼ 1,547) or underwent CABG
(n ¼ 1,495) between January 2003 and December 2005, and
for whom complete follow-up data were available for
a median 5.6 years (interquartile range: 4.6 to 6.3 years). We
compared adverse outcomes (death; a composite outcome of
death, myocardial infarction, or stroke; and repeat
revascularization).
Results After adjustment for differences in baseline risk
factors, 5-year risk of death (hazard ratio [HR]: 1.00; 95%
conﬁdence interval [CI]: 0.76 to 1.32, p ¼ 0.99) and the
combined risk of death, myocardial infarction, or stroke
(HR: 0.97; 95% CI: 0.76 to 1.24, p ¼ 0.81) were similar
between the DES group and the CABG group. However,
the rates of revascularization were signiﬁcantly higher in the
DES group (HR: 2.93; 95% CI: 2.20 to 3.90, p < 0.001).
Similar results were obtained in comparisons of DES with
CABG for high-risk clinical and anatomic subgroups with
diabetes mellitus, abnormal ventricular function, age 65
years or more, and 3-vessel and left main disease. However,
mortality beneﬁt with DES implantation relative to CABG
was noted in patients with 2-vessel disease (HR: 0.57; 95%
CI: 0.36 to 0.92, p ¼ 0.02).
Conclusions For patients with multivessel disease, DES
treatment, compared with CABG, showed similar rates of
mortality and of the composite safety outcomes, but higher
rates of revascularization up to 5 years (465).Comparative Validation of a Novel Risk Score for
Predicting Bleeding Risk in Anticoagulated
Patients With Atrial Fibrillation: The HAS-BLED
(Hypertension, Abnormal Renal/Liver Function,
Stroke, Bleeding History or Predisposition, Labile
INR, Elderly, Drugs/Alcohol Concomitantly) Score
Objectives The purpose of this study was to investigate
predictors of bleeding in a cohort of anticoagulated patients
and to evaluate the predictive value of several bleeding risk
stratiﬁcation schemas.
Background The risk of bleeding during antithrombotic
therapy in patients with atrial ﬁbrillation (AF) is not
homogeneous, and several clinical risk factors have been
incorporated into clinical bleeding risk stratiﬁcation
schemas. Current risk stratiﬁcation schemas for bleeding
during anticoagulation therapy have been based on complex
scoring systems that are difﬁcult to apply in clinical practice,
and few have been derived and validated in AF cohorts.
Methods We investigated predictors of bleeding in
a cohort of 7,329 patients with AF participating in the
SPORTIF (Stroke Prevention Using an ORal Thrombin
Inhibitor in Atrial Fibrillation) III and V clinical trials and
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schemas by multivariate analysis. Patients were anti-
coagulated orally with either adjusted-dose warfarin (target
international normalized ratio 2 to 3) or ﬁxed-dose xime-
lagatran 36 mg twice daily. Major bleeding was centrally
adjudicated, and concurrent aspirin therapy was allowed in
patients with clinical atherosclerosis.
Results By multivariate analyses, signiﬁcant predictors of
bleeding were concurrent aspirin use (hazard ratio [HR]:
2.10; 95% conﬁdence interval [CI]: 1.59 to 2.77; p < 0.001);
renal impairment (HR: 1.98; 95% CI: 1.42 to 2.76; p <
0.001); age 75 years or older (HR: 1.63; 95% CI: 1.23 to
2.17; p ¼ 0.0008); diabetes (HR: 1.47; 95% CI: 1.10 to
1.97; p ¼ 0.009), and heart failure or left ventricular
dysfunction (HR: 1.32; 95% CI: 1.01 to 1.73; p ¼ 0.041).
Of the tested schemas, the new HAS-BLED (Hyperten-
sion, Abnormal Renal/Liver Function, Stroke, Bleeding
History or Predisposition, Labile INR, Elderly, Drugs/
Alcohol Concomitantly) score performed best, with a step-
wise increase in rates of major bleeding with increasing
HAS-BLED score (ptrend <0.0001). The c statistic for
bleeding varied between 0.50 and 0.67 in the overall entire
cohort and 0.68 among patients naive to warfarin at baseline
(n ¼ 769).
Conclusions This analysis identiﬁes diabetes and heart
failure or left ventricular dysfunction as potential risk factors
for bleeding in AF beyond those previously recognized. Of
the contemporary bleeding risk stratiﬁcation schemas, the
new HAS-BLED scheme offers useful predictive capacity
for bleeding over previously published schemas and may be
simpler to apply (466).Multiple Biomarkers at Admission Signiﬁcantly
Improve the Prediction of Mortality in Patients
Undergoing Primary Percutaneous Coronary
Intervention for Acute ST-Segment Elevation
Myocardial Infarction
Objectives We investigated whether multiple biomarkers
improve prognostication in ST-segment elevation myocar-
dial infarction (STEMI) patients undergoing primary
percutaneous coronary intervention.
Background Few data exist on the prognostic value of
combined biomarkers.
Methods We used data from 1,034 STEMI patients
undergoing primary percutaneous coronary intervention in
a high-volume percutaneous coronary intervention center in
the Netherlands and investigated whether combining N-
terminal pro-brain natriuretic peptide, glucose, C-reactive
protein, estimated glomerular ﬁltration rate, and cardiac
troponin T improved the prediction of mortality. A risk
score was developed based on the strongest predicting
biomarkers in multivariate Cox regression. The additional
prognostic value of the strongest predicting biomarkers to
the established prognostic factors (age, body weight, dia-
betes, hypertension, systolic blood pressure, heart rate,anterior myocardial infarction, and time to treatment) was
assessed in multivariable Cox regression.
Results During follow-up (median, 901 days), 120 of the
1,034 patients died. In Cox regression, glucose, estimated
glomerular ﬁltration rate, and N-terminal pro-brain natri-
uretic peptide were the strongest predictors for mortality
(p < 0.05, for all). A risk score incorporating these
biomarkers identiﬁed a high-risk STEMI subgroup with
a signiﬁcantly higher mortality when compared with an
intermediate- or low-risk subgroup (p < 0.001). Addition
of the 3 biomarkers to established prognostic factors
signiﬁcantly improved prediction for mortality, as shown by
the net reclassiﬁcation improvement (0.494, p < 0.001)
and integrated discrimination improvement (0.0295, p <
0.01).
Conclusions Our data suggest that addition of a multi-
marker to a model including established risk factors
improves the prediction of mortality in STEMI patients
undergoing primary percutaneous coronary intervention.
Furthermore, the use of a simple risk score based on these
biomarkers identiﬁes a high-risk subgroup (467).Cerebral Embolism Following Transcatheter Aortic
Valve Implantation: Comparison of Transfemoral
and Transapical Approaches
Objectives The objective of this study was to compare the
incidence of cerebral embolism (CE) as evaluated by
diffusion-weighted magnetic resonance imaging (DW-
MRI) following transapical (TA) transcatheter aortic valve
implantation (TAVI) versus transfemoral (TF) TAVI.
Background The TA-TAVI approach avoids both the
manipulation of large catheters in the aortic arch/ascending
aorta and the retrograde crossing of the aortic valve, and this
avoidance might lead to a lower rate of CE.
Methods This was a prospective multicenter study
including 60 patients who underwent cerebral DW-MRI
the day before and within the 6 days following TAVI (TF
approach: 29 patients; TA approach: 31 patients). Neuro-
logic and cognitive function assessments were performed at
DW-MRI time points.
Results The TAVI procedure was performed with the
Edwards valve and was successful in all cases but one (98%).
A total of 41 patients (68%) had 251 new cerebral ischemic
lesions at the DW-MRI performed 4  1 days after the
procedure, 19 patients in the TF group (66%) and 22
patients in the TA group (71%; p ¼ 0.78). Most patients
(76%) with new ischemic lesions had multiple lesions
(median number of lesions per patient: 3, range 1 to 31).
There were no differences in lesion number and size
between the TF and TA groups. No baseline or procedural
factors were found to be predictors of new ischemic lesions.
The occurrence of CE was not associated with a measurable
impairment in cognitive function, but 2 patients (3.3%) had
a clinically apparent stroke within the 24 h following the
procedure (1 patient in each group).
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cerebral ischemic lesions as evaluated by DW-MRI, with no
differences between the TF and TA approaches. These results
provide important novel insight into the mechanisms of CE
associated with TAVI and support the need for further
research to both reduce the incidence of CE during these
procedures and better determine their clinical relevance (468).The Aging Heart and Post-Infarction Left
Ventricular Remodeling
Aging is a risk factor for heart failure, which is a leading
cause of death world-wide. Elderly patients are more likely
than young patients to experience a myocardial infarction
(MI) and are more likely to develop heart failure following
MI. The poor clinical outcome of aging in cardiovascular
disease is recapitulated on the cellular level. Increase in stress
exposure and shifts in signaling pathways with age change
the biology of cardiomyocytes. The progressive ac-
cumulation of metabolic waste and damaged organelles in
cardiomyocytes blocks the intracellular recycling process of
autophagy and increases the cell’s propensity toward
apoptosis. Additionally, the decreased cardiomyocyte
renewal capacity in the elderly, due to reduction in cellular
division and impaired stem cell function, leads to further
cardiac dysfunction and maladaptive responses to disease or
stress. We review the cellular and molecular aspects of post-
infarction remodeling in the aged heart, and relate them to
the clinical problem of post-infarction remodeling in elderly
patients (469).5-Year Follow-Up After Primary Percutaneous
Coronary Intervention With a Paclitaxel-Eluting
Stent Versus a Bare-Metal Stent in Acute ST-
Segment Elevation Myocardial Infarction: A Follow-
Up Study of the PASSION (Paclitaxel-Eluting
Versus Conventional Stent in Myocardial Infarction
With ST-Segment Elevation) Trial
Objectives The purpose of this study was to evaluate the
long-term outcomes of the PASSION (Paclitaxel-Eluting
Versus Conventional Stent in Myocardial Infarction with
ST-Segment Elevation) trial.
Background In primary percutaneous coronary interven-
tion for acute ST-segment elevation myocardial infarction
(STEMI), the use of drug-eluting stents (DES) is still
controversial. Several randomized controlled trials of DES,
compared with bare-metal stents (BMS), with short-term
follow-up showed a reduction in target lesion revasculari-
zation (TLR), but no differences in rates of cardiac death or
recurrent myocardial infarction. Moreover, the occurrence of
(very) late stent thrombosis (ST) continues to be of major
concern, and, therefore, long-term follow-up results are
needed.
Methods We randomly assigned 619 patients presenting
with STEMI to a paclitaxel-eluting stent (PES) or thesimilar BMS. The primary end point was the composite of
cardiac death, recurrent myocardial infarction, or TLR. We
performed clinical follow-up at 5 years.
Results At 5 years, the occurrence of the composite of
cardiac death, recurrent myocardial infarction, or TLR was
comparable at 18.6% versus 21.8% in PES and BMS,
respectively (hazard ratio [HR]: 0.82, 95% conﬁdence
interval [CI]: 0.58 to 1.18, p ¼ 0.28). The incidence of
deﬁnite or probable ST was 12 (4.2%) in the PES group and
10 (3.4%) in the BMS group (HR: 1.19, 95% CI: 0.51 to
276, p ¼ 0.68).
Conclusions In the present analysis of PES compared with
BMS in primary percutaneous coronary intervention for
STEMI, no signiﬁcant difference in major adverse cardiac
events was observed. In addition, no difference in the inci-
dence of deﬁnite or probable ST was seen, although very late
ST was almost exclusively seen after the use of PES.
(Paclitaxel-Eluting Versus Conventional Stent in Myocar-
dial Infarction with ST-Segment Elevation [PASSION];
ISRCTN65027270) (470).Very Late Stent Thrombosis After Primary
Percutaneous Coronary Intervention With Bare-
Metal and Drug-Eluting Stents for ST-Segment
Elevation Myocardial Infarction: A 15-Year
Single-Center Experience
Objectives The purpose of this study was to assess the
frequency of very late stent thrombosis (VLST) after
stenting with bare-metal stents (BMS) and drug-eluting
stents (DES) for ST-segment elevation myocardial infarc-
tion (STEMI).
Background Stent thrombosis occurs more frequently after
stenting for STEMI than after elective stenting, but there
are little data regarding VLST.
Methods Consecutive patients (n ¼ 1,463) who underwent
stenting for STEMI were prospectively enrolled in our
database. BMS were implanted exclusively from 1995 to
2002, and DES and BMS were implanted from 2003 to
2009. Follow-up was obtained at 1 to 15 years.
Results BMS patients (n ¼ 1,095) were older and had
more shock, whereas DES patients (n ¼ 368) had more
diabetes and smaller vessels. Stent thrombosis occurred in
107 patients, of which 42 were VLST (>1 year). Stent
thrombosis continued to increase to at least 11 years with
BMS and to at least 4.5 years with DES. Stent thrombosis
rates with BMS versus DES were similar at 1 year (5.1% and
4.0%, respectively) but increased more with DES after the
ﬁrst year (1.9%/year vs. 0.6%/year, respectively). Landmark
analysis (>1 year) found DES had a higher frequency of
VLST (p < 0.001) and reinfarction (p ¼ 0.003). DES was
the only signiﬁcant independent predictor of VLST (hazard
ratio: 3.79, 95% conﬁdence interval: 1.64 to 8.79, p ¼
0.002).
Conclusions VLST after primary PCI for STEMI occurs
with relatively high frequency to at least 11 years with BMS
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bosis and reinfarction (>1 year) were more frequent
with DES. New strategies are needed to manage this
problem (471).Incidence, Predictors, Management, Immediate
and Long-Term Outcomes Following Grade III
Coronary Perforation
Objectives The aim of this study was to evaluate the
incidence, predictors, management, and clinical outcomes in
patients with grade III coronary perforation during percu-
taneous coronary intervention.
Background Grade III coronary perforation is a rare but
recognized complication associated with high morbidity and
mortality.
Methods From 24,465 patients undergoing percutaneous
coronary intervention from May 1993 to December 2009,
56 patients had grade III coronary perforation.
Results Most lesions were complex: 44.6% type B2, 51.8%
type C, and 28.6% chronic total occlusions, and within
a small vessel (2.5 mm) in 32.1%. Glycoprotein IIb/IIIa
inhibitors were administered in 17.9% of patients. The
device causing perforation was intracoronary balloon in 50%:
53.6% compliant, 46.4% noncompliant; intracoronary
guidewire in 17.9%; rotablation in 3.6%; and directional
atherectomy in 3.6%. Following perforation, immediate
treatment and success rates, respectively, were prolonged
balloon inﬂation 58.9%, 54.5%; covered stent implantation
46.4%, 84.6%; coronary artery bypass graft surgery (CABG)
and surgical repair 16.0%, 44.4%; and coil embolization
1.8%, 100%. Multiple methods were required in 39.3%.
During the procedure (n ¼ 56), 19.6% required cardiopul-
monary resuscitation and 3.6% died. In-hospital (n ¼ 54),
3.7% required CABG, 14.8% died. The combined proce-
dural and in-hospital myocardial infarction rate was 42.9%,
and major adverse cardiac event rate was 55.4%. At clinical
follow-up (n ¼ 46) (median: 38.1 months, range 7.6 to
122.8), 4.3% had a myocardial infarction, 4.3% required
CABG, and 15.2% died. The target lesion revascularization
rate was 13%, with target vessel revascularization in 19.6%,
and major adverse cardiac events in 41.3%.
Conclusions Grade III coronary perforation is associated
with complex lesions and high acute and long-term major
adverse cardiac event rates (472).Late Restenosis Following Sirolimus-Eluting Stent
Implantation
Objectives This serial angiographic study evaluated the
incidence and predictors of late restenosis after sirolimus-
eluting stent (SES) implantation.
Background Previous studies showed late restenosis (i.e.,
late catch-up phenomenon) after implantation of 7-
hexanoyltaxol-eluting stents and nonpolymeric, paclitaxel-
eluting stents.Methods Between August 2004 and December 2006, SES
implantation was performed in 1,393 patients with 2,008
lesions, in whom 8-month and 2-year follow-up coronary
angiography were planned.
Results Of 2,008 lesions, 1,659 (83%) underwent 8-month
follow-up angiography (8.3  2.2 months). Restenosis was
observed in 122 lesions (7.4%). Coronary angiography 2
years (1.9  0.4 years) after SES deployment was performed
in 1,168 lesions (74% of lesions without restenosis at 8-
month follow-up angiography). Late restenosis was
observed in 83 lesions (7.1%). There was signiﬁcant decrease
in minimum luminal diameter (MLD) between 8-month
and 2-year follow-up (2.56  0.56 mm vs. 2.35  0.71
mm, p < 0.001). Multivariate analysis showed in-stent
restenosis before SES implantation and MLD at 8-month
follow-up as independent predictors of late restenosis.
Conclusions Between 8-month and 2-year follow-up after
SES implantation, MLD decreases, which results in late
restenosis in some lesions. In-stent restenosis before SES
implantation and MLD at 8-month follow-up are inde-
pendent predictors of late restenosis (473).Persistent Coronary No Flow After Wire Insertion
Is an Early and Readily Available Mortality Risk
Factor Despite Successful Mechanical
Intervention in Acute Myocardial Infarction: A
Pooled Analysis From the STRATEGY (Single High-
Dose Bolus Tiroﬁban and Sirolimus-Eluting Stent
Versus Abciximab and Bare-Metal Stent in Acute
Myocardial Infarction) and MULTISTRATEGY
(Multicenter Evaluation of Single High-Dose Bolus
Tiroﬁban Versus Abciximab With Sirolimus-Eluting
Stent or Bare-Metal Stent in Acute Myocardial
Infarction Study) Trials
Objectives These studies sought to investigate the impact
on mortality of coronary ﬂow after passage of the wire
through the culprit vessel in patients with ST-segment
elevation myocardial infarction (STEMI) undergoing
mechanical reperfusion.
Background Reduced spontaneous coronary ﬂow before
percutaneous coronary intervention inﬂuences mortality in
patients with STEMI. Response to vessel wiring in patients
with an occluded coronary artery before intervention might
further discriminate outcomes irrespective of pre- and post-
intervention coronary ﬂow.
Methods Data from the STRATEGY (Single High-Dose
Bolus Tiroﬁban and Sirolimus-Eluting Stent Versus
Abciximab and Bare-Metal Stent in Acute Myocardial
Infarction) and MULTISTRATEGY (Multicenter Evalu-
ation of Single High-Dose Bolus Tiroﬁban Versus Abcix-
imab With Sirolimus-Eluting Stent or Bare-Metal Stent in
Acute Myocardial Infarction Study) trials were pooled: of
919 index procedures, 902 ﬁlms (98%) were technically
adequate for core laboratory TIMI (Thrombolysis In
Myocardial Infarction) ﬂow determination.
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neous coronary intervention in 59% of infarct vessels, TIMI
ﬂow grade 1 to 2 was found in 21%, whereas the remainder
of infarct arteries presented with TIMI ﬂow grade 3. In 49%
of patients who showed persistent TIMI ﬂow grade 0 after
wire insertion (AWI), mortality was higher at 30 days
(5.3%) and 1 year (9.4%) compared with patients in whom
TIMI ﬂow grade before percutaneous coronary intervention
was either >0 (0.8%; p < 0.003 and 3.6%, p < 0.008) or
improved from 0 AWI (1.5%, p < 0.04 and 3.6%, p <
0.02). After correcting for multiple imbalances, including
baseline and ﬁnal ﬂow, persistent TIMI ﬂow grade 0 AWI
remained associated at 30 days to 2-fold (risk ratio [RR]:
2.1, 95% conﬁdence interval [CI]: 1.08 to 5.00; p ¼ 0.038)
and at 1 year to almost 3-fold increases of mortality (RR:
2.7, 95% CI: 1.3 to 5.6; p ¼ 0.008).
Conclusions STEMI patients displaying persistent no-
ﬂow AWI have a lower survival rate despite an apparently
successful mechanical intervention. As an early marker for
high residual mortality risk, persistent no-ﬂow AWI may
qualify STEMI patients for dedicated pharmacomechanical
treatment strategies (474).Four-Year Follow-Up of TYPHOON (Trial to Assess
the Use of the CYPHer Sirolimus-Eluting Coronary
Stent in Acute Myocardial Infarction Treated With
BallOON Angioplasty)
Objectives The aim of this study was to assess the long-
term safety and efﬁcacy of the CYPHER (Cordis, Johnson
and Johnson, Bridgewater, New Jersey) sirolimus-eluting
coronary stent (SES) in percutaneous coronary interven-
tion (PCI) for ST-segment elevation myocardial infarction
(STEMI).
Background Concern over the safety of drug-eluting stents
implanted during PCI for STEMI remains, and long-term
follow-up from randomized trials are necessary.
TYPHOON (Trial to assess the use of the cYPHer
sirolimus-eluting stent in acute myocardial infarction treated
with ballOON angioplasty) randomized 712 patients with
STEMI treated by primary PCI to receive either SES (n ¼
355) or bare-metal stents (BMS) (n ¼ 357). The primary
end point, target vessel failure at 1 year, was signiﬁcantly
lower in the SES group than in the BMS group (7.3% vs.
14.3%, p ¼ 0.004) with no increase in adverse events.
Methods A 4-year follow-up was performed. Complete
data were available in 501 patients (70%), and the survival
status is known in 580 patients (81%).
Results Freedom from target lesion revascularization
(TLR) at 4 years was signiﬁcantly better in the SES group
(92.4% vs. 85.1%; p ¼ 0.002); there were no signiﬁcant
differences in freedom from cardiac death (97.6% and
95.9%; p ¼ 0.37) or freedom from repeat myocardial
infarction (94.8% and 95.6%; p ¼ 0.85) between the SES
and BMS groups. No difference in deﬁnite/probable stent
thrombosis was noted at 4 years (SES: 4.4%, BMS: 4.8%,p ¼ 0.83). In the 580 patients with known survival status at
4 years, the all-cause death rate was 5.8% in the SES and
7.0% in the BMS group (p ¼ 0.61).
Conclusions In the 70% of patients with complete follow-
up at 4 years, SES demonstrated sustained efﬁcacy to reduce
TLR with no difference in death, repeat myocardial
infarction or stent thrombosis. (The Study to Assess AMI
Treated With Balloon Angioplasty [TYPHOON];
NCT00232830) (475).Prediction of 1-Year Clinical Outcomes Using the
SYNTAX Score in Patients With Acute ST-Segment
Elevation Myocardial Infarction Undergoing
Primary Percutaneous Coronary Intervention: A
Substudy of the STRATEGY (Single High-Dose
Bolus Tiroﬁban and Sirolimus-Eluting Stent Versus
Abciximab and Bare-Metal Stent in Acute
Myocardial Infarction) and MULTISTRATEGY
(Multicenter Evaluation of Single High-Dose Bolus
Tiroﬁban Versus Abciximab With Sirolimus-Eluting
Stent or Bare-Metal Stent in Acute Myocardial
Infarction Study) Trials
Objectives This study sought to evaluate the impact of
SYNTAX score (SXscore), and compare its performance
in isolation and combination with the PAMI (The
Primary Angioplasty in Myocardial Infarction Study)
score, for the prediction of 1-year clinical outcomes in
patients with ST-segment elevation myocardial infarction
(STEMI) undergoing primary percutaneous coronary
intervention.
Background Patients with STEMI were excluded from the
original SYNTAX score (SXscore) algorithm. Therefore,
the utility of using the SXscore in this patient group remains
undeﬁned.
Methods SXscore was calculated retrospectively in 807
patients with STEMI enrolled in the randomized
STRATEGY (Single High-Dose Bolus Tiroﬁban and
Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal
Stent in Acute Myocardial Infarction) and MULTI-
STRATEGY (Multicenter Evaluation of Single High-Dose
Bolus Tiroﬁban Versus Abciximab With Sirolimus-Eluting
Stent or Bare-Metal Stent in Acute Myocardial Infarction
Study) clinical trials. Clinical outcomes of all-cause death,
reinfarction, and clinically driven target vessel revasculari-
zation were subsequently stratiﬁed according to SXscore
tertiles: SXLOW 9 (n ¼ 311), 9 < SXMID 16 (n ¼ 234),
SXHIGH >16 (n ¼ 262).
Results At 1-year follow-up, all clinical outcomes
including mortality, mortality/reinfarction, major adverse
cardiac events (MACE) (a composite of all-cause death,
reinfarction and target vessel revascularization), and deﬁ-
nite, deﬁnite/probable, and any stent thrombosis were all
signiﬁcantly higher in patients in the highest SXscore
tertile. SXscore was identiﬁed as an independent predictor
of mortality, MACE, and stent thrombosis out to 1-year
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a net reclassiﬁcation improvement of 15.7% and 4.6% for
mortality and MACE, respectively. The C-statistics for the
SXscore, PAMI score, and the combined SYNTAX-
PAMI score were 0.65, 0.81, and 0.73 for 1-year
mortality, and 0.68, 0.64, and 0.69 for 1-year MACE,
respectively.
Conclusions SXscore does have a role in the risk stratiﬁ-
cation of patients with STEMI having primary percutaneous
coronary intervention; however, this ability can be improved
through a combination with clinical variables. (Multicentre
22 Factorial Randomised Study Comparing Tiroﬁban
Versus Abciximab and SES Versus BMS in AMI;
NCT00229515) (476).Drug-Eluting Introducer Sheath Prevents Local
Peripheral Complications: Pre-Clinical Evaluation
of Nitric Oxide–Coated Sheath
Objectives This study evaluated the protective effect of
nitric oxide–coating of introducer sheath on the local
complications in juvenile porcine femoral arteries with
similar size to human radial arteries.
Background Insertion of an introducer sheath induces
vasospasm and transient or permanent vessel occlusion of
radial arteries.
Methods Nitric oxide–coated or control introducer
sheaths with or without spasmolytic cocktail (control þ C-
sheath) were inserted into porcine femoral arteries, fol-
lowed by percutaneous coronary intervention (PCI). The
diameter of the femoral artery at the puncture site, distally
and proximally, was measured by quantitative angiography.
Histopathological and histomorphometric parameters of
the femoral arteries were analyzed 1 h or 1 week after
PCI.
Results Insertion of femoral sheath led to mild or severe
spasms, with signiﬁcantly higher vessel diameter at the
access site (2.69  0.81 mm vs. 1.77  0.77 mm and
1.85  0.66 mm, p < 0.001), and proximal and distal to
it, during PCI in the nitric oxide–sheath group versus the
control-sheath and control þ C-sheath groups, respec-
tively. Immediately following PCI, signiﬁcantly less
luminal thrombosis (12% vs. 33% and 31% of all
analyzed segments, p < 0.001) was observed in the nitric
oxide–sheath arteries. At 1 week, lower intimal inﬂam-
mation score (0.43  11 vs. 1.03  0.35 and 1.04 
0.32, p < 0.05), less luminal thrombosis (8% vs. 21%
and 30% p < 0.05), and smaller intimal hyperplasia (0.31
 0.31 mm2 vs. 0.47  1.00 mm2 and 0.86  0.82
mm2, p < 0.05) were observed in NO-sheath arteries at
the injury site.
Conclusions Nitric oxide coating on the introducer sheath
prevents local complications during PCI and results in less
vascular thrombosis and inﬂammation at the access site,
contributing to patency of the access vessel with similar size
to the radial artery (477).Survival of Patients Undergoing Rescue
Percutaneous Coronary Intervention: Development
and Validation of a Predictive Tool
Objectives This study sought to develop a tool for pre-
dicting an individual’s risk of mortality following rescue
percutaneous coronary intervention (PCI).
Background Although ﬁbrinolytic therapy is appropriate
and improves survival for certain ST-segment elevation
myocardial infarction patients, a substantial proportion
suffer ongoing myocardial ischemia, a class I indication for
emergent percutaneous coronary intervention (rescue PCI).
Methods Using the National Cardiovascular Data Registry
(NCDR), rescue PCI was deﬁned as nonelective PCI
following failed ﬁbrinolysis in patients with continuing or
recurrent myocardial ischemia. Multivariable logistic
regression was used to determine mortality predictors and
the C-statistic for model discrimination. The NCDR-
RESCUE (Real-World Estimator of Survival in Cathe-
terized STEMI Patients Following Unsuccessful Earlier
Fibrinolysis) score was developed using a shortened list of 6
pre-angiographic variables and 70% of the cohort; perfor-
mance was subsequently validated against the remaining
30%.
Results Among 166,516 PCI procedures on patients with
an admission diagnosis of ST-segment elevation myocardial
infarction, 8,007 (4.8%) represented rescue PCI. In-hospital
mortality occurred in 464 (5.8%). Factors in the ﬁnal model
were age, glomerular ﬁltration rate, history of congestive
heart failure, insulin-treated diabetes, cardiogenic shock, and
salvage status. The NCDR-RESCUE score effectively
segregated individuals into 6 clinically meaningful risk
categories, with 0.4% (0.0% to 1.3%), 1.6% (0.9% to 2.4%),
7.6% (5.3% to10.4%), 27.5% (20.7% to 35.1%), 64.2%
(49.8% to 76.9%), or 100% (59.0% to 100.0%) risk,
respectively, of in-hospital mortality (mean  95% conﬁ-
dence interval, C-index ¼ 0.88, Hosmer-Lemeshow p ¼
0.898).
Conclusions In-hospital mortality risk among individuals
undergoing rescue PCI varies from minimal to extreme and
can be easily calculated using the NCDR-RESCUE score.
This information can be of value in counseling patients,
families, and referring caregivers (478).
Difference of Culprit Lesion Morphologies
Between ST-Segment Elevation Myocardial
Infarction and Non–ST-Segment Elevation Acute
Coronary Syndrome: An Optical Coherence
Tomography Study
Objectives The aim of this study was to investigate the
difference of culprit lesion morphologies assessed by optical
coherence tomography (OCT) between ST-segment eleva-
tion myocardial infarction (STEMI) and non–ST-segment
elevation acute coronary syndrome (NSTEACS).
Background Autopsy studies have reported that rupture of
a thin-cap ﬁbroatheroma and subsequent thrombus
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coronary syndrome (ACS). Optical coherence tomography is
a high-resolution imaging modality that is capable of
investigating detailed coronary plaque morphology in vivo.
Methods We examined the culprit lesion morphologies by
OCT in 89 consecutive patients with acute coronary
syndrome (STEMI ¼ 40; NSTEACS ¼ 49).
Results The incidence of plaque rupture, thin-cap ﬁbroa-
theroma, and red thrombus was signiﬁcantly higher in
STEMI compared with NSTEACS (70% vs. 47%, p ¼
0.033, 78% vs. 49%, p ¼ 0.008, and 78% vs. 27%, p <
0.001, respectively). Although the lumen area at the site of
plaque rupture was similar in the both groups (2.44  1.34
mm2 vs. 2.96  1.91 mm2, p ¼ 0.250), the area of ruptured
cavity was signiﬁcantly larger in STEMI compared with
NSTEACS (2.52  1.36 mm2 vs. 1.67  1.37 mm2, p ¼
0.034). Furthermore, the ruptured plaque of which aperture
was open-wide against the direction of coronary ﬂow was
more often seen in STEMI compared with NSTEACS
(46% vs. 17%, p ¼ 0.036).
Conclusions The present OCT study demonstrated the
differences of the culprit lesion morphologies between
STEMI and NSTEACS. The morphological feature of
plaque rupture and the intracoronary thrombus could relate
to the clinical presentation in patients with acute coronary
disease (479).
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